FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Novak, RM Debes, R Chmiel, JS Brooks, JT Buchacz, K Dean, B AF Novak, R. M. Debes, R. Chmiel, J. S. Brooks, J. T. Buchacz, K. Dean, B. TI DISPARITIES IN INITIATION OF HAART AND IN VIROLOGIC SUPPRESSION AMONG PATIENTS IN THE HIV OUTPATIENT STUDY (HOPS), 2000-2010 SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Novak, R. M.] Univ Illinois, Chicago, IL USA. [Debes, R.] Cemer Corp, North Kansas City, MO USA. [Chmiel, J. S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Brooks, J. T.; Buchacz, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dean, B.] Cemer Res, Culver City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2013 VL 16 IS 3 BP A97 EP A97 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 144CE UT WOS:000318916400502 ER PT J AU Vemula, SV Ahi, YS Swaim, AM Katz, JM Donis, R Sambhara, S Mittal, SK AF Vemula, Sai V. Ahi, Yadvinder S. Swaim, Anne-Marie Katz, Jacqueline M. Donis, Ruben Sambhara, Suryaprakash Mittal, Suresh K. TI Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness SO PLOS ONE LA English DT Article ID H5N1 INFLUENZA; HIV-1 VACCINE; A VIRUSES; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODY; IMMUNE-RESPONSES; NUCLEOPROTEIN; HEMAGGLUTININ; INFECTION; EFFICACY AB Recurrent outbreaks of H5, H7 and H9 avian influenza viruses in domestic poultry accompanied by their occasional transmission to humans have highlighted the public health threat posed by these viruses. Newer vaccine approaches for pandemic preparedness against these viruses are needed, given the limitations of vaccines currently approved for H5N1 viruses in terms of their production timelines and the ability to induce protective immune responses in the absence of adjuvants. In this study, we evaluated the feasibility of an adenovirus (AdV)-based multivalent vaccine approach for pandemic preparedness against H5, H7 and H9 avian influenza viruses in a mouse model. Replication-defective AdV vectors expressing hemagglutinin (HA) from different subtypes and nucleoprotein (NP) from one subtype induced high levels of humoral and cellular immune responses and conferred protection against virus replication following challenge with H5, H7 and H9 avian influenza virus subtypes. Inclusion of HA from the 2009 H1N1 pandemic virus in the vaccine formulation further broadened the vaccine coverage. Significantly high levels of HA stalk-specific antibodies were observed following immunization with the multivalent vaccine. Inclusion of NP into the multivalent HA vaccine formulation resulted in the induction of CD8 T cell responses. These results suggest that a multivalent vaccine strategy may provide reasonable protection in the event of a pandemic caused by H5, H7, or H9 avian influenza virus before a strain-matched vaccine can be produced. C1 [Vemula, Sai V.; Ahi, Yadvinder S.; Swaim, Anne-Marie; Mittal, Suresh K.] Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. [Vemula, Sai V.; Ahi, Yadvinder S.; Swaim, Anne-Marie; Mittal, Suresh K.] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA. [Katz, Jacqueline M.; Donis, Ruben; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Sambhara, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM ssambhara@cdc.gov; mittal@purdue.edu OI Ahi, Yadvinder/0000-0001-9331-8349 FU Public Health Service grant from the National Institute of Allergy and Infectious Diseases [AI059374] FX This work was supported by Public Health Service grant AI059374 from the National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 19 Z9 19 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 30 PY 2013 VL 8 IS 4 AR UNSP e62496 DI 10.1371/journal.pone.0062496 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 146GG UT WOS:000319077300069 PM 23638099 ER PT J AU Reeves, WC Lin, JMS Nater, UM AF Reeves, William C. Lin, Jin-Mann S. Nater, Urs M. TI Mental illness in metropolitan, urban and rural Georgia populations SO BMC PUBLIC HEALTH LA English DT Article ID COMORBIDITY SURVEY REPLICATION; FUNCTIONAL SOMATIC SYNDROMES; DSM-IV DISORDERS; UNITED-STATES; HEALTH-SERVICES; RISK-FACTOR; DEPRESSION; PREVALENCE; ASSOCIATION; CARE AB Background: Mental illness represents an important public health problem. Local-level data concerning mental illness in different populations (e.g., socio-demographics and residence - metropolitan/urban/rural) provides the evidence-base for public health authorities to plan, implement and evaluate control programs. This paper describes prevalence and covariates of psychiatric conditions in Georgia populations in three defined geographic areas. Methods: Data came from the Georgia population-based random-digit-dialing study investigating unwellness and chronic fatigue syndrome (CFS) in Georgia populations of three defined geographic areas (metropolitan, urban, and rural). Respondents were screened for symptoms of fatigue, sleep, cognition, and pain at household screening interviews, and a randomly selected sample completed detailed individual phone interviews. Based on the detailed phone interviews, we conducted one-day clinical evaluations of 292 detailed interview participants classified as unwell with a probable CFS (i.e. CFS-like; a functional somatic syndrome), 268 classified as other unwell, and 223 well (matched to CFS-like). Clinical evaluation included psychiatric classification by means of the Structured Clinical Interview for DSM (SCID). To derive prevalence estimates we used sample weighting to account for the complexity of the multistage sampling design. We used 2- and 3-way table analyses to examine socio-demographic and urbanicity specific associations and multiple logistic regression to calculate adjusted odds ratios. Results: Anxiety and mood disorders were the most common psychiatric conditions. Nineteen percent of participants suffered a current anxiety disorder, 18% a mood disorder and 10% had two or more conditions. There was a significant linear trend in occurrence of anxiety or mood disorders from well to CFS-like. The most common anxiety disorders were post-traumatic stress disorder (PTSD) (6.6%) and generalized anxiety disorder (GAD) (5.8%). Logistic regression showed that lower education and female sex contributed significantly to risk for both PTSD and GAD. In addition, rural/urban residence and Hispanic ethnicity were associated with PTSD. We defined moderate to severe depression as Major Depressive Disorder or a Zung score >60 and logistic regression found lower education to be significantly associated but sex, age and urbanicity were not. Conclusions: Overall occurrence of anxiety and mood disorders in Georgia mirrored national findings. However, PTSD and GAD occurred at twice the published national rates (3.6 and 2.7%, respectively). State and local prevalence and associations with education, sex and urbanicity comprise important considerations for developing control programs. The increased prevalence of anxiety and mood disorders in people with a functional somatic syndrome (or CFS-like illness) is important for primary care providers, who should consider additional psychiatric screening or referral of individuals presenting with somatoform symptoms. C1 [Reeves, William C.; Lin, Jin-Mann S.] Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Atlanta, GA 30333 USA. [Lin, Jin-Mann S.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Nater, Urs M.] Univ Marburg, Dept Psychol, D-35032 Marburg, Germany. RP Lin, JMS (reprint author), Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Mail Stop E-33,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM dwe3@cdc.gov RI Nater, Urs/J-6898-2013; OI Nater, Urs/0000-0002-2430-5090 FU US Centers for Disease Control and Prevention (CDC); Centers for Disease Control and Prevention; VolksWagen Foundation; Swiss National Science Foundation FX This study was fully funded by the US Centers for Disease Control and Prevention (CDC). The authors are indebted to Abt Associates staff responsible for field work and in particular to Ms. Rebecca Devlin for study management. We especially appreciate the time Dr. Anil T. Mangla (Acting State Epidemiologist, Georgia Department of Community Health) took to review and discuss this paper.; Drs. Reeves and Lin are fully supported by the Centers for Disease Control and Prevention. The study was fully funded by the Centers for Disease Control and Prevention. Dr. Nater acknowledges funding by the VolksWagen Foundation and the Swiss National Science Foundation. NR 40 TC 4 Z9 4 U1 2 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD APR 30 PY 2013 VL 13 AR 414 DI 10.1186/1471-2458-13-414 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 145XZ UT WOS:000319054500001 PM 23631737 ER PT J AU Wong, J Bayoh, N Olang, G Killeen, GF Hamel, MJ Vulule, JM Gimnig, JE AF Wong, Jacklyn Bayoh, Nabie Olang, George Killeen, Gerry F. Hamel, Mary J. Vulule, John M. Gimnig, John E. TI Standardizing operational vector sampling techniques for measuring malaria transmission intensity: evaluation of six mosquito collection methods in western Kenya SO MALARIA JOURNAL LA English DT Article DE Anopheles gambiae; Anopheles arabiensis; Anopheles funestus; Mosquito sampling; Human biting rate; Human landing catch; CDC light trap; Ifakara tent trap; Window exit trap ID TREATED BED NETS; ENTOMOLOGIC INOCULATION RATES; ANOPHELES-GAMBIAE COMPLEX; HUMAN LANDING CATCH; SUB-SAHARAN AFRICA; CDC LIGHT-TRAPS; DAR-ES-SALAAM; CHILD-MORTALITY; TANZANIAN VILLAGES; EQUATORIAL-GUINEA AB Background: Operational vector sampling methods lack standardization, making quantitative comparisons of malaria transmission across different settings difficult. Human landing catch (HLC) is considered the research gold standard for measuring human-mosquito contact, but is unsuitable for large-scale sampling. This study assessed mosquito catch rates of CDC light trap (CDC-LT), Ifakara tent trap (ITT), window exit trap (WET), pot resting trap (PRT), and box resting trap (BRT) relative to HLC in western Kenya to 1) identify appropriate methods for operational sampling in this region, and 2) contribute to a larger, overarching project comparing standardized evaluations of vector trapping methods across multiple countries. Methods: Mosquitoes were collected from June to July 2009 in four districts: Rarieda, Kisumu West, Nyando, and Rachuonyo. In each district, all trapping methods were rotated 10 times through three houses in a 3 x 3 Latin Square design. Anophelines were identified by morphology and females classified as fed or non-fed. Anopheles gambiae s.l. were further identified as Anopheles gambiae s.s. or Anopheles arabiensis by PCR. Relative catch rates were estimated by negative binomial regression. Results: When data were pooled across all four districts, catch rates (relative to HLC indoor) for An. gambiae s.l (95.6% An. arabiensis, 4.4% An. gambiae s.s) were high for HLC outdoor (RR = 1.01), CDC-LT (RR = 1.18), and ITT (RR = 1.39); moderate for WET (RR = 0.52) and PRT outdoor (RR = 0.32); and low for all remaining types of resting traps (PRT indoor, BRT indoor, and BRT outdoor; RR < 0.08 for all). For Anopheles funestus, relative catch rates were high for ITT (RR = 1.21); moderate for HLC outdoor (RR = 0.47), CDC-LT (RR = 0.69), and WET (RR = 0.49); and low for all resting traps (RR < 0.02 for all). At finer geographic scales, however, efficacy of each trap type varied from district to district. Conclusions: ITT, CDC-LT, and WET appear to be effective methods for large-scale vector sampling in western Kenya. Ultimately, choice of collection method for operational surveillance should be driven by trap efficacy and scalability, rather than fine-scale precision with respect to HLC. When compared with recent, similar trap evaluations in Tanzania and Zambia, these data suggest that traps which actively lure host-seeking females will be most useful for surveillance in the face of declining vector densities. C1 [Wong, Jacklyn; Bayoh, Nabie; Olang, George; Hamel, Mary J.; Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Bayoh, Nabie; Olang, George; Hamel, Mary J.; Vulule, John M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Killeen, Gerry F.] Univ Liverpool, Liverpool Sch Trop Med, Vector Grp, Liverpool L3 5QA, Merseyside, England. [Killeen, Gerry F.] Ifakara Hlth Inst, Environm Sci Themat Grp, Ifakara, Tanzania. RP Wong, J (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. EM vsm0@cdc.gov FU Bill and Melinda Gates Foundation through the Malaria Transmission Consortium [45114] FX We thank Dr Kayla Laserson for facilitating this study as the director of KEMRI/CDC, Dr Nicodem Govella for arranging supply of ITTs and for guidance on how to deploy them, and Ryan Wiegand for statistical advice and SAS help. We are grateful to the volunteers who served as mosquito collectors and the residents of the households where sampling was conducted. Funding was provided by the Bill and Melinda Gates Foundation through the Malaria Transmission Consortium (grant no. 45114). This paper was published with the permission of the director of the Kenya Medical Research Institute. NR 59 TC 21 Z9 21 U1 1 U2 19 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 30 PY 2013 VL 12 AR 143 DI 10.1186/1475-2875-12-143 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 142FT UT WOS:000318783000001 PM 23631641 ER PT J AU Swei, A Russell, BJ Naccache, SN Kabre, B Veeraraghavan, N Pilgard, MA Johnson, BJB Chiu, CY AF Swei, Andrea Russell, Brandy J. Naccache, Samia N. Kabre, Beniwende Veeraraghavan, Narayanan Pilgard, Mark A. Johnson, Barbara J. B. Chiu, Charles Y. TI The Genome Sequence of Lone Star Virus, a Highly Divergent Bunyavirus Found in the Amblyomma americanum Tick SO PLOS ONE LA English DT Article ID ERYTHEMA MIGRANS; UNITED-STATES; BHANJA VIRUS; SEARCH TOOL; DISEASE; MISSOURI; ILLNESS; FEVER; ALIGNMENT; AGENT AB Viruses in the family Bunyaviridae infect a wide range of plant, insect, and animal hosts. Tick-borne bunyaviruses in the Phlebovirus genus, including Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) in China, Heartland virus (HRTV) in the United States, and Bhanja virus in Eurasia and Africa have been associated with acute febrile illness in humans. Here we sought to characterize the growth characteristics and genome of Lone Star virus (LSV), an unclassified bunyavirus originally isolated from the lone star tick Amblyomma americanum. LSV was able to infect both human (HeLa) and monkey (Vero) cells. Cytopathic effects were seen within 72 h in both cell lines; vacuolization was observed in infected Vero, but not HeLa, cells. Viral culture supernatants were examined by unbiased deep sequencing and analysis using an in-house developed rapid computational pipeline for viral discovery, which definitively identified LSV as a phlebovirus. De novo assembly of the full genome revealed that LSV is highly divergent, sharing <61% overall amino acid identity with any other bunyavirus. Despite this sequence diversity, LSV was found by phylogenetic analysis to be part of a well-supported clade that includes members of the Bhanja group viruses, which are most closely related to SFSTV/HRTV. The genome sequencing of LSV is a critical first step in developing diagnostic tools to determine the risk of arbovirus transmission by A. americanum, a tick of growing importance given its expanding geographic range and competence as a disease vector. This study also underscores the power of deep sequencing analysis in rapidly identifying and sequencing the genomes of viruses of potential clinical and public health significance. C1 [Swei, Andrea; Naccache, Samia N.; Kabre, Beniwende; Veeraraghavan, Narayanan; Chiu, Charles Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Swei, Andrea; Naccache, Samia N.; Kabre, Beniwende; Veeraraghavan, Narayanan; Chiu, Charles Y.] UCSF Abbott Viral Diagnost & Discovery Ctr, San Francisco, CA USA. [Russell, Brandy J.; Pilgard, Mark A.; Johnson, Barbara J. B.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Swei, Andrea] San Francisco State Univ, Dept Biol, San Francisco, CA 94132 USA. RP Chiu, CY (reprint author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. EM charles.chiu@ucsf.edu OI Chiu, Charles/0000-0003-2915-2094 FU National Institutes of Health (NIH) [R56-AI089532, R01-HL105704]; Abbott Viral Discovery Award; QB3 Swartz Foundation Lyme Disease Grant; National Research Fund for Tick-borne Diseases; UCSF Microbial Pathogenesis training grant; Centers for Disease Control and Prevention FX This work is supported by National Institutes of Health (NIH) grants R56-AI089532 and R01-HL105704 (C.Y.C.), an Abbott Viral Discovery Award (C.Y.C.), a QB3 Swartz Foundation Lyme Disease Grant (C.Y.C.), and a tick-borne research grant from the National Research Fund for Tick-borne Diseases (C.Y.C.). The authors also acknowledge support from a UCSF Microbial Pathogenesis training grant (A.S.) and funding from the Centers for Disease Control and Prevention in support of pathogen discovery efforts in STARI (B.J.J.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 24 Z9 26 U1 0 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 29 PY 2013 VL 8 IS 4 AR e62083 DI 10.1371/journal.pone.0062083 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 181JC UT WOS:000321662800023 PM 23637969 ER PT J AU Salmon, DA Proschan, M Forshee, R Gargiullo, P Bleser, W Burwen, DR Cunningham, F Garman, P Greene, SK Lee, GM Vellozzi, C Yih, WK Gellin, B Lurie, N AF Salmon, Daniel A. Proschan, Michael Forshee, Richard Gargiullo, Paul Bleser, William Burwen, Dale R. Cunningham, Francesca Garman, Patrick Greene, Sharon K. Lee, Grace M. Vellozzi, Claudia Yih, W. Katherine Gellin, Bruce Lurie, Nicole CA H1N1 GBS Meta-Anal Working Grp TI Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis SO LANCET LA English DT Article ID SAFETY DATALINK PROJECT; PRACTICE RESEARCH DATABASE; UNITED-STATES; IMMUNIZATION-SAFETY; VACCINATION; SURVEILLANCE; RECEIPT; PROGRAM; KINGDOM; COHORT AB Background The influenza A (H1N1) 2009 monovalent vaccination programme was the largest mass vaccination initiative in recent US history. Commensurate with the size and scope of the vaccination programme, a project to monitor vaccine adverse events was undertaken, the most comprehensive safety surveillance agenda in the USA to date. The adverse event monitoring project identified an increased risk of Guillain-Barre syndrome after vaccination; however, some individual variability in results was noted. Guillain-Barre syndrome is a rare but serious health disorder in which a person's own immune system damages their nerve cells, causing muscle weakness, sometimes paralysis, and infrequently death. We did a meta-analysis of data from the adverse event monitoring project to ascertain whether influenza A (H1N1) 2009 monovalent inactivated vaccines used in the USA increased the risk of Guillain-Barre syndrome. Methods Data were obtained from six adverse event monitoring systems. About 23 million vaccinated people were included in the analysis. The primary analysis entailed calculation of incidence rate ratios and attributable risks of excess cases of Guillain-Barre syndrome per million vaccinations. We used a self-controlled risk-interval design. Findings Influenza A (H1N1) 2009 monovalent inactivated vaccines were associated with a small increased risk of Guillain-Barre syndrome (incidence rate ratio 2.35, 95% CI 1.42-4.01, p=0.0003). This finding translated to about 1.6 excess cases of Guillain-Barre syndrome per million people vaccinated. Interpretation The modest risk of Guillain-Barre syndrome attributed to vaccination is consistent with previous estimates of the disorder after seasonal influenza vaccination. A risk of this small magnitude would be difficult to capture during routine seasonal influenza vaccine programmes, which have extensive, but comparatively less, safety monitoring. In view of the morbidity and mortality caused by 2009 H1N1 influenza and the effectiveness of the vaccine, clinicians, policy makers, and those eligible for vaccination should be assured that the benefits of inactivated pandemic vaccines greatly outweigh the risks. C1 [Salmon, Daniel A.; Bleser, William; Gellin, Bruce] Dept Hlth & Human Serv, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC USA. [Lurie, Nicole] Dept Hlth & Human Serv, Washington, DC USA. [Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA. [Proschan, Michael] NIH, Bethesda, MD 20892 USA. [Forshee, Richard; Burwen, Dale R.] US FDA, Rockville, MD 20857 USA. [Gargiullo, Paul; Vellozzi, Claudia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cunningham, Francesca] US Dept Vet Affairs, Hines, IL USA. [Garman, Patrick] US Dept Def, Washington, DC 20305 USA. [Greene, Sharon K.; Lee, Grace M.; Yih, W. Katherine] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Greene, Sharon K.; Lee, Grace M.; Yih, W. Katherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. RP Salmon, DA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA. EM dsalmon@jhsph.edu OI Jacobsen, Steven/0000-0002-8174-8533; Bleser, William/0000-0002-4640-8680 FU US Federal Government FX US Federal Government. NR 40 TC 55 Z9 55 U1 0 U2 74 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD APR 27 PY 2013 VL 381 IS 9876 BP 1461 EP 1468 DI 10.1016/S0140-6736(12)62189-8 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 139TK UT WOS:000318607300035 PM 23498095 ER PT J AU Huff, S Stocks, JM Saito, R Bilhartz, P Levin, J Glazer, C Bailey, R Cummings, K Kreiss, K McCague, AB AF Huff, Sharon Stocks, James M. Saito, Rena Bilhartz, Patty Levin, Jeffrey Glazer, Craig Bailey, Rachel Cummings, Kristin Kreiss, Kathleen McCague, Anna-Binney TI Obliterative Bronchiolitis in Workers in a Coffee-Processing Facility - Texas, 2008-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ROASTED COFFEE C1 [Huff, Sharon; Stocks, James M.; Saito, Rena; Bilhartz, Patty; Levin, Jeffrey] Univ Texas Tyler, Hlth Sci Ctr, Dept Occupat Hlth Sci, Tyler, TX 75799 USA. [Huff, Sharon; Stocks, James M.; Saito, Rena; Bilhartz, Patty; Levin, Jeffrey] Univ Texas Tyler, Hlth Sci Ctr, Dept Med, Tyler, TX 75799 USA. [Glazer, Craig] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [McCague, Anna-Binney] CDC, Atlanta, GA 30333 USA. RP McCague, AB (reprint author), CDC, Atlanta, GA 30333 USA. EM wja6@cdc.gov NR 9 TC 11 Z9 11 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 26 PY 2013 VL 62 IS 16 BP 305 EP 307 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FS UT WOS:000322178600002 ER PT J AU Wang, SA Mantel, CF Gacic-Dobo, M Dumolard, L Cherian, T Flannery, B Loo, JD Verani, JR Whitney, CG AF Wang, Susan A. Mantel, Carsten F. Gacic-Dobo, Marta Dumolard, Laure Cherian, Thomas Flannery, Brendan Loo, Jennifer D. Verani, Jennifer R. Whitney, Cynthia G. TI Progress in Introduction of Pneumococcal Conjugate Vaccine - Worldwide, 2000-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Wang, Susan A.; Mantel, Carsten F.; Gacic-Dobo, Marta; Dumolard, Laure; Cherian, Thomas] World Hlth Org, Dept Immunizat Vaccines & Biol, Geneva, Switzerland. [Loo, Jennifer D.; Verani, Jennifer R.; Whitney, Cynthia G.] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Loo, JD (reprint author), CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jloo@cdc.gov NR 9 TC 27 Z9 27 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 26 PY 2013 VL 62 IS 16 BP 308 EP 311 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FS UT WOS:000322178600003 ER PT J AU Jereb, J Mase, S Chorba, T Castro, K AF Jereb, John Mase, Sundari Chorba, Terence Castro, Kenneth TI National Shortage of Purified-Protein Derivative Tuberculin Products SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Jereb, John; Mase, Sundari; Chorba, Terence; Castro, Kenneth] CDC, Div TB Eliminat, Natl Ctr HIV Hepatitis STDs & TB Prevent, Atlanta, GA 30333 USA. RP Jereb, J (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV Hepatitis STDs & TB Prevent, Atlanta, GA 30333 USA. EM jjereb@cdc.gov NR 5 TC 3 Z9 3 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 26 PY 2013 VL 62 IS 16 BP 312 EP 312 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FS UT WOS:000322178600004 ER PT J AU Rodriguez, L Prado, J Holland, A Beckman, J Calvert, GM AF Rodriguez, Luis Prado, Joanne Holland, April Beckman, John Calvert, Geoffrey M. TI Acute Pesticide-Related Illness Resulting from Occupational Exposure to Acrolein - Washington and California, 1993-2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Rodriguez, Luis; Prado, Joanne] Washington State Dept Hlth, Washington, DC USA. [Calvert, Geoffrey M.] CDC, NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Atlanta, GA 30333 USA. RP Calvert, GM (reprint author), CDC, NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Atlanta, GA 30333 USA. EM gcalvert@cdc.gov NR 5 TC 1 Z9 1 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 26 PY 2013 VL 62 IS 16 BP 313 EP 314 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FS UT WOS:000322178600005 ER PT J AU Fendick, R King, JC Tincher, T Radke, M Begluitti, G Cruz, M Keim, M Schwartz, M Delaney, L AF Fendick, Russell King, J. C. Tincher, Terry Radke, Marilyn Begluitti, Gino Cruz, Miguel Keim, Mark Schwartz, Michael Delaney, Lisa TI Exposures to Discarded Sulfur Mustard Munitions - Mid-Atlantic and New England States 2004-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Delaney, Lisa] CDC, Natl Inst Occupat Safety & Health, Atlanta, GA 30333 USA. EM ttincher@cdc.gov NR 5 TC 1 Z9 1 U1 1 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 26 PY 2013 VL 62 IS 16 BP 315 EP 316 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FS UT WOS:000322178600006 ER PT J AU Wagner, G Yamanaka, LE Moura, H Lukemeyer, DD Schlindwein, AD Stoco, PH Ferreira, HB Barr, JR Steindel, M Grisard, EC AF Wagner, Glauber Yamanaka, Lais Eiko Moura, Hercules Luekemeyer, Debora Denardin Schlindwein, Aline Daiane Stoco, Patricia Hermes Ferreira, Henrique Bunselmeyer Barr, John Robert Steindel, Mario Grisard, Edmundo Carlos TI The Trypanosoma rangeli trypomastigote surfaceome reveals novel proteins and targets for specific diagnosis SO JOURNAL OF PROTEOMICS LA English DT Article DE Trypanosoma rangeli; Proteomic; Surface proteins; Antigens; GPI-anchored proteins ID ANCHORED MEMBRANE-PROTEINS; CHAGAS-DISEASE; TRANS-SIALIDASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS; CELL RESPONSES; MUCIN GENES; CRUZI; GLYCOPROTEIN; FORMS; DIVERSITY AB Sympatric distribution and sharing of hosts and antigens by Trypanosoma rangeli and Trypanosoma cruzi, the etiological agent of Chagas' disease, often incur in misdiagnosis and improper epidemiological inferences. Many secreted and surface proteins (SP) have been described as important antigens shared by these species. This work describes the T. rangeli surfaceome obtained by gel-free (LC-ESI-MS/MS) and gel-based (GeLC-ESI-MS/MS) proteomic approaches, and immunoblotting analyses and the comparison of these SP with T. cruzi. A total of 138 T. rangeli proteins and 343 T. cruzi proteins were obtained, among which, 42 and 157 proteins were exclusively identified in T. rangeli or T. cruzi trypomastigotes, respectively. Immunoblotting assays using sera from experimentally infected mice revealed a distinct band pattern for each species. MS/MS analysis of T. rangeli exclusive bands revealed two unique GP63-related proteins and flagellar calcium-binding protein. Also, a similar to 32 kDa band composed of 12 distinct proteins was exclusively recognized by anti-T. cruzi serum. This highly sensitive proteomic assessment of surface proteins characterized the T. rangeli surfaceome, revealing several differences and similarities between these two parasites. The study reports new T. rangeli-specific proteins with promising use in differential diagnosis from T. cruzi. Biological significance In this manuscript, we report the first proteomic analysis of the T. rangeli surface (surfaceome), a non-pathogenic parasite occurring in sympatry with T. cruzi, the etiological agent of Chagas disease. This comparative proteomic analysis was performed using high-throughput in-gel and gel-free proteomic approaches combined with immunoblotting, allowing us to identify new T. rangeli-specific proteins with promising use in differential serodiagnosis, among several other protein not previously reported for this taxon. Additionally, cross-recognition assays showed that T. cruzi surface proteins were recognized by heterologous serum (anti-T. rangeli) that strengthens the possibility of misdiagnosis of Chagas disease in humans and other mammals. Thus, this work provides new insights to understand the serological cross-reactivity between T. cruzi and T. rangeli, as well as, the identification of targets for specific T. rangeli diagnosis as revealed by the comparative surfaceome analysis. We strongly believe that this research is of importance to the readers of Journal of Proteomics since it provides new potential markers for diagnosis of both T. cruzi and T. rangeli parasites increasing the spectrum of specific targets for unambiguous diagnosis of T. rangeli and T. cruzi infections, besides describing new approaches to assess the trypanosomatids proteome. (C) 2013 Elsevier B.V. All rights reserved. C1 [Wagner, Glauber; Yamanaka, Lais Eiko; Luekemeyer, Debora Denardin; Schlindwein, Aline Daiane; Stoco, Patricia Hermes; Steindel, Mario; Grisard, Edmundo Carlos] Univ Fed Santa Catarina, Lab Protozool & Bioinformat, BR-88040970 Florianopolis, SC, Brazil. [Wagner, Glauber] Univ Oeste Santa Catarina, Lab Doencas Infecciosas & Parasitarias, Joacaba, Brazil. [Wagner, Glauber; Moura, Hercules; Barr, John Robert] Ctr Dis Control & Prevent, Biol Mass Spectrometry Lab, Atlanta, GA USA. [Ferreira, Henrique Bunselmeyer] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Lab Genom Estrutural & Func, Porto Alegre, RS, Brazil. RP Grisard, EC (reprint author), Univ Fed Santa Catarina, Lab Protozool, Dept Microbiol Imunol & Parasitol, Ctr Ciencias Biol, Setor F,Bloco A,Caixa Postal 476, BR-88040970 Florianopolis, SC, Brazil. EM edmundo.grisard@ufsc.br RI Grisard, Edmundo/A-7338-2015; Ferreira, Henrique/H-4189-2012; Wagner, Glauber/B-2369-2013 OI Grisard, Edmundo/0000-0001-8916-8296; Ferreira, Henrique/0000-0003-3611-6040; Wagner, Glauber/0000-0001-5003-6595 FU FINEP (Brazilian Research Agency); Centers for Disease Control and Prevention (CDC); CNPq; CAPES FX We are thankful to Dr. Santuza Teixeira, Dr. Alvaro Romanha, Dr. Yulanda Williamson and Mariel Marlow MSc. for their contributions. This study was supported by FINEP (Brazilian Research Agency) and by the Centers for Disease Control and Prevention (CDC). GW, LEY, DDL, ADS, and PHS were recipients of CNPq or CAPES (Brazilian Government Agencies) scholarships. NR 74 TC 6 Z9 6 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1874-3919 EI 1876-7737 J9 J PROTEOMICS JI J. Proteomics PD APR 26 PY 2013 VL 82 BP 52 EP 63 DI 10.1016/j.jprot.2013.02.011 PG 12 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 154AG UT WOS:000319643300005 PM 23466310 ER PT J AU Adachi, K Coleman, MS Hurst, CD Vargas, ML Oladele, A Weinberg, MS AF Adachi, Kenji Coleman, Margaret S. Hurst, Christopher de la Motte Vargas, Monica L. Oladele, Alawode Weinberg, Michelle S. TI Costs of, and reimbursement for, vaccines: A case study at the Board of Health Refugee Services in DeKalb county, Georgia SO VACCINE LA English DT Article DE Cost analysis; Refugees; Vaccine reimbursement ID VACCINATIONS; INFLUENZA; TIME; MEASLES; SCHOOL; CARE AB Background: Approximately 70,000 refugees are resettled to the United States each year. Providing vaccination to arriving refugees is important to both reduce the health-related barriers to successful resettlement, and protect the health of communities where refugees resettle. It is crucial to understand the process and resources expended at the state/local and federal government levels to provide vaccinations to refugees resettling to the United States. Objectives: We estimated costs associated with delivering vaccines to refugees at the Board of Health Refugee Services, DeKalb county, Georgia (DeKalb clinic). Methods: Vaccination costs were estimated from two perspectives: the federal government and the DeKalb clinic. Data were collected at the DeKalb clinic regarding resources used for vaccination: staff numbers and roles; type and number of vaccine doses administered; and number of patients. Clinic costs included labor and facility-related overhead. The federal government incurred costs for vaccine purchases and reimbursements for vaccine administration. Results: The DeKalb clinic average cost to administer the first dose of vaccine was $12.70, which is lower than Georgia Medicaid reimbursement ($14.81), but higher than the State of Georgia Refugee Health Program reimbursement ($8.00). Federal government incurred per-dose costs for vaccine products and administrative reimbursement were $42.45 (adults) and $46.74 (children). Conclusions: The total costs to the DeKalb clinic for administering vaccines to refugees are covered, but with little surplus. Because the DeKalb clinic 'breaks even,' it is likely they will continue to vaccinate refugees as recommended by the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Adachi, Kenji; Coleman, Margaret S.; Hurst, Christopher de la Motte; Weinberg, Michelle S.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Vargas, Monica L.] Georgia Dept Publ Hlth, Div Hlth Protect, Atlanta, GA 30303 USA. [Oladele, Alawode] DeKalb Cty Board Hlth, Refugee Hlth Program, Decatur, GA 30030 USA. RP Adachi, K (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, MS E-03 1600 Clifton Rd, Atlanta, GA 30333 USA. EM kenji.adachi@bayer.com; mcoleman@cdc.gov; cdelamottehurst@cdc.gov; mlvargas@dhr.state.ga.us; axoladele@dhr.state.ga.us; mweinberg@cdc.gov NR 29 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 26 PY 2013 VL 31 IS 18 BP 2317 EP 2322 DI 10.1016/j.vaccine.2012.08.016 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 135ZP UT WOS:000318329500015 PM 22910285 ER PT J AU van't Hoog, AH Marston, BJ Ayisi, JG Agaya, JA Muhenje, O Odeny, LO Hongo, J Laserson, KF Borgdorff, MW AF van't Hoog, Anna H. Marston, Barbara J. Ayisi, John G. Agaya, Janet A. Muhenje, Odylia Odeny, Lazarus O. Hongo, John Laserson, Kayla F. Borgdorff, Martien W. TI Risk Factors for Inadequate TB Case Finding in Rural Western Kenya: A Comparison of Actively and Passively Identified TB Patients SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; TUBERCULOSIS CASE DETECTION; AFRICAN GOLD MINERS; PULMONARY TUBERCULOSIS; INFECTIOUS TUBERCULOSIS; HOUSEHOLD CONTACTS; SEEKING BEHAVIOR; RANDOMIZED-TRIAL; DIAGNOSTIC DELAY; HIV AB Background: The findings of a prevalence survey conducted in western Kenya, in a population with 14.9% HIV prevalence suggested inadequate case finding. We found a high burden of infectious and largely undiagnosed pulmonary tuberculosis (PTB), that a quarter of the prevalent cases had not yet sought care, and a low case detection rate. Objective and methods: We aimed to identify factors associated with inadequate case finding among adults with PTB in this population by comparing characteristics of 194 PTB patients diagnosed in a health facility after self-report, i.e., through passive case detection, with 88 patients identified through active case detection during the prevalence survey. We examined associations between method of case detection and patient characteristics, including HIV-status, sociodemographic variables and disease severity in univariable and multivariable logistic regression analyses. Findings: HIV-infection was associated with faster passive case detection in univariable analysis (crude OR 3.5, 95% confidence interval (CI) 2.0-5.9), but in multivariable logistic regression this was largely explained by the presence of cough, illness and clinically diagnosed smear-negative TB (adjusted OR (aOR) HIV 1.8, 95% CI 0.85-3.7). Among the HIV-uninfected passive case detection was less successful in older patients aOR 0.76, 95% CI 0.60-0.97 per 10 years increase), and women (aOR 0.27, 95% CI 0.10-0.73). Reported current or past alcohol use reduced passive case detection in both groups (0.42, 95% CI 0.23-0.79). Among smear-positive patients median durations of cough were 4.0 and 6.9 months in HIV-infected and uninfected patients, respectively. Conclusion: HIV-uninfected patients with infectious TB who were older, female, relatively less ill, or had a cough of a shorter duration were less likely found through passive case detection. In addition to intensified case finding in HIV-infected persons, increasing the suspicion of TB among HIV-uninfected women and the elderly are needed to improve TB case detection in Kenya. C1 [van't Hoog, Anna H.; Borgdorff, Martien W.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [van't Hoog, Anna H.; Agaya, Janet A.; Odeny, Lazarus O.; Hongo, John; Laserson, Kayla F.] Kenya Med Res Inst KEMRI, KEMRI Ctr Dis Control CDC, Res & Publ Hlth Collaborat, Kisumu, Kenya. [Marston, Barbara J.] United States Ctr Dis Control & Prevent CDC, Div Global AIDS, Atlanta, GA USA. [Ayisi, John G.] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya. [Muhenje, Odylia] United States Ctr Dis Control & Prevent CDC, Global AIDS Program, Nairobi, Kenya. [Borgdorff, Martien W.] Publ Hlth Serv, Dept Infect Dis, Amsterdam, Netherlands. RP van't Hoog, AH (reprint author), Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. EM a.h.vanthoog@aighd.org FU United States President's Emergency Plan for AIDS Relief (PEPFAR); USAID through John's Hopkins University FX The studies were supported by the United States President's Emergency Plan for AIDS Relief (PEPFAR), and by USAID through John's Hopkins University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 2 Z9 2 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 25 PY 2013 VL 8 IS 4 AR e61162 DI 10.1371/journal.pone.0061162 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 136DM UT WOS:000318341400008 PM 23634206 ER PT J AU Oria, PA Arunga, G Lebo, E Wong, JM Emukule, G Muthoka, P Otieno, N Mutonga, D Breiman, RF Katz, MA AF Oria, Prisca Adhiambo Arunga, Geoffrey Lebo, Emmaculate Wong, Joshua M. Emukule, Gideon Muthoka, Philip Otieno, Nancy Mutonga, David Breiman, Robert F. Katz, Mark A. TI Assessing parents' knowledge and attitudes towards seasonal influenza vaccination of children before and after a seasonal influenza vaccination effectiveness study in low-income urban and rural Kenya, 2010-2011 SO BMC PUBLIC HEALTH LA English DT Article DE Seasonal influenza; Vaccination; Attitude; Parent; Children; Low-income; Kenya ID YOUNG-CHILDREN; VIRUS; TRANSMISSION; SAFETY; INFANTS; DISEASE; AGE AB Background: Influenza vaccine is rarely used in Kenya, and little is known about attitudes towards the vaccine. From June-September 2010, free seasonal influenza vaccine was offered to children between 6 months and 10 years old in two Population-Based Infectious Disease Surveillance (PBIDS) sites. This survey assessed attitudes about influenza, uptake of the vaccine and experiences with childhood influenza vaccination. Methods: We administered a questionnaire and held focus group discussions with parents of children of enrollment age in the two sites before and after first year of the vaccine campaign. For pre-vaccination focus group discussions, we randomly selected mothers and fathers who had an eligible child from the PBIDS database to participate. For the post-vaccination focus group discussions we stratified parents whose children were eligible for vaccination into fully vaccinated, partially vaccinated and non-vaccinated groups. Results: Overall, 5284 and 5755 people completed pre and post-vaccination questionnaires, respectively, in Kibera and Lwak. From pre-vaccination questionnaire results, among parents who were planning on vaccinating their children, 2219 (77.6%) in Kibera and 1780 (89.6%) in Lwak said the main reason was to protect the children from seasonal influenza. In the pre-vaccination discussions, no parent had heard of the seasonal influenza vaccine. At the end of the vaccine campaign, of 18,652 eligible children, 5,817 (31.2%) were fully vaccinated, 2,073 (11.1%) were partially vaccinated and, 10,762 (57.7%) were not vaccinated. In focus group discussions, parents who declined vaccine were concerned about vaccine safety or believed seasonal influenza illness was not severe enough to warrant vaccination. Parents who declined the vaccine were mainly too busy [251(25%) in Kibera and 95 (10.5%) in Lwak], or their child was away during the vaccination period [199(19.8%) in Kibera; 94(10.4%) in Lwak]. Conclusion: If influenza vaccine were to be introduced more broadly in Kenya, effective health messaging will be needed on vaccine side effects and frequency and potential severity of influenza infection. C1 [Oria, Prisca Adhiambo; Arunga, Geoffrey; Lebo, Emmaculate; Wong, Joshua M.; Emukule, Gideon; Otieno, Nancy; Breiman, Robert F.; Katz, Mark A.] Ctr Dis Control & Prevent KEMRI CDC, Kenya Med Res Inst, Nairobi, Kenya. [Katz, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Muthoka, Philip; Mutonga, David] Minist Publ Hlth & Sanitat, Nairobi, Kenya. RP Oria, PA (reprint author), Ctr Dis Control & Prevent KEMRI CDC, Kenya Med Res Inst, Nairobi, Kenya. EM oriahp@yahoo.com FU CDC FX We thank Beatrice Olack, Godfrey Bigogo, Rachel Ochola, Laura Hooper, Jackie Mwendwa, and Deborah Caselton for providing oversight. We thank Beryl Oyier and Hezron Ochieng' for collecting data. We thank Sanofi Pasteur for donating vaccine. We thank the participants. Finally, we thank CDC for funding this study. CDC had no role in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. NR 27 TC 7 Z9 7 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD APR 25 PY 2013 VL 13 AR 391 DI 10.1186/1471-2458-13-391 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 136OU UT WOS:000318372000001 PM 23617891 ER PT J AU Ali, MK Bullard, KM Saaddine, JB Cowie, CC Imperatore, G Gregg, EW AF Ali, Mohammed K. Bullard, Kai McKeever Saaddine, Jinan B. Cowie, Catherine C. Imperatore, Giuseppina Gregg, Edward W. TI Achievement of Goals in U.S. Diabetes Care, 1999-2010 SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID BLOOD-GLUCOSE CONTROL; CARDIOVASCULAR-DISEASE; PERFORMANCE-MEASURES; GLYCEMIC TARGETS; US ADULTS; FOLLOW-UP; TYPE-2; HEALTH; RISK; COMPLICATIONS AB Background Tracking national progress in diabetes care may aid in the evaluation of past efforts and identify residual gaps in care. Methods We analyzed data for adults with self-reported diabetes from the National Health and Nutrition Examination Survey and the Behavioral Risk Factor Surveillance System to examine risk-factor control, preventive practices, and risk scores for coronary heart disease over the 1999-2010 period. Results From 1999 through 2010, the weighted proportion of survey participants who met recommended goals for diabetes care increased, by 7.9 percentage points (95% confidence interval [CI], 0.8 to 15.0) for glycemic control (glycated hemoglobin level <7.0%), 9.4 percentage points (95% CI, 3.0 to 15.8) for individualized glycemic targets, 11.7 percentage points (95% CI, 5.7 to 17.7) for blood pressure (target, <130/80 mm Hg), and 20.8 percentage points (95% CI, 11.6 to 30.0) for lipid levels (target level of low-density lipoprotein [LDL] cholesterol, <100 mg per deciliter [2.6 mmol per liter]). Tobacco use did not change significantly, but the 10-year probability of coronary heart disease decreased by 2.8 to 3.7 percentage points. However, 33.4 to 48.7% of persons with diabetes still did not meet the targets for glycemic control, blood pressure, or LDL cholesterol level. Only 14.3% met the targets for all three of these measures and for tobacco use. Adherence to the recommendations for annual eye and dental examinations was unchanged, but annual lipid-level measurement and foot examination increased by 5.5 percentage points (95% CI, 1.6 to 9.4) and 6.8 percentage points (95% CI, 4.8 to 8.8), respectively. Annual vaccination for influenza and receipt of pneumococcal vaccination for participants 65 years of age or older rose by 4.5 percentage points (95% CI, 0.8 to 8.2) and 6.9 percentage points (95% CI, 3.4 to 10.4), respectively, and daily glucose monitoring increased by 12.7 percentage points (95% CI, 10.3 to 15.1). Conclusions Although there were improvements in risk-factor control and adherence to preventive practices from 1999 to 2010, tobacco use remained high, and almost half of U.S. adults with diabetes did not meet the recommended goals for diabetes care. C1 [Ali, Mohammed K.; Bullard, Kai McKeever; Saaddine, Jinan B.; Imperatore, Giuseppina; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Ali, Mohammed K.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Cowie, Catherine C.] NIDDK, NIH, Bethesda, MD USA. RP Ali, MK (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K10,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM ise1@cdc.gov NR 41 TC 254 Z9 260 U1 5 U2 38 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 25 PY 2013 VL 368 IS 17 BP 1613 EP 1624 DI 10.1056/NEJMsa1213829 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 130YK UT WOS:000317956300010 PM 23614587 ER PT J AU Belser, JA Szretter, KJ Katz, JM Tumpey, TM AF Belser, Jessica A. Szretter, Kristy J. Katz, Jacqueline M. Tumpey, Terrence M. TI Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice SO VIROLOGY LA English DT Article DE Simvastatin; Oseltamivir; H5N1; Influenza virus; Mice ID INDUCED LUNG INJURY; NEURAMINIDASE INHIBITORS; IN-VITRO; STATINS; MORTALITY; INFLAMMATION; PROTECTION; PNEUMONIA; SURVIVAL; MAMMALS AB Nonspecific anti-inflammatory drugs have been purported to reduce the burden of severe influenza disease. We demonstrate that, unlike oseltamivir administration, simvastatin administration did not reduce morbidity, mortality, or viral load of mice infected with H1N1 or H5N1 viruses. No added benefit to the efficacy of oseltamivir therapy was observed when mice were treated in combination with simvastatin. Modest reductions in lung cytokine production in H5N1 but not H1N1 virus-infected simvastatin-treated mice indicate a potential benefit for statin use in mitigating disease following severe virus infection. Published by Elsevier Inc. C1 [Belser, Jessica A.; Szretter, Kristy J.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Mail Stop G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tumpey@msn.com OI Szretter, Kristy/0000-0003-0391-2307 NR 32 TC 14 Z9 14 U1 0 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR 25 PY 2013 VL 439 IS 1 BP 42 EP 46 DI 10.1016/j.virol.2013.01.017 PG 5 WC Virology SC Virology GA 115SL UT WOS:000316832100005 PM 23453580 ER PT J AU Slutsker, L Kachur, SP AF Slutsker, Laurence Kachur, S. Patrick TI It is time to rethink tactics in the fight against malaria SO MALARIA JOURNAL LA English DT Editorial Material AB April 25 marks World Malaria Day, an opportunity for those who work to defeat the illness, to review progress and renew commitments. After a decade of steady success, this year's commemoration of the date is also an opportunity to reconsider current approaches and assess the state of the science needed to keep pace in the global effort to combat malaria. C1 [Slutsker, Laurence; Kachur, S. Patrick] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Kachur, SP (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd,MS A-06, Atlanta, GA 30333 USA. EM skachur@cdc.gov NR 0 TC 1 Z9 2 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 24 PY 2013 VL 12 AR 140 DI 10.1186/1475-2875-12-140 PG 2 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 137IB UT WOS:000318427900003 PM 23617700 ER PT J AU Kanny, D Liu, Y Brewer, RD Eke, PI Cox, SN Cheal, NE Green, Y AF Kanny, Dafna Liu, Yong Brewer, Robert D. Eke, Paul I. Cox, Shanna N. Cheal, Nancy E. Green, Yvonne TI Vital Signs: Binge Drinking Among Women and High School Girls-United States, 2011 (Reprinted from MMWR, vol 1, pg 9-13, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Kanny, Dafna; Liu, Yong; Brewer, Robert D.; Eke, Paul I.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Cox, Shanna N.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Cheal, Nancy E.] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Green, Yvonne] CDC, Off Womens Hlth, Atlanta, GA 30333 USA. RP Kanny, D (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM dkanny@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 24 PY 2013 VL 309 IS 16 BP 1675 EP 1677 DI 10.1001/jama.2013.355 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 130IG UT WOS:000317906700009 ER PT J AU Lovegrove, M Hampton, LM Budnitz, DS Geller, AI AF Lovegrove, Maribeth Hampton, Lee M. Budnitz, Daniel S. Geller, Andrew I. TI Notes From the Field: Emergency Department Visits and Hospitalizations for Buprenorphine Ingestion by Children-United States, 2010-2011 (Reprinted from MMWR, vol 3, pg 56, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Lovegrove, Maribeth; Hampton, Lee M.; Budnitz, Daniel S.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Geller, Andrew I.] CDC, EIS, Atlanta, GA 30333 USA. RP Geller, AI (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM wia0@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 24 PY 2013 VL 309 IS 16 BP 1677 EP 1678 DI 10.1001/jama.2013.975 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 130IG UT WOS:000317906700010 ER PT J AU Flegal, KM Kit, BK Graubard, BI AF Flegal, Katherine M. Kit, Brian K. Graubard, Barry I. TI Overweight, Obesity, and All-Cause Mortality Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID ILLNESS C1 [Flegal, Katherine M.; Kit, Brian K.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Graubard, Barry I.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM kmf2@cdc.gov OI Flegal, Katherine/0000-0002-0838-469X NR 4 TC 10 Z9 11 U1 0 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 24 PY 2013 VL 309 IS 16 BP 1681 EP 1682 DI 10.1001/jama.2013.3101 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 130IG UT WOS:000317906700016 PM 23613067 ER PT J AU Christensen, J Gronborg, TK Sorensen, MJ Schendel, D Parner, ET Pedersen, LH Vestergaard, M AF Christensen, Jakob Gronborg, Therese Koops Sorensen, Merete Juul Schendel, Diana Parner, Erik Thorlund Pedersen, Lars Henning Vestergaard, Mogens TI Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID BEHAVIORAL ALTERATIONS; ANTIEPILEPTIC DRUGS; ANIMAL-MODEL; ACID; CHILDREN; REGISTRATION; PREGNANCY; MALFORMATIONS; VALIDATION; EPILEPSY AB Importance Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential. However, prenatal exposure to valproate may increase the risk of autism. Objective To determine whether prenatal exposure to valproate is associated with an increased risk of autism in offspring. Design, Setting, and Participants Population-based study of all children born alive in Denmark from 1996 to 2006. National registers were used to identify children exposed to valproate during pregnancy and diagnosed with autism spectrum disorders (childhood autism [autistic disorder], Asperger syndrome, atypical autism, and other or unspecified pervasive developmental disorders). We analyzed the risks associated with all autism spectrum disorders as well as childhood autism. Data were analyzed by Cox regression adjusting for potential confounders (maternal age at conception, paternal age at conception, parental psychiatric history, gestational age, birth weight, sex, congenital malformations, and parity). Children were followed up from birth until the day of autism spectrum disorder diagnosis, death, emigration, or December 31, 2010, whichever came first. Main Outcomes and Measures Absolute risk (cumulative incidence) and the hazard ratio (HR) of autism spectrum disorder and childhood autism in children after exposure to valproate in pregnancy. Results Of 655 615 children born from 1996 through 2006, 5437 were identified with autism spectrum disorder, including 2067 with childhood autism. The mean age of the children at end of follow-up was 8.84 years (range, 4-14; median, 8.85). The estimated absolute risk after 14 years of follow-up was 1.53% (95% CI, 1.47%-1.58%) for autism spectrum disorder and 0.48% (95% CI, 0.46%-0.51%) for childhood autism. Overall, the 508 children exposed to valproate had an absolute risk of 4.42% (95% CI, 2.59%-7.46%) for autism spectrum disorder (adjusted HR, 2.9 [95% CI, 1.7-4.9]) and an absolute risk of 2.50% (95% CI, 1.30%-4.81%) for childhood autism (adjusted HR, 5.2 [95% CI, 2.7-10.0]). When restricting the cohort to the 6584 children born to women with epilepsy, the absolute risk of autism spectrum disorder among 432 children exposed to valproate was 4.15% (95% CI, 2.20%-7.81%) (adjusted HR, 1.7 [95% CI, 0.9-3.2]), and the absolute risk of childhood autism was 2.95% (95% CI, 1.42%-6.11%) (adjusted HR, 2.9 [95% CI, 1.4-6.0]) vs 2.44% (95% CI, 1.88%-3.16%) for autism spectrum disorder and 1.02% (95% CI, 0.70%-1.49%) for childhood autism among 6152 children not exposed to valproate. Conclusions and Relevance Maternal use of valproate during pregnancy was associated with a significantly increased risk of autism spectrum disorder and childhood autism in the offspring, even after adjusting for maternal epilepsy. For women of childbearing potential who use antiepileptic medications, these findings must be balanced against the treatment benefits for women who require valproate for epilepsy control. JAMA. 2013;309(16):1696-1703 www.jama.com C1 [Christensen, Jakob] Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus C, Denmark. [Christensen, Jakob] Aarhus Univ Hosp, Dept Clin Pharmacol, DK-8000 Aarhus C, Denmark. [Gronborg, Therese Koops; Parner, Erik Thorlund] Aarhus Univ, Inst Publ Hlth, Dept Biostat, Aarhus, Denmark. [Pedersen, Lars Henning] Aarhus Univ, Inst Publ Hlth, Dept Epidemiol, Aarhus, Denmark. [Pedersen, Lars Henning] Aarhus Univ, Inst Clin Med, Dept Obstet & Gynaecol, Aarhus, Denmark. [Vestergaard, Mogens] Aarhus Univ, Inst Publ Hlth, Res Unit, Aarhus, Denmark. [Vestergaard, Mogens] Aarhus Univ, Inst Publ Hlth, Sect Gen Practice, Aarhus, Denmark. [Sorensen, Merete Juul] Aarhus Univ Hosp, Reg Ctr Child & Adolescent Psychiat, Risskov, Denmark. [Schendel, Diana] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Christensen, J (reprint author), Aarhus Univ Hosp, Dept Neurol, Norrebrogade 44, DK-8000 Aarhus C, Denmark. EM jakob@farm.au.dk RI Vestergaard, Mogens/M-9333-2014 OI Vestergaard, Mogens/0000-0001-8830-2174 FU UCB Nordic; Danish Epilepsy Association; Danish Council for Independent Research; European Research Council (European Union) [260242]; Danish Medical Research Council [09-072986] FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Christensen reported receiving honoraria for serving on the scientific advisory boards of UCB Nordic and Eisai AB; receiving lecture honoraria from UCB Nordic and Eisai AB; and receiving travel funding from UCB Nordic. Dr Parner reported receiving grants from Autism Speaks and the National Institutes of Health. No other authors reported disclosures.; Dr Christensen receives research support from the Danish Epilepsy Association. Dr Pedersen is supported by a Sapere Aude-Postdoctoral grant from the Danish Council for Independent Research. This study was supported by grants from the European Research Council (the European Union Seventh Framework Programme, ERC-2010-StG No. 260242) and the Danish Medical Research Council (09-072986). NR 36 TC 179 Z9 188 U1 4 U2 43 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 24 PY 2013 VL 309 IS 16 BP 1696 EP 1703 DI 10.1001/jama.2013.2270 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 130IG UT WOS:000317906700026 PM 23613074 ER PT J AU Smith, RM Nguyen, TA Ha, HTT Thang, PH Thuy, C Lien, TX Bui, HT Le, TH Struminger, B McConnell, MS Fanfair, RN Park, BJ Harris, JR AF Smith, Rachel M. Tuan Anh Nguyen Hoang Thi Thanh Ha Pham Hong Thang Cao Thuy Truong Xuan Lien Bui, Hien T. Thai Hung Le Struminger, Bruce McConnell, Michelle S. Fanfair, Robyn Neblett Park, Benjamin J. Harris, Julie R. TI Prevalence of Cryptococcal Antigenemia and Cost-Effectiveness of a Cryptococcal Antigen Screening Program - Vietnam SO PLOS ONE LA English DT Article ID HIV-INFECTED PATIENTS; COMBINATION ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; CHI-MINH-CITY; OPPORTUNISTIC INFECTIONS; PHNOM-PENH; FUNGAL-INFECTIONS; CONTROLLED TRIAL; LIFE EXPECTANCY; SOUTH-AFRICA AB Background: An estimated 120,000 HIV-associated cryptococcal meningitis (CM) cases occur each year in South and Southeast Asia; early treatment may improve outcomes. The World Health Organization (WHO) recently recommended screening HIV-infected adults with CD4<100 cells/mm(3) for serum cryptococcal antigen (CrAg), a marker of early cryptococcal infection, in areas of high CrAg prevalence. We evaluated CrAg prevalence and cost-effectiveness of this screening strategy in HIV-infected adults in northern and southern Vietnam. Methods: Serum samples were collected and stored during 2009-2012 in Hanoi and Ho Chi Minh City, Vietnam, from HIV-infected, ART-naive patients presenting to care in 12 clinics. All specimens from patients with CD4<100 cells/mm(3) were tested using the CrAg lateral flow assay. We obtained cost estimates from laboratory staff, clinicians and hospital administrators in Vietnam, and evaluated cost-effectiveness using WHO guidelines. Results: Sera from 226 patients [104 (46%) from North Vietnam and 122 (54%) from the South] with CD4<100 cells/mm(3) were available for CrAg testing. Median CD4 count was 40 (range 0-99) cells/mm(3). Nine (4%; 95% CI 2-7%) specimens were CrAg-positive. CrAg prevalence was higher in South Vietnam (6%; 95% CI 3-11%) than in North Vietnam (2%; 95% CI 0-6%) (p = 0.18). Cost per life-year gained under a screening scenario was $190, $137, and $119 at CrAg prevalences of 2%, 4% and 6%, respectively. Conclusion: CrAg prevalence was higher in southern compared with northern Vietnam; however, CrAg screening would be considered cost-effective by WHO criteria in both regions. Public health officials in Vietnam should consider adding cryptococcal screening to existing national guidelines for HIV/AIDS care. C1 [Smith, Rachel M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30329 USA. [Smith, Rachel M.; Fanfair, Robyn Neblett; Park, Benjamin J.; Harris, Julie R.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Tuan Anh Nguyen; Hoang Thi Thanh Ha; Pham Hong Thang] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. [Cao Thuy] Natl Hosp Trop Dis, Hanoi, Vietnam. [Truong Xuan Lien] Inst Pasteur, Ho Chi Minh City, Vietnam. [Bui, Hien T.; Struminger, Bruce] Ctr Dis Control & Prevent, Div Global HIV AIDS, Hanoi, Vietnam. [Thai Hung Le; McConnell, Michelle S.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ho Chi Minh City, Vietnam. RP Smith, RM (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30329 USA. EM vih9@cdc.gov RI sebastianovitsch, stepan/G-8507-2013 FU PEPFAR/CDC FX Funding for this study came from PEPFAR/CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 14 Z9 14 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 23 PY 2013 VL 8 IS 4 AR e62213 DI 10.1371/journal.pone.0062213 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 131QH UT WOS:000318008400156 PM 23626792 ER PT J AU Asavapiriyanont, S Lolekha, R Roongpisuthipong, A Wiratchai, A Kaoiean, S Suksripanich, O Chalermchockcharoenkit, A Ausavapipit, J Srifeungfung, S Pattanasin, S Katz, KA AF Asavapiriyanont, Suvanna Lolekha, Rangsima Roongpisuthipong, Anuvat Wiratchai, Amornpan Kaoiean, Surasak Suksripanich, Orapin Chalermchockcharoenkit, Amphan Ausavapipit, Jaruensook Srifeungfung, Somporn Pattanasin, Sarika Katz, Kenneth A. TI Sexually transmitted infections among HIV-infected women in Thailand SO BMC PUBLIC HEALTH LA English DT Article DE HIV-infected women; STI prevalence; Number needed to screen; Chlamydia; Gonorrhea; Thailand ID CHLAMYDIA-TRACHOMATIS INFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS; PREGNANT-WOMEN; TRACT INFECTIONS; PREVALENCE; DISEASES; CARE; TRANSMISSION; GUIDELINES; MANAGEMENT AB Background: Data on sexually transmitted infections (STI) prevalence among HIV-infected women in Thailand are limited. We studied, among HIV-infected women, prevalence of STI symptoms and signs; prevalence and correlates of having any STI; prevalence and correlates of Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (GC) among women without CT and/or GC symptoms or signs; and number of women without CT and/or GC symptoms or signs needed to screen (NNS) to detect one woman with CT and/or GC overall, among pregnant women, and among women <= 25 years. Methods: During October 2004-September 2006, HIV-infected women at 3 obstetrics and gynecology clinics were asked about sexual behaviors and STI symptoms, physically examined, and screened for chlamydia, gonorrhea, trichomoniasis, and syphilis. Multivariate logistic regression was used to identify correlates of infections. NNS was calculated using standard methods. Results: Among 1,124 women, 526 (47.0%) had STI symptoms or signs, 469 (41.7%) had CT and/or GC symptoms or signs, and 133 (11.8%) had an STI. Correlates of having an STI included pregnancy and having STI signs. Among 469 women and 655 women with vs. without CT and/or GC symptoms or signs, respectively, 43 (9.2%) vs. 31 (4.7%), 2 (0.4%) vs. 9 (1.4%), and 45 (9.6%) vs. 38 (5.8%) had CT, GC, or "CT or GC", respectively; correlates included receiving care at university hospitals and having sex with a casual partner within 3 months. NNS for women overall and women <= 25 years old were 18 (95% CI, 13-25) and 11 (95% CI, 6-23), respectively; and for pregnant and non-pregnant women, 8 (95% CI, 4-24) and 19 (95% CI, 14-27), respectively. Conclusions: STI prevalence among HIV-infected women, including CT and GC among those without symptoms or signs, was substantial. Screening for CT and GC, particularly for pregnant women, should be considered. C1 [Asavapiriyanont, Suvanna; Kaoiean, Surasak] Rajavithi Hosp, Bangkok, Thailand. [Lolekha, Rangsima; Suksripanich, Orapin; Pattanasin, Sarika; Katz, Kenneth A.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [Roongpisuthipong, Anuvat; Chalermchockcharoenkit, Amphan; Srifeungfung, Somporn] Siriraj Hosp, Fac Med, Bangkok, Thailand. [Wiratchai, Amornpan; Ausavapipit, Jaruensook] Bamrasnaradura Infect Dis Inst, Nonthaburi, Thailand. [Katz, Kenneth A.] US Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. RP Lolekha, R (reprint author), US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. EM RangsimaL@th.cdc.gov OI chalermchockcharoenkit, amphan/0000-0001-5776-6988 FU President's Emergency Plans for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention FX This research has been supported by the President's Emergency Plans for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention under the terms of SR01 project. NR 28 TC 4 Z9 4 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD APR 22 PY 2013 VL 13 AR 373 DI 10.1186/1471-2458-13-373 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 145XM UT WOS:000319052900001 PM 23601556 ER PT J AU Nair, H Simoes, EAF Rudan, I Gessner, BD Azziz-Baumgartner, E Zhang, JSF Feikin, DR Mackenzie, GA Moisi, JC Roca, A Baggett, HC Zaman, SMA Singleton, RJ Lucero, MG Chandran, A Gentile, A Cohen, C Krishnan, A Bhutta, ZA Arguedas, A Clara, AW Andrade, AL Ope, M Ruvinsky, RO Hortal, M McCracken, JP Madhi, SA Bruce, N Qazi, SA Morris, SS El Arifeen, S Weber, MW Scott, JAG Brooks, WA Breiman, RF Campbell, H AF Nair, Harish Simoes, Eric A. F. Rudan, Igor Gessner, Bradford D. Azziz-Baumgartner, Eduardo Zhang, Jian Shayne F. Feikin, Daniel R. Mackenzie, Grant A. Moisi, Jennifer C. Roca, Anna Baggett, Henry C. Zaman, Syed M. A. Singleton, Rosalyn J. Lucero, Marilla G. Chandran, Aruna Gentile, Angela Cohen, Cheryl Krishnan, Anand Bhutta, Zulfiqar A. Arguedas, Adriano Clara, Alexey Wilfrido Andrade, Ana Lucia Ope, Maurice Ruvinsky, Raul Oscar Hortal, Maria McCracken, John P. Madhi, Shabir A. Bruce, Nigel Qazi, Shamim A. Morris, Saul S. El Arifeen, Shams Weber, Martin W. Scott, J. Anthony G. Brooks, W. Abdullah Breiman, Robert F. Campbell, Harry CA Severe Acute Lower Resp Infections TI Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis SO LANCET LA English DT Article ID INVASIVE PNEUMOCOCCAL DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; ALASKA NATIVE CHILDREN; AGED 2-59 MONTHS; TRACT INFECTIONS; CONJUGATE VACCINE; ORAL AMOXICILLIN; RURAL BANGLADESH; SYNCYTIAL VIRUS AB Background The annual number of hospital admissions and in-hospital deaths due to severe acute lower respiratory infections (ALRI) in young children worldwide is unknown. We aimed to estimate the incidence of admissions and deaths for such infections in children younger than 5 years in 2010. Methods We estimated the incidence of admissions for severe and very severe ALRI in children younger than 5 years, stratified by age and region, with data from a systematic review of studies published between Jan 1, 1990, and March 31, 2012, and from 28 unpublished population-based studies. We applied these incidence estimates to population estimates for 2010, to calculate the global and regional burden in children admitted with severe ALRI in that year. We estimated in-hospital mortality due to severe and very severe ALRI by combining incidence estimates with case fatality ratios from hospital-based studies. Findings We identified 89 eligible studies and estimated that in 2010, 11.9 million (95% CI 10.3-13.9 million) episodes of severe and 3.0 million (2.1-4.2 million) episodes of very severe ALRI resulted in hospital admissions in young children worldwide. Incidence was higher in boys than in girls, the sex disparity being greatest in South Asian studies. On the basis of data from 37 hospital studies reporting case fatality ratios for severe ALRI, we estimated that roughly 265 000 (95% CI 160 000-450 000) in-hospital deaths took place in young children, with 99% of these deaths in developing countries. Therefore, the data suggest that although 62% of children with severe ALRI are treated in hospitals, 81% of deaths happen outside hospitals. Interpretation Severe ALRI is a substantial burden on health services worldwide and a major cause of hospital referral and admission in young children. Improved hospital access and reduced inequities, such as those related to sex and rural status, could substantially decrease mortality related to such infection. Community-based management of severe disease could be an important complementary strategy to reduce pneumonia mortality and health inequities. C1 [Nair, Harish; Rudan, Igor; Campbell, Harry] Univ Edinburgh, Global Hlth Acad, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland. [Nair, Harish] Publ Hlth Fdn India, New Delhi, India. [Simoes, Eric A. F.] Univ Colorado Denver, Denver, CO USA. [Simoes, Eric A. F.] Childrens Hosp, Denver, CO 80218 USA. [Simoes, Eric A. F.] Padjadjaran State Univ, Bandung, Indonesia. [Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Zhang, Jian Shayne F.] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic 3010, Australia. [Feikin, Daniel R.; Breiman, Robert F.] Ctr Dis Control & Prevent, Nairobi, Kenya. [Feikin, Daniel R.; Chandran, Aruna] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Mackenzie, Grant A.; Zaman, Syed M. A.] Gambia Unit, MRC, Banjul, Gambia. [Moisi, Jennifer C.; Scott, J. Anthony G.] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya. [Roca, Anna] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain. [Roca, Anna] Minist Saude, Ctr Invest Saude Manhica, Maputo, Mozambique. [Baggett, Henry C.] Thailand MOPH US CDC Collaborat, Global Dis Detect Reg Ctr, Int Emerging Infect Program, Nonthaburi, Thailand. [Zaman, Syed M. A.] Hlth Protect Agcy, Hlth Protect Serv Colindale, London, England. [Singleton, Rosalyn J.] CDC, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Lucero, Marilla G.] Res Inst Trop Med, Dept Hlth, Alabang, Muntinlupa, Philippines. [Gentile, Angela] Ricardo Gutierrez Childrens Hosp, Buenos Aires, DF, Argentina. [Cohen, Cheryl; Madhi, Shabir A.] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Johannesburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa. [Krishnan, Anand] All India Inst Med Sci, Ctr Community Med, New Delhi, India. [Bhutta, Zulfiqar A.] Aga Khan Univ, Div Women & Child Hlth, Karachi, Pakistan. [Arguedas, Adriano] Univ Ciencias Med Ctr Amer, Inst Atenc Pediat, San Jose, Costa Rica. [Clara, Alexey Wilfrido] CDC Cent Amer Reg, Guatemala City, Guatemala. [Andrade, Ana Lucia] Univ Fed Goias, Goiania, Go, Brazil. [Ope, Maurice] East African Community Secretariat, Arusha, Tanzania. [Ruvinsky, Raul Oscar] Natl Univ Buenos Aires, Buenos Aires, DF, Argentina. [Hortal, Maria] Natl Univ PNUD, Program Basic Sci Dev, Montevideo, Uruguay. [McCracken, John P.] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Bruce, Nigel] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Qazi, Shamim A.] WHO, Dept Maternal Neonatal & Child & Adolescent Hlth, CH-1211 Geneva, Switzerland. [Morris, Saul S.] Bill & Melinda Gates Fdn, Seattle, WA USA. [El Arifeen, Shams; Brooks, W. Abdullah] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Weber, Martin W.] WHO, Indonesia Country Off, Jakarta, Indonesia. RP Nair, H (reprint author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland. EM harish.nair@ed.ac.uk RI Theodoratou, Evropi/C-3430-2014; Nair, Harish/E-7431-2010; Andrade, Ana Lucia/L-5751-2013; Rudan, Igor/I-1467-2012; OI Krishnan, Anand/0000-0002-9173-7811; Theodoratou, Evropi/0000-0001-5887-9132; Nair, Harish/0000-0002-9432-9100; Rudan, Igor/0000-0001-6993-6884; Hanlon, Peter/0000-0002-5828-3934; McAllister, David/0000-0003-3550-1764; Gupta, Vivek/0000-0002-6157-3705 FU WHO Global Influenza Program [HQGIP1002906]; GlaxoSmithKline (GSK); Wyeth; Pfizer; Sanofi Pasteur; Crucell; Merck; Novartis; Bill & Melinda Gates Foundation FX AA has received research grants, honoraria for participation in advisory boards, and travel grants from GlaxoSmithKline (GSK), Wyeth, and Pfizer. BDG works for Agence de Medecine Preventive, which receives unrestricted funding from Sanofi Pasteur, and has received grant support from Crucell, GSK, Merck, Pfizer, and Sanofi Pasteur. JAGS has received research funding from GSK and a travel grant from Merck. SAM has been a clinical trialist in studies of vaccines against pneumonia-causing pathogens from GSK, Pfizer, Sanofi-Aventis, Novartis, and Medimmune; his institution has received research grants from GSK, Pfizer, and Novartis; and he has been on the speaker's bureau of GSK, Pfizer, and Sanofi-Aventis, has received travel support and honoraria, and has acted on advisory boards of GSK, Pfizer, and Novartis. HNo is part of ARIVAC consortium that includes Sanofi Pasteur, undertook a phase 3 trial of an 11-valent pneumococcal conjugate vaccine (Sanofi Pasteur, Lyon, France) in the Philippines in 2002-04, and has received research funding from GSK. ALA has received research grant from GSK, financial support from Pfizer and GSK to attend meetings, and has served as an adviser to Pfizer. WAB has received funding from the Bill & Melinda Gates Foundation for vaccine-related work related to childhood pneumonia; donation of vaccine from Sanofi Pasteur for a vaccine trial against early childhood pneumonia; project funding from Sanofi Pasteur for pneumococcal vaccine trials and a study in pneumococcal pneumonia disease burden in young children; and has been on the speakers bureau for Sanofi Pasteur. SSM is an employee of the Bill & Melinda Gates Foundation. SAQ, AWM, and MWW are WHO staff members. All other authors declare that they have no conflicts of interest.; Financial support for this work was provided by WHO Global Influenza Program (Grant number HQGIP1002906). The findings and conclusions in this report are those of the authors and do not necessarily represent the policies of the United States Centers for Disease Control and Prevention or WHO. This work was done as part of the wider programme of the Child Health Epidemiology Working Group (CHERG) and Global Health Epidemiology Reference Group (GHERG) to establish the major causes of global childhood disease burden. Endang Sedyaningsih sadly died suddenly and unexpectedly while this paper was being prepared for publication. We would like to acknowledge her important contribution to this study and her role as a promoter of child health in Indonesia. We thank Johannes Forster (Department of Paediatrics, St Josefskrankenhaus Freiburg and University of Freiburg, Freiburg, Germany); Gabriele Ihorst (Clinical Trials Center, University Medical Center Freiburg, Freiburg, Germany); and Carlos G Grijalva (Vanderbilt University, US) for providing additional data from their published papers. We are grateful to Felicity Cutts (London School of Hygiene and Tropical Medicine, London, UK); Fatema Khatun, Peter Kim Streatfield, Sajal Kumar Saha, Kamrun Nahar, Amina Tahia Sharmeen, Anjali Bilkis Ara, Sultana Yeasmin (International Centre for Diarrhoeal Disease Research, Bangladesh); Leilani T Nillos (Research Institute for Tropical Medicine, Philippines); Elias Jimenez, Ana Laura Jimenez, Carolina Soley (Instituto de Atencion Pediatrica, Costa Rica); Ron Dagan, Nurith Porat (Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Guiron University of the Negav, Beer-Sheva, Israel); Gail Rodgers, Sharon Gray, Darmendra Ramcharran (Pfizer Inc. Collegeville, PA, USA); Uchendu Uchendu, David Ameh, Bolanle Akinsola, Readon Ideh, Bernard Ebruke, Debasish Saha, Momodou Jasseh (MRC Unit, The Gambia); Pedro L Alonso, Llorenc Quinto (Barcelona Centre for International Health Research (CRESIB, Hospital Clinic-Universitat de Barcelona) and Centro de Investigacao em Saude de Manhica, Mozambique); Maria Aparecida da Silva Vieira (Pontifical Catholic University of Goias, Goiania, Brazil); Renato Mauricio Oliveira (Federal University of Goias, Goiania, Brazil); Vicente Porfirio Pessoa-Jr (Secretariat of Health of Municipality of Goiania, Brazil); Simonne Nouer (UTHSC-Department of Preventive Medicine, Memphis, TN, USA); Licia Kamilla Assis Melo Thorn (Karolinska Institutet, Stockholm); Luiza Helena Ribeiro (Samaritano Hospital, Goiania, Brazil); Jose Cassio de Moraes (Santa Casa School of Medical Sciences, Sao Paulo, Brazil); David Rodriguez (Ministry of Health of El Salvador); Celina de Lozano (National Influenza Center of El Salvador); Kim A Lindblade, Jennifer Verani (US Centers for Disease Control and Prevention Regional Office for Central America and Panama, International Emerging Infections Program, Guatemala); Somsak Thamthitiwat, Sununta Henchaichon, Prabda Prapasiri, Sathapana Naorat (International Emerging Infections Program, Global Disease Detection Regional Center, Thailand Ministry of Public Health - U. S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand); Peera Areerat (Nakhon Phanom Provincial Health Office, Nakhon Phanom, Thailand); Asadang Ruayajin (Sa Kaeo Provincial Health Office, Sa Kaeo, Thailand) for their assistance.; The Indian Council for Medical Research (ICMR) led a multisite study with funding provided by the Hib Initiative; we thank the investigators at ICMR and the study sites of Christian Medical College, Vellore; Post Graduate Institute of Medical Education and Research, Chandigarh; and the National Institute of Cholera and Enteric Diseases, Kolkata. Costa Rica's LEAP study team thank all the physicians within the study area, in private practice, and from the Caja Costarricense de Seguro Social for referring their patients to participate in the active epidemiological surveillance. We thank the South African Severe Acute Respiratory Infections Surveillance Group, Wyeth-Pfizer, CNPq-Brazilian Council for Scientific Development and Technology, MRC Gambia Pneumococcal Surveillance Project and Severe Pneumonia Studies teams, MRC Gambia Basse Health and Demographic Surveillance System, Gambia Government, Basse Health Centre staff, the MRC Gambia Pneumococcal Vaccine Trial team for their assistance; Ana Ceballos, (CEDEPAP, Cordoba, Argentina), Jane Crawley (University of Oxford), and Olaf Muller (Ruprecht-Karls-University Heidelberg, Germany) for participating in the Working Group Meeting and providing valuable inputs; and Arti Nair (University of Edinburgh) for assistance with extracting data from the DHS and MICS databases. NR 79 TC 138 Z9 143 U1 6 U2 31 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD APR 20 PY 2013 VL 381 IS 9875 BP 1380 EP 1390 DI 10.1016/S0140-6736(12)61901-1 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 130EF UT WOS:000317894800035 PM 23369797 ER PT J AU Naumann, RB Beck, LF AF Naumann, Rebecca B. Beck, Laurie F. TI Motor Vehicle Traffic-Related Pedestrian Deaths - United States, 200-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Naumann, Rebecca B.; Beck, Laurie F.] CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. RP Beck, LF (reprint author), CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. EM lbeck@cdc.gov NR 10 TC 9 Z9 9 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 19 PY 2013 VL 62 IS 15 BP 277 EP 282 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FQ UT WOS:000322178400001 ER PT J AU Gilliss, D Cronquist, AB Cartter, M Tobin-D'Angelo, M Blythe, D Smith, K Lathrop, S Zansky, S Cieslak, PR Dunn, J Holt, KG Lance, S Crim, SM Henao, OL Patrick, M Griffin, PM Tauxe, RV AF Gilliss, Debra Cronquist, Alicia B. Cartter, Matthew Tobin-D'Angelo, Melissa Blythe, David Smith, Kirk Lathrop, Sarah Zansky, Shelley Cieslak, Paul R. Dunn, John Holt, Kristin G. Lance, Susan Crim, Stacy M. Henao, Olga L. Patrick, Mary Griffin, Patricia M. Tauxe, Robert V. TI Incidence and Trends of Infection with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 US Sites, 1996-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SPORADIC CAMPYLOBACTER INFECTION; UNITED-STATES; OYSTERS C1 [Gilliss, Debra] Calif Dept Publ Health, Atlanta, GA 30333 USA. [Lathrop, Sarah] Univ New Mexico, Albuquerque, NM 87131 USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY 12237 USA. [Crim, Stacy M.; Henao, Olga L.; Patrick, Mary; Griffin, Patricia M.; Tauxe, Robert V.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Crim, SM (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM scrim@cdc.gov NR 10 TC 101 Z9 101 U1 0 U2 9 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 19 PY 2013 VL 62 IS 15 BP 283 EP 287 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FQ UT WOS:000322178400002 ER PT J AU Clark, P Pringle, J Simeone, RM Gilboa, SM Honein, MA Oster, M Ailes, EC AF Clark, Pamela Pringle, Johanna Simeone, Regina M. Gilboa, Suzanne M. Honein, Margaret A. Oster, Matthew Ailes, Elizabeth C. TI Assessment of Current Practices and Feasibility of Routine Screening for Critical Congenital Heart Defects - Georgia, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PULSE OXIMETRY; DISEASE C1 [Ailes, Elizabeth C.] CDC, Atlanta, GA 30333 USA. RP Ailes, EC (reprint author), CDC, Atlanta, GA 30333 USA. EM eailes@cdc.gov NR 9 TC 9 Z9 9 U1 1 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 19 PY 2013 VL 62 IS 15 BP 288 EP 291 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FQ UT WOS:000322178400003 ER PT J AU Garg, LF Knapp, MM Beres, LM Braun, KVN Hinton, CF Cassell, CH Olney, RS Peterson, C Glidewell, J AF Garg, Lorraine F. Knapp, Mary M. Beres, Leslie M. Braun, Kim Van Naarden Hinton, Cynthia F. Cassell, Cynthia H. Olney, Richard S. Peterson, Cora Glidewell, Jill TI Rapid Implementation of Pulse Oximetry Newborn Screening to Detect Critical Congenital Heart Defects - New Jersey, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Glidewell, Jill] CDC, Atlanta, GA 30333 USA. RP Glidewell, J (reprint author), CDC, Atlanta, GA 30333 USA. EM mglidewell@cdc.gov OI Peterson, Cora/0000-0001-7955-0977 NR 4 TC 11 Z9 11 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 19 PY 2013 VL 62 IS 15 BP 292 EP 294 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FQ UT WOS:000322178400004 ER PT J AU Raczniak, GA Thomas, TK Bulkow, LR Negus, SE Zanis, CL Bruce, MG Spradling, PR Teshale, EH McMahon, BJ AF Raczniak, Gregory A. Thomas, Timothy K. Bulkow, Lisa R. Negus, Susan E. Zanis, Carolyn L. Bruce, Michael G. Spradling, Philip R. Teshale, Eyasu H. McMahon, Brian J. TI Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children SO VACCINE LA English DT Article DE Hepatitis A virus; Inactivated hepatitis A vaccine; RNA viruses; Enterovirus infections ID LONG-TERM PERSISTENCE; VIRUS-INFECTION; B-VACCINE; FOLLOW-UP; IMMUNOGENICITY; ALASKA; ADOLESCENTS; IMMUNIZATION; POPULATION; ANTIBODIES AB Background: Hepatitis A is mostly a self-limiting disease but causes substantial economic burden. Consequently, United States Advisory Committee for Immunization Practices recommends inactivated hepatitis A vaccination for all children beginning at age 1 year and for high risk adults. The hepatitis A vaccine is highly effective but the duration of protection is unknown. Methods: We examined the proportion of children with protective hepatitis A antibody levels (anti-HAV >= 20 mIU/mL) as well as the geometric mean concentration (GMC) of anti-HAV in a cross sectional convenience sample of individuals aged 12-24 years, who had been vaccinated with a two-dose schedule in childhood, with the initial dose at least 5 years ago. We compared a subset of data from persons vaccinated with two-doses (720 EL.U.) at age 3-6 years with a demographically similar prospective cohort that received a three-dose (360 EL.U.) schedule and have been followed for 17 years. Results: No significant differences were observed when comparing GMC between the two cohorts at 10 (P=0.467), 12 (P=0.496), and 14 (P=0.175) years post-immunization. For the three-dose cohort, protective antibody levels remain for 17 years and have leveled-off over the past 7 years. Conclusion: The two- and three-dose schedules provide similar protection >14 years after vaccination, indicating a booster dose is not needed at this time. Plateauing anti-HAV GMC levels suggest protective antibody levels may persist long-term. Published by Elsevier Ltd. C1 [Raczniak, Gregory A.; Bulkow, Lisa R.; Zanis, Carolyn L.; Bruce, Michael G.; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 99508 USA. [Raczniak, Gregory A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Thomas, Timothy K.] Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, Anchorage, AK 99508 USA. [Negus, Susan E.; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, Liver Dis & Hepatitis Program, Anchorage, AK 99508 USA. [Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA 30333 USA. RP Raczniak, GA (reprint author), Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM GRaczniak@cdc.gov FU Centers for Disease Control and Prevention [U50/CCU022279, U01PS001097] FX This work was supported by Centers for Disease Control and Prevention through a Cooperative Agreement Grant to the Alaska Native Tribal Health Consortium [U50/CCU022279 and U01PS001097]. NR 20 TC 9 Z9 9 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 19 PY 2013 VL 31 IS 17 BP 2152 EP 2155 DI 10.1016/j.vaccine.2013.02.048 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 135ZO UT WOS:000318329400008 PM 23470239 ER PT J AU Yoo, BK Humiston, SG Szilagyi, PG Schaffer, SJ Long, C Kolasa, M AF Yoo, Byung-Kwang Humiston, Sharon G. Szilagyi, Peter G. Schaffer, Stanley J. Long, Christine Kolasa, Maureen TI Cost effectiveness analysis of elementary school-located vaccination against influenza-Results from a randomized controlled trial SO VACCINE LA English DT Article DE Cost analysis; Cost effectiveness analysis; School-located vaccination against influenza; Randomized controlled trial ID SEASONAL INFLUENZA; AGED CHILDREN; BURDEN; BENEFITS; US AB School-located vaccination against influenza (SLV-I) has been suggested to help meet the need for annual vaccination of large numbers of school-aged children with seasonal influenza vaccine. However, little is known about the cost and cost-effectiveness of SLV-I. We conducted a cost-analysis and a cost-effectiveness analysis based on a randomized controlled trial (RCT) of an SLV-I program implemented in Monroe County, New York during the 2009-2010 vaccination season. We hypothesized that SLV-I is more cost effective, or less-costly, compared to a conventional, office-located influenza vaccination delivery. First and second SLV-I clinics were offered in 21 intervention elementary schools (n = 9027 children) with standard of care (no SLV-I) in 11 control schools (n = 4534 children). The direct costs, to purchase and administer vaccines, were estimated from our RCT. The effectiveness measure, receipt of >= 1 dose of influenza vaccine, was 13.2 percentage points higher in SLV-I schools than control schools. The school costs ($9.16/dose in 2009 dollars) plus project costs ($23.00/dose) plus vendor costs excluding vaccine purchase ($19.89/dose) was higher in direct costs ($52.05/dose) than the previously reported mean/median cost [$38.23/$21.44 per dose] for providing influenza vaccination in pediatric practices. However SLV-I averted parent costs to visit medical practices ($35.08 per vaccine). Combining direct and averted costs through Monte Carlo Simulation, SLV-I costs were $19.26/dose in net costs, which is below practice-based influenza vaccination costs. The incremental cost-effectiveness ratio (ICER) was estimated to be $92.50 or $38.59 (also including averted parent costs). When additionally accounting for the costs averted by disease prevention (i.e., both reduced disease transmission to household members and reduced loss of productivity from caring for a sick child), the SLV-I model appears to be cost-saving to society, compared to "no vaccination". Our findings support the expanded implementation of SLV-I, but also the need to focus on efficient delivery to reduce direct costs. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Yoo, Byung-Kwang] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Humiston, Sharon G.] Childrens Mercy Hosp & Clin, Dept Pediat, Kansas City, MO USA. [Szilagyi, Peter G.; Schaffer, Stanley J.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Long, Christine] Univ Rochester, Ctr Community Hlth, Rochester, NY USA. [Kolasa, Maureen] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Yoo, BK (reprint author), Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, 1 Shields Ave, Davis, CA 95616 USA. EM byoo@ucdavis.edu OI Schaffer, Stanley/0000-0001-7993-1374 FU Centers for Disease Control and Prevention [U01IP000195]; National Institute of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) [1K25AI073915] FX The authors wish to thank Dr. Andrew Doniger, William Russell, Tahleah Chappel, Kim DiMattia, Jill Szydlowski, and Aaron Blumkin. We also are grateful to the many school personnel who helped implement the SLV-I program.Note: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, US Department of Health and Human Services.Financial disclosure and conflict of interest: Supported by the Centers for Disease Control and Prevention, Grant #: U01IP000195 "School-Based Influenza Immunization Program"; Dr. Byung-Kwang Yoo is also supported by National Institute of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID), Mentored Quantitative Research Development Award (K25), Grant #: 1K25AI073915; "Effects of Individual Behavioral Responses on Benefits of Influenza Vaccination" NR 28 TC 7 Z9 7 U1 2 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 19 PY 2013 VL 31 IS 17 BP 2156 EP 2164 DI 10.1016/j.vaccine.2013.02.052 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 135ZO UT WOS:000318329400009 PM 23499607 ER PT J AU Fairbrother, G Donauer, S Staat, MA Broder, K Salisbury, S Morrow, AL Tabangin, ME Altaye, M Holloway, M Schwartz, B AF Fairbrother, Gerry Donauer, Stephanie Staat, Mary Allen Broder, Karen Salisbury, Shelia Morrow, Ardythe L. Tabangin, Meredith E. Altaye, Mekibib Holloway, Michol Schwartz, Benjamin TI Cincinnati pediatricians' measured and reported immunizing behavior for children during the national shortages of pneumococcal conjugate vaccine SO VACCINE LA English DT Article DE Heptavalent pneumococcal conjugate vaccine; Vaccine shortage ID RESPONSE RATES; RECOMMENDATIONS; IMMUNIZATIONS; KNOWLEDGE; PROVIDERS; DISEASE AB Background: The United States has experienced two shortages of heptavalent pneumococcal conjugate vaccine (PCV7). National guidelines called for deferring the third and fourth PCV7 doses from healthy children during these shortages. However, recommendations were not the same during the first and second shortages, and recommendations changed over time during each of the shortages as shortages worsened. Objectives: To measure PCV7 immunizing behavior for healthy children during shortage and non-shortage periods and assess the accuracy of the physicians' reported immunizing behavior when compared to their actual immunizing behavior. Methods: We reviewed medical records in 14 randomly selected practices to measure actual immunizing behavior during shortage and non-shortage periods. We surveyed pediatricians in the Greater Cincinnati area to ascertain reported immunizing behavior. Actual and reported immunizing behaviors were compared. Results: 2888 medical records were reviewed; surveys were obtained from 51 pediatricians (65% response rate). During periods of non-shortage, 74% of healthy children received their first two doses of PCV7 on time, whereas during periods of shortage, only 66% of healthy children received their first two doses of PCV7 on time. Compared with measured immunizing behavior from chart reviews, 54-76% of the pediatricians overestimated their compliance with guidelines to defer the fourth PCV7 dose while only 5-20% underestimated their compliance. Conclusions: Physicians often overestimated the percentage of children whose vaccine doses they deferred during vaccine shortages. Despite these findings, physicians were able to maintain high coverage with the first two PCV7 doses among healthy children. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Fairbrother, Gerry] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, James M Anderson Ctr Hlth Syst Excellence, Acad Hlth, Cincinnati, OH 45221 USA. [Donauer, Stephanie] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. [Staat, Mary Allen] Univ Cincinnati, Div Infect Dis, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA. [Broder, Karen] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Salisbury, Shelia; Tabangin, Meredith E.; Altaye, Mekibib] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45221 USA. [Morrow, Ardythe L.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Neonatol & Pulm Biol, Cincinnati, OH 45221 USA. [Holloway, Michol] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. RP Donauer, S (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. EM stephanie.donauer@cchmc.org RI Altaye, Mekibib/N-5274-2015 FU Centers for Disease Control New Vaccine Surveillance Network project [U38/CCU522352001] FX This work was funded by the Centers for Disease Control New Vaccine Surveillance Network project (U38/CCU522352001). NR 35 TC 1 Z9 1 U1 0 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 19 PY 2013 VL 31 IS 17 BP 2177 EP 2183 DI 10.1016/j.vaccine.2013.02.038 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 135ZO UT WOS:000318329400012 PM 23474316 ER PT J AU Ioannidis, JPA Khoury, MJ AF Ioannidis, John P. A. Khoury, Muin J. TI Are randomized trials obsolete or more important than ever in the genomic era? SO GENOME MEDICINE LA English DT Editorial Material ID CLINICAL-TRIAL; MEDICINE; DESIGN C1 [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Humanities & Sci, Dept Stat, Stanford, CA 94305 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Rockville, MD 20892 USA. RP Ioannidis, JPA (reprint author), Stanford Univ, Sch Med, Dept Med, Stanford Prevent Res Ctr, 1265 Welch Rd,MSOB X306, Stanford, CA 94305 USA. EM jioannid@stanford.edu NR 8 TC 14 Z9 14 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PD APR 18 PY 2013 VL 5 AR 32 DI 10.1186/gm436 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA 143ZA UT WOS:000318907000001 PM 23673134 ER PT J AU Chan, M Lake, A Fauci, A Berkley, S Phumaphi, J Elias, C Alonso, P de Quadros, C Bates, N Bhutta, Z Dare, L Evans, H Hall, L John, TJ Okwo-Bele, JM Levine, O Salisbury, D Schuchat, A Singer, PA Slamet, L Tambini, G Vandelaer, J Wrobel, S AF Chan, Margaret Lake, Anthony Fauci, Anthony Berkley, Seth Phumaphi, Joy Elias, Christopher Alonso, Pedro de Quadros, Ciro Bates, Nicole Bhutta, Zulfiqar Dare, Lola Evans, Helen Hall, Lee John, T. Jacob Okwo-Bele, Jean-Marie Levine, Orin Salisbury, David Schuchat, Anne Singer, Peter A. Slamet, Lucky Tambini, Gina Vandelaer, Jos Wrobel, Sandy CA Decade Vaccine Collaboration TI Global Vaccine Action Plan SO VACCINE LA English DT Editorial Material C1 [Chan, Margaret] World Hlth Org, Geneva, Switzerland. [Lake, Anthony] UNICEF, New York, NY USA. [Fauci, Anthony; Hall, Lee] NIAID, Bethesda, MD 20892 USA. [Berkley, Seth; Evans, Helen] GAVI Alliance, Geneva, Switzerland. [Phumaphi, Joy] African Leaders Malaria Alliance, Geneva, Switzerland. [Alonso, Pedro] Barcelona Inst Global Hlth, DoVC Steering Comm, Barcelona, Spain. [de Quadros, Ciro] Sabin Vaccine Inst, DoVC Steering Comm, Washington, DC USA. [John, T. Jacob] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Okwo-Bele, Jean-Marie] World Hlth Org, Delivery Working Grp, Geneva, Switzerland. [Levine, Orin] Johns Hopkins Bloomberg Sch Publ Hlth, Global Access Working Grp, Baltimore, MD USA. [Schuchat, Anne] US Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Singer, Peter A.] Univ Hlth Network, Sandra Rotman Ctr, Publ & Polit Support Working Grp, Toronto, ON, Canada. [Singer, Peter A.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Vandelaer, Jos] UNICEF, Delivery Working Grp, New York, NY USA. RP Chan, M (reprint author), World Hlth Org, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 2 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 18 PY 2013 VL 31 SU 2 BP B5 EP B31 DI 10.1016/j.vaccine.2013.02.015 PG 27 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 137TV UT WOS:000318462000003 ER PT J AU Griffiths, P Plotkin, S Mocarski, E Pass, R Schleiss, M Krause, P Bialek, S AF Griffiths, Paul Plotkin, Stanley Mocarski, Edward Pass, Robert Schleiss, Mark Krause, Philip Bialek, Stephanie TI Desirability and feasibility of a vaccine against cytomegalovirus SO VACCINE LA English DT Review DE Vaccine; Prevention; Reinfection; Burden of disease; Hearing loss; Clinical trials ID PLACEBO-CONTROLLED TRIAL; GLYCOPROTEIN-B VACCINE; CD8(+) T-CELLS; VIRUS-INFECTION; IMMUNOCOMPROMISED HOSTS; ANTIRETROVIRAL THERAPY; TRANSPLANT RECIPIENTS; LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; ELDERLY INDIVIDUALS AB Publication of a report from the Institute of Medicine in 2000 showing that a vaccine against cytomegalovirus (CMV) would likely be cost saving was very influential and encouraged the clinical evaluation of candidate vaccines. The major objective of a CMV vaccination program would be to reduce disease caused by congenital CMV infection, which is the leading viral cause of sensorineural hearing loss and neurodevelopmental delay. CMV has challenges as a vaccine target because it is a herpesvirus, it persists lifelong despite host immunity, infected individuals can be reinfected with new strains, overt disease occurs in those with immature or impaired immune systems and persons with this infection do not usually report symptoms. Nevertheless, natural immunity against CMV provides some protection against infection and disease, natural history studies have defined the serological and molecular biological techniques needed for endpoints in future clinical trials of vaccines and CMV is not highly communicable, suggesting that it may not be necessary to achieve very high levels of population immunity through vaccination in order to affect transmission. Three phase 2 CMV vaccine studies have been completed in the last 3 years and all report encouraging outcomes. A key international meeting was organized by the Food and Drug Administration in January 2012 at which interested parties from regulatory bodies, industry and academia discussed and prioritised designs for phase 2 and phase 3 clinical trials. Vaccines able to prevent primary infection with CMV and to boost the immune response of those already infected are desirable. The major target populations for a CMV vaccine include women of childbearing age and adolescents. Toddlers represent another potential population, since an effect of vaccine in this age group could potentially decrease transmission to adults. In addition, prospective recipients of transplants and patients with AIDS would be expected to benefit. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Griffiths, Paul] UCL, London, England. [Plotkin, Stanley] Univ Penn, Philadelphia, PA 19104 USA. [Mocarski, Edward] Emory Univ, Atlanta, GA 30322 USA. [Pass, Robert] Univ Alabama Birmingham, Birmingham, AL USA. [Schleiss, Mark] Univ Minnesota, Minneapolis, MN 55455 USA. [Krause, Philip] US FDA, Washington, DC 20204 USA. [Bialek, Stephanie] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Griffiths, P (reprint author), UCL Med Sch, Ctr Virol, Rowland Hill St, London NW3 2PF, England. EM p.griffiths@ucl.ac.uk OI Krause, Philip/0000-0002-1045-7536 FU Wellcome Trust [078332]; MedImmune, LLC FX Work in the authors' laboratories is supported by the following grants: Wellcome Trust 078332.; EM is a paid consultant in the area of CMV vaccines for MedImmune, LLC. All other authors declare that they have no personal conflicts of interest. NR 70 TC 46 Z9 49 U1 1 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 18 PY 2013 VL 31 SU 2 BP B197 EP B203 DI 10.1016/j.vaccine.2012.10.074 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 137TV UT WOS:000318462000023 PM 23598482 ER PT J AU Lee, LA Franzel, L Atwell, J Datta, SD Friberg, IK Goldie, SJ Reef, SE Schwalbe, N Simons, E Strebel, PM Sweet, S Suraratdecha, C Tam, Y Vynnycky, E Walker, N Walker, DG Hansen, PM AF Lee, Lisa A. Franzel, Lauren Atwell, Jessica Datta, S. Deblina Friberg, Ingrid K. Goldie, Sue J. Reef, Susan E. Schwalbe, Nina Simons, Emily Strebel, Peter M. Sweet, Steven Suraratdecha, Chutima Tam, Yvonne Vynnycky, Emilia Walker, Neff Walker, Damian G. Hansen, Peter M. TI The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance SO VACCINE LA English DT Review DE Immunization; Mortality; Impact; Developing countries ID INFLUENZAE TYPE-B; CONGENITAL-RUBELLA-SYNDROME; COST-EFFECTIVENESS ANALYSIS; CERVICAL-CANCER PREVENTION; JAPANESE ENCEPHALITIS; ROTAVIRUS VACCINATION; CHILD-MORTALITY; BACTERIAL-MENINGITIS; MATHEMATICAL-MODELS; SYSTEMATIC ANALYSIS AB Introduction: From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. Methods: The number of deaths averted in persons projected to be vaccinated during 2011-2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese encephalitis, human papillomavirus, measles, and rubella. Impact was calculated as the difference in the number of deaths expected over the lifetime of vaccinated cohorts compared to the number of deaths expected in those cohorts with no vaccination. Numbers of persons vaccinated were based on 2011 GAVI Strategic Demand Forecasts with projected dates of vaccine introductions, vaccination coverage, and target population size in each country. Results: By 2020, nearly all GAVI-supported countries with endemic disease are projected to have introduced hepatitis B, Hib, pneumococcal, rotavirus, rubella, yellow fever, N. meningitidis serogroup A, and Japanese encephalitis-containing vaccines; 55 (75 percent) countries are projected to have introduced human papillomavirus vaccine. Projected use of these vaccines during 2011-2020 is expected to avert an estimated 9.9 million deaths. Routine and supplementary immunization activities with measles vaccine are expected to avert an additional 13.4 million deaths. Estimated numbers of deaths averted per 1000 persons vaccinated were highest for first-dose measles (16.5), human papillomavirus (15.1), and hepatitis B (8.3) vaccination. Approximately 52 percent of the expected deaths averted will be in Africa, 27 percent in Southeast Asia, and 13 percent in the Eastern Mediterranean. Conclusion: Vaccination of persons during 2011-2020 in 73 GAVI-eligible countries is expected to have substantial public health impact, particularly in Africa and Southeast Asia, two regions with high mortality. The actual impact of vaccination in these countries may be higher than our estimates because several widely used antigens were not included in the analysis. The quality of our estimates is limited by lack of data on underlying disease burden and vaccine effectiveness against fatal disease outcomes in developing countries. We plan to update the estimates annually to reflect updated demand forecasts, to refine model assumptions based on results of new information, and to extend the analysis to include morbidity and economic benefits. (C) 2013 Published by Elsevier Ltd. C1 [Franzel, Lauren; Suraratdecha, Chutima] PATH, Seattle, WA USA. [Atwell, Jessica; Friberg, Ingrid K.; Tam, Yvonne; Walker, Neff] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Bethesda, MD USA. [Datta, S. Deblina; Schwalbe, Nina; Hansen, Peter M.] GAVI Alliance, CH-1202 Geneva, Switzerland. [Goldie, Sue J.] Harvard Univ, Harvard Global Hlth Inst, Cambridge, MA 02138 USA. [Goldie, Sue J.; Sweet, Steven] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Reef, Susan E.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Simons, Emily; Strebel, Peter M.] World Hlth Org, Dept Immunizat Vaccines & Biol, Geneva, Switzerland. [Vynnycky, Emilia] Hlth Protect Agcy Ctr Infect, Modelling & Econ Unit, London, England. [Walker, Damian G.] Bill & Melinda Gates Fdn, Seattle, WA USA. RP Hansen, PM (reprint author), GAVI Alliance, 2 Chemin Mines, CH-1202 Geneva, Switzerland. EM phansen@gavialliance.org NR 81 TC 26 Z9 26 U1 2 U2 30 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 18 PY 2013 VL 31 SU 2 BP B61 EP B72 DI 10.1016/j.vaccine.2012.11.035 PG 12 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 137TV UT WOS:000318462000007 PM 23598494 ER PT J AU Thompson, KM Strebel, PM Dabbagh, A Cherian, T Cochi, SL AF Thompson, Kimberly M. Strebel, Peter M. Dabbagh, Alya Cherian, Thomas Cochi, Stephen L. TI Enabling implementation of the Global Vaccine Action Plan: Developing investment cases to achieve targets for measles and rubella prevention SO VACCINE LA English DT Review DE Global Vaccine Action Plan; Measles; Rubella; Economic analysis; Coordination ID UNITED-STATES; COST-EFFECTIVENESS; INFECTIOUS-DISEASES; ECONOMIC-EVALUATION; CHILDRENS VACCINES; POLIO VACCINATION; HERD-IMMUNITY; ERADICATION; ELIMINATION; IMPACT AB Global prevention and control of infectious diseases requires significant investment of financial and human resources and well-functioning leadership and management structures. The reality of competing demands for limited resources leads to trade-offs and questions about the relative value of specific investments. Developing investment cases can help to provide stakeholders with information about the benefits, costs, and risks associated with available options, including examination of social, political, governance, and ethical issues. We describe the process of developing investment cases for globally coordinated management of action plans for measles and rubella as tools for enabling the implementation of the Global Vaccine Action Plan (GVAP). We focus on considerations related to the timing of efforts to achieve measles and rubella goals independently and within the context of ongoing polio eradication efforts, other immunization priorities, and other efforts to control communicable diseases or child survival initiatives. Our analysis suggests that the interactions between the availability and sustainability of financial support, sufficient supplies of vaccines, capacity of vaccine delivery systems, and commitments at all levels will impact the feasibility and timing of achieving national, regional, and global goals. The timing of investments and achievements will determine the net financial and health benefits obtained. The methodology, framing, and assumptions used to characterize net benefits and uncertainties in the investment cases will impact estimates and perceptions about the value of prevention achieved overall by the GVAP. We suggest that appropriately valuing the benefits of investments of measles and rubella prevention will require the use of integrated dynamic disease, economic, risk, and decision analytic models in combination with consideration of qualitative factors, and that synthesizing information in the form of investment cases may help stakeholders manage expectations as they chart the course ahead and navigate the decade of vaccines. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Thompson, Kimberly M.] Univ Cent Florida, Coll Med, Orlando, FL 32827 USA. [Strebel, Peter M.; Dabbagh, Alya; Cherian, Thomas] World Hlth Org, Geneva, Switzerland. [Cochi, Stephen L.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Thompson, KM (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Suite 204-364, Orlando, FL 32832 USA. EM kimt@kidrisk.org FU World Health Organization [PO 200470477 APW]; US Centers for Disease Control [U66IP000519-01] FX KMT acknowledges support for this work from the World Health Organization under Contract PO 200470477 APW and the US Centers for Disease Control under Contract U66IP000519-01. The contents of this article are solely the responsibility of the authors and do not represent the official views of the World Health Organization or the US Centers for Disease Control and Prevention. NR 57 TC 5 Z9 5 U1 1 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 18 PY 2013 VL 31 SU 2 BP B149 EP B156 DI 10.1016/j.vaccine.2012.11.091 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 137TV UT WOS:000318462000017 PM 23598476 ER PT J AU Wang, SA Hyde, TB Mounier-Jack, S Brenzel, L Favin, M Gordon, WS Shearer, JC Mantel, CF Arora, N Durrheim, D AF Wang, Susan A. Hyde, Terri B. Mounier-Jack, Sandra Brenzel, Logan Favin, Michael Gordon, W. Scott Shearer, Jessica C. Mantel, Carsten F. Arora, Narendra Durrheim, David TI New vaccine introductions: Assessing the impact and the opportunities for immunization and health systems strengthening SO VACCINE LA English DT Review DE Vaccine introduction; Health systems; Immunization programmes; Health planning; Systems integration; Human resources ID FUND-SUPPORTED PROGRAMS AB In 2010, global immunization partners posed the question, "Do new vaccine introductions (NVIs) have positive or negative impacts on immunization and health systems of countries?" An Ad-hoc Working Group was formed for WHO's Strategic Advisory Group of Experts on immunization (SAGE) to examine this question through five approaches: a published literature review, a grey literature review, in-depth interviews with regional and country immunization staff, in-depth studies of recent NVIs in 3 countries, and a statistical analysis of the impact of NVI on DTP3 coverage in 176 countries. The WHO Health System Framework of building blocks was used to organize the analysis of these data to assess potential areas of impact of NVI on health systems. In April 2012, the Ad-hoc Working Group presented its findings to SAGE. While reductions in disease burden and improvements in disease and adverse events surveillance, training, cold chain and logistics capacity and injection safety were commonly documented as beneficial impacts, opportunities for strengthening the broader health system were consistently missed during NVI. Weaknesses in planning for human and financial resource needs were highlighted as a concern. Where positive impacts on health systems following NVI occurred, these were often in areas where detailed technical guidance or tools and adequate financing were available. SAGE supported the Ad-hoc Working Group's conclusion that future NVI should explicitly plan to optimize and document the impact of NVI on broader health systems. Furthermore, opportunities for improving integration of delivery of immunization services, commodities, and messages with other parts of the health system should be actively sought with the recognition that integration is a bidirectional process. To avoid the gaps in planning for NVI that can compromise existing immunization and health systems, donors and partners should provide sufficient and timely support to facilitate country planning. Areas for future research were also identified. Finally, to support countries in using NVI as an opportunity to strengthen immunization and health systems, the WHO guidance for countries on new vaccine introduction is being updated to reflect ways this might be accomplished. Published by Elsevier Ltd. C1 [Wang, Susan A.; Mantel, Carsten F.] World Hlth Org, CH-1204 Geneva, Switzerland. [Hyde, Terri B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Mounier-Jack, Sandra] London Sch Hyg & Trop Med, London WC1H 9SH, England. [Brenzel, Logan] Cascadia Hlth & Dev, Cascade, Port Of Spain, Trinid & Tobago. [Favin, Michael] MCHIP, Washington, DC 20036 USA. [Gordon, W. Scott] PATH, Seattle, WA 98109 USA. [Shearer, Jessica C.] McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada. [Arora, Narendra] INCLEN Trust Int, New Delhi 110020, India. [Arora, Narendra] CHNRI, Okhla Ind Area, New Delhi 110020, India. [Durrheim, David] Hunter Med Res Inst, Wallsend 2287, Australia. RP Wang, SA (reprint author), World Hlth Org, Expanded Programme Immunizat, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM wangsu@who.int; thyde@cdc.gov; Sandra.Mounier-Jack@lshtm.ac.uk; loganbrenzel@gmail.com; mfavin@manoffgroup.com; sgordon@path.org; shearejc@mcmaster.ca; mantelc@who.int; nkarora@inclentrust.org; David.Durrheim@newcastle.edu.au FU Intramural CDC HHS [CC999999] NR 13 TC 13 Z9 13 U1 1 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 18 PY 2013 VL 31 SU 2 BP B122 EP B128 DI 10.1016/j.vaccine.2012.10.116 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 137TV UT WOS:000318462000014 PM 23598473 ER PT J AU Engelman, D Martin, DL Hay, RJ Chosidow, O McCarthy, JS Fuller, LC Steer, AC AF Engelman, Daniel Martin, Diana L. Hay, Roderick J. Chosidow, Olivier McCarthy, James S. Fuller, L. Claire Steer, Andrew C. TI Opportunities to investigate the effects of ivermectin mass drug administration on scabies SO PARASITES & VECTORS LA English DT Letter DE Scabies; Ivermectin; Mass drug administration; Neglected tropical disease AB The recent article by Mohammed et al. demonstrates an impressive effect of ivermectin mass drug administration for lymphatic filariasis on the burden of scabies. Partnering scabies research within the evaluation and monitoring of Neglected Tropical Disease programmes could potentially increase our understanding of the epidemiology and control of scabies and its important bacterial complications. C1 [Engelman, Daniel; Steer, Andrew C.] Univ Melbourne, Ctr Int Child Hlth, Royal Childrens Hosp Melbourne, Melbourne, Vic 3052, Australia. [Martin, Diana L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hay, Roderick J.] Int Fdn Dermatol, London, England. [Chosidow, Olivier] Univ Paris 12, Hop Henri Mondor, AP HP, Dept Dermatol, F-94010 Creteil, France. [McCarthy, James S.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. [Fuller, L. Claire] Chelsea & Westminster Hosp, London, England. [Steer, Andrew C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. RP Steer, AC (reprint author), Univ Melbourne, Ctr Int Child Hlth, Royal Childrens Hosp Melbourne, Flemington Rd, Melbourne, Vic 3052, Australia. EM Andrew.Steer@rch.org.au OI Engelman, Daniel/0000-0002-4909-1287 NR 4 TC 5 Z9 6 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD APR 17 PY 2013 VL 6 AR 106 DI 10.1186/1756-3305-6-106 PG 2 WC Parasitology SC Parasitology GA 140HL UT WOS:000318645000001 PM 23594459 ER PT J AU Ali, MK Rabadan-Diehl, C Flanigan, J Blanchard, C Narayan, KMV Engelgau, M AF Ali, Mohammed K. Rabadan-Diehl, Cristina Flanigan, John Blanchard, Claire Narayan, K. M. Venkat Engelgau, Michael TI Systems and Capacity to Address Noncommunicable Diseases in Low- and Middle-Income Countries SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID GLOBAL BURDEN; CERVICAL-CANCER; HEALTH; BREAST AB Noncommunicable diseases (NCDs) are increasingly getting attention from different forums, including media outlets, health agencies, and the public and private sectors. Progress is being made in addressing NCDs, though more slowly in low-and middle-income countries (LMICs) as compared with high-income settings. Here, we of er an analysis of the challenges faced in LMICs. We discuss realistic strategies to understand and develop capacity needs (workforce, finances, and infrastructure) and systems (institutions and processes) to sustainably optimize NCD prevention and care in LMICs. C1 [Ali, Mohammed K.; Narayan, K. M. Venkat] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Rabadan-Diehl, Cristina] NHLBI, NIH, Bethesda, MD 20824 USA. [Flanigan, John] NCI, NIH, Bethesda, MD 20814 USA. [Blanchard, Claire] Int Union Hlth Promot & Educ, F-93203 St Denis, France. [Engelgau, Michael] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ali, MK (reprint author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM mkali@emory.edu RI Narayan, K.M. Venkat /J-9819-2012 OI Narayan, K.M. Venkat /0000-0001-8621-5405 NR 31 TC 12 Z9 12 U1 3 U2 13 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD APR 17 PY 2013 VL 5 IS 181 AR 181cm4 DI 10.1126/scitranslmed.3005121 PG 4 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 127SZ UT WOS:000317720300001 PM 23596201 ER PT J AU Singh, S Henley, SJ Wilson, R King, J Eheman, C AF Singh, Simple Henley, S. Jane Wilson, Reda King, Jessica Eheman, Christie TI Invasive Cancer Incidence-United States, 2009 (Reprinted from MMWR, vol 62, pg 113-118, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Singh, Simple; Henley, S. Jane; Wilson, Reda; King, Jessica; Eheman, Christie] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Singh, S (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM sdsingh@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 17 PY 2013 VL 309 IS 15 BP 1579 EP 1581 DI 10.1001/jama.2013.2455 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 126FY UT WOS:000317599500009 ER PT J AU Pisney, L Barron, M Janelle, SJ Bamberg, W MacCannell, D Kallen, A Gould, C Limbago, B Epson, E Wendt, J AF Pisney, Larissa Barron, Michelle Janelle, Sarah Jackson Bamberg, Wendy MacCannell, Duncan Kallen, Alexander Gould, Carolyn Limbago, Brandi Epson, Erin Wendt, Joyanna TI Notes from the Field: Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lactamase-Denver, Colorado, 2012 (Reprinted from MMWR, vol 62, pg 108, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Pisney, Larissa; Barron, Michelle] Univ Colorado, Div Infect Dis, Boulder, CO 80309 USA. [Epson, Erin; Wendt, Joyanna] CDC, Atlanta, GA 30333 USA. RP Epson, E (reprint author), CDC, Atlanta, GA 30333 USA. EM erin.epson@state.co.us NR 1 TC 0 Z9 0 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 17 PY 2013 VL 309 IS 15 BP 1582 EP 1582 DI 10.1001/jama.2013.2135 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 126FY UT WOS:000317599500010 ER PT J AU He, KY Qi, Q Chan, CB Xiao, G Liu, X Tucker-Burden, C Wang, LY Mao, H Lu, X McDonald, FE Luo, HB Fan, QW Weiss, WA Sun, SY Brat, DJ Ye, KQ AF He, Kunyan Qi, Qi Chan, Chi-Bun Xiao, Ge Liu, Xia Tucker-Burden, Carol Wang, Liya Mao, Hui Lu, Xiang McDonald, Frank E. Luo, Hongbo Fan, Qi-wen Weiss, William A. Sun, Shi-yong Brat, Daniel J. Ye, Keqiang TI Blockade of glioma proliferation via allosteric inhibition of JAK2 SO CANCER RESEARCH LA English DT Meeting Abstract CT 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR) CY APR 06-10, 2013 CL Washington, DC SP Amer Assoc Canc Res C1 [He, Kunyan; Qi, Qi; Chan, Chi-Bun; Liu, Xia; Tucker-Burden, Carol; Sun, Shi-yong; Brat, Daniel J.; Ye, Keqiang] Emory Univ, Sch Med, Atlanta, GA USA. [Xiao, Ge] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wang, Liya; Mao, Hui] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [McDonald, Frank E.] Emory Univ, Atlanta, GA 30322 USA. [Luo, Hongbo] Harvard Univ, Sch Med, Boston, MA USA. [Luo, Hongbo] Childrens Hosp, Boston, MA 02115 USA. [Fan, Qi-wen; Weiss, William A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2013 VL 73 IS 8 SU 1 MA 5683 DI 10.1158/1538-7445.AM2013-5683 PG 1 WC Oncology SC Oncology GA AA6PP UT WOS:000331220606159 ER PT J AU Hampp, C Asal, N Lipowski, E Kauf, T Schneider, E Kubilis, P Winterstein, A AF Hampp, Christian Asal, Nabih Lipowski, Earlene Kauf, Teresa Schneider, Eileen Kubilis, Paul Winterstein, Almut TI Validity of Laboratory-based Surveillance for Detection of Respiratory Syncytial Virus Seasons SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE immunoprophylaxis; Medicaid; palivizumab; pediatrics; respiratory syncytial virus; seasonality; validity ID UNITED-STATES; HOSPITALIZATION; PALIVIZUMAB; INFECTIONS; PREVENTION; CHILDREN; INFANTS; BRONCHIOLITIS; FLORIDA AB In this study, we validated the Centers for Disease Control and Preventions use of a 10 threshold of median proportion of positive laboratory tests (median proportion positive (MPP)) to identify respiratory syncytial virus (RSV) seasons against a standard based on hospitalization claims. Medicaid fee-for-service recipients under 2 years of age from California, Florida, Illinois, and Texas (19992004), continuously eligible since birth, were categorized for each week as high-risk or low-risk with regard to RSV-related hospitalization based on medical and pharmacy claims data and birth certificates. Weeks were categorized as on-season if the RSV hospitalization incidence rate in high-risk children exceeded the seasonal peak of the incidence rate in low-risk children. Receiver operating characteristic (ROC) curves were used to measure the ability of MPP to discriminate between on-season and off-season weeks as determined from hospitalization data. Areas under the ROC curve ranged from 0.88 (95 confidence interval: 0.83, 0.92) in Illinois to 0.96 (95 confidence interval: 0.94, 0.98) in California. Requiring at least 5 positive tests in addition to the 10 MPP threshold optimized accuracy, as indicated by minimized root mean square errors. The 10 MPP with the added requirement of at least 5 positive tests is a valid method for identifying clinically significant RSV seasons across geographically diverse states. C1 [Hampp, Christian] US FDA, Div Epidemiol 1, Off Pharmacovigilance & Epidemiol, Off Surveillance & Epidemiol,Ctr Drug Evaluat & R, Silver Spring, MD 20993 USA. [Asal, Nabih; Winterstein, Almut] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol & Biostat, Gainesville, FL USA. [Asal, Nabih] Univ Florida, Coll Med, Dept Epidemiol, Gainesville, FL USA. [Lipowski, Earlene; Kauf, Teresa; Kubilis, Paul; Winterstein, Almut] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, Gainesville, FL USA. [Schneider, Eileen] Ctr Dis Control & Prevent, Div Viral Dis, Off Infect Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Hampp, C (reprint author), US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA. EM christian.hampp@fda.hhs.gov RI winterstein, Almut/A-3017-2014 OI winterstein, Almut/0000-0002-6518-5961 FU Florida Agency for Healthcare Administration [MED054 under CFDA 93.778] FX This study was supported by a grant from the Florida Agency for Healthcare Administration (grant MED054 under CFDA 93.778). It was conducted in collaboration with the University of Florida Center for Medicaid and the Uninsured. NR 35 TC 3 Z9 3 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 15 PY 2013 VL 177 IS 8 BP 841 EP 851 DI 10.1093/aje/kws304 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 124AT UT WOS:000317435600014 PM 23479344 ER PT J AU Schulte, PA McKernan, LT Heidel, DS Okun, AH Dotson, GS Lentz, TJ Geraci, CL Heckel, PE Branche, CM AF Schulte, Paul A. McKernan, Lauralynn T. Heidel, Donna S. Okun, Andrea H. Dotson, Gary Scott Lentz, Thomas J. Geraci, Charles L. Heckel, Pamela E. Branche, Christine M. TI Occupational safety and health, green chemistry, and sustainability: a review of areas of convergence SO ENVIRONMENTAL HEALTH LA English DT Review DE Environmental health; Life cycle analysis; Workers; Alternatives; Nanomaterials; 1-Bromopropane ID RESEARCH-AND-DEVELOPMENT; SOLVENT 1-BROMOPROPANE; PHYSICIAN RECOGNITION; EXPOSURE; SURVEILLANCE; TOXICITY; PREVENTION; MANAGEMENT; HIERARCHY; EVENTS AB With increasing numbers and quantities of chemicals in commerce and use, scientific attention continues to focus on the environmental and public health consequences of chemical production processes and exposures. Concerns about environmental stewardship have been gaining broader traction through emphases on sustainability and "green chemistry" principles. Occupational safety and health has not been fully promoted as a component of environmental sustainability. However, there is a natural convergence of green chemistry/sustainability and occupational safety and health efforts. Addressing both together can have a synergistic effect. Failure to promote this convergence could lead to increasing worker hazards and lack of support for sustainability efforts. The National Institute for Occupational Safety and Health has made a concerted effort involving multiple stakeholders to anticipate and identify potential hazards associated with sustainable practices and green jobs for workers. Examples of potential hazards are presented in case studies with suggested solutions such as implementing the hierarchy of controls and prevention through design principles in green chemistry and green building practices. Practical considerations and strategies for green chemistry, and environmental stewardship could benefit from the incorporation of occupational safety and health concepts which in turn protect affected workers. C1 [Schulte, Paul A.; McKernan, Lauralynn T.; Heidel, Donna S.; Okun, Andrea H.; Dotson, Gary Scott; Lentz, Thomas J.; Geraci, Charles L.; Heckel, Pamela E.; Branche, Christine M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Heidel, Donna S.] Bur Veritas, Edison, NJ USA. RP Schulte, PA (reprint author), NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. EM PSchulte@cdc.gov NR 59 TC 11 Z9 11 U1 2 U2 66 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD APR 15 PY 2013 VL 12 AR 31 DI 10.1186/1476-069X-12-31 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 134YQ UT WOS:000318252100002 PM 23587312 ER PT J AU Mody, RK Griffin, PM AF Mody, Rajal K. Griffin, Patricia M. TI Fecal Shedding of Shiga Toxin-Producing Escherichia coli: What Should Be Done to Prevent Secondary Cases? SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE shedding; STEC; HUS ID HEMOLYTIC-UREMIC SYNDROME; DAY-CARE-CENTER; O157 INFECTION; VIRULENCE FACTORS; NURSERY-SCHOOL; OUTBREAK; ASSOCIATION; CHILDREN; RISK; SURVEILLANCE C1 [Mody, Rajal K.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Mody, RK (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, MS C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM rmody@cdc.gov NR 53 TC 2 Z9 2 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2013 VL 56 IS 8 BP 1141 EP 1144 DI 10.1093/cid/cis1222 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 113WM UT WOS:000316700100016 PM 23300239 ER PT J AU Sinkowitz-Cochran, RL AF Sinkowitz-Cochran, Ronda L. TI Survey Design: To Ask or Not to Ask? That is the Question ... SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE survey; measurement error; response rate; question development; rating scales ID RESPONSE RATES; INCENTIVES; PHYSICIANS AB Surveys are one of the most frequent modes of observation and measurement. Survey research can be exploratory, descriptive, and/or explanatory. Modes of survey administration vary and include face-to-face, telephone, mail, and Internet. There are numerous considerations that that must be taken into account when designing and conducting a survey. Deciding what information is needed and why is important when developing questions for a survey; it is essential to define the purpose of the survey and to be as specific as possible in terms of the data to be collected. Response rate varies by target audience and is influenced by a number of factors such as incentives, survey length, and perceived burden. From question development to survey construction, the goal is to minimize measurement error with systematic planning and execution. C1 Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Sinkowitz-Cochran, RL (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. EM rls7@cdc.gov NR 30 TC 9 Z9 9 U1 3 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2013 VL 56 IS 8 BP 1159 EP 1164 DI 10.1093/cid/cit005 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 113WM UT WOS:000316700100021 PM 23315318 ER PT J AU Hanna, DB Buchacz, K Gebo, KA Hessol, NA Horberg, MA Jacobson, LP Kirk, GD Kitahata, MM Korthuis, PT Moore, RD Napravnik, S Patel, P Silverberg, MJ Sterling, TR Willig, JH Lau, B Althoff, KN Crane, HM Collier, AC Samji, H Thorne, JE Gill, MJ Klein, MB Martin, JN Rodriguez, B Rourke, SB Gange, SJ AF Hanna, David B. Buchacz, Kate Gebo, Kelly A. Hessol, Nancy A. Horberg, Michael A. Jacobson, Lisa P. Kirk, Gregory D. Kitahata, Mari M. Korthuis, P. Todd Moore, Richard D. Napravnik, Sonia Patel, Pragna Silverberg, Michael J. Sterling, Timothy R. Willig, James H. Lau, Bryan Althoff, Keri N. Crane, Heidi M. Collier, Ann C. Samji, Hasina Thorne, Jennifer E. Gill, M. John Klein, Marina B. Martin, Jeffrey N. Rodriguez, Benigno Rourke, Sean B. Gange, Stephen J. CA North Amer AIDS Cohort TI Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE antiretroviral therapy; healthcare disparities; HIV; time factors; viral load ID VIRAL LOAD SUPPRESSION; INJECTION-DRUG USERS; UNITED-STATES; OPPORTUNISTIC INFECTIONS; CLINICAL-OUTCOMES; OF-HEALTH; CARE; ADHERENCE; ADULTS; PREVENTION AB Background. Since the mid-1990s, effective antiretroviral therapy (ART) regimens have improved in potency, tolerability, ease of use, and class diversity. We sought to examine trends in treatment initiation and resulting human immunodeficiency virus (HIV) virologic suppression in North America between 2001 and 2009, and demographic and geographic disparities in these outcomes. Methods. We analyzed data on HIV-infected individuals newly clinically eligible for ART (ie, first reported CD4(+) count <350 cells/mu L or AIDS-defining illness, based on treatment guidelines during the study period) from 17 North American AIDS Cohort Collaboration on Research and Design cohorts. Outcomes included timely ART initiation (within 6 months of eligibility) and virologic suppression (<= 500 copies/mL, within 1 year). We examined time trends and considered differences by geographic location, age, sex, transmission risk, race/ethnicity, CD4(+) count, and viral load, and documented psychosocial barriers to ART initiation, including non-injection drug abuse, alcohol abuse, and mental illness. Results. Among 10 692 HIV-infected individuals, the cumulative incidence of 6-month ART initiation increased from 51% in 2001 to 72% in 2009 (P-trend < .001). The cumulative incidence of 1-year virologic suppression increased from 55% to 81%, and among ART initiators, from 84% to 93% (both P-trend < .001). A greater number of psychosocial barriers were associated with decreased ART initiation, but not virologic suppression once ART was initiated. We found significant heterogeneity by state or province of residence (P < .001). Conclusions. In the last decade, timely ART initiation and virologic suppression have greatly improved in North America concurrent with the development of better-tolerated and more potent regimens, but significant barriers to treatment uptake remain, both at the individual level and systemwide. C1 [Hanna, David B.; Gebo, Kelly A.; Jacobson, Lisa P.; Kirk, Gregory D.; Moore, Richard D.; Lau, Bryan; Althoff, Keri N.; Thorne, Jennifer E.; Gange, Stephen J.] Johns Hopkins Univ, Baltimore, MD USA. [Buchacz, Kate; Patel, Pragna] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hessol, Nancy A.; Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Horberg, Michael A.] Mid Atlantic Permanente Res Inst, Rockville, MD USA. [Kitahata, Mari M.; Crane, Heidi M.; Collier, Ann C.] Univ Washington, Seattle, WA 98195 USA. [Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Napravnik, Sonia] Univ N Carolina, Chapel Hill, NC USA. [Silverberg, Michael J.] Kaiser Permanente No Calif, Oakland, CA USA. [Sterling, Timothy R.] Vanderbilt Univ, Nashville, TN USA. [Willig, James H.] Univ Alabama Birmingham, Birmingham, AL USA. [Samji, Hasina] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Gill, M. John] Univ Calgary, Calgary, AB T2N 1N4, Canada. [Klein, Marina B.] McGill Univ, Montreal, PQ, Canada. [Rodriguez, Benigno] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Rourke, Sean B.] Univ Toronto, Toronto, ON M5S 1A1, Canada. RP Hanna, DB (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Belfer 1315, Bronx, NY 10461 USA. EM david.hanna@einstein.yu.edu RI Rodriguez, Benigno/C-3365-2009; Gill, John/G-7083-2016; OI Rodriguez, Benigno/0000-0001-9736-7957; Gill, John/0000-0002-8546-8790; Mayor, Angel M./0000-0002-7705-837X; Gange, Stephen/0000-0001-7842-512X FU National Institutes of Health [F31-DA30254, U01-AI069918, U01AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI42590, U01-HD32632, UL1-RR024131, M01-RR-00052]; Centers for Disease Control and Prevention [CDC200-2006-18797]; Canadian Institutes of Health Research [TGF-96118, HCP97105, CBR-86906, CBR-94036, KRS-86251, 169621]; Canadian HIV Trials Network [24]; government of British Columbia; Tibotec; Merck; Pfizer; BMS; NIH [P30-AI036219, R01-DA04334, R01-DA12568, R01-DA11602, R01-AA16893, R24-AI067039, AHQ29001-0012]; N.I.H [N02-CP55504, K01-AI071725, K01-AI071754, K01-AI093197, K23-AI610320, K24-DA00432, K24-AI1065298, P30-AI27757, P30-AI27767, P30-AI27763, P30-AI50410, P30-AI54999, M01-RR00071, M01-RR00079, M01RR00083, M01-RR00722, M01-RR025747] FX This work was supported by the National Institutes of Health (grant numbers F31-DA30254, U01-AI069918, U01AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI42590, U01-HD32632, UL1-RR024131, UL1-RR024131, M01-RR-00052, M01-RR00071, M01-RR00079, M01RR00083, M01-RR00722, M01-RR025747, P30-AI27757, P30-AI27767, P30-AI27763, P30-AI50410, P30-AI54999, P30-AI036219, R01-DA04334, R01-DA12568, R01-DA11602, R01-AA16893, R24-AI067039, AHQ29001- 0012, N02-CP55504, K01-AI071725, K01-AI071754, K01-AI093197, K23-AI610320, K24-DA00432, and K24-AI1065298); the Centers for Disease Control and Prevention (contract CDC200-2006-18797); the Canadian Institutes of Health Research (grant numbers TGF-96118, HCP97105, CBR-86906, CBR-94036, KRS-86251, and 169621); the Canadian HIV Trials Network (project 24); and the government of British Columbia.; K. A. G. has served as a consultant to Tibotec and Bristol-Myers Squibb (BMS) and has received research funding from Tibotec. M. A. H. has received research funding from Merck and Pfizer. L. P. J. has served as a consultant to BMS. G. D. K. has served as a consultant to GlaxoSmithKline (GSK) and Merck, and has received payment for educational presentations from GSK. R. D. M. has served as a consultant to Gilead. M. J. S. has received research funding from Merck and Pfizer. T. R. S. has received research funding from Pfizer and BMS and has served on an advisory board for Otsuka. J. H. W. has served as a consultant to BMS, Definicare, and Gilead, and has received research funding from BMS, Definicare, Gilead, Pfizer, and Tibotec. H. M. C. has received payment for educational presentations from Medscape. A. C. C. has received research funding from Schering-Plough and Merck, has served on an advisory board for Merck, and has past stock options from Abbott, BMS, Johnson & Johnson, and Pfizer. J. E. T. has served on an advisory board for Allergan and has served as a consultant to Santen and XOMA. M. J. G. has served on advisory boards for Abbott, ViiV, Gilead, Janssen, and Merck. M. B. K. has served as a consultant to ViiV, has received research funding from Merck, and has received payment for lectures or educational presentations from BMS, Gilead, and ViiV. B. R. has served as a consultant to Gilead. S. B. R. has served as a consultant to and has received payment for lectures and educational presentations from Abbott. S. J. G. has served on an advisory board for Merck. NR 51 TC 37 Z9 37 U1 0 U2 26 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2013 VL 56 IS 8 BP 1174 EP 1182 DI 10.1093/cid/cit003 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 113WM UT WOS:000316700100023 PM 23315317 ER PT J AU Bateman, AC Kieke, BA Irving, SA Meece, JK Shay, DK Belongia, EA AF Bateman, Allen C. Kieke, Burney A. Irving, Stephanie A. Meece, Jennifer K. Shay, David K. Belongia, Edward A. TI Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010-2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE case-control studies; effectiveness; epidemiology; influenza; vaccine ID IMMUNIZATION PRACTICES ACIP; LONG-TERM IMMUNOGENICITY; UNITED-STATES; ADVISORY-COMMITTEE; IMMUNE-RESPONSE; EFFICACY; ADULTS; RECOMMENDATIONS; VACCINATION; PREVENTION AB Background. The 2009 influenza A virus subtype H1N1 (A[H1N1] pdm09) did not exhibit antigenic drift during the 2010-2011 influenza season, providing an opportunity to investigate the duration of protection after vaccination. We estimated the independent effects of 2010-2011 seasonal trivalent inactivated influenza vaccine (TIV) and A (H1N1) pdm09 vaccine for preventing medically attended influenza A virus infection during the 2010-2011 season. Methods. Individuals were tested for influenza A virus by real-time reverse transcription polymerase chain reaction (rRT-PCR) after a clinical encounter for acute respiratory illness. Case-control analyses compared participants with rRT-PCR-confirmed influenza A virus infection and test-negative controls. Vaccine effectiveness was estimated separately for monovalent pandemic vaccine and TIV and was calculated as 100 x [1 - adjusted odds ratio], where the odds ratio was adjusted for potential confounders. Results. The effectiveness of TIV against influenza A virus infection was 63% (95% confidence interval [CI], 37%-78%). The effectiveness of TIV against A(H1N1)pdm09 infection was 77% (95% CI, 44%-90%). Monovalent vaccine administered between October 2009 and April 2010 was not protective during the 2010-2011 season, with an effectiveness of -1% (95% CI, -146% to 59%) against A(H1N1)pdm09 infection. Conclusions. Monovalent vaccine provided no sustained protection against A(H1N1)pdm09 infection during the 2010-2011 season. This waning effectiveness supports the need for annual revaccination, even in the absence of antigenic drift in A(H1N1)pdm09. C1 [Bateman, Allen C.; Kieke, Burney A.; Irving, Stephanie A.; Meece, Jennifer K.; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Belongia, EA (reprint author), Marshfield Clin Res Fdn, Epidemiol Res Ctr ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM belongia.edward@marshfieldclinic.org OI Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention [1 U01 CI000192-01]; MedImmune FX This work was supported by the Centers for Disease Control and Prevention (cooperative agreement 1 U01 CI000192-01).; Dr Belongia, Dr Meece, Ms Irving, and Mr Kieke receive research support from MedImmune. All other authors report no potential conflicts. NR 33 TC 14 Z9 14 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 15 PY 2013 VL 207 IS 8 BP 1262 EP 1269 DI 10.1093/infdis/jit020 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 113WT UT WOS:000316700800011 PM 23341536 ER PT J AU Budd, J Fowler, B Brown, A Swann, S Leung, J Marin, M AF Budd, Jeremy Fowler, Brian Brown, Alise Swann, Sandy Leung, Jessica Marin, Mona TI Varicella Death of an Unvaccinated, Previously Healthy Adolescent - Ohio, 2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Leung, Jessica; Marin, Mona] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Budd, J (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. EM jleung@cdc.gov NR 7 TC 1 Z9 1 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 12 PY 2013 VL 62 IS 14 BP 261 EP 263 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FO UT WOS:000322178200001 ER PT J AU Hasan, A Le, M Pasko, J Ravin, KA Clauss, H Hasz, R Hunt, EA Bosserman, E McAuliffe, I Montgomery, SP Kuehnert, MJ Hocevar, SN Abanyie, F AF Hasan, Anjum Le, Marie Pasko, Jessica Ravin, Karen A. Clauss, Heather Hasz, Richard Hunt, Elizabeth A. Bosserman, Elizabeth McAuliffe, Isabel Montgomery, Susan P. Kuehnert, Matthew J. Hocevar, Susan N. Abanyie, Francisca TI Transmission of Strongyloides stercoralis Through Transplantation of Solid Organs - Pennsylvania, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Hasan, Anjum; Le, Marie; Pasko, Jessica; Ravin, Karen A.] CDC, Geisinger Med Ctr, Atlanta, GA 30333 USA. [Clauss, Heather] CDC, Temple Univ Hosp, Atlanta, GA 30333 USA. [Hasz, Richard] CDC, Gift Life Donor Program, Atlanta, GA 30333 USA. [Hunt, Elizabeth A.] CDC, Penn Dept Hlth, Atlanta, GA 30333 USA. [Bosserman, Elizabeth; McAuliffe, Isabel; Montgomery, Susan P.] CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Kuehnert, Matthew J.; Hocevar, Susan N.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Abanyie, Francisca] CDC, Atlanta, GA 30333 USA. RP Abanyie, F (reprint author), CDC, Atlanta, GA 30333 USA. EM why6@cdc.gov NR 9 TC 7 Z9 8 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 12 PY 2013 VL 62 IS 14 BP 264 EP 266 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FO UT WOS:000322178200002 ER PT J AU Kellogg, F Niehus, N DiOrio, M Smith, K Chipman, R Kirby, J Blanton, J Dyer, J Franka, R Hummel, K Recuenco, S Rupprecht, C Wallace, R Vora, NM AF Kellogg, Frank Niehus, Nancy DiOrio, Mary Smith, Kathleen Chipman, Richard Kirby, Jordona Blanton, Jesse Dyer, Jessie Franka, Richard Hummel, Kim Recuenco, Sergio Rupprecht, Charles Wallace, Ryan Vora, Neil M. TI Human Contacts with Oral Rabies Vaccine Baits Distributed for Wildlife Rabies Management - Ohio, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID STRIPED SKUNKS; SURVEILLANCE; INFECTION; ONTARIO; CANADA C1 [Kellogg, Frank; Niehus, Nancy] CDC, Lake Cty Gen Hlth Dist, Atlanta, GA 30333 USA. [DiOrio, Mary; Smith, Kathleen] CDC, Ohio Dept Hlth, Atlanta, GA 30333 USA. [Kirby, Jordona] CDC, USDA, Atlanta, GA 30333 USA. [Blanton, Jesse; Dyer, Jessie; Franka, Richard; Hummel, Kim; Recuenco, Sergio; Rupprecht, Charles] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Wallace, Ryan; Vora, Neil M.] CDC, Atlanta, GA 30333 USA. RP Vora, NM (reprint author), CDC, Atlanta, GA 30333 USA. EM nvora@cdc.gov OI Recuenco-Cabrera, Sergio/0000-0002-8446-7411 NR 10 TC 1 Z9 1 U1 0 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 12 PY 2013 VL 62 IS 14 BP 267 EP 269 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FO UT WOS:000322178200003 ER PT J AU Sein, C AF Sein, Carolyn TI Evaluating Surveillance Indicators Supporting the Global Polio Eradication Initiative, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID TRACKING PROGRESS; WORLDWIDE C1 WHO, Polio Eradicat Dept, CH-1211 Geneva, Switzerland. CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. [Sein, Carolyn] CDC, Atlanta, GA 30333 USA. RP Sein, C (reprint author), CDC, Atlanta, GA 30333 USA. EM csein@cdc.gov NR 9 TC 16 Z9 16 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 12 PY 2013 VL 62 IS 14 BP 270 EP 274 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FO UT WOS:000322178200004 ER PT J AU Sundaram, ME Talbot, HK Zhu, YW Griffin, MR Spencer, S Shay, DK Coleman, LA AF Sundaram, Maria E. Talbot, H. Keipp Zhu, Yuwei Griffin, Marie R. Spencer, Sarah Shay, David K. Coleman, Laura A. TI Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old SO VACCINE LA English DT Article DE Vitamin D; Influenza; Vaccine; Vaccine response ID D SUPPLEMENTATION; PROTECTION; INCREASE; PEOPLE; TRIAL AB Vitamin D deficiency has been implicated in risk of respiratory illness. We determined whether serum vitamin D levels are related to influenza vaccine response measured by hemagglutination antibody inhibition (HAI) titer in adults aged >= 50 years old. The study was a prospective cohort study conducted over two influenza seasons (fall 2008-spring 2009 and fall 2009-spring 2010) in Marshfield, WI and Nashville, TN including 1103 community-dwelling adult volunteers >= 50 years of age. Pre-vaccination levels of serum vitamin D and HAI titer levels pre- and 21-28 days post-influenza vaccination were measured. Seroprotection was defined as HAI >= 40; seroconversion was defined as >= 4-fold rise in HAI titers from pre- to post-vaccination. More than 25% of participants were vitamin D deficient (<25 ng/mL). Vitamin D measured as a continuous variable was not related to pre- or post-vaccination seroprotection or seroconversion for any vaccine strain in any year. Vitamin D deficiency was associated with a greater frequency of post-vaccination seroprotection for seasonal H1N1 in the first year of the study, but was not related to seroprotection or seroconversion for any other strain in either year. No consistent association was found between vitamin D levels or vitamin D deficiency and serologic response to influenza vaccination in older adults. Cell-mediated immune parameters should also be explored in order to further investigate possible relationships between micronutrient status and influenza vaccine response. (c) 2013 Elsevier Ltd. All rights reserved. C1 [Sundaram, Maria E.; Coleman, Laura A.] Marshfield Clin Res Fdn, Marshfield, WI 54449 USA. [Talbot, H. Keipp; Zhu, Yuwei; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Med Ctr N, Nashville, TN 37232 USA. [Spencer, Sarah; Shay, David K.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Coleman, Laura A.] Abbott Nutr, Columbus, OH 43219 USA. RP Sundaram, ME (reprint author), Marshfield Clin Res Fdn, 1000 North Oak St, Marshfield, WI 54449 USA. EM sundaram.maria@marshfieldclinic.org OI Sundaram, Maria/0000-0001-8056-3302; Shay, David/0000-0001-9619-4820 FU CDC [5 U18 IP000183-02, 1 U18 IP000184-01, K23 A1074863-01A1]; US Department of Energy FX This project has been funded in part by CDC grants 5 U18 IP000183-02, 1 U18 IP000184-01, and K23 A1074863-01A1 (Talbot). This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. Contributions: D.K.S., E.A.B., H.K.T., and L.A.C. designed the research and provided oversight for conducting the research. Y.Z. and M.S. performed statistical analysis. M.S. and L.A.C. wrote the paper. M.S. had primary responsibility for final content; valuable input for final content was provided by all authors. All authors read and approved the final manuscript. NR 28 TC 13 Z9 13 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 12 PY 2013 VL 31 IS 16 BP 2057 EP 2061 DI 10.1016/j.vaccine.2013.02.028 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 128WE UT WOS:000317799600009 PM 23453766 ER PT J AU Hicks, LA Taylor, TH Hunkler, RJ AF Hicks, Lauri A. Taylor, Thomas H., Jr. Hunkler, Robert J. TI U.S. Outpatient Antibiotic Prescribing, 2010 SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Hicks, Lauri A.; Taylor, Thomas H., Jr.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Hunkler, Robert J.] IMS Hlth, Plymouth Meeting, PA USA. RP Hicks, LA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM lhicks@cdc.gov NR 2 TC 78 Z9 79 U1 1 U2 15 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 11 PY 2013 VL 368 IS 15 BP 1461 EP 1462 DI 10.1056/NEJMc1212055 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 122QT UT WOS:000317333600031 PM 23574140 ER PT J AU Hook, EW Shafer, W Deal, C Kirkcaldy, RD Iskander, J AF Hook, Edward W., III Shafer, William Deal, Carolyn Kirkcaldy, Robert D. Iskander, John TI CDC Grand Rounds: The Growing Threat of Multidrug-Resistant Gonorrhea (Reprinted from MMWR, vol 62, pg 103-106, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID SEXUALLY-TRANSMITTED-DISEASES; NEISSERIA-GONORRHOEAE; GONOCOCCAL INFECTIONS; TREATMENT-GUIDELINES; NO LONGER; CEFTRIAXONE; UPDATE C1 [Hook, Edward W., III] Univ Alabama Birmingham, Birmingham, AL USA. [Shafer, William] Emory Univ, Atlanta, GA 30322 USA. [Deal, Carolyn] NIAID, NIH, Bethesda, MD 20892 USA. [Kirkcaldy, Robert D.] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. EM rkirkcaldy@cdc.gov NR 15 TC 1 Z9 1 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 10 PY 2013 VL 309 IS 14 BP 1453 EP 1455 DI 10.1001/jama.2013.2131 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 121VD UT WOS:000317271700007 ER PT J AU Marsden-Haug, N Meyer, S Bidol, SA Schmitz, J Culpepper, W Behravesh, CB Morris, J Anderson, TC AF Marsden-Haug, Nicola Meyer, Stephanie Bidol, Sally A. Schmitz, Jennifer Culpepper, Wright Behravesh, Casey Barton Morris, Jamae Anderson, Tara Creel TI Notes from the Field: Multistate Outbreak of Human Salmonella Typhimurium Infections Linked to Contact with Pet Hedgehogs-United States, 2011-2013 (Reprinted from MMWR, vol 62, pg 73, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Marsden-Haug, Nicola] Washington State Dept Hlth, Washington, DC USA. [Bidol, Sally A.] Minnesota Dept Hlth, Acute Dis Invest & Control Sect, Infect Dis Epidemiol Prevent & Control Div, Minneapolis, MN 55414 USA. [Schmitz, Jennifer] USDA, Washington, DC USA. [Morris, Jamae; Anderson, Tara Creel] CDC, Atlanta, GA 30333 USA. RP Anderson, TC (reprint author), CDC, Atlanta, GA 30333 USA. EM tcanderson1@cdc.gov NR 1 TC 1 Z9 1 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 10 PY 2013 VL 309 IS 14 BP 1456 EP 1456 DI 10.1001/jama.2013.1525 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 121VD UT WOS:000317271700008 ER PT J AU Williams, HA Hering, H Spiegel, P AF Williams, Holly A. Hering, Heiko Spiegel, Paul TI Discourse on malaria elimination: where do forcibly displaced persons fit in these discussions? SO MALARIA JOURNAL LA English DT Editorial Material DE Malaria; Malaria elimination; Refugees ID ERADICATION; PROGRAM; TRENDS; BORDER AB Background: Individuals forcibly displaced are some of the poorest people in the world, living in areas where infrastructure and services are at a bare minimum. Out of a total of 10,549,686 refugees protected and assisted by the United Nations High Commissioner for Refugees globally, 6,917,496 (65.6%) live in areas where malaria is transmitted. Historically, national malaria control programmes have excluded displaced populations. Results: The current discourse on malaria elimination rarely includes discussion of forcibly displaced persons who reside within malaria-eliminating countries. Of the 100 malaria-endemic countries, 64 are controlling malaria and 36 are in some stage of elimination. Of these, 30 malaria-controlling countries and 13 countries in some phase of elimination host displaced populations of >= 50,000, even though 13 of the 36 (36.1%) malaria-elimination countries host displaced populations of >= 50,000 people. Discussion: Now is the time for the malaria community to incorporate forcibly displaced populations residing within malarious areas into malaria control activities. Beneficiaries, whether they are internally displaced persons or refugees, should be viewed as partners in the delivery of malaria interventions and not simply as recipients. Conclusion: Until equitable and sustainable malaria control includes everyone residing in an endemic area, the goal of malaria elimination will not be met. C1 [Williams, Holly A.] Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Atlanta, GA 30341 USA. RP Williams, HA (reprint author), Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Mail Stop F-60,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM hbw2@cdc.gov NR 41 TC 8 Z9 8 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 10 PY 2013 VL 12 AR 121 DI 10.1186/1475-2875-12-121 PG 5 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 127FT UT WOS:000317683500001 PM 23575209 ER PT J AU Belser, JA Maines, TR Gustin, KM Katz, JM Tumpey, TM AF Belser, Jessica A. Maines, Taronna R. Gustin, Kortney M. Katz, Jacqueline M. Tumpey, Terrence M. TI Kinetics of viral replication and induction of host responses in ferrets differs between ocular and intranasal routes of inoculation SO VIROLOGY LA English DT Article DE Influenza; Ferret; H7 subtype; Pathogenesis ID INFLUENZA-A VIRUSES; EPITHELIAL-CELLS; IMMUNE-RESPONSES; INFECTION; CYTOKINE; H7; TRANSMISSION; PATHOGENESIS; EXPRESSION; VIRULENCE AB While influenza viruses are typically considered respiratory pathogens, the ocular system represents a secondary entry point for virus to establish a productive respiratory infection and the location for rare instances of virus-induced conjunctivitis. We used the ferret model to conduct a side-by-side comparison of virus infectivity, kinetics of viral replication, and induction of host responses following inoculation by either the intranasal or ocular routes with two viruses, A/Netherlands/230/03 (H7N7) and A/Panama/2007/99 (H3N2). We show that ocular inoculation resulted in delayed virus replication and reduced levels of proinflammatory cytokine and chemokine transcript in respiratory tract but not ocular tissues compared with intranasally inoculated animals. We identified numerous proinflammatory mediators with known roles in ocular disease elicited in ferret eye tissue following influenza virus infection. These findings provide a greater understanding of the modulation of host responses following different inoculation routes and underscore the risk associated with ocular exposure to influenza viruses. Published by Elsevier Inc. C1 [Belser, Jessica A.; Maines, Taronna R.; Gustin, Kortney M.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Influenza Div, MS G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tft9@cdc.gov FU Oak Ridge Institute for Science and Education FX The authors thank Shannon Emery for expertise in real-time RT-PCR analysis. K.M.G. received financial support from the Oak Ridge Institute for Science and Education. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agency. NR 29 TC 6 Z9 6 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR 10 PY 2013 VL 438 IS 2 BP 56 EP 60 DI 10.1016/j.virol.2013.01.012 PG 5 WC Virology SC Virology GA 110KA UT WOS:000316439800002 PM 23415392 ER PT J AU Habib, MA Soofi, S Ali, N Sutter, RW Palansch, M Qureshi, H Akhtar, T Molodecky, NA Okayasu, H Bhutta, ZA AF Habib, M. A. Soofi, S. Ali, N. Sutter, R. W. Palansch, M. Qureshi, H. Akhtar, T. Molodecky, N. A. Okayasu, H. Bhutta, Zulfiqar A. TI A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan SO VACCINE LA English DT Article DE Vaccine; Poliomyelitis; Seroconversion; Risk factors ID ERADICATION; CHILDREN; VACCINE; POLIOMYELITIS; RESPONSES; DIARRHEA; INFANTS; AFRICA; IMPACT; EGYPT AB Background: Seroprevalence studies provide important data on performance of immunization programs, susceptible groups and populations at-risk of future outbreaks. Identifying risk factors that affect seroconversion of the oral polio vaccine (OPV) will enable the polio eradication initiatives to increase seroprevalence. This paper describes the first population-based seroprevalence survey in Pakistan. Methods: This study evaluated the seroprevalence of poliovirus (PV) types 1, 2, and 3 antibodies to OPV in an illustrative sample of 554 subjects 6-11 months of age in three geographic locations of Pakistan (Lahore, Karachi, and Peshawar) representing a low socioeconomic at-risk populations. Antibody titers were measured and sero protection rates and geometric median titers were compared among different geographic regions and populations, as were demographics and OPV vaccination history collected by questionnaire. Univariate and multivariate analyses were conducted on subject characteristics to assess for potential risk factors for failure to sero-convert. Results: The average seroprevalence of PV1, PV2, and PV3 was 96.0%, 87.9% and 86.7%, respectively. The lowest sero protection rate for all three serotypes was for Karachi with 90.2%, 73.8%, and 78.8% for PV1, PV2, and PV3, respectively. Significant regional variation in PV3 seroprevalence was found (range: 74.2-100%). In the univariate analysis, age, total and campaign OPV doses were associated with higher seroprevalence, whereas stunting, respondent education and diarrhea in the past six months were significant risk factors for failure to sero-convert. Conclusions: These findings demonstrate consistently high levels of antibody response to PV1 and more geographically varied response to PV2 and PV3. Additionally, important risk factors affecting seropositivity were identified. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Habib, M. A.; Soofi, S.; Ali, N.; Bhutta, Zulfiqar A.] Aga Khan Univ, Karachi, Pakistan. [Sutter, R. W.; Molodecky, N. A.; Okayasu, H.] WHO, CH-1211 Geneva 27, Switzerland. [Palansch, M.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Qureshi, H.] Pakistan Med & Res Council PMRC, Islamabad, Pakistan. [Akhtar, T.] Khyber Med Univ KMU, Peshawar, Pakistan. RP Bhutta, ZA (reprint author), Aga Khan Univ, Div Women & Child Hlth, Karachi, Pakistan. EM zulfiqar.bhutta@aku.edu NR 40 TC 5 Z9 5 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 8 PY 2013 VL 31 IS 15 BP 1987 EP 1993 DI 10.1016/j.vaccine.2013.02.003 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 125QY UT WOS:000317557600017 PM 23429005 ER PT J AU Sirin, GS Zhang, YK AF Sirin, G. Sarah Zhang, Yingkai TI Irreversible inhibition mechanism of acetylcholinesterase and soman determined by Born-Oppenheimer ab initio QM/MM molecular dynamics simulations SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 245th National Meeting of the American-Chemical-Society (ACS) CY APR 07-11, 2013 CL New Orleans, LA SP Amer Chem Soc C1 [Sirin, G. Sarah] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30341 USA. [Sirin, G. Sarah; Zhang, Yingkai] NYU, Dept Chem, New York, NY 10003 USA. EM gs1240@nyu.edu NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD APR 7 PY 2013 VL 245 MA 394-COMP PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 210RD UT WOS:000323851304398 ER PT J AU Tie, Y Sirin, GS Holler, JS Demchuk, E AF Tie, Yunfeng Sirin, G. Sarah Holler, James S. Demchuk, Eugene TI Quantitative structure-activity relationships (QSAR) for oral chemical health guidance values SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 245th National Meeting of the American-Chemical-Society (ACS) CY APR 07-11, 2013 CL New Orleans, LA SP Amer Chem Soc C1 [Tie, Yunfeng; Sirin, G. Sarah; Holler, James S.; Demchuk, Eugene] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. EM gs1240@nyu.edu; cpox@wolke7.net NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD APR 7 PY 2013 VL 245 MA 357-COMP PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 210RD UT WOS:000323851304372 ER PT J AU Luis, AD Hayman, DTS O'Shea, TJ Cryan, PM Gilbert, AT Pulliam, JRC Mills, JN Timonin, ME Willis, CKR Cunningham, AA Fooks, AR Rupprecht, CE Wood, JLN Webb, CT AF Luis, Angela D. Hayman, David T. S. O'Shea, Thomas J. Cryan, Paul M. Gilbert, Amy T. Pulliam, Juliet R. C. Mills, James N. Timonin, Mary E. Willis, Craig K. R. Cunningham, Andrew A. Fooks, Anthony R. Rupprecht, Charles E. Wood, James L. N. Webb, Colleen T. TI A comparison of bats and rodents as reservoirs of zoonotic viruses: are bats special? SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES LA English DT Article DE trait-based approaches; zoonoses; viral richness; reservoir host; spillover; Chiroptera ID EMERGING INFECTIOUS-DISEASES; PLACENTAL MAMMAL PHYLOGENY; WILD PRIMATES; LIFE-HISTORY; WEST-AFRICA; HOST-RANGE; EMERGENCE; ECOLOGY; EVOLUTION; PATTERNS AB Bats are the natural reservoirs of a number of high-impact viral zoonoses. We present a quantitative analysis to address the hypothesis that bats are unique in their propensity to host zoonotic viruses based on a comparison with rodents, another important host order. We found that bats indeed host more zoonotic viruses per species than rodents, and we identified life-history and ecological factors that promote zoonotic viral richness. More zoonotic viruses are hosted by species whose distributions overlap with a greater number of other species in the same taxonomic order (sympatry). Specifically in bats, there was evidence for increased zoonotic viral richness in species with smaller litters (one young), greater longevity and more litters per year. Furthermore, our results point to a new hypothesis to explain in part why bats host more zoonotic viruses per species: the stronger effect of sympatry in bats and more viruses shared between bat species suggests that interspecific transmission is more prevalent among bats than among rodents. Although bats host more zoonotic viruses per species, the total number of zoonotic viruses identified in bats (61) was lower than in rodents (68), a result of there being approximately twice the number of rodent species as bat species. Therefore, rodents should still be a serious concern as reservoirs of emerging viruses. These findings shed light on disease emergence and perpetuation mechanisms and may help lead to a predictive framework for identifying future emerging infectious virus reservoirs. C1 [Luis, Angela D.; Hayman, David T. S.; Webb, Colleen T.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Luis, Angela D.; Pulliam, Juliet R. C.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Hayman, David T. S.; Wood, James L. N.] Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Cambridge CB3 0ES, England. [Hayman, David T. S.; Fooks, Anthony R.] Anim Hlth & Vet Labs Agcy Weybridge, Wildlife Zoonoses & Vector Borne Dis Res Grp, Addlestone KT15 3NB, Surrey, England. [Hayman, David T. S.; Cunningham, Andrew A.] Zool Soc London, Inst Zool, London NW1 4RY, England. [O'Shea, Thomas J.] US Geol Survey, Ft Collins, CO 80526 USA. [Cryan, Paul M.] US Geol Survey, Ft Collins Sci Ctr, Ft Collins, CO 80526 USA. [Gilbert, Amy T.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Pulliam, Juliet R. C.] Univ Florida, Dept Biol, Gainesville, FL 32611 USA. [Pulliam, Juliet R. C.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32611 USA. [Mills, James N.] Emory Univ, Populat Biol Ecol & Evolut Program, Atlanta, GA 30322 USA. [Timonin, Mary E.; Willis, Craig K. R.] Univ Winnipeg, Dept Biol, Winnipeg, MB R3B 2E9, Canada. [Timonin, Mary E.; Willis, Craig K. R.] Univ Winnipeg, Ctr Forest Interdisciplinary Res, Winnipeg, MB R3B 2E9, Canada. [Fooks, Anthony R.] Natl Consortium Zoonosis Res, Neston CH64 7TE, South Wirral, England. [Rupprecht, Charles E.] Global Alliance Rabies Control, Manhattan, KS 66502 USA. RP Luis, AD (reprint author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. EM angela.d.luis@gmail.com RI Wood, James/A-1626-2008; Willis, Craig/F-5218-2013; APHA, Staff publications/E-6082-2010; Cunningham, Andrew/E-7536-2010; Fooks, Anthony/F-5418-2010; OI Cryan, Paul/0000-0002-2915-8894; Wood, James/0000-0002-0258-3188; Pulliam, Juliet/0000-0003-3314-8223 FU Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate (US Department of Homeland Security); Fogarty International Center (National Institutes of Health); Wellcome Trust; David H. Smith post-doctoral fellowship; Royal Society Wolfson Research Merit award; Alborada Trust; Natural Sciences and Engineering Research Council (NSERC Canada) FX This work was supported by the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate (US Department of Homeland Security) and the Fogarty International Center (National Institutes of Health). D.T.S.H. acknowledges funding from the Wellcome Trust and a David H. Smith post-doctoral fellowship. A.A.C. is partially funded by a Royal Society Wolfson Research Merit award, and J.L.N.W. is supported by the Alborada Trust. C.K.R.W. is funded by a Discovery Grant from the Natural Sciences and Engineering Research Council (NSERC Canada). We thank Dan Horton for useful discussions. The findings and conclusions in this report are those of the authors and the US Geological Survey, but not of the other institutions. Any use of trade product or firm names is for descriptive purposes only and does not imply endorsement by the US Government. NR 59 TC 119 Z9 126 U1 13 U2 206 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 0962-8452 J9 P ROY SOC B-BIOL SCI JI Proc. R. Soc. B-Biol. Sci. PD APR 7 PY 2013 VL 280 IS 1756 AR 20122753 DI 10.1098/rspb.2012.2753 PG 9 WC Biology; Ecology; Evolutionary Biology SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences & Ecology; Evolutionary Biology GA 097GH UT WOS:000315461500012 PM 23378666 ER PT J AU Fang, J Ayala, C Loustalot, F Dai, SF AF Fang, Jing Ayala, Carma Loustalot, Fleetwood Dai, Shifan TI Self-Reported Hypertension and Use of Antihypertensive Medication Among Adults - United States, 2005-2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PREVALENCE; STROKE; AWARENESS; DISEASE C1 [Fang, Jing; Ayala, Carma; Loustalot, Fleetwood; Dai, Shifan] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Fang, J (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM jfang@cdc.gov NR 10 TC 10 Z9 11 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 5 PY 2013 VL 62 IS 13 BP 237 EP 244 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FJ UT WOS:000322177500001 ER PT J AU Wheeler, W Brown, MJ AF Wheeler, William Brown, Mary Jean TI Blood Lead Levels in Children Aged 1-5 Years - United States, 1999-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Wheeler, William] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Brown, Mary Jean] CDC, Div Emergency & Environm Hlth Svcs, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Brown, MJ (reprint author), CDC, Div Emergency & Environm Hlth Svcs, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM mjb5@cdc.gov NR 10 TC 72 Z9 72 U1 1 U2 8 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 5 PY 2013 VL 62 IS 13 BP 245 EP 248 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FJ UT WOS:000322177500003 ER PT J AU Gavin, L Warner, L O'Neil, ME Duong, LM Marshall, C Hastings, PA Harrison, AT Barfield, W AF Gavin, Lorrie Warner, Lee O'Neil, Mary Elizabeth Duong, Linh M. Marshall, Cassondra Hastings, Philip A. Harrison, Ayanna T. Barfield, Wanda TI Vital Signs: Repeat Births Among Teens - United States, 2007-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ACTING REVERSIBLE CONTRACEPTION; CARE AB Background: Teen childbearing has potential negative health, economic, and social consequences for mother and child. Repeat teen childbearing further constrains the mother's education and employment possibilities. Rates of preterm and low birth weight are higher in teens with a repeat birth, compared with first births. Methods: To assess patterns of repeat childbearing and postpartum contraceptive use among teens, CDC analyzed natality data from the National Vital Statistics System (NVSS) and the Pregnancy Risk Assessment Monitoring System (PRAMS) from 2007-2010. Results: Based on 2010 NVSS data from all 50 states and the District of Columbia, of more than 367,000 births to teens aged 15-19 years, 18.3% were repeat births. The percentage of teen births that represented repeat births decreased by 6.2% between 2007 and 2010. Disparities in repeat teen births exist by race/ethnicity, with the highest percentages found among American Indian/Alaska Natives (21.6%), Hispanics (20.9%), and non-Hispanic blacks (20.4%) and lowest among non-Hispanic whites (14.8%). Wide geographic disparities in the percentage of teen births that were repeat births also exist, ranging from 22% in Texas to 10% in New Hampshire. PRAMS data from 16 reporting areas (15 states and New York City) indicate that 91.2% of teen mothers used a contraceptive method 2-6 months after giving birth, but only 22.4% of teen mothers used the most effective methods. Teens with a previous live birth were significantly more likely to use the most effective methods postpartum compared with those with no prior live birth (29.6% versus 20.9%, respectively). Non-Hispanic white and Hispanic teens were significantly more likely to use the most effective methods than non-Hispanic black teens (24.6% and 27.9% versus 14.3%, respectively). The percentage of teens reporting postpartum use of the most effective methods varied greatly geographically across the PRAMS reporting areas, ranging from 50.3% in Colorado to 7.2% in New York State. Conclusions: Although the prevalence of repeat teen birth has declined in recent years, nearly one in five teen births is a repeat birth. Large disparities exist in repeat teen births and use of the most effective contraceptive methods postpartum, which was reported by fewer than one out of four teen mothers. Implications for Public Health Practice: Evidence-based approaches are needed to reduce repeat teen childbearing. These include linking pregnant and parenting teens to home visiting and similar programs that address a broad range of needs, and offering postpartum contraception to teens, including long-acting methods of reversible contraception. C1 [Gavin, Lorrie; Warner, Lee; O'Neil, Mary Elizabeth; Duong, Linh M.; Marshall, Cassondra; Hastings, Philip A.; Harrison, Ayanna T.; Barfield, Wanda] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Gavin, L (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM lgavin1@cdc.gov NR 20 TC 20 Z9 21 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD APR 5 PY 2013 VL 62 IS 13 BP 249 EP 255 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FJ UT WOS:000322177500004 ER PT J AU Marder, E Kirschke, D Robbins, D Dunn, J Jones, TF Racoosin, J Paulozzi, L Chang, A AF Marder, Ellyn Kirschke, David Robbins, Donna Dunn, John Jones, Timothy F. Racoosin, Judy Paulozzi, Leonard Chang, Art TI Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated With Intravenous Opana ER Abuse-Tennessee, 2012 (Reprinted from MMWR, vol 1, pg 1-4, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID ADAMTS13 C1 [Marder, Ellyn; Kirschke, David; Robbins, Donna; Dunn, John; Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Racoosin, Judy] US FDA, Div Anesthesia Analgesia & Addict Prod, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA. [Paulozzi, Leonard] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Chang, Art] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Kirschke, D (reprint author), Tennessee Dept Hlth, Nashville, TN USA. EM david.kirschke@tn.gov NR 10 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 3 PY 2013 VL 309 IS 13 BP 1338 EP 1340 DI 10.1001/jama.2013.357 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 117EC UT WOS:000316934500008 ER PT J AU Garcia, BR Rullan, J O'Neill, M Garrison, G Santella, D Maddaloni, MM Evangelista, P Cirillo, A Huerta-Montanez, G Caldwell, K Dignam, T Brown, MJ AF Garcia, Brenda Rivera Rullan, John O'Neill, Maureen Garrison, Geoff Santella, Dennis Maddaloni, Mark M. Evangelista, Pat Cirillo, Argie Huerta-Montanez, Gredia Caldwell, Kathleen Dignam, Timothy Brown, Mary Jean TI Take-Home Lead Exposure Among Children With Relatives Employed at a Battery Recycling Facility-Puerto Rico, 2011 (Reprinted from MMWR, vol 47, pg 967-970, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Huerta-Montanez, Gredia] Carter Consulting Inc, Atlanta, GA USA. [Caldwell, Kathleen] CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Dignam, Timothy; Brown, Mary Jean] CDC, Div Emergency & Environm Hlth Svcs, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Dignam, T (reprint author), CDC, Div Emergency & Environm Hlth Svcs, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM tdignam@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 3 PY 2013 VL 309 IS 13 BP 1340 EP 1342 DI 10.1001/jama.2012.165290 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 117EC UT WOS:000316934500009 ER PT J AU Meeker, JD Cantonwine, DE Rivera-Gonzalez, LO Ferguson, KK Mukherjee, B Calafat, AM Ye, XY Del Toro, LVA Crespo-Hernandez, N Jimenez-Velez, B Alshawabkeh, AN Cordero, JF AF Meeker, John D. Cantonwine, David E. Rivera-Gonzalez, Luis O. Ferguson, Kelly K. Mukherjee, Bhramar Calafat, Antonia M. Ye, Xiaoyun Del Toro, Liza V. Anzalota Crespo-Hernandez, Noe Jimenez-Velez, Braulio Alshawabkeh, Akram N. Cordero, Jose F. TI Distribution, Variability, and Predictors of Urinary Concentrations of Phenols and Parabens among Pregnant Women in Puerto Rico SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID ENDOCRINE-DISRUPTING CHEMICALS; BISPHENOL-A CONCENTRATIONS; HORMONE-LEVELS; US POPULATION; EXPOSURE; CHILDREN; OBESITY; BIRTH; PREVALENCE; OVERWEIGHT AB Puerto Rico has higher rates of a range of endocrine-related diseases and disorders compared to the United States. However, little is known to date about human exposures to known or potential endocrine disrupting chemicals (EDCs) in Puerto Rico. We recruited 105 pregnant women in Northern Puerto Rico who provided urine samples and questionnaire data at three times (18 +/- 2, 22 +/- 2, and 26 +/- 2 weeks) during gestation. We measured the urinary concentrations of five phenols and three parabens: 2,4-dichlorophenol (24-DCP), 2,5-dichlorophenol (25-DCP), benzophenone-3 (BP-3), bisphenol A (BPA), triclosan (TCS), butyl paraben (B-PB), methyl paraben (M-PB), and propyl paraben (P-PB). The frequent detection of these chemicals suggests that exposure is highly prevalent among these Puerto Rican pregnant women. Urinary concentrations of TCS,BP-3, and 25-DCP were higher than among women of reproductive age in the US general population, while concentrations of BPA, 24-DCP, and parabens were similar. Intraclass correlation coefficients (ICC) varied widely between biomarkers; BPA had the lowest ICC (0.24) and BP-3 had the highest (0.62), followed by 25-DCP (0.49) and TCS (0.47). We found positive associations between biomarker concentrations with self-reported use of liquid soap (TCS), sunscreen (BP-3), lotion (BP-3 and parabens), and cosmetics (parabens). Our results can inform future epidemiology studies and strategies to reduce exposure to these chemicals or their precursors. C1 [Meeker, John D.; Cantonwine, David E.; Rivera-Gonzalez, Luis O.; Ferguson, Kelly K.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Mukherjee, Bhramar] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Atlanta, GA USA. [Del Toro, Liza V. Anzalota; Crespo-Hernandez, Noe; Jimenez-Velez, Braulio; Cordero, Jose F.] Univ Puerto Rico, Grad Sch Publ Hlth, San Juan, PR 00936 USA. [Alshawabkeh, Akram N.] Northeastern Univ, Coll Engn, Boston, MA 02115 USA. RP Meeker, JD (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Room M6017 SPH Tower,1415 Washington Hts, Ann Arbor, MI 48109 USA. EM meekerj@umich.edu OI Meeker, John/0000-0001-8357-5085; Ferguson, Kelly/0000-0001-8467-3250 FU National Institute of Environmental Health Sciences (NIEHS) [P42ES017198, P30ES017885] FX The project described was supported by P42ES017198 and P30ES017885 from the National Institute of Environmental Health Sciences (NIEHS). The content is solely the responsibility of the authors and does not necessarily represent the official views of Centers for Disease Control and Prevention, the National Institute of Environmental Health Sciences, or the National Institutes of Health. We gratefully acknowledge Xiaoliu Zhou, Tao Jia, and Joshua Kramer for technical assistance in measuring the urinary concentrations of the phenols and parabens. NR 45 TC 87 Z9 88 U1 6 U2 87 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X EI 1520-5851 J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD APR 2 PY 2013 VL 47 IS 7 BP 3439 EP 3447 DI 10.1021/es400510g PG 9 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 120LZ UT WOS:000317173100055 PM 23469879 ER PT J AU Kamimoto, L Euler, GL Lu, PJ Reingold, A Hadler, J Gershman, K Farley, M Terebuh, P Ryan, P Lynfield, R Albanese, B Thomas, A Craig, AS Schaffner, W Finelli, L Bresee, J Singleton, JA AF Kamimoto, Laurie Euler, Gary L. Lu, Peng-Jun Reingold, Arthur Hadler, James Gershman, Ken Farley, Monica Terebuh, Pauline Ryan, Patricia Lynfield, Ruth Albanese, Bernadette Thomas, Ann Craig, Allen S. Schaffner, William Finelli, Lyn Bresee, Joseph Singleton, James A. TI Seasonal Influenza Morbidity Estimates Obtained From Telephone Surveys, 2007 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; PRESCRIBING PRACTICES; ILLNESS; VACCINATION AB Objectives. We assessed telephone surveys as a novel surveillance method, comparing data obtained by telephone with existing national influenza surveillance systems, and evaluated the utility of telephone surveys. Methods. We used the 2007 Behavioral Risk Factor Surveillance System (BRFSS) and the 2007 National Immunization Survey-Adult (NIS-Adult) to estimate the incidence of influenza-like illness (ILI), medically attended ILI, provider-diagnosed influenza, influenza testing, and treatment of influenza with antiviral medications during the 2006-2007 influenza season. Results. With the January-May BRFSS, among persons aged 18 years and older, the cumulative incidence of seasonal ILI and provider-diagnosed influenza was 37.9 and 5.7 adults per 100 persons, respectively. Monthly medically attended ILI and provider-diagnosed influenza among adults were temporally associated with influenza activity, as documented by national surveillance. With the NIS-Adult survey data, estimated provider-diagnosed influenza, influenza testing, and antiviral treatment were 2.8%, 1.4%, and 0.6%, respectively. Conclusions. Our telephone interview-based estimates of influenza morbidity were consistent with those from national influenza surveillance systems. Telephone surveys may provide an alternative method by which population-based influenza morbidity information can be gathered. C1 [Kamimoto, Laurie; Finelli, Lyn; Bresee, Joseph] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Euler, Gary L.; Lu, Peng-Jun; Singleton, James A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Reingold, Arthur] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Hadler, James] Connecticut Dept Publ Hlth, Hartford, CT USA. [Gershman, Ken] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Farley, Monica] Emory Univ, Sch Med, Atlanta, GA USA. [Farley, Monica] VA Med Ctr, Atlanta, GA USA. [Terebuh, Pauline] Georgia Dept Human Resources, Div Publ Hlth, Atlanta, GA USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Albanese, Bernadette] New Mexico Dept Hlth, Santa Fe, NM USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Craig, Allen S.] Tennessee Dept Hlth, Nashville, TN USA. [Schaffner, William] Vanderbilt Univ Sch Med, Nashville, TN USA. RP Kamimoto, L (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd MS E-45, Atlanta, GA 30333 USA. EM lkamimoto@cdc.gov FU Centers for Disease Control and Prevention FX Support for the Emerging Infections Program is provided by the Centers for Disease Control and Prevention. NR 29 TC 2 Z9 2 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2013 VL 103 IS 4 BP 755 EP 763 DI 10.2105/AJPH.2012.300799 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA0DU UT WOS:000330766100046 PM 23237164 ER PT J AU Culwell, KR Curtis, KM AF Culwell, Kelly R. Curtis, Kathryn M. TI Contraceptive options for women with SLE: response to Mansour letter SO JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE LA English DT Letter ID SYSTEMIC-LUPUS-ERYTHEMATOSUS C1 [Culwell, Kelly R.] Univ Calif Davis, Dept Obstet & Gynecol, Davis, CA 95616 USA. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Culwell, KR (reprint author), Univ Calif Davis, Dept Obstet & Gynecol, Davis, CA 95616 USA. EM kelly.culwell@ucdmc.ucdavis.edu; kmc6@cdc.gov NR 5 TC 1 Z9 1 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1471-1893 EI 2045-2098 J9 J FAM PLAN REPROD H JI J. Fam. Plan. Reprod. Health Care PD APR PY 2013 VL 39 IS 2 BP 151 EP U101 DI 10.1136/jfprhc-2012-100574 PG 2 WC Family Studies; Obstetrics & Gynecology; Social Sciences, Biomedical SC Family Studies; Obstetrics & Gynecology; Biomedical Social Sciences GA 301FM UT WOS:000330518200023 PM 23493600 ER PT J AU Ashman, JJ Beresovsky, V AF Ashman, Jill Jacobsen Beresovsky, Vladislav TI Multiple Chronic Conditions Among US Adults Who Visited Physician Offices: Data From the National Ambulatory Medical Care Survey, 2009 SO PREVENTING CHRONIC DISEASE LA English DT Article AB Most research on adults with chronic conditions focuses on a single disease or condition, such as hypertension or diabetes, rather than on multiple chronic conditions (MCC). Our study's objective was to compare physician office visits by adults with MCC with visits by adults without MCC, by selected patient demographic characteristics. We also identified the most prevalent dyads and triads of chronic conditions among these patients. We used the National Ambulatory Medical Care Survey, a nationally representative survey of office visits to nonfederal physicians and used 1 3 of the 20 conditions defined by the National Strategic Framework on Multiple Chronic Conditions. Descriptive estimates were generated and significant differences were tested. In 2009, an estimated 326 million physician office visits, were made by adults aged 1 8 years or older with MCC representing 37.6% of all medical office visits by adults. Hypertension was the most prevalent chronic condition that appeared in the top 5 MCC dyads and triads, by sex and age groups. The number of visits by patients with MCC increased with age and was greater for men than for women and for adults with public rather than private insurance. Physicians were more likely to prescribe medications at office visits made by patients with MCC. Physician office visits by adults with MCC were not evenly distributed by demographic characteristics C1 [Ashman, Jill Jacobsen] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth Care Stat, Hyattsville, MD 20782 USA. [Beresovsky, Vladislav] Ctr Dis Control & Prevent, Hyattsville, MD 20782 USA. RP Ashman, JJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth Care Stat, 3311 Toledo Rd,Room 3229, Hyattsville, MD 20782 USA. EM JAshman@cdc.gov NR 3 TC 6 Z9 6 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120308 DI 10.5888/pcd10.120308 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700018 ER PT J AU Ford, ES Croft, JB Posner, SF Goodman, RA Giles, WH AF Ford, Earl S. Croft, Janet B. Posner, Samuel F. Goodman, Richard A. Giles, Wayne H. TI Co-Occurrence of Leading Lifestyle-Related Chronic Conditions Among Adults in the United States, 2002-2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID MULTIPLE CHRONIC CONDITIONS; CHRONIC DISEASES; HEALTH OUTCOMES; COMORBIDITY; POPULATION; PREVALENCE; QUALITY; CONSEQUENCES; MORTALITY; DEATH AB Introduction Public health and clinical strategies for meeting the emerging challenges of multiple chronic conditions must address the high prevalence of lifestyle-related causes. Our objective was to assess prevalence and trends in the chronic conditions that are leading causes of disease and death among adults in the United States that are amenable to preventive lifestyle interventions. Methods We used self-reported data from 196,240 adults aged 25 years or older who participated in the National Health Interview Surveys from 2002 to 2009. We included data on cardiovascular disease (coronary heart disease, angina pectoris, heart attack, and stroke), cancer, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), diabetes, and arthritis. Results In 2002, an unadjusted 63.6% of participants did not have any of the 5 chronic conditions we assessed; 23.9% had 1, 9.0% had 2, 2.9% had 3, and 0.7% had 4 or 5. By 2009, the distribution of co-occurrence of the 5 chronic conditions had shifted subtly but significantly. From 2002 to 2009, the age-adjusted percentage with 2 or more chronic conditions increased from 12.7% to 14.7% (P < .001), and the number of adults with 2 or more conditions increased from approximately 23.4 million to 30.9 million. Conclusion The prevalence of having 1 or more or 2 or more of the leading lifestyle-related chronic conditions increased steadily from 2002 to 2009. If these increases continue, particularly among younger adults, managing patients with multiple chronic conditions in the aging population will continue to challenge public health and clinical practice. C1 [Ford, Earl S.; Croft, Janet B.; Posner, Samuel F.; Goodman, Richard A.; Giles, Wayne H.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Goodman, Richard A.] Emory Univ, Sch Med, Atlanta, GA USA. [Goodman, Richard A.] US Dept Hlth & Human Serv, Washington, DC USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 33 TC 6 Z9 6 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120316 DI 10.5888/pcd10.120316 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700014 ER PT J AU Friedman, DB Rose, ID Anderson, LA Hunter, R Bryant, LL Wu, B Deokar, AJ Tseng, W AF Friedman, Daniela B. Rose, India D. Anderson, Lynda A. Hunter, Rebecca Bryant, Lucinda L. Wu, Bei Deokar, Angela J. Tseng, Winston TI Beliefs and Communication Practices Regarding Cognitive Functioning Among Consumers and Primary Care Providers in the United States, 2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID OLDER-ADULTS; ALZHEIMER-DISEASE; HEALTHY BRAIN; INFORMATION; AWARENESS; POPULATION; IMPAIRMENT; PHYSICIANS; MAGAZINES; TRUST AB Introduction Limited research has examined primary care providers' communication with patients about maintaining cognitive functioning. Our study's objective was to compare the perceptions of consumers and primary care providers related to beliefs and communication practices about lifestyle behaviors beneficial for overall health and for maintaining cognitive functioning. Methods In 2009, we submitted 10 questions to Porter Novelli's HealthStyles survey and 6 questions to their DocStyles survey. We compared consumers' (n = 4,728) and providers' (n = 1,250) beliefs, practices, and information sources related to maintaining health and cognitive functioning. We made comparisons using nonparametric statistics. Results Approximately 7 6% of consumers considered their health to be good or very good; 73.4% were concerned or very concerned about the possibility that their memory may worsen with age. Women were significantly more concerned than men, and white consumers were more concerned than black and Hispanic consumers. Consumers reported they believed that intellectual stimulation (86.6%), physical activity (82.6%), and healthful diet (82.5%) prevented or delayed cognitive impairment. Providers reported advising patients to reduce cognitive impairment risk through physical activity (85.9%), intellectual stimulation (80.3%), and social involvement (67.4%). Few consumers (7.8%) reported receiving this information from providers but reported learning about strategies to maintain memory, primarily from television (50.1%), magazines (44.1%), and newspapers (33.7%). Conclusion Providers reported advising patients about how to reduce risks of cognitive impairment. Consumers reported receiving this information from other sources. Findings suggest a need to examine and assess media messages and to better understand patient-provider communication about cognitive functioning. C1 [Rose, India D.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA. [Friedman, Daniela B.] Univ S Carolina, Columbia, SC 29208 USA. [Anderson, Lynda A.; Deokar, Angela J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Anderson, Lynda A.] Emory Univ, Atlanta, GA 30322 USA. [Hunter, Rebecca] Univ N Carolina, Chapel Hill, NC USA. [Bryant, Lucinda L.] Univ Colorado, Denver, CO 80202 USA. [Wu, Bei] Duke Univ, Durham, NC USA. [Tseng, Winston] Univ Calif Berkeley, Berkeley, CA 94720 USA. RP Rose, ID (reprint author), Univ S Carolina, Arnold Sch Publ Hlth, Dept Hlth Promot Educ & Behav, 800 Sumter St, Columbia, SC 29208 USA. EM irose@teenpregnancysc.org FU CDC Healthy Aging Program; CDC's Prevention Research Centers program: Special Interest Project (SIP) [13-04, SIP 8-06, SIP 09-027,]; [U48-DP-000025]; [U48-DP-000033]; [U48-DP-000045]; [U48-DP-000048]; [U48-DP-000050]; [U48-DP-000051]; [U48-DP-000052]; [U48-DP-000054]; [U48-DP-000059]; [U48-DP-001936]; [U48-DP-001938]; [U48-DP-001944]; [U48-DP-001908] FX This research is the result of work conducted by CDC's Healthy Aging Research Network, a CDC Prevention Research Centers program funded by the CDC Healthy Aging Program. The research was supported in part by cooperative agreements from CDC's Prevention Research Centers program: Special Interest Project (SIP) 13-04, SIP 8-06, SIP 09-027, and by cooperative agreement nos. U48-DP-000025, U48-DP-000033, U48-DP-000045, U48-DP-000048, U48-DP-000050, U48-DP-000051, U48-DP-000052, U48-DP-000054, U48-DP-000059, U48-DP-001936, U48-DP-001938, U48-DP-001944, and U48-DP-001908. NR 33 TC 3 Z9 3 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120249 DI 10.5888/pcd10.120249 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700012 ER PT J AU Goodman, AB Blanck, HM Sherry, B Park, S Nebeling, L Yaroch, AL AF Goodman, Alyson B. Blanck, Heidi M. Sherry, Bettylou Park, Sohyun Nebeling, Linda Yaroch, Amy L. TI Behaviors and Attitudes Associated With Low Drinking Water Intake Among US Adults, Food Attitudes and Behaviors Survey, 2007 SO PREVENTING CHRONIC DISEASE LA English DT Article ID WEIGHT-LOSS; ENERGY-INTAKE; CONSUMPTION PATTERNS; CALORIC BEVERAGES; NATIONAL-HEALTH; BODY-WEIGHT; DIET; BMI; ADOLESCENTS; COMMUNITY AB Introduction Water is vital for life, and plain water is a calorie-free option for hydration. Increasing consumption of drinking water is a strategy to reduce energy intake and lose or maintain weight; however, information on the characteristics of consumers who drink water is limited. Our objective was to describe the characteristics of people who have a low intake of drinking water and to determine associations between their behaviors and attitudes and their intake of water. Methods We analyzed data from a nationally representative sample of 3,397 US adults who participated in the National Cancer Institute's 2007 Food Attitudes and Behaviors Survey. Multivariable logistic regression was used to identify sociodemographic characteristics and health-related behaviors and attitudes associated with self-reported drinking water intake of less than 4 cups per day. Results Overall, 7% of adults reported no daily consumption of drinking water, 36% reported drinking 1 to 3 cups, 35% reported drinking 4 to 7 cups, and 22% reported drinking 8 cups or more. The likelihood of drinking less than 4 cups of water daily was significantly higher among participants aged 55 years or older than among those aged 18 to 34 (adjusted odds ratio [AOR], 1.3), among residents of the Northeast than among residents of the South (AOR, 1.4), among participants who consumed 1 cup or less of fruits or vegetables per day than among those who consumed 4.5 cups or more (AOR, 3.0), among participants who did not exercise than among those who exercised 150 minutes or more per week (AOR, 1.7), and among participants who were neither trying to gain nor lose weight than among those trying to lose weight (AOR, 1.3). Conclusion Low drinking water intake was associated with age, region of residence, and several unhealthful behaviors and attitudes. Understanding characteristics associated with low drinking water intake may help to identify populations that could benefit from interventions to help adults drink more water. C1 [Goodman, Alyson B.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Blanck, Heidi M.; Sherry, Bettylou; Park, Sohyun] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Nebeling, Linda] NCI, Washington, DC USA. [Yaroch, Amy L.] Swanson Ctr Nutr, Omaha, NE USA. RP Goodman, AB (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Highway NE,Mailstop K-26, Atlanta, GA 30341 USA. EM agoodman@cdc.gov NR 29 TC 3 Z9 3 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120248 DI 10.5888/pcd10.120248 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700006 ER PT J AU Goodman, RA Posner, SF Huang, ES Parekh, AK Koh, HK AF Goodman, Richard A. Posner, Samuel F. Huang, Elbert S. Parekh, Anand K. Koh, Howard K. TI Defining and Measuring Chronic Conditions: Imperatives for Research, Policy, Program, and Practice SO PREVENTING CHRONIC DISEASE LA English DT Article ID CHRONIC HEALTH CONDITIONS; CARE; DISEASE; ILLNESS AB Current trends in US population growth, age distribution, and disease dynamics foretell rises in the prevalence of chronic diseases and other chronic conditions. These trends include the rapidly growing population of older adults, the increasing life expectancy associated with advances in public health and clinical medicine, the persistently high prevalence of some risk factors, and the emerging high prevalence of multiple chronic conditions. Although preventing and mitigating the effect of chronic conditions requires sufficient measurement capacities, such measurement has been constrained by lack of consistency in definitions and diagnostic classification schemes and by heterogeneity in data systems and methods of data collection. We outline a conceptual model for improving understanding of and standardizing approaches to defining, identifying, and using information about chronic conditions in the United States. We illustrate this model's operation by applying a standard classification scheme for chronic conditions to 5 national-level data systems. Although the literature does not support a single uniform definition for chronic disease, recurrent themes include the non-self-limited nature, the association with persistent and recurring health problems, and a duration measured in months and years, not days and weeks. Thrall (1) So far, many different approaches have been used to measure the prevalence and consequences of chronic diseases and health conditions in children, resulting in a wide variability of prevalence estimates that cannot be readily compared. van der Lee et al (2) C1 [Goodman, Richard A.; Posner, Samuel F.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Goodman, Richard A.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Atlanta, GA USA. [Goodman, Richard A.] Emory Univ, Div Gen Med & Geriatr, Atlanta, GA 30322 USA. [Huang, Elbert S.] Univ Chicago, Chicago, IL 60637 USA. [Parekh, Anand K.; Koh, Howard K.] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Washington, DC USA. RP Goodman, RA (reprint author), Ctr Dis Control & Prevent, Mailstop K-40,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM rag4@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 35 TC 48 Z9 49 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120239 DI 10.5888/pcd10.120239 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700020 ER PT J AU Hunter, RH Anderson, LA Belza, B Bodiford, K Hooker, SP Kochtitzky, CS Marquez, DX Satariano, WA AF Hunter, Rebecca H. Anderson, Lynda A. Belza, Basia Bodiford, Kristin Hooker, Steven P. Kochtitzky, Chris S. Marquez, David X. Satariano, William A. TI Environments for Healthy Aging: Linking Prevention Research and Public Health Practice SO PREVENTING CHRONIC DISEASE LA English DT Article ID PHYSICAL-ACTIVITY; OLDER-ADULTS AB Safe and well-designed community environments support healthful behaviors that help prevent chronic conditions and unintentional injuries and enable older adults to be active and engaged in community life for as long as possible. We describe the work of the Healthy Aging Research Network (HAN) and partners over the past decade to better understand place-based determinants of health and translate that knowledge to real-world practice, with a focus on environmental strategies. Using key components of the Knowledge to Action framework, we document the importance of a sustained, multidisciplinary, collaborative approach and ongoing interaction between researchers and communities. We share examples of practical tools and strategies designed to engage and support critical sectors with the potential to enhance the health and well-being of older adults and their communities. We conclude with a description of lessons learned in facilitating the translation of prevention research into practice. C1 [Hunter, Rebecca H.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC 27514 USA. [Anderson, Lynda A.; Kochtitzky, Chris S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Anderson, Lynda A.] Emory Univ, Atlanta, GA 30322 USA. [Belza, Basia] Univ Washington, Seattle, WA 98195 USA. [Bodiford, Kristin] Community Strengths, Alamo, CA USA. [Hooker, Steven P.] Arizona State Univ, Phoenix, AZ USA. [Marquez, David X.] Univ Illinois, Chicago, IL USA. [Satariano, William A.] Univ Calif Berkeley, Berkeley, CA 94720 USA. RP Hunter, RH (reprint author), Univ N Carolina, Ctr Hlth Promot & Dis Prevent, 228 Indian Trail Rd, Chapel Hill, NC 27514 USA. EM Rebecca_Hunter@unc.edu OI Hooker, Steven/0000-0001-9969-6244 FU CDC Healthy Aging Program; CDC's Prevention Research Centers Program [U48-DP-001911, 001908, 001921, 001924, 001936, 001938, 001944] FX This article is the result of work conducted by the CDC HAN, a Prevention Research Centers thematic network funded by the CDC Healthy Aging Program. Efforts were supported in part by cooperative agreements from CDC's Prevention Research Centers Program nos. U48-DP-001911, 001908, 001921, 001924, 001936, 001938, and 001944. We express gratitude to James LoGerfo, MD, MPH, who guided the development of HAN in its early years and who set the stage for this work. We also thank Gwen Moni, manager of the HAN Coordinating Center since its inception and a steadfast contributor to all of our work. NR 21 TC 4 Z9 4 U1 2 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120244 DI 10.5888/pcd10.120244 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700009 ER PT J AU Xuan, LTT Minh, HV Giang, KB Nga, PTQ Hai, PT Minh, NT Hsia, J AF Le Thi Thanh Xuan Hoang Van Minh Kim Bao Giang Pham Thi Quynh Nga Phan Thi Hai Nguyen Thac Minh Hsia, Jason TI Prevalence of Waterpipe Tobacco Smoking Among Population Aged 15 Years or Older, Vietnam, 2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID GLOBAL EPIDEMIC; STUDENTS; UNIVERSITY; SMOKERS AB Introduction The prevalence of waterpipe tobacco smoking is increasing globally and is associated with adverse outcomes requiring tobacco control interventions. We estimated the prevalence of waterpipe tobacco use among adult populations in Vietnam in 2010 and examined its association with sociodemographic factors. Methods We used data from the Global Adult Tobacco Survey (GATS) conducted in Vietnam in 2010. GATS surveyed a national representative sample of adults aged 15 years or older from 11,142 households by using a 2-phase sampling design analogous to a 3-stage stratified cluster sampling. Descriptive statistical analyses and multivariate logistic regression modeling were conducted. Results A total of 6.4% of Vietnamese aged 15 years or older (representing about 4.1 million adult waterpipe smokers) reported current waterpipe tobacco smoking. The prevalence of waterpipe tobacco smoking was significantly higher among men than women (13% vs 0.1%). Area of residence (rural or urban), age group, asset-based wealth quintile, and geographic region of residence were significantly associated with waterpipe tobacco smoking among men. The significant correlates of current waterpipe tobacco smoking among men were lower education levels, being middle-aged (45-54 years), lower asset-based wealth levels, living in rural areas, not living in the South East and the Mekong River Delta geographic regions, and the belief that smoking does not causes diseases. Conclusion Rural dwellers who are poor should be targeted in tobacco control programs. Further studies are needed that examine perceptions of the adverse health effects and the cultural factors of waterpipe tobacco smoking. C1 [Le Thi Thanh Xuan; Hoang Van Minh; Kim Bao Giang] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam. [Pham Thi Quynh Nga] World Hlth Org Off Vietnam, Hanoi, Vietnam. [Phan Thi Hai; Nguyen Thac Minh] Vietnam Steering Comm Smoking & Hlth, Hanoi, Vietnam. [Hsia, Jason] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Xuan, LTT (reprint author), Hanoi Med Univ, Inst Prevent Med & Publ Hlth, 1 Ton That Tung, Hanoi, Vietnam. EM lethithanhxuan@hmu.edu.vn FU Bloomberg Philanthropies FX This study was funded by the Bloomberg Philanthropies. We appreciate the contributions to the success of the survey made by the Centers for Disease Control and Prevention in Atlanta, the CDC Foundation, the World Health Organization, the General Statistics Office of Vietnam, and Hanoi Medical University. The authors have no competing interests to declare. NR 25 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120100 DI 10.5888/pcd10.120100 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700011 ER PT J AU Slonim, A Benson, W Anderson, LA Jones, E AF Slonim, Amy Benson, William Anderson, Lynda A. Jones, Ellen TI Strategic Priorities to Increase Use of Clinical Preventive Services Among Older US Adults SO PREVENTING CHRONIC DISEASE LA English DT Article AB The objective of this project was to obtain professionals' perceptions of system-level strategies with potential to increase use of clinical preventive services (CPS) among adults aged 50 years or older through community settings. Public health, aging services, and medical professionals participated in guided discussions and a modified Delphi process. Priority strategies, determined on the basis of a 70% or higher a priori agreement level, included enhancing community capacity; promoting the design of health information technologies to exchange data between clinical and community settings; promoting care coordination; broadening scope of practice; providing incentives to employers; and eliminating cost-sharing. Findings provide insights about preferences for system-level strategies that align with national and state initiatives to increase CPS use. C1 [Slonim, Amy] Ctr Dis Control & Prevent AARP Liaison, Washington, DC 20049 USA. [Benson, William] CDC, Hlth Benefits ABCs, Hlth Aging Program, Atlanta, GA 30333 USA. [Anderson, Lynda A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jones, Ellen] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. RP Slonim, A (reprint author), Ctr Dis Control & Prevent AARP Liaison, 601 E St NW, Washington, DC 20049 USA. EM aslonim@aarp.org FU National Association of Chronic Disease Directors (NACDD); Centers for Disease Control and Prevention (CDC) [5U58DP002759-03] FX This public health project was conducted under the auspices of the National Association of Chronic Disease Directors (NACDD), and we acknowledge the contribution of the NACDD to this publication. Publication was supported by grant/cooperative agreement no. 5U58DP002759-03 from the Centers for Disease Control and Prevention (CDC). The contents of this article are solely the responsibility of the authors and do not necessarily reflect the view of CDC or NACDD. NACDD and CDC also shall have the right to obtain, reproduce, publish, or otherwise use any data first developed or produced by the Contractor pursuant to this Agreement. Use of trade names is for identification only and does not imply endorsement by any of the groups named. We thank the following people for their contributions to the acquisition and interpretation of data or review of the manuscript: Paula Zdanowicz, MPH, AARP; Jolie Crowder, RN, MSN, Consultant, Health Benefits ABCs; Kelly E. Griffin, MMA, AARP (now at Corporation for National and Community Service, Washington, DC); Andree C. Harris, CDC; and Susan Diane Baker (Toal), MPH, Consultant, NACDD. NR 11 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120231 DI 10.5888/pcd10.120231 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700007 ER PT J AU Ward, BW Schiller, JS AF Ward, Brian W. Schiller, Jeannine S. TI Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From the National Health Interview Survey, 2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID MULTIMORBIDITY; CARE; POPULATION; QUALITY; COSTS AB Preventing and ameliorating chronic conditions has long been a priority in the United States; however, the increasing recognition that people often have multiple chronic conditions (MCC) has added a layer of complexity with which to contend. The objective of this study was to present the prevalence of MCC and the most common MCC dyads/triads by selected demographic characteristics. We used respondent-reported data from the 2010 National Health Interview Survey (NHIS) to study the US adult civilian noninstitutionalized population aged 18 years or older (n = 27,157). We categorized adults as having 0 to 1, 2 to 3, or 4 or more of the following chronic conditions: hypertension, coronary heart disease, stroke, diabetes, cancer, arthritis, hepatitis, weak or failing kidneys, chronic obstructive pulmonary disease, or current asthma. We then generated descriptive estimates and tested for significant differences. Twenty-six percent of adults have MCC; the prevalence of MCC has increased from 21.8% in 2001 to 26.0% in 2010. The prevalence of MCC significantly increased with age, was significantly higher among women than men and among non-Hispanic white and non-Hispanic black adults than Hispanic adults. The most common dyad identified was arthritis and hypertension, and the combination of arthritis, hypertension, and diabetes was the most common triad. The findings of this study contribute information to the field of MCC research. The NHIS can be used to identify population subgroups most likely to have MCC and potentially lead to clinical guidelines for people with more common MCC combinations. C1 [Ward, Brian W.] Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Schiller, Jeannine S.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Ward, BW (reprint author), Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 2330, Hyattsville, MD 20782 USA. EM bwward@cdc.gov NR 21 TC 77 Z9 78 U1 7 U2 18 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2013 VL 10 AR UNSP 120203 DI 10.5888/pcd10.120203 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JS UT WOS:000329390700019 PM 23618545 ER PT J AU Wright, NC Looker, AC Saag, KG Curtis, JR Delzell, ES Randall, S Dawson-Hughes, B AF Wright, Nicole C. Looker, Ann C. Saag, Kenneth G. Curtis, Jeffrey R. Delzell, Elizabeth S. Randall, Susan Dawson-Hughes, Bess TI THE RECENT BURDEN OF OSTEOPOROSIS AND LOW BONE MASS IN THE UNITED STATES SO OSTEOPOROSIS INTERNATIONAL LA English DT Meeting Abstract CT Interdisciplinary Symposium on Osteoporosis - Patient-Centered Care - Developing Successful Bone Health Teams CY APR 18-21, 2013 CL Chicago, IL SP Natl Osteoporosis Fdn C1 [Wright, Nicole C.; Saag, Kenneth G.; Curtis, Jeffrey R.; Delzell, Elizabeth S.] Univ Alabama, Tuscaloosa, AL 35487 USA. [Looker, Ann C.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Dawson-Hughes, Bess] Tufts Univ, Medford, MA 02155 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD APR PY 2013 VL 24 SU 2 MA P43 BP S440 EP S441 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 270WN UT WOS:000328350000033 ER PT J AU Peters, PJ Brooks, JT McAllister, SK Limbago, B Lowery, HK Fosheim, G Guest, JL Gorwitz, RJ Bethea, M Hageman, J Mindley, R McDougal, LK Rimland, D AF Peters, Philip J. Brooks, John T. McAllister, Sigrid K. Limbago, Brandi Lowery, H. Ken Fosheim, Gregory Guest, Jodie L. Gorwitz, Rachel J. Bethea, Monique Hageman, Jeffrey Mindley, Rondeen McDougal, Linda K. Rimland, David TI Methicillin-Resistant Staphylococcus aureus Colonization of the Groin and Risk for Clinical Infection among HIV-infected Adults SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NASAL CARRIAGE; UNITED-STATES; SKIN INFECTIONS; PREVALENCE; EMERGENCE; POPULATION; CARE; MRSA; SEX; MEN AB Data on the interaction between methicillin-resistant Staphylococcus aureus (MRSA) colonization and clinical infection are limited. During 2007-2008, we enrolled HIV-infected adults in Atlanta, Georgia, USA, in a prospective cohort study. Nares and groin swab specimens were cultured for S. aureus at enrollment and after 6 and 12 months. MRSA colonization was detected in 13%-15% of HIV-infected participants (n = 600, 98% male) at baseline, 6 months, and 12 months. MRSA colonization was detected in the nares only (41%), groin only (21%), and at both sites (38%). Over a median of 2.1 years of follow-up, 29 MRSA clinical infections occurred in 25 participants. In multivariate analysis, MRSA clinical infection was significantly associated with MRSA colonization of the groin (adjusted risk ratio 4.8) and a history of MRSA infection (adjusted risk ratio 3.1). MRSA prevention strategies that can effectively prevent or eliminate groin colonization are likely necessary to reduce clinical infections in this population. C1 [Peters, Philip J.; Brooks, John T.; McAllister, Sigrid K.; Limbago, Brandi; Fosheim, Gregory; Gorwitz, Rachel J.; Hageman, Jeffrey; McDougal, Linda K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Lowery, H. Ken; Guest, Jodie L.; Bethea, Monique; Mindley, Rondeen; Rimland, David] Vet Affairs Med Ctr, Atlanta, GA 30033 USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. RP Peters, PJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E45, Atlanta, GA 30333 USA. EM pjpeters@cdc.gov FU Division of HIV/AIDS Prevention; Division of Healthcare Quality Promotion, CDC FX This publication was made possible by support from the Division of HIV/AIDS Prevention and the Division of Healthcare Quality Promotion, CDC. These data were presented in part at the 48th Annual Infectious Disease Society of America Meeting, Vancouver, British Columbia, Canada, October 21-24, 2010. NR 31 TC 16 Z9 16 U1 3 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2013 VL 19 IS 4 BP 623 EP 629 DI 10.3201/eid1904.121353 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LV UT WOS:000328173100013 PM 23631854 ER PT J AU Munoz-Jordan, JL Santiago, GA Margolis, H Stark, L AF Munoz-Jordan, Jorge L. Santiago, Gilberto A. Margolis, Harold Stark, Lillian TI Genetic Relatedness of Dengue Viruses in Key West, Florida, USA, 2009-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article AB Sequencing of dengue virus type 1 (DENV-1) strains isolated in Key West/Monroe County, Florida, indicate endemic transmission for >= 2 years of a distinct and predominant sublineage of the American-African genotype. DENV-1 strains isolated elsewhere in Florida grouped within a separate Central American lineage. Findings indicate endemic transmission of DENV into the continental United States. C1 [Munoz-Jordan, Jorge L.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00969 USA. [Santiago, Gilberto A.; Margolis, Harold] Ctr Dis Control & Prevent, San Juan, PR 00969 USA. [Stark, Lillian] Florida Dept Hlth, Tampa, FL USA. RP Munoz-Jordan, JL (reprint author), Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00969 USA. EM ckq2@cdc.gov NR 14 TC 10 Z9 10 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2013 VL 19 IS 4 BP 652 EP 654 DI 10.3201/eid1904.121295 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LV UT WOS:000328173100020 PM 23632064 ER PT J AU Feng, Y Fu, SH Zhang, HL Petersen, LR Zhang, BS Gao, XY Yang, WH Zhang, YZ Dao, BQ Li, KH Li, N Yin, ZL Liu, YH Nasci, R Wang, HY Liang, GD AF Feng, Yun Fu, Shihong Zhang, Hailin Petersen, Lyle R. Zhang, Baosen Gao, Xiaoyan Yang, Weihong Zhang, Yuzhen Dao, Baoqing Li, Kunhong Li, Na Yin, Zhengliu Liu, Yonghua Nasci, Roger Wang, Huanyu Liang, Guodong TI High Incidence of Japanese Encephalitis, Southern China SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID MAINLAND CHINA C1 [Feng, Yun; Zhang, Hailin; Yang, Weihong; Zhang, Yuzhen] Yunnan Inst Endem Dis Control & Prevent, Dali, Peoples R China. [Fu, Shihong; Gao, Xiaoyan; Wang, Huanyu; Liang, Guodong] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control Prevent, Beijing 100052, Peoples R China. [Petersen, Lyle R.; Nasci, Roger] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Zhang, Baosen; Dao, Baoqing; Li, Kunhong; Li, Na] Dehong Prefecture Ctr Dis Control & Prevent, Mangshi, Peoples R China. [Yin, Zhengliu; Liu, Yonghua] Ruili Ctr Dis Control & Prevent, Ruili, Peoples R China. RP Liang, GD (reprint author), Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Inst Viral Dis Control & Prevent, Beijing 100052, Peoples R China. EM gdliang@hotmail.com FU CGH CDC HHS [U19-GH000004] NR 7 TC 4 Z9 8 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2013 VL 19 IS 4 BP 672 EP 673 DI 10.3201/eid1904.120137 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LV UT WOS:000328173100027 PM 23750863 ER PT J AU Appleby, BS Lu, M Bizzi, A Phillips, MD Berri, SM Harbison, MD Schonberger, LB AF Appleby, Brian S. Lu, Mei Bizzi, Alberto Phillips, Michael D. Berri, Sally M. Harbison, Madeleine D. Schonberger, Lawrence B. TI Iatrogenic Creutzfeldt-Jakob Disease from Commercial Cadaveric Human Growth Hormone SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Appleby, Brian S.; Lu, Mei; Phillips, Michael D.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Bizzi, Alberto] Inst Clin Humanitas, Milan, Italy. [Berri, Sally M.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Harbison, Madeleine D.] Mt Sinai Sch Med, New York, NY USA. [Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Appleby, BS (reprint author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 9500 Euclid Ave U10, Cleveland, OH 44195 USA. EM applebb@ccf.org RI Appleby, Brian/A-3390-2008; Bizzi, Alberto/K-3141-2016 OI Bizzi, Alberto/0000-0002-0253-5274 NR 6 TC 2 Z9 3 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2013 VL 19 IS 4 BP 682 EP 684 DI 10.3201/eid1904.121504 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LV UT WOS:000328173100032 PM 23750511 ER PT J AU Slayton, RB Date, KA Mintz, ED AF Slayton, Rachel B. Date, Kashmira A. Mintz, Eric D. TI Vaccination for typhoid fever in Sub-Saharan Africa SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE Typhoid fever; Salmonella Typhi; Africa; vaccination; epidemiology ID ASIAN COUNTRIES; OUTBREAK; VACCINES; TY21A; IMMUNIZATION; INFECTIONS; BURDEN; WATER AB Emerging data on the epidemiologic, clinical and microbiologic aspects of typhoid fever in sub-Saharan Africa call for new strategies and new resources to bring the regional epidemic under control. Areas with endemic disease at rates approaching those in south Asia have been identified; large, prolonged and severe outbreaks are occurring more frequently; and resistance to antimicrobial agents, including fluoroquinolones is increasing. Surveillance for typhoid fever is hampered by the lack of laboratory resources for rapid diagnosis, culture confirmation and antimicrobial susceptibility testing. Nonetheless, in 2010, typhoid fever was estimated to cause 725 incident cases and 7 deaths per 100,000 person years in sub-Saharan Africa. Efforts for prevention and outbreak control are challenged by limited access to safe drinking water and sanitation and by a lack of resources to initiate typhoid immunization. A comprehensive approach to typhoid fever prevention including laboratory and epidemiologic capacity building, investments in water, sanitation and hygiene and reconsideration of the role of currently available vaccines could significantly reduce the disease burden. Targeted vaccination using currently available typhoid vaccines should be considered as a short- to intermediate-term risk reduction strategy for high-risk groups across sub-Saharan Africa. C1 [Slayton, Rachel B.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Slayton, Rachel B.; Mintz, Eric D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Date, Kashmira A.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. RP Slayton, RB (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM via3@cdc.gov OI Slayton, Rachel/0000-0003-4699-8040 NR 32 TC 10 Z9 10 U1 0 U2 1 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD APR 1 PY 2013 VL 9 IS 4 BP 903 EP 906 DI 10.4161/hv.23007 PG 4 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 259TP UT WOS:000327549500034 PM 23563513 ER PT J AU Chapman, DP Presley-Cantrell, LR Liu, Y Perry, GS Wheaton, AG Croft, JB AF Chapman, Daniel P. Presley-Cantrell, Letitia R. Liu, Yong Perry, Geraldine S. Wheaton, Anne G. Croft, Janet B. TI Frequent Insufficient Sleep and Anxiety and Depressive Disorders Among US Community Dwellers in 20 States, 2010 SO PSYCHIATRIC SERVICES LA English DT Article ID QUALITY-OF-LIFE; HEALTH BEHAVIORS; ASSOCIATIONS AB Objective: This investigation examined the association of anxiety or depressive disorder and frequent insufficient sleep. Methods: Data were obtained from a 2010 telephone survey of a population-based sample of 113,936 adults in 20 states. Respondents were asked how often they did not get enough rest or sleep and if they had ever received a diagnosis of an anxiety or depressive disorder. Frequent insufficient sleep was defined as insufficient rest or sleep during >= 14 of the past 30 days. Results: Frequent insufficient sleep was reported by 27.0% of the sample and was significantly more common (p<.05) among respondents who reported both anxiety and depressive disorders (48.6%), depressive disorders only (39.0%), or anxiety only (37.5%) than among adults who reported neither disorder (23.1%). Conclusions: Frequent insufficient sleep is associated with depressive and anxiety disorders, and the odds of the sleep disorder are increased when both classes of psychiatric disorders are diagnosed. C1 [Chapman, Daniel P.; Presley-Cantrell, Letitia R.; Liu, Yong; Perry, Geraldine S.; Wheaton, Anne G.; Croft, Janet B.] Ctr Dis Control & Prevent, Epidemiol Support Branch, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Chapman, DP (reprint author), Ctr Dis Control & Prevent, Epidemiol Support Branch, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-67, Atlanta, GA 30341 USA. EM dpc2@cdc.gov NR 10 TC 9 Z9 9 U1 0 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2013 VL 64 IS 4 BP 385 EP 387 DI 10.1176/appi.ps.201200226 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 255VL UT WOS:000327268100024 PM 23543168 ER PT J AU DeGue, S Massetti, GM Holt, MK Tharp, AT Valle, LA Matjasko, JL Lippy, C AF DeGue, Sarah Massetti, Greta M. Holt, Melissa K. Tharp, Andra Teten Valle, Linda Anne Matjasko, Jennifer L. Lippy, Caroline TI Identifying Links Between Sexual Violence and Youth Violence Perpetration: New Opportunities for Sexual Violence Prevention SO PSYCHOLOGY OF VIOLENCE LA English DT Article DE rape; bullying; prevention; risk factors ID MIDDLE SCHOOL STUDENTS; SERIOUS JUVENILE-OFFENDERS; PAST BASE-LINE; RISK-FACTORS; SUBSTANCE USE; MULTISYSTEMIC THERAPY; ALCOHOL AVAILABILITY; AGGRESSIVE-BEHAVIOR; DELINQUENT-BEHAVIOR; BULLYING BEHAVIOR AB Objective: One promising opportunity for advancing sexual violence (SV) research and identifying new avenues for prevention involves examining other forms of violence that may share risk factors with SV. Youth violence (YV) is ideal for consideration given evidence of overlap in SV and YV risk factors, a large set of established YV risk factors across the social ecology, and the number of evidence-based YV prevention strategies available. The current paper identifies shared and unique risk factors for SV and YV and highlights evidence-based YV prevention strategies that impact these shared risk factors. Conclusions: Researchers and program developers should consider adapting and evaluating evidence-based YV prevention strategies to prevent SV. Modifying these programs to address SV's unique risk factors may maximize their potential effectiveness. In addition, expanding SV research at the outer levels of the social ecology is critical to developing community-level prevention strategies. The YV literature suggests several potential risk factors at these levels in need of research for SV, including school connectedness, social disorganization, and availability of alcohol and drugs. Using the YV literature as a starting point for expanding SV research leverages prior investments in YV research, may help identify new SV prevention strategies at a limited cost, and moves the field more quickly toward implementation of cost-effective, multidomain violence prevention strategies in communities. C1 [DeGue, Sarah; Massetti, Greta M.; Tharp, Andra Teten; Valle, Linda Anne; Matjasko, Jennifer L.; Lippy, Caroline] Ctr Dis Control & Prevent, Atlanta, GA USA. [Holt, Melissa K.] Boston Univ, Sch Educ, Boston, MA 02215 USA. RP DeGue, S (reprint author), 4770 Buford Highway,NE MS F-64, Atlanta, GA 30341 USA. EM sdegue@cdc.gov OI Massetti, Greta/0000-0002-3813-9839 NR 106 TC 7 Z9 7 U1 3 U2 14 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 EI 2152-081X J9 PSYCHOL VIOLENCE JI Psychol. Violence PD APR PY 2013 VL 3 IS 2 BP 140 EP 156 DI 10.1037/a0029084 PG 17 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA 246TS UT WOS:000326562600004 ER PT J AU Harley, KG Schall, RA Chevrier, J Tyler, K Aguirre, H Bradman, A Holland, NT Lustig, RH Calafat, AM Eskenazi, B AF Harley, Kim G. Schall, Raul Aguilar Chevrier, Jonathan Tyler, Kristin Aguirre, Helen Bradman, Asa Holland, Nina T. Lustig, Robert H. Calafat, Antonia M. Eskenazi, Brenda TI Prenatal and Postnatal Bisphenol A Exposure and Body Mass Index in Childhood in the CHAMACOS Cohort SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE bisphenol A; BMI; CHAMACOS; children; obesity ID PERINATAL EXPOSURE; URINARY CONCENTRATIONS; TEMPORAL VARIABILITY; REPRODUCTIVE-TRACT; METABOLIC SYNDROME; NEONATAL EXPOSURE; UNITED-STATES; OBESITY; RATS; MICE AB BACKGROUND: Bisphenol A (BPA), a widely used endocrine-disrupting chemical, has been associated with increased body weight and fat deposition in rodents. OBJECTIVES: We examined whether prenatal and postnatal urinary BPA concentrations were associated with body mass index (BMI), waist circumference, percent body fat, and obesity in 9-year-old children (n = 311) in the CHAMACOS longitudinal cohort study. METHODS: BPA was measured in spot urine samples collected from mothers twice during pregnancy and from children at 5 and 9 years of age. RESULTS: Prenatal urinary BPA concentrations were associated with decreased BMI at 9 years of age in girls but not boys. Among girls, being in the highest tertile of prenatal BPA concentrations was associated with decreased BMI z-score (beta = -0.47, 95% CI: -0.87, -0.07) and percent body fat (beta = -4.36, 95% CI: -8.37, -0.34) and decreased odds of overweight/obesity [odds ratio (OR) = 0.37, 95% CI: 0.16, 0.91] compared with girls in the lowest tertile. These findings were strongest in prepubertal girls. Urinary BPA concentrations at 5 years of age were not associated with any anthropometric parameters at 5 or 9 years, but BPA concentrations at 9 years were positively associated with BMI, waist circumference, fat mass, and overweight/obesity at 9 years in boys and girls. CONCLUSIONS: Consistent with other cross-sectional studies, higher urinary BPA concentrations at 9 years of age were associated with increased adiposity at 9 years. However, increasing BPA concentrations in mothers during pregnancy were associated with decreased BMI, body fat, and overweight/obesity among their daughters at 9 years of age. C1 [Harley, Kim G.; Schall, Raul Aguilar; Chevrier, Jonathan; Tyler, Kristin; Aguirre, Helen; Bradman, Asa; Holland, Nina T.; Eskenazi, Brenda] Univ Calif Berkeley, Ctr Environm Res & Childrens Hlth, Sch Publ Hlth, Berkeley, CA 94704 USA. [Lustig, Robert H.] Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Harley, KG (reprint author), Univ Calif Berkeley, Ctr Environm Res & Childrens Hlth, Sch Publ Hlth, 1995 Univ Ave,Suite 265, Berkeley, CA 94704 USA. EM kharley@berkeley.edu FU National Institute of Environmental Health Sciences [1RC2 ES018792, PO1 ES009605]; U.S. Environmental Protection Agency [R82670901, RD83171001, RD83451301] FX This work was supported by grants 1RC2 ES018792 and PO1 ES009605 from the National Institute of Environmental Health Sciences and grants R82670901, RD83171001, and RD83451301 from the U.S. Environmental Protection Agency. NR 45 TC 66 Z9 67 U1 1 U2 45 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD APR PY 2013 VL 121 IS 4 BP 514 EP 520 DI 10.1289/ehp.1205548 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208UM UT WOS:000323706100038 PM 23416456 ER PT J AU Coleman, CN Blumenthal, DJ Casto, CA Alfant, M Simon, SL Remick, AL Gepford, HJ Bowman, T Telfer, JL Blumenthal, PM Noska, MA AF Coleman, C. Norman Blumenthal, Daniel J. Casto, Charles A. Alfant, Michael Simon, Steven L. Remick, Alan L. Gepford, Heather J. Bowman, Thomas Telfer, Jana L. Blumenthal, Pamela M. Noska, Michael A. TI Recovery and Resilience After a Nuclear Power Plant Disaster: A Medical Decision Model for Managing an Effective, Timely, and Balanced Response SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE nuclear power plant; disaster resilience; disaster recovery; medical decision model ID CANCER-RISKS; HEALTH; JAPAN; FALLOUT AB Resilience after a nuclear power plant or other radiation emergency requires response and recovery activities that are appropriately safe, timely, effective, and well organized. Timely informed decisions must be made, and the logic behind them communicated during the evolution of the incident before the final outcome is known. Based on our experiences in Tokyo responding to the Fukushima Daiichi nuclear power plant crisis, we propose a real-time, medical decision model by which to make key health-related decisions that are central drivers to the overall incident management. Using this approach, on-site decision makers empowered to make interim decisions can act without undue delay using readily available and high-level scientific, medical, communication, and policy expertise. Ongoing assessment, consultation, and adaption to the changing conditions and additional information are additional key features. Given the central role of health and medical issues in all disasters, we propose that this medical decision model, which is compatible with the existing US National Response Framework structure, be considered for effective management of complex, large-scale, and large-consequence incidents. C1 [Coleman, C. Norman] NCI, Off Assistant Secretary Preparedness & Response, Radiat Res Program, Div Canc Treatment & Diag,NIH, Bethesda, MD 20892 USA. [Simon, Steven L.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Blumenthal, Daniel J.; Remick, Alan L.] Natl Nucl Secur Adm, Dept Energy, Washington, DC USA. [Casto, Charles A.; Gepford, Heather J.] Nucl Regulatory Commiss, Rockville, MD USA. [Alfant, Michael] Amer Chamber Commerce Japan, Tokyo, Japan. [Bowman, Thomas] Ctr Dis Control & Prevent, Div Strateg Natl Stockpile, Atlanta, GA USA. [Telfer, Jana L.] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Blumenthal, Pamela M.] Dept Housing & Urban Dev, Washington, DC USA. [Noska, Michael A.] US FDA, Silver Spring, MD USA. RP Coleman, CN (reprint author), 9609 Med Ctr Dr,Room 3W102, Rockville, MD 20850 USA. EM ccoleman@mail.nih.gov NR 33 TC 3 Z9 3 U1 0 U2 23 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD APR PY 2013 VL 7 IS 2 BP 136 EP 145 DI 10.1017/dmp.2013.5 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 200AF UT WOS:000323037100009 PM 24618164 ER PT J AU Groenewold, MR Konicki, DL Luckhaupt, SE Gomaa, A Koonin, LM AF Groenewold, Matthew R. Konicki, Doris L. Luckhaupt, Sara E. Gomaa, Ahmed Koonin, Lisa M. TI Exploring National Surveillance for Health-Related Workplace Absenteeism: Lessons Learned From the 2009 Influenza A Pandemic SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE surveillance; absenteeism; influenza; human ID NEW-YORK-CITY; SYNDROMIC SURVEILLANCE; SICKNESS ABSENCE; ILLNESS AB Background: During the 2009 influenza A (H1N1) virus pandemic, the Centers for Disease Control and Prevention did a pilot study to test the feasibility of using national surveillance of workplace absenteeism to assess the pandemic's impact on the workplace to plan for preparedness and continuity of operations and to contribute to health awareness during the emergency response. Methods: Population-based and sentinel worksite approaches were used. Monthly measures of the 1-week prevalence of health-related absenteeism among full-time workers were estimated using nationally representative data from the Current Population Survey. Enhanced passive surveillance of absenteeism was conducted using weekly data from a convenience sample of sentinel worksites. Results: Nationally, the pandemic's impact on workplace absenteeism was small. Estimates of 1-week absenteeism prevalence did not exceed 3.7%. However, peak workplace absenteeism was correlated with the highest occurrence of both influenza-like illness and influenza-positive laboratory tests. Conclusions: Systems for monitoring workplace absenteeism should be included in pandemic preparedness planning. C1 [Groenewold, Matthew R.; Luckhaupt, Sara E.; Gomaa, Ahmed] NIOSH, Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Konicki, Doris L.] Amer Coll Occupat & Environm Med, Elk Grove Village, IL USA. [Koonin, Lisa M.] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA USA. RP Groenewold, MR (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,MS R-17, Cincinnati, OH 45226 USA. EM gyr5@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 1 Z9 1 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD APR PY 2013 VL 7 IS 2 BP 160 EP 166 DI 10.1017/dmp.2013.8 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 200AF UT WOS:000323037100012 PM 24618167 ER PT J AU Strine, TW Neff, LJ Crawford, S AF Strine, Tara W. Neff, Linda J. Crawford, Sara TI Health-Related Quality of Life Domains and Household Preparedness for Public Health Emergencies: Behavioral Risk Factor Surveillance System, 2006-2010 SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE Quality of life; Public health preparedness; General health status; BRFSS ID DISASTER PREPAREDNESS; MENTAL-HEALTH; INTEGRATION; ADULTS AB Background: This study examined the association between self-reported levels of household disaster preparedness and a range of physical and mental health quality of life outcomes. Methods: Data collected from 14 states participating in a large state-based telephone survey were analyzed (n = 104 654). Household disaster-preparedness items included having a 3-day supply of food, water, and prescription medications; a working battery-powered radio and flashlight; an evacuation plan; and a willingness to evacuate when instructed to do so. Quality-of-life items were categorized into 2 domains: physical health (general health, unhealthy physical days, and activity-limited days) and mental health (unhealthy mental days, social and emotional support, and life satisfaction). Results: Persons with self-reported impaired mental health were generally less likely to report being prepared for a disaster than those who did not report impairment in each domain. Persons with low life satisfaction were among the least likely to be prepared, followed by those with inadequate social and emotional support, and then by those with frequent mental distress. Persons reporting physical impairments also reported deficits in many of the preparedness items. However, after adjusting for sociodemographic characteristics, some of the associations were attenuated and no longer significant. Conclusion: Persons reporting impaired quality of life are vulnerable to increased mental and physical distress during a disaster, and their vulnerability is compounded if they are ill-prepared. Therefore, persons reporting impaired quality of life should be included in the list of vulnerable populations that need disaster preparedness and response outreach. C1 [Strine, Tara W.; Neff, Linda J.; Crawford, Sara] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Off Sci & Publ Hlth Practice, Atlanta, GA 30333 USA. RP Strine, TW (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Off Sci & Publ Hlth Practice, 1600 Clifton Rd NE,MS K-72, Atlanta, GA 30333 USA. EM tws2@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 6 Z9 6 U1 3 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD APR PY 2013 VL 7 IS 2 BP 191 EP 200 DI 10.1017/dmp.2013.23 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 200AF UT WOS:000323037100016 PM 24618171 ER PT J AU Bayer, DK Seth, N Pearson, NM Chan, SK Bellini, WJ Baker, MW Noroski, LM Demmler-Harrison, GM Hanson, IC Seeborg, FO AF Bayer, Diana K. Seth, Neha Pearson, Nadia M. Chan, Sanny K. Bellini, William J. Baker, Mei W. Noroski, Lenora M. Demmler-Harrison, Gail M. Hanson, Imelda Celine Seeborg, Filiz O. TI ATYPICAL SCID WITH CD4 LYMPHOPENIA, HYPERGAMMAGLOBULINEMIA, AND NEUTROPENIA PRESENTING WITH DISSEMINATED VACCINE-STRAIN VARICELLA AND RUBELLA INFECTIONS SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Meeting Abstract C1 [Bayer, Diana K.; Seth, Neha; Chan, Sanny K.; Noroski, Lenora M.; Hanson, Imelda Celine; Seeborg, Filiz O.] Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA. [Bayer, Diana K.; Seth, Neha; Pearson, Nadia M.; Chan, Sanny K.; Noroski, Lenora M.; Demmler-Harrison, Gail M.; Hanson, Imelda Celine; Seeborg, Filiz O.] Texas Childrens Hosp, Houston, TX 77030 USA. [Pearson, Nadia M.] Baylor Coll Med, Dept Pediat, Sect Pediat Emergency Med, Houston, TX 77030 USA. [Bellini, William J.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Atlanta, GA USA. [Baker, Mei W.] Univ Wisconsin, Dept Pediat, Div Genet & Metab, Sch Med & Publ Hlth, Madison, WI USA. [Demmler-Harrison, Gail M.] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0271-9142 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD APR PY 2013 VL 33 IS 3 BP 694 EP 694 PG 1 WC Immunology SC Immunology GA 201EO UT WOS:000323123700080 ER PT J AU Roberts, JR McKinney, W Kan, H Krajnak, K Frazer, DG Thomas, TA Waugh, S Kenyon, A MacCuspie, RI Hackley, VA Castranova, V AF Roberts, Jenny R. McKinney, Walter Kan, Hong Krajnak, Kristine Frazer, David G. Thomas, Treye A. Waugh, Stacey Kenyon, Allison MacCuspie, Robert I. Hackley, Vincent A. Castranova, Vincent TI Pulmonary and Cardiovascular Responses of Rats to Inhalation of Silver Nanoparticles SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES LA English DT Article ID PARTICULATE AIR-POLLUTION; SPRAGUE-DAWLEY RATS; LUNG-FUNCTION CHANGES; COREXIT EC9500A; DISSOLUTION; EXPOSURE; TOXICITY; INFLAMMATION; MODEL; INCREASES AB Exposure to wet aerosols generated during use of spray products containing silver (Ag) has not been evaluated. The goal was to assess the potential for cardiopulmonary toxicity following an acute inhalation of wet silver colloid. Rats were exposed by inhalation to a low concentration (100 g/m(3) ) using an undiluted commercial antimicrobial product (20 mg/L total silver; approximately 33 nm mean aerodynamic diameter [MAD]) or to a higher concentration (1000 g/m(3)) using a suspension (200 mg/L total silver; approximately 39 nm MAD) synthesized to possess a similar size distribution of Ag nanoparticles for 5 h. Estimated lung burdens from deposition models were 0, 1.4, or 14 g Ag/rat after exposure to control aerosol, low, and high doses, respectively. At 1 and 7 d postexposure, the following parameters were monitored: pulmonary inflammation, lung cell toxicity, alveolar air/blood barrier damage, alveolar macrophage activity, blood cell differentials, responsiveness of tail artery to vasoconstrictor or vasodilatory agents, and heart rate and blood pressure in response to isoproterenol or norepinephrine, respectively. Changes in pulmonary or cardiovascular parameters were absent or nonsignificant at 1 or 7 d postexposure with the exceptions of increased blood monocytes 1 d after high-dose Ag exposure and decreased dilation of tail artery after stimulation, as well as elevated heart rate in response to isoproterenol 1 d after low-dose Ag exposure, possibly due to bioavailable ionic Ag in the commercial product. In summary, short-term inhalation of nano-Ag did not produce apparent marked acute toxicity in this animal model. C1 [Roberts, Jenny R.; McKinney, Walter; Kan, Hong; Krajnak, Kristine; Frazer, David G.; Waugh, Stacey; Kenyon, Allison; Castranova, Vincent] NIOSH, Morgantown, WV 26505 USA. [Thomas, Treye A.] US Consumer Prod Safety Commiss, Bethesda, MD USA. [MacCuspie, Robert I.; Hackley, Vincent A.] NIST, Gaithersburg, MD 20899 USA. RP Roberts, JR (reprint author), NIOSH, HELD, Ctr Dis Control & Prevent CDC, 1095 Willowdale Rd M-S 2015, Morgantown, WV 26505 USA. EM jur6@cdc.gov OI MacCuspie, Robert/0000-0002-6618-6499 FU U.S. Consumer Product Safety Commission [CPSC-I-11-005] FX This project was supported in part by an Interagency Agreement (CPSC-I-11-005) from the U.S. Consumer Product Safety Commission to the National Institute for Occupational Safety and Health. The findings and conclusions in this article are those of the authors and do not necessarily represent the view of the National Institute for Occupational Safety and Health or the U.S. Consumer Product Safety Commission. NR 42 TC 16 Z9 17 U1 1 U2 27 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1528-7394 J9 J TOXICOL ENV HEAL A JI J. Toxicol. Env. Health Part A PD APR 1 PY 2013 VL 76 IS 11 BP 651 EP 668 DI 10.1080/15287394.2013.792024 PG 18 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 199WL UT WOS:000323026100002 PM 23941635 ER PT J AU Zaccone, EJ Thompson, JA Ponnoth, DS Cumpston, AM Goldsmith, WT Jackson, MC Kashon, ML Frazer, DG Hubbs, AF Shimko, MJ Fedan, JS AF Zaccone, Eric J. Thompson, Janet A. Ponnoth, Dovenia S. Cumpston, Amy M. Goldsmith, W. Travis Jackson, Mark C. Kashon, Michael L. Frazer, David G. Hubbs, Ann F. Shimko, Michael J. Fedan, Jeffrey S. TI Popcorn Flavoring Effects on Reactivity of Rat Airways in Vivo and in Vitro SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES LA English DT Article ID INHALATION EXPOSURE SYSTEM; WORKERS PRODUCING DIACETYL; SPRAGUE-DAWLEY RATS; BRONCHIOLITIS OBLITERANS; MICROWAVE-POPCORN; BUTTER FLAVORANT; SMOOTH-MUSCLE; EPITHELIUM REMOVAL; ARGININE RESIDUE; FOOD FLAVORINGS AB Popcorn workers' lung is an obstructive pulmonary disease produced by inhalation of volatile artificial butter flavorings. In rats, inhalation of diacetyl, a major component of butter flavoring, and inhalation of a diacetyl substitute, 2,3-pentanedione, produce similar damage to airway epithelium. The effects of diacetyl and 2,3-pentanedione and mixtures of diacetyl, acetic acid, and acetoin, all components of butter flavoring, on pulmonary function and airway reactivity to methacholine (MCh) were investigated. Lung resistance (R-L) and dynamic compliance (C-dyn) were negligibly changed 18 h after a 6-h inhalation exposure to diacetyl or 2,3-pentanedione (100-360 ppm). Reactivity to MCh was not markedly changed after diacetyl, but was modestly decreased after 2,3-pentanedione inhalation. Inhaled diacetyl exerted essentially no effect on reactivity to mucosally applied MCh, but 2,3-pentanedione (320 and 360 ppm) increased reactivity to MCh in the isolated, perfused trachea preparation (IPT). In IPT, diacetyl and 2,3-pentanedione (3 mM) applied to the serosal and mucosal surfaces of intact and epithelium-denuded tracheas initiated transient contractions followed by relaxations. Inhaled acetoin (150 ppm) exerted no effect on pulmonary function and airway reactivity in vivo; acetic acid (27 ppm) produced hyperreactivity to MCh; and exposure to diacetyl + acetoin + acetic acid (250 + 150 + 27 ppm) led to a diacetyl-like reduction in reactivity. Data suggest that the effects of 2,3-pentanedione on airway reactivity are greater than those of diacetyl, and that flavorings are airway smooth muscle relaxants and constrictors, thus indicating a complex mechanism. C1 [Zaccone, Eric J.; Shimko, Michael J.] W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA. [Thompson, Janet A.; Ponnoth, Dovenia S.; Cumpston, Amy M.; Goldsmith, W. Travis; Jackson, Mark C.; Kashon, Michael L.; Frazer, David G.; Hubbs, Ann F.; Fedan, Jeffrey S.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Fedan, JS (reprint author), NIOSH, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM jsf2@cdc.gov FU Intramural CDC HHS [CC999999] NR 54 TC 5 Z9 5 U1 1 U2 16 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1528-7394 J9 J TOXICOL ENV HEAL A JI J. Toxicol. Env. Health Part A PD APR 1 PY 2013 VL 76 IS 11 BP 669 EP 689 DI 10.1080/15287394.2013.796302 PG 21 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 199WL UT WOS:000323026100003 PM 23941636 ER PT J AU Maddox, RA Holman, RC Minino, AM Blevins, JE Schonberger, LB Belay, ED AF Maddox, Ryan A. Holman, Robert C. Minino, Arialdi M. Blevins, Janis E. Schonberger, Lawrence B. Belay, Ermias D. TI Prion disease among Asians and Pacific Islanders in the United States, 2003-2009 SO PRION LA English DT Meeting Abstract C1 [Maddox, Ryan A.; Holman, Robert C.; Schonberger, Lawrence B.; Belay, Ermias D.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Minino, Arialdi M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Blevins, Janis E.] Case Western Reserve Univ, NPDPSC, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 J9 PRION JI Prion PD APR-MAY PY 2013 VL 7 SU S BP 60 EP 60 PG 1 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 202LL UT WOS:000323217500139 ER PT J AU Holman, RC Maddox, RA Folkema, AM Minino, AM Belay, ED Schonberger, LB AF Holman, Robert C. Maddox, Ryan A. Folkema, Arianne M. Minino, Arialdi M. Belay, Ermias D. Schonberger, Lawrence B. TI Creutzfeldt-Jakob disease among American Indians and Alaska natives in the United States, 1983-2009 SO PRION LA English DT Meeting Abstract C1 [Holman, Robert C.; Maddox, Ryan A.; Folkema, Arianne M.; Minino, Arialdi M.; Belay, Ermias D.; Schonberger, Lawrence B.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 J9 PRION JI Prion PD APR-MAY PY 2013 VL 7 SU S BP 64 EP 64 PG 1 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 202LL UT WOS:000323217500147 ER PT J AU Dokubo, EK Kim, AA Le, LV Nadol, PJ Prybylski, D Wolfe, MI AF Dokubo, E. Kainne Kim, Andrea A. Linh-Vi Le Nadol, Patrick J. Prybylski, Dimitri Wolfe, Mitchell I. TI HIV Incidence in Asia: A Review of Available Data and Assessment of the Epidemic SO AIDS REVIEWS LA English DT Review DE HIV; HIV incidence; HIV surveillance; Asia; Systematic review ID INJECTION-DRUG USERS; HUMAN-IMMUNODEFICIENCY-VIRUS; CAPTURE ENZYME-IMMUNOASSAY; FEMALE SEX WORKERS; SEXUALLY-TRANSMITTED INFECTIONS; NORTHERN THAILAND; PROSPECTIVE COHORT; RISK-FACTORS; HEPATITIS-B; TYPE-1 SEROCONVERSION AB Rates of new HIV infections in Asia are poorly characterized, likely resulting in knowledge gaps about infection trends and the most important areas to target for interventions. We conducted a systematic review of peer-reviewed English language publications and conference abstracts on HIV incidence in thirteen countries - Bangladesh, Cambodia, China, India, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore,Taiwan,Thailand, and Vietnam. We obtained data on HIV incidence rate, incidence estimation method, population, and risk factors for incident infection. Our search yielded 338 unique incidence estimates from 70 published articles and 41 conference abstracts for eight countries. A total of 138 (41%) were obtained from prospective cohort studies and 106 (31%) were from antibody-based tests for recent infection. High HIV incidence rates were observed among commercial sex workers (0.4-27.8 per 100 person-years), people who inject drugs (0.0-43.6 per 100 person-years) and men who have sex with men (0.7-15.0 per 100 person-years). Risk factors for incident HIV infection include brothel-based sex work and cervicitis among commercial sex workers; young age, frequent injection use and sharing needles or syringes among people who inject drugs; multiple male sexual partners, receptive anal intercourse and syphilis infection among men who have sex with men. In the countries with available data, incidence rates were highest in key populations and varied widely by incidence estimation method. Established surveillance systems that routinely monitor trends in HIV incidence are needed to inform prevention planning, prioritize resources, measure impact, and improve the HIV response in Asia. C1 [Dokubo, E. Kainne] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. [Dokubo, E. Kainne; Kim, Andrea A.; Nadol, Patrick J.; Prybylski, Dimitri; Wolfe, Mitchell I.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Linh-Vi Le; Nadol, Patrick J.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Hanoi, Vietnam. [Prybylski, Dimitri; Wolfe, Mitchell I.] Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Global AIDS Program Thailand Asia Reg Off, Nonthaburi, Thailand. RP Dokubo, EK (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA. EM KDokubo@cdc.gov FU NIMH Traineeships in AIDS Prevention Studies Grant [T32 MH-19105-21]; Centers for Disease Control and Prevention FX This work was supported in part by NIMH Traineeships in AIDS Prevention Studies Grant (T32 MH-19105-21; E. Kainne Dokubo) and with funding from Centers for Disease Control and Prevention. NR 132 TC 8 Z9 9 U1 1 U2 25 PU PERMANYER PUBL PI BARCELONA PA MALLORCA, 310, BARCELONA, 00000, SPAIN SN 1139-6121 J9 AIDS REV JI Aids Rev. PD APR-JUN PY 2013 VL 15 IS 2 BP 67 EP 76 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 186MD UT WOS:000322047500001 PM 23681434 ER PT J AU Armour, BS Courtney-Long, EA Campbell, VA Wethington, HR AF Armour, Brian S. Courtney-Long, Elizabeth A. Campbell, Vincent A. Wethington, Holly R. TI Disability Prevalence Among Healthy Weight, Overweight, and Obese Adults SO OBESITY LA English DT Article ID BODY-MASS INDEX; US ADULTS AB Objective: Obesity is associated with adverse health outcomes in people with and without disabilities. However, little is known about disability prevalence among people who are obese. The purpose of this study is to determine the prevalence and type of disability among adults who are obese. Design and Methods: Pooled data from the 2003-2009 National Health Interview Survey (NHIS) were analyzed to obtain national prevalence estimates of disability, disability type and obesity. The disability prevalence was stratified by body mass index (BMI): healthy weight (BMI 18.5-<25.0), overweight (BMI 25.0-<30.0), and obese (BMI >= 30.0). Results: In this pooled sample, among the 25.4% of US adults who were obese, 41.7% reported a disability. In contrast, 26.7% of those with a healthy weight and 28.5% of those who were overweight reported a disability. The most common disabilities among respondents with obesity were movement difficulty (32.5%) and work limitation (16.6%). Conclusions: This research contributes to the literature on obesity by including disability as a demographic in assessing the burden of obesity. Because of the high prevalence of disability among those who are obese, public health programs should consider the needs of those with disabilities when designing obesity prevention and treatment programs. C1 [Armour, Brian S.; Courtney-Long, Elizabeth A.; Campbell, Vincent A.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Wethington, Holly R.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Armour, BS (reprint author), Ctr Dis Control & Prevent, Div Human Dev & Disabil, Atlanta, GA 30333 USA. EM BArmour@cdc.gov NR 14 TC 8 Z9 8 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 J9 OBESITY JI Obesity PD APR PY 2013 VL 21 IS 4 BP 852 EP 855 DI 10.1002/oby.20312 PG 4 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 187AM UT WOS:000322087800028 PM 23712989 ER PT J AU Lau, DT AF Lau, Denys T. TI Showcasing Pharmaceutical Economics, Outcomes, and Health Policy: An Update in Clinical Therapeutics SO CLINICAL THERAPEUTICS LA English DT Editorial Material C1 [Lau, Denys T.] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL USA. RP Lau, DT (reprint author), Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Atlanta, GA 30329 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD APR PY 2013 VL 35 IS 4 BP 354 EP 355 DI 10.1016/j.clinthera.2013.02.025 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 185AA UT WOS:000321936300002 PM 23522659 ER PT J AU Abraham, BK Winston, CA Magee, E Miramontes, R AF Abraham, Bisrat K. Winston, Carla A. Magee, Elvin Miramontes, Roque TI Tuberculosis Among Africans Living in the United States, 2000-2009 SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Tuberculosis; HIV infection; Surveillance; United States; Africa ID FOREIGN-BORN PERSONS; SUB-SAHARAN AFRICA; HIV-INFECTION; EXTRAPULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; PATHOLOGY; MINNESOTA; MORTALITY; HOMELESS AB The incidence of tuberculosis (TB) has declined steadily in the United States; however, foreign-born persons are disproportionately affected. The aim of our study was to describe characteristics of TB patients diagnosed in the United States who originated from the African continent. Using data from the U. S. National Tuberculosis Surveillance System, we calculated TB case rates and analyzed differences between foreign-born patients from Africa compared with other foreign-born and U. S.-born patients. The 2009 TB case rate among Africans (48.1/100,000) was 3 times as high as among other foreign-born and 27 times as high as among U. S.-born patients. Africans living in the United States have high rates of TB disease; they are more likely to be HIV-positive and to have extrapulmonary TB. Identification and treatment of latent TB infection, HIV testing and treatment, and a high index of suspicion for extrapulmonary TB are needed to better address TB in this population. C1 [Abraham, Bisrat K.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Abraham, Bisrat K.; Winston, Carla A.; Magee, Elvin; Miramontes, Roque] Ctr Dis Control & Prevent CDC, Div TB Eliminat, Atlanta, GA 30333 USA. RP Abraham, BK (reprint author), Ctr Dis Control & Prevent CDC, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM bka9002@nyp.org OI Miramontes, Roque/0000-0001-9535-460X NR 31 TC 2 Z9 2 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 EI 1557-1920 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD APR PY 2013 VL 15 IS 2 BP 381 EP 389 DI 10.1007/s10903-012-9624-4 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175OK UT WOS:000321239800019 PM 22535020 ER PT J AU Spradling, PR Xing, J Phippard, A Fonseca-Ford, M Montiel, S Guzman, NL Campuzano, RV Vaughan, G Xia, GL Drobeniuc, J Kamili, S Cortes-Alcala, R Waterman, SH AF Spradling, Philip R. Xing, Jian Phippard, Alba Fonseca-Ford, Maureen Montiel, Sonia Luna Guzman, Norma Vazquez Campuzano, Roberto Vaughan, Gilberto Xia, Guo-liang Drobeniuc, Jan Kamili, Saleem Cortes-Alcala, Ricardo Waterman, Stephen H. CA BIDS Investigators TI Acute Viral Hepatitis in the United States-Mexico Border Region: Data from the Border Infectious Disease Surveillance (BIDS) Project, 2000-2009 SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Acute viral hepatitis; Border; Mexico; Surveillance ID C VIRUS; HISPANIC CHILDREN; DRUG-USERS; A VACCINE; EPIDEMIOLOGY; PREVALENCE; US; SEROPREVALENCE; TATTOOS AB Little is known about the characteristics of acute viral hepatitis cases in the United States (US)-Mexico border region. We analyzed characteristics of acute viral hepatitis cases collected from the Border Infectious Disease Surveillance Project from January 2000-December 2009. Over the study period, 1,437 acute hepatitis A, 311 acute hepatitis B, and 362 acute hepatitis C cases were reported from 5 Mexico and 2 US sites. Mexican hepatitis A cases most frequently reported close personal contact with a known case, whereas, US cases most often reported cross-border travel. Injection drug use was common among Mexican and US acute hepatitis B and C cases. Cross-border travel during the incubation period was common among acute viral hepatitis cases in both countries. Assiduous adherence to vaccination and prevention guidelines in the US is needed and strategic implementation of hepatitis vaccination and prevention programs south of the border should be considered. C1 [Spradling, Philip R.; Xing, Jian; Vaughan, Gilberto; Xia, Guo-liang; Drobeniuc, Jan; Kamili, Saleem] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Phippard, Alba; Fonseca-Ford, Maureen; Montiel, Sonia; Waterman, Stephen H.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Luna Guzman, Norma; Cortes-Alcala, Ricardo] Gen Directorate Epidemiol, Mexico City, DF, Mexico. [Vazquez Campuzano, Roberto] Natl Inst Epidemiol Diag & Reference, Mexico City, DF, Mexico. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov NR 29 TC 1 Z9 1 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD APR PY 2013 VL 15 IS 2 BP 390 EP 397 DI 10.1007/s10903-012-9604-8 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175OK UT WOS:000321239800020 PM 22447176 ER PT J AU Sorn, S Sok, T Ly, S Rith, S Tung, N Viari, A Gavotte, L Holl, D Seng, H Asgari, N Richner, B Laurent, D Chea, N Duong, V Toyoda, T Yasuda, CY Kitsutani, P Zhou, P Bing, S Deubel, V Donis, R Frutos, R Buchy, P AF Sorn, San Sok, Touch Ly, Sovann Rith, Sareth Nguyen Tung Viari, Alain Gavotte, Laurent Holl, Davun Seng, Heng Asgari, Nima Richner, Beat Laurent, Denis Chea, Nora Duong, Veasna Toyoda, Tetsuya Yasuda, Chadwick Y. Kitsutani, Paul Zhou, Paul Bing, Sun Deubel, Vincent Donis, Ruben Frutos, Roger Buchy, Philippe TI Dynamic of H5N1 virus in Cambodia and emergence of a novel endemic sub-clade SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE H5N1; Avian influenza; Emergence; Cambodia; Polymorphism ID MULTIPLE SEQUENCE ALIGNMENT; INFLUENZA-VIRUS; MAXIMUM-LIKELIHOOD; DNA POLYMORPHISM; SUBSTITUTION; PHYLOGENY; INTERFACE; EVOLUTION; SEAVIEW; POULTRY AB In Cambodia, the first detection of HPAI H5N1 virus in birds occurred in January 2004 and since then there have been 33 outbreaks in poultry while 21 human cases were reported. The origin and dynamics of these epizootics in Cambodia remain unclear. In this work we used a range of bioinformatics methods to analyze the Cambodian virus sequences together with those from neighboring countries. Six HA lineages belonging to clades 1 and 1.1 were identified since 2004. Lineage I shares an ancestor with viruses from Thailand and disappeared after 2005, to be replaced by lineage 2 originating from Vietnam and then by lineage 3. The highly adapted lineage 4 was seen only in Cambodia. Lineage 5 is circulating both in Vietnam and Cambodia since 2008 and was probably introduced in Cambodia through unregistered transboundary poultry trade. Lineage 6 is endemic to Cambodia since 2010 and could be classified as a new clade according to WHO/OIE/FAO criteria for H5N1 virus nomenclature. We propose to name it clade 1.1A. There is a direct filiation of lineages 2 to 6 with a temporal evolution and geographic differentiation for lineages 4 and 6. By the end of 2011, two lineages, i.e. lineages 5 and 6, with different transmission paths cocirculate in Cambodia. The presence of lineage 6 only in Cambodia suggests the existence of a transmission specific to this country whereas the presence of lineage 5 in both Cambodia and Vietnam indicates a distinct way of circulation of infected poultry. (C) 2012 Elsevier B.V. All rights reserved. C1 [Sorn, San; Rith, Sareth; Duong, Veasna; Deubel, Vincent; Buchy, Philippe] Inst Pasteur Cambodia, Virol Unit, Natl Influenza Ctr, Phnom Penh, Cambodia. [Sorn, San; Holl, Davun] Minist Agr Forestry & Fisheries, Natl Inst Vet Res, Phnom Penh, Cambodia. [Sok, Touch; Ly, Sovann; Seng, Heng] Minsitry Hlth, Communicable Dis Dept, Phnom Penh, Cambodia. [Nguyen Tung] Natl Ctr Vet Diagnost, Virol Sect, Hanoi, Vietnam. [Viari, Alain] Inria Rhone Alpes Projet Bamboo, F-38330 Montbonnot St Martin, France. [Gavotte, Laurent] Univ Montpellier 2, CC065, UM2, CNRS,IRD,ISEM,UMR 5554, F-34095 Montpellier 5, France. [Asgari, Nima; Chea, Nora] World Hlth Org, Phnom Penh, Cambodia. [Richner, Beat; Laurent, Denis] Kantha Bopha Hosp, Phnom Penh, Cambodia. [Toyoda, Tetsuya; Zhou, Paul; Bing, Sun] Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai, Peoples R China. [Yasuda, Chadwick Y.] US Naval Med Res Unit 2, Phnom Penh, Cambodia. [Kitsutani, Paul] Ctr Dis Control & Prevent, Cambodia Off, Phnom Penh, Cambodia. [Donis, Ruben] Ctr Dis Control & Prevent, Atlanta, GA USA. [Frutos, Roger] Ird, Cirad, UMR17, F-34398 Montpellier 5, France. RP Buchy, P (reprint author), Inst Pasteur Cambodia, Virol Unit, Natl Influenza Ctr, 5 Monivong Blvd,POB 983, Phnom Penh, Cambodia. EM pbuchy@pasteur-kh.org RI Valle, Ruben/A-7512-2013; OI Duong, Veasna/0000-0003-0353-1678 FU French Ministry of Research; Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services; Armed Forces Health Surveillance Center/Global Emerging Infections Surveillance; WHO Cambodia; US CDC FX We thank the staff of the Virology Unit of Institut Pasteur in Cambodia, the Ministry of Health Cambodia, the Ministry of Agriculture Forestry and Fisheries Cambodia, and of WHO Cambodia office for their precious technical assistance. This work was supported by the French Ministry of Research, by the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, by WHO Cambodia and US CDC. The surveillance conducted by the NAMRU-2 laboratory in Cambodia was supported by the Armed Forces Health Surveillance Center/Global Emerging Infections Surveillance. The views expressed are those of the authors and do not represent those of the US Department of Defense and of the US Department of the Navy. NR 38 TC 15 Z9 15 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD APR PY 2013 VL 15 BP 87 EP 94 DI 10.1016/j.meegid.2012.05.013 PG 8 WC Infectious Diseases SC Infectious Diseases GA 169AV UT WOS:000320750200013 PM 22683363 ER PT J AU Irwin, DJ Abrams, JY Schonberger, LB Leschek, EW Mills, JL Lee, VMY Trojanowski, JQ AF Irwin, David J. Abrams, Joseph Y. Schonberger, Lawrence B. Leschek, Ellen Werber Mills, James L. Lee, Virginia M. -Y. Trojanowski, John Q. TI Evaluation of Potential Infectivity of Alzheimer and Parkinson Disease Proteins in Recipients of Cadaver-Derived Human Growth Hormone SO JAMA NEUROLOGY LA English DT Article ID CREUTZFELDT-JAKOB-DISEASE; CEREBRAL BETA-AMYLOIDOSIS; ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISEASES; SPONGIFORM ENCEPHALOPATHY; GRAFTED NEURONS; LONG-TERM; TRANSMISSION; PATHOLOGY; PITUITARY AB Importance: Growing evidence of cell-to-cell transmission of neurodegenerative disease (ND)-associated proteins (NDAPs) (ie, tau, A beta, and alpha-synuclein) suggests possible similarities to the infectious prion protein (PrPsc) in spongiform encephalopathies. There are limited data on the potential human-to-human transmission of NDAPs associated with Alzheimer disease (AD) and other non-PrPsc ND. Objective: To examine evidence for human-to-human transmission of AD, Parkinson disease (PD), and related NDAPs in cadaveric human growth hormone (c-hGH) recipients. Design: We conducted a detailed immunohistochemical analysis of pathological NDAPs other than PrPsc in human pituitary glands. We also searched for ND in recipients of pituitary-derived c-hGH by reviewing the National Hormone and Pituitary Program (NHPP) cohort database and medical literature. Setting: University-based academic center and agencies of the US Department of Health and Human Services. Participants: Thirty-four routine autopsy subjects (10 non-ND controls and 24 patients with ND) and a US cohort of c-hGH recipients in the NHPP. Main Outcome Measures: Detectable NDAPs in human pituitary sections and death certificate reports of non-PrPsc ND in the NHPP database. Results: We found mild amounts of pathological tau, A beta, and alpha-synuclein deposits in the adeno/neurohypophysis of patients with ND and control patients. No cases of AD or PD were identified, and 3 deaths attributed to amyotrophic lateral sclerosis (ALS) were found among US NHPP c-hGH recipients, including 2 of the 796 decedents in the originally confirmed NHPP c-hGH cohort database. Conclusions and Relevance: Despite the likely frequent exposure of c-hGH recipients to NDAPs, and their markedly elevated risk of PrPsc-related disease, this population of NHPP c-hGH recipients does not appear to be at increased risk of AD or PD. We discovered 3 ALS cases of unclear significance among US c-hGH recipients despite the absence of pathological deposits of ALS-associated proteins (TDP-43, FUS, and ubiquilin) in human pituitary glands. In this unique in vivo model of human-to-human transmission, we found no evidence to support concerns that NDAPs underlying AD and PD transmit disease in humans despite evidence of their cell-to-cell transmission in model systems of these disorders. Further monitoring is required to confirm these conclusions. C1 [Irwin, David J.; Lee, Virginia M. -Y.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med,Inst Aging, Philadelphia, PA 19104 USA. [Irwin, David J.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Leschek, Ellen Werber] NIDDKD, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Mills, James L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Dept Hlth & Human Serv, Bethesda, MD USA. [Abrams, Joseph Y.; Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Trojanowski, JQ (reprint author), Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Maloney 3rd Floor,36th & Spruce St, Philadelphia, PA 19104 USA. EM trojanow@mail.med.upenn.edu FU AstraZeneca; Bristol-Myers Squibb; AD Core Centre grant; National Institute on Aging and Intramural Research Program [T32-AG000255]; National Institute of Child Health and Development, National Institutes of Health; [P30 AG010124-20] FX The authors report no financial disclosures related to the current study. Drs Lee and Trojanowski report single consulting services to Pfizer, Johnson & Johnson, MetLife, and Bristol-Myers Squibb; royalty payments through Penn licenses; and research support from AstraZeneca and Bristol-Myers Squibb.; This study was supported by grant P30 AG010124-20, an AD Core Centre grant, and grant T32-AG000255 from the National Institute on Aging and Intramural Research Program and the National Institute of Child Health and Development, National Institutes of Health. NR 46 TC 62 Z9 63 U1 1 U2 21 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 J9 JAMA NEUROL JI JAMA Neurol. PD APR PY 2013 VL 70 IS 4 BP 462 EP 468 DI 10.1001/jamaneurol.2013.1933 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 160NS UT WOS:000320127000006 PM 23380910 ER PT J AU Gordon, PH Mehal, JM Holman, RC Rowland, LP Rowland, AS Cheek, JE AF Gordon, Paul H. Mehal, Jason M. Holman, Robert C. Rowland, Lewis P. Rowland, Andrew S. Cheek, James E. TI Incidence of Amyotrophic Lateral Sclerosis Among American Indians and Alaska Natives SO JAMA NEUROLOGY LA English DT Article ID MOTOR-NEURON DISEASE; ALS; POPULATION; MORTALITY; FRANCE; EPIDEMIOLOGY; PREVALENCE; COUNTY AB Importance: More thorough evaluation of amyotrophic lateral sclerosis (ALS) and motor neuron disease in unique populations could provide clues to etiologies for these idiopathic conditions, and educational programs for American Indian and Alaska Native (AI/AN) people and health care professionals on reservations could improve awareness, understanding, diagnosis, and treatment. In the ongoing search for susceptibility genes, studying particular racial groups, such as AI/ANs, might facilitate the identification of new mutations. Objective: To provide better understanding of ALS and secondarily of motor neuron disease among AI/AN people by estimating the incidence and prevalence among AI/ANs served by the Indian Health Service health care system. Design and Setting: Analysis of electronic records for AI/ANs with ALS and with motor neuron disease separately for the calendar years 2002-2009 using inpatient and outpatient visit data from the Indian Health Service, which provides health care to eligible AI/ANs nationwide. Participants: Cases were defined by at least 2 inpatient or outpatient visits with the diagnosis. Main Outcome Measures: Crude and age-adjusted incidence and prevalence rates were calculated. Results: Seventy-one AI/ANs were diagnosed with ALS, yielding an average annual crude incidence rate of 0.63 cases per 100 000 and an age-adjusted incidence of 0.92. The median age at onset was 56.0 years and was higher among women than men (62.0 vs 55.0 years; P=.06). Age-specific incidence increased to 70 to 74 years. The crude and age-adjusted point prevalence rates were 2.00 and 4.12, respectively. The crude and age-adjusted incidence rates for motor neuron disease were 1.08 and 1.50, respectively. The annual rates were unchanged across the study period. Conclusions and Relevance: The incidence of ALS among AI/ANs appears to be lower than that reported for white populations, a finding congruent with reports of other minority populations. Community-based studies are important to confirm these findings and to examine reasons for the low rate of ALS among AI/ANs. C1 [Gordon, Paul H.] Northern Navajo Med Ctr, US Dept Hlth & Human Serv, Indian Hlth Serv, Shiprock, NM 87420 USA. [Rowland, Andrew S.; Cheek, James E.] Univ New Mexico, Hlth Sci Ctr, Dept Family & Community Med, Publ Hlth Program, Albuquerque, NM 87131 USA. [Mehal, Jason M.; Holman, Robert C.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Rowland, Lewis P.] Columbia Univ, Dept Neurol, New York, NY USA. RP Gordon, PH (reprint author), Northern Navajo Med Ctr, Med Staff Off, Hwy 491 N, Shiprock, NM 87420 USA. EM paul.gordon@ihs.gov OI Gordon, Paul/0000-0001-5714-9875 NR 37 TC 5 Z9 5 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 J9 JAMA NEUROL JI JAMA Neurol. PD APR PY 2013 VL 70 IS 4 BP 476 EP 480 DI 10.1001/jamaneurol.2013.929 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 160NS UT WOS:000320127000008 PM 23440294 ER PT J AU Bell, JL Collins, JW Tiesman, HM Ridenour, M Konda, S Wolf, L Evanoff, B AF Bell, Jennifer L. Collins, James W. Tiesman, Hope M. Ridenour, Marilyn Konda, Srinivas Wolf, Laurie Evanoff, Bradley TI Slip, Trip, and Fall Injuries Among Nursing Care Facility Workers SO WORKPLACE HEALTH & SAFETY LA English DT Article ID MUSCULOSKELETAL INJURY; PREVENTION PROGRAM; JOB-SATISFACTION; CEILING LIFTS; HOMES; RISK; WORKING; AGE AB The objective of this research was to describe the slip, trip, and fall injury experience and trends in a population of nursing home workers, identify risk factors for slip, trip, and fall injuries, and develop prevention strategies for slip, trip, and fall hazards. Workers' compensation injury claims data and payroll data from 1996 through 2003 were obtained from six nursing homes and used to calculate injury incidence rates. Narrative information was used to describe details of slip, trip, and fall events. A total of 86 slip, trip, and fall-related workers' compensation claims were filed during the 8-year period. Slip, trip, and fall claim rates showed a nonsignificant increase during the 8-year period. Most slips, trips, and falls were attributed to hazards that can be mitigated (e.g., water on the floor or loose cords in a walkway). Nursing home workers experience more slip, trip, and fall-related injury claims than workers in other industries. Preventive programs should be implemented and evaluated in this industry. C1 [Bell, Jennifer L.; Collins, James W.; Tiesman, Hope M.; Ridenour, Marilyn; Konda, Srinivas] Ctr Dis Control & Prevent, NIOSH, Div Safety Res, Morgantown, WV USA. [Wolf, Laurie] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Evanoff, Bradley] Washington Univ, Sch Med, St Louis, MO USA. RP Bell, JL (reprint author), Ctr Dis Control & Prevent, NIOSH, Div Safety Res, Morgantown, WV USA. EM JBell@cdc.gov RI Konda, Srinivas/G-2747-2015; OI Konda, Srinivas/0000-0002-8934-4111; Evanoff, Bradley A./0000-0003-0085-333X FU Intramural CDC HHS [CC999999] NR 28 TC 5 Z9 5 U1 1 U2 19 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 2165-0799 J9 WORKPLACE HEALTH SAF JI Workplace Health Saf. PD APR PY 2013 VL 61 IS 4 BP 147 EP 152 DI 10.3928/21650799-20130318-28 PG 6 WC Nursing SC Nursing GA 173TW UT WOS:000321103800002 PM 23521142 ER PT J AU Ahuja, JK Pehrsson, P Haytowitz, D Holden, J Nickle, M Showell, B Thomas, R Hoy, K Martin, C Sebastian, R Moshfegh, A Gillespie, C Cogswell, M AF Ahuja, Jaspreet K. Pehrsson, Pamela Haytowitz, David Holden, Joanne Nickle, Melissa Showell, Bethany Thomas, Robin Hoy, Kathy Martin, Carrie Sebastian, Rhonda Moshfegh, Alanna Gillespie, Cathleen Cogswell, Mary TI Monitoring sodium in commercial packaged and restaurant foods SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Ahuja, Jaspreet K.; Pehrsson, Pamela; Haytowitz, David; Holden, Joanne; Nickle, Melissa; Showell, Bethany; Thomas, Robin; Hoy, Kathy; Martin, Carrie; Sebastian, Rhonda; Moshfegh, Alanna] ARS, USDA, Beltsville Human Nutr Res Ctr, Beltsville, MD USA. [Gillespie, Cathleen; Cogswell, Mary] Natl Ctr Chron Dis & Hlth Promot, CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 354.2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883500127 ER PT J AU Allen, J Longenecker, HB Perrine, CG Scanlon, KS AF Allen, Jessica Longenecker, Holly B. Perrine, Cria G. Scanlon, Kelley S. TI Baby-Friendly Hospital Practices and Birth Costs SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Allen, Jessica; Perrine, Cria G.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA. [Longenecker, Holly B.] Northrop Grumman Corp, Nutr Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 124.2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 156YK UT WOS:000319860501187 ER PT J AU Aufreiter, S Colapinto, CK Tremblay, MS Bushnik, T Pfeiffer, CM O'Connor, DL AF Aufreiter, Susanne Colapinto, Cynthia K. Tremblay, Mark S. Bushnik, Tracey Pfeiffer, Christine M. O'Connor, Deborah L. TI Comparison study between RBC folate measured by microbiologic assay and Immulite 2000 immunoassay SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Aufreiter, Susanne; O'Connor, Deborah L.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada. [Colapinto, Cynthia K.; Tremblay, Mark S.] Childrens Hosp Eastern Ontario, Res Inst, Hlth Act Living & Obes Res Grp, Ottawa, ON K1H 8L1, Canada. [Bushnik, Tracey] STAT Canada, Hlth Anal Div, Ottawa, ON, Canada. [Pfeiffer, Christine M.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 1077.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505522 ER PT J AU Bailey, RL Durazo-Arvizu, R Carmel, R Green, R Pfeiffer, CM Sempos, CT Yetley, EA AF Bailey, Regan L. Durazo-Arvizu, Ramon Carmel, Ralph Green, Ralph Pfeiffer, Christine M. Sempos, Christopher T. Yetley, Elizabeth A. TI Modeling an MMA-derived inflection point for serum vitamin B12 (SB12) in the US SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Bailey, Regan L.; Sempos, Christopher T.; Yetley, Elizabeth A.] NIH, ODS, Bethesda, MD 20892 USA. [Durazo-Arvizu, Ramon] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA. [Carmel, Ralph] NY Methodist Hosp, Brooklyn, NY USA. [Carmel, Ralph] Weill Cornell Med Coll, New York, NY USA. [Green, Ralph] UC Davis Med Ctr, Sacramento, CA USA. [Pfeiffer, Christine M.] CDC, NCEH, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 848.2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505477 ER PT J AU Bailey, RL Gahche, JJ Thomas, PR Dwyer, JT AF Bailey, Regan L. Gahche, Jaime J. Thomas, Paul R. Dwyer, Johanna T. TI Why children use dietary supplements SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Bailey, Regan L.; Thomas, Paul R.; Dwyer, Johanna T.] NIH, ODS, Bethesda, MD 20892 USA. [Gahche, Jaime J.] CDC, NCHS, Hyattsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 242.5 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883500098 ER PT J AU Colapinto, CK Tremblay, MS Aufreiter, S Bushnik, T Pfeiffer, CM O'Connor, DL AF Colapinto, Cynthia K. Tremblay, Mark S. Aufreiter, Susanne Bushnik, Tracey Pfeiffer, Christine M. O'Connor, Deborah L. TI A comparison of American and Canadian RBC folate concentrations SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Colapinto, Cynthia K.; Tremblay, Mark S.] Childrens Hosp Eastern Ontario, Res Inst, Hlth Act Living & Obes Res Grp, Ottawa, ON K1H 8L1, Canada. [Aufreiter, Susanne; O'Connor, Deborah L.] Hosp Sick Children, Physiol & Expt Med Program, Toronto, ON M5G 1X8, Canada. [Bushnik, Tracey] STAT Canada, Hlth Anal Div, Ottawa, ON, Canada. [Pfeiffer, Christine M.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 1077.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883500469 ER PT J AU Coleman, LA Mishina, M Thompson, M Spencer, S Cheng, PY Talbot, HK Sundaram, ME Griffin, M Sambhara, S AF Coleman, Laura A. Mishina, Margarita Thompson, Mark Spencer, Sarah Cheng, Po-Yung Talbot, H. Keipp Sundaram, Maria E. Griffin, Marie Sambhara, Suryaprakash TI Age and Vitamin D Receptor (VDR) Expression and Functionality in Peripheral Blood Mononuclear Cells (PBMC) SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Coleman, Laura A.] Abbott Nutr, Columbus, OH USA. [Mishina, Margarita; Thompson, Mark; Spencer, Sarah; Cheng, Po-Yung; Sambhara, Suryaprakash] CDC, Atlanta, GA 30333 USA. [Talbot, H. Keipp; Griffin, Marie] Vanderbilt Univ, Nashville, TN USA. [Sundaram, Maria E.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA lb252 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505411 ER PT J AU Derby, KS Sullivan, KM Ruth, LJ Williams, TN Suchdev, PS AF Derby, Kiersten Smith Sullivan, Kevin M. Ruth, Laird J. Williams, Thomas N. Suchdev, Parminder S. TI The relationship between inherited blood disorders and iron biomarkers among young children in Kenya SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Derby, Kiersten Smith; Sullivan, Kevin M.; Suchdev, Parminder S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Sullivan, Kevin M.; Ruth, Laird J.; Suchdev, Parminder S.] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA. [Williams, Thomas N.] Ctr Geog Med Res Coast, Kilifi, Kenya. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 107.8 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883501144 ER PT J AU Dwyer, J Andrews, KW Bailey, RL Betz, JM Burt, VL Costello, RB Emenaker, NJ Gahche, JJ Hardy, CJ Pehrsson, PR Roseland, JM Saldanha, LG AF Dwyer, Johanna Andrews, Karen W. Bailey, Regan L. Betz, Joseph M. Burt, Vicki L. Costello, Rebecca B. Emenaker, Nancy J. Gahche, Jaime J. Hardy, Constance J. Pehrsson, Pamela R. Roseland, Janet M. Saldanha, Leila G. TI Progress in the Development of Federal Resources to Assess Dietary Supplement (DS) Exposures SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Dwyer, Johanna; Bailey, Regan L.; Betz, Joseph M.; Costello, Rebecca B.; Saldanha, Leila G.] ODS, NIH, Bethesda, MD USA. [Emenaker, Nancy J.] NCI, NIH, Bethesda, MD 20892 USA. [Andrews, Karen W.; Pehrsson, Pamela R.; Roseland, Janet M.] ARS, USDA, Beltsville, MD USA. [Burt, Vicki L.; Gahche, Jaime J.] CDC, NCHS, Hyattsville, MD USA. [Hardy, Constance J.] CFSAN, FDA, College Pk, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 242.3 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883503526 ER PT J AU Flax, VL Bentley, ME Combs, GF Chasela, CS Kayira, D Tegha, G Daza, EJ Kourtis, AP Jamieson, DJ van der Horst, CM Adair, LS AF Flax, Valerie L. Bentley, Margaret E. Combs, Gerald F., Jr. Chasela, Charles S. Kayira, Dumbani Tegha, Gerald Daza, Eric J. Kourtis, Athena P. Jamieson, Denise J. van der Horst, Charles M. Adair, Linda S. TI Plasma and breastmilk selenium in HIV-infected Malawian mothers is positively associated with infant selenium status at 2 or 6 and 24 weeks postpartum but is not associated with maternal supplementation SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Flax, Valerie L.; Bentley, Margaret E.; Daza, Eric J.; van der Horst, Charles M.; Adair, Linda S.] Univ N Carolina, Chapel Hill, NC USA. [Combs, Gerald F., Jr.] USDA ARS, Grand Forks, ND USA. [Chasela, Charles S.; Kayira, Dumbani; Tegha, Gerald] UNC Project, Lilongwe, Malawi. [Kourtis, Athena P.; Jamieson, Denise J.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 845.16 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505402 ER PT J AU Gahche, JJ Bailey, R Burt, V Dwyer, J AF Gahche, Jaime Jacqueline Bailey, Regan Burt, Vicki Dwyer, Johanna TI Dietary Supplement Use Among Older Adults in the United States, NHANES 2007-2010 SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Gahche, Jaime Jacqueline; Burt, Vicki] Ctr Dis Control & Prevent, Div Natl Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Bailey, Regan; Dwyer, Johanna] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 242.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883504007 ER PT J AU Gillespie, C Maalouf, J Yuan, K Cogswell, ME Gunn, J Levings, J Moshfegh, A Merritt, R AF Gillespie, Cathleen Maalouf, J. Yuan, K. Cogswell, M. E. Gunn, J. Levings, J. Moshfegh, A. Merritt, R. TI Sodium content in US packaged foods, 2009 SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Gillespie, Cathleen; Maalouf, J.; Yuan, K.; Cogswell, M. E.; Gunn, J.; Levings, J.; Merritt, R.] CDC, Chamblee, GA USA. [Moshfegh, A.] USDA, Beltsville, MD 20705 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 354.3 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883504241 ER PT J AU Keim, S Branum, AM Peck, J AF Keim, Sarah Branum, Amy M. Peck, Joshua TI What are US Children Under Two Eating? Results from NHANES (2003-2008) SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Keim, Sarah; Peck, Joshua] Nationwide Childrens Hosp, Columbus, OH USA. [Keim, Sarah] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Branum, Amy M.] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Peck, Joshua] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA. RI Keim, Sarah/F-8929-2013 OI Keim, Sarah/0000-0003-3490-3649 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 1060.3 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505546 ER PT J AU Kim, MH Park, S Lee, HS AF Kim, Mi-Hyun Park, Sohyun Lee, Haeng-Shin TI Factors Associated with Low Water Intake among Korean Adolescents - Korea National Health and Nutrition Examination Survey, 2007-2010 SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Kim, Mi-Hyun] Kangwon Natl Univ, Samcheok, Gangwon Do, South Korea. [Park, Sohyun] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lee, Haeng-Shin] Korea Hlth Ind Dev Inst, Osong, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 622.18 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883504511 ER PT J AU Luttter, C Mir, R Pachon, H Cheung, E Sullivan, K Creed-Kanashiro, H Panjwani, A Escobar, J Alam, K AF Luttter, Chessa Mir, Roger Pachon, Helena Cheung, Edith Sullivan, Kevin Creed-Kanashiro, Hillary Panjwani, Anita Escobar, Jessica Alam, Khurshid TI ProPAN 2.0 (Process for the Promotion of Child Feeding): a Tool for Infant and Young Child Feeding Programming SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Luttter, Chessa] Pan Amer Hlth Org, Washington, DC USA. [Mir, Roger] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Pachon, Helena; Sullivan, Kevin; Panjwani, Anita] Emory Univ, Atlanta, GA 30322 USA. [Cheung, Edith] UNICEF, New York, NY USA. [Creed-Kanashiro, Hillary] Inst Invest Nutr, Lima, Peru. [Escobar, Jessica] Univ S Carolina, Columbia, SC 29208 USA. [Alam, Khurshid] Recruiting Minds, Monmouth Jct, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 620.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883504151 ER PT J AU Maalouf, J Cogswell, ME Gunn, JP Curtis, CJ Rhodes, D Hoy, K Pehrsson, P Nickle, M Merritt, R AF Maalouf, Joyce Cogswell, Mary E. Gunn, Janelle P. Curtis, Christine J. Rhodes, Donna Hoy, Kathy Pehrsson, Pamela Nickle, Melissa Merritt, Robert TI Monitoring the sodium content of restaurant foods: public health challenges and opportunities SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Maalouf, Joyce; Cogswell, Mary E.; Gunn, Janelle P.; Merritt, Robert] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Maalouf, Joyce] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Curtis, Christine J.] NYC Dept Hlth & Mental Hyg, New York, NY USA. [Rhodes, Donna; Hoy, Kathy; Pehrsson, Pamela; Nickle, Melissa] ARS, USDA, Beltsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 842.7 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883503288 ER PT J AU McNeill, M Venci, BJ Park, S Lee, SY AF McNeill, Meghan Venci, Brittany Jeanne Park, Sohyun Lee, Seung-Yeon TI Are physical activity and food insecurity associated with depressive feelings in US adults? SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [McNeill, Meghan; Venci, Brittany Jeanne; Lee, Seung-Yeon] Univ Cincinnati, Dept Nutr Sci, Cincinnati, OH USA. [Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RI Nguyen, Giang/D-9027-2016 NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 1054.8 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883500048 ER PT J AU Namaste, S Suchdev, P Aaron, G AF Namaste, Sorrel Suchdev, Parminder Aaron, Grant TI Biomarkers Reflecting Inflammation and Nutrition Determinants of Anemia (BRINDA): Project Overview SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Namaste, Sorrel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Growth & Nutr Branch, NIH, Bethesda, MD USA. [Suchdev, Parminder] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA. [Aaron, Grant] Global Alliance Improved Nutr, Geneva, Switzerland. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA lb270 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505565 ER PT J AU Pan, LP May, A Wethington, H Dalenius, K Grummer-Strawn, L AF Pan, Liping May, Ashleigh Wethington, Holly Dalenius, Karen Grummer-Strawn, Laurence TI Three-Year Incidence of Obesity Among US Children Aged 0-23 Months Living in Low-Income Families SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Pan, Liping; May, Ashleigh; Wethington, Holly; Dalenius, Karen; Grummer-Strawn, Laurence] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 343.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883503382 ER PT J AU Panicker, G Vo, T Rajbhandari, I Uddin, N Mangalathu, R Unger, ER D'Souza, M AF Panicker, Gitika Trinh Vo Rajbhandari, Ira Uddin, Nasir Mangalathu, Rajeevan Unger, Elizabeth R. D'Souza, Martin TI Development of a microparticulate HPV vaccine for oral delivery SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Panicker, Gitika; Rajbhandari, Ira; Mangalathu, Rajeevan; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Trinh Vo; D'Souza, Martin] Mercer Univ, Atlanta, GA USA. [Uddin, Nasir] Lake Erie Coll Osteopath Med, Erie, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA lb218 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 156YK UT WOS:000319860506069 ER PT J AU Park, S Onufrak, S Sherry, B Blanck, HM AF Park, Sohyun Onufrak, Stephen Sherry, Bettylou Blanck, Heidi M. TI Health-related Knowledge and Attitudes Are Associated with Sugars-Sweetened Beverages Intake among US Adults SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Park, Sohyun; Onufrak, Stephen; Sherry, Bettylou; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 7 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 622.4 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883506037 ER PT J AU Patel, KD Bentley, ME Flax, VL Shahab-Ferdows, S Allen, LH Chasela, CS Kayira, D Tegha, G Jamieson, DJ van der Horst, CM Adair, LS AF Patel, K. D. Bentley, M. E. Flax, V. L. Shahab-Ferdows, S. Allen, L. H. Chasela, C. S. Kayira, D. Tegha, G. Jamieson, D. J. van der Horst, C. M. Adair, L. S. TI Prevalence of Vitamin A Deficiency and Associations with Socioeconomic Status in Lactating HIV-infected Malawian Mothers SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Patel, K. D.; Bentley, M. E.; Flax, V. L.; van der Horst, C. M.; Adair, L. S.] UNC CH, Chapel Hill, NC USA. [Shahab-Ferdows, S.; Allen, L. H.] ARS, USDA, WHNRC, Davis, CA USA. [Chasela, C. S.; Kayira, D.; Tegha, G.] UNC Project, Lilongwe, Malawi. [Jamieson, D. J.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 619.8 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883503243 ER PT J AU Patel, S Cobb, P Saydah, S Zhang, XP De Jesus, J Cogswell, M AF Patel, Sheena Cobb, Paul Saydah, Sharon Zhang, Xuanping De Jesus, Janet Cogswell, Mary TI A systematic review of the effects of sodium reduction on glucose levels SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Patel, Sheena; Cobb, Paul; Cogswell, Mary] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Zhang, Xuanping] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Patel, Sheena] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Hyattsville, MD USA. [De Jesus, Janet] NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 622.7 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505502 ER PT J AU Perrine, CG Scanlon, KS AF Perrine, Cria G. Scanlon, Kelley S. TI Use of human milk in US advanced care neonatal units SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Perrine, Cria G.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 849.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883504189 ER PT J AU Saldanha, LG Dwyer, JT Bailen, RA Chang, FF Andrews, KW Bailey, RL Betz, JM Burt, VL Costello, RB Emenaker, NJ Gahche, JJ Hardy, CJ Pehrsson, PR Roseland, JM AF Saldanha, Leila G. Dwyer, Johanna T. Bailen, Richard A. Chang, Florence F. Andrews, Karen W. Bailey, Regan L. Betz, Joseph M. Burt, Vicki L. Costello, Rebecca B. Emenaker, Nancy J. Gahche, Jaime J. Hardy, Constance J. Pehrsson, Pamela R. Roseland, Janet M. TI Dietary Supplement Label Database (DSLD) Will Capture Information from Dietary Supplement (DS) Labels SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Saldanha, Leila G.; Dwyer, Johanna T.; Bailen, Richard A.; Bailey, Regan L.; Betz, Joseph M.; Costello, Rebecca B.] NIH, ODS, Bethesda, MD 20892 USA. [Chang, Florence F.] NIH, Natl Lib Med, Bethesda, MD 20892 USA. [Emenaker, Nancy J.] NCI, NIH, Bethesda, MD 20892 USA. [Andrews, Karen W.; Pehrsson, Pamela R.; Roseland, Janet M.] ARS, USDA, Beltsville, MD USA. [Burt, Vicki L.; Gahche, Jaime J.] CDC, NCHS, Hyattsville, MD USA. [Hardy, Constance J.] US FDA, CFSAN, College Pk, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 848.1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505448 ER PT J AU Shahab-Ferdows, S Allen, LH Hampel, D Bentley, ME Adair, LS Flax, VL Kayira, D Chasela, CS Kacheche, Z Tegha, G Kourtis, AP Jamieson, DJ van der Horst, C AF Shahab-Ferdows, S. Allen, L. H. Hampel, D. Bentley, M. E. Adair, L. S. Flax, V. L. Kayira, D. Chasela, C. S. Kacheche, Z. Tegha, G. Kourtis, A. P. Jamieson, D. J. van der Horst, C. TI Maternal and breastmilk vitamin B12 correlated with infant status but was not influenced by maternal supplementation among HIV-infected Malawian women in the Breastfeeding, Antiretrovirals and Nutrition Study (BAN) SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Shahab-Ferdows, S.; Allen, L. H.; Hampel, D.] ARS, WHNRC, USDA, Davis, CA USA. [Bentley, M. E.; Adair, L. S.; Flax, V. L.] UNC, Chapel Hill, NC USA. [Kayira, D.; Chasela, C. S.; Kacheche, Z.; Tegha, G.] UNC Project, Lilongwe, Malawi. [Kourtis, A. P.; Jamieson, D. J.; van der Horst, C.] CDC, Atlana, GA USA. RI Hampel, Daniela/K-2047-2014 OI Hampel, Daniela/0000-0003-0288-7680 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 107.2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883500055 ER PT J AU Suchdev, PS Davis, S Ruth, L Worrell, C Wiegand, R Montgomery, JM Foxe, L AF Suchdev, Parminder Singh Davis, Stephanie Ruth, Laird Worrell, Caitlin Wiegand, Ryan Montgomery, Joel M. Foxe, LeAnne TI Soil-transmitted helminthic infection and nutritional status among urban slum children in Kenya SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Suchdev, Parminder Singh] Emory Univ, Atlanta, GA 30322 USA. [Suchdev, Parminder Singh; Davis, Stephanie; Ruth, Laird; Worrell, Caitlin; Wiegand, Ryan; Foxe, LeAnne] CDC, Atlanta, GA 30333 USA. [Montgomery, Joel M.] CDC, Int Emerging Infect Program, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 357.8 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 156YK UT WOS:000319860501206 ER PT J AU Tian, N Zhang, ZF Loustalot, F Yang, QH Cogswell, ME AF Tian, Niu Zhang, Zefeng Loustalot, Fleetwood Yang, Quanhe Cogswell, Mary E. TI Sodium and Potassium Intake among US Infants and Preschool Children, 2003-2010 SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Tian, Niu; Zhang, Zefeng; Loustalot, Fleetwood; Yang, Quanhe; Cogswell, Mary E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 841.2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883504541 ER PT J AU Unger, ER Panicker, G Wong, J Wallstrom, G Haddad, R D'Souza, G Posner, M Anderson, KS AF Unger, Elizabeth R. Panicker, Gitika Wong, Jessica Wallstrom, Garrick Haddad, Robert D'Souza, Gypsyamber Posner, Marshall Anderson, Karen S. TI Differential antibody responses to HPV16 in cervical and oropharyngeal cancer SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Unger, Elizabeth R.; Panicker, Gitika] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wong, Jessica; Haddad, Robert] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wallstrom, Garrick; Anderson, Karen S.] Arizona State Univ, Tempe, AZ USA. [D'Souza, Gypsyamber] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. [Posner, Marshall] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 1087.10 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 156YK UT WOS:000319860504008 ER PT J AU Venci, BJ Park, S Lee, SY AF Venci, Brittany Jeanne Park, Sohyun Lee, Seung-Yeon TI Functional limitation and chronic diseases are associated with food insecurity among US adults SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Venci, Brittany Jeanne; Lee, Seung-Yeon] Univ Cincinnati, Dept Nutr Sci, Cincinnati, OH USA. [Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RI Nguyen, Giang/D-9027-2016 NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 1054.7 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883505334 ER PT J AU Zytnick, D Park, S Onufrak, S Kingsley, B Sherry, B AF Zytnick, Deena Park, Sohyun Onufrak, Stephen Kingsley, Beverly Sherry, Bettylou TI Sports drink consumption and associated knowledge and characteristics among US adults SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Zytnick, Deena; Park, Sohyun; Onufrak, Stephen; Kingsley, Beverly; Sherry, Bettylou] CDC, DNPAO, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA lb368 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883506034 ER PT J AU Zytnick, D Park, S Onufrak, SJ AF Zytnick, Deena Park, Sohyun Onufrak, Stephen J. TI Associations between Knowledge and Attitudes about Sports Drinks and Sports Drink Intake among US Youth SO FASEB JOURNAL LA English DT Meeting Abstract CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB) CY APR 20-24, 2013 CL Boston, MA SP ASPET, British Pharmacol Soc (BPS) C1 [Zytnick, Deena; Park, Sohyun; Onufrak, Stephen J.] CDC, DNPAO, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 1 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2013 VL 27 MA 1063.6 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 157GG UT WOS:000319883502107 ER PT J AU Hirth, S Cena, L Cox, G Tomovic, Z Peters, T Wohlleben, W AF Hirth, Sabine Cena, Lorenzo Cox, Gerhard Tomovic, Zeljko Peters, Thomas Wohlleben, Wendel TI Scenarios and methods that induce protruding or released CNTs after degradation of nanocomposite materials SO JOURNAL OF NANOPARTICLE RESEARCH LA English DT Article DE Nanocomposites; Degradation; Life-cycle; Characterization for toxicology purposes ID MULTIWALLED CARBON NANOTUBES; EPOXY-BASED NANOCOMPOSITE; NANOPARTICLE RELEASE; ANALYTICAL ULTRACENTRIFUGATION; COMPOSITES; PARTICLES; COATINGS; STABILIZATION; NANOMATERIALS; ENVIRONMENT AB Nanocomposite materials may be considered as a low-risk application of nanotechnology, if the nanofillers remain embedded throughout the life-cycle of the products in which they are embedded. We hypothesize that release of free CNTs occurs by a combination of mechanical stress and chemical degradation of the polymer matrix. We experimentally address limiting cases: Mechanically released fragments may show tubular protrusions on their surface. Here we identify these protrusions unambiguously as naked CNTs by chemically resolved microscopy and a suitable preparation protocol. By size-selective quantification of fragments we establish as a lower limit that at least 95 % of the CNTs remain embedded. Contrary to classical fiber composite approaches, we link this phenomenon to matrix materials with only a few percent elongation at break, predicting which materials should still cover their CNT nanofillers after machining. Protruding networks of CNTs remain after photochemical degradation of the matrix, and we show that it takes the worst case combinations of weathering plus high-shear wear to release free CNTs in the order of mg/m(2)/year. Synergy of chemical degradation and mechanical energy input is identified as the priority scenario of CNT release, but its lab simulation by combined methods is still far from real-world validation. C1 [Hirth, Sabine; Cox, Gerhard; Wohlleben, Wendel] BASF SE, D-67056 Ludwigshafen, Germany. [Cena, Lorenzo] NIOSH, CDC, Morgantown, WV 26505 USA. [Tomovic, Zeljko] BASF Polyurethanes GmbH, GMU UE, D-49448 Lemfoerde, Germany. [Peters, Thomas] Univ Iowa, Iowa City, IA 52242 USA. RP Wohlleben, W (reprint author), BASF SE, D-67056 Ludwigshafen, Germany. EM thomas-m-peters@uiowa.edu; wendel.wohlleben@basf.com OI Wohlleben, Wendel/0000-0003-2094-3260 NR 53 TC 21 Z9 21 U1 2 U2 35 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1388-0764 J9 J NANOPART RES JI J. Nanopart. Res. PD APR PY 2013 VL 15 IS 4 AR UNSP 1504 DI 10.1007/s11051-013-1504-x PG 15 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA 139AS UT WOS:000318554400011 ER PT J AU Abraham, AG D'Souza, G Jing, YZ Gange, SJ Sterling, TR Silverberg, MJ Saag, MS Rourke, SB Rachlis, A Napravnik, S Moore, RD Klein, MB Kitahata, MM Kirk, GD Hogg, RS Hessol, NA Goedert, JJ Gill, MJ Gebo, KA Eron, JJ Engels, EA Dubrow, R Crane, HM Brooks, JT Bosch, RJ Strickler, HD AF Abraham, Alison G. D'Souza, Gypsyamber Jing, Yuezhou Gange, Stephen J. Sterling, Timothy R. Silverberg, Michael J. Saag, Michael S. Rourke, Sean B. Rachlis, Anita Napravnik, Sonia Moore, Richard D. Klein, Marina B. Kitahata, Mari M. Kirk, Gregory D. Hogg, Robert S. Hessol, Nancy A. Goedert, James J. Gill, M. John Gebo, Kelly A. Eron, Joseph J. Engels, Eric A. Dubrow, Robert Crane, Heidi M. Brooks, John T. Bosch, Ronald J. Strickler, Howard D. CA North Amer AIDS Cohort Collaborati TI Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT Eurogin Conference CY JUL 08-11, 2012 CL Prague, CZECH REPUBLIC DE human papillomavirus; HIV-infection; invasive cervical cancer; immunosuppression ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS INFECTION; ABNORMAL PAPANICOLAOU SMEARS; FOLLOW-UP RECOMMENDATIONS; CYTOLOGIC ABNORMALITIES; ANTIRETROVIRAL THERAPY; POSITIVE WOMEN; UNITED-STATES; PAP TESTS AB Objective: HIV infection and low CD4(+) T-cell count are associated with an increased risk of persistent oncogenic human papillomavirus infection-the major risk factor for cervical cancer. Few reported prospective cohort studies have characterized the incidence of invasive cervical cancer (ICC) in HIV-infected women. Methods: Data were obtained from HIV-infected and -uninfected female participants in the North American AIDS Cohort Collaboration on Research and Design with no history of ICC at enrollment. Participants were followed from study entry or January 1996 through ICC, loss to follow-up, or December 2010. The relationship of HIV infection and CD4(+) T-cell count with risk of ICC was assessed using age-adjusted Poisson regression models and standardized incidence ratios. All cases were confirmed by cancer registry records and/or pathology reports. Cervical cytology screening history was assessed through medical record abstraction. Results: A total of 13,690 HIV-infected and 12,021 HIV-uninfected women contributed 66,249 and 70,815 person-years of observation, respectively. Incident ICC was diagnosed in 17 HIV-infected and 4 HIV-uninfected women (incidence rate of 26 and 6 per 100,000 person-years, respectively). HIV-infected women with baseline CD4(+) T-cells of >= 350, 200-349, and <200 cells per microliter had a 2.3, 3.0, and 7.7 times increase in ICC incidence, respectively, compared with HIV-uninfected women (P-trend = 0.001). Of the 17 HIV-infected women, medical records for the 5 years before diagnosis showed that 6 had no documented screening, 5 had screening with low-grade or normal results, and 6 had high-grade results. Conclusions: This study found elevated incidence of ICC in HIV-infected compared with -uninfected women, and these rates increased with immunosuppression. C1 [Abraham, Alison G.; D'Souza, Gypsyamber; Jing, Yuezhou; Gange, Stephen J.; Kirk, Gregory D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Strickler, Howard D.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN 37212 USA. [Silverberg, Michael J.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Saag, Michael S.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. [Rourke, Sean B.; Rachlis, Anita] Univ Toronto, Ontario Treatment Network, Toronto, ON, Canada. [Napravnik, Sonia; Eron, Joseph J.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA. [Moore, Richard D.; Gebo, Kelly A.] Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA. [Klein, Marina B.] McGill Univ, Dept Med, Div Infect Dis, Chron Viral Illness Serv, Montreal, PQ, Canada. [Kitahata, Mari M.; Crane, Heidi M.] Univ Washington, Dept Med, Seattle, WA USA. [Hogg, Robert S.] Simon Fraser Univ, British Columbia Ctr Excellence & HIV AIDS, Dept Hlth Sci, Vancouver, BC, Canada. [Hessol, Nancy A.] Univ Calif San Francisco, Dept Clin Pharm & Med, San Francisco, CA 94143 USA. [Goedert, James J.; Engels, Eric A.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA. [Gill, M. John] Univ Calgary, Dept Med, Calgary, AB, Canada. [Dubrow, Robert] Yale Univ, Sch Med, Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA. [Brooks, John T.] Ctr Dis Control & Prevent, Epidemiol Branch, Atlanta, GA USA. [Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP D'Souza, G (reprint author), Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 North Wolfe St,Suite E6132B, Baltimore, MD 21205 USA. EM aabraham@jhsph.edu; gdsouza@jhsph.edu RI Gill, John/G-7083-2016; OI Gill, John/0000-0002-8546-8790; Gange, Stephen/0000-0001-7842-512X; Hogg, Robert/0000-0003-3463-5488 FU Canadian Institutes of Health Research [169621, CBR-86906, CBR-94036, HCP-97105, KRS-86251, TGF-96118]; Intramural NIH HHS [Z01 CP010176-05, Z01 CP010176-07]; NCI NIH HHS [N02CP55504, P30 CA033572, R01 CA085178, R01-CA085178, R03 CA143956, Z01 CP010176]; NCRR NIH HHS [5-M01-RR-00052, M01 RR000052, RR025747, UL1 RR024131, UL1 RR025747, UL1-RR024131]; NIA NIH HHS [R01 AG026250]; NIAAA NIH HHS [U01 AA013566, U01-AA013566]; NIAID NIH HHS [AI-69432, AI-69434, K01 AI071725, K01 AI071754, K01-AI071725, K01-AI071754, K01AI071725, K23 AI001789, K23-AI-61-0320, P30 AI027757, P30 AI027763, P30 AI027767, P30 AI050410, P30 AI054999, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, R24 AI067039, R24-AI067039, U01 AI031834, U01 AI034989, U01 AI034993, U01 AI034994, U01 AI035004, U01 AI035039, U01 AI035040, U01 AI035041, U01 AI035042, U01 AI035043, U01 AI038855, U01 AI038858, U01 AI042590, U01 AI068634, U01 AI068636, U01 AI069432, U01 AI069434, U01 AI069918, U01-AI-31834, U01-AI-34989, U01-AI-34993, U01-AI-34994, U01-AI-35004, U01-AI-35039, U01-AI-35040, U01-AI-35041, U01-AI-35042, U01-AI-35043, U01-AI-42590, U01-AI069918, U01-AI38855, U01-AI38858, U01-AI68634, U01-AI68636, UM1 AI069432, UM1 AI069434]; NICHD NIH HHS [U01 HD032632, U01-HD-32632]; NIDA NIH HHS [R01 DA004334, R01 DA011602, R01 DA012568, R01-DA04334, R01-DA11602, R01-DA12568, U01 DA036297]; NIDCR NIH HHS [R01 DE021395, R01DE021395]; NIDDK NIH HHS [R01 DK080792]; NIMH NIH HHS [R01 MH054907, R01-MH54907]; NINDS NIH HHS [D43 NS078280]; PHS HHS [CDC200-2006-18797, AHQ290-01-0012, K24-00432] NR 35 TC 40 Z9 41 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 1 PY 2013 VL 62 IS 4 BP 405 EP 413 DI 10.1097/QAI.0b013e31828177d7 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 145SM UT WOS:000319037700011 PM 23254153 ER PT J AU Abanyie, F Bosserman, E Montgomery, S Kuehnert, M Hocevar, S Chin-Hong, P AF Abanyie, F. Bosserman, E. Montgomery, S. Kuehnert, M. Hocevar, S. Chin-Hong, P. TI Donor-Derived Strongyloidiasis in Transplant Recipients - United States 2009-2012. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 13th American Transplant Congress (ATC) CY MAY 18-22, 2013 CL Seattle, WA C1 [Abanyie, F.; Bosserman, E.; Montgomery, S.; Kuehnert, M.; Hocevar, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chin-Hong, P.] UCSF, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2013 VL 13 SU 5 SI SI BP 139 EP 139 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 134UL UT WOS:000318240300350 ER PT J AU Berger, JR Aksamit, AJ Clifford, DB Davis, L Koralnik, IJ Sejvar, JJ Bartt, R Major, EO Nath, A AF Berger, Joseph R. Aksamit, Allen J. Clifford, David B. Davis, Larry Koralnik, Igor J. Sejvar, James J. Bartt, Russell Major, Eugene O. Nath, Avindra TI PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section SO NEUROLOGY LA English DT Review ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN IMMUNODEFICIENCY VIRUS; POLYMERASE-CHAIN-REACTION; STEREOTAXIC BRAIN BIOPSY; JC-VIRUS; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; ANTIRETROVIRAL THERAPY; IMMUNE RECONSTITUTION; NATALIZUMAB AB Objective: To establish criteria for the diagnosis of progressive multifocal leukoencephalopathy (PML). Methods: We reviewed available literature to identify various diagnostic criteria employed. Several search strategies employing the terms "progressive multifocal leukoencephalopathy" with or without "JC virus" were performed with PubMed, SCOPUS, and EMBASE search engines. The articles were reviewed by a committee of individuals with expertise in the disorder in order to determine the most useful applicable criteria. Results: A consensus statement was developed employing clinical, imaging, pathologic, and virologic evidence in support of the diagnosis of PML. Two separate pathways, histopathologic and clinical, for PML diagnosis are proposed. Diagnostic classification includes certain, probable, possible, and not PML. Conclusion: Definitive diagnosis of PML requires neuropathologic demonstration of the typical histopathologic triad (demyelination, bizarre astrocytes, and enlarged oligodendroglial nuclei) coupled with the techniques to show the presence of JC virus. The presence of clinical and imaging manifestations consistent with the diagnosis and not better explained by other disorders coupled with the demonstration of JC virus by PCR in CSF is also considered diagnostic. Algorithms for establishing the diagnosis have been recommended. C1 [Berger, Joseph R.] Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA. [Aksamit, Allen J.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Clifford, David B.] Washington Univ, St Louis, MO USA. [Davis, Larry] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA. [Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Div Neurovirol, Dept Neurol, Boston, MA 02215 USA. [Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Dept Med, Boston, MA 02215 USA. [Sejvar, James J.] Ctr Dis Control, Atlanta, GA 30333 USA. [Bartt, Russell] Blue Sky Neurosci, Englewood, CO USA. [Major, Eugene O.] NINDS, Lab Mol Med & Neurosci, NIH, Bethesda, MD 20892 USA. [Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA. RP Berger, JR (reprint author), Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA. EM jrbneuro@uky.edu FU CMSC; AAN; Bayer; BiogenIdec; PML Consortium; NIH [U10 NS077384, MH22005, AI25903, R56-NS041198, R01-NS047029, R01-NS074995, K24-NS060950]; Alzheimer Association; Biogen Idec; NeurogesX; Tibotec; Pfizer; University of Kentucky and CMSC/ACTRIMS; ECTRIMS; National MS Society; Bristol-Myers Squibb; Ono Pharmaceuticals; Merck Serono; Hoffmann La Roche; GlaxoSmithKline; Perseid Therapeutics; Vertex Pharmaceutical; Johnson Johnson FX J. Berger serves on Data Safety Boards for Millennium and Amgen; has served on scientific advisory boards or as a consultant for Amgen, Bayer, BiogenIdec, Eisai, Genzyme, GlaxoSmithKline, Genentech, Novartis, and Pfizer; has received speaking fees from CMSC, AAN, Bayer, and BiogenIdec; and receives research support from the PML Consortium. A. Aksamit reports no disclosures. D. Clifford is funded by NIH grants U10 NS077384, MH22005, AI25903, and the Alzheimer Association. He serves on Data Safety Boards for Biogen, GSK, Millennium, Genzyme, Genentech, and Pfizer; has been a consultant to Amgen, Brinker, Biddle, Reath (PML Consortium), Genentech, Genzyme, Bristol-Myers Squibb, Millennium, Biogen Idec, and Pfizer; has received research support from Biogen Idec, NeurogesX, Tibotec, and Pfizer; and has received speaking fees from University of Kentucky and CMSC/ACTRIMS and ECTRIMS. L. Davis reports no disclosures. I. Koralnik is funded by NIH grants R56-NS041198, R01-NS047029, R01-NS074995, and K24-NS060950; has received a research grant from Biogen Idec and the National MS Society; served on scientific advisory boards for Hoffmann La-Roche, GlaxoSmithKline, and Merck Serono; received consulting fees from Bristol-Myers Squibb, Ono Pharmaceuticals, Merck Serono, Hoffmann La Roche, GlaxoSmithKline, Perseid Therapeutics, Vertex Pharmaceutical, and Johnson & Johnson; and receives royalties from Up-To-Date for topics on the management of HIV and CNS mass lesions and on PML. J. Sejvar, R. Bartt, E. Major, and A. Nath report no disclosures. Go to Neurology.org for full disclosures. NR 61 TC 122 Z9 125 U1 0 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2013 VL 80 IS 15 BP 1430 EP 1438 DI 10.1212/WNL.0b013e31828c2fa1 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 139RM UT WOS:000318601600017 PM 23568998 ER PT J AU Awosika, OO Lyons, JL Ciarlini, P Phillips, RE Alfson, ED Johnson, EL Koo, S Marty, F Drew, C Zaki, S Folkerth, RD Klein, JP AF Awosika, Oluwole O. Lyons, Jennifer L. Ciarlini, Pedro Phillips, Richard E. Alfson, Elizabeth D. Johnson, Emily L. Koo, Sophia Marty, Francisco Drew, Clifton Zaki, Sherif Folkerth, Rebecca D. Klein, Joshua P. TI FATAL ADENOVIRUS ENCEPHALOMYELORADICULITIS IN AN UMBILICAL CORD STEM CELL TRANSPLANT RECIPIENT SO NEUROLOGY LA English DT Editorial Material ID INFECTIONS; EFFICACY; CMX001 C1 [Awosika, Oluwole O.; Lyons, Jennifer L.; Ciarlini, Pedro; Phillips, Richard E.; Alfson, Elizabeth D.; Johnson, Emily L.; Koo, Sophia; Marty, Francisco; Folkerth, Rebecca D.; Klein, Joshua P.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Awosika, Oluwole O.; Lyons, Jennifer L.; Ciarlini, Pedro; Phillips, Richard E.; Alfson, Elizabeth D.; Johnson, Emily L.; Koo, Sophia; Marty, Francisco; Folkerth, Rebecca D.; Klein, Joshua P.] Harvard Univ, Sch Med, Boston, MA USA. [Drew, Clifton; Zaki, Sherif] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Awosika, OO (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM awosikaoo@ninds.nih.gov FU NIAID NIH HHS [K23 AI097225]; NIMH NIH HHS [R25 MH080663] NR 7 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2013 VL 80 IS 18 BP 1715 EP 1717 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 141AC UT WOS:000318696600022 PM 23596062 ER PT J AU Gutman, J Eckert, E Mangiaterra, V Bardaji, A Aponte, JJ Menendez, C Nahlen, B Slutsker, L AF Gutman, Julie Eckert, Erin Mangiaterra, Viviana Bardaji, Azucena Aponte, John J. Menendez, Clara Nahlen, Bernard Slutsker, Laurence TI Weighing for results: assessing the effect of IPTp SO LANCET INFECTIOUS DISEASES LA English DT Letter ID MALARIA PREVENTION; NEONATAL-MORTALITY; BIRTH-WEIGHT; PREGNANCY C1 [Gutman, Julie; Slutsker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis, Ctr Global Hlth, Atlanta, GA 30333 USA. [Eckert, Erin; Nahlen, Bernard] US Agcy Int Dev, Presidents Malaria Initiat, Washington, DC 20523 USA. [Mangiaterra, Viviana] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland. [Bardaji, Azucena; Aponte, John J.; Menendez, Clara] Hosp Clin Univ Barcelona, CRESIB, Barcelona Ctr Int Hlth Res, Barcelona, Spain. RP Gutman, J (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, Ctr Global Hlth, Atlanta, GA 30333 USA. EM jgutman@cdc.gov NR 6 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2013 VL 13 IS 4 BP 292 EP 292 DI 10.1016/S1473-3099(13)70013-6 PG 1 WC Infectious Diseases SC Infectious Diseases GA 136TL UT WOS:000318386200012 PM 23538220 ER PT J AU Lawn, SD Mwaba, P Bates, M Piatek, A Alexander, H Marais, BJ Cuevas, LE McHugh, TD Zijenah, L Kapata, N Abubakar, I McNerney, R Hoelscher, M Memish, ZA Migliori, GB Kim, P Maeurer, M Schito, M Zumla, A AF Lawn, Stephen D. Mwaba, Peter Bates, Matthew Piatek, Amy Alexander, Heather Marais, Ben J. Cuevas, Luis E. McHugh, Timothy D. Zijenah, Lynn Kapata, Nathan Abubakar, Ibrahim McNerney, Ruth Hoelscher, Michael Memish, Ziad A. Migliori, Giovanni Battista Kim, Peter Maeurer, Markus Schito, Marco Zumla, Alimuddin TI Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test SO LANCET INFECTIOUS DISEASES LA English DT Article ID POSITIVE RIFAMPICIN RESISTANCE; HIV-ASSOCIATED TUBERCULOSIS; RESOURCE-LIMITED SETTINGS; RAPID MOLECULAR-DETECTION; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; EXTRAPULMONARY TUBERCULOSIS; LOW-COST AB Rapid progress has been made in the development of new diagnostic assays for tuberculosis in recent years. New technologies have been developed and assessed, and are now being implemented. The Xpert MTB/RIF assay, which enables simultaneous detection of Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance, was endorsed by WHO in December, 2010. This assay was specifically recommended for use as the initial diagnostic test for suspected drug-resistant or HIV-associated pulmonary tuberculosis. By June, 2012, two-thirds of countries with a high tuberculosis burden and half of countries with a high multidrug-resistant tuberculosis burden had incorporated the assay into their national tuberculosis programme guidelines. Although the development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and programmatic effects and cost-effectiveness remain to be defined. We review the rapidly growing body of scientific literature and discuss the advantages and challenges of using the Xpert MTB/RIF assay in areas where tuberculosis is endemic. We also review other prospects within the developmental pipeline. A rapid, accurate point-of-care diagnostic test that is affordable and can be readily implemented is urgently needed. Investment in the tuberculosis diagnostics pipeline should remain a major priority for funders and researchers. C1 [Lawn, Stephen D.; McNerney, Ruth] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England. [Lawn, Stephen D.] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa. [Mwaba, Peter; Bates, Matthew; Kapata, Nathan; Zumla, Alimuddin] Univ Zambia Univ Coll London Med Sch UNZA UCLMS R, Univ Teaching Hosp, Lusaka, Zambia. [Mwaba, Peter; Kapata, Nathan] Minist Hlth, Lusaka, Zambia. [Bates, Matthew; McHugh, Timothy D.; Zumla, Alimuddin] UCL, Ctr Clin Microbiol, Div Infect & Immun, London NW3 2PF, England. [Abubakar, Ibrahim] UCL, Ctr Infect Dis Epidemiol, Dept Infect & Populat Hlth, London NW3 2PF, England. [Piatek, Amy] US Agcy Int Dev, Bur Global Hlth, Off Hlth Infect Dis & Nutr, Washington, DC 20523 USA. [Alexander, Heather] US Ctr Dis Control & Prevent, Div Global HIVAIDS, Ctr Global Hlth, Atlanta, GA USA. [Marais, Ben J.] Univ Sydney, Sydney Emerging Infect & Biosecur Inst, Sydney, NSW 2006, Australia. [Marais, Ben J.] Univ Sydney, Childrens Hosp Westmead, Sydney Med Sch, Sydney, NSW 2006, Australia. [Cuevas, Luis E.] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Zijenah, Lynn] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe. [Abubakar, Ibrahim] Hlth Protect Agcy, London, England. [Hoelscher, Michael] Klinikum Univ Munich, Dept Infect Dis & Trop Med, Munich, Germany. [Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia. [Memish, Ziad A.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia. [Migliori, Giovanni Battista] WHO Collaborating Ctr TB & Lung Dis, Fdn S Maugeri, Care & Res Inst, Tradate, Italy. [Kim, Peter] NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA. [Maeurer, Markus] Karolinska Inst, Div Therapeut Immunol LabMed & Microbiol, S-10401 Stockholm, Sweden. [Maeurer, Markus] Karolinska Hosp, Ctr Allogene Stem Cell Transplantat, S-10401 Stockholm, Sweden. [Schito, Marco] NIAID, Henry M Jackson Fdn, Div AIDS, NIH, Bethesda, MD 20892 USA. RP Zumla, A (reprint author), UCL, Royal Free Hosp, Div Infect & Immun, Ctr Clin Microbiol, Royal Free Campus, London NW3 2PF, England. EM a.zumla@ucl.ac.uk RI Hoelscher, Michael/D-3436-2012; OI McHugh, Timothy D/0000-0003-4658-8594; MCNERNEY, Ruth/0000-0002-1957-443X; Abubakar, Ibrahim/0000-0002-0370-1430; Zumla, Alimuddin/0000-0002-5111-5735; Migliori, Giovanni Battista/0000-0002-2597-574X; Cuevas, Luis E./0000-0002-6581-0587 FU Wellcome Trust, UK; European and Developing Countries Clinical Trials Partnership (EDCTP), Netherlands; UK Medical Research Council (MRC); UBS Optimus Foundation, Switzerland; University College London Hospitals Comprehensive Biomedical Research Centre (UCLH-CBRC); UCLH National Health Service Foundation Trust; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200800014C]; President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX SDL is supported by the Wellcome Trust, UK. PM, MB, MH, and AZ are supported by the European and Developing Countries Clinical Trials Partnership (EDCTP grants REMOX, PANACEA, and TB-NEAT), Netherlands. AZ receives support from the UK Medical Research Council (MRC); UBS Optimus Foundation, Switzerland; University College London Hospitals Comprehensive Biomedical Research Centre (UCLH-CBRC); and the UCLH National Health Service Foundation Trust. This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272200800014C, and by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. The opinions expressed herein are those of the authors and do not reflect the official views or policies of the US Department of Health and Human Services or the authors' national governments, nor does mention of trade names, commercial practices, or organisations imply endorsement by the US Government or the authors' national governments. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 92 TC 164 Z9 174 U1 4 U2 55 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2013 VL 13 IS 4 BP 349 EP 361 DI 10.1016/S1473-3099(13)70008-2 PG 13 WC Infectious Diseases SC Infectious Diseases GA 136TL UT WOS:000318386200033 PM 23531388 ER PT J AU Branson, BM Pandori, M AF Branson, Bernard M. Pandori, Mark TI 2012 HIV Diagnostics Conference: the molecular diagnostics perspective SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review AB 2012 HIV Diagnostic Conference Atlanta, GA, USA, 12-14 December 2012 This report highlights the presentations and discussions from the 2012 National HIV Diagnostic Conference held in Atlanta (GA, USA), on 12-14 December 2012. Reflecting changes in the evolving field of HIV diagnostics, the conference provided a forum for evaluating developments in molecular diagnostics and their role in HIV diagnosis. In 2010, the HIV Diagnostics Conference concluded with the proposal of a new diagnostic algorithm which included nucleic acid testing to resolve discordant screening and supplemental antibody test results. The 2012 meeting, picking up where the 2010 meeting left off, focused on scientific presentations that assessed this new algorithm and the role played by RNA testing and new developments in molecular diagnostics, including detection of total and integrated HIV-1 DNA, detection and quantification of HIV-2 RNA, and rapid formats for detection of HIV-1 RNA. C1 [Branson, Bernard M.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Pandori, Mark] San Francisco Dept Publ Hlth Lab, San Francisco, CA 94122 USA. RP Branson, BM (reprint author), CDC, Div HIV AIDS Prevent, 1600 Clifton Rd MS D-21, Atlanta, GA 30333 USA. EM bbranson@cdc.gov NR 2 TC 2 Z9 2 U1 0 U2 4 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD APR PY 2013 VL 13 IS 3 BP 243 EP 245 DI 10.1586/ERM.13.5 PG 3 WC Pathology SC Pathology GA 133MQ UT WOS:000318142900009 PM 23570401 ER PT J AU Forteza, A Ruiz, CB Visvesvara, G Ribas, JM Vidal, JB Couce, ME AF Forteza, Ana Ballester Ruiz, Carmen Visvesvara, Govinda Muncunill Ribas, Josep Besalduch Vidal, Juan Couce, Marta E. TI Resolution of refractory thrombotic thrombocytopenic purpura (TTP) after successful treatment of a fulminant colitis due to Entamoeba histolytica SO GASTROENTEROLOGIA Y HEPATOLOGIA LA English DT Letter C1 [Forteza, Ana; Couce, Marta E.] Hosp Comarcal de Inca, Dept Pathol, Mallorca, Spain. [Ballester Ruiz, Carmen; Muncunill Ribas, Josep; Besalduch Vidal, Juan] Hosp Univ Son Espases, Dept Haematol, Palma De Mallorca, Spain. [Visvesvara, Govinda] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. RP Couce, ME (reprint author), Hosp Comarcal de Inca, Dept Pathol, Mallorca, Spain. EM marta.couce@ssib.es NR 5 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER DOYMA SL PI BARCELONA PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN SN 0210-5705 J9 GASTROENT HEPAT-BARC JI Gastroenterol. Hepatol. PD APR PY 2013 VL 36 IS 4 BP 294 EP 295 DI 10.1016/j.gastrohep.2012.11.004 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 134HH UT WOS:000318200500009 PM 23453561 ER PT J AU Tao, Y Shi, M Conrardy, C Kuzmin, IV Recuenco, S Agwanda, B Alvarez, DA Ellison, JA Gilbert, AT Moran, D Niezgoda, M Lindblade, KA Holmes, EC Breiman, RF Rupprecht, CE Tong, SX AF Tao, Ying Shi, Mang Conrardy, Christina Kuzmin, Ivan V. Recuenco, Sergio Agwanda, Bernard Alvarez, Danilo A. Ellison, James A. Gilbert, Amy T. Moran, David Niezgoda, Michael Lindblade, Kim A. Holmes, Edward C. Breiman, Robert F. Rupprecht, Charles E. Tong, Suxiang TI Discovery of diverse polyomaviruses in bats and the evolutionary history of the Polyomaviridae SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID SEQUENCE; PHYLOGENY; VIRUSES; HOSTS; IDENTIFICATION; CORONAVIRUSES; COEVOLUTION; PROGRAM; GENOMES; PROTEIN AB Polyomaviruses (PyVs) have been identified in a wide range of avian and mammalian species. However, little is known about their occurrence, genetic diversity and evolutionary history in bats, even though bats are important reservoirs for many emerging viral pathogens. This study screened 380 specimens from 35 bat species from Kenya and Guatemala for the presence of PyVs by semi-nested pan-PyV FOR assays. PyV DNA was detected in 24 of the 380 bat specimens. Phylogenetic analysis revealed that the bat PyV sequences formed 12 distinct lineages. Full-genome sequences were obtained for seven representative lineages and possessed similar genomic features to known PyVs. Strikingly, this evolutionary analysis revealed that the bat PyVs were paraphyletic, suggestive of multiple species jumps between bats and other mammalian species, such that the theory of virus-host co-divergence for mammalian PyVs as a whole could be rejected. In addition, evidence was found for strong heterogeneity in evolutionary rate and potential recombination in a number of PyV complete genomes, which complicates both phylogenetic analysis and virus classification. In summary, this study revealed that bats are important reservoirs of PyVs and that these viruses have a complex evolutionary history. C1 [Tao, Ying; Conrardy, Christina; Tong, Suxiang] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Shi, Mang; Holmes, Edward C.] Univ Sydney, Sch Biol Sci, Sydney Emerging Infect & Biosecur Inst, Sydney, NSW 2006, Australia. [Shi, Mang; Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. [Kuzmin, Ivan V.; Recuenco, Sergio; Ellison, James A.; Gilbert, Amy T.; Niezgoda, Michael; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Agwanda, Bernard] Kenya Wildlife Serv, Natl Museum, Nairobi, Kenya. [Alvarez, Danilo A.; Moran, David] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Lindblade, Kim A.] Ctr Dis Control & Prevent Cent Amer & Panama, Guatemala City, Guatemala. [Holmes, Edward C.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Breiman, Robert F.] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya. RP Tong, SX (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM sot1@cdc.gov RI Shi, Mang/D-5118-2013; OI Ellison, James/0000-0003-4492-4857; Recuenco-Cabrera, Sergio/0000-0002-8446-7411; Holmes, Edward/0000-0001-9596-3552 FU Global Disease Detection Program TSC funds in the Centers for Disease Control and Prevention, Atlanta, Georgia FX The study was supported in part by the Global Disease Detection Program TSC funds in the Centers for Disease Control and Prevention, Atlanta, Georgia. We thank Shur-Wern Chem (Division of Viral Diseases, CDC, Atlanta, GA, USA) for her work in the validation of the pan-PyV PCR assay. We thank Ramon Medrano and Maria Luisa Muller from Universidad del Valle de Guatemala (Guatemala City, Guatemala) for support in the fieldwork and thank the Ministry of Agriculture and Ministry of Health from Guatemala. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 38 TC 15 Z9 15 U1 2 U2 14 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 J9 J GEN VIROL JI J. Gen. Virol. PD APR PY 2013 VL 94 BP 738 EP 748 DI 10.1099/vir.0.047928-0 PN 4 PG 11 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 131LM UT WOS:000317995200005 PM 23239573 ER PT J AU Zarecki, SLM Bennett, SD Hall, J Yaeger, J Lujan, K Adams-Cameron, M Quinn, KW Brenden, R Biggerstaff, G Hill, VR Sholtes, K Garrett, NM Lafon, PC Behravesh, CB Sodha, SV AF Zarecki, Shauna L. Mettee Bennett, Sarah D. Hall, Julia Yaeger, Jill Lujan, Kate Adams-Cameron, Marguerite Quinn, Kim Winpisinger Brenden, Rita Biggerstaff, Gwen Hill, Vincent R. Sholtes, Kari Garrett, Nancy Marie Lafon, Patti C. Behravesh, Casey Barton Sodha, Samir V. CA Salmonella Typhimurium Outbreak TI US Outbreak of Human Salmonella Infections Associated With Aquatic Frogs, 2008-2011 SO PEDIATRICS LA English DT Article DE children; pediatric; Salmonella; outbreak; zoonoses; amphibians; frogs; pets ID TURTLE-ASSOCIATED SALMONELLOSIS; UNITED-STATES; MULTISTATE OUTBREAK; PUBLIC-HEALTH; EXPOSURE AB OBJECTIVE: Although amphibians are known Salmonella carriers, no such outbreaks have been reported. We investigated a nationwide outbreak of human Salmonella Typhimurium infections occurring predominantly among children from 2008 to 2011. METHODS: We conducted a matched case-control study. Cases were defined as persons with Salmonella Typhimurium infection yielding an isolate indistinguishable from the outbreak strain. Controls were persons with recent infection with Salmonella strains other than the outbreak strain and matched to cases by age and geography. Environmental samples were obtained from patients' homes; traceback investigations were conducted. RESULTS: We identified 376 cases from 44 states from January 1, 2008, to December 31, 2011; 29% (56/193) of patients were hospitalized and none died. Median patient age was 5 years (range,1-86 years); 69% were children,10 years old (253/367). Among 114 patients interviewed, 69 (61%) reported frog exposure. Of patients who knew frog type, 79% (44/56) reported African dwarf frogs (ADF), a type of aquatic frog. Among 18 cases and 29 controls, illness was significantly associated with frog exposure (67% cases versus 3% controls, matched odds ratio 12.4, 95% confidence interval 1.9-infinity). Environmental samples from aquariums containing ADFs in 8 patients' homes, 2 ADF distributors, and a day care center yielded isolates indistinguishable from the outbreak strain. Traceback investigations of ADFs from patient purchases converged to a common ADF breeding facility. Environmental samples from the breeding facility yielded the outbreak strain. CONCLUSIONS: ADFs were the source of this nationwide pediatric predominant outbreak. Pediatricians should routinely inquire about pet ownership and advise families about illness risks associated with animals. C1 [Zarecki, Shauna L. Mettee; Bennett, Sarah D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Zarecki, Shauna L. Mettee; Bennett, Sarah D.; Biggerstaff, Gwen; Hill, Vincent R.; Garrett, Nancy Marie; Lafon, Patti C.; Behravesh, Casey Barton; Sodha, Samir V.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Zarecki, Shauna L. Mettee] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sholtes, Kari] Ctr Dis Control & Prevent, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Sodha, Samir V.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Zarecki, Shauna L. Mettee; Bennett, Sarah D.; Behravesh, Casey Barton; Sodha, Samir V.] United States Public Hlth Serv Commissioned Corps, Salt Lake City, UT USA. [Hall, Julia] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Yaeger, Jill] Madera Cty Environm Hlth Dept, Madera, CA USA. [Lujan, Kate] Colorado Dept Publ Hlth & Environm, Publ Hlth Nurse Consultant Off Planning & Partner, Dis Control Environm Epidemiol Div, Grand Junction, CO USA. [Adams-Cameron, Marguerite] New Mexico Dept Hlth, Epidemiol & Response Div, Albuquerque, NM USA. [Quinn, Kim Winpisinger] Ohio Dept Hlth, Outbreak Response & BT Invest Team, Columbus, OH 43266 USA. [Brenden, Rita] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, Microbial Dis Lab Branch, Richmond, CA USA. RP Zarecki, SLM (reprint author), Ctr Dis Control & Prevent, Off Natl Prevent Strategy, Off Associate Director Policy, 1600 Clifton RD NE,Mailstop D-28, Atlanta, GA 30333 USA. EM smettee@cdc.gov NR 20 TC 12 Z9 12 U1 1 U2 23 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2013 VL 131 IS 4 BP 724 EP 731 DI 10.1542/peds.2012-2031 PG 8 WC Pediatrics SC Pediatrics GA 135EF UT WOS:000318269500058 ER PT J AU Clayton, HB Li, RW Perrine, CG Scanlon, KS AF Clayton, Heather B. Li, Ruowei Perrine, Cria G. Scanlon, Kelley S. TI Prevalence and Reasons for Introducing Infants Early to Solid Foods: Variations by Milk Feeding Type SO PEDIATRICS LA English DT Article DE nutrition; infant; breastfeeding ID LOW-INCOME WOMEN; 1ST YEAR; KNOWLEDGE; ATTITUDES; RECOMMENDATIONS; PHYSICIANS; RISK; LIFE; CARE AB OBJECTIVE: To examine the prevalence of, and mothers' self-reported reasons for, introducing solid foods to infants earlier than recommended (aged <4 months) and the variation in reasons for early introduction by milk feeding type. METHODS: The study included 1334 mothers who participated in the national longitudinal Infant Feeding Practices Study II (2005-2007). Monthly 7-day food-frequency questions throughout infancy were used to determine infant age at solid food introduction and to classify infant's milk feeding at introduction as breast milk only, formula only, or mixed. Reasons for introducing solid foods at age <4 months were assessed through maternal responses to a list of 12 potential reasons. Analyses included descriptive statistics and multivariable logistic regression. RESULTS: Overall, 40.4% of mothers introduced solid foods before age 4 months. Prevalence varied by milk feeding type (24.3%, 52.7%, and 50.2% for breastfed, formula-fed, and mixed-fed infants, respectively). The most commonly cited reasons for early introduction of solid food were as follows: "My baby was old enough," "My baby seemed hungry," "I wanted to feed my baby something in addition to breast milk or formula," "My baby wanted the food I ate," "A doctor or other health care professional said my baby should begin eating solid food," and "It would help my baby sleep longer at night." Four of these reasons varied by milk feeding type. CONCLUSIONS: Our findings highlight the high prevalence of early introduction of solids and provide details on why mothers introduced solid foods early. C1 [Clayton, Heather B.] Off Workforce Dev, Epidem Intelligence Serv, Atlanta, GA USA. [Clayton, Heather B.; Li, Ruowei; Perrine, Cria G.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Clayton, HB (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy,MSK 25, Atlanta, GA 30341 USA. EM hhc9@cdc.gov FU US Food and Drug Administration, Centers for Disease Control and Prevention, Office of Women's Health, National Institutes of Health (NIH); Maternal and Child Health Bureau in the US Department of Health and Human Services FX This study was supported by the US Food and Drug Administration, Centers for Disease Control and Prevention, Office of Women's Health, National Institutes of Health (NIH), and the Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 30 TC 34 Z9 34 U1 3 U2 21 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2013 VL 131 IS 4 BP E1108 EP E1114 DI 10.1542/peds.2012-2265 PG 7 WC Pediatrics SC Pediatrics GA 135EF UT WOS:000318269500008 PM 23530169 ER PT J AU Gastanaduy, PA Sanchez-Uribe, E Esparza-Aguilar, M Desai, R Parashar, UD Patel, M Richardson, V AF Gastanaduy, Paul A. Sanchez-Uribe, Edgar Esparza-Aguilar, Marcelino Desai, Rishi Parashar, Umesh D. Patel, Manish Richardson, Vesta TI Effect of Rotavirus Vaccine on Diarrhea Mortality in Different Socioeconomic Regions of Mexico SO PEDIATRICS LA English DT Article DE rotavirus vaccines; diarrhea; mortality; Mexico ID CHILDHOOD DIARRHEA; CHILDREN AB OBJECTIVE: In Mexico, declines in childhood diarrhea deaths have been documented during 2008-2010 after rotavirus vaccine introduction in 2007. Because of concerns about variation in rotavirus vaccine efficacy by socioeconomic status, we compared reductions in diarrhea mortality in the lesser developed southern region versus the more developed northern and central regions of Mexico. METHODS: We obtained data from national vital statistics on diarrhea deaths among children aged <5 years from 2002 through 2011. We compared region-specific diarrhea mortality before (2003-2006) and after (2009-2011) vaccine introduction. Regional vaccine coverage was estimated from administrative data, and socioeconomic status was assessed by using the Human Development Index. RESULTS: In northern, central, and southern Mexico, the 2007 Human Development Index was 0.84, 0.82, and 0.77, respectively, and by 2010 an estimated 99%, 84%, and 89% of children aged <12 months had completed rotavirus vaccination. Diarrhea mortality among children <5 years old declined from 8.3, 17.9, and 28.5 deaths per 100 000 children during 2003-2006 to 4.5, 8.1, and 16.2 in 2009-2011 in northern, central, and southern Mexico, respectively, corresponding to rate reductions of 45%, 55%, and 43%. No significant differences were observed in rate reductions between regions (P > .8). CONCLUSIONS: After introduction of rotavirus vaccination, marked and sustained declines in diarrhea deaths were seen among children in all regions of Mexico, including in the least developed southern region with the highest baseline diarrhea mortality. This finding indicates equitable vaccine delivery to children with varying risk of mortality and reaffirms the beneficial effects of rotavirus vaccination against fatal diarrheal disease. C1 [Gastanaduy, Paul A.; Desai, Rishi] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Gastanaduy, Paul A.; Desai, Rishi; Parashar, Umesh D.; Patel, Manish] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Sanchez-Uribe, Edgar; Esparza-Aguilar, Marcelino; Richardson, Vesta] Minist Hlth, Natl Ctr Child & Adolescent Hlth, Mexico City, DF, Mexico. RP Gastanaduy, PA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Epidemiol Branch,Viral Gastroenteritis Team, 1600 Clifton Rd NE,Mailstop A-34, Atlanta, GA 30333 USA. EM vid7@cdc.gov NR 21 TC 24 Z9 24 U1 0 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2013 VL 131 IS 4 BP E1115 EP E1120 DI 10.1542/peds.2012-2797 PG 6 WC Pediatrics SC Pediatrics GA 135EF UT WOS:000318269500009 PM 23460689 ER PT J AU Lee, RD Fang, XM Luo, FJ AF Lee, Rosalyn D. Fang, Xiangming Luo, Feijun TI The Impact of Parental Incarceration on the Physical and Mental Health of Young Adults SO PEDIATRICS LA English DT Article DE parental incarceration; prison; adverse childhood experiences; depression; anxiety; young adults; self-reported health ID ADVERSE CHILDHOOD EXPERIENCES; SEXUAL RISK BEHAVIOR; ADOLESCENT HEALTH; COMMUNITY REENTRY; UNITED-STATES; DRUG-USE; MALTREATMENT; PRISON; ABUSE; CONSEQUENCES AB OBJECTIVES: We investigated the relationship between parental incarceration history and young adult physical and mental health outcomes using Wave 1 and Wave 4 data from the National Longitudinal Study of Adolescent Health. METHODS: Dependent variables included self-reported fair/poor health and health diagnoses. The independent variable was parental incarceration history. Cross-tabulations and logistic regression models were run. RESULTS: Positive, significant associations were found between parental incarceration and 8 of 16 health problems (depression, posttraumatic stress disorder, anxiety, cholesterol, asthma, migraines, HIV/AIDS, and fair/poor health) in adjusted logistic regression models. Those who reported paternal incarceration had increased odds of 8 mental and physical health problems, whereas those who reported maternal incarceration had increased odds of depression. For paternal incarceration, with the exception of HIV/AIDS, larger associations were found for mental health (odds ratios range 1.43-1.72) as compared with physical health (odds ratios range 1.26-1.31) problems. The association between paternal incarceration and HIV/AIDs should be interpreted with caution because of the low sample prevalence of HIV/AIDs. CONCLUSIONS: This study suggests exposure to parental incarceration in childhood is associated with health problems in young adulthood. Extant literature suggests underlying mechanisms that link parental incarceration history to poor outcomes in offspring may include the lack of safe, stable, nurturing relationships and exposure to violence. To prevent poor health in offspring of the incarcerated, additional studies are needed to (1) confirm the aforementioned associations and (2) assess whether adverse experiences and violence exposure in childhood mediate the relationship between parental incarceration history and offspring health problems. Pediatrics 2013; 131: e1188-e1195 C1 [Lee, Rosalyn D.; Fang, Xiangming; Luo, Feijun] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA USA. RP Fang, XM (reprint author), China Agr Univ, Coll Econ & Management, Int Ctr Appl Econ & Policy, 17 Qinghua East Rd, Beijing 10094, Peoples R China. EM xmfang@cau.edu.cn RI Fang, Xiangming/O-1653-2014 OI Fang, Xiangming/0000-0001-9922-8977 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [P01-HD31921]; National Institutes of Health; [01-HD31921] FX This research uses data from Add Health, a program project directed by Kathleen Mullan Harris and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. Special acknowledgment is due Ronald R. Rindfuss and Barbara Entwisle for assistance in the original design. Information on how to obtain the Add Health data files is available on the Add Health Web site (http://www.cpc.unc.edu/addhealth). No direct support was received from grant P01-HD31921 for this analysis.; No outside funding was provided for this study, however data used for this research were provided by Add Health, a longitudinal survey supported by funding from the National Institutes of Health. NR 54 TC 26 Z9 27 U1 9 U2 45 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2013 VL 131 IS 4 BP E1188 EP E1195 DI 10.1542/peds.2012-0627 PG 8 WC Pediatrics SC Pediatrics GA 135EF UT WOS:000318269500019 PM 23509174 ER PT J AU Lotstein, DS Seid, M Klingensmith, G Case, D Lawrence, JM Pihoker, C Dabelea, D Mayer-Davis, EJ Gilliam, LK Corathers, S Imperatore, G Dolan, L Anderson, A Bell, RA Waitzfelder, B AF Lotstein, Debra S. Seid, Michael Klingensmith, Georgeanna Case, Doug Lawrence, Jean M. Pihoker, Catherine Dabelea, Dana Mayer-Davis, Elizabeth J. Gilliam, Lisa K. Corathers, Sarah Imperatore, Giuseppina Dolan, Lawrence Anderson, Andrea Bell, Ronny A. Waitzfelder, Beth CA SEARCH Diabet Youth Study Grp TI Transition From Pediatric to Adult Care for Youth Diagnosed With Type 1 Diabetes in Adolescence SO PEDIATRICS LA English DT Article DE Transition of Care; adolescence; diabetes ID GLYCEMIC CONTROL; YOUNG-ADULTS; HEALTH-CARE; MELLITUS; SYSTEMS; FAMILY AB OBJECTIVE: Youth with type 1 diabetes mellitus are at risk for poor glycemic control as they age into adulthood. The aim of this study was to describe sociodemographic and clinical correlates of poor glycemic control associated with the transfer of care from pediatric to adult diabetes providers among a cohort of youth with type 1 diabetes diagnosed in adolescence. METHODS: Analyses included 185 adolescent participants with recently diagnosed type 1 diabetes in the SEARCH for Diabetes in Youth Study with pediatric care at baseline who were age >= 18 years at follow-up. Demographic and clinical factors were measured by survey and laboratory results. Survival analysis was used to estimate the age of transition. Logistic regression analysis assessed the association of demographic and clinical factors with the transition of care and poor glycemic control at follow-up. RESULTS: Fifty-seven percent of participants had transitioned to adult diabetes care providers by the follow-up visit. The estimated median age of transition of care was 20.1 years (95% confidence interval 19.8-20.4). Older age, lower baseline glycosylated hemoglobin, and less parental education were independently associated with increased odds of transition. The odds of poor glycemic control at follow-up were 2.5 times higher for participants who transitioned to adult care compared with those who remained in pediatric care. CONCLUSIONS: Transferring from pediatric to adult care, experienced by more than half the sample, was associated with an increased risk of poor glycemic control at follow-up. These findings suggest that young adults need additional support when moving to adult care. C1 [Lotstein, Debra S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Seid, Michael] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, Cincinnati, OH USA. [Seid, Michael] Cincinnati Childrens Hosp Med Ctr, Anderson Ctr Hlth Syst Excellence, Cincinnati, OH USA. [Klingensmith, Georgeanna] Univ Colorado, Denver Sch Med, Barbara Davis Ctr, Aurora, CO USA. [Case, Doug; Anderson, Andrea] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Serv, Winston Salem, NC USA. [Bell, Ronny A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Lawrence, Jean M.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Gilliam, Lisa K.] Univ Washington, Dept Med, Seattle, WA USA. [Dabelea, Dana] Colorado Sch Publ Hlth, Dept Epidemiol, Denver, CO USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Corathers, Sarah; Dolan, Lawrence] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH USA. [Corathers, Sarah; Dolan, Lawrence] Univ Cincinnati, Cincinnati, OH USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Waitzfelder, Beth] Kaiser Permanente Hawaii, Ctr Hlth Res Hawaii, Honolulu, HI USA. RP Lotstein, DS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Box 951752,22-464 MDCC, Los Angeles, CA 90095 USA. EM dlotstein@mednet.ucla.edu FU Centers for Disease Control and Prevention [00097, DP-05- 069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; General Clinical Research Centers at the South Carolina Clinical and Translational Research Institute, at the Medical University of South Carolina (National Institutes of Health/National Center for Research Resources [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; Institutional Clinical and Translational Science Award, National Institutes of Health/National Center for Research Resources at the University of Cincinnati [1UL1RR026314-01] FX The SEARCH for Diabetes in Youth Study is indebted to the many youth and their families, and their health care providers, whose participation made this study possible. SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05- 069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases.; Site Contract Numbers: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708-01), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), and Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171).; The authors acknowledge the involvement of General Clinical Research Centers at the South Carolina Clinical and Translational Research Institute, at the Medical University of South Carolina (National Institutes of Health/National Center for Research Resources grant number UL1RR029882); Children's Hospital and Regional Medical Center (grant Number M01RR00037); Colorado Pediatric General Clinical Research Center (grant Number M01 RR00069) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the Institutional Clinical and Translational Science Award, National Institutes of Health/National Center for Research Resources at the University of Cincinnati (grant Number 1UL1RR026314-01). The writing group for this article acknowledges the contributions of the following individuals to the SEARCH for Diabetes in Youth Study: NR 24 TC 51 Z9 51 U1 2 U2 15 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2013 VL 131 IS 4 BP E1062 EP E1070 DI 10.1542/peds.2012-1450 PG 9 WC Pediatrics SC Pediatrics GA 135EF UT WOS:000318269500003 PM 23530167 ER PT J AU Tartof, SY Lewis, M Kenyon, C White, K Osborn, A Liko, J Zell, E Martin, S Messonnier, NE Clark, TA Skoff, TH AF Tartof, Sara Y. Lewis, Melissa Kenyon, Cynthia White, Karen Osborn, Andrew Liko, Juventila Zell, Elizabeth Martin, Stacey Messonnier, Nancy E. Clark, Thomas A. Skoff, Tami H. TI Waning Immunity to Pertussis Following 5 Doses of DTaP SO PEDIATRICS LA English DT Article DE Pertussis; DTaP; immunity; Immunization Information Systems; vaccines ID IMMUNIZATION INFORMATION-SYSTEMS; UNITED-STATES; VACCINE EFFECTIVENESS; ROTAVIRUS VACCINE; US CHILDREN; EPIDEMIC; DTP AB OBJECTIVE: To assess the risk of pertussis by time since vaccination in children in Minnesota and Oregon who received 5 doses of acellular pertussis vaccines (DTaP). METHODS: These cohort analyses included Minnesota and Oregon children born between 1998 and 2003 who had 5 DTaP doses recorded in state Immunization Information Systems. Immunization records and statewide pertussis surveillance data were combined. Incidence rates and risk ratios for pertussis were calculated for the 6 years after receipt of the fifth DTaP dose. RESULTS: The cohorts included 224 378 Minnesota children and 179 011 from Oregon; 458 and 89 pertussis cases were identified in Minnesota and Oregon, respectively. Pertussis incidence rates rose each year of follow-up: 15.6/100 000 (95% confidence interval [CI]: 11.1-21.4) at year 1 to 138.4/100 000 (CI: 113.3-166.9) at year 6 (Minnesota); 6.2/100 000 (CI: 3.3-10.6) in year 1 to 24.4/100 000 (CI: 15.0-37.8) in year 6 (Oregon). Risk ratios increased from 1.9 (CI: 1.3-2.9) in year 2 to 8.9 (CI: 6.0-13.0) in year 6 (Minnesota) and from 1.3 (CI: 0.6-2.8) in year 2 to 4.0 (CI: 1.9-8.4) in year 6 (Oregon). CONCLUSIONS: This evaluation reports steady increase in risk of pertussis in the years after completion of the 5-dose DTaP series. This rise is likely attributable in part to waning immunity from DTaP vaccines. Continuing to monitor disease burden and vaccine effectiveness in fully vaccinated children in coming years will be important to assess ongoing risk as additional cohorts vaccinated solely with acellular pertussis vaccines are introduced. C1 [Tartof, Sara Y.; Lewis, Melissa; Zell, Elizabeth; Martin, Stacey; Messonnier, Nancy E.; Clark, Thomas A.; Skoff, Tami H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kenyon, Cynthia; White, Karen] Minnesota Dept Hlth, St Paul, MN USA. [Osborn, Andrew; Liko, Juventila] Oregon Hlth Author, Portland, OR USA. RP Tartof, SY (reprint author), So Calif Permanente Med Grp, 100 S Los Robles, Pasadena, CA 91101 USA. EM sara.y.tartof@kp.org NR 34 TC 90 Z9 90 U1 0 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2013 VL 131 IS 4 BP E1047 EP E1052 DI 10.1542/peds.2012-1928 PG 6 WC Pediatrics SC Pediatrics GA 135EF UT WOS:000318269500001 PM 23478868 ER PT J AU Sharp, TM Hunsperger, E Santiago, GA Munoz-Jordan, JL Santiago, LM Rivera, A Rodriguez-Acosta, RL Feliciano, LG Margolis, HS Tomashek, KM AF Sharp, Tyler M. Hunsperger, Elizabeth Santiago, Gilberto A. Munoz-Jordan, Jorge L. Santiago, Luis M. Rivera, Aidsa Rodriguez-Acosta, Rosa L. Feliciano, Lorenzo Gonzalez Margolis, Harold S. Tomashek, Kay M. TI Virus-Specific Differences in Rates of Disease during the 2010 Dengue Epidemic in Puerto Rico SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID SEROTYPE-SPECIFIC DIFFERENCES; LINKED-IMMUNOSORBENT-ASSAY; HEMORRHAGIC-FEVER; IMMUNOGLOBULIN-M; MOLECULAR EVOLUTION; ANTIBODY-RESPONSE; THAILAND; MANIFESTATIONS; SEVERITY; OUTBREAK AB Background: Dengue is a potentially fatal acute febrile illness (AFI) caused by four mosquito-transmitted dengue viruses (DENV-1-4) that are endemic in Puerto Rico. In January 2010, the number of suspected dengue cases reported to the passive dengue surveillance system exceeded the epidemic threshold and an epidemic was declared soon after. Methodology/Principal Findings: To characterize the epidemic, surveillance and laboratory diagnostic data were compiled. A suspected case was a dengue-like AFI in a person reported by a health care provider with or without a specimen submitted for diagnostic testing. Laboratory-positive cases had: (i) DENV nucleic acid detected by reverse transcriptase-polymerase chain reaction (RT-PCR) in an acute serum specimen; (ii) anti-DENV IgM antibody detected by ELISA in any serum specimen; or (iii) DENV antigen or nucleic acid detected in an autopsy-tissue specimen. In 2010, a total of 26,766 suspected dengue cases (7.2 per 1,000 residents) were identified, of which 46.6% were laboratory-positive. Of 7,426 RT-PCR-positive specimens, DENV-1 (69.0%) and DENV-4 (23.6%) were detected more frequently than DENV-2 (7.3%) and DENV-3 (< 0.1%). Nearly half (47.1%) of all laboratory-positive cases were adults, 49.7% had dengue with warning signs, 11.1% had severe dengue, and 40 died. Approximately 21% of cases were primary DENV infections, and 1-4 year olds were the only age group for which primary infection was more common than secondary. Individuals infected with DENV-1 were 4.2 (95% confidence interval [CI]: 1.7-9.8) and 4.0 (95% CI: 2.4-6.5) times more likely to have primary infection than those infected with DENV-2 or -4, respectively. Conclusions/Significance: This epidemic was long in duration and yielded the highest incidence of reported dengue cases and deaths since surveillance began in Puerto Rico in the late 1960's. This epidemic re-emphasizes the need for more effective primary prevention interventions to reduce the morbidity and mortality of dengue. C1 [Sharp, Tyler M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Sharp, Tyler M.; Hunsperger, Elizabeth; Santiago, Gilberto A.; Munoz-Jordan, Jorge L.; Santiago, Luis M.; Rivera, Aidsa; Rodriguez-Acosta, Rosa L.; Margolis, Harold S.; Tomashek, Kay M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, Atlanta, GA USA. [Feliciano, Lorenzo Gonzalez] Puerto Rico Dept Hlth, San Juan, PR USA. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM tsharp@cdc.gov FU US Centers for Disease Control and Prevention; Puerto Rico Department of Health FX This investigation was funded by the US Centers for Disease Control and Prevention and Puerto Rico Department of Health. The funders contributed to all study stages, including investigation design, data collection and analysis, decision to publish, and preparation of the report. NR 58 TC 27 Z9 28 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2013 VL 7 IS 4 AR e2159 DI 10.1371/journal.pntd.0002159 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 133QC UT WOS:000318153100020 PM 23593526 ER PT J AU Sodahlon, YK Dorkenoo, AM Morgah, K Nabiliou, K Agbo, K Miller, R Datagni, M Seim, A Mathieu, E AF Sodahlon, Yao K. Dorkenoo, Ameyo Monique Morgah, Kodjo Nabiliou, Komlan Agbo, Kossivi Miller, Rebecca Datagni, Michel Seim, Anders Mathieu, Els TI A Success Story: Togo Is Moving toward Becoming the First Sub-Saharan African Nation to Eliminate Lymphatic Filariasis through Mass Drug Administration and Countrywide Morbidity Alleviation SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID BANCROFTIAN FILARIASIS; WEST-AFRICA; STRATEGIES; PROGRAM; ONCHOCERCIASIS; COVERAGE; SYSTEM; BENIN C1 [Sodahlon, Yao K.] Mectizan Donat Program, Decatur, GA USA. [Sodahlon, Yao K.; Dorkenoo, Ameyo Monique; Morgah, Kodjo; Nabiliou, Komlan; Agbo, Kossivi; Datagni, Michel] Minist Sante, Lome, Togo. [Dorkenoo, Ameyo Monique; Agbo, Kossivi] Univ Lome, Fac Mixte Med & Pharm, Lome, Togo. [Miller, Rebecca] Emory Univ, Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Seim, Anders] HDI, Fjellstrand, Norway. [Mathieu, Els] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Sodahlon, YK (reprint author), Mectizan Donat Program, Decatur, GA USA. EM ysodahlon@taskforce.org FU Health & Development International (HDI); GFATM; CNTD of Liverpool School of Tropical Medicine; Centers for Disease Control (CDC); USAID; World Health Organization; IMA World Health FX The achievements of the NPELF in Togo were made possible through generous funding from Health & Development International (HDI), the GFATM, CNTD of Liverpool School of Tropical Medicine, the Centers for Disease Control (CDC), USAID, the World Health Organization, and IMA World Health; as well as through generous drug donations from GlaxoSmithKline (GSK), Merck & Co., Inc., and the Mectizan Donation Program (MDP). NR 30 TC 19 Z9 19 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2013 VL 7 IS 4 AR e2080 DI 10.1371/journal.pntd.0002080 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 133QC UT WOS:000318153100004 PM 23593512 ER PT J AU Lam, TK Schully, SD Rogers, SD Benkeser, R Reid, B Khoury, MJ AF Lam, Tram Kim Schully, Sheri D. Rogers, Scott D. Benkeser, Rachel Reid, Britt Khoury, Muin J. TI Provocative Questions in Cancer Epidemiology in a Time of Scientific Innovation and Budgetary Constraints SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article AB In a time of scientific and technological developments and budgetary constraints, the National Cancer Institute's (NCI) Provocative Questions Project offers a novel funding mechanism for cancer epidemiologists. We reviewed the purposes underlying the Provocative Questions Project, present information on the contributions of epidemiologic research to the current Provocative Questions portfolio, and outline opportunities that the cancer epidemiology community might capitalize on to advance a research agenda that spans a translational continuum from scientific discoveries to population health impact. Cancer Epidemiol Biomarkers Prev; 22(4); 496-500. (c) 2013 AACR. C1 [Lam, Tram Kim; Schully, Sheri D.; Rogers, Scott D.; Reid, Britt; Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Benkeser, Rachel] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Lam, TK (reprint author), NCI, NIH, 6130 Execut Blvd,Suite 5143, Rockville, MD 20852 USA. EM lamt@mail.nih.gov FU Intramural CDC HHS [CC999999] NR 8 TC 2 Z9 2 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2013 VL 22 IS 4 BP 496 EP 500 DI 10.1158/1055-9965.EPI-13-0101 PG 5 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 130ZW UT WOS:000317960900003 PM 23413299 ER PT J AU Khoury, MJ Lam, TK Ioannidis, JPA Hartge, P Spitz, MR Buring, JE Chanock, SJ Croyle, RT Goddard, KA Ginsburg, GS Herceg, Z Hiatt, RA Hoover, RN Hunter, DJ Kramer, BS Lauer, MS Meyerhardt, JA Olopade, OI Palmer, JR Sellers, TA Seminara, D Ransohoff, DF Rebbeck, TR Tourassi, G Winn, DM Zauber, A Schully, SD AF Khoury, Muin J. Lam, Tram Kim Ioannidis, John P. A. Hartge, Patricia Spitz, Margaret R. Buring, Julie E. Chanock, Stephen J. Croyle, Robert T. Goddard, Katrina A. Ginsburg, Geoffrey S. Herceg, Zdenko Hiatt, Robert A. Hoover, Robert N. Hunter, David J. Kramer, Barnet S. Lauer, Michael S. Meyerhardt, Jeffrey A. Olopade, Olufunmilayo I. Palmer, Julie R. Sellers, Thomas A. Seminara, Daniela Ransohoff, David F. Rebbeck, Timothy R. Tourassi, Georgia Winn, Deborah M. Zauber, Ann Schully, Sheri D. TI Transforming Epidemiology for 21st Century Medicine and Public Health SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID CANCER-EPIDEMIOLOGY; TRANSLATIONAL RESEARCH; KNOWLEDGE INTEGRATION; GENOMICS RESEARCH; UNITED-STATES; BIG-DATA; OPPORTUNITIES; SCIENCE; THINKING; LESSONS AB In 2012, the National Cancer Institute (NCI) engaged the scientific community to provide a vision for cancer epidemiology in the 21st century. Eight overarching thematic recommendations, with proposed corresponding actions for consideration by funding agencies, professional societies, and the research community emerged from the collective intellectual discourse. The themes are (i) extending the reach of epidemiology beyond discovery and etiologic research to include multilevel analysis, intervention evaluation, implementation, and outcomes research; (ii) transforming the practice of epidemiology by moving toward more access and sharing of protocols, data, metadata, and specimens to foster collaboration, to ensure reproducibility and replication, and accelerate translation; (iii) expanding cohort studies to collect exposure, clinical, and other information across the life course and examining multiple health-related endpoints; (iv) developing and validating reliable methods and technologies to quantify exposures and outcomes on a massive scale, and to assess concomitantly the role of multiple factors in complex diseases; (v) integrating "big data" science into the practice of epidemiology; (vi) expanding knowledge integration to drive research, policy, and practice; (vii) transforming training of 21st century epidemiologists to address interdisciplinary and translational research; and (viii) optimizing the use of resources and infrastructure for epidemiologic studies. These recommendations can transform cancer epidemiology and the field of epidemiology, in general, by enhancing transparency, interdisciplinary collaboration, and strategic applications of new technologies. They should lay a strong scientific foundation for accelerated translation of scientific discoveries into individual and population health benefits. Cancer Epidemiol Biomarkers Prev; 22(4); 508-16. (c) 2013 AACR. C1 [Khoury, Muin J.; Lam, Tram Kim; Croyle, Robert T.; Seminara, Daniela; Winn, Deborah M.; Schully, Sheri D.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Hartge, Patricia; Chanock, Stephen J.; Hoover, Robert N.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Kramer, Barnet S.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA. [Lauer, Michael S.] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Med, Stanford Prevent Res Ctr, Dept Hlth Res & Policy,Sch Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Stat, Sch Humanities & Sci, Stanford, CA 94305 USA. [Spitz, Margaret R.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Buring, Julie E.] Brigham & Womens Hosp, Div Med, Boston, MA 02115 USA. [Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Cambridge, MA 02138 USA. [Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Nutr, Cambridge, MA 02138 USA. [Palmer, Julie R.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Goddard, Katrina A.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. [Ginsburg, Geoffrey S.] Duke Univ, Sch Med, Ctr Genom Med, Inst Genome Sci & Policy, Durham, NC USA. [Herceg, Zdenko] Int Agcy Res Canc, F-69372 Lyon, France. [Hiatt, Robert A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Olopade, Olufunmilayo I.] Univ Chicago Med, Dept Med, Ctr Clin Canc Genet & Global Hlth, Chicago, IL USA. [Sellers, Thomas A.] Univ S Florida, H Lee Moffitt Canc Ctr, Off Director, Tampa, FL 33682 USA. [Ransohoff, David F.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Ransohoff, David F.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Rebbeck, Timothy R.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Rebbeck, Timothy R.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Tourassi, Georgia] Oak Ridge Natl Lab, Computat Sci & Engn Div, Oak Ridge, TN USA. [Zauber, Ann] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM muk1@CDC.GOV RI Lauer, Michael/L-9656-2013; OI Lauer, Michael/0000-0002-9217-8177; Palmer, Julie/0000-0002-6534-335X; Tourassi, Georgia/0000-0002-9418-9638 FU Novartis FX G.S. Ginsburg has a commercial research grant from Novartis. No potential conflicts of interest were disclosed by the other authors. NR 51 TC 50 Z9 52 U1 9 U2 79 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2013 VL 22 IS 4 BP 508 EP 516 DI 10.1158/1055-9965.EPI-13-0146 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 130ZW UT WOS:000317960900005 PM 23462917 ER PT J AU Roland, KB Benard, VB Soman, A Breen, N Kepka, D Saraiya, M AF Roland, Katherine B. Benard, Vicki B. Soman, Ashwini Breen, Nancy Kepka, Deanna Saraiya, Mona TI Cervical Cancer Screening Among Young Adult Women in the United States SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID SERVICES TASK-FORCE; HUMAN-PAPILLOMAVIRUS; PAP-SMEAR; HORMONAL CONTRACEPTION; NATIONAL-HEALTH; US WOMEN; GUIDELINES; PREVENTION; BREAST; IMPACT AB Background: Cervical cancer screening guidelines have evolved significantly in the last decade for young adult women, with current recommendations promoting later initiation and longer intervals. Methods: Using self-reported cross-sectional National Health Interview Survey (NHIS) 2000-2010 data, trends in Papanicolaou (Pap) testing among women ages 18-29 years were examined. NHIS 2010 data were used to investigate age at first Pap test (N = 2,198), time since most recent Pap test (n = 1,622), and predictors of Pap testing within the last 12 months (n = 1,622). Results: The percentage of 18-year-olds who reported ever having a Pap test significantly decreased from 49.9% in 2000 to 37.9% in 2010. Mean age at first Pap test in 2010 was significantly younger for non-Hispanic black women (16.9 years), women < high school education (16.9 years), women who received the HPV vaccine (17.1 years), and women who have ever given birth (17.3 years). The majority reported their last Pap test within the previous 12 months (73.1%). Usual source of healthcare (OR, 2.31) and current birth control use (OR, 1.64) significantly increased chances of having a Pap test within the previous 12 months. Conclusions: From 2000 to 2010, there was a gradual decline in Pap test initiation among 18-year-olds; however, in 2010, many women reported <= 12 months since last screening. Evidence-based guidelines should be promoted, as screening young adult women for cervical cancer more frequently than recommended can cause considerable harms. Impact: A baseline of cervical cancer screening among young adult women in the United States to assess adherence to evidence-based screening guidelines. Cancer Epidemiol Biomarkers Prev; 22(4); 580-8. (C) 2013 AACR. C1 [Roland, Katherine B.; Benard, Vicki B.; Saraiya, Mona] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Soman, Ashwini] Northrop Grumman, Atlanta, GA USA. [Breen, Nancy] NCI, Div Canc Control & Populat Sci, Appl Res Program, Hlth Serv & Econ Branch, Rockville, MD USA. [Kepka, Deanna] Univ Utah, Huntsman Canc Inst, Coll Nursing, Salt Lake City, UT USA. RP Roland, KB (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS K-55, Atlanta, GA 30341 USA. EM kroland@cdc.gov FU U.S. Government FX The study was supported by the U.S. Government. NR 50 TC 11 Z9 12 U1 2 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2013 VL 22 IS 4 BP 580 EP 588 DI 10.1158/1055-9965.EPI-12-1266 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 130ZW UT WOS:000317960900014 PM 23355601 ER PT J AU Xie, J Terry, KL Poole, EM Wilson, KM Rosner, BA Willett, WC Vesper, HW Tworoger, SS AF Xie, Jing Terry, Kathryn L. Poole, Elizabeth M. Wilson, Kathryn M. Rosner, Bernard A. Willett, Walter C. Vesper, Hubert W. Tworoger, Shelley S. TI Acrylamide Hemoglobin Adduct Levels and Ovarian Cancer Risk: A Nested Case-Control Study SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID FOOD FREQUENCY QUESTIONNAIRE; NATIONAL DEATH INDEX; DIETARY ACRYLAMIDE; BREAST-CANCER; PROSPECTIVE COHORT; PROSTATE-CANCER; POSTMENOPAUSAL WOMEN; SWEDISH WOMEN; EXPOSURE; SMOKING AB Background: Acrylamide is a probable human carcinogen formed during cooking of starchy foods. Two large prospective cohort studies of dietary acrylamide intake and ovarian cancer risk observed a positive association, although two other studies reported no association. Methods: We measured acrylamide exposure using red blood cell acrylamide and glycidamide hemoglobin adducts among women in two large prospective cohorts: the Nurses' Health Study and Nurses' Health Study II. Between blood collection and 2010, we identified 263 incident cases of epithelial ovarian cancer, matching two controls per case. We used logistic regression models to examine the association between acrylamide exposure and ovarian cancer risk, adjusting for matching factors, family history of ovarian cancer, tubal ligation, oral contraceptive use, body mass index, parity, alcohol intake, smoking, physical activity, and caffeine intake. Results: The multivariate-adjusted relative risk (RR) of ovarian cancer comparing the highest versus lowest tertile of total acrylamide adducts was 0.79 (95% CI, 0.50-1.24, P trend 0.08). The comparable RR of ovarian cancer among non-smokers at blood draw was 0.85 (95% CI, 0.57-1.27, P trend 0.14). The association did not differ by tumor histology (serous invasive versus not), P for heterogeneity 0.86. Individual adduct types (acrylamide or glycidamide) were not associated with risk. Conclusions: We observed no evidence that acrylamide exposure as measured by adducts to hemoglobin is associated with an increased risk of ovarian cancer. Impact: Our finding indicates that acrylamide intake may not increase risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev; 22(4); 653-60. (C) 2013 AACR. C1 [Xie, Jing; Poole, Elizabeth M.; Wilson, Kathryn M.; Rosner, Bernard A.; Willett, Walter C.; Tworoger, Shelley S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Terry, Kathryn L.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA. [Tworoger, Shelley S.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Xie, Jing; Terry, Kathryn L.; Wilson, Kathryn M.; Willett, Walter C.; Tworoger, Shelley S.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Rosner, Bernard A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Vesper, Hubert W.] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Tworoger, SS (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. EM nhsst@channing.harvard.edu OI Tworoger, Shelley/0000-0002-6986-7046 FU National Institutes of Health [R01CA49449, R01CA67262, R01CA50385, P01 CA87969]; Harvard University FX This project was supported by the National Institutes of Health (R01CA49449, R01CA67262, R01CA50385, P01 CA87969). J. Xie is supported by scholarships of Harvard University. NR 49 TC 12 Z9 12 U1 2 U2 18 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2013 VL 22 IS 4 BP 653 EP 660 DI 10.1158/1055-9965.EPI-12-1387 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 130ZW UT WOS:000317960900022 PM 23417989 ER PT J AU Bellcross, CA Leadbetter, S Alford, SH Peipins, LA AF Bellcross, Cecelia A. Leadbetter, Steven Alford, Sharon Hensley Peipins, Lucy A. TI Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID REDUCING SALPINGO-OOPHORECTOMY; OVARIAN-CANCER SUSCEPTIBILITY; SCREEN-POSITIVE RATES; BREAST-CANCER; MUTATION CARRIERS; BREAST/OVARIAN CANCER; RISK-ASSESSMENT; PROPHYLACTIC MASTECTOMY; HEREDITARY BREAST; UNITED-STATES AB Background: In 2005, the United States Preventive Services Task Force (USPSTF) released guidelines which outlined specific family history patterns associated with an increased risk for BRCA1/2 mutations, and recommended at-risk individuals be referred for genetic counseling and evaluation for BRCA testing. The purpose of this study was to assess the prevalence of individuals with a USPSTF increased-risk family history pattern, the frequency with which specific patterns were met, and resulting healthcare actions among women from the Henry Ford Health System. Methods: As part of a study evaluating ovarian cancer risk perception and screening, 2,524 randomly selected participants completed a detailed interview (response rate 76%) from an initial eligible cohort of 16,720 women. Results: Approximately 6% of participants had a family history fulfilling one or more of the USPSTF patterns. Although 90% of these women had shared their family history with their provider, less than 20% had been referred for genetic counseling and only8% had undergone genetic testing. Caucasian women with higher income and education levels were more likely to receive referrals. Among the 95 participants in the total study cohort who reported BRCA testing, 78% did not have a family history that met one of the USPSTF patterns. Conclusions: These results suggest a higher prevalence of women with an increased-risk family history than originally predicted by the USPSTF, and lack of provider recognition and referral for genetic services. Impact: Improvements in healthcare infrastructure and clinician education will be required to realize population level benefits from BRCA genetic counseling and testing. Cancer Epidemiol Biomarkers Prev; 22(4); 728-35. (C) 2013 AACR. C1 [Bellcross, Cecelia A.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. [Leadbetter, Steven; Peipins, Lucy A.] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA USA. [Alford, Sharon Hensley] Henry Ford Hlth Syst, Josephine Ford Canc Ctr, Detroit, MI USA. RP Bellcross, CA (reprint author), Emory Univ, Sch Med, Dept Human Genet, Whitehead Bldg,Suite 301,615 Michael St, Atlanta, GA 30322 USA. EM cbellcr@emory.edu FU Centers for Disease Control and Prevention [200-2002-00574, 0015] FX This study was supported by funding from the Centers for Disease Control and Prevention (Contract No. 200-2002-00574, Task order 0015) to ICF International and partial salary support to Dr. Cecelia A. Bellcross. NR 40 TC 13 Z9 15 U1 0 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD APR PY 2013 VL 22 IS 4 BP 728 EP 735 DI 10.1158/1055-9965.EPI-12-1280 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 130ZW UT WOS:000317960900031 PM 23371291 ER PT J AU Pyrzanowski, J Curtis, CR Crane, LA Barrow, J Beaty, B Kempe, A Daley, MF AF Pyrzanowski, Jennifer Curtis, C. Robinette Crane, Lori A. Barrow, Jennifer Beaty, Brenda Kempe, Allison Daley, Matthew F. TI Adolescents' Perspectives on Vaccination Outside the Traditional Medical Home: A Survey of Urban Middle and High School Students SO CLINICAL PEDIATRICS LA English DT Article DE immunization delivery; school-based health centers; public health clinics; emergency departments; family planning clinics; obstetrics and gynecology clinics ID HEALTH-CARE; PREVENTIVE CARE; UNITED-STATES; VACCINES; CHILDREN; DELIVERY; US; KNOWLEDGE; ATTITUDES; SERVICES AB Eleventh- and 6th-grade students from an urban public school district were surveyed concerning vaccination outside the traditional medical home. Survey response rates were 50% for 11th- and 73% for 6th-grade students. Seventy-two percent of 11th-grade students reported that public health clinics were definitely or probably acceptable locations for vaccination; 70% reported this for emergency departments, 65% for school-based health centers, 55% for family planning clinics, and 44% for obstetrics/gynecology clinics. Corresponding percentages for 6th-grade students were 60% for public health clinics, 49% for emergency departments, 39% for school-based health centers, and 36% for family planning clinics. Sixth-grade students were not asked about obstetrics/gynecology clinics. Forty-seven percent of respondents identified a doctor's office as the "best" setting to receive vaccines, more than identified any other setting. We concluded that vaccination in one or more settings outside the traditional medical home was acceptable to most adolescents. C1 [Pyrzanowski, Jennifer; Crane, Lori A.; Barrow, Jennifer; Beaty, Brenda; Kempe, Allison; Daley, Matthew F.] Colorado Childrens Hosp, Childrens Outcomes Res Program, Aurora, CO USA. [Curtis, C. Robinette] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Crane, Lori A.] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Aurora, CO USA. [Beaty, Brenda; Kempe, Allison] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA. [Kempe, Allison; Daley, Matthew F.] Univ Colorado, Dept Pediat, Aurora, CO USA. [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80231 USA. RP Daley, MF (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 10065 E Harvard Ave 300, Denver, CO 80231 USA. EM matthew.f.daley@kp.org FU Centers for Disease Control and Prevention [1-U01-IP000110] FX This investigation was supported by Cooperative Agreement No. 1-U01-IP000110 from the Centers for Disease Control and Prevention. NR 39 TC 2 Z9 2 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD APR PY 2013 VL 52 IS 4 BP 329 EP 337 DI 10.1177/0009922813475703 PG 9 WC Pediatrics SC Pediatrics GA 129OP UT WOS:000317851100007 PM 23406720 ER PT J AU Shrestha, SS Zhang, P Li, R Thompson, TJ Chapman, DP Barker, L AF Shrestha, Sundar S. Zhang, Ping Li, Rui Thompson, Theodore J. Chapman, Daniel P. Barker, Lawrence TI Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008 SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Insulin; Depression; Insulin-treated diabetes; Medical costs; Antidepressant medication ID HEALTH-CARE UTILIZATION; COMORBID DEPRESSION; COST-EFFECTIVENESS; MENTAL-DISORDERS; GLYCEMIC CONTROL; MELLITUS; COMPLICATIONS; PREVALENCE; ADHERENCE; SYMPTOMS AB Aim: We aimed at estimating excess medical expenditures associated with major depressive disorder (MDD) among working-age adults diagnosed with diabetes, disaggregated by treatment mode: insulin-treated diabetes (ITDM) or non-insulin-treated diabetes (NITDM). Methods: We analyzed data for over 500,000 individuals with diagnosed diabetes from the 2008 U.S. MarketScan claims database. We grouped diabetic patients first by treatment mode (ITDM or NITDM), then by MDD status (with or without MDD), and finally by whether those with MDD used antidepressant medication. We estimated annual mean excess outpatient, inpatient, prescription drug, and total expenditures using regression models, controlling for demographics, types of health coverage, and comorbidities. Results: Among persons having ITDM, the estimated annual total mean expenditure for those with no MDD (the comparison group) was $19,625. For those with MDD, the expenditures were $12,406 (63%) larger if using antidepressant medication and $7322 (37%) larger if not using antidepressant medication. Among persons having NITDM, the corresponding estimated expenditure for the comparison group was $10,746, the excess expenditures were $10,432 (97%) larger if using antidepressant medication and $5579 (52%) larger if not using antidepressant medication, respectively. Inpatient excess expenditures were the largest of total excess expenditure for those with ITDM and MDD treated with antidepressant medication; for all others with diabetes and MDD, outpatient expenditures were the largest excess expenditure. Conclusions: Among working-age adults with diabetes, MDD was associated with substantial excess medical expenditures. Implementing the effective interventions demonstrated in clinical trials and treatment guidelines recommended by professional organizations might reduce the economic burden of MDD in this population. Published by Elsevier Ireland Ltd. C1 [Shrestha, Sundar S.; Zhang, Ping; Li, Rui; Thompson, Theodore J.; Chapman, Daniel P.; Barker, Lawrence] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Shrestha, SS (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Highway,MS K-10, Atlanta, GA 30341 USA. EM gqm2@cdc.gov FU Intramural CDC HHS [CC999999] NR 32 TC 6 Z9 6 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD APR PY 2013 VL 100 IS 1 BP 102 EP 110 DI 10.1016/j.diabres.2013.02.002 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 128BY UT WOS:000317744300022 PM 23490596 ER PT J AU Ekwaru, JP Campbell, J Malamba, S Moore, DM Were, W Mermin, J AF Ekwaru, John P. Campbell, James Malamba, Samuel Moore, David M. Were, Willy Mermin, Jonathan TI The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Article DE ART; CD4+T cell lymphocyte count; HIV RNA viral load; HIV; opportunistic infections; Uganda ID IMMUNODEFICIENCY-VIRUS TYPE-1; COTRIMOXAZOLE PROPHYLAXIS; BACTERIAL PNEUMONIA; PROSPECTIVE COHORT; INFECTED PATIENTS; MALARIA; IMPACT; TUBERCULOSIS; TRANSMISSION; DISEASE AB Introduction: HIV RNA viral load (VL) has been shown to increase during opportunistic illnesses (OIs), suggesting active HIV replication in response to infection among patients not taking antiretroviral therapy (ART). We assessed the effects of OIs on HIV RNA VL and CD4+ T cell counts among patients on ART with initially suppressed VL. Methods: Between 2003 and 2007, we enrolled and followed 1094 HIV-1-infected adults who initiated ART and had quarterly blood draws for VL and CD4+ T cell count. In VL/CD4+ T cell measurement intervals following undetectable VL, we compared the elevation in VL to detectable levels and CD4+ T cell count changes between intervals when participants had episodes of OIs and intervals when they did not have OIs. Results: VL was more likely to be detectable if participants had OIs in the prior three months compared to when they did not (OR = 4.0 (95% CI = 1.9-8.6)). The CD4+ T cell counts declined 24.1 cells/mu L per three months in intervals where the participants had OIs compared to an increase of 21.3 cells/mu L per three months in intervals where they did not have OIs (adjusted difference in the rate of CD4+ T cell count change of 61.7 cells/mu L per three months (95% CI = 13.7-109.7), P value = 0.012). The rate of CD4+ T cell count increase was 25.6 cells/mu L per three months (95% CI = 11.6-39.6) higher for females compared to males (p value = <0.001), 1.4 cells/mu L per three months lower per one year increase in age (p value = 0.046) and 4 cells/mu L per three months lower per 10 cells/mu L increase in the starting CD4+ T cell count value (p value = <0.001). Conclusion: Episodes of opportunistic infections among patients taking ART with undetectable VL were associated with elevation of HIV RNA VL to detectable levels and decline in CD4+ T cell counts. C1 [Ekwaru, John P.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA. [Ekwaru, John P.; Campbell, James; Malamba, Samuel; Were, Willy] CDC Uganda, Entebbe, Uganda. [Ekwaru, John P.; Campbell, James; Malamba, Samuel; Were, Willy] Uganda Virus Res Inst, Entebbe, Uganda. [Moore, David M.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Moore, David M.] Univ British Columbia, Fac Med, Vancouver, BC, Canada. [Mermin, Jonathan] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis Sexually Transmitted, Div HIV AIDS Prevent, Atlanta, GA USA. RP Ekwaru, JP (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, 101 Haviland Hall, Berkeley, CA 94720 USA. EM pekwaru@gmail.com FU Ugandan Ministry of Health; The AIDS Support Organization (TASO); U.S. Department of Health and Human Services/CDC through the Emergency Plan for AIDS Relief; Fogarty AIDS International Training and Research Program at the University of California, Berkeley [1-D43-TW00003] FX The authors would like to thank the participants in the HBAC project, the CDC-Uganda staff who cared for the participants, collected and compiled the data for analysis. We also acknowledge the support of the Ugandan Ministry of Health and The AIDS Support Organization (TASO).; Funding for the study was provided by the U.S. Department of Health and Human Services/CDC through the Emergency Plan for AIDS Relief. John Paul Ekwaru was also supported by the Fogarty AIDS International Training and Research Program (1-D43-TW00003) at the University of California, Berkeley. NR 19 TC 3 Z9 3 U1 0 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD APR 1 PY 2013 VL 16 AR 17355 DI 10.7448/IAS.16.1.17355 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 131ST UT WOS:000318017000001 PM 23547778 ER PT J AU Bowen, RA O'Shea, TJ Shankar, V Neubaum, MA Neubaum, DJ Rupprecht, CE AF Bowen, Richard A. O'Shea, Thomas J. Shankar, Vidya Neubaum, Melissa A. Neubaum, Daniel J. Rupprecht, Charles E. TI PREVALENCE OF NEUTRALIZING ANTIBODIES TO RABIES VIRUS IN SERUM OF SEVEN SPECIES OF INSECTIVOROUS BATS FROM COLORADO AND NEW MEXICO, UNITED STATES SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Bats; Chiroptera; Colorado; New Mexico; rabies; serology; virus-neutralizing antibodies ID BIG BROWN BATS; EPTESICUS-FUSCUS; NORTH-AMERICA; TADARIDA-BRASILIENSIS; EXPOSURE; ECOLOGY; HISTORY; ANESTHESIA; INFECTION; SURVIVAL AB We determined the presence of rabies-virus-neutralizing antibodies (RVNA) in serum of 721 insectivorous bats of seven species captured, sampled, and released in Colorado and New Mexico, United States in 2003-2005. A subsample of 160 bats was tested for rabies-virus RNA in saliva. We sampled little brown bats (Myotis lucifugus) at two maternity roosts in Larimer County, Colorado; big brown bats (Eptesicus fuscus) at three maternity roosts in Morgan County, Colorado; and big brown bats at five maternity roosts in Larimer County. We also sampled hoary bats (Lasiurus cinereus) and silver-haired bats (Lasionycteris noctivagans) captured while drinking or foraging over water in Bernalillo County, New Mexico and at various locations in Larimer County. Big brown bats, little brown bats, long-legged myotis (Myotis volans), long-eared nip:A:is (Myotis evotis), and fringed myotis (Myotis thysanodes) were also sampled over water in Larimer County. All species except long-eared myotis included individuals with RVNA, with prevalences ranging from 7% in adult female silver-haired bats to 32% in adult female hoary bats. None of the bats had detectable rabies-virus RNA in oropharyngeal swabs, including 51 bats of 5 species that had RVNA in serum. Antibody-positive bats were present in nine of the 10 maternity colonies sampled. These data suggest that wild bats are commonly exposed to rabies virus and develop a humoral immune response suggesting some degree of viral replication, but many infections fail to progress to clinical disease. C1 [Bowen, Richard A.; Shankar, Vidya; Neubaum, Melissa A.; Neubaum, Daniel J.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. [O'Shea, Thomas J.] US Geol Survey, Ft Collins Sci Ctr, Ft Collins, CO 80526 USA. [Shankar, Vidya; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Bowen, RA (reprint author), Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. EM richard.bowen@colostate.edu FU National Science Foundation EID grant [0094959]; US Geological Survey; Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate (US Department of Homeland Security); Fogarty International Center (National Institutes of Health) FX We thank the following for assistance in capturing and sampling bats during 2003-2005: S. Almon, T. Barnes, J. Benson, J. Boland, S. Cooper, T. Dawes, L. Ellison, D. Emptage, M. Hayes, B. Iannone, E. Kennedy, R. Kerscher, J. LaPlante, G. Nance, S. Neils, C. Newby, V. Price, C. Reynolds, L. Taraba, J. Tharp, and M. Vrabely. C. Andrews provided technical support in rabies-virus serology. P. Cryan and E. Valdez showed us productive capture sites in New Mexico and worked with us in the field. Financial support was provided via National Science Foundation EID grant 0094959 to Colorado State University, and by the US Geological Survey. R.A.B. and T.J.O. were supported by the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate (US Department of Homeland Security) and the Fogarty International Center (National Institutes of Health) during preparation of the manuscript. Any use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the US Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control; they do represent the views of the US Geological Survey. NR 42 TC 4 Z9 4 U1 4 U2 28 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD APR PY 2013 VL 49 IS 2 BP 367 EP 374 DI 10.7589/2012-05-124 PG 8 WC Veterinary Sciences SC Veterinary Sciences GA 128YP UT WOS:000317805900017 PM 23568912 ER PT J AU Minor, C Kersh, GJ Gelatt, T Kondas, AV Pabilonia, KL Weller, CB Dickerson, BR Duncan, CG AF Minor, Cody Kersh, Gilbert J. Gelatt, Tom Kondas, Ashley V. Pabilonia, Kristy L. Weller, Christina B. Dickerson, Bobette R. Duncan, Colleen G. TI Coxiella burnetii in Northern Fur Seals and Steller Sea Lions of Alaska SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Antibody prevalence; Coxiella burnetii; marine mammals; northern fur seal; Steller sea lion ID Q-FEVER; INFECTION AB Coxiella burnetii, a zoonotic bacterium, has recently been identified in several marine mammal species on the Pacific Coast of North America, but little is known about the epidemiology, transmission, and pathogenesis in these species. We tested sera archived from northern fur seals (NFS, Callorhinus ursinus; n=236) and Steller sea lions (SSL, Eumetopias jubatus; n=72) sampled in Alaska for C. burnetii antibodies, and vaginal swabs from NFS (n=40) for C. burnetii by qPCR. The antibody prevalence in NFS samples from 2009 and 2011 (69%) was significantly higher than in 1994 (49%). The antibody prevalence of SSL samples from 2007 to 2011 was 59%. All NFS vaginal swabs were negative for C. burnetii, despite an 80% antibody prevalence in the matched sera. The significant increase in antibody prevalence in NFS from 1994 to 2011 suggests that the pathogen may be increasingly common or that there is marked temporal variation within the vulnerable NFS population. The high antibody prevalence in SSL suggests that this pathogen may also be significant in the endangered SSL population. These results confirm that C. burnetii is more prevalent within these populations than previously known. More research is needed to determine how this bacterium may affect individual, population, and reproductive health of marine mammals. C1 [Minor, Cody; Pabilonia, Kristy L.; Weller, Christina B.; Duncan, Colleen G.] Colorado State Univ, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA. [Kersh, Gilbert J.; Kondas, Ashley V.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. [Gelatt, Tom; Dickerson, Bobette R.] NOAA, Natl Marine Mammal Lab, Alaska Fisheries Sci Ctr, Natl Marine Fisheries Serv, Seattle, WA USA. RP Duncan, CG (reprint author), Colorado State Univ, Coll Vet Med & Biomed Sci, 300 West Drake Ave, Ft Collins, CO 80523 USA. EM colleen.duncan@colostate.edu FU US Department of Agriculture, National Institute of Food and Agriculture, Animal Health and Disease Program; Centers for Disease Control and Prevention (CDC) FX C.M. was supported by an appointment to the Merial Veterinary Scholars Program and funded by the US Department of Agriculture, National Institute of Food and Agriculture, Animal Health and Disease Program. A.V.K. was supported by an appointment to the Emerging Infectious Diseases Fellowship program administered by the Association of Public Health Laboratories and funded by the Centers for Disease Control and Prevention (CDC). Serum samples from NFS sub-adult males were collected with cooperation from the Aleut Community of Saint Paul Island Tribal Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC or the Department of Health and Human Services. All tissue samples were collected under authority of US Marine Mammal Permit 782-1708 issued to the National Marine Mammal Lab, Seattle, Washington, USA. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the National Marine Fisheries Service, National Oceanic and Atmospheric Administration (NMFS, NOAA). Reference to trade names does not imply endorsement by NMFS, NOAA. We thank Katie Sweeney for creating Figure 1. NR 11 TC 3 Z9 3 U1 1 U2 19 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD APR PY 2013 VL 49 IS 2 BP 441 EP 446 DI 10.7589/2012-09-226 PG 6 WC Veterinary Sciences SC Veterinary Sciences GA 128YP UT WOS:000317805900030 PM 23568925 ER PT J AU Mortenson, JA Bartlett, KH Wilson, RW Lockhart, SR AF Mortenson, Jack A. Bartlett, Karen H. Wilson, Randy W. Lockhart, Shawn R. TI Detection of Cryptococcus gattii in Selected Urban Parks of the Willamette Valley, Oregon SO MYCOPATHOLOGIA LA English DT Article DE Cryptococcus gattii; Oregon; Environmental sampling; Urban parks; Douglas fir tree; Bark mulch; Pseudotsuga menziesii var. menziesii ID NEOFORMANS VAR GATTII; PACIFIC-NORTHWEST; BRITISH-COLUMBIA; UNITED-STATES; VANCOUVER-ISLAND; OUTBREAK; CANADA; SPREAD; INFECTION; PATHOGEN AB Human and animal infections of the fungus Cryptococcus gattii have been recognized in Oregon since 2006. Transmission is primarily via airborne environmental spores and now thought to be locally acquired due to infection in non-migratory animals and humans with no travel history. Previous published efforts to detect C. gattii from tree swabs and soil samples in Oregon have been unsuccessful. This study was conducted to determine the presence of C. gattii in selected urban parks of Oregon cities within the Willamette Valley where both human and animal cases of C. gattii have been diagnosed. Urban parks were sampled due to spatial and temporal overlap of humans, companion animals and wildlife. Two of 64 parks had positive samples for C. gattii. One park had a positive tree and the other park, 60 miles away, had positive bark mulch samples from a walkway. Genotypic subtypes identified included C. gattii VGIIa and VGIIc, both considered highly virulent in murine host models. C1 [Mortenson, Jack A.; Wilson, Randy W.] Vet Serv, USDA, APHIS, Salem, OR USA. [Mortenson, Jack A.] Vet Serv, USDA, Tumwater, WA USA. [Bartlett, Karen H.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Mortenson, JA (reprint author), Vet Serv, USDA, 1550 Irving St SW Suite 100, Tumwater, WA USA. EM jack.a.mortenson@usda.gov FU USDA; APHIS; VS FX We thank Robert Dyk, Brian Thomas, Trevor Lock, Andrea Mortenson, and Dr. Sara Walker for help with environmental sampling, plus Naureen Iqbal for help with MLST typing. In addition, we thank Darren Bruning and Dr. John Huntley for project design suggestions, Al Shay for tree species identification, Andrew Fox for cartography services, and USDA, APHIS, VS for financial support of the project. NR 19 TC 2 Z9 2 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0301-486X J9 MYCOPATHOLOGIA JI Mycopathologia PD APR PY 2013 VL 175 IS 3-4 BP 351 EP 355 DI 10.1007/s11046-013-9614-7 PG 5 WC Mycology SC Mycology GA 126NH UT WOS:000317623800020 PM 23354596 ER PT J AU Dudeck, MA Horan, TC Peterson, KD Allen-Bridson, K Morrell, G Anttila, A Pollock, DA Edwards, JR AF Dudeck, Margaret A. Horan, Teresa C. Peterson, Kelly D. Allen-Bridson, Katherine Morrell, Gloria Anttila, Angela Pollock, Daniel A. Edwards, Jonathan R. TI National Healthcare Safety Network report, data summary for 2011, device-associated module SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article ID NHSN C1 [Dudeck, Margaret A.; Horan, Teresa C.; Peterson, Kelly D.; Allen-Bridson, Katherine; Morrell, Gloria; Anttila, Angela; Pollock, Daniel A.; Edwards, Jonathan R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Publ Hlth Serv,US Dept HHS, Atlanta, GA 30329 USA. RP Dudeck, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot & Infect Dis, MS A-24, Atlanta, GA 30329 USA. EM margaret.dudeck@cdc.hhs.gov FU Intramural CDC HHS [CC999999] NR 10 TC 50 Z9 54 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD APR PY 2013 VL 41 IS 4 BP 286 EP 300 DI 10.1016/j.ajic.2013.01.002 PG 15 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 123UG UT WOS:000317416000003 PM 23538117 ER PT J AU Vagi, SJ Sheikh, S Brackney, M Smolinske, S Warrick, B Reuter, N Schier, JG AF Vagi, Sara J. Sheikh, Sophia Brackney, Monica Smolinske, Susan Warrick, Brandon Reuter, Nicholas Schier, Joshua G. TI Passive Multistate Surveillance for Neutropenia After Use of Cocaine or Heroin Possibly Contaminated With Levamisole SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID HIV; AGRANULOCYTOSIS; URINE; NECROSIS; MODEL AB Study objective: To characterize the demographic, clinical, and epidemiologic features of levamisole-associated neutropenia in cocaine or heroin users. Methods: State health departments were recruited for participation when the Centers for Disease Control and Prevention (CDC) was notified of potential cases by a clinician, a health department official, or a poison center between October 15, 2009, and May 31, 2010. A case was defined as a person with an absolute neutrophil count less than 1,000 cells/mu L (or a WBC count <2,000 cells/mu L) and a self-reported history or laboratory confirmation of cocaine or heroin use. Health department officials abstracted data from medical charts, attempted a patient interview, and submitted data to CDC for descriptive analysis. Results: Of the 46 potential cases reported from 6 states, half met eligibility criteria and had medical chart abstractions completed (n=23; 50%). Of these, close to half of the patients were interviewed (n=10; 43%). The average age was 44.4 years; just over half were men (n=12; 52%). The majority of patients presented to emergency departments (n=19; 83%). More than half presented with infectious illnesses (n=12; 52%), and nearly half reported active skin lesions (n=10; 44%). The majority of interview respondents used cocaine greater than 2 to 3 times a week (n=9; 90%), used cocaine more than 2 years (n=6; 60%), and preferred crack cocaine (n=6; 60%). All were unaware of exposure to levamisole through cocaine and of levamisole's inherent toxicity (n=10; 100%). Conclusion: Physicians should suspect levamisole exposure in patients using illicit drugs, cocaine in particular, who present with unexplained neutropenia. Most patients reported chronic cocaine use and were unaware of levamisole exposure. Cocaine use is more prevalent among men; however, our results identified a higher-than-expected proportion of female users with neutropenia, suggesting women may be at higher risk. Emergency physicians and practitioners are uniquely positioned to recognize these patients early during their hospital course, elucidate a history of cocaine or other drug exposure, and optimize the likelihood of confirming exposure by arranging for appropriate drug testing. [Ann Emerg Med. 2013;61:468-474.] C1 [Vagi, Sara J.; Sheikh, Sophia; Schier, Joshua G.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Brackney, Monica] New Mexico Dept Hlth, Santa Fe, NM 87505 USA. [Smolinske, Susan; Warrick, Brandon] Childrens Hosp Michigan, Reg Poison Ctr, Detroit, MI USA. [Reuter, Nicholas] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA. RP Vagi, SJ (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM svagi@cdc.gov RI Schier, Joshua/F-9861-2013; Sheikh, Sophia/F-9746-2015 NR 27 TC 7 Z9 7 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD APR PY 2013 VL 61 IS 4 BP 468 EP 474 DI 10.1016/j.annemergmed.2012.10.036 PG 7 WC Emergency Medicine SC Emergency Medicine GA 123GP UT WOS:000317376700016 PM 23374417 ER PT J AU Saydah, SH Pavkov, ME Zhang, C Lacher, DA Eberhardt, MS Burrows, NR Narva, AS Eggers, PW Williams, DE AF Saydah, Sharon H. Pavkov, Meda E. Zhang, Cindy Lacher, David A. Eberhardt, Mark S. Burrows, Nilka Rios Narva, Andrew S. Eggers, Paul W. Williams, Desmond E. TI Albuminuria Prevalence in First Morning Void Compared with Previous Random Urine from Adults in the National Health and Nutrition Examination Survey, 2009-2010 SO CLINICAL CHEMISTRY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CREATININE RATIO; KIDNEY-FUNCTION; US POPULATION; SPOT URINE; MICROALBUMINURIA; EXCRETION; EQUATION; SAMPLES; ISSUES AB BACKGROUND: Albuminuria, defined as urine albumin/creatinine ratio (ACR) >= 30 mg/g, is a diagnostic component of chronic kidney disease (CKD). National estimates of ACR and CKD prevalence have been based on single random urine samples. Although 2 urine samples or a first morning void are known to produce different estimates of ACR, the impact of differing urine sampling schemes on nationally estimated rates of CKD is unknown. METHODS: In 2009-2010, the National Health and Nutrition Examination Survey (NHANES) participants provided 2 untimed urine samples for sequential ACR measurement: an initial random urine collected in the NHANES mobile examination center and a subsequent first morning void collected at home. Rates of albuminuria were calculated in the overall population and broken down by demographics, diagnosed diabetes and hypertension status, and estimated glomerular filtration rate (eGFR). RESULTS: Overall, 43.5% of adults with increased ACR (>= 30 mg/g) in a random urine also had increased ACR in a first morning urine. This percentage was higher among individuals >= 50 years old (48.9%), males (53.3%), participants with diagnosed diabetes (56.3%) and hypertension (51.5%), and eGFR <60 mL/min/1.72m(2) (56.9%). The use of confirmed increased ACR (defined as the presence of ACR >= 30 mg/g in both samples taken within 10 days) to define CKD resulted in a lower overall prevalence (11.6%) than first morning urine (12.7%) or random spot urine only (15.2%). CONCLUSIONS: ACR measured on random urine samples appears to overestimate the prevalence of albuminuria compared to first morning urine collections. (C) 2013 American Association for Clinical Chemistry C1 [Saydah, Sharon H.; Pavkov, Meda E.; Burrows, Nilka Rios; Williams, Desmond E.] CDC, Div Diabet Translat, Atlanta, GA 30333 USA. [Zhang, Cindy; Lacher, David A.; Eberhardt, Mark S.] CDC, Natl Ctr Hlth Stat, Div Hlth Examinat Stat, Atlanta, GA 30333 USA. [Narva, Andrew S.; Eggers, Paul W.] NIDDKD, NIH, Bethesda, MD 20892 USA. RP Saydah, SH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM ssaydah@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 12 Z9 14 U1 0 U2 4 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD APR PY 2013 VL 59 IS 4 BP 675 EP 683 DI 10.1373/clinchem.2012.195644 PG 9 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 122SK UT WOS:000317338200016 PM 23315482 ER PT J AU Hoepner, LA Whyatt, RM Just, AC Calafat, AM Perera, FP Rundle, AG AF Hoepner, Lori A. Whyatt, Robin M. Just, Allan C. Calafat, Antonia M. Perera, Frederica P. Rundle, Andrew G. TI Urinary concentrations of bisphenol A in an urban minority birth cohort in New York City, prenatal through age 7 years SO ENVIRONMENTAL RESEARCH LA English DT Article DE Bisphenol A; Urine; Child; Prenatal; Minority ID PHTHALATE METABOLITES; ENDOCRINE DISRUPTORS; TEMPORAL VARIABILITY; PRESCHOOL-CHILDREN; MASS-SPECTROMETRY; PREGNANT-WOMEN; HUMAN EXPOSURE; US POPULATION; DAY-CARE; SAMPLES AB Background: Despite growing concern over potential health effects associated with exposures to the endocrine disruptor, bisphenol A (BPA), insufficient information is available on determinants of BPA concentrations among minority populations in the US. Objectives: To describe concentrations and predictors of BPA in an inner-city longitudinal birth cohort. Methods: We analyzed spot urines for total BPA collected during pregnancy and child ages 3, 5, and 7 years from African Americans and Dominicans (n=568) enrolled in the Columbia Center for Children's Environmental Health birth cohort and residing in Northern Manhattan and the South Bronx. Adjusting for specific gravity, generalized estimating equations were used to compare BPA concentrations across paired samples and linear regression analyses were used to determine relationships between BPA, season of sample collection, soda-demographic variables and urinary, concentrations of phthalate metabolites. Results: BPA was detected in >= 94% of samples. Prenatal concentrations were significantly lower than postnatal concentrations. Geometric means were higher among African Americans compared to Dominicans in prenatal (p=0.008), 5 year (p<0.001) and 7 year (p=0.017) samples. Geometric means at 5 and 7 years were higher (p=0.021, p=0.041 respectively) for children of mothers never married compared to mothers ever married at enrollment. BPA concentrations were correlated with phthalate metabolite concentrations at prenatal, 3, 5 and 7 years (p-values <0.05). Postnatal BPA concentrations were higher in samples collected during the summer. Conclusions: This study shows widespread BPA exposure in an inner-city minority population. BPA concentration variations were associated with socio-demographic characteristics and other xenobiotics. (C) 2012 Elsevier Inc. All rights reserved. C1 [Hoepner, Lori A.; Whyatt, Robin M.; Just, Allan C.; Perera, Frederica P.; Rundle, Andrew G.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Hoepner, Lori A.; Whyatt, Robin M.; Perera, Frederica P.] Columbia Univ, Columbia Ctr Childrens Environm Hlth, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Rundle, Andrew G.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA. RP Hoepner, LA (reprint author), Columbia Univ, Dept Environm Hlth Sci, Joseph L Mailman Sch Publ Hlth, 1051 Riverside Dr,Unit 47, New York, NY 10032 USA. EM lah45@columbia.edu RI Rundle, Andrew/A-5282-2009; OI Rundle, Andrew/0000-0003-0211-7707; Hoepner, Lori/0000-0002-4404-8140; Just, Allan/0000-0003-4312-5957 FU National Institute of Environmental Health Sciences [1RC2ES018784]; US Environmental Protection Agency [RD-83214101]; National Institute of Health [P01ES09600]; John and Wendy Neu Family Foundation FX Funding for the study is provided by the National Institute of Environmental Health Sciences (Grant 1RC2ES018784), the US Environmental Protection Agency (Grant RD-83214101), the National Institute of Health (Grant P01ES09600), and the John and Wendy Neu Family Foundation. The authors gratefully acknowledge the technical assistance of Manori Silva, Ella Samandar, Jim Preau, Xiaoyun Ye, Ryan Hennings, Xiaoliu Zhou and Lily Jia for measuring the urinary concentrations of phthalate metabolites and bisphenol A We are grateful to the participating families who have so generously contributed their time and effort to the study. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 58 TC 19 Z9 20 U1 2 U2 37 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD APR PY 2013 VL 122 BP 38 EP 44 DI 10.1016/j.envres.2012.12.003 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 121OG UT WOS:000317253500006 PM 23312110 ER PT J AU Storm, JE Mazor, KA Shost, SJ Serle, J Aldous, KM Blount, BC AF Storm, Jan E. Mazor, Kimberly A. Shost, Stephen J. Serle, Janet Aldous, Kenneth M. Blount, Benjamin C. TI Socioeconomic disparities in indoor air, breath, and blood perchloroethylene level among adult and child residents of buildings with or without a dry cleaner SO ENVIRONMENTAL RESEARCH LA English DT Article DE Dry cleaners; Tetrachloroethylene; Perchloroethylene; Perc; Environmental disparities; Biomarkers of exposure ID VOLATILE ORGANIC-COMPOUNDS; ENVIRONMENTAL-HEALTH DISPARITIES; VISUAL CONTRAST SENSITIVITY; ASSESSMENT SURVEY NHEXAS; NEW-YORK-CITY; EXPOSURE ASSESSMENT; NEW-JERSEY; DRINKING-WATER; TETRACHLOROETHYLENE; POPULATION AB In many cities, dry cleaners using perchloroethylene are frequently located in multifamily residential buildings and often cause elevated indoor air levels of perchloroethylene throughout the building. To assess individual perchloroethylene exposures associated with co-located dry cleaners, we measured perchloroethylene in residential indoor air, and in blood and breath of adults and children residing in buildings with a dry cleaner as part of the New York City (NYC) Perc Project We also measured perchloroethylene in indoor air, and in blood and breath of residents of buildings without a dry cleaner for comparison. Here, we evaluate whether an environmental disparity in perchloroethylene exposures is present. Study participants are stratified by residential building type (dry cleaner or reference) and socioeconomic characteristics (race/ethnicity and income); measures of perchloroethylene exposure are examined; and, the influence of stratified variables and other factors on perchloroethylene exposure is assessed using multivariate regression. All measures of perchloroethylene exposure for residents of buildings with a dry cleaner indicated a socioeconomic disparity. Mean indoor air perchloroethylene levels were about five times higher in minority (82.5 ug/m(3)) than in non-minority (16.5 ug/m(3)) households, and about six times higher in low-income (105.5 ug/m(3)) than in high income (17.8 ug/m(3)) households. Mean blood perchloroethylene levels in minority children (0.27 ng/mL) and adults (0.46 ng/mL) were about two and three times higher than in non-minority children (0.12 ng/mL) and adults (0.15 ng/mL), respectively. Mean blood perchloroethylene levels in low income children (0.34 ng/mL) and adults (0.62 ng/mL) were about three and four times higher than in high income children (0.11 ng/mL) and adults (0.14 ng/mL), respectively. A less marked socioeconomic disparity was observed in perchloroethylene breath levels with minority and low income residents having slightly higher levels than non-minority and high income residents. Multivariate regression affirmed that indoor air perchloroethylene level in dry cleaner buildings was the single most important factor determining perchloroethylene in blood and breath. Neither age, gender, nor socioeconomic status significantly influenced perchloroethylene levels in breath or blood. We previously reported that increased indoor air, breath, and blood perchloroethylene levels among NYC Perc Project child participants were associated with an increased risk for slightly altered vision. Thus, the disproportionately elevated perchloroethylene exposures of minority and low-income child residents of buildings with a dry cleaner shown here constitutes an environmental exposure disparity with potential public health consequences. Among residents of buildings without a dry cleaner, we observed some small increases in perchloroethylene breath and blood levels among non-minority or high income residents compared to minority or low income residents. These differences were not attributable to differences in indoor air levels of perchloroethylene which did not differ across socioeconomic categories, but appear to be associated with more frequent exposures dry cleaned garments. (C) 2013 Elsevier Inc. All rights reserved. C1 [Storm, Jan E.; Mazor, Kimberly A.; Shost, Stephen J.] New York State Dept Hlth, Bur Tox Substance Assessment, Ctr Environm Hlth, Albany, NY 12237 USA. [Aldous, Kenneth M.] New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA. [Blount, Benjamin C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Serle, Janet] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY 10029 USA. RP Storm, JE (reprint author), New York State Dept Hlth, Bur Tox Substance Assessment, Empire State Plaza,Corning Tower Room 1743, Albany, NY 12237 USA. EM jes19@health.state.ny.us FU United States Environmental Protection Agency through STAR Grant [827446010]; United States Environmental Protection Agency (EPA) [R827446010] FX Funded by the United States Environmental Protection Agency through STAR Grant #827446010 to the New York State Department of Health.; Although the research described in this article has been funded wholly or in part by the United States Environmental Protection Agency (EPA) through Grant number R827446010 to the New York State Department of Health, it has not been subjected to EPA's required peer and policy review and therefore does not necessarily reflect the views of EPA. Therefore, no official endorsement should be inferred. NR 66 TC 1 Z9 1 U1 1 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD APR PY 2013 VL 122 BP 88 EP 97 DI 10.1016/j.envres.2013.02.001 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 121OG UT WOS:000317253500013 PM 23453848 ER PT J AU Medalla, F Hoekstra, RM Whichard, JM Barzilay, EJ Chiller, TM Joyce, K Rickert, R Krueger, A Stuart, A Griffin, PM AF Medalla, Felicita Hoekstra, Robert M. Whichard, Jean M. Barzilay, Ezra J. Chiller, Tom M. Joyce, Kevin Rickert, Regan Krueger, Amy Stuart, Andrew Griffin, Patricia M. TI Increase in Resistance to Ceftriaxone and Nonsusceptibility to Ciprofloxacin and Decrease in Multidrug Resistance Among Salmonella Strains, United States, 1996-2009 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID ANTIMICROBIAL RESISTANCE; SPECTRUM CEPHALOSPORINS; SEROTYPE TYPHIMURIUM; NEWPORT INFECTIONS; ENTERICA; SURVEILLANCE; ENTERITIDIS; OUTBREAKS; FOODNET; ILLNESS AB Background: Salmonella is a major bacterial pathogen transmitted commonly through food. Increasing resistance to antimicrobial agents (e. g., ceftriaxone, ciprofloxacin) used to treat serious Salmonella infections threatens the utility of these agents. Infection with antimicrobial-resistant Salmonella has been associated with increased risk of severe infection, hospitalization, and death. We describe changes in antimicrobial resistance among nontyphoidal Salmonella in the United States from 1996 through 2009. Methods: The Centers for Disease Control and Prevention's National Antimicrobial Resistance Monitoring System conducts surveillance of resistance among Salmonella isolated from humans. From 1996 through 2009, public health laboratories submitted isolates for antimicrobial susceptibility testing. We used interpretive criteria from the Clinical and Laboratory Standards Institute and defined isolates with ciprofloxacin resistance or intermediate susceptibility as nonsusceptible to ciprofloxacin. Using logistic regression, we modeled annual data to assess changes in antimicrobial resistance. Results: From 1996 through 2009, the percentage of nontyphoidal Salmonella isolates resistant to ceftriaxone increased from 0.2% to 3.4% (odds ratio [OR] = 20, 95% confidence interval [CI] 6.3-64), and the percentage with nonsusceptibility to ciprofloxacin increased from 0.4% to 2.4% (OR = 8.3, 95% CI 3.3-21). The percentage of isolates that were multidrug resistant (resistant to >= 3 antimicrobial classes) decreased from 17% to 9.6% (OR = 0.6, 95% CI 0.5-0.7), which was driven mainly by a decline among serotype Typhimurium. However, multidrug resistance increased from 5.9% in 1996 to a peak of 31% in 2001 among serotype Newport and increased from 12% in 1996 to 26% in 2009 (OR = 2.6, 95% CI 1.1-6.2) among serotype Heidelberg. Conclusions: We describe an increase in resistance to ceftriaxone and nonsusceptibility to ciprofloxacin and an overall decline in multidrug resistance. Trends varied by serotype. Because of evidence that antimicrobial resistance among Salmonella is predominantly a consequence of antimicrobial use in food animals, efforts are needed to reduce unnecessary use, especially of critically important agents. C1 [Medalla, Felicita; Hoekstra, Robert M.; Whichard, Jean M.; Barzilay, Ezra J.; Chiller, Tom M.; Joyce, Kevin; Rickert, Regan; Krueger, Amy; Stuart, Andrew; Griffin, Patricia M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Medalla, F (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS C-09, Atlanta, GA 30329 USA. EM fhm1@cdc.gov FU Centers for Disease Control and Prevention; U.S. Food and Drug Administration Center for Veterinary Medicine FX We thank state and local health departments and their public health laboratories for their contributions. We acknowledge Fred Angulo for his guidance and critical review. This work was supported by the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration Center for Veterinary Medicine. NR 37 TC 15 Z9 16 U1 1 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD APR PY 2013 VL 10 IS 4 BP 302 EP 309 DI 10.1089/fpd.2012.1336 PG 8 WC Food Science & Technology SC Food Science & Technology GA 122YB UT WOS:000317353400002 PM 23464603 ER PT J AU Kendall, ME Mody, RK Mahon, BE Doyle, MP Herman, KM Tauxe, RV AF Kendall, Magdalena E. Mody, Rajal K. Mahon, Barbara E. Doyle, Michael P. Herman, Karen M. Tauxe, Robert V. TI Emergence of Salsa and Guacamole as Frequent Vehicles of Foodborne Disease Outbreaks in the United States, 1973-2008 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID FRESH PRODUCE; RIPE TOMATOES; RAW PRODUCE; SALMONELLA; SURVIVAL; GROWTH; PATHOGENS; SURVEILLANCE; RESTAURANTS; VEGETABLES AB Fresh salsa and guacamole often contain diced raw produce, are often made in large batches, and are often poorly refrigerated, which may make them prone to contamination that can cause foodborne illness. The safety of salsa and guacamole is increasingly important as these foods gain popularity. Since 1973, local, state, and territorial health departments have voluntarily reported foodborne disease outbreaks to the Centers for Disease Control and Prevention's Foodborne Disease Outbreak Surveillance System (FDOSS) using a standard reporting form. FDOSS used paper-based reporting for 1973-1997 and switched to electronic reporting for 1998-2008. We reviewed all reports of outbreaks during 1973-2008 in which salsa or guacamole was reported as a vehicle. We found 136 outbreaks in which salsa or guacamole was reported as a possible vehicle, which resulted in 5,658 illnesses. Of these 136 salsa- or guacamole-associated (SGA) outbreaks additional possible food vehicles were reported for 33 (24%) outbreaks. There were no SGA outbreaks reported before 1984. Among reported outbreaks, most were caused by norovirus (24%), nontyphoidal Salmonella (19%), and Shigella (7%). Eighty-four percent of outbreaks were caused by foods prepared in restaurants or delis; of these, 19% reported ill foodworkers, and 29% reported improper storage as possible contributing factors. Among all foodborne disease outbreaks with a reported food vehicle during 1984-1997, 26 (0.9%) of 2,966 outbreaks were SGA, and during 1998-2008, 110 (1.4%) of 7,738 outbreaks were SGA. The number of reported foodborne disease outbreaks attributable to salsa or guacamole increased in the United States from 1984 to 2008, especially in later years, and especially in restaurants. Fresh salsa and guacamole require careful preparation and storage. Focused prevention strategies should reduce the risk of illness and ensure that these foods are enjoyed safely. C1 [Kendall, Magdalena E.; Mody, Rajal K.; Mahon, Barbara E.; Herman, Karen M.; Tauxe, Robert V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Doyle, Michael P.] Univ Georgia, Ctr Food Safety, Griffin, GA USA. RP Kendall, ME (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C-09, Atlanta, GA 30333 USA. EM mkendall@cdc.gov NR 35 TC 11 Z9 11 U1 3 U2 33 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD APR PY 2013 VL 10 IS 4 BP 316 EP 322 DI 10.1089/fpd.2012.1328 PG 7 WC Food Science & Technology SC Food Science & Technology GA 122YB UT WOS:000317353400004 PM 23461608 ER PT J AU Rosner, W Hankinson, SE Sluss, PM Vesper, HW Wierman, ME AF Rosner, William Hankinson, Susan E. Sluss, Patrick M. Vesper, Hubert W. Wierman, Margaret E. TI Challenges to the Measurement of Estradiol: An Endocrine Society Position Statement SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BREAST-CANCER RISK; ENDOGENOUS SEX-HORMONES; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; MASS-SPECTROMETRY; SERUM ESTRADIOL; DIRECT RADIOIMMUNOASSAYS; CIRCULATING ESTRADIOL; ENDOMETRIAL CANCER; ESTROGEN-RECEPTORS AB Objective: The objective of the study was to evaluate the current state of clinical assays for estradiol in the context of their applications. Participants: The participants were appointed by the Council of The Endocrine Society and charged with attaining the objective using published data and expert opinion. Evidence: Data were gathered from published sources via online databases (principally PubMed, Ovid MEDLINE, Google Scholar), and the clinical and laboratory experience of the participants. Consensus Process: The statement was an effort of the committee and was reviewed by each member. The Clinical Affairs Committee, the Council of The Endocrine Society, and JCEM reviewers reviewed the manuscript and made recommendations. Conclusions: The measurement of estradiol in biological fluids is important in human biology from cradle to grave. In addition to its centrality in sexual development, it has significant effects on skin, blood vessels, bone, muscle, coagulation, hepatic cells, adipose tissue, the kidney, the gastrointestinal tract, brain, lung, and pancreas. Alterations in its plasma concentration have been implicated in coronary artery disease, stroke, and breast cancer. Although modern immunoassays and liquid chromatography/tandem mass spectrometry-based methods for estradiol are reasonably well suited to the diagnosis and management of infertility (nonetheless, imprecision and method-to-method differences remain problematic), the very low concentrations that appear to be crucial in nonreproductive tissues are a separate and more difficult issue. Such levels of estradiol are too low to be routinely measured accurately or precisely, and further evolution of analytical methods and the way in which estradiol is standardized is needed. (J Clin Endocrinol Metab 98: 1376-1387, 2013) C1 [Rosner, William] Columbia Univ, Coll Phys & Surg, New York, NY 10019 USA. [Rosner, William] St Lukes Roosevelt Hosp, New York, NY 10019 USA. [Hankinson, Susan E.] Univ Massachusetts, Div Biostat & Epidemiol, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA. [Hankinson, Susan E.] Brigham & Womens Hosp, Div Network Med, Boston, MA 02115 USA. [Sluss, Patrick M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Vesper, Hubert W.] US Ctr Dis Control & Prevent, Div Sci Lab, Clin Chem Branch, Atlanta, GA 30341 USA. [Wierman, Margaret E.] Univ Colorado, Sch Med, Aurora, CO 80045 USA. [Wierman, Margaret E.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Rosner, W (reprint author), St Lukes Roosevelt Hosp, Dept Med, AJA 403,1000 10th Ave, New York, NY 10019 USA. EM wr7@columbia.edu FU National Institutes of Health [R01 CA49449, R01 CA6762] FX S.E.H. is funded by National Institutes of Health Grants R01 CA49449 and R01 CA6762. W.R., P.M.S., H.W.V., and M.E.W. have no conflicts to declare. NR 86 TC 80 Z9 83 U1 1 U2 19 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2013 VL 98 IS 4 BP 1376 EP 1387 DI 10.1210/jc.2012-3780 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 120TJ UT WOS:000317195600038 PM 23463657 ER PT J AU Merrill, RM Johnson, EM Sloan, A Lanier, WA AF Merrill, Ray M. Johnson, Erin M. Sloan, Arielle Lanier, William A. TI Characterizing Unintentional Nonillicit and Illicit Drug-Related Deaths SO JOURNAL OF DRUG ISSUES LA English DT Article DE illicit; nonillicit; pain medication; drug use; mental illness; overdose ID SUBSTANCE USE; OVERDOSE DEATHS; UNITED-STATES; ALCOHOL; COCAINE; INVOLVEMENT; PREDICTORS; ADULTHOOD; MARRIAGE; PATTERNS AB This study characterized individuals dying from illicit and nonillicit drug overdoses in Utah. Data were gathered from medical examiner records, death certificates, and next-of-kin interviews, 2008-2009. Among 374 decedents, 92 (25%) involved illicit drugs, 244 (65%) involved nonillicit drugs, and 38 (10%) involved a combination of both as the cause of death. Nonillicit compared with illicit drug-related decedents were more likely older, married, and of normal or overweight, and had a history of chronic pain. Nonillicit drug-related decedents were less likely to have had a history of alcohol and/or illicit drug use. Nevertheless, most decedents in both drug categories had a history of alcohol drinking and illicit substance use. Several psychological maladies characterized both illicit and nonillicit decedent cases, with a majority experiencing past anxiety, sadness, pain, insomnia, mood swings, irritability, hopelessness, and excessive daytime sleepiness. Impulsive tendencies and mood swings were more common in illicit drug-related deaths. C1 [Merrill, Ray M.; Sloan, Arielle] Brigham Young Univ, Dept Hlth Sci, Provo, UT 84602 USA. [Johnson, Erin M.] Utah Dept Hlth, Prescript Pain Medicat Program, Salt Lake City, UT 84116 USA. [Lanier, William A.] Utah Dept Hlth, Atlanta, GA USA. [Lanier, William A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Merrill, RM (reprint author), Brigham Young Univ, 229-A Richards Bldg, Provo, UT 84602 USA. EM Ray_Merrill@byu.edu NR 26 TC 0 Z9 0 U1 2 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0426 J9 J DRUG ISSUES JI J. Drug Issues PD APR PY 2013 VL 43 IS 2 BP 144 EP 153 DI 10.1177/0022042612462217 PG 10 WC Substance Abuse SC Substance Abuse GA 123NR UT WOS:000317397400002 ER PT J AU Kading, R Crabtree, M Miller, B AF Kading, Rebekah Crabtree, Mary Miller, Barry TI Inactivation of infectious virus and serological detection of virus antigen in Rift Valley fever virus-exposed mosquitoes fixed with paraformaldehyde SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Rift Valley fever virus; Paraformaldehyde fixation; Trypsin; Mosquito; Pathology ID NORTH-AMERICAN MOSQUITOS; AEDES-ALBOPICTUS; VIRAL-ANTIGENS; NSM GENES; IN-VIVO; FIXATION; IMMUNOHISTOCHEMISTRY; BIOSAFETY; LACKING; TRANSMISSION AB Formaldehyde is routinely used to fix tissues in preparation for pathology studies, however concerns remain that treatment of tissues with cellular fixatives may not entirely inactivate infectious virus particles. This concern is of particular regulatory importance for research involving viruses that are classified as select agents such as Rift Valley fever virus (RVFV). Therefore, the specific aims of this study were to (1) assay RVFV-exposed Aedes aegypti mosquitoes fixed in 4% paraformaldehyde for the presence of infectious RVFV particles at various time points following infection and (2) demonstrate the utility of immunofluorescence assay (IFA) for the detection of RVFV antigen in various tissues of paraformaldehyde-fixed mosquitoes. Mosquitoes were administered an infectious blood meal containing one of two strains of RVFV, harvested at various time points following infection, intrathoracically inoculated with 4% paraformaldehyde, and fixed overnight at 4 degrees C. The infection status of a subset of mosquitoes was verified by IFA on leg tissues prior to fixation, and infectivity of RVFV in fixed mosquito carcasses was determined by Vero cell plaque assay. Paraformaldehyde-fixed mosquitoes harvested 14 days post infection were also paraffin-embedded and sectioned for detection of RVFV antigen to particular tissues by IFA. None of the RVFV-exposed mosquitoes tested by Vero cell plaque assay contained infectious RVFV after fixation. Furthermore, incubation of mosquito sections with trypsin prior to antibody staining is recommended for optimal visualization of RVFV antigen in infected mosquito tissues by IFA. Published by Elsevier B.V. C1 [Kading, Rebekah; Crabtree, Mary; Miller, Barry] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, Ft Collins, CO 80521 USA. RP Kading, R (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, 3156 Rampart Rd,Mail Stop P02, Ft Collins, CO 80521 USA. EM fxk7@cdc.gov RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X FU CDC Division of Vector-borne Diseases, Arbovirus Diseases Branch FX Mouse anti-RVFV hyperimmune ascitic fluid was provided by Dr. Brian Bird and Dr. Stuart Nichol of the CDC Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology. This work was supported by the CDC Division of Vector-borne Diseases, Arbovirus Diseases Branch. NR 31 TC 3 Z9 3 U1 4 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD APR PY 2013 VL 189 IS 1 BP 184 EP 188 DI 10.1016/j.jviromet.2013.01.014 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 124HT UT WOS:000317455100029 PM 23391826 ER PT J AU Buchanan, N Roland, KB Rodriguez, JL Miller, JW Fairley, T AF Buchanan, Natasha Roland, Katherine B. Rodriguez, Juan L. Miller, Jacqueline W. Fairley, Temeika TI Opportunities for Public Health Communication, Intervention, and Future Research on Breast Cancer in Younger Women SO JOURNAL OF WOMENS HEALTH LA English DT Article ID CHEMOTHERAPY; GUIDELINES; RESERVE; ISSUES; AGE AB Background: Approximately 6% of breast cancers in the United States occur in women under the age of 40 years. Compared with women >= 40 years of age, younger women are diagnosed at later stages, have higher rates of recurrence and death, and may be predisposed to secondary breast or ovarian cancer. An informal meeting of experts discussed opportunities for research and public health communication related to breast cancer among young (<40 and/or premenopausal) women. Methods: In September 2011, the Centers for Disease Control and Prevention hosted 18 experts in oncology, genetics, behavioral science, survivorship and advocacy, public health, communication, ethics, nutrition, physical activity, and environmental health. They (1) reviewed research and programmatic knowledge on risk and preventive factors, early detection, and survivorship; and (2) discussed ideas for research, communication, and programmatic efforts related to young women diagnosed with or at risk for early onset breast cancer. Results: Levels of evidence and themes for future research regarding risk and preventive factors, including exposures, were discussed. Early detection strategies, including screening, risk assessment, and genetic counseling, as well as survivorship issues, follow-up care, fertility and reproductive health, and psychosocial care were highlighted. Conclusion: Community and academic researchers, providers, advocates, and the federal public health community discussed strategies and opportunities for this unique population. Although the evidence is limited, future research and communication activities may be useful to organize future public health initiatives. C1 [Buchanan, Natasha; Roland, Katherine B.; Rodriguez, Juan L.] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. [Miller, Jacqueline W.] Ctr Dis Control & Prevent, Program Serv Branch, Atlanta, GA 30341 USA. [Fairley, Temeika] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Off Director, Atlanta, GA 30341 USA. RP Buchanan, N (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway Northeast,MS K-55, Atlanta, GA 30341 USA. EM nbuchanan@cdc.gov FU Centers for Disease Control and Prevention FX All authors have read and approved the manuscript as well as any additional information that may impact the review process. This manuscript has not been previously accepted or reviewed by any other journal publication. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This special topic manuscript utilizes information collected from meeting presentations, discussions, and transcription notes. Authors of this manuscript served as CDC ad hoc committee members and speakers during this informal meeting of experts. The collection of these materials and related activities was funded by the Centers for Disease Control and Prevention. No competing financial interests exist. NR 16 TC 4 Z9 4 U1 1 U2 18 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2013 VL 22 IS 4 BP 293 EP 298 DI 10.1089/jwh.2012.4239 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 126FZ UT WOS:000317599700001 PM 23514347 ER PT J AU Robbins, CL Keyserling, TC Pitts, SBJ Morrow, J Majette, N Sisneros, JA Ronay, A Farr, SL Urrutia, RP Dietz, PM AF Robbins, Cheryl L. Keyserling, Thomas C. Pitts, Stephanie B. Jilcott Morrow, John Majette, Nadya Sisneros, Jessica A. Ronay, Ashley Farr, Sherry L. Urrutia, Rachel Peragallo Dietz, Patricia M. TI Screening Low-Income Women of Reproductive Age for Cardiovascular Disease Risk Factors SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HEART-DISEASE; UNITED-STATES; HEALTH-CARE; PREVENTION; PREVALENCE; SERVICES; PROGRAM; ADULTS; TRENDS AB Background: Identifying and treating chronic diseases, their precursors, and other cardiovascular disease (CVD) risk factors during family planning visits may improve long-term health and reproductive outcomes among low-income women. A cross-sectional study design was used to describe the prevalence of chronic diseases (hypertension, high cholesterol, and diabetes), their precursors (pre-hypertension, borderline high cholesterol, and pre-diabetes), and related CVD risk factors (such as obesity, smoking, and physical inactivity) among low-income women of reproductive age. Methods: Prevalence of chronic diseases, their precursors, and related CVD risk factors were assessed for 462 out of 859 (53.8%) female family planning patients, ages 18-44 years, who attended a Title X clinic in eastern North Carolina during 2011 and 2012 and consented to participate. Data were obtained from clinical measurements, blood test results, and questionnaire. Differences in distribution of demographic and health care characteristics and CVD risk factors by presence of prehypertension and pre-diabetes were assessed by Pearson chi-square tests. Results: The prevalence of hypertension was 12%, high cholesterol 16%, and diabetes 3%. Nearly two-thirds of women with hypertension were newly diagnosed (62%) as were 75% of women with diabetes. The prevalence of pre-hypertension was 35%, pre-diabetes 31%, obesity 41%, smoking 32%, and physical inactivity 42%. The majority of participants (87%) had one or more chronic disease or related cardiovascular disease risk factor. Conclusions: CVD screening during family planning visits can identify significant numbers of women at risk for poor pregnancy outcomes and future chronic disease and can provide prevention opportunities if effective interventions are available and acceptable to this population. C1 [Robbins, Cheryl L.; Farr, Sherry L.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Keyserling, Thomas C.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Keyserling, Thomas C.; Sisneros, Jessica A.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA. [Pitts, Stephanie B. Jilcott; Majette, Nadya; Ronay, Ashley] E Carolina Univ, Dept Publ Hlth, Greenville, NC USA. [Morrow, John] Pitt Cty Hlth Dept, Greenville, NC USA. [Urrutia, Rachel Peragallo] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA. [Urrutia, Rachel Peragallo] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA. RP Robbins, CL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway Northeast,Mailstop K-23, Atlanta, GA 30333 USA. EM ggf9@cdc.gov OI Ronay, Ashley/0000-0003-1839-7248 FU Centers for Disease Control and Prevention [5U48DP001944] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This work was supported by Cooperative Agreement Number 5U48DP001944 from the Centers for Disease Control and Prevention. The authors gratefully acknowledge the Pitt County Health Department nurses and leadership for assisting in this study, particularly Deborah B. Herring, BSN, MHA, Stephanie Hart, RN, MA, and Susan S. Shelton, BSN. We also thank all of the women who participated in this project. The authors also express appreciation to Hubert W. Vesper, PhD, for his expert analysis of the cholesterol test results, Larry Johnston, MA; Anne Cole, BA; and Ziya Gizlice, PhD, for their roles in assuring data quality, and Merry-K Moos for her expert review of the manuscript. NR 25 TC 6 Z9 6 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2013 VL 22 IS 4 BP 314 EP 321 DI 10.1089/jwh.2012.4149 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 126FZ UT WOS:000317599700005 PM 23531099 ER PT J AU Oliver, JS Martin, MY Richardson, L Kim, Y Pisu, M AF Oliver, JoAnn S. Martin, Michelle Y. Richardson, Lisa Kim, Young Pisu, Maria TI Gender Differences in Colon Cancer Treatment SO JOURNAL OF WOMENS HEALTH LA English DT Article ID ADJUVANT CHEMOTHERAPY USE; METASTATIC BREAST-CANCER; COLORECTAL-CANCER; OLDER WOMEN; DISPARITIES; FLUOROURACIL; TOXICITY; THERAPY; AGE; PREDICTORS AB Background: Despite women suffering a disproportionate burden of colon cancer mortality, few studies have examined gender differences in evidence-based treatment, especially in poorer states like Alabama. Objective: To describe colon cancer treatment in older patients diagnosed in Alabama by gender. Methods: Colon cancer patients 65 years and older diagnosed in 2000-2002 were identified from the Alabama Statewide Cancer Registry (N=1785). Treatment was identified from Medicare claims for 1999-2003. Outcomes were (1) receipt of surgery and adjuvant 5-fluorouracil chemotherapy (5FU) and (2) 5FU treatment duration (0-4, 5-7, and >7 months). Generalized Estimating Equation (GEE) models were used to determine significant gender differences, adjusting for clustering at the reporting hospital level, and controlling for race, age, stage, comorbid conditions, census tract-level socioeconomic variables, and adverse chemotherapy effects (when analyzing 5FU duration). Results: Overall, 93.9% of the patients received surgery. Of stage II-III patients undergoing surgery, 60.4% stage III and 25.6% stage II patients received 5FU. Compared with men, women were more likely to have surgery (95.5% vs. 92.2%, p=0.003), less likely to have 5FU (38.6% vs. 45.2%, p=0.02), and more likely to have 0-4 months of 5FU (32.9% vs. 24.9%, p=0.05). Gender differences were significant for having chemotherapy (adjusted odds ratio [aOR] 0.78, confidence interval [CI] 0.61-1.00, p=0.049), but not for having 0-4 months of 5FU when adjusting for adverse effects (aOR 1.36, CI 0.95-1.94, p=0.09). Conclusions: In Alabama, some gender differences in stage-specific colon cancer treatment are worth further scrutiny. C1 [Oliver, JoAnn S.] Univ Alabama, Capstone Coll Nursing, Tuscaloosa, AL USA. [Martin, Michelle Y.; Kim, Young; Pisu, Maria] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35205 USA. [Martin, Michelle Y.; Kim, Young; Pisu, Maria] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35205 USA. [Richardson, Lisa] Ctr Dis Control & Prevent, Canc Prevent Div, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Pisu, M (reprint author), Univ Alabama Birmingham, Dept Med, Div Prevent Med, 1717 11th Ave South,MT 636, Birmingham, AL 35205 USA. EM mpisu@uab.edu FU Centers for Disease Control and Prevention's Prevention Research Centers Program [U48 DP000225-01] FX The authors are grateful for the collaboration with the staff at the Alabama Statewide Cancer Registry. This study was supported by Cooperative Agreement U48 DP000225-01 from the Centers for Disease Control and Prevention's Prevention Research Centers Program. The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention. NR 44 TC 2 Z9 2 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2013 VL 22 IS 4 BP 344 EP 351 DI 10.1089/jwh.2012.3988 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 126FZ UT WOS:000317599700009 PM 23531098 ER PT J AU Brisson, D Perron, P Kahn, HS Gaudet, D Bouchard, L AF Brisson, Diane Perron, Patrice Kahn, Henry S. Gaudet, Daniel Bouchard, Luigi TI The Lipid Accumulation Product for the Early Prediction of Gestational Insulin Resistance and Glucose Dysregulation SO JOURNAL OF WOMENS HEALTH LA English DT Article ID DIABETES-MELLITUS; BODY-FAT; WOMEN; RISK; PREGNANCY; INDEX; MARKER; BMI AB Background: Recent insights linking insulin resistance and lipid overaccumulation suggest a novel approach for the early identification of women who may soon experience glucose dysregulation. Among women without a history of gestational diabetes, we tested the association between the lipid accumulation product (LAP) obtained in early pregnancy and glucose dysregulation or insulin resistance in the second trimester. Methods: A total of 180 white pregnant women of French-Canadian origin were included in this study. At 11-14 weeks' gestation, fasting insulin, glucose, C-peptide concentrations, and estimated insulin resistance (HOMA-IR) were obtained. The waist circumference (WC) and fasting triglycerides (TG) were measured to calculate LAP as (WC[cm] - 58) x TG([mmol/L]). At 24-28 weeks' gestation, glucose was measured 2 hours after a 75-g oral glucose challenge and other fasting variables were repeated. Results: Among the nulliparous women tested at the end of the second trimester, fasting insulin, C-peptide, insulin resistance (HOMA-IR index), fasting glucose, and 2-hour glucose progressively increased (p <= 0.002) according to their first-trimester LAP tertiles. Similar results were observed in parous women except for the glucose variables. The first-trimester LAP tended to show a stronger correlation to the second-trimester HOMA-IR index (r = 0.56) than fasting triglyceride levels alone (r = 0.40) or waist circumference alone (r = 0.44) among nulliparous women. Similar associations were observed for parous women. Adjustment for body mass index weakened these associations, especially among parous women. Conclusions: An increased value of LAP at the beginning of a pregnancy could be associated with an increased risk of insulin resistance or hyperglycemia later in gestation. C1 [Brisson, Diane; Perron, Patrice; Gaudet, Daniel; Bouchard, Luigi] Univ Montreal, Dept Med, ECOGENE 21, Saguenay, PQ, Canada. [Brisson, Diane; Perron, Patrice; Gaudet, Daniel; Bouchard, Luigi] Chicoutimi Hosp, Lipid Clin, Saguenay, PQ, Canada. [Perron, Patrice] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1K 2R1, Canada. [Kahn, Henry S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bouchard, Luigi] Univ Sherbrooke, Dept Biochem, Sherbrooke, PQ J1K 2R1, Canada. RP Brisson, D (reprint author), Univ Montreal, ECOGENE 21, Chicoutimi Hosp, 305 St Vallier, Chicoutimi, PQ G7H 7P2, Canada. EM diane.brisson@ecogene21.org OI Kahn, Henry/0000-0003-2533-1562 FU FRQ-S; ECOGENE-21; Canadian Institutes of Health Research [CTP-82941]; Fonds de la Recherche en Sante du Quebec (FRSQ); Diabete Quebec FX We warmly acknowledge all the women who participated in the study. DG is the chairholder of the Canada Research Chair in preventive genetics and community genomics (www.chairs.gc.ca). LB is junior research scholar from the Fonds de recherche du Quebec-Sante (FRQ-S) and a member of the FRQ-S funded Centre de recherche clinique Etienne-Le Bel (affiliated to the Centre Hospitalier de l'Universite de Sherbrooke). This project was supported by ECOGENE-21, the Canadian Institutes of Health Research (CIHR team in community genetics [grant CTP-82941]), Fonds de la Recherche en Sante du Quebec (FRSQ), and Diabete Quebec. The findings and conclusions in this article are those of the authors and do not necessarily reflect the views of the Centers for Disease Control and Prevention. This article is dedicated to the memory of Marta Santure who co-led the development of this study. NR 28 TC 7 Z9 7 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2013 VL 22 IS 4 BP 362 EP 367 DI 10.1089/jwh.2012.3807 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 126FZ UT WOS:000317599700011 PM 23717842 ER PT J AU Guzman, C Mattar, S Levis, S Pini, N Figueiredo, T Mills, J Salazar-Bravo, J AF Guzman, Camilo Mattar, Salim Levis, Silvana Pini, Noemi Figueiredo, Tadeu Mills, James Salazar-Bravo, Jorge TI Prevalence of antibody to hantaviruses in humans and rodents in the Caribbean region of Colombia determined using Araraquara and Maciel virus antigens SO MEMORIAS DO INSTITUTO OSWALDO CRUZ LA English DT Article DE hantavirus; Colombia; epidemiological surveillance; Rodentia; public health; immunoassay ID CARDIOPULMONARY SYNDROME; PULMONARY-SYNDROME; GENETIC DIVERSITY; INFECTION; ARGENTINA; EPIDEMIOLOGY; AMERICA; PANAMA AB We tested sera from 286 agricultural workers and 322 rodents in the department of Cordoba, northeastern Colombia, for antibodies against two hantaviruses. The sera were analysed by indirect ELISA using the lysate of Vero E6 cells infected with Maciel virus (MACV) or the N protein of Araraquara virus (ARAV) as antigens for the detection of antibodies against hantaviruses. Twenty-four human sera were IgG positive using one or both antigens. We detected anti-MACV IgG antibodies in 10 sera (3.5%) and anti-ARAV antibodies in 21 sera (7.34%). Of the 10 samples that were positive for MACV, seven (70%) were cross-reactive with ARAV; seven of the 21 ARAV-positive samples were cross-reactive with MACV. Using an ARAV IgM ELISA, two of the 24 human sera (8.4%) were positive. We captured 322 rodents, including 210 Cricetidae (181 Zygodontomys brevicauda, 28 Oligoryzomys fulvescens and 1 Oecomys trinitatis), six Heteromys anomalus (Heteromyidae), one Proechimys sp. (Echimyidae) and 105 Muridae (34 Rattus rattus and 71 Mus musculus). All rodent sera were negative for both antigens. The 8.4% detection rate of hantavirus antibodies in humans is much higher than previously found in serosurveys in North America, suggesting that rural agricultural workers in northeastern Colombia are frequently exposed to hantaviruses. Our results also indicate that tests conducted with South American hantavirus antigens could have predictive value and could represent a useful alternative for the diagnosis of hantavirus infection in Colombia. C1 [Guzman, Camilo; Mattar, Salim] Univ Cordoba, Inst Invest Biol Trop, Monteria, Colombia. [Figueiredo, Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, Ctr Pesquisa Virol, Sao Paulo, Brazil. [Mills, James] Ctr Dis Control & Prevent, Atlanta, GA USA. [Salazar-Bravo, Jorge] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. RP Mattar, S (reprint author), Univ Cordoba, Inst Invest Biol Trop, Monteria, Colombia. EM mattarsalim@hotmail.com FU UCO, Colombia FX UCO, Colombia NR 23 TC 4 Z9 5 U1 2 U2 4 PU FUNDACO OSWALDO CRUZ PI RIO DE JANEIRO, RJ PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL SN 0074-0276 J9 MEM I OSWALDO CRUZ JI Mem. Inst. Oswaldo Cruz PD APR PY 2013 VL 108 IS 2 BP 167 EP 171 PG 5 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA 125FS UT WOS:000317525600007 PM 23579795 ER PT J AU Wasse, H Cardarelli, F De Staercke, C Hooper, WC Long, Q AF Wasse, Haimanot Cardarelli, Francesca De Staercke, Christine Hooper, W. Craig Long, Qi TI Accumulation of retained nonfunctional arteriovenous grafts correlates with severity of inflammation in asymptomatic ESRD patients SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE AVG; ESRD; hemodialysis; inflammation ID CHRONIC KIDNEY-DISEASE; HEMODIALYSIS ACCESS; DIALYSIS PATIENTS; VASCULAR ACCESS; CASE SERIES; INFECTION; TRANSPLANT; MORTALITY; INTERLEUKIN-6; PREDICTORS AB The contribution of multiple retained nonfunctional arteriovenous grafts (AVGs) to the burden of chronic inflammation in chronic hemodialysis patients has not been well studied. Here, we sought to evaluate the association between plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and albumin and the number of retained nonfunctional AVGs. This cross-sectional study enrolled 91 prevalent patients undergoing in-center hemodialysis without evidence of infection or inflammation. A baseline blood sample was obtained at study enrollment. A general linear model (GLM) was used to compare levels of biomarkers of systemic inflammation across groups defined by the number of retained, nonfunctional AVGs. A total of 43 patients had one or more retained thrombosed AVG and had significantly greater plasma log-CRP levels compared with patients without a previous AVG (P 0.036), regardless of the current AV access type. Using a GLM, we found that for every additional retained thrombosed AVG, plasma log-CRP, log-IL-6 and TNF-alpha concentrations increased significantly by 0.30 mg/L (P 0.011), 0.18 pg/mL (P 0.046) and 0.72 pg/mL (P 0.046), respectively, following adjustment. Hence, the severity of inflammation increases with the number of retained nonfunctional AVGs, suggesting that AVG accumulation may contribute to the cardiovascular morbidity and mortality associated with chronic inflammation in asymptomatic end-stage renal disease (ESRD) patients. Further study is indicated to determine whether patients with one or more thrombosed, retained AVG may benefit from periodic screening with CRP monitoring to identify those patients who may benefit from AVG resection. C1 [Wasse, Haimanot] Emory Univ, Div Nephrol, Atlanta, GA 30322 USA. [Cardarelli, Francesca] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA. [De Staercke, Christine; Hooper, W. Craig] Emory Univ, Div Blood Disorders, Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Long, Qi] Emory Univ, Dept Biostat & Bioinformat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Wasse, H (reprint author), Emory Univ, Div Nephrol, Atlanta, GA 30322 USA. EM hwasse@emory.edu FU NIH [DK65634]; Davita Clinical Research Grant; PHS Grant from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources [UL1 RR02008, KL2 RR025009, TL1 RR025010] FX This study was supported by an NIH K23 Grant DK65634 (H. W.), a Davita Clinical Research Grant (H. W.) and a PHS Grant (UL1 RR02008, KL2 RR025009 or TL1 RR025010) from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources. NR 27 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD APR PY 2013 VL 28 IS 4 BP 991 EP 997 DI 10.1093/ndt/gfs349 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 126JQ UT WOS:000317611000035 PM 23090982 ER PT J AU Thompson, KM Pallansch, MA Tebbens, RJD Wassilak, SG Kim, JH Cochi, SL AF Thompson, Kimberly M. Pallansch, Mark A. Tebbens, Radboud J. Duintjer Wassilak, Steve G. Kim, Jong-Hoon Cochi, Stephen L. TI Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control SO RISK ANALYSIS LA English DT Review DE Policy options; poliovirus; vaccination ID ORAL POLIOMYELITIS VACCINE; ENHANCED-POTENCY; CONTROLLED-TRIAL; IMMUNE-RESPONSE; RISK-MANAGEMENT; IMMUNOLOGICAL RESPONSE; ANTIBODY-RESPONSES; SEROLOGIC RESPONSE; PARALYTIC DISEASE; ECONOMIC-ANALYSIS AB With the circulation of wild poliovirus (WPV) types 1 and 3 continuing more than a decade after the original goal of eradicating all three types of WPVs by 2000, policymakers consider many immunization options as they strive to stop transmission in the remaining endemic and outbreak areas and prevent reintroductions of live polioviruses into nonendemic areas. While polio vaccination choices may appear simple, our analysis of current options shows remarkable complexity. We offer important context for current and future polio vaccine decisions and policy analyses by developing decision trees that clearly identify potential options currently used by countries as they evaluate national polio vaccine choices. Based on a comprehensive review of the literature we (1) identify the current vaccination options that national health leaders consider for polio vaccination, (2) characterize current practices and factors that appear to influence national and international choices, and (3) assess the evidence of vaccine effectiveness considering sources of variability between countries and uncertainties associated with limitations of the data. With low numbers of cases occurring globally, the management of polio risks might seem like a relatively low priority, but stopping live poliovirus circulation requires making proactive and intentional choices to manage population immunity in the remaining endemic areas and to prevent reestablishment in nonendemic areas. Our analysis shows remarkable variability in the current national polio vaccine product choices and schedules, with combination vaccine options containing inactivated poliovirus vaccine and different formulations of oral poliovirus vaccine making choices increasingly difficult for national health leaders. C1 [Thompson, Kimberly M.; Tebbens, Radboud J. Duintjer; Kim, Jong-Hoon] Kid Risk Inc, Orlando, FL 32832 USA. [Thompson, Kimberly M.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Wassilak, Steve G.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Thompson, KM (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM kimt@kidrisk.org FU Bill and Melinda Gates Foundation [4533-17492] FX Drs. Thompson and Duintjer Tebbens thank the Bill and Melinda Gates Foundation for providing a contract to Kid Risk, Inc. to support their work on this article under Work Order 4533-17492. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Bill and Melinda Gates Foundation or the U.S. Centers for Disease Control. NR 110 TC 29 Z9 29 U1 3 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 J9 RISK ANAL JI Risk Anal. PD APR PY 2013 VL 33 IS 4 BP 516 EP 543 DI 10.1111/risa.12019 PG 28 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 122DG UT WOS:000317295900002 PM 23461599 ER PT J AU Tebbens, RJD Pallansch, MA Chumakov, KM Halsey, NA Hovi, T Minor, PD Modlin, JF Patriarca, PA Sutter, RW Wright, PF Wassilak, SGF Cochi, SL Kim, JH Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Chumakov, Konstantin M. Halsey, Neal A. Hovi, Tapani Minor, Philip D. Modlin, John F. Patriarca, Peter A. Sutter, Roland W. Wright, Peter F. Wassilak, Steven G. F. Cochi, Stephen L. Kim, Jong-Hoon Thompson, Kimberly M. TI Expert Review on Poliovirus Immunity and Transmission SO RISK ANALYSIS LA English DT Review DE Dynamic modeling; polio eradication; risk management ID ORAL POLIOMYELITIS VACCINE; ENTERIC VIRUS INFECTIONS; ANTIBODY-RESPONSE; MUCOSAL IMMUNITY; IMMUNIZATION SCHEDULES; UNITED-STATES; NATURAL IMMUNITY; CONTROLLED-TRIAL; LIVE VIRUS; NEUTRALIZING ANTIBODIES AB Successfully managing risks to achieve wild polioviruses (WPVs) eradication and address the complexities of oral poliovirus vaccine (OPV) cessation to stop all cases of paralytic poliomyelitis depends strongly on our collective understanding of poliovirus immunity and transmission. With increased shifting from OPV to inactivated poliovirus vaccine (IPV), numerous risk management choices motivate the need to understand the tradeoffs and uncertainties and to develop models to help inform decisions. The U.S. Centers for Disease Control and Prevention hosted a meeting of international experts in April 2010 to review the available literature relevant to poliovirus immunity and transmission. This expert review evaluates 66 OPV challenge studies and other evidence to support the development of quantitative models of poliovirus transmission and potential outbreaks. This review focuses on characterization of immunity as a function of exposure history in terms of susceptibility to excretion, duration of excretion, and concentration of excreted virus. We also discuss the evidence of waning of host immunity to poliovirus transmission, the relationship between the concentration of poliovirus excreted and infectiousness, the importance of different transmission routes, and the differences in transmissibility between OPV and WPV. We discuss the limitations of the available evidence for use in polio risk models, and conclude that despite the relatively large number of studies on immunity, very limited data exist to directly support quantification of model inputs related to transmission. Given the limitations in the evidence, we identify the need for expert input to derive quantitative model inputs from the existing data. C1 [Tebbens, Radboud J. Duintjer; Kim, Jong-Hoon; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Chumakov, Konstantin M.] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. [Halsey, Neal A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Hovi, Tapani] Natl Inst Hlth & Welf THL, Helsinki, Finland. [Minor, Philip D.] Natl Inst Biol Stand & Controls, Hlth Protect Agcy, Potters Bar, Herts, England. [Modlin, John F.; Wright, Peter F.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Patriarca, Peter A.] Biol Consulting Grp Inc, Bethesda, MD USA. [Sutter, Roland W.] WHO, Polio Eradicat Initiat, CH-1211 Geneva, Switzerland. [Wassilak, Steven G. F.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, 10524 Moss Pk Rd Ste 204-364, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU U.S. Centers for Disease Control and Prevention (CDC) [200-2010-M-33379] FX We thank the U.S. Centers for Disease Control and Prevention (CDC) for its support of the work described in this article by hosting the expert meeting mentioned in the article and providing financial support to Kid Risk, Inc. under Contract 200-2010-M-33379. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the World Health Organization. We thank Drs. Walter Dowdle, Olen Kew, and Walter Orenstein for helpful comments. NR 145 TC 33 Z9 34 U1 3 U2 40 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 J9 RISK ANAL JI Risk Anal. PD APR PY 2013 VL 33 IS 4 BP 544 EP 605 DI 10.1111/j.1539-6924.2012.01864.x PG 62 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 122DG UT WOS:000317295900003 ER PT J AU Tebbens, RJD Pallansch, MA Chumakov, KM Halsey, NA Hovi, T Minor, PD Modlin, JF Patriarca, PA Sutter, RW Wright, PF Wassilak, SGF Cochi, SL Kim, JH Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Chumakov, Konstantin M. Halsey, Neal A. Hovi, Tapani Minor, Philip D. Modlin, John F. Patriarca, Peter A. Sutter, Roland W. Wright, Peter F. Wassilak, Steven G. F. Cochi, Stephen L. Kim, Jong-Hoon Thompson, Kimberly M. TI Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs SO RISK ANALYSIS LA English DT Article DE Dynamic modeling; expert judgment; polio eradication ID VACCINE-DERIVED POLIOVIRUS; EXPERT JUDGMENT; SENSITIVITY ANALYSES; CONTROLLED-TRIAL; GLOBAL POLICIES; OPV CESSATION; DOUBLE-BLIND; POLIOMYELITIS; ERADICATION; MANAGEMENT AB With the intensifying global efforts to eradicate wild polioviruses, policymakers face complex decisions related to achieving eradication and managing posteradication risks. These decisions and the expanding use of inactivated poliovirus vaccine (IPV) trigger renewed interest in poliovirus immunity, particularly the role of mucosal immunity in the transmission of polioviruses. Sustained high population immunity to poliovirus transmission represents a key prerequisite to eradication, but poliovirus immunity and transmission remain poorly understood despite decades of studies. In April 2010, the U.S. Centers for Disease Control and Prevention convened an international group of experts on poliovirus immunology and virology to review the literature relevant for modeling poliovirus transmission, develop a consensus about related uncertainties, and identify research needs. This article synthesizes the quantitative assessments and research needs identified during the process. Limitations in the evidence from oral poliovirus vaccine (OPV) challenge studies and other relevant data led to differences in expert assessments, indicating the need for additional data, particularly in several priority areas for research: (1) the ability of IPV-induced immunity to prevent or reduce excretion and affect transmission, (2) the impact of waning immunity on the probability and extent of poliovirus excretion, (3) the relationship between the concentration of poliovirus excreted and infectiousness to others in different settings, and (4) the relative role of fecal-oral versus oropharyngeal transmission. This assessment of current knowledge supports the immediate conduct of additional studies to address the gaps. C1 [Tebbens, Radboud J. Duintjer; Kim, Jong-Hoon; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Chumakov, Konstantin M.] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. [Halsey, Neal A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Hovi, Tapani] Natl Inst Hlth & Welf THL, Helsinki, Finland. [Minor, Philip D.] Natl Inst Biol Stand & Controls, Hlth Protect Agcy, Potters Bar, Herts, England. [Modlin, John F.; Wright, Peter F.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. [Patriarca, Peter A.] Biol Consulting Grp Inc, Bethesda, MD USA. [Sutter, Roland W.] WHO, Polio Eradicat Initiat, CH-1211 Geneva, Switzerland. [Wassilak, Steven G. F.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Thompson, Kimberly M.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU U.S. Centers for Disease Control and Prevention (CDC) [200-2010-M-33379, 200-2010-M-35172] FX We thank the U.S. Centers for Disease Control and Prevention (CDC) for its support of the work described in this article by hosting the expert meeting mentioned in the article and providing financial support to Kid Risk, Inc. under Contracts 200-2010-M-33379 and 200-2010-M-35172. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the World Health Organization. We thank Drs. Walter Dowdle, Olen Kew, and Walter Orenstein for helpful comments. NR 60 TC 32 Z9 32 U1 3 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 J9 RISK ANAL JI Risk Anal. PD APR PY 2013 VL 33 IS 4 BP 606 EP 646 DI 10.1111/risa.12031 PG 41 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 122DG UT WOS:000317295900004 ER PT J AU Thompson, KM Pallansch, MA Tebbens, RJD Wassilak, SG Cochi, SL AF Thompson, Kimberly M. Pallansch, Mark A. Tebbens, Radboud J. Duintjer Wassilak, Steve G. Cochi, Stephen L. TI Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses SO RISK ANALYSIS LA English DT Article DE Immunity; poliovirus; vaccine ID VACCINE-DERIVED POLIOVIRUS; UNITED-STATES; PARALYTIC POLIOMYELITIS; ERADICATION; OUTBREAK; EPIDEMIOLOGY; IMMUNIZATION; EFFICACY; POLICIES; IMMUNOGENICITY AB Eradication of wild poliovirus (WPV) types 1 and 3, prevention and cessation of circulating vaccine-derived polioviruses, and achievement and maintenance of a world free of paralytic polio cases requires active risk management by focusing on population immunity and coordinated cessation of oral poliovirus vaccine (OPV). We suggest the need for a complementary and different conceptual approach to achieve eradication compared to the current case-based approach using surveillance for acute flaccid paralysis (AFP) to identify symptomatic poliovirus infections. Specifically, we describe a modeling approach to characterize overall population immunity to poliovirus transmission. The approach deals with the realities that exposure to live polioviruses (e.g., WPV, OPV) and/or vaccination with inactivated poliovirus vaccine provides protection from paralytic polio (i.e., disease), but does not eliminate the potential for reinfection or asymptomatic participation in poliovirus transmission, which may increase with time because of waning immunity. The AFP surveillance system provides evidence of symptomatic poliovirus infections detected, which indicate immunity gaps after outbreaks occur, and this system represents an appropriate focus for controlling disease outbreaks. We describe a conceptual dynamic model to characterize population immunity to poliovirus transmission that helps identify risks created by immunity gaps before outbreaks occur, which provides an opportunity for national and global policymakers to manage the risk of poliovirus and prevent outbreaks before they occur. We suggest that dynamically modeling risk represents an essential tool as the number of cases approaches zero. C1 [Thompson, Kimberly M.; Tebbens, Radboud J. Duintjer] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Wassilak, Steve G.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Thompson, Kimberly M.] Univ Cent Florida, Coll Medicine, Orlando, FL 32816 USA. RP Thompson, KM (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM kimt@kidrisk.org FU Bill and Melinda Gates Foundation [4533-17492] FX Drs. Thompson and Duintjer Tebbens thank the Bill and Melinda Gates Foundation for providing a contract to Kid Risk, Inc. to support their work on this article under Work Order 4533-17492. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Bill and Melinda Gates Foundation or the U.S. Centers for Disease Control and Prevention. NR 74 TC 31 Z9 31 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 J9 RISK ANAL JI Risk Anal. PD APR PY 2013 VL 33 IS 4 BP 647 EP 663 DI 10.1111/j.1539-6924.2012.01891.x PG 17 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 122DG UT WOS:000317295900005 PM 22985171 ER PT J AU Lowther, SA Roesel, S O'Connor, P Landaverde, M Oblapenko, G Deshevoi, S Ajay, G Buff, A Safwat, H Salla, M Tangermann, R Khetsuriani, N Martin, R Wassilak, S AF Lowther, Sara A. Roesel, Sigrun O'Connor, Patrick Landaverde, Mauricio Oblapenko, George Deshevoi, Sergei Ajay, Goel Buff, Ann Safwat, Hala Salla, Mbaye Tangermann, Rudi Khetsuriani, Nino Martin, Rebecca Wassilak, Steven TI World Health Organization Regional Assessments of the Risks of Poliovirus Outbreaks SO RISK ANALYSIS LA English DT Article DE Disease outbreaks; immunization programs; polio vaccine; poliomyelitis; risk assessment ID PARALYTIC POLIOMYELITIS; IMMUNIZATION COVERAGE; POOR; EPIDEMIOLOGY; ERADICATION; COUNTRIES; PROGRESS; SYSTEMS; AFRICA; IMPACT AB While global polio eradication requires tremendous efforts in countries where wild polioviruses (WPVs) circulate, numerous outbreaks have occurred following WPV importation into previously polio-free countries. Countries that have interrupted endemic WPV transmission should continue to conduct routine risk assessments and implement mitigation activities to maintain their polio-free status as long as wild poliovirus circulates anywhere in the world. This article reviews the methods used by World Health Organization (WHO) regional offices to qualitatively assess risk of WPV outbreaks following an importation. We describe the strengths and weaknesses of various risk assessment approaches, and opportunities to harmonize approaches. These qualitative assessments broadly categorize risk as high, medium, or low using available national information related to susceptibility, the ability to rapidly detect WPV, and other population or program factors that influence transmission, which the regions characterize using polio vaccination coverage, surveillance data, and other indicators (e.g., sanitation), respectively. Data quality and adequacy represent a challenge in all regions. WHO regions differ with respect to the methods, processes, cut-off values, and weighting used, which limits comparisons of risk assessment results among regions. Ongoing evaluation of indicators within regions and further harmonization of methods between regions are needed to effectively plan risk mitigation activities in a setting of finite resources for funding and continued WPV circulation. C1 [Lowther, Sara A.; O'Connor, Patrick; Buff, Ann; Khetsuriani, Nino; Martin, Rebecca; Wassilak, Steven] Ctr Dis Control & Prevent CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Roesel, Sigrun] WHO, Western Pacific Reg Off, Manila, Philippines. [O'Connor, Patrick] WHO, Southeast Asia Reg Off, New Delhi, India. [Landaverde, Mauricio] WHO, Pan Amer Hlth Org, Washington, DC USA. [Oblapenko, George; Deshevoi, Sergei; Ajay, Goel] WHO, European Reg Off, Copenhagen, Denmark. [Buff, Ann; Safwat, Hala] WHO, Eastern Mediterranean Reg Off, Cairo, Egypt. [Salla, Mbaye] WHO, Reg Off Africa, Brazzaville, Congo. [Tangermann, Rudi] WHO, CH-1211 Geneva, Switzerland. RP Lowther, SA (reprint author), CDC, Ctr Global Hlth, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM sgl6@cdc.gov NR 33 TC 11 Z9 11 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 J9 RISK ANAL JI Risk Anal. PD APR PY 2013 VL 33 IS 4 BP 664 EP 679 DI 10.1111/risa.12032 PG 16 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 122DG UT WOS:000317295900006 PM 23520991 ER PT J AU Tebbens, RJD Pallansch, MA Kim, JH Burns, CC Kew, OM Oberste, MS Diop, OM Wassilak, SGF Cochi, SL Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Kim, Jong-Hoon Burns, Cara C. Kew, Olen M. Oberste, M. Steven Diop, Ousmane M. Wassilak, Steven G. F. Cochi, Stephen L. Thompson, Kimberly M. TI Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs) SO RISK ANALYSIS LA English DT Review DE Dynamic modeling; outbreak risks; poliovirus ID SABIN TYPE-1 POLIOVIRUS; PARALYTIC POLIOMYELITIS; IMMUNODEFICIENT PATIENT; UNITED-STATES; ATTENUATION PHENOTYPE; NONCODING REGION; WILD POLIOVIRUS; GENETIC-BASIS; TEMPERATURE SENSITIVITY; 5'-UNTRANSLATED REGION AB The live, attenuated oral poliovirus vaccine (OPV) provides a powerful tool for controlling and stopping the transmission of wild polioviruses (WPVs), although the risks of vaccine-associated paralytic polio (VAPP) and circulating vaccine-derived poliovirus (cVDPV) outbreaks exist as long as OPV remains in use. Understanding the dynamics of cVDPV emergence and outbreaks as a function of population immunity and other risk factors may help to improve risk management and the development of strategies to respond to possible outbreaks. We performed a comprehensive review of the literature related to the process of OPV evolution and information available from actual experiences with cVDPV outbreaks. Only a relatively small fraction of poliovirus infections cause symptoms, which makes direct observation of the trajectory of OPV evolution within a population impractical and leads to significant uncertainty. Despite a large global surveillance system, the existing genetic sequence data largely provide information about transmitted virulent polioviruses that caused acute flaccid paralysis, and essentially no data track the changes that occur in OPV sequences as the viruses transmit largely asymptomatically through real populations with suboptimal immunity. We updated estimates of cVDPV risks based on actual experiences and identified the many limitations in the existing data on poliovirus transmission and immunity and OPV virus evolution that complicate modeling. Modelers should explore the space of potential model formulations and inputs consistent with the available evidence and future studies should seek to improve our understanding of the OPV virus evolution process to provide better information for policymakers working to manage cVDPV risks. C1 [Tebbens, Radboud J. Duintjer; Kim, Jong-Hoon; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.; Burns, Cara C.; Kew, Olen M.; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Diop, Ousmane M.] WHO, Global Polio Eradicat Initiat, CH-1211 Geneva, Switzerland. [Wassilak, Steven G. F.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Thompson, Kimberly M.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU World Health Organization (WHO) Polio Research Committee [APW200179134]; U.S. Centers for Disease Control and Prevention (CDC) [U66IP000519-01] FX The authors thank the World Health Organization (WHO) Polio Research Committee for Grant APW200179134 that supported the review and synthesis of the evidence related to OPV evolution. We thank the U.S. Centers for Disease Control and Prevention (CDC) for supporting the updated assessment of cVPDV risks under Cooperative Agreement U66IP000519-01. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the WHO or CDC. The authors thank Drs. Qi Chen, Jagadish Desphande, Jane Iber, Jing Shaw, Roland Sutter, Gregory Wallace, Wenbo Xu, and Shuangli Zhu for helpful input and the Global Polio Laboratory Network for information. NR 144 TC 18 Z9 18 U1 2 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 J9 RISK ANAL JI Risk Anal. PD APR PY 2013 VL 33 IS 4 BP 680 EP 702 DI 10.1111/risa.12022 PG 23 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 122DG UT WOS:000317295900007 ER PT J AU Tebbens, RJD Pallansch, MA Kalkowska, DA Wassilak, SGF Cochi, SL Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Kalkowska, Dominika A. Wassilak, Steven G. F. Cochi, Stephen L. Thompson, Kimberly M. TI Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine-Related Polioviruses SO RISK ANALYSIS LA English DT Review DE Polio eradication; dynamic modeling; disease outbreaks ID UNITED-STATES; PARALYTIC POLIOMYELITIS; INFECTIOUS-DISEASES; SENSITIVITY ANALYSES; GLOBAL ERADICATION; ECONOMIC-ANALYSIS; MASS VACCINATION; CONTACT PATTERNS; POLICY OPTIONS; OUTBREAK AB With national and global health policymakers facing numerous complex decisions related to achieving and maintaining polio eradication, we expanded our previously developed dynamic poliovirus transmission model using information from an expert literature review process and including additional immunity states and the evolution of oral poliovirus vaccine (OPV). The model explicitly considers serotype differences and distinguishes fecal-oral and oropharyngeal transmission. We evaluated the model by simulating diverse historical experiences with polioviruses, including one country that eliminated wild poliovirus using both OPV and inactivated poliovirus vaccine (IPV) (USA), three importation outbreaks of wild poliovirus (Albania, the Netherlands, Tajikistan), one situation in which no circulating vaccine-derived polioviruses (cVDPVs) emerge despite annual OPV use and cessation (Cuba), three cVDPV outbreaks (Haiti, Madura Island in Indonesia, northern Nigeria), one area of current endemic circulation of all three serotypes (northern Nigeria), and one area with recent endemic circulation and subsequent elimination of multiple serotypes (northern India). We find that when sufficient information about the conditions exists, the model can reproduce the general behavior of poliovirus transmission and outbreaks while maintaining consistency in the generic model inputs. The assumption of spatially homogeneous mixing remains a significant limitation that affects the performance of the differential equation-based model when significant heterogeneities in immunity and mixing may exist. Further studies on OPV virus evolution and improved understanding of the mechanisms of mixing and transmission may help to better characterize poliovirus transmission in populations. Broad application of the model promises to offer insights in the context of global and national policy and economic models. C1 [Tebbens, Radboud J. Duintjer; Kalkowska, Dominika A.; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Kalkowska, Dominika A.] Delft Univ Technol, Delft Inst Appl Math, NL-2628 CD Delft, Netherlands. [Wassilak, Steven G. F.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Thompson, Kimberly M.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU U.S. Centers for Disease Control and Prevention (CDC) [U66IP000519-01] FX The authors thank the U.S. Centers for Disease Control and Prevention (CDC) for supporting the development of an expanded poliovirus transmission model under Cooperative Agreement U66IP000519-01. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The authors thank Drs. Gregory Armstrong, Concepcion Estivariz, Johannes Everts, Marta Gacic-Dobo, Alex Gasasira, Olen Kew, Benjamin Lopman, Patrick O'Connor, Becky Prevots, Roland Sutter, Rudi Tangermann, Iris Tetford, Gregory Wallace, Chris Wolff, and the Global Polio Laboratory Network for information. NR 128 TC 23 Z9 23 U1 5 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 EI 1539-6924 J9 RISK ANAL JI Risk Anal. PD APR PY 2013 VL 33 IS 4 BP 703 EP 749 DI 10.1111/risa.12044 PG 47 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 122DG UT WOS:000317295900008 ER PT J AU Landi, D Beckman, MG Shah, NR Bockenstedt, P Grant, AM Heit, JA Key, NS Kulkarni, R Manco-Johnson, M Moll, S Philipp, CS Andersen, JC Ortel, TL AF Landi, Daniel Beckman, Michele G. Shah, Nirmish R. Bockenstedt, Paula Grant, Althea M. Heit, John A. Key, Nigel S. Kulkarni, Roshni Manco-Johnson, Marilyn Moll, Stephan Philipp, Claire S. Andersen, Judith C. Ortel, Thomas L. TI Characteristics of abdominal vein thrombosis in children and adults SO THROMBOSIS AND HAEMOSTASIS LA English DT Article DE Venous thromboembolism; deep venous thrombosis; paediatrics; abdominal vein thrombosis ID PROTHROMBOTIC RISK-FACTORS; VENOUS THROMBOEMBOLISM; REGISTRY; COMPLICATIONS; THROMBOPHILIA; CHILDHOOD AB The demographic and clinical characteristics of adults and children with lower extremity deep-vein thrombosis and/or pulmonary embolism (LE DVT/PE) may differ from those with abdominal vein thrombosis (abdominal VT). Abdominal VT can be a presenting sign of an underlying prothrombotic state, and its presence in the setting of known disease might have prognostic implications different from LE DVT/PE. This study describes clinical presentations of abdominal VT compared to LE DVT/PE in adults and children. We analysed prospectively-collected data from consecutive consenting patients enrolled in one of seven Centers for Disease Control and Prevention (CDC) funded Thrombosis and Hemostasis Network Centers from August 2003 to April 2011 to compare the demographic and clinical characteristics of adults and children with abdominal VT. Both adults and children with abdominal VT tended to be younger and have a lower body mass index (BMI) than those with LE DVT/PE. Of patients with abdominal VT, children were more likely to have inferior vena cava (IVC) thrombosis than adults. For adults with venous thromboembolism (VTE), relatively more women had abdominal VT than LE DVT/PE, while the proportions with LE DVT/PE and abdominal VT by sex were similar in children. Children with abdominal VT were more likely to have diagnosed inherited thrombophilia, while trauma was more common in children with LE DVT/PE. In conclusion, both children and adults with abdominal VT were younger with a lower BMI than those with LE DVT/PE. Significant differences exist between children and adults in respect to abdominal VT compared to LE DVT/PE. C1 [Landi, Daniel; Shah, Nirmish R.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA. [Beckman, Michele G.; Grant, Althea M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Shah, Nirmish R.; Ortel, Thomas L.] Duke Univ, Med Ctr, Div Hematol, Durham, NC USA. [Bockenstedt, Paula] Univ Michigan, Ann Arbor, MI 48109 USA. [Heit, John A.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA. [Kulkarni, Roshni] Michigan State Univ, E Lansing, MI 48824 USA. [Manco-Johnson, Marilyn] Univ Colorado, Aurora, CO USA. [Manco-Johnson, Marilyn] Childrens Hosp, Aurora, CO USA. [Moll, Stephan] Univ N Carolina, Chapel Hill, NC USA. [Philipp, Claire S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Andersen, Judith C.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. RP Ortel, TL (reprint author), Duke Thrombosis & Hemostasis Ctr, Box 3422 DUMC, Durham, NC 27710 USA. EM thomas.ortel@duke.edu FU Centers for Disease Control and Prevention [DD000014, DD000015, DD000016, DD000017, DD07-004, DD07-005]; National Institutes of Health [K12 HL 087097] FX This work was supported by grants from the Centers for Disease Control and Prevention (DD000014 to T.L.O, DD000015 to P.B., R.K., and J.C.A;, DD000016 to M.M.J.; DD000017 to C.S.P.; DD07-004 to T.L.O, C.S.P., and M.M.J.; and DD07-005 to J.A.H and S.M.) and the National Institutes of Health (K12 HL 087097 to N.R.S). NR 22 TC 2 Z9 2 U1 0 U2 1 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 0340-6245 J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD APR PY 2013 VL 109 IS 4 BP 625 EP 632 DI 10.1160/TH12-08-0568 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 125RD UT WOS:000317558100010 PM 23407670 ER PT J AU Iwane, MK Chaves, SS Szilagyi, PG Edwards, KM Hall, CB Staat, MA Brown, CJ Griffin, MR Weinberg, GA Poehling, KA Prill, MM Williams, JV Bridges, CB AF Iwane, Marika K. Chaves, Sandra S. Szilagyi, Peter G. Edwards, Kathryn M. Hall, Caroline B. Staat, Mary A. Brown, Cedric J. Griffin, Marie R. Weinberg, Geoffrey A. Poehling, Katherine A. Prill, Mila M. Williams, John V. Bridges, Carolyn B. TI Disparities Between Black and White Children in Hospitalizations Associated With Acute Respiratory Illness and Laboratory-confirmed Influenza and Respiratory Syncytial Virus in 3 US Counties-2002-2009 SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE child; continental population groups; hospitalization; influenza; respiratory syncytial virus; respiratory tract infections ID UNITED-STATES; ETHNIC DISPARITIES; CHILDHOOD ASTHMA; YOUNG-CHILDREN; HEALTH-CARE; INFECTIONS; QUALITY; INFANTS; BURDEN; ALASKA AB Few US studies have assessed racial disparities in viral respiratory hospitalizations among children. This study enrolled black and white children under 5 years of age who were hospitalized for acute respiratory illness (ARI) in 3 US counties during October May 2002-2009. Population-based rates of hospitalization were calculated by race for ARI and laboratory-confirmed influenza and respiratory syncytial virus (RSV), using US Census denominators. Relative rates of hospitalization between racial groups were estimated. Of 1,415 hospitalized black children and 1,824 hospitalized white children with ARI enrolled in the study, 108 (8%) black children and 111(6%) white children had influenza and 230 (19%) black children and 441 (29%) white children had RSV. Hospitalization rates were higher among black children than among white children for ARI (relative rate (RR) = 1.7, 95% confidence interval (CI): 1.6, 1.8) and influenza (RR = 2.1, 95% Cl: 1.6, 2.9). For RSV, rates were similar among black and white children under age 12 months but higher for black children aged 12 months or more (for ages 12-23 months, RR = 1.7, 95% Cl: 1.1, 2.5; for ages 24-59 months, RR = 2.2, 95% Cl: 1.3, 3.6). Black children versus white children were significantly more likely to have public insurance or no insurance (85% vs. 43%) and a history of asthma/wheezing (28% vs. 18%) but not more severe illness. The observed racial disparities require further study. C1 [Iwane, Marika K.; Brown, Cedric J.; Prill, Mila M.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Chaves, Sandra S.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Szilagyi, Peter G.; Hall, Caroline B.; Weinberg, Geoffrey A.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. [Edwards, Kathryn M.; Williams, John V.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Staat, Mary A.] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA. [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN USA. [Poehling, Katherine A.] Wake Forest Sch Med, Dept Pediat, Winston Salem, NC USA. [Poehling, Katherine A.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Bridges, Carolyn B.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Iwane, MK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30333 USA. EM miwane@cdc.gov RI Williams, John/F-6962-2010 OI Williams, John/0000-0001-8377-5175 FU Centers for Disease Control and Prevention [U38/CCU217969, U01/IP000017, U38/CCU417958, U01/IP000022, U38/CCU522352, U01/IP000147]; Novartis (Basel, Switzerland); MedImmune (Gaithersburg, Maryland); MedImmune FX This work was supported by the Centers for Disease Control and Prevention (cooperative agreements U38/CCU217969, U01/IP000017, U38/CCU417958, U01/IP000022, U38/CCU522352, and U01/IP000147).; Dr. Edwards received grant funding from Novartis (Basel, Switzerland) for an unrelated vaccine and previously was a consultant to NexBio (San Diego, California). Dr. Griffin received grant funding from MedImmune (Gaithersburg, Maryland). Dr. Hall has served on the MedImmune Advisory Board and has been a consultant for MedImmune and GlaxoSmithKline (London, United Kingdom). Dr. Williams served on the Scientific Advisory Board of Quidel (San Diego, California). Dr. Staat received funding from MedImmune for RSV studies and has served on the MedImmune Advisory Board. NR 22 TC 13 Z9 14 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 1 PY 2013 VL 177 IS 7 BP 656 EP 665 DI 10.1093/aje/kws299 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 120CH UT WOS:000317147700009 PM 23436899 ER PT J AU Banerjee, T Crews, D Wesson, D Hedgeman, E Saran, R Burrows, N Williams, D Powe, N AF Banerjee, Tanushree Crews, Deidra Wesson, Donald Hedgeman, Elizabeth Saran, Rajiv Burrows, Nilka Williams, Desmond Powe, Neil TI HIGH DIETARY ACID LOAD AND PROGRESSION TO ESRD AMONG CHRONIC KIDNEY DISEASE (CKD) PATIENTS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT International Conference on Glomerular Diseases CY APR 27, 2012 CL Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens, Great Neck, NY SP N Shore LIJ Hlth Syst, Natl Kidney Fdn HO Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens C1 [Banerjee, Tanushree; Powe, Neil] UCSF, San Francisco, CA USA. [Wesson, Donald] Texas A&M Coll Med, College Stn, TX USA. [Burrows, Nilka; Williams, Desmond] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2013 VL 61 IS 4 MA 31 BP A23 EP A23 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 121WG UT WOS:000317274900033 ER PT J AU Rein-Weston, A Banerjee, T Plantinga, L Hedgeman, E Saran, R Powe, N Burrows, NR Williams, D AF Rein-Weston, Annie Banerjee, Tanushree Plantinga, Laura Hedgeman, Elizabeth Saran, Rajiv Powe, Neil Burrows, Nilka Rios Williams, Desmond CA CDC CKD Surveillance Team TI DEVELOPMENT OF A CHRONIC KIDNEY DISEASE (CKD) SURVEILLANCE SYSTEM FOR THE UNITED STATES: A CENTERS FOR DISEASE CONTROL AND PREVENTION INITIATIVE SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT International Conference on Glomerular Diseases CY APR 27, 2012 CL Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens, Great Neck, NY SP N Shore LIJ Hlth Syst, Natl Kidney Fdn HO Hofstra N Shore LIJ Sch Med, Div Kidney Dis & Hypertens C1 [Rein-Weston, Annie; Banerjee, Tanushree; Powe, Neil] UCSF, San Francisco, CA USA. [Plantinga, Laura] Emory Univ, Atlanta, GA 30322 USA. [Hedgeman, Elizabeth; Saran, Rajiv] UM, Ann Arbor, MI USA. [Burrows, Nilka Rios; Williams, Desmond] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2013 VL 61 IS 4 MA 268 BP A82 EP A82 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 121WG UT WOS:000317274900270 ER PT J AU Zhu, JL Hasle, H Correa, A Schendel, D Friedman, JM Olsen, J Rasmussen, SA AF Zhu, Jin Liang Hasle, Henrik Correa, Adolfo Schendel, Diana Friedman, J. M. Olsen, Jorn Rasmussen, Sonja A. TI Hospitalizations among people with Down syndrome: A nationwide population-based study in Denmark SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE Down syndrome; hospitalization; register; comorbidity; congenital heart defects ID ONE-YEAR PERIOD; HEALTH-SERVICES; CHILDREN; ADULTS; CARE; PREVALENCE; DEFECTS; INFANTS; DISEASE; COMPLICATIONS AB Most persons with Down syndrome (DS) now survive to adulthood, but their health care needs beyond childhood are not well described. We followed a national cohort of 3,212 persons with DS and a reference cohort of persons without DS through the Danish National Hospital Register from January 1, 1977, to May 31, 2008. Poisson regression was used to calculate rate ratios for numbers of overnight hospital admissions and hospital days. During the study period, persons with DS had more than twice the rate of hospital admissions and nearly three times as many bed-days as the population as a whole. Malformations, diseases of the respiratory system, and diseases of the nervous system or sensory organs were the principal indications for hospital admissions. The higher rate ratios for hospital admissions were seen especially among persons less than 20 years of age. Hospitalizations for neoplasms or for diseases of the musculoskeletal system or connective tissue were much less frequent among adults with DS. As survival among persons with DS continues to improve, these findings are likely to be useful for health care planning, although the potential utility may be different for different health care systems. (c) 2013 Wiley Periodicals, Inc. C1 [Zhu, Jin Liang; Olsen, Jorn] Univ Aarhus, Epidemiol Sect, Dept Publ Hlth, DK-8000 Aarhus C, Denmark. [Hasle, Henrik] Aarhus Univ Hosp, Dept Pediat, DK-8000 Aarhus, Denmark. [Correa, Adolfo; Schendel, Diana; Rasmussen, Sonja A.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Friedman, J. M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. RP Zhu, JL (reprint author), Univ Aarhus, Epidemiol Sect, Dept Publ Hlth, Bartholins Alle 2, DK-8000 Aarhus C, Denmark. EM zjl@soci.au.dk RI Olsen, Jorn/F-8801-2015; OI Olsen, Jorn/0000-0001-7462-5140; Friedman, Jan/0000-0002-7482-9570; Hasle, Henrik/0000-0003-3976-9231 FU U.S. Centers for Disease Control and Prevention (CDC) [5 U10 DD000230-06] FX We thank Claus Svaerke from University of Aarhus and Jan Hansen from the Danish Cytogenetic Registry for data arrangement. The study was supported by a cooperative agreement from the U.S. Centers for Disease Control and Prevention (CDC) (# 5 U10 DD000230-06). NR 38 TC 10 Z9 11 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD APR PY 2013 VL 161A IS 4 BP 650 EP 657 DI 10.1002/ajmg.a.35711 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 112YM UT WOS:000316631300004 PM 23404922 ER PT J AU Morof, D Cookson, ST Laver, S Chirundu, D Desai, S Mathenge, P Shambare, D Charimari, L Midzi, S Blanton, C Handzel, T AF Morof, Diane Cookson, Susan T. Laver, Susan Chirundu, Daniel Desai, Sarika Mathenge, Penninah Shambare, Donald Charimari, Lincoln Midzi, Stanley Blanton, Curtis Handzel, Thomas TI Community Mortality from Cholera: Urban and Rural Districts in Zimbabwe SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ORAL REHYDRATION THERAPY; EPIDEMIC CHOLERA; OUTBREAK AB In 2008-2009, Zimbabwe experienced an unprecedented cholera outbreak with more than 4,000 deaths. More than 60% of deaths occurred at the community level. We conducted descriptive and case control studies to describe community deaths. Cases were in cholera patients who died outside health facilities. Two surviving cholera patients were matched by age, time of symptom onset, and location to each case-patient. Proxies completed questionnaires regarding mortality risk factors. Cholera awareness and importance of rehydration was high but availability of oral rehydration salts was low. A total of 55 case-patients were matched to 110 controls. The odds of death were higher among males (adjusted odd ratio [AOR] = 5.00, 95% confidence interval [CI] = 1.54-14.30) and persons with larger household sizes (AOR = 1.21, 95% CI = 1.00-1.46). Receiving home-based rehydration (AOR = 0.21, 95% CI = 0.06-0.71) and visiting cholera treatment centers (CTCs) (AOR = 0.07, 95% CI = 0.02-0.23) were protective. Receiving cholera information was associated with home-based rehydration and visiting CTCs. When we compared cases and controls who did not go to CTCs, males were still at increased odds of death (AOR = 5.00, 95% CI = 1.56-16.10) and receiving home-based rehydration (AOR = 0.14, 95% CI = 0.04-0.53) and being married (AOR = 0.26, 95% CI = 0.08-0.83) were protective. Inability to receive home-based rehydration or visit CTCs was associated with mortality. Community education must reinforce the importance of prompt rehydration and CTC referral. C1 [Morof, Diane; Cookson, Susan T.; Blanton, Curtis] Ctr Dis Control & Prevent, Int Emergency Refugee Hlth Branch, Atlanta, GA 30341 USA. [Laver, Susan; Mathenge, Penninah] United Nations Int Childrens Fund, Head Collaborating Ctr Operat Res & Evaluat, Harare, Zimbabwe. [Chirundu, Daniel] Kadoma City Hlth Dept, Kadoma, Midlands Provin, Zimbabwe. [Desai, Sarika] Hlth Protect Agcy, Hlth Protect Serv Colindale, HIV & STI Dept, London, England. [Shambare, Donald; Charimari, Lincoln] World Hlth Org Country Off, Harare, Zimbabwe. RP Morof, D (reprint author), Ctr Dis Control & Prevent, Int Emergency Refugee Hlth Branch, 4770 Buford Highway NE,Mailstop F-57, Atlanta, GA 30341 USA. EM dmorof@cdc.gov; sgc0@cdc.gov; slaver@unicef.org; dchirundu@healthnet.org.zw; sarika.desai@hpa.org.uk; pmathenge@unicef.org; shambared@zw.afro.who.int; charimaril@zw.afro.who.int; midzis@zw.afro.who.int; cblanton@cdc.gov; tnh7@cdc.gov OI Chirundu, Daniel/0000-0001-5278-065X FU Ministry of Health and Child Welfare; United Nations International Children's Fund; World Health Organization; GAA-Medical Emergency Relief International; European Commission Humanitarian Aid Office; Great Minds; Centers for Disease Control and Prevention FX We thank the families and patients who participated in this study for their assistance; the Ministry of Health and Child Welfare; national, provincial, and district leaders; environmental health technicians; village health workers; United Nations International Children's Fund; World Health Organization; GAA-Medical Emergency Relief International; the European Commission Humanitarian Aid Office; Great Minds; and surveyors for support.; This study was supported by the Centers for Disease Control and Prevention. NR 29 TC 5 Z9 5 U1 3 U2 11 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2013 VL 88 IS 4 BP 645 EP 650 DI 10.4269/ajtmh.11-0696 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 118KP UT WOS:000317024700008 PM 23400576 ER PT J AU Benacer, D Zain, SNM Amran, F Galloway, RL Thong, KL AF Benacer, Douadi Zain, Siti Nursheena Mohd Amran, Fairuz Galloway, Renee L. Thong, Kwai Lin TI Isolation and Molecular Characterization of Leptospira interrogans and Leptospira borgpetersenii Isolates from the Urban Rat Populations of Kuala Lumpur, Malaysia SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID FIELD GEL-ELECTROPHORESIS; POLYMERASE-CHAIN-REACTION; BACTERIOLOGICAL CULTURE; PATHOGENIC LEPTOSPIRES; PCR; DIAGNOSIS; SEROVAR; SAMPLES; URINE; SPP. AB Rats are considered the principal maintenance hosts of Leptospira. The objectives of this study were isolation and identification of Leptospira serovars circulating among urban rat populations in Kuala Lumpur. Three hundred urban rats (73% Rattus rattus and 27% R. norvegicus) from three different sites were trapped. Twenty cultures were positive for Leptospira using dark-field microscopy. R. rattus was the dominant carrier (70%). Polymerase chain reaction (PCR) confirmed that all isolates were pathogenic Leptospira species. Two Leptospira serogroups, Javanica and Bataviae, were identified using microscopic agglutination test (MAT). Pulsed-field gel electrophoresis (PFGE) identified two serovars in the urban rat populations: L. borgpetersenii serovar Javanica (85%) and L. interrogans serovar Bataviae (15%). We conclude that these two serovars are the major serovars circulating among the urban rat populations in Kuala Lumpur. Despite the low infection rate reported, the high pathogenicity of these serovars raises concern of public health risks caused by rodent transmission of leptospirosis. C1 [Benacer, Douadi; Zain, Siti Nursheena Mohd; Thong, Kwai Lin] Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur 50603, Malaysia. [Benacer, Douadi; Thong, Kwai Lin] Univ Malaya, Inst Grad Studies, Lab Biomed Sci & Mol Microbiol, Kuala Lumpur 50603, Malaysia. [Amran, Fairuz] Minist Hlth, Inst Med Res, Bacteriol Unit, Kuala Lumpur, Malaysia. [Galloway, Renee L.] Ctr Dis Control & Prevent, Bacterial Zoonoses Special Pathogens Branch, Atlanta, GA USA. RP Thong, KL (reprint author), Univ Malaya, Fac Sci, Inst Biol Sci, Kuala Lumpur 50603, Malaysia. EM benacer_dvt@hotmail.com; nsheena@um.edu.my; fairuz@imr.gov.my; zul0@cdc.gov; thongkl@um.edu.my RI Thong, Kwai Lin/B-3946-2009; MOHD ZAIN, SITI NURSHEENA/B-9804-2010; OI MOHD ZAIN, SITI NURSHEENA/0000-0001-6716-1712; Thong, Kwai Lin/0000-0001-8557-5185 FU University of Malaya [RG053/11BIO] FX This work was supported by University of Malaya Research Grant RG053/11BIO. NR 44 TC 18 Z9 18 U1 0 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2013 VL 88 IS 4 BP 704 EP 709 DI 10.4269/ajtmh.12-0662 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 118KP UT WOS:000317024700017 PM 23358635 ER PT J AU Collins, W AF Collins, William TI Short Report: Origin of the St. Elizabeth Strain of Plasmodium vivax SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RETROSPECTIVE EXAMINATION; HUMANS AB The St. Elizabeth strain of Plasmodium vivax originated in the South Carolina State Hospital instead of the St. Elizabeth Hospital in Washington, DC. C1 [Collins, William] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Collins, W (reprint author), 1600 Clifton Rd NE,Mailstop D-67, Atlanta, GA 30333 USA. EM wecl@cdc.gov NR 4 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2013 VL 88 IS 4 BP 726 EP 726 DI 10.4269/ajtmh.12-0351 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 118KP UT WOS:000317024700020 PM 23358641 ER PT J AU Kakuru, A Jagannathan, P Arinaitwe, E Wanzira, H Muhindo, M Bigira, V Osilo, E Homsy, J Kamya, MR Tappero, JW Dorsey, G AF Kakuru, Abel Jagannathan, Prasanna Arinaitwe, Emmanuel Wanzira, Humphrey Muhindo, Mary Bigira, Victor Osilo, Emmanuel Homsy, Jaco Kamya, Moses R. Tappero, Jordan W. Dorsey, Grant TI The Effects of ACT Treatment and TS Prophylaxis on Plasmodium falciparum Gametocytemia in a Cohort of Young Ugandan Children SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PLUS SULFADOXINE-PYRIMETHAMINE; TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; TREATING UNCOMPLICATED MALARIA; RANDOMIZED CLINICAL-TRIAL; NON-INFERIORITY TRIAL; ARTEMETHER-LUMEFANTRINE; DIHYDROARTEMISININ-PIPERAQUINE; BURKINA-FASO; COTRIMOXAZOLE PROPHYLAXIS; COMBINATION THERAPY AB Artemisinin-based combination therapies (ACTs) and trimethoprim-sulfamethoxazole (TS) prophylaxis are important tools for malaria control, but there are concerns about their effect on gametocytes, the stage of the parasite responsible for transmission. We conducted a longitudinal clinical trial in a cohort of HIV-infected and uninfected children living in an area of high malaria transmission intensity in Uganda. Study participants were randomized to artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) for all treatments of uncomplicated malaria (N = 4,380) as well as TS prophylaxis for different durations. The risks of gametocytemia detected by microscopy in the 28 days after antimalarial therapy were compared using multivariate analyses. The risk of gametocyte detection was significantly higher in patients treated with DP compared with AL (adjusted relative risk = 1.85, P < 0.001) and among children prescribed TS prophylaxis (adjusted relative risk = 1.76, P < 0.001). The risk of gametocytemia and its potential for increasing transmission should be considered when evaluating different ACTs and TS prophylaxis for malaria control. C1 [Kakuru, Abel; Arinaitwe, Emmanuel; Wanzira, Humphrey; Muhindo, Mary; Bigira, Victor; Osilo, Emmanuel] Infect Dis Res Collaborat, Kampala 256, Uganda. [Jagannathan, Prasanna; Dorsey, Grant] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA. [Homsy, Jaco] Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94143 USA. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. RP Kakuru, A (reprint author), Infect Dis Res Collaborat, POB 749, Kampala 256, Uganda. EM abelkakuru@gmail.com; jagannathanp@medsfgh.ucsf.edu; emmy3md@yahoo.com; wanzirah@yahoo.com; marymkakuru@gmail.com; vbigira@gmail.com; goodbeads@yahoo.co.uk; jhomsy@psg.ucsf.edu; mkamya@infocom.co.ug; jwt0@cdc.gov; gdorsey@medsfgh.ucsf.edu FU US President's Emergency Plan for AIDS Relief from Centers for Disease Control and Prevention (CDC) [U62P024421]; National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); Global AIDS Program (GAP); National Institutes of Health [2 T32 AI 60530-6]; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship; Doris Duke Charitable Foundation FX Participants in this study were enrolled in programs supported by the US President's Emergency Plan for AIDS Relief and Cooperative Agreement No. U62P024421 from the Centers for Disease Control and Prevention (CDC); National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); and Global AIDS Program (GAP). P.J. is supported by National Institutes of Health T32 Training Grant 2 T32 AI 60530-6 and a Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship. Funding was also provided by the Doris Duke Charitable Foundation (G.D. is a recipient of the Clinical Scientist Development Award). NR 39 TC 7 Z9 7 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2013 VL 88 IS 4 BP 736 EP 743 DI 10.4269/ajtmh.12-0654 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 118KP UT WOS:000317024700023 PM 23382157 ER PT J AU Foote, EM Sullivan, KM Ruth, LJ Oremo, J Sadumah, I Williams, TN Suchdev, PS AF Foote, Eric M. Sullivan, Kevin M. Ruth, Laird J. Oremo, Jared Sadumah, Ibrahim Williams, Thomas N. Suchdev, Parminder S. TI Determinants of Anemia among Preschool Children in Rural, Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RETINOL-BINDING-PROTEIN; IRON-DEFICIENCY ANEMIA; PLASMODIUM-FALCIPARUM MALARIA; SICKLE-CELL-DISEASE; HELMINTH INFECTIONS; MALAWIAN CHILDREN; PLASMA RETINOL; INFLAMMATION; HEALTH; HEMOGLOBINOPATHIES AB Although anemia in preschool children is most often attributed to iron deficiency, other nutritional, infectious, and genetic contributors are rarely concurrently measured. In a population-based, cross-sectional survey of 858 children 6-35 months of age in western Kenya, we measured hemoglobin, malaria, inflammation, sickle cell, alpha-thalassemia, iron deficiency, vitamin A deficiency, anthropometry, and socio-demographic characteristics. Anemia (Hb < 11 g/dL) and severe anemia (Hb < 7 g/dL) prevalence ratios (PRs) for each exposure were determined using multivariable modeling. Anemia (71.8%) and severe anemia (8.4%) were common. Characteristics most strongly associated with anemia were malaria (PR: 1.7; 95% confidence interval [CI] = 1.5-1.9), iron deficiency (1.3; 1.2-1.4), and homozygous a-thalassemia (1.3; 1.1-1.4). Characteristics associated with severe anemia were malaria (10.2; 3.5-29.3), inflammation (6.7; 2.3-19.4), and stunting (1.6; 1.0-2.4). Overall 16.8% of anemia cases were associated with malaria, 8.3% with iron deficiency, and 6.1% with inflammation. Interventions should address malaria, iron deficiency, and non-malarial infections to decrease the burden of anemia in this population. C1 Emory Univ, Sch Med, Atlanta, GA USA. [Sullivan, Kevin M.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Ruth, Laird J.; Suchdev, Parminder S.] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA 30341 USA. [Oremo, Jared; Sadumah, Ibrahim] Safe Water & AIDS Project, Kisumu, Kenya. [Williams, Thomas N.] Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya. Nuffield Dept Clin Med, Oxford, England. [Foote, Eric M.] Univ Washington, Sch Med, Seattle, WA USA. RP Suchdev, PS (reprint author), Ctr Dis Control & Prevent, Nutr Branch, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM efoote@uw.edu; cdckms@sph.emory.edu; lruth@cdc.gov; jerryoresh@yahoo.com; sirahimah@yahoo.com; twilliams@kilifi.kemri-wellcome.org; psuchdev@cdc.gov OI Suchdev, Parmi/0000-0002-0350-3469 FU National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000454, TL1TR000456]; Emory University School of Medicine; Centers for Disease Control and Prevention; Wellcome Trust, UK [091758] FX This work is supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000454 and TL1TR000456, Emory University School of Medicine, the Centers for Disease Control and Prevention, and a senior fellowship from the Wellcome Trust, UK (091758). NR 47 TC 20 Z9 22 U1 0 U2 12 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2013 VL 88 IS 4 BP 757 EP 764 DI 10.4269/ajtmh.12-0560 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 118KP UT WOS:000317024700026 PM 23382166 ER PT J AU Sobelson, RK Young, AC AF Sobelson, Robyn K. Young, Andrea C. TI Evaluation of a federally funded workforce development program: The Centers for Public Health Preparedness SO EVALUATION AND PROGRAM PLANNING LA English DT Article DE Program evaluation; Training; Education; Public health; Preparedness and response AB The Centers for Public Health Preparedness (CPHP) program was a five-year cooperative agreement funded by the Centers for Disease Control and Prevention (CDC). The program was initiated in 2004 to strengthen terrorism and emergency preparedness by linking academic expertise to state and local health agency needs. The purposes of the evaluation study were to identify the results achieved by the Centers and inform program planning for future programs. The evaluation was summative and retrospective in its design and focused on the aggregate outcomes of the CPHP program. The evaluation results indicated progress was achieved on program goals related to development of new training products, training members of the public health workforce, and expansion of partnerships between accredited schools of public health and state and local public health departments. Evaluation results, as well as methodological insights gleaned during the planning and conduct of the CPHP evaluation, were used to inform the design of the next iteration of the CPHP Program, the Preparedness and Emergency Response Learning Centers (PERLC). Published by Elsevier Ltd. C1 [Sobelson, Robyn K.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30329 USA. [Young, Andrea C.] Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Atlanta, GA 30345 USA. RP Sobelson, RK (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, 1600 Clifton Rd NE,Mailstop D-44, Atlanta, GA 30329 USA. EM rsobelson@cdc.gov NR 14 TC 3 Z9 3 U1 0 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7189 J9 EVAL PROGRAM PLANN JI Eval. Program Plan. PD APR PY 2013 VL 37 BP 50 EP 57 DI 10.1016/j.evalprogPlan.2013.01.001 PG 8 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA 121RJ UT WOS:000317261600006 PM 23380597 ER PT J AU Hanafiah, KM Groeger, J Flaxman, AD Wiersma, ST AF Hanafiah, Khayriyyah Mohd Groeger, Justina Flaxman, Abraham D. Wiersma, Steven T. TI Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence SO HEPATOLOGY LA English DT Review ID UNITED-STATES; PREVALENCE; CIRRHOSIS; AREA; RECOMMENDATIONS; TRANSMISSION; PROGRESSION; PREVENTION; DONATION; PAYMENT AB In efforts to inform public health decision makers, the Global Burden of Diseases, Injuries, and Risk Factors 2010 (GBD2010) Study aims to estimate the burden of disease using available parameters. This study was conducted to collect and analyze available prevalence data to be used for estimating the hepatitis C virus (HCV) burden of disease. In this systematic review, antibody to HCV (anti-HCV) seroprevalence data from 232 articles were pooled to estimate age-specific seroprevalence curves in 1990 and 2005, and to produce age-standardized prevalence estimates for each of 21 GBD regions using a model-based meta-analysis. This review finds that globally the prevalence and number of people with anti-HCV has increased from 2.3% (95% uncertainty interval [UI]: 2.1%-2.5%) to 2.8% (95% UI: 2.6%-3.1%) and >122 million to >185 million between 1990 and 2005. Central and East Asia and North Africa/Middle East are estimated to have high prevalence (>3.5%); South and Southeast Asia, sub-Saharan Africa, Andean, Central, and Southern Latin America, Caribbean, Oceania, Australasia, and Central, Eastern, and Western Europe have moderate prevalence (1.5%-3.5%); whereas Asia Pacific, Tropical Latin America, and North America have low prevalence (<1.5%). Conclusion: The high prevalence of global HCV infection necessitates renewed efforts in primary prevention, including vaccine development, as well as new approaches to secondary and tertiary prevention to reduce the burden of chronic liver disease and to improve survival for those who already have evidence of liver disease. (HEPATOLOGY 2013) C1 [Hanafiah, Khayriyyah Mohd] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Groeger, Justina] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Flaxman, Abraham D.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Wiersma, Steven T.] WHO, Global Hepatitis Programme, CH-1211 Geneva, Switzerland. RP Wiersma, ST (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 2448 Luthuli Rd NIMR Complex,POB 9123, Dar Es Salaam, Tanzania. EM wiersmas@tz.cdc.gov OI Mohd Hanafiah, Khayriyyah/0000-0003-2976-1965 FU Global Hepatitis Prevention Cooperative FX We thank Don Ward and his team who abstracted the studies. We thank Erica Din, Craig Lammert, Gail Bang, and Melissa Creary for searching, abstracting, and organizing data. We thank Claire Preaud, Johan Lemarchand, Zaki Hanafiah, and Sandra Garnier for providing support for the prevalence graphs and mapping, and Gretchen Stevens for technical insight in the use of DisMod III. Financial support was made possible through the Global Hepatitis Prevention Cooperative. Agreement between the U.S. Centers for Disease Control and Prevention and the World Health Organization, the University of Washington's Institute for Health Metrics and Evaluation and by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U. S. Department of Energy and CDC. NR 35 TC 245 Z9 258 U1 12 U2 91 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2013 VL 57 IS 4 BP 1333 EP 1342 DI 10.1002/hep.26141 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 123BQ UT WOS:000317363600008 ER PT J AU Anderson, R Rota, P Papania, M AF Anderson, R. Rota, P. Papania, M. TI ADVANCED METHODS TO ASSESS THE POTENCY OF AEROSOLIZED LIVE ATTENUATED VIRAL VACCINES SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY LA English DT Meeting Abstract C1 [Anderson, R.; Rota, P.; Papania, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1941-2711 J9 J AEROSOL MED PULM D JI J. Aerosol Med. Pulm. Drug Deliv. PD APR PY 2013 VL 26 IS 2 BP A48 EP A48 PG 1 WC Respiratory System SC Respiratory System GA 118QI UT WOS:000317040000132 ER PT J AU Knaus, DA Friets, EM Papania, MJ Barry, JJ AF Knaus, D. A. Friets, E. M. Papania, M. J. Barry, J. J. TI THREE-DIMENSIONAL DEPOSITION IMAGING USING DUAL ENERGY COMPUTED TOMOGRAPHY SO JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY LA English DT Meeting Abstract C1 [Knaus, D. A.; Friets, E. M.; Barry, J. J.] Creare Res & Dev Inc, Hanover, NH USA. [Papania, M. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1941-2711 J9 J AEROSOL MED PULM D JI J. Aerosol Med. Pulm. Drug Deliv. PD APR PY 2013 VL 26 IS 2 BP A15 EP A15 PG 1 WC Respiratory System SC Respiratory System GA 118QI UT WOS:000317040000043 ER PT J AU Tirabassi, J Fang, J Ayala, C AF Tirabassi, Jill Fang, Jing Ayala, Carma TI Attitudes of Primary Care Providers and Recommendations of Home Blood Pressure Monitoring-DocStyles, 2010 SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID HYPERTENSION CONTROL; PREVALENCE; SOCIETY; OFFICE AB To assess primary care providers' (PCPs) opinions related to recommending home blood pressure monitoring (HBPM) for their hypertensive patients, the authors analyzed a Web-based 2010 DocStyles survey, which included PCPs' demographics, health-related behaviors, recommendations on HBPM, views of patient knowledge, and use of continuing medical education. Of the 1254 PCPs who responded, 539 were family practitioners, 461 were internists, and 254 were nurse practitioners; 32% recommended HBPM to 90% of their patients and 26% recommended it to 40% of their patients. Nurse practitioners were significantly more likely to recommend HBPM than were internists (odds ratio, 0.55; 95% confidence interval, 0.400.78). The top reasons for not recommending HBPM were patient can't afford it and patient doesn't need it. A total of 20% of PCPs indicated that their patients were poor to lower middle class; these PCPs were less likely to recommend HBPM to their patients than were those PCPs with most patients in higher economic classes. Additional efforts are needed to provide education to providers, especially physicians, about the benefits of HBPM in improved and cost-effective blood pressure control in the United States. C1 [Tirabassi, Jill; Fang, Jing; Ayala, Carma] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Fang, J (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Chamblee, GA 30341 USA. EM cvy8@cdc.gov NR 16 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD APR PY 2013 VL 15 IS 4 BP 224 EP 229 DI 10.1111/jch.12059 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 119YK UT WOS:000317135700002 PM 23551720 ER PT J AU Maenner, MJ Schieve, LA Rice, CE Cunniff, C Giarelli, E Kirby, RS Lee, LC Nicholas, JS Wingate, MS Durkin, MS AF Maenner, Matthew J. Schieve, Laura A. Rice, Catherine E. Cunniff, Christopher Giarelli, Ellen Kirby, Russell S. Lee, Li-Ching Nicholas, Joyce S. Wingate, Martha S. Durkin, Maureen S. TI Frequency and Pattern of Documented Diagnostic Features and the Age of Autism Identification SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE autism; autism spectrum disorder; identification; diagnosis; population-based ID PERVASIVE DEVELOPMENTAL DISORDER; SPECTRUM DISORDERS; REPETITIVE BEHAVIOR; GENERAL-POPULATION; 2ND YEAR; CHILDREN; SURVEILLANCE; LIFE; STABILITY; SYMPTOMS AB Objective: The DSM-IV-TR specifies 12 behavioral features that can occur in hundreds of possible combinations to meet diagnostic criteria for autism spectrum disorder (ASD). This paper describes the frequency and variability with which the 12 behavioral features are documented in a population-based cohort of 8-year-old children under surveillance for ASD, and examines whether documentation of certain features, alone or in combination with other features, is associated with earlier age of community identification of ASD. Method: Statistical analysis of behavioral features documented for a population-based sample of 2,757 children, 8 years old, with ASD in 11 geographically-defined areas in the US participating in the Autism and Developmental Disabilities Monitoring Network in 2006. Results: The median age at ASD identification was inversely associated with the number of documented behavioral features, decreasing from 8.2 years for children with only seven behavioral features to 3.8 years for children with all 12. Documented impairments in nonverbal communication, pretend play, inflexible routines, and repetitive motor behaviors were associated with earlier identification, whereas impairments in peer relations, conversational ability, and idiosyncratic speech were associated with later identification. Conclusions: The age dependence of some of the behavioral features leading to an autism diagnosis, as well as the inverse association between age at identification and number of behavioral features documented, have implications for efforts to improve early identification. Progress in achieving early identification and provision of services for children with autism may be limited for those with fewer ASD behavioral features, as well as features likely to be detected at later ages. J. Am. Acad. Child Adolesc. Psychiatry, 2013; 52(4):401-413. C1 [Maenner, Matthew J.; Durkin, Maureen S.] Univ Wisconsin Madison, Madison, WI USA. [Schieve, Laura A.; Rice, Catherine E.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Cunniff, Christopher] Univ Arizona, Coll Med, Tucson, AZ USA. [Giarelli, Ellen] Drexel Univ, Philadelphia, PA USA. [Kirby, Russell S.] Univ S Florida, Tampa, FL 33620 USA. [Lee, Li-Ching] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Nicholas, Joyce S.] Med Univ S Carolina, Charleston, SC USA. [Wingate, Martha S.] Univ Alabama Birmingham, Birmingham, AL USA. RP Maenner, MJ (reprint author), 1500 Highland Ave Rm 529A, Madison, WI 53705 USA. RI Durkin, Maureen/B-7834-2015; Rice, Catherine/D-6305-2016 FU Autism Science Foundation; CDC Cooperative Agreements [UR3/CCU523235, UR3/DD000078, UR3/DD000677]; University of Wisconsin-Madison; Waisman Center [P30 HD03352] FX This work was supported by a grant from the Autism Science Foundation and by the CDC Cooperative Agreements UR3/CCU523235, UR3/DD000078, and UR3/DD000677. Additional support has been provided by the University of Wisconsin-Madison and the Waisman Center (P30 HD03352, M R. Mailick, PI). We are grateful to the many staff, scientists, and clinicians that have contributed to the Autism and Developmental Disabilities Monitoring (ADDM) Network project. We also thank Mark Albanese, Ph.D., of the University of Wisconsin-Madison, for his advice regarding the descriptive analyses in this manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 43 TC 13 Z9 13 U1 3 U2 29 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD APR PY 2013 VL 52 IS 4 BP 401 EP 413 DI 10.1016/j.jaac.2013.01.014 PG 13 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 122LL UT WOS:000317319500009 PM 23582871 ER PT J AU Vaughan, C Fowler, R Goodman, R Graves, T Flacker, J Johnson, T AF Vaughan, C. Fowler, R. Goodman, R. Graves, T. Flacker, J. Johnson, T. TI Identifying Landmark Articles for the Practice of Geriatrics. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2013 CL Grapevine, TX SP Amer Geriatr Soc C1 [Vaughan, C.; Goodman, R.; Graves, T.; Flacker, J.; Johnson, T.] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Vaughan, C.; Johnson, T.] Birmingham Atlanta GRECC, Dept Vet Affairs, Decatur, GA USA. [Fowler, R.] Florida Atlantic Univ, Boca Raton, FL 33431 USA. [Goodman, R.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2013 VL 61 SU 1 SI SI BP S40 EP S40 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 120QW UT WOS:000317187600114 ER PT J AU Li, H Bai, JY Wang, LY Zeng, L Shi, YS Qiu, ZL Ye, HH Zhang, XF Lu, QB Kosoy, M Liu, W Cao, WC AF Li, Hao Bai, Jie-Ying Wang, Li-Yuan Zeng, Lin Shi, Yan-Sheng Qiu, Zheng-Liang Ye, Hua-Hu Zhang, Xiao-Fei Lu, Qing-Bin Kosoy, Michael Liu, Wei Cao, Wu-Chun TI Genetic diversity of Bartonella quintana in macaques suggests zoonotic origin of trench fever SO MOLECULAR ECOLOGY LA English DT Article DE Bacteria; Bartonella quintana; macaque; MLST; trench fever; zoonotic disease ID HENSELAE; CAT; ENDOCARDITIS; POPULATION; EPIDEMIOLOGY; EVOLUTIONARY; INFECTIONS; BACTEREMIA; DISEASES AB Bartonella quintana is a bacterium that causes a broad spectrum of diseases in humans including trench fever. Humans were previously considered to be the primary, if not the only, reservoir hosts for B.quintana. To identify the animal reservoir and extend our understanding of the ecological and evolutionary history of B.quintana, we examined blood samples from macaques and performed multilocus sequence typing (MLST) analysis. We demonstrated the prevalence of B.quintana infection was common in macaques from main primate centres in mainland China. Overall, 18.0% (59/328) of rhesus macaques and 12.7% (39/308) of cynomolgus macaques were found to be infected with B.quintana by blood culture and/or polymerase chain reaction. The infection was more frequently identified in juvenile and young monkeys compared with adult animals. In contrast with the relatively low level of sequence divergence of B.quintana reported in humans, our investigation revealed much higher genetic diversity in nonhuman primates. We identified 44 new nucleotide variable sites and 14 novel sequence types (STs) among the B.quintana isolates by MLST analysis. Some STs were found only in cynomolgus macaques, while some others were detected only in rhesus macaques, suggesting evidence of host-cospeciation, which were further confirmed by phylogenetic analysis and Splits decomposition analysis. Our findings suggest that trench fever may primarily be a zoonotic disease with macaques as the natural hosts. C1 [Li, Hao; Wang, Li-Yuan; Lu, Qing-Bin; Liu, Wei; Cao, Wu-Chun] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China. [Bai, Jie-Ying; Zeng, Lin; Shi, Yan-Sheng; Qiu, Zheng-Liang; Ye, Hua-Hu; Zhang, Xiao-Fei] Acad Mil Med Sci, Lab Anim Ctr, Beijing, Peoples R China. [Wang, Li-Yuan] Anhui Med Univ, Grad Sch, Hefei, Peoples R China. [Lu, Qing-Bin] Shangdong Univ, Sch Publ Hlth, Jinan, Peoples R China. [Kosoy, Michael] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Cao, WC (reprint author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China. EM mck3@cdc.gov; liu_weis@sohu.com; caowc@bmi.ac.cn OI Lu, Qing-Bin/0000-0002-2804-0827 FU Natural Science Foundation of China [81290344, 81222037, 81130086, 31272385]; Health Industry Research Projects [201202019] FX This study is supported by the Natural Science Foundation of China (81290344, 81222037, 81130086 and 31272385) and Health Industry Research Projects (201202019). The founders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 37 TC 7 Z9 8 U1 1 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1083 J9 MOL ECOL JI Mol. Ecol. PD APR PY 2013 VL 22 IS 8 BP 2118 EP 2127 DI 10.1111/mec.12261 PG 10 WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology; Evolutionary Biology GA 119YX UT WOS:000317137200006 PM 23517327 ER PT J AU Fletcher, J Leach, JE Eversole, K Tauxe, R AF Fletcher, Jacqueline Leach, Jan E. Eversole, Kellye Tauxe, Robert TI Human Pathogens on Plants: Designing a Multidisciplinary Strategy for Research SO PHYTOPATHOLOGY LA English DT Article ID ENTERICA SEROVAR TYPHIMURIUM; ESCHERICHIA-COLI O157-H7; CONTAMINATED MANURE COMPOSTS; SALMONELLA-ENTERICA; FRESH PRODUCE; PSEUDOMONAS-AERUGINOSA; BIOFILM FORMATION; IRRIGATION WATER; INNATE IMMUNITY; FOOD SAFETY AB Fletcher, J., Leach, J. E., Eversole, K., and Tauxe, R. 2013. Human pathogens on plants: Designing a multidisciplinary strategy for research. Phytopathology 103:306-315. Recent efforts to address concerns about microbial contamination of food plants and resulting foodborne illness have prompted new collaboration and interactions between the scientific communities of plant pathology and food safety. This article provides perspectives from scientists of both disciplines and presents selected research results and concepts that highlight existing and possible future synergisms for audiences of both disciplines. Plant pathology is a complex discipline that encompasses studies of the dissemination, colonization, and infection of plants by microbes such as bacteria, viruses, fungi, and oomycetes. Plant pathologists study plant diseases as well as host plant defense responses and disease management strategies with the goal of minimizing disease occurrences and impacts. Repeated outbreaks of human illness attributed to the contamination of fresh produce, nuts and seeds, and other plant-derived foods by human enteric pathogens such as Shiga toxin-producing Escherichia coli and Salmonella spp. have led some plant pathologists to broaden the application of their science in the past two decades, to address problems of human pathogens on plants (HPOPs). Food microbiology, which began with the study of microbes that spoil foods and those that are critical to produce food, now also focuses study on how foods become contaminated with pathogens and how this can be controlled or prevented. Thus, at the same time, public health researchers and food microbiologists have become more concerned about plant microbe interactions before and after harvest. New collaborations are forming between members of the plant pathology and food safety communities, leading to enhanced research capacity and greater understanding of the issues for which research is needed. The two communities use somewhat different vocabularies and conceptual models. For example, traditional plant pathology concepts such as the disease triangle and the disease cycle can help to define cross-over issues that pertain also to HPOP research, and can suggest logical strategies for minimizing the risk of microbial contamination. Continued interactions and communication among these two disciplinary communities is essential and can be achieved by the creation of an interdisciplinary research coordination network. We hope that this article, an introduction to the multidisciplinary HPOP arena, will be useful to researchers in many related fields. C1 [Fletcher, Jacqueline] Oklahoma State Univ, Dept Entomol & Plant Pathol, Natl Inst Microbial Forens & Food & Agr Biosecur, Stillwater, OK 74078 USA. [Leach, Jan E.] Colorado State Univ, Ft Collins, CO 80523 USA. [Eversole, Kellye] Eversole Associates, Bethesda, MD USA. [Tauxe, Robert] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Fletcher, J (reprint author), Oklahoma State Univ, Dept Entomol & Plant Pathol, Natl Inst Microbial Forens & Food & Agr Biosecur, Stillwater, OK 74078 USA. EM jacqueline.fletcher@okstate.edu NR 91 TC 16 Z9 18 U1 5 U2 79 PU AMER PHYTOPATHOLOGICAL SOC PI ST PAUL PA 3340 PILOT KNOB ROAD, ST PAUL, MN 55121 USA SN 0031-949X J9 PHYTOPATHOLOGY JI Phytopathology PD APR PY 2013 VL 103 IS 4 BP 306 EP 315 DI 10.1094/PHYTO-09-12-0236-IA PG 10 WC Plant Sciences SC Plant Sciences GA 119HD UT WOS:000317087500002 PM 23406434 ER PT J AU Rosado-Odom, VM Daoud, J Johnson, R Allen, SD Lockhart, SR Iqbal, N Shieh, WJ Zaki, S Sharfuddin, AA AF Rosado-Odom, V. M. Daoud, J. Johnson, R. Allen, S. D. Lockhart, S. R. Iqbal, N. Shieh, W. -J. Zaki, S. Sharfuddin, A. A. TI Cutaneous presentation of progressive disseminated histoplasmosis nine years after renal transplantation SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE histoplasmosis; cutaneous lesion; renal transplant; Histoplasma capsulatum ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECIPIENTS; CELLULITIS; MANAGEMENT; CAPSULATUM; DIAGNOSIS; ITRACONAZOLE; INFECTION AB Initial presentation of invasive fungal infections such as histoplasmosis can include non-specific clinical manifestations, especially in immunocompromised patients. A high index of suspicion is required to identify atypical manifestations of these diseases, which carry a high risk of mortality, if the diagnosis is delayed or missed. We describe a case of a kidney transplant recipient with cutaneous lesions as initial manifestation of progressive disseminated histoplasmosis where a skin biopsy was crucial to an early diagnosis. C1 [Rosado-Odom, V. M.; Daoud, J.; Johnson, R.; Allen, S. D.; Sharfuddin, A. A.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA. [Lockhart, S. R.; Iqbal, N.] Ctr Dis Control & Prevent CDC, Mycot Dis Branch, Atlanta, GA USA. [Shieh, W. -J.; Zaki, S.] CDC, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. RP Sharfuddin, AA (reprint author), 550 North Univ Blvd,UH 4620, Indianapolis, IN 46202 USA. EM asharfud@iupui.edu NR 26 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD APR PY 2013 VL 15 IS 2 BP E64 EP E69 DI 10.1111/tid.12059 PG 6 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 122AT UT WOS:000317287900004 PM 23387927 ER PT J AU Ford, ES Dietz, WH AF Ford, Earl S. Dietz, William H. TI Trends in energy intake among adults in the United States: findings from NHANES SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID SUGAR-SWEETENED BEVERAGES; US ADULTS; OBESITY; CONSUMPTION AB Background: Energy intake is a key determinant of weight. Objective: Our objective was to examine trends in energy intake in adults in the United States from 1971-1975 to 2009-2010. Design: The study was a trend analysis of 9 national surveys in the United States that included data from 63,761 adults aged 20-74 y. Results: Adjusted mean energy intake increased from 1955 kcal/d during 1971-1975 to 2269 kcal/d during 2003-2004 and then declined to 2195 kcal/d during 2009-2010 (P-linear trend < 0.001, P-nonlinear trend < 0.001). During the period from 1999-2000 to 2009-2010, no significant linear trend in energy intake was observed (P = 0.058), but a significant nonlinear trend was noted (P = 0.042), indicating a downward trend in energy intake. Significant decreases in energy intake from 1999-2000 to 2009-2010 were noted for participants aged 20-39 y, men, women, and participants with a BMI (in kg/m(2)) of 18.5 to <25 and >= 30. Conclusion: After decades of increases, mean energy intake has decreased significantly since 2003-2004. Am J Clin Nutr 2013;97:848-53. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. [Dietz, William H.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 46 Z9 47 U1 0 U2 17 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD APR PY 2013 VL 97 IS 4 BP 848 EP 853 DI 10.3945/ajcn.112.052662 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 113CQ UT WOS:000316644200022 PM 23426032 ER PT J AU Dietz, PM Kuklina, EV Bateman, BT Callaghan, WM AF Dietz, Patricia M. Kuklina, Elena V. Bateman, Brian T. Callaghan, William M. TI Assessing Cardiovascular Disease Risk among Young Women with a History of Delivering a Low-Birth-Weight Infant SO AMERICAN JOURNAL OF PERINATOLOGY LA English DT Article DE low birth weight; fetal growth; cardiovascular disease; preterm ID FETAL-GROWTH RESTRICTION; ISCHEMIC-HEART-DISEASE; PREGNANCY COMPLICATIONS; RETROSPECTIVE COHORT; PRETERM DELIVERY; SERUM COTININE; UNITED-STATES; MORTALITY; MOTHERS; PREECLAMPSIA AB Objective To assess the prevalence and risk factors of cardiovascular disease (CVD) among younger women by pregnancy history. Methods Cross-sectional study using 1999 to 2006 National Health and Nutrition Examination Survey including women aged 20 to 64 years who had delivered at least one infant (n = 4820). Women self-reported pregnancy history and a clinician diagnosed CVD; CVD risk factors included hypertension (mean systolic blood pressure [BP] >= 140 mm Hg or mean diastolic BP >= 90 mm Hg, or currently treated), high cholesterol (total cholesterol >= 240 mg/dL or currently treated), diabetes (self-report or hemoglobin A1c >= 6.5), and smoking (self-report or cotinine-verified). Multivariable logistic regression was used to assess the association between pregnancy history and CVD. Results Of the women we studied, 4.6% had CVD; 3.1% had delivered a term low-birth-weight infant (TLBWI). Women with a history of TLBWI had an adjusted odds ratio (AOR) of 2.07 (95% confidence intervals [CI] 1.08 to 3.99) for CVD compared with women without a history of LBWI. Adjustment for hypertension and high cholesterol mildly attenuated the association (AOR 1.85, 95% CI 0.89 to 3.83). Among women without CVD (n = 4555), 23.11 with a history of TLBWI had two risk factors compared with 14.0% of those without a history of LBWI (p = 0.0016). Conclusion Women with a history of TLBWI should be informed of a possible increased risk of CVD and encouraged to receive screenings as recommended. C1 [Dietz, Patricia M.; Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. RP Dietz, PM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Hwy NE,MS K-23, Atlanta, GA 30341 USA. EM PDietz@cdc.gov NR 37 TC 4 Z9 4 U1 1 U2 9 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0735-1631 J9 AM J PERINAT JI Am. J. Perinatol. PD APR PY 2013 VL 30 IS 4 BP 267 EP 273 DI 10.1055/s-0032-1323589 PG 7 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 115SF UT WOS:000316831500003 PM 22875656 ER PT J AU Albright, AL Gregg, EW AF Albright, Ann L. Gregg, Edward W. TI Preventing Type 2 Diabetes in Communities Across the U.S. The National Diabetes Prevention Program SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID LIFE-STYLE INTERVENTION; SUGAR-SWEETENED BEVERAGES; PUBLIC-HEALTH; FOLLOW-UP; UNITED-STATES; RISK; OBESITY; US; INDIVIDUALS; MELLITUS AB There are as many as 79 million people in the U.S. with prediabetes, and their risk of developing type 2 diabetes is four to 12 times higher than it is for people with normal glucose tolerance. Although advances in diabetes treatment are still needed, there is a critical need to implement effective strategies to stem the current and projected growth in new cases of type 2 diabetes. RCTs and translation studies have demonstrated that type 2 diabetes can be prevented or delayed in those at high risk, through a structured lifestyle intervention that can be delivered cost effectively. In order to bring this compelling lifestyle intervention to communities across America, Congress authorized the CDC to establish and lead the National Diabetes Prevention Program. Several aspects of the etiology of type 2 diabetes suggest that strategies addressing both those at high risk and the general population are necessary to make a major impact on the diabetes epidemic. (Am J Prev Med 2013;44(4S4):S346-S351) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Albright, Ann L.; Gregg, Edward W.] CDC, Div Diabet Translat, Atlanta, GA 30341 USA. RP Albright, AL (reprint author), CDC, Div Diabet Translat, 4770 Buford Hwy,Mailstop K-10, Atlanta, GA 30341 USA. EM aalbright@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 43 Z9 43 U1 1 U2 33 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2013 VL 44 IS 4 SU 4 BP S346 EP S351 DI 10.1016/j.amepre.2012.12.009 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 113NH UT WOS:000316674200009 PM 23498297 ER PT J AU Gregg, EW Geiss, L Zhang, P Zhuo, XH Williamson, DF Albright, AL AF Gregg, Edward W. Geiss, Linda Zhang, Ping Zhuo, Xiaohui Williamson, David F. Albright, Ann L. TI Implications of Risk Stratification for Diabetes Prevention The Case of Hemoglobin A1c SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; FASTING PLASMA-GLUCOSE; LIFE-STYLE MODIFICATION; CARDIOVASCULAR-DISEASE; GLYCATED HEMOGLOBIN; DIAGNOSTIC-TEST; US ADULTS; FOLLOW-UP; PROGRAM; MELLITUS AB Although glycated hemoglobin (HbA1c) has been widely recommended for the diagnosis of diabetes, considerable ambiguity remains about how HbA1c should be used to identify people with prediabetes or other high-risk states for preventive interventions. The current paper provides a synthesis of the epidemiologic basis and the health and economic implications of using various HbA1c-based risk-stratification approaches for diabetes prevention. HbA1c predicts diabetes and related outcomes across a wide range of HbA1c values. However, the authors estimate that, among U. S. adults, the top 15% of the nondiabetic HBA1c distribution (HbA1c of 5.7%-6.4%) accounts for 47% of diabetes cases over 5 years, and the top 30% (5.5%-6.4%) accounts for about 70% of cases. Although this clustering of eventual cases at the high end of the HbA1c risk distribution means that intervention resources will be more efficient when applied to the upper end of the distribution, no obvious threshold exists to prioritize people for preventive interventions. Thus, the choice of optimal thresholds is a tradeoff, wherein selecting a lower HbA1c cut-point will lead to a higher rate of eligibility and health benefits for more people, and a higher HbA1c cut-point will lead to fewer cases of diabetes prevented but greater "economic efficiency" in terms of diabetes cases prevented per intervention participant. Selection of optimal HbA1c thresholds also may change with the evolving science, as better evidence on the biologic effectiveness of lower-intensity interventions and effects of lifestyle interventions on additional outcomes could pave the way for a more comprehensive, tiered approach to risk stratification. (Am J Prev Med 2013;44(4S4):S375-S380) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Gregg, Edward W.; Geiss, Linda; Zhang, Ping; Zhuo, Xiaohui; Williamson, David F.; Albright, Ann L.] CDC, Div Diabet Translat, Atlanta, GA 30333 USA. RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Hwy NE,MS K-10, Atlanta, GA 30341 USA. EM Edg7@cdc.gov FU Joslin Diabetes Center; Novo Nordisk FX Publication of this supplement was supported by Joslin Diabetes Center and Novo Nordisk. NR 47 TC 8 Z9 10 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2013 VL 44 IS 4 SU 4 BP S375 EP S380 DI 10.1016/j.amepre.2012.12.012 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 113NH UT WOS:000316674200014 PM 23498302 ER PT J AU Akinsanya-Beysolow, I Jenkins, R Meissner, HC AF Akinsanya-Beysolow, Iyabode Jenkins, Renee Meissner, H. Cody CA ACIP Childhood Adolescent Immun TI Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years-United States, 2013 (Reprinted from MMWR, vol 62, pg 2, 2013) SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint C1 [Akinsanya-Beysolow, Iyabode] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jenkins, Renee] Howard Univ, Coll Med, Dept Pediat & Child Hlth, Washington, DC USA. [Meissner, H. Cody] Tufts Med Ctr, Boston, MA USA. RP Akinsanya-Beysolow, I (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM iakinsanyabeysolow@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2013 VL 13 IS 4 BP 1098 EP 1105 DI 10.1111/ajt.12233 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 116VT UT WOS:000316911900039 ER PT J AU Byrd, TL Wilson, KM Smith, JL Coronado, G Vernon, SW Fernandez-Esquer, ME Thompson, B Ortiz, M Lairson, D Fernandez, ME AF Byrd, Theresa L. Wilson, Katherine M. Smith, Judith Lee Coronado, Gloria Vernon, Sally W. Fernandez-Esquer, Maria Eugenia Thompson, Beti Ortiz, Melchor Lairson, David Fernandez, Maria E. TI AMIGAS: A multicity, multicomponent cervical cancer prevention trial among Mexican American women SO CANCER LA English DT Article DE uterine cervical cancer screening; Mexican origin; clinical trial; health education; Hispanic women ID HISPANIC WOMEN; UNITED-STATES; LA-SALUD; HEALTH AB BACKGROUND: Considerable efforts have been undertaken in the United States to reduce cervical cancer incidence and mortality by increasing screening; however, disparities in screening rates continue to exist among certain racial and ethnic minority groups. The objective of the current study was to determine the effectiveness of a lay health worker-delivered interventionAMIGAS (Ayudando a las Mujeres con Informacion, Guia, y Amor para su Salud [helping women with information, guidance, and love for their health])to increase Papanicolaou (Pap) test screening among 3 populations of women of Mexican origin. METHODS: Six hundred thirteen women of Mexican origin in 3 treatment sites were randomized among 4 study arms: the full AMIGAS program with a video and a flip chart (n = 151), the AMIGAS program without the video (n = 154), the AMIGAS program without the flip chart (n = 155), and a usual care control group (n = 153). Six months after enrollment, women were surveyed and reported whether or not they had been screened. RESULTS: Women in any of the intervention arms were statistically significantly more likely to report being screened than those in the usual care group in both an intent-to-treat analysis and a per-protocol analysis. In the intent-to-treat analysis, 25% of women in the control group and 52% in the full AMIGAS program group reported having had Pap tests (P < .001); in the per-protocol analysis, the percentages were 29% and 62%, respectively (P < .001). CONCLUSIONS: AMIGAS was effective in increasing Pap test screening among women of Mexican descent when used in a 1-to-1 setting. Future research should compare the 1-on-1 intervention with the group-based intervention. Cancer 2013. (c) 2012 American Cancer Society. C1 [Byrd, Theresa L.; Ortiz, Melchor] Texas Tech Paul L Foster Sch Med, El Paso, TX 79905 USA. [Wilson, Katherine M.; Smith, Judith Lee] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA USA. [Coronado, Gloria] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Vernon, Sally W.; Fernandez-Esquer, Maria Eugenia; Lairson, David; Fernandez, Maria E.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Thompson, Beti] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Byrd, TL (reprint author), Texas Tech Paul L Foster Sch Med, 5001 El Paso Dr, El Paso, TX 79905 USA. EM theresa.byrd@ttuhsc.edu FU Centers for Disease Control and Prevention [U48-DP000057] FX This study was supported by the Centers for Disease Control and Prevention cooperative agreement U48-DP000057 to the University of Texas School of Public Health at El Paso. NR 30 TC 24 Z9 25 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD APR 1 PY 2013 VL 119 IS 7 BP 1365 EP 1372 DI 10.1002/cncr.27926 PG 8 WC Oncology SC Oncology GA 115KU UT WOS:000316811900012 PM 23280399 ER PT J AU Spradling, PR Xing, J Williams, R Masunu-Faleafaga, Y Dulski, T Mahamud, A Drobeniuc, J Teshale, EH AF Spradling, Philip R. Xing, Jian Williams, Roxanne Masunu-Faleafaga, Yolanda Dulski, Theresa Mahamud, Abdirahman Drobeniuc, Jan Teshale, Eyasu H. TI Immunity to Hepatitis B Virus (HBV) Infection Two Decades after Implementation of Universal Infant HBV Vaccination: Association of Detectable Residual Antibodies and Response to a Single HBV Challenge Dose SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article AB Most persons who receive hepatitis B vaccine during infancy will have a level of antibody to hepatitis B surface antigen (anti-HBsAg) of < 10 IU/liter 10 to 15 years later; however, most will demonstrate immune memory by an anamnestic response to a vaccine challenge dose. To determine whether there was a difference in anamnestic response among college students vaccinated during infancy, we compared anti-HBsAg levels after a 20-mu g dose of Engerix-B in those with a residual anti-HBsAg level of 0 IU/liter and those with levels of 1 to 9 IU/liter. Anti-HBsAg was measured before (baseline) and 2 weeks after a challenge dose; a response was defined as a level of >= 10 IU/liter after the dose among those with < 10 IU/liter at the baseline. Of the 153 students who completed the study, 130 (85%) had an anti-HBsAg level of < 10 IU/liter at the baseline, 72 had a level of 0 IU/liter, and 58 had levels ranging from 1 to 9 IU/liter. Students with a levels of 1 to 9 IU/liter were more likely to respond to the challenge dose than those with a baseline anti-HBsAg level of 0 IU/liter (83% versus 50%; P < 0.001). The presence of any detectable anti-HBsAg among persons vaccinated in the remote past may indicate the persistence of immune memory. C1 [Spradling, Philip R.; Xing, Jian; Williams, Roxanne; Drobeniuc, Jan; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Dulski, Theresa] Emory Univ, Sch Med, Atlanta, GA USA. [Mahamud, Abdirahman] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU U.S. Centers for Disease Control and Prevention FX Financial support for this study was received from the U.S. Centers for Disease Control and Prevention. NR 6 TC 17 Z9 19 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD APR PY 2013 VL 20 IS 4 BP 559 EP 561 DI 10.1128/CVI.00694-12 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 113JH UT WOS:000316662400016 PM 23408522 ER PT J AU Reichard, A Fox, MH AF Reichard, Amanda Fox, Michael H. TI Using population-based data to examine preventive services by disability type among dually eligible (Medicare/Medicaid) adults SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Dual eligible; Medicare; Medicaid; Disability; Preventive health services ID MEDICARE-MEDICAID BENEFICIARIES; HEALTH-CARE EXPENDITURES; UNITED-STATES; DEVELOPMENTAL-DISABILITIES; PHYSICAL-DISABILITIES; WOMEN; DISPARITIES; LIMITATIONS; BREAST; INDIVIDUALS AB Background: Individuals dually eligible for Medicaid and Medicare constitute a small percentage of these program's populations but account for a disproportionately large percent of their total costs. While much work has examined high expenditures, little is known about their health and details of their health care utilization. Objective/hypothesis: Utilize an important public health surveillance tool to better understand preventive service use among the dual eligible population. Methods: This study involved descriptive and regression analyses of dual eligibles in the Medical Expenditure Panel Survey data from pooled alternate years 2000-2008. We classified the sample into 4 mutually exclusive groups: cognitive limitations, physical disabilities, double diagnosis (cognitive limitations and physical disability), or neither cognitive limitations nor physical disability. Results: For most groups, age was significantly associated with preventive services, though direction varies. Older age was linked to greater receipt of flu shots while younger age was associated with greater receipt of Pap tests, mammograms and dental services. Black women in all groups (except cognitive limitations) had an increased likelihood of receiving a Pap test and a mammogram. Conclusions: A subset of dual eligibles drives the majority of expenditures. People with physical disabilities, regardless of whether they also have a cognitive limitation, are among the highest costing and sickest of our non-institutionalized dual eligible population. Efforts to understand and address the challenges faced by women with physical disabilities in accessing Pap tests or mammograms may be helpful in improving the overall health status for this disability group, but also for all dual eligibles. Published by Elsevier Inc. C1 [Reichard, Amanda] Univ Kansas, Res & Training Ctr Independent Living, Lawrence, KS 66045 USA. [Fox, Michael H.] Ctr Dis Control & Prevent CDC, NCBDDD, DHDD, Atlanta, GA 30333 USA. RP Reichard, A (reprint author), Univ Kansas, Res & Training Ctr Independent Living, 1000 Sunnyside Ave,Suite 4089, Lawrence, KS 66045 USA. EM reichard@ku.edu; mhfox@cdc.gov FU Research and Training Center from the National Institute on Disability and Rehabilitation Research [H133B060018, H133B110006] FX This work was funded, in part under two Research and Training Center grants from the National Institute on Disability and Rehabilitation Research, award numbers H133B060018 and H133B110006. NR 53 TC 9 Z9 9 U1 3 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD APR PY 2013 VL 6 IS 2 BP 75 EP 86 DI 10.1016/j.dhjo.2012.12.001 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 115IU UT WOS:000316806600003 PM 23507157 ER PT J AU Campo, P Morata, TC Hong, OS AF Campo, Pierre Morata, Thais C. Hong, OiSaeng TI Chemical exposure and hearing loss SO DM DISEASE-A-MONTH LA English DT Article ID AUDITORY BRAIN-STEM; CENTRAL-NERVOUS-SYSTEM; HAIR CELL LOSS; NICOTINIC ACETYLCHOLINE-RECEPTORS; VOLATILE ORGANIC-COMPOUNDS; ABUSED SOLVENT TOLUENE; HIGH-FREQUENCY HEARING; EAR ACOUSTIC REFLEX; LONG-TERM EXPOSURE; CARBON-MONOXIDE C1 [Morata, Thais C.] NIOSH, Cincinnati, OH 45226 USA. [Hong, OiSaeng] Univ San Francisco, San Francisco, CA 94117 USA. FU Intramural CDC HHS [CC999999] NR 177 TC 11 Z9 12 U1 0 U2 18 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-5029 EI 1557-8194 J9 DM-DIS MON JI DM-Dis.-a-Mon. PD APR PY 2013 VL 59 IS 4 BP 119 EP 138 DI 10.1016/j.disamonth.2013.01.003 PG 20 WC Medicine, General & Internal SC General & Internal Medicine GA 114UY UT WOS:000316769400003 PM 23507352 ER PT J AU Evans, JP Khoury, MJ AF Evans, James P. Khoury, Muin J. TI The arrival of genomic medicine to the clinic is only the beginning of the journey SO GENETICS IN MEDICINE LA English DT Editorial Material C1 [Evans, James P.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Evans, JP (reprint author), Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA. EM jpevans@med.unc.edu FU Intramural CDC HHS [CC999999]; NHGRI NIH HHS [U01 HG006487] NR 6 TC 17 Z9 17 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD APR PY 2013 VL 15 IS 4 BP 268 EP 269 DI 10.1038/gim.2012.133 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA 118OR UT WOS:000317035400003 PM 23306801 ER PT J AU Rupert, DJ Poehlman, JA Damon, SA Williams, PN AF Rupert, Douglas J. Poehlman, Jon A. Damon, Scott A. Williams, Peyton N. TI Risk and protective behaviours for residential carbon monoxide poisoning SO INJURY PREVENTION LA English DT Article ID UNITED-STATES; DEATHS AB Background Unintentional, non-fire-related carbon monoxide (CO) poisoning is a leading cause of poisoning death and injury in the USA. Residential poisonings caused by faulty furnaces are the most common type of CO exposure. However, these poisonings are largely preventable with annual furnace inspections and CO alarm installation. Objective This study aimed to identify the knowledge, attitudes and beliefs that might lead consumers to adopt these protective behaviours. Methods In August 2009, four focus groups (n=29) were conducted with homeowners in Chicago, Illinois, USA, to identify the knowledge, attitudes and beliefs that lead consumers to adopt risk and protective behaviours. Discussions were transcribed and the findings were analysed using an ordered meta-matrix. Results Focus group participants were aware of CO poisoning and supported the idea of regular furnace inspections. However, few participants consistently scheduled professional inspections for fear of costly repairs and unscrupulous contractors. Participants often owned CO alarms, but many did not locate them properly, nor maintain them. Some participants confused CO and natural gas and were unsure how to react if a CO alarm sounds. Participants stated that incentives, such as discounts and inspector selection tips, would make them more likely to schedule furnace inspections. Participants also identified trustworthy sources for CO education, including realtors, fire departments, home insurance agents and local media outlets. Conclusions Participants' residential CO risk behaviours are not random but driven by underlying knowledge, attitudes and beliefs. Correcting misperceptions, providing incentives and partnering with trustworthy sources might encourage greater consumer adoption of protective behaviours. C1 [Rupert, Douglas J.; Poehlman, Jon A.; Williams, Peyton N.] RTI Int, Hlth Commun Program, Publ Hlth & Environm Div, Res Triangle Pk, NC 27709 USA. [Damon, Scott A.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Rupert, DJ (reprint author), RTI Int, Hlth Commun Program, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM drupert@rti.org FU US Centers for Disease Control and Prevention (CDC) FX This research was supported by the US Centers for Disease Control and Prevention (CDC). The findings and conclusions are those of the authors and do not necessarily reflect the view of the CDC or the US Department of Health and Human Services. NR 20 TC 1 Z9 1 U1 1 U2 11 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD APR PY 2013 VL 19 IS 2 BP 119 EP 123 DI 10.1136/injuryprev-2012-040339 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 108QZ UT WOS:000316312400008 PM 22653781 ER PT J AU Colson, PW Hirsch-Moverman, Y Bethel, J Vempaty, R Salcedo, K Wall, K Miranda, W Collins, S Horsburgh, CR AF Colson, P. W. Hirsch-Moverman, Y. Bethel, J. Vempaty, R. Salcedo, K. Wall, K. Miranda, W. Collins, S. Horsburgh, C. R. CA TB Epidemiologic Studies TI Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE Mycobacterium tuberculosis; medical care; public health clinic; prospective survey ID INJECTION-DRUG USERS; COMPLETION; PROGRAMS AB SETTING: An estimated 300000 individuals are treated for latent tuberculosis infection (LTBI) in the United States and Canada annually. Little is known about the proportion or characteristics of those who decline treatment. OBJECTIVE: To define the proportion of individuals in various groups who accept LTBI treatment and to identify factors associated with non-acceptance of treatment. DESIGN: Persons offered LTBI treatment at 30 clinics in 12 Tuberculosis Epidemiologic Studies Consortium sites were prospectively enrolled. Multivariate regression models were constructed based on manual stepwise assessment of potential predictors. RESULTS: Of 1692 participants enrolled from March 2007 to September 2008, 1515 (89.5%) accepted treatment and 177 (10.5%) declined. Predictors of acceptance included believing one could personally spread TB germs, having greater TB knowledge, finding clinic schedules convenient and having low acculturation. Predictors of non-acceptance included being a health care worker, being previously recommended for treatment and believing that taking medicines would be problematic. CONCLUSION: This is the first prospective multisite study to examine predictors of LTBI treatment acceptance in general clinic populations. Greater efforts should be made to increase acceptance among health care workers, those previously recommended for treatment and those who expect problems with LTBI medicines. Ensuring convenient clinic schedules and TB education to increase knowledge could be important for ensuring acceptance. C1 [Colson, P. W.; Hirsch-Moverman, Y.] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, Charles P Felton Natl TB Ctr, New York, NY 10027 USA. [Bethel, J.] WESTAT Corp, Rockville, MD 20850 USA. [Vempaty, R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Salcedo, K.] Calif Dept Publ Hlth, Div Communicable Dis Control, Ctr Infect Dis, Richmond, CA USA. [Wall, K.] Denver Publ Hlth & Hosp Author, Denver, CO USA. [Miranda, W.] New York State Dept Hlth, Albany, NY USA. [Collins, S.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Horsburgh, C. R.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Colson, PW (reprint author), Columbia Univ, Mailman Sch Publ Hlth, ICAP, 1st Floor,Suite A,215 W 125th St, New York, NY 10027 USA. EM pwc2@columbia.edu FU CDC; Tuberculosis Epidemiologic Studies Consortium (TBESC); US Centers for Disease Control and Prevention (CDC) FX This study was supported by the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.; The authors thank the Tuberculosis Epidemiologic Studies Consortium (TBESC) and the US Centers for Disease Control and Prevention (CDC), which supported this study; all the patients who participated in the study; and the investigators and staff at all the participating TBESC sites: J McAuley (Principal Investigator [PI]), J Beison (Project Coordinator [PC]), Respiratory Health Association of Metropolitan Chicago; J Flood (PI), K Salcedo (PC), N Palermo, California Department of Health Services; R Reves (PI), K Wall (PC), Denver Public Health and Hospital Authority; H Blumberg (PI), J Tapia (PC), Emory University; P Colson (PI), Y Hirsch-Moverman (PC), Columbia University/Charles P Felton National TB Center at Harlem Hospital; T Venkatappa (PC), Hawaii Department of Health; W Cronin (PI), S Collins (PC), H Rutz (PC), Maryland Department of Health and Mental Hygiene; R Horsburgh (PI), S Etkind (PI), S Sharnprapai (PC), Massachusetts Department of Health; S Hughes (PI), W Miranda (PC), New York State Department of Health; T Sterling (PI), T Chavez-Lindell (PC), T Stein-Hart (PC), K Gordon (PC), Tennessee Department of Health; M Naus (PI), K Alasaly (PC), University of British Columbia; S Weis (PI), G Bayona (PC), University of North Texas. NR 21 TC 8 Z9 8 U1 0 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2013 VL 17 IS 4 BP 473 EP 479 DI 10.5588/ijtld.12.0697 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 117BD UT WOS:000316926200009 PM 23485381 ER PT J AU Swindells, S Komarow, L Tripathy, S Cain, KP MacGregor, RR Achkar, JM Gupta, A Veloso, VG Asmelash, A Omoz-Oarhe, AE Gengiah, S Lalloo, U Allen, R Shiboski, C Andersen, J Qasba, SS Katzenstein, DK AF Swindells, S. Komarow, L. Tripathy, S. Cain, K. P. MacGregor, R. R. Achkar, J. M. Gupta, A. Veloso, V. G. Asmelash, A. Omoz-Oarhe, A. E. Gengiah, S. Lalloo, U. Allen, R. Shiboski, C. Andersen, J. Qasba, S. S. Katzenstein, D. K. CA AIDS Clinical Trials Grp 5253 TI Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; diagnostics; HIV infection; sensitivity; specificity ID SOUTH-AFRICA; DIAGNOSIS; PEOPLE; CARE AB BACKGROUND: Improved tuberculosis (TB) screening is urgently needed for human immunodeficiency virus (HIV) infected patients. METHODS: An observational, multi-country, cross-sectional study of HIV-infected patients to compare a standardized diagnostic evaluation (SDE) for TB with standard of care (SOC). SOC evaluations included TB symptom review (current cough, fever, night sweats and/or weight loss), sputum Ziehl-Neelsen staining and chest radiography. SDE screening added extended clinical signs and symptoms and fluorescent microscopy (FM). All participants underwent all evaluations. Mycobacterium tuberculosis on sputum culture was the primary outcome. RESULTS: A total of 801 participants were enrolled from Botswana, Malawi, South Africa, Zimbabwe, India, Peru and Brazil. The median age was 33 years; 37% were male, and median CD4 count was 275 cells/mm(3). Thirty-one participants (4%) had a positive culture on Lowenstein-Jensen media and 54 (8%) on MGIT. All but one positive culture came from sub-Saharan Africa, where the prevalence of TB was 54/445 (12%). SOC screening had 54% sensitivity (95%CI 40-67) and 76% specificity (95%CI 72-80). Positive and negative predictive values were respectively 24% and 92%. No elements of the SDE improved the predictive values of SOC. CONCLUSIONS: Symptom-based screening with smear microscopy was insufficiently sensitive. More sensitive diagnostic testing is required for HIV-infected patients. C1 [Swindells, S.] Univ Nebraska Med Ctr, Omaha, NE 68198 USA. [Komarow, L.; Andersen, J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Tripathy, S.] Natl AIDS Res Inst, Pune, Maharashtra, India. [Cain, K. P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [MacGregor, R. R.] Univ Penn, Philadelphia, PA 19104 USA. [Achkar, J. M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Gupta, A.] Johns Hopkins Univ, Baltimore, MD USA. [Veloso, V. G.] Inst Pesquisa Clin Evandro, Rio De Janeiro, Brazil. [Asmelash, A.] Scottish Livingstone Hosp, Molepole, Botswana. [Omoz-Oarhe, A. E.] Princess Marina Hosp, Gaborone, Botswana. [Gengiah, S.] Ctr AIDS Programme Res South Africa, Durban, South Africa. [Lalloo, U.] Univ KwaZulu Natal, Durban, South Africa. [Allen, R.] AIDS Clin Trials Grp Operat Ctr, Silver Spring, MD USA. [Shiboski, C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Qasba, S. S.] Montgomery Cty Hlth Dept, Silver Spring, MD USA. [Katzenstein, D. K.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. RP Swindells, S (reprint author), Univ Nebraska Med Ctr, Dept Internal Med, 988106 Nebraska Med Ctr, Omaha, NE 68198 USA. EM sswindells@unmc.edu FU NIH from the NIAID [U01AI068636]; Clinical Trials Unit (CTU) [U01 AIO69417-05]; Prevention & Treatment Center, Botswana (Site 12702) CTU [U01 AI069456]; Prevention & Treatment Center, Botswana (Site 12701) CTU [U01 AI069456]; CAPRISA eThekwini Clinical Research Site (CRS), Durban, South Africa (Site 31422) CTU [5U01AI069469-05]; Durban International Clinical Trials Unit, South Africa (Site 11201) CTU [5U1AI069426-05]; Byramjee Jeejeebhoy Medical College CTS, Pune, India (Site 31441) CTU [U01 AI069497]; Wits HIV CRS, Johannesburg, South Africa (Site 11101) CTU [5UM1 AI069463-05]; Soweto ACTG CRS, South Africa (Site 12301) CTU [U01AI69453]; Instituto de Pesquisa Clinica Evandro Chagas CRS, Brazil (Site 12101) CTU [U01AI069476]; University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi (Site 12001) CTU [U01 AI069518]; Investigaciones Medicas en Salud, Lima, Peru (Site 11302) CTU [U01AI069438]; UZ Parirenyatwa Clinical Research Site, Harare, Zimbabwe (Site 30313), CTU [U01 A1069436]; [U01 AI068634]; [AI51519] FX This work was supported by NIH grants U01AI068636 from the NIAID; U01 AI068634 for the Statistical and Data Management Center for the AIDS Clinical Trials Group; and AI51519 for the Center for AIDS Research at the Albert Einstein College of Medicine (supplement for JMA). This study was presented in part at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 5-8 March 2012.; Sites and contributors: R R Gangakhedkar and A Risbud, International Clinical Trials Unit Pune, India (Site 11601) Clinical Trials Unit (CTU) Grant U01 AIO69417-05; S Selebaleng and R Molefe-Molepolole, Prevention & Treatment Center, Botswana (Site 12702) CTU Grant U01 AI069456; K Kooreng and M Raesi, Gaborone Prevention & Treatment Center, Botswana (Site 12701) CTU Grant U01 AI069456; K Naidoo, CAPRISA eThekwini Clinical Research Site (CRS), Durban, South Africa (Site 31422) CTU Grant 5U01AI069469-05; S Pillay, Durban International Clinical Trials Unit, South Africa (Site 11201) CTU Grant 5U1AI069426-05; D Kadam and V Mave, Byramjee Jeejeebhoy Medical College CTS, Pune, India (Site 31441) CTU Grant U01 AI069497; P lye and M Hero, Wits HIV CRS, Johannesburg, South Africa (Site 11101) CTU Grant 5UM1 AI069463-05; L Mohapi and R Lourens, Soweto ACTG CRS, South Africa (Site 12301) CTU Grant U01AI69453; V Gs Veloso and M C da Silva Lourenco, Instituto de Pesquisa Clinica Evandro Chagas CRS, Brazil (Site 12101) CTU Grant U01AI069476; A Mwafongo and A Moses, University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi (Site 12001) CTU Grant U01 AI069518; P Segura and C Ganoza, Barranco CRS, Lima, Peru (Site 11301); C Ganoza, and P Segura, Investigaciones Medicas en Salud, Lima, Peru (Site 11302) CTU Grant U01AI069438; G Kadzirange and R Mahachi, UZ Parirenyatwa Clinical Research Site, Harare, Zimbabwe (Site 30313), CTU Grant U01 A1069436. NR 20 TC 10 Z9 10 U1 0 U2 7 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2013 VL 17 IS 4 BP 532 EP 539 DI 10.5588/ijtld.12.0737 PG 8 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 117BD UT WOS:000316926200019 PM 23485388 ER PT J AU Budge, PJ Lazensky, B Van Zile, KW Elliott, KE Dooyema, CA Visvesvara, GS Beach, MJ Yoder, JS AF Budge, Philip J. Lazensky, Becky Van Zile, Kathleen W. Elliott, Karen E. Dooyema, Carrie A. Visvesvara, Govinda S. Beach, Michael J. Yoder, Jonathan S. TI Primary Amebic Meningoencephalitis in Florida: A Case Report and Epidemiological Review of Florida Cases SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Review ID NAEGLERIA-FOWLERI; BALAMUTHIA-MANDRILLARIS; ACANTHAMOEBA SPP. AB Primary amebic meningoencephalitis (PAM) is a rare but nearly always fatal infection of the central nervous system caused by the thermophilic, free-living ameba Naegleria fowl en. Since its first description in 1965 through 2010, 118 cases have been reported in the U.S.; all cases are related to enviromnental exposure to warm freshwater; most have occurred in children and adolescents and are associated with recreational water activities, such as swimming, diving, or playing in freshwater lakes, ponds, or rivers. Over one-fourth of all national PAM cases have occurred in Florida. The authors describe here a fatal case of PAM in a resident of northeast Florida and the ensuing environmental and public health investigation; they also provide a review of all cases of PAM in Florida from 1962 to 2010 and discuss public health responses to PAM in Florida, highlighting opportunities for positive collaboration between state and local environmental health specialists, epidemiologists, and the Centers for Disease Control and Prevention. C1 [Budge, Philip J.; Dooyema, Carrie A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Lazensky, Becky; Van Zile, Kathleen W.] Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. [Elliott, Karen E.] Florida Dept Hlth, Duval Cty Hlth Dept, Tallahassee, FL USA. [Visvesvara, Govinda S.; Beach, Michael J.; Yoder, Jonathan S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Budge, PJ (reprint author), Vanderbilt Univ, Div Infect Dis, Dept Med, Med Ctr North A2200, 1161 21st Ave South, Nashville, TN 37232 USA. EM Philip.budge@vanderbilt.edu FU Agency of Healthcare Research and Quality [T32 HS 013833] FX Philip J. Budge was supported in part by the Agency of Healthcare Research and Quality T32 HS 013833. His current affiliation is with the Division of Infectious Diseases, Vanderbilt University Department of Medicine. Carrie A. Dooyema's current affiliation is with the National Center for Chronic Disease Prevention and Health Promotion, CDC. NR 14 TC 8 Z9 8 U1 2 U2 22 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD APR PY 2013 VL 75 IS 8 BP 26 EP 31 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 115XU UT WOS:000316846000004 PM 23621053 ER PT J AU Nasci, RS AF Nasci, Roger S. TI Monitoring and Controlling West Nile Virus: Are Your Prevention Practices in Place? SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material ID CALIFORNIA; DISEASE; SYSTEM; USA C1 [Nasci, Roger S.] CDC, Arboviral Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. RP Nasci, RS (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM RNasci@cdc.gov NR 15 TC 4 Z9 4 U1 0 U2 11 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD APR PY 2013 VL 75 IS 8 BP 42 EP 44 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 115XU UT WOS:000316846000007 PM 23621056 ER PT J AU Branum, AM Bailey, R Singer, BJ AF Branum, Amy M. Bailey, Regan Singer, Barbara J. TI Dietary Supplement Use and Folate Status during Pregnancy in the United States SO JOURNAL OF NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; CHILDBEARING AGE; NATIONAL-HEALTH; FOLIC-ACID; WOMEN; NHANES; ADULTS; IRON; PRECONCEPTION; REQUIREMENTS AB Adequate folate and iron intake during pregnancy is critical for maternal and fetal health. No previous studies to our knowledge have reported dietary supplement use and folate status among pregnant women sampled in NHANES, a nationally representative, cross-sectional survey. We analyzed data on 1296 pregnant women who participated in NHANES from 1999 to 2006 to characterize overall supplement use, iron and folic acid use, and R BC folate status. The majority of pregnant women (77%) reported use of a supplement in the previous 30 d, most frequently a multivitamin/-mineral containing folic acid (mean 817 mu g/d) and iron 148 mg/d). Approximately 55-60% of women in their first trimester reported taking a folic acid- or iron-containing supplement compared with 76-78% in their second trimester and 89% in their third trimester. ABC folate was lowest in the first trimester and differed by supplement use across all trimesters. Median RBC folate was 1628 nmol/L among users and 1041 nmol/L among nonusers. Among all pregnant women, median RBC folate increased with trimester (1256 nmol/L in the first, 1527 nmol/L in the second, and 1773 nmol/L in the third). Given the role of folic acid in the prevention of neural tube defects, it is notable that supplement use and median ABC folate was lowest in the first trimester of pregnancy, with 55% of women taking a supplement containing folic acid. Future research is needed to determine the reasons for low compliance with supplement recommendations, particularly folic acid, in early pregnancy. J. Nutr. 143: 486-492, 2013. C1 [Branum, Amy M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Bailey, Regan] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Singer, Barbara J.] Univ Maryland, Sch Publ Hlth, Dept Family Sci, College Pk, MD 20742 USA. RP Branum, AM (reprint author), Natl Ctr Hlth Stat, Off Anal & Epidemiol, 3311 Toledo Rd,Room 6113, Hyattsville, MD 20782 USA. EM ambranum@cdc.gov FU Intramural CDC HHS [CC999999] NR 46 TC 36 Z9 36 U1 2 U2 38 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD APR PY 2013 VL 143 IS 4 BP 486 EP 492 DI 10.3945/jn.112.169987 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 110JB UT WOS:000316437300013 PM 23365107 ER PT J AU Kavanaugh, ML Frohwirth, L Jerman, J Popkin, R Ethier, K AF Kavanaugh, Megan L. Frohwirth, Lori Jerman, Jenna Popkin, Ronna Ethier, Kathleen TI Long-acting Reversible Contraception for Adolescents and Young Adults: Patient and Provider Perspectives SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY LA English DT Article DE Long-acting reversible contraception; Young adults; Adolescents; Unplanned pregnancy; Teen pregnancy; Contraception ID UNINTENDED PREGNANCY; WOMENS KNOWLEDGE; UNITED-STATES; INTRAUTERINE-DEVICES; HEALTH-CARE; ATTITUDES; DISPARITIES AB Study Objective: To describe and explore provider- and patient-level perspectives regarding long-acting reversible contraception (LARC) for teens and young adults (ages 16-24). Methods: Data collection occurred between June and December 2011. We first conducted telephone interviews with administrative directors at 20 publicly funded facilities that provide family planning services. At 6 of these sites, we conducted a total of 6 focus group discussions (FGDs) with facility staff and 48 in-depth interviews (IDIs) with facility clients ages 16-24. Results: Staff in the FGDs did not generally equate being a teen with ineligibility for IUDs. In contrast to staff, one-quarter of the young women did perceive young age as rendering them ineligible. Clients and staff agreed that the "forgettable" nature of the methods and their duration were some of LARC's most significant advantages. They also agreed that fear of pain associated with both insertion and removal and negative side effects were disadvantages. Some aspects of IUDs and implants were perceived as advantages by some clients but disadvantages by others. Common challenges to providing LARC-specific services to younger patients included extra time required to counsel young patients about LARC methods, outdated clinic policies requiring multiple visits to obtain IUDs, and a perceived higher removal rate among young women. The most commonly cited strategy for addressing many of these challenges was securing supplementary funding to support the provision of these services to young patients. Conclusion: Incorporating young women's perspectives on LARC methods into publicly funded family planning facilities' efforts to provide these methods to a younger population may increase their use among young women. C1 [Kavanaugh, Megan L.; Frohwirth, Lori; Jerman, Jenna] Guttmacher Inst, Div Res, New York, NY 10038 USA. [Popkin, Ronna] Columbia Univ, New York, NY USA. [Ethier, Kathleen] Ctr Dis Control & Prevent, Off Director, Atlanta, GA USA. RP Kavanaugh, ML (reprint author), Guttmacher Inst, 125 Maiden Lane,7th Floor, New York, NY 10038 USA. EM mkavanaugh@guttmacher.org FU Office of Population Affairs, U.S. Department of Health and Human Services; Guttmacher Institute FX The research on which this report was based was funded through a cooperative agreement between the Office of Population Affairs, U.S. Department of Health and Human Services, and the Guttmacher Institute. Authors have no conflicts of interest to disclose. NR 38 TC 33 Z9 33 U1 2 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-3188 J9 J PEDIATR ADOL GYNEC JI J. Pediatr Adolesc. Gynecol. PD APR PY 2013 VL 26 IS 2 BP 86 EP 95 DI 10.1016/j.jpag.2012.10.006 PG 10 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 117AM UT WOS:000316924500003 PM 23287602 ER PT J AU Inn, KGW Johnson, CM Oldham, W Jerome, S Tandon, L Schaaff, T Jones, R Mackney, D MacKill, P Palmer, B Smith, D LaMont, S Griggs, J AF Inn, Kenneth G. W. Johnson, C. Martin, Jr. Oldham, Warren Jerome, Simon Tandon, Lav Schaaff, Thomas Jones, Robert Mackney, Daniel MacKill, Pam Palmer, Brett Smith, Donna LaMont, Stephen Griggs, John TI The urgent requirement for new radioanalytical certified reference materials for nuclear safeguards, forensics, and consequence management SO JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY LA English DT Article DE Reference materials; Metrology; Nuclear; Safeguards; Post-detonation; Detecting technologies; Consequence management AB A multi-agency workshop was held from 25 to 27 August 2009, at the National Institute of Standards and Technology (NIST), to identify and prioritize the development of radioanalytical Certified Reference Materials (CRMs, generally provided by National Metrology Institutes; Standard Reference Materials, a CRM issued by NIST) for field and laboratory nuclear measurement methods to be used to assess the consequences of a domestic or international nuclear event. Without these CRMs, policy makers concerned with detecting proliferation and trafficking of nuclear materials, attribution and retribution following a nuclear event, and public health consequences of a nuclear event would have difficulty making decisions based on analytical data that would stand up to scientific, public, and judicial scrutiny. The workshop concentrated on three areas: post-incident Improvised Nuclear Device (IND) nuclear forensics, safeguard materials characterization, and consequence management for an IND or a Radiological Dispersion Device detonation scenario. The workshop identified specific CRM requirements to fulfill the needs for these three measurement communities. Of highest priority are: (1) isotope dilution mass spectrometry standards, specifically U-233, Np-236g, Pu-244, and Am-243, used for quantitative analysis of the respective elements that are in critically short supply and in urgent need of replenishment and certification; (2) CRMs that are urgently needed for post-detonation debris analysis of actinides and fission fragments, and (3) CRMs used for destructive and nondestructive analyses for safeguards measurements, and radioisotopes of interest in environmental matrices. C1 [Inn, Kenneth G. W.] NIST, Gaithersburg, MD 20899 USA. [Johnson, C. Martin, Jr.] USAF, San Antonio, TX USA. [Oldham, Warren; Tandon, Lav; Smith, Donna; LaMont, Stephen] Los Alamos Natl Lab, Los Alamos, NM USA. [Jerome, Simon] Natl Phys Lab, London, England. [Schaaff, Thomas] Y12 Natl Secur Complex, Oak Ridge, TN USA. [Jones, Robert] Ctr Dis Control & Prevent, NCEH, Atlanta, GA USA. [Mackney, Daniel; Griggs, John] US EPA, NAREL, Montgomery, AL USA. [MacKill, Pam] US FDA, WEAC, Winchester, MA USA. [Palmer, Brett] Navarro Res & Engn Inc, Oak Ridge, TN USA. RP Inn, KGW (reprint author), NIST, 100 Bur Dr,MS 8462, Gaithersburg, MD 20899 USA. EM kenneth.inn@nist.gov OI Oldham, Warren/0000-0002-0997-2653 NR 19 TC 12 Z9 12 U1 2 U2 32 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0236-5731 J9 J RADIOANAL NUCL CH JI J. Radioanal. Nucl. Chem. PD APR PY 2013 VL 296 IS 1 BP 5 EP 22 DI 10.1007/s10967-012-1972-y PG 18 WC Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology SC Chemistry; Nuclear Science & Technology GA 112CM UT WOS:000316569600003 ER PT J AU Smith, DB Purdy, MA Simmonds, P AF Smith, Donald B. Purdy, Michael A. Simmonds, Peter TI Genetic Variability and the Classification of Hepatitis E Virus SO JOURNAL OF VIROLOGY LA English DT Article ID MOLECULAR-CLONING; C VIRUS; EVOLUTION; GENOME; SEQUENCES; GENOTYPE; HUMANS; HEV; RECOMBINATION; NOMENCLATURE AB The classification of hepatitis E virus (HEV) variants is currently in transition without agreed definitions for genotypes and subtypes or for deeper taxonomic groupings into species and genera that could incorporate more recently characterized viruses assigned to the Hepeviridae family that infect birds, bats, rodents, and fish. These conflicts arise because of differences in the viruses and genomic regions compared and in the methodology used. We have reexamined published sequences and found that synonymous substitutions were saturated in comparisons between and within virus genotypes. Analysis of complete genome sequences or concatenated ORF1/ORF2 amino acid sequences indicated that HEV variants most closely related to those infecting humans can be consistently divided into six genotypes (types 1 to 4 and two additional genotypes from wild boar). Variants isolated from rabbits, closely related to genotype 3, occupy an intermediate position. No consistent criteria could be defined for the assignment of virus subtypes. Analysis of amino acid sequences from these viruses with the more divergent variants from chickens, bats, and rodents in three conserved subgenomic regions (residues 1 to 452 or 974 to 1534 of ORF1 or residues 105 to 458 of ORF2) provided consistent support for a division into 4 groups, corresponding to HEV variants infecting humans and pigs, those infecting rats and ferrets, those from bats, and those from chickens. This approach may form the basis for a future genetic classification of HEV into four species, with the more divergent HEV-like virus from fish (cutthroat trout virus) representing a second genus. C1 [Smith, Donald B.; Simmonds, Peter] Univ Edinburgh, Ctr Immunol Infect & Evolut, Ashworth Labs, Edinburgh, Midlothian, Scotland. [Purdy, Michael A.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Smith, DB (reprint author), Univ Edinburgh, Ctr Immunol Infect & Evolut, Ashworth Labs, Edinburgh, Midlothian, Scotland. EM D.B.Smith@ed.ac.uk FU Wellcome Trust FX This work was supported by a grant from the Wellcome Trust to the CIIE at the University of Edinburgh. NR 40 TC 67 Z9 69 U1 3 U2 19 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD APR PY 2013 VL 87 IS 8 BP 4161 EP 4169 DI 10.1128/JVI.02762-12 PG 9 WC Virology SC Virology GA 113MC UT WOS:000316671000003 PM 23388713 ER PT J AU Abraham, I MacDonald, K Song, M Ciesielski, G Pacheco, C Lee, C Cholette, M Kinsey, K Speaks, P Hermans, C Brie, H Reel, S Van der Niepen, P Yee, B Vancayzeele, S AF Abraham, I. MacDonald, K. Song, M. Ciesielski, G. Pacheco, C. Lee, C. Cholette, M. Kinsey, K. Speaks, P. Hermans, C. Brie, H. Reel, S. Van der Niepen, P. Yee, B. Vancayzeele, S. TI Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study) SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES LA English DT Article DE Hypertension; Obesity; Angiotensin II receptor blocker; Valsartan; Effectiveness; Body mass index; Pharmacoepidemiology ID CARDIOVASCULAR-DISEASE; PRIMARY-CARE; HYPERTENSION; RISK; OUTCOMES; OBESITY; POPULATION; PREVALENCE; MANAGEMENT; BELGIUM AB Background and aims: Obesity combined with hypertension places patients at greater risk for target-organ damage and cardiovascular disease. The purpose of this secondary analysis was to identify physician-and patient-levels determinants of blood pressure (BP) values and predictors of uncontrolled BP through subgroup analysis by body mass index (BMI). Methods and results: We conducted a subgroup analysis of 3006 patients with High-BMI (BMI >25 kg/m(2); n = 2124) and Normal-BMI (BMI<25 kg/m(2); n = 882) treated by 504 physicians and enrolled in PREVIEW, a Belgian prospective, multi-center, pharmaco-epidemiological study of 90-day second-line treatment with valsartan. Physician-and patient-level determinants of BP values and BP control were identified by means of hierarchical linear and logistic regression. Blood pressure values and control after 90 days of treatment were consistently lower for the High-BMI group. The 25.5% of variance in 90-day systolic and 28.3% of the variance in 90-day diastolic BP were attributable to physician-level determinants for the High-BMI group; versus 27.3% and 29.8% for the Normal-BMI group (ICC = 0.273 and 0.298, respectively). Determinants of 90-day BP values and predictors of uncontrolled BP varied considerably by BMI status. Conclusion: Several common and unique patient- and physician-level determinants of BP values and control were identified for the High-BMI and Normal-BMI groups. These findings highlight the need for differentiating healthcare interventions to account for patient and physician variables, particularly with respect to effective BP management in vulnerable populations. (C) 2011 Elsevier B.V. All rights reserved. C1 [Abraham, I.] Univ Arizona, Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ 85721 USA. [Abraham, I.] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA. [Abraham, I.; MacDonald, K.; Song, M.; Ciesielski, G.; Pacheco, C.; Lee, C.] Matrix45, Earlysville, VA USA. [Song, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ciesielski, G.; Pacheco, C.; Cholette, M.; Kinsey, K.; Speaks, P.; Reel, S.] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA. [Lee, C.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Hermans, C.; Brie, H.; Vancayzeele, S.] Novartis Pharmaceut, Vilvoorde, Belgium. [Van der Niepen, P.] Univ Ziekenhuis, Dept Hypertens & Nephrol, Brussels, Belgium. [Yee, B.] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. RP Abraham, I (reprint author), Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Ctr Hlth Outcomes & PharmacoEcon Res, 1295 N Martin, Tucson, AZ 85721 USA. EM abraham@pharmacy.arizona.edu FU Novartis Pharma; Novartis FX The PREVIEW study was sponsored by Novartis Pharma through research grants and contracts. The analyses reported in this manuscript were not done under these grants and contracts, but independently by the external authors. Statistical analysis and manuscript development were done independently from the sponsor. Any issues related to results or manuscripts were addressed by the external authors. Sponsor had right of review and comment. Authors employed by sponsor refrained from undue influence.; I. Abraham, K. MacDonald, M. Song, G. Ciesielski, C. Pacheco, and B. Yee are or were employees of Matrix45. Company policy prohibits employees from owning equity in client organizations of Matrix45 (except for independently administered, collective funds). Matrix45 performs similar studies for other pharmaceutical companies on a non-exclusivity basis. C. Hermans, H. Brie, and S. Vancayzeele are employees of Novartis. P. Van der Niepen has received research grants from Novartis. All other authors report no conflicts. NR 19 TC 0 Z9 0 U1 0 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0939-4753 J9 NUTR METAB CARDIOVAS JI Nutr. Metab. Carbiovasc. Dis. PD APR PY 2013 VL 23 IS 4 BP 314 EP 322 DI 10.1016/j.numecd.2011.06.005 PG 9 WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition & Dietetics SC Cardiovascular System & Cardiology; Endocrinology & Metabolism; Nutrition & Dietetics GA 114SS UT WOS:000316763400006 PM 21930367 ER PT J AU Nelson, GE Aguon, A Valencia, E Oliva, R Guerrero, ML Reyes, R Lizama, A Diras, D Mathew, A Camacho, EJ Monforte, MN Chen, TH Mahamud, A Kutty, PK Hickman, C Bellini, WJ Seward, JF Gallagher, K Fiebelkorn, AP AF Nelson, George E. Aguon, Annette Valencia, Engracia Oliva, Rita Guerrero, Michele Leon Reyes, Richard Lizama, Anna Diras, Daryl Mathew, Annakutty Camacho, E. Jessica Monforte, Moryne-Nicole Chen, Tai-Ho Mahamud, Abdirahman Kutty, Preeta K. Hickman, Carole Bellini, William J. Seward, Jane F. Gallagher, Kathleen Fiebelkorn, Amy Parker TI Epidemiology of a Mumps Outbreak in a Highly Vaccinated Island Population and Use of a Third Dose of Measles-Mumps-Rubella Vaccine for Outbreak Control-Guam 2009 to 2010 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE mumps; outbreak control; third dose measles-mumps-rubella intervention; vaccine preventable disease; immunization ID UNITED-STATES; MMR VACCINATIONS; ORCHITIS; IMPACT AB Background: Despite high 2-dose measles-mumps-rubella (MMR) vaccine coverage, a large mumps outbreak occurred on the US Territory of Guam during 2009 to 2010, primarily in school-aged children. Methods: We implemented active surveillance in April 2010 during the outbreak peak and characterized the outbreak epidemiology. We administered third doses of MMR vaccine to eligible students aged 9-14 years in 7 schools with the highest attack rates (ARs) between May 18, 2010, and May 21, 2010. Baseline surveys, follow-up surveys and case-reports were used to determine mumps ARs. Adverse events postvaccination were monitored. Results: Between December 1, 2009, and December 31, 2010, 505 mumps cases were reported. Self-reported Pohnpeians and Chuukese had the highest relative risks (54.7 and 19.7, respectively) and highest crowding indices (mean: 3.1 and 3.0 persons/bedroom, respectively). Among 287 (57%) school-aged case-patients, 270 (93%) had >= 2 MMR doses. A third MMR dose was administered to 1068 (33%) eligible students. Three-dose vaccinated students had an AR of 0.9/1000 compared with 2.4/1000 among students vaccinated with <= 2 doses >1 incubation period postintervention, but the difference was not significant (P = 0.67). No serious adverse events were reported. Conclusions: This mumps outbreak occurred in a highly vaccinated population. The highest ARs occurred in ethnic minority populations with the highest household crowding indices. After the third dose MMR intervention in highly affected schools, 3-dose recipients had an AR 60% lower than students with <= 2 doses, but the difference was not statistically significant and the intervention occurred after the outbreak peaked. This outbreak may have persisted due to crowding at home and high student contact rates. C1 [Nelson, George E.; Mahamud, Abdirahman; Kutty, Preeta K.; Hickman, Carole; Bellini, William J.; Seward, Jane F.; Fiebelkorn, Amy Parker] Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Nelson, George E.; Mahamud, Abdirahman] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Gallagher, Kathleen] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. RP Fiebelkorn, AP (reprint author), CDC NCIRD, 1600 Clifton Rd,MS A-34, Atlanta, GA 30333 USA. EM AParker@cdc.gov FU NIAID NIH HHS [T32 AI007291] NR 43 TC 24 Z9 24 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD APR PY 2013 VL 32 IS 4 BP 374 EP 380 DI 10.1097/INF.0b013e318279f593 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 113LM UT WOS:000316669200025 PM 23099425 ER PT J AU Callinan, LS Schonberger, LB Belay, ED Vugia, DJ AF Callinan, Laura S. Schonberger, Lawrence B. Belay, Ermias D. Vugia, Duc J. TI Diagnosis and Treatment of Suspected Kawasaki Disease Before the Fifth Day of Illness Reply SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Letter ID MANAGEMENT C1 [Callinan, Laura S.; Schonberger, Lawrence B.; Belay, Ermias D.] Ctr Dis Control & Prevent, Div High Consequences Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Vugia, Duc J.] Calif Dept Publ Hlth, Div Communicable Dis Control, Infect Dis Branch, Richmond, CA USA. RP Callinan, LS (reprint author), Ctr Dis Control & Prevent, Div High Consequences Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. NR 7 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD APR PY 2013 VL 32 IS 4 BP 425 EP 425 DI 10.1097/INF.0b013e31827b190a PG 1 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 113LM UT WOS:000316669200041 PM 23552681 ER PT J AU Patel, MM Pitzer, VE Alonso, WJ Vera, D Lopman, B Tate, J Viboud, C Parashar, UD AF Patel, Manish M. Pitzer, Virginia E. Alonso, Wladimir J. Vera, David Lopman, Ben Tate, Jacqueline Viboud, Cecile Parashar, Umesh D. TI Global Seasonality of Rotavirus Disease SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE rotavirus; seasonality; season; diarrhea; global; surveillance ID HOSPITAL-BASED SURVEILLANCE; AGED LESS-THAN-5 YEARS; GROUP-A ROTAVIRUS; THAN 5 YEARS; WATERBORNE GASTROENTERITIS OUTBREAK; MOLECULAR EPIDEMIOLOGY; ECONOMIC BURDEN; ACUTE DIARRHEA; BUENOS-AIRES; SENTINEL HOSPITALS AB Background: A substantial number of surveillance studies have documented rotavirus prevalence among children admitted for dehydrating diarrhea. We sought to establish global seasonal patterns of rotavirus disease before the introduction of widespread vaccination. Methods: We reviewed studies of rotavirus detection in children with diarrhea published since 1995. We assessed potential relationships between seasonal prevalence and locality by plotting the average monthly proportion of diarrhea cases positive for rotavirus according to geography, country development and latitude. We used linear regression to identify variables that were potentially associated with the seasonal intensity of rotavirus. Results: Among a total of 99 studies representing all 6 geographic regions of the world, patterns of year-round disease were more evident in low- and low-middle income countries compared with upper-middle and high-income countries where disease was more likely to be seasonal. The level of country development was a stronger predictor of strength of seasonality (P = 0.001) than geographic location or climate. However, the observation of distinctly different seasonal patterns of rotavirus disease in some countries with similar geographic location, climate and level of development indicate that a single unifying explanation for variation in seasonality of rotavirus disease is unlikely. Conclusion: While no unifying explanation emerged for varying rotavirus seasonality globally, the country income level was somewhat more predictive of the likelihood of having seasonal disease than other factors. Future evaluation of the effect of rotavirus vaccination on seasonal patterns of disease in different settings may help understand factors that drive the global seasonality of rotavirus disease. C1 [Patel, Manish M.; Vera, David; Lopman, Ben; Tate, Jacqueline; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Pitzer, Virginia E.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA. [Pitzer, Virginia E.; Alonso, Wladimir J.; Viboud, Cecile] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Pitzer, Virginia E.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. RP Patel, MM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-47, Atlanta, GA 30333 USA. EM mpatel@cdc.gov OI Pitzer, Virginia/0000-0003-1015-2289 FU Bill and Melinda Gates Foundation; RAPIDD program of the Science & Technology Directorate; Department of Homeland Security; Fogarty International Center, National Institutes of Health FX This work was partially supported by the Bill and Melinda Gates Foundation and the RAPIDD program of the Science & Technology Directorate, Department of Homeland Security and the Fogarty International Center, National Institutes of Health (VEP). The funders had no role in study design, data collection, analysis and interpretation, or writing of the report. Manish Patel had full access to all the data in the study and had final responsibility for the decision to submit for publication. The authors have no other funding or conflicts of interest to disclose. NR 128 TC 24 Z9 25 U1 0 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD APR PY 2013 VL 32 IS 4 BP E134 EP E147 DI 10.1097/INF.0b013e31827d3b68 PG 14 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 113LM UT WOS:000316669200003 PM 23190782 ER PT J AU Greene, SK Li, LL Shay, DK Fry, AM Lee, GM Jacobsen, SJ Baxter, R Irving, SA Jackson, ML Naleway, AL Nordin, JD Narwaney, KJ Lieu, TA AF Greene, Sharon K. Li, Lingling Shay, David K. Fry, Alicia M. Lee, Grace M. Jacobsen, Steven J. Baxter, Roger Irving, Stephanie A. Jackson, Michael L. Naleway, Allison L. Nordin, James D. Narwaney, Komal J. Lieu, Tracy A. TI Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 20072010 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE influenza; oseltamivir; adverse events; psychiatric events; matched cohort; propensity scores; pharmacoepidemiology ID NEUROLOGIC COMPLICATIONS; VALIDATED METHODS; PROPENSITY SCORE; CHILDREN; INFECTION; DATABASES; BIAS; TEXAS AB Purpose An association between the influenza antiviral medication oseltamivir and neuropsychiatric events has been suggested by post-marketing case reports in Japan. This possible association was not supported by cohort studies in the U.S. conducted prior to the 2009 influenza A (H1N1) pandemic, when usage rates were comparatively low. We assessed oseltamivir safety before and during the pandemic using biologically plausible risk intervals, particularly focusing on psychiatric events. Methods Outpatients with influenza episodes from January 2007 through June 2010 were identified using diagnosis codes and positive tests at eight health care systems (sites) in the Vaccine Safety Datalink Project. Oseltamivir-treated and untreated patients were matched according to calendar week, age, sex, site, and propensity for treatment. Within this matched cohort, conditional logistic regression models were used to estimate the risk of four neuropsychiatric and five other adverse events (AEs) during pre-specified risk intervals. Results Among 27684 matched pairs, no associations were identified between oseltamivir treatment and any pre-defined AE. The absolute risks of incident psychiatric events in the 17 day risk interval were 0.126% for oseltamivir-treated and 0.105% for untreated patients (odds ratio=1.21, 95% confidence interval [CI]: 0.74, 1.97; risk difference=0.022%, 95% CI: 0.035%, 0.078%); the most common diagnosis was unspecified anxiety state. Results were similar for 114 and 12 day risk intervals and for pediatric/adolescent subgroups. Conclusions Consistent with prior U.S. cohort studies, no evidence was identified for an increased risk of neuropsychiatric or other AEs following oseltamivir treatment. Safety should be prospectively monitored to inform antiviral medication usage recommendations. Copyright (c) 2012 John Wiley & Sons, Ltd. C1 [Greene, Sharon K.; Li, Lingling; Lee, Grace M.; Lieu, Tracy A.] Harvard Univ, Dept Populat Med, Sch Med, Boston, MA 02215 USA. [Greene, Sharon K.; Li, Lingling; Lee, Grace M.; Lieu, Tracy A.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Shay, David K.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Lee, Grace M.] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Lee, Grace M.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Baxter, Roger] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Irving, Stephanie A.] Marshfield Clin Fdn Med Res & Educ, Epidemiol Res Ctr, Marshfield, WI 54449 USA. [Jackson, Michael L.] Grp Hlth Res Inst, Seattle, WA USA. [Naleway, Allison L.] Kaiser Permanente NW Ctr Hlth Res, Portland, OR USA. [Nordin, James D.] HealthPartners Res Fdn, Minneapolis, MN USA. [Narwaney, Komal J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Lieu, Tracy A.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. RP Greene, SK (reprint author), Harvard Univ, Dept Populat Med, Sch Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM Sharon_Greene@harvardpilgrim.org OI Naleway, Allison/0000-0001-5747-4643; Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820; Jacobsen, Steven/0000-0002-8174-8533 FU Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX This work was supported by a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). We appreciate the contributions of Ruihua Yin (programming), Robert Jin (quality control), Melisa Rett (project management), Natalie McCarthy, Rich Fox, Nick Berger, Vidhu Choudhary, Bradley Crane (data management), and Drs. Andrew Mosholder, Elizabeth Maloney, Paul Gargiullo, Martin Kulldorff, and Rich Platt (scientific guidance). NR 44 TC 6 Z9 7 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD APR PY 2013 VL 22 IS 4 BP 335 EP 344 DI 10.1002/pds.3363 PG 10 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 118FM UT WOS:000317009200001 PM 23129321 ER PT J AU Haegerich, TM Massetti, GM AF Haegerich, Tamara M. Massetti, Greta M. TI Commentary on Subgroup Analysis in Intervention Research: Opportunities for the Public Health Approach to Violence Prevention SO PREVENTION SCIENCE LA English DT Editorial Material DE Subgroup analysis; Preventive intervention research; Violence prevention ID OUTCOMES AB The public health approach to prevention places a unique emphasis on understanding which populations are at greatest risk for poor health; the factors that place different populations at risk for experiencing injury, death, disability, and related health outcomes; the preventive interventions that are most effective for universal, selected, and indicated populations; and the best methods for encouraging the translation, dissemination, and adoption of preventive interventions for various populations. This information can be valuable in maximizing the efficiency and effectiveness of public health prevention approaches. The present article provides a commentary on the contributions of rigorous subgroup analysis to intervention research and, in particular, the Centers for Disease Control and Prevention's (CDC) public health approach to violence prevention. C1 [Haegerich, Tamara M.; Massetti, Greta M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Massetti, GM (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,NE,MS F-64, Atlanta, GA 30341 USA. EM GMassetti@cdc.gov OI Massetti, Greta/0000-0002-3813-9839 NR 14 TC 1 Z9 1 U1 2 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1389-4986 J9 PREV SCI JI Prev. Sci. PD APR PY 2013 VL 14 IS 2 SI SI BP 193 EP 198 DI 10.1007/s11121-012-0331-0 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 119CN UT WOS:000317074800010 PM 22996604 ER PT J AU Sullivan, KM Perrine, CG Pearce, EN Caldwell, KL AF Sullivan, Kevin M. Perrine, Cria G. Pearce, Elizabeth N. Caldwell, Kathleen L. TI Monitoring the Iodine Status of Pregnant Women in the United States SO THYROID LA English DT Letter ID AMERICAN-THYROID-ASSOCIATION; NATIONAL-HEALTH; URINARY IODINE; NUTRITION; DEFICIENCY C1 [Sullivan, Kevin M.; Perrine, Cria G.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Caldwell, Kathleen L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Sullivan, Kevin M.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Pearce, Elizabeth N.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. RP Sullivan, KM (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM cdckms@emory.edu FU Intramural CDC HHS [CC999999] NR 13 TC 5 Z9 6 U1 0 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD APR PY 2013 VL 23 IS 4 BP 520 EP 521 DI 10.1089/thy.2012.0217 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 115FT UT WOS:000316798700021 PM 23157653 ER PT J AU Lo, TQ Oeltmann, JE Odhiambo, FO Beynon, C Pevzner, E Cain, KP Laserson, KF Phillips-Howard, PA AF Lo, T. Q. Oeltmann, J. E. Odhiambo, F. O. Beynon, C. Pevzner, E. Cain, K. P. Laserson, K. F. Phillips-Howard, P. A. TI Alcohol use, drunkenness and tobacco smoking in rural western Kenya SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE drinking alcohol; smoking; rural; western Kenya ID TREATED BED NETS; AFRICAN COUNTRIES; HOUSEHOLD SURVEYS; GLOBAL BURDEN; UNSAFE SEX; DISEASES; PREVALENCE; DRINKING; RISK; SUBSTANCE AB Objectives To describe the prevalence of smoking and alcohol use and abuse in an impoverished rural region of western Kenya. Methods Picked from a population-based longitudinal database of demographic and health census data, 72292 adults (18years) were asked to self-report their recent (within the past 30days) and lifetime use of tobacco and alcohol and frequency of recent drunkenness'. Results Overall prevalence of ever smoking was 11.2% (11.011.5) and of ever drinking, 20.7% (20.421.0). The prevalence of current smoking was 6.3% (6.16.5); 5.7% (5.55.9) smoked daily. 7.3% (7.17.5) reported drinking alcohol within the past 30days. Of these, 60.3% (58.961.6) reported being drunk on half or more of all drinking occasions. The percentage of current smokers rose with the number of drinking days in a month (P<0.0001). Tobacco and alcohol use increased with decreasing socio-economic status and amongst women in the oldest age group (P<0.0001). Conclusions Tobacco and alcohol use are prevalent in this rural region of Kenya. Abuse of alcohol is common and likely influenced by the availability of cheap, home-manufactured alcohol. Appropriate evidence-based policies to reduce alcohol and tobacco use should be widely implemented and complemented by public health efforts to increase awareness of their harmful effects. Objectifs Decrire la prevalence de la consommation et l'abus de tabac et d'alcool dans une region rurale pauvre de l'ouest du Kenya. Methodes Selectionnes a partir d'une base de donnees longitudinale basee sur la population des donnees du recensement demographique et de sante, 72292 adultes (18ans) ont ete invites a auto-declarer leur usage recent (au cours des 30 derniers jours) et general du tabac et de l'alcool et la frequence de recentes << ivresses >>. Resultats La prevalence globale des occasions d'avoir deja fume etait de 11.2% (de 11.0 a 11.5) et d'avoir deja bu, 20.7% (20.4 a 21.0). La prevalence du tabagisme actuel etait de 6.3% (6.16.5); 5.7% (5.5 a 5.9) fumaient tous les jours. Of 7.3% (7.1 a 7.5) ont declare avoir consomme de l'alcool au cours des 30 derniers jours. Parmi ceux-ci, 60.3% (58.9 a 61.6) ont declare avoir ete ivre pour la moitie ou plus de l'ensemble des occasions de consommation d'alcool. Le pourcentage de fumeurs actuels augmentait avec le nombre de jours de consommation d'alcool dans un mois (P<0.0001). La consommation de tabac et d'alcool augmentait avec la diminution du statut socio-economique et chez les femmes dans la tranche d'age la plus elevee (P<0.0001). Conclusions La consommation de tabac et d'alcool est frequente dans cette region rurale du Kenya. L'abus d'alcool est frequent et probablement influence par la disponibilite d'alcool pas cher, fabrique localement. Des politiques fondees sur des preuves pour reduire la consommation d'alcool et de tabac devraient etre largement mises en OEuvre, completees par des efforts de sante publique pour mieux conscientiser sur leurs effets nocifs. Objetivos Describir la prevalencia del uso y abuso del tabaco y del alcohol en una region rural empobrecida de Kenia occidental. Metodos De una base de datos poblacional y longitudinal, con datos del censo demografico y sanitario, se escogieron 72292 adultos (18anos) y se les pidio que autoreportaran su uso reciente (en los ultimos 30 dias) y a lo largo de toda su vida del tabaco y del alcohol, asi como la frecuencia de borracheras recientes. Resultados La prevalencia total de haber fumado alguna vez, era del 11.2% (11.011.5) y de haber bebido alguna vez, 20.7% (20.421.0). La prevalencia del fumar en la actualidad era del 6.3% (6.16.5); 5.7% (5.55.9) fumaba a diario. Of 7.3% (7.17.5) reportaron haber bebido alcohol en los ultimos 30 dias. De estos, un 60.3% (58.961.6) reportaron haber estado borrachos en la mitad o mas de las ocasiones en las que habian bebido. El porcentaje de fumadores actuales aumento con el numero de dias en que bebian al mes (P<0.0001). El uso del tabaco y del alcohol aumento con una disminucion del estatus socio-economico y entre las mujeres dentro del grupo de mayor edad (P<0.0001). Conclusiones El uso del tabaco y del alcohol son prevalentes en esta region rural de Kenia. El abuso del alcohol es comun y probablemente ha estado influenciado por la disponibilidad de alcohol barato, elaborado en los hogares. Se deberian implementar politicas apropiadas, basadas en la evidencia, para reducir el uso del alcohol y del tabaco, complementadas con esfuerzos de salud publica para aumentar la conciencia sobre sus efectos daninos. C1 [Lo, T. Q.; Oeltmann, J. E.; Pevzner, E.; Cain, K. P.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Odhiambo, F. O.; Cain, K. P.; Laserson, K. F.] Ctr Dis Control & Prevent, Res & Publ Hlth Collaborat, Kenya Med Res Inst, Atlanta, GA 30333 USA. [Beynon, C.] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 5UX, Merseyside, England. [Laserson, K. F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. [Phillips-Howard, P. A.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Lo, TQ (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM terrencelo@cdc.gov OI Phillips-Howard, Penelope A/0000-0003-1018-116X FU KEMRI CDC collaboration FX We wish to acknowledge the staff at Kenyan Medical Research Institute (KEMRI) CDC who have spent countless hours collecting and processing data from the Health and Demographic Surveillance System (HDSS) in Kisumu, Kenya. The Health HDSS is supported through funding by the KEMRI CDC collaboration. NR 46 TC 7 Z9 7 U1 4 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD APR PY 2013 VL 18 IS 4 BP 506 EP 515 DI 10.1111/tmi.12066 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 112XF UT WOS:000316627200017 PM 23489316 ER PT J AU Patel, A Holman, RC Callinan, LS Sreenivasan, N Schonberger, LB Fischer, TK Belay, ED AF Patel, Amy Holman, Robert C. Callinan, Laura S. Sreenivasan, Nandini Schonberger, Lawrence B. Fischer, Thea K. Belay, Ermias D. TI Evaluation of clinical characteristics of Kawasaki syndrome and risk factors for coronary artery abnormalities among children in Denmark SO ACTA PAEDIATRICA LA English DT Article DE Children; Denmark; Kawasaki syndrome ID AMERICAN-HEART-ASSOCIATION; UNITED-STATES; SYNDROME HOSPITALIZATIONS; RHEUMATIC-FEVER; DISEASE; DIAGNOSIS; CRITERIA; AGE AB Aim To examine clinical characteristics, treatment and outcome of Kawasaki syndrome patients in Denmark. Methods A retrospective chart review of hospitalization records for children <15years of age with a Kawasaki syndrome discharge diagnosis identified through the Danish National Patient Registry during 1994 through June 2008 was conducted. Results A total of 284 cases <15years of age were identified as Kawasaki syndrome (n=279) and atypical Kawasaki syndrome (n=5); 70.4% were <5years of age and 64.4% were male. Most patients (91.5%; 258/282) were treated with intravenous immunoglobulin and 74.6% of these patients (191/256) received intravenous immunoglobulin before the 10th day of illness. A total of 37 (13.3%) Kawasaki syndrome patients were diagnosed with coronary artery abnormalities. Not receiving intravenous immunoglobulin treatment before the 10th day of illness, young age and male sex were significantly associated with the development of coronary artery abnormalities. Conclusions In Denmark, more than one in 10 children with Kawasaki syndrome develop coronary artery abnormalities. Physicians should increase their index of suspicion for early diagnosis and treatment of Kawasaki syndrome among patients susceptible to increased risk of coronary artery abnormalities, particularly in infants who may have a more atypical presentation of the illness. C1 [Patel, Amy] Univ Copenhagen, Copenhagen, Denmark. [Holman, Robert C.; Callinan, Laura S.; Schonberger, Lawrence B.; Belay, Ermias D.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, US Dept HHS, Atlanta, GA USA. [Sreenivasan, Nandini] Koge Hosp, Dept Emergency Med, Koge, Denmark. [Fischer, Thea K.] Statens Serum Inst, Dept Virol, DK-2300 Copenhagen, Denmark. RP Patel, A (reprint author), Hillerod Hosp, Dept Surg, Hillerod, Denmark. EM amygronholt@gmail.com OI Fischer, Thea Kolsen/0000-0003-4812-980X FU Centers for Disease Control and Prevention FX Funded through the Centers for Disease Control and Prevention. NR 30 TC 2 Z9 2 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0803-5253 J9 ACTA PAEDIATR JI Acta Paediatr. PD APR PY 2013 VL 102 IS 4 BP 385 EP 390 DI 10.1111/apa.12142 PG 6 WC Pediatrics SC Pediatrics GA 108VX UT WOS:000316325400026 PM 23278838 ER PT J AU Lu, PJ Williams, WW Li, J Dorell, C Yankey, D Kepka, D Dunne, EF AF Lu, Peng-jun Williams, Walter W. Li, Jun Dorell, Christina Yankey, David Kepka, Deanna Dunne, Eileen F. TI Human Papillomavirus Vaccine Initiation and Awareness US Young Men in the 2010 National Health Interview Survey SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES; CERVICAL-CANCER; HPV VACCINE; ADULT VACCINATION; ADOLESCENT MALES; WOMEN; COVERAGE; DISPARITIES; PREVENTION; CARE AB Background: In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9-26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing HPV vaccine administration to this group. Purpose: To assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV vaccine, and identify factors independently associated with such awareness among men aged 18-26 years. Methods: Data from the 2010 National Health Interview Survey were analyzed in 2011. Results: In 2010, HPV vaccination initiation among men aged 18-26 years was 1.1%. Among the 1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a higher likelihood of awareness of both HPV and HPV vaccine among men aged 18-26 years included having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician contacts; private health insurance; received other vaccines; and reported risk behaviors related to sexually transmitted diseases, including HIV. Conclusions: HPV vaccination initiation among men aged 18-26 years in 2010 was low. HPV and HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP published a recommendation for routine use of HPV4 among men/boys in December 2011, continued monitoring of HPV vaccination uptake among men aged 18-26 years is useful for evaluating the vaccination campaigns, and planning and implementing strategies to increase coverage. (Am J Prey Med 2013:44(4):330-338) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Lu, Peng-jun; Williams, Walter W.; Dorell, Christina; Yankey, David] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Li, Jun] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Dunne, Eileen F.] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Kepka, Deanna] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Lu, PJ (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 49 TC 9 Z9 9 U1 2 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2013 VL 44 IS 4 BP 330 EP 338 DI 10.1016/j.amepre.2012.11.027 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 111GM UT WOS:000316509800002 PM 23498097 ER PT J AU Helmick, CG Sacks, JJ Gelfand, JM Bebo, B Lee-Han, H Baird, T Bartlett, C AF Helmick, Charles G. Sacks, Jeffrey J. Gelfand, Joel M. Bebo, Bruce, Jr. Lee-Han, Hyewon Baird, Tiffany Bartlett, Chris TI Psoriasis and Psoriatic Arthritis A Public Health Agenda SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID UNITED-STATES; EPIDEMIOLOGY; CARE C1 [Helmick, Charles G.] CDC, Arthrit Program, Atlanta, GA 30341 USA. [Sacks, Jeffrey J.] Sue Binder Consulting Inc, Atlanta, GA USA. [Baird, Tiffany] SciMetrika, Atlanta, GA USA. [Gelfand, Joel M.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Gelfand, Joel M.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Gelfand, Joel M.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Bebo, Bruce, Jr.] Natl Psoriasis Fdn, Portland, OR USA. [Lee-Han, Hyewon; Bartlett, Chris] SciMetrika, Durham, NC USA. RP Helmick, CG (reprint author), CDC, 4770 Buford Hwy,K51, Atlanta, GA 30341 USA. EM CHelmick@cdc.gov FU Intramural CDC HHS [CC999999]; PHS HHS [200-2008-27889] NR 7 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2013 VL 44 IS 4 BP 424 EP 426 DI 10.1016/j.amepre.2013.01.004 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 111GM UT WOS:000316509800015 PM 23498110 ER PT J AU Dahm, MM Evans, DE Schubauer-Berigan, MK Birch, ME Deddens, JA AF Dahm, Matthew M. Evans, Douglas E. Schubauer-Berigan, Mary K. Birch, M. Eileen Deddens, James A. TI Occupational Exposure Assessment in Carbon Nanotube and Nanofiber Primary and Secondary Manufacturers: Mobile Direct-Reading Sampling SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE carbon nanofibers; carbon nanotubes; exposure assessment; nanomaterials; nanoparticles ID POTENTIAL INHALATION EXPOSURE; ASSESSMENT TECHNIQUE NEAT; ENGINEERED NANOMATERIALS; NANOSTRUCTURED PARTICLES; ENVIRONMENTAL-HEALTH; ULTRAFINE PARTICLES; EMISSION; PART; NANOPARTICLES; IDENTIFICATION AB Toxicological evidence suggests the potential for a wide range of health effects from exposure to carbon nanotubes (CNTs) and carbon nanofibers (CNFs). To date, there has been much focus on the use of direct-reading instruments (DRIs) to assess multiple airborne exposure metrics for potential exposures to CNTs and CNFs due to their ease of use and ability to provide instantaneous results. Still, uncertainty exists in the usefulness and interpretation of the data. To address this gap, air-monitoring was conducted at six sites identified as CNT and CNF manufacturers or users and results were compared with filter-based metrics. Particle number, respirable mass, and active surface area concentrations were monitored with a condensation particle counter, a photometer, and a diffusion charger, respectively. The instruments were placed on a mobile cart and used as area monitors in parallel with filter-based elemental carbon (EC) and electron microscopy samples. Repeat samples were collected on consecutive days, when possible, during the same processes. All instruments in this study are portable and routinely used for industrial hygiene sampling. Differences were not observed among the various sampled processes compared with concurrent indoor or outdoor background samples while examining the different DRI exposure metrics. Such data were also inconsistent with results for filter-based samples collected concurrently at the same sites [Dahm MM, Evans DE, Schubauer-Berigan MK et al. (2012) Occupational exposure assessment in CNT and nanofiber primary and secondary manufacturers. Ann Occup Hyg; 56: 54256]. Significant variability was seen between these processes as well as the indoor and outdoor backgrounds. However, no clear pattern emerged linking the DRI results to the EC or the microscopy data (CNT and CNF structure counts). Overall, no consistent trends were seen among similar processes at the various sites. The DRI instruments employed were limited in their usefulness in assessing and quantifying potential exposures at the sampled sites but were helpful for hypothesis generation, control technology evaluations, and other air quality issues. The DRIs employed are nonspecific, aerosol monitors, and, therefore, subject to interferences. As such, it is necessary to collect samples for analysis by more selective, time-integrated, laboratory-based methods to confirm and quantify exposures. C1 [Dahm, Matthew M.; Schubauer-Berigan, Mary K.; Deddens, James A.] NIOSH, Div Surveillance Hazard Evaluat & Field Studi, Industrywide Studies Branch, Cincinnati, OH 45226 USA. [Evans, Douglas E.; Birch, M. Eileen] NIOSH, Div Appl Res & Technol, Chem Exposure & Monitoring Branch, Cincinnati, OH 45226 USA. RP Dahm, MM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studi, Industrywide Studies Branch, 4676 Columbia Pkwy,MS R14, Cincinnati, OH 45226 USA. EM mdahm@cdc.gov RI Dahm, Matthew/I-2131-2012; Schubauer-Berigan, Mary/B-3149-2009 OI Schubauer-Berigan, Mary/0000-0002-5175-924X FU NIOSH Nanotechnology Research Center FX NIOSH Nanotechnology Research Center supplemental funding. NR 51 TC 39 Z9 44 U1 1 U2 53 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD APR PY 2013 VL 57 IS 3 BP 328 EP 344 DI 10.1093/annhyg/mes079 PG 17 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 108CW UT WOS:000316270000007 PM 23100605 ER PT J AU Sinkule, EJ Powell, JB Goss, FL AF Sinkule, Edward James Powell, Jeffrey Bryon Goss, Fredric Lee TI Evaluation of N95 Respirator Use with a Surgical Mask Cover: Effects on Breathing Resistance and Inhaled Carbon Dioxide SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE breathing resistance; effects from using N95 respirators; extending N95 respirators during influenza outbreak; inhaled carbon dioxide; inhaled oxygen; metabolic simulator; N95 respirator; respiratory protection; surgical mask; using N95 respirators with surgical or procedure masks ID HEALTH-CARE WORKERS; INCREMENTAL EXERCISE; ELASTIC LOADS; INCREASE; ABILITY; DETECT; BLOOD AB For pandemic influenza outbreaks, the Institute of Medicine has recommended using a surgical mask cover (SM) over N95 filtering facepiece respirators (FFRs) among healthcare workers as one strategy to avoid surface contamination of the FFR which would extend its efficacy and reduce the threat of exhausting FFR supplies. The objective of this investigation was to measure breathing air quality and breathing resistance when using FFRs with US Food and Drug Administration-cleared SM and without SM. Thirty National Institute for Occupational Safety and Health (NIOSH)-approved FFR models with and without SM were evaluated using the NIOSH Automated Breathing and Metabolic Simulator (ABMS) through six incremental work rates. Generally, concentrations of average inhaled CO2 decreased and average inhaled O-2 increased with increasing O-2 consumption for FFRSM and FFR-only. For most work rates, peak inhalation and exhalation pressures were statistically higher in FFRSM as compared with FFR-only. The type of FFR and the presence of exhalation valves (EVs) had significant effects on average inhaled CO2, average inhaled O-2, and breathing pressures. The evidence suggests that placement of an SM on one type of FFR improved inhaled breathing gas concentrations over the FFR without SM; the placement of an SM over an FFREV probably will prevent the EV from opening, regardless of activity intensity; and, at lower levels of energy expenditure, EVs in FFR do not open either with or without an SM. The differences in inhaled gas concentrations in FFRSM and FFR-only were significant, especially at lower levels of energy expenditure. The orientation of the SM on the FFR may have a significant effect on the inhaled breathing quality and breathing resistance, although the measurable inhalation and exhalation pressures caused by SM over FFR for healthcare users probably will be imperceptible at lower activity levels. C1 [Sinkule, Edward James; Powell, Jeffrey Bryon] NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. [Goss, Fredric Lee] Univ Pittsburgh, Ctr Exercise & Hlth Fitness Res, Pittsburgh, PA USA. RP Sinkule, EJ (reprint author), NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. EM ESinkule@cdc.gov NR 33 TC 8 Z9 8 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD APR PY 2013 VL 57 IS 3 BP 384 EP 398 DI 10.1093/annhyg/mes068 PG 15 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 108CW UT WOS:000316270000011 PM 23108786 ER PT J AU Pappas, PG Kontoyiannis, DP Perfect, JR Chillerd, TM AF Pappas, Peter G. Kontoyiannis, Dimitrios P. Perfect, John R. Chillerd, Tom M. TI Real-Time Treatment Guidelines: Considerations during the Exserohilum rostratum Outbreak in the United States SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Editorial Material ID NERVOUS-SYSTEM ASPERGILLOSIS; CONVENTIONAL AMPHOTERICIN-B; CRYPTOCOCCAL MENINGITIS; VORICONAZOLE; TRIAL; PHARMACOKINETICS; FORMULATIONS; FLUCONAZOLE; COMBINATION; MULTICENTER C1 [Pappas, Peter G.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Div Internal Med, Unit 1460, Houston, TX 77030 USA. [Perfect, John R.] Duke Univ, Med Ctr, Duke Hosp, Div Infect Dis, Durham, NC USA. [Chillerd, Tom M.] CDC, Div Foodborne Waterborne & Environm Dis, Mycot Dis Branch, Atlanta, GA 30333 USA. RP Pappas, PG (reprint author), Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. EM pappas@uab.edu NR 25 TC 14 Z9 14 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2013 VL 57 IS 4 BP 1573 EP 1576 DI 10.1128/AAC.00205-13 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 106CN UT WOS:000316119100002 PM 23384532 ER PT J AU Reeves, AZ Campbell, PJ Sultana, R Malik, S Murray, M Plikaytis, BB Shinnick, TM Posey, JE AF Reeves, Analise Z. Campbell, Patricia J. Sultana, Razvan Malik, Seidu Murray, Megan Plikaytis, Bonnie B. Shinnick, Thomas M. Posey, James E. TI Aminoglycoside Cross-Resistance in Mycobacterium tuberculosis Due to Mutations in the 5 ' Untranslated Region of whiB7 SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID LEVEL STREPTOMYCIN RESISTANCE; GENE-EXPRESSION; EFFLUX PUMP; ANTIBIOTIC-RESISTANCE; MOLECULAR ANALYSIS; KANAMYCIN; MACROPHAGES; TRANSCRIPTION; CAPREOMYCIN; REGULATOR AB Since the discovery of streptomycin's bactericidal activity against Mycobacterium tuberculosis, aminoglycosides have been utilized to treat tuberculosis (TB). Today, the aminoglycosides kanamycin and amikacin are used to treat multidrug-resistant (MDR) TB, and resistance to any of the second-line injectable antibiotics, including kanamycin, amikacin, or capreomycin, is a defining characteristic of extensively drug-resistant (XDR) TB. Resistance to kanamycin and streptomycin is thought to be due to the acquisition of unlinked chromosomal mutations. However, we identified eight independent mutations in the 5' untranslated region of the transcriptional activator whiB7 that confer low-level resistance to both aminoglycosides. The mutations lead to 23- to 145-fold increases in whiB7 transcripts and subsequent increased expression of both eis (Rv2416c) and tap (Rv1258c). Increased expression of eis confers kanamycin resistance in these mutants, while increased expression of tap, which encodes an efflux pump, is a previously uncharacterized mechanism of low-level streptomycin resistance. Additionally, high-level resistance to streptomycin arose at a much higher frequency in whiB7 mutants than in a wild-type (WT) strain. Although whiB7 is typically associated with intrinsic antibiotic resistance in M. tuberculosis, these data suggest that mutations in an uncharacterized regulatory region of whiB7 contribute to cross-resistance against clinically used second-line antibiotics. As drug resistance continues to develop and spread, understanding the mechanisms and molecular basis of antibiotic resistance is critical for the development of rapid molecular tests to diagnose drug-resistant TB strains and ultimately for designing regimens to treat drug-resistant cases of TB. C1 [Reeves, Analise Z.; Campbell, Patricia J.] Emory Univ, Dept Microbiol & Immunol, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA. [Reeves, Analise Z.; Campbell, Patricia J.; Malik, Seidu; Plikaytis, Bonnie B.; Shinnick, Thomas M.; Posey, James E.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Sultana, Razvan] Boston Univ, Dept Bioinformat, Boston, MA 02215 USA. [Murray, Megan] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Posey, JE (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM jposey@cdc.gov NR 37 TC 30 Z9 30 U1 1 U2 16 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2013 VL 57 IS 4 BP 1857 EP 1865 DI 10.1128/AAC.02191-12 PG 9 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 106CN UT WOS:000316119100041 PM 23380727 ER PT J AU Coulliette, AD Perry, KA Edwards, JR Noble-Wang, JA AF Coulliette, A. D. Perry, K. A. Edwards, J. R. Noble-Wang, J. A. TI Persistence of the 2009 Pandemic Influenza A (H1N1) Virus on N95 Respirators SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID FILTERING FACEPIECE RESPIRATORS; STAINLESS-STEEL SURFACES; PROTECTIVE EQUIPMENT; ABSOLUTE-HUMIDITY; DECONTAMINATION; TRANSMISSION; SURVIVAL; INACTIVATION; PARTICLES AB In the United States, the 2009 pandemic influenza A (H1N1) virus (pH1N1) infected almost 20% of the population and caused >200,000 hospitalizations and > 10,000 deaths from April 2009 to April 2010. On 24 April 2009, the CDC posted interim guidance on infection control measures in health care settings explicitly for pH1N1 and recommended using filtering face respirators (FFRs) when in close contact with a suspected- or confirmed-to-be-infected individual, particularly when performing aerosol-generating procedures. The persistence and infectivity of pH1N1 were evaluated on FFRs, specifically N95 respirators, under various conditions of absolute humidity (AH) (4.1 x 10(5) mPa, 6.5 x 10(5) mPa, and 14.6 x 10(5) mPa), sample matrices (2% fetal bovine serum [FBS], 5 mg/ml mucin, and viral medium), and times (4, 12, 24, 48, 72, and 144 h). pH1N1 was distributed onto N95 coupons (3.8 to 4.2 cm(2)) and extracted by a vortex-centrifugation-filtration process, and the ability of the remaining virus to replicate was quantified using an enzyme-linked immunosorbent assay (ELISA) to determine the log(10) concentration of the infectious virus per coupon. Overall, pH1N1 remained infectious for 6 days, with an approximately 1-log(10) loss of virus concentrations over this time period. Time and AH both affected virus survival. We found significantly higher (P <= 0.01) reductions in virus concentrations at time points beyond 24 to 72 h (-0.52-log(10) reduction) and 144 h (-0.74) at AHs of 6.5 x 10(5) mPa (-0.53) and 14.6 x 10(5) mPa (-0.47). This research supports discarding respirators after close contact with a person with suspected or confirmed influenza infection due to the virus's demonstrated ability to persist and remain infectious. C1 [Coulliette, A. D.; Perry, K. A.; Edwards, J. R.; Noble-Wang, J. A.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Coulliette, AD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM acoulliette@cdc.gov FU CDC Pandemic Influenza Scientific Agenda FX This study was made possible by the CDC Pandemic Influenza Scientific Agenda funding. NR 37 TC 4 Z9 4 U1 1 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD APR PY 2013 VL 79 IS 7 BP 2148 EP 2155 DI 10.1128/AEM.03850-12 PG 8 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 106ZE UT WOS:000316183500005 PM 23335770 ER PT J AU Lee, S Rakic-Martinez, M Graves, LM Ward, TJ Siletzky, RM Kathariou, S AF Lee, Sangmi Rakic-Martinez, M. Graves, L. M. Ward, T. J. Siletzky, R. M. Kathariou, S. TI Genetic Determinants for Cadmium and Arsenic Resistance among Listeria monocytogenes Serotype 4b Isolates from Sporadic Human Listeriosis Patients SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID BENZALKONIUM CHLORIDE RESISTANCE; TURKEY-PROCESSING PLANTS; PLASMID-BORNE CADMIUM; EPIDEMIC CLONES; UNITED-STATES; HEAVY-METAL; FOOD SAFETY; RNA GENES; STRAINS; SEQUENCE AB In Listeria monocytogenes serotype 4b isolates from sporadic listeriosis, heavy metal resistance was primarily encountered in certain clonal groups (ECI, ECII, and ECIa). All arsenic-resistant isolates harbored the arsenic resistance cassette previously identified in pLI100; ECIa harbored additional arsenic resistance genes and a novel cadmium resistance determinant in a conserved chromosomal locus. C1 [Lee, Sangmi; Rakic-Martinez, M.; Siletzky, R. M.; Kathariou, S.] N Carolina State Univ, Dept Food Bioproc & Nutr Sci, Raleigh, NC 27695 USA. [Graves, L. M.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Ward, T. J.] ARS, Bacterial Foodborne Pathogens & Mycol Res Unit, USDA, Peoria, IL USA. RP Lee, S (reprint author), N Carolina State Univ, Dept Food Bioproc & Nutr Sci, Raleigh, NC 27695 USA. EM slee19@ncsu.edu FU USDA [2006-35201-17377]; U.S. Department of Agriculture's Agricultural Research Service FX This study was partially supported by USDA grant 2006-35201-17377 and the U.S. Department of Agriculture's Agricultural Research Service. NR 37 TC 8 Z9 8 U1 1 U2 18 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD APR PY 2013 VL 79 IS 7 BP 2471 EP 2476 DI 10.1128/AEM.03551-12 PG 6 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 106ZE UT WOS:000316183500045 PM 23377929 ER PT J AU Phaneuf, CR Oh, K Pak, N Saunders, DC Conrardy, C Landers, JP Tong, SX Forest, CR AF Phaneuf, Christopher R. Oh, Kyudam Pak, Nikita Saunders, D. Curtis Conrardy, Christina Landers, James P. Tong, Suxiang Forest, Craig R. TI Sensitive, microliter PCR with consensus degenerate primers for Epstein Barr virus amplification SO BIOMEDICAL MICRODEVICES LA Malay DT Article DE Microfluidics; Sensitivity; Virus detection; Polymerase chain reaction; Consensus degenerate; Passivation ID POLYMERASE-CHAIN-REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; REAL-TIME; PROTEIN ADSORPTION; DNA AMPLIFICATION; QUANTITATIVE PCR; MICROFLUIDIC DEVICES; SURFACE PASSIVATION; INFECTIOUS-DISEASES; GENETIC-ANALYSIS AB Sensitive identification of the etiology of viral diseases is key to implementing appropriate prevention and treatment. The gold standard for virus identification is the polymerase chain reaction (PCR), a technique that allows for highly specific and sensitive detection of pathogens by exponentially amplifying a specific region of DNA from as little as a single copy through thermocycling a biochemical cocktail. Today, molecular biology laboratories use commercial instruments that operate in 0.5-2 h/analysis using reaction volumes of 5-50 mu L contained within polymer tubes or chambers. Towards reducing this volume and maintaining performance, we present a semi-quantitative, systematic experimental study of how PCR yield is affected by tube/chamber substrate, surface-area-to-volume ratio (SA:V), and passivation methods. We perform PCR experiments using traditional PCR tubes as well as using disposable polymer microchips with 1 mu L reaction volumes thermocycled using water baths. We report the first oil encapsulation microfluidic PCR method without fluid flow and its application to the first microfluidic amplification of Epstein Barr virus using consensus degenerate primers, a powerful and broad PCR method to screen for both known and novel members of a viral family. The limit of detection is measured as 140 starting copies of DNA from a starting concentration of 3 x 10(5) copies/mL, regarded as an accepted sensitivity threshold for diagnostic purposes, and reaction specificity was improved as compared to conventional methods. Also notable, these experiments were conducted with conventional reagent concentrations, rather than commonly spiked enzyme and/or template mixtures. This experimental study of the effects of substrate, SA:V, and passivation, together with sensitive and specific microfluidic PCR with consensus degenerate primers represent advances towards lower cost and higher throughput pathogen screening. C1 [Phaneuf, Christopher R.; Pak, Nikita; Saunders, D. Curtis; Forest, Craig R.] Georgia Inst Technol, Dept Mech Engn, Atlanta, GA 30332 USA. [Oh, Kyudam; Landers, James P.] Univ Virginia, Dept Chem, Charlottesville, VA USA. [Conrardy, Christina; Tong, Suxiang] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Phaneuf, CR (reprint author), Georgia Inst Technol, Dept Mech Engn, Atlanta, GA 30332 USA. EM christopher.phaneuf@gatech.edu FU NSF [CISE 1110947, EHR 0965945]; American Heart Association [10GRNT4430029]; Georgia Economic Development Association; Wallace H. Coulter Foundation; Centers for Disease Control and Prevention (CDC); NSF National Nanotechnology Infrastructure Network (NNIN); Georgia Tech: Institute for Bioengineering and Biosciences Junior Faculty Award; Technology Fee Fund; Invention Studio; George W. Woodruff School of Mechanical Engineering; Department of Homeland Security (DHS) Scholarship; Fellowship Program; DOE [DE-AC05-06OR23100] FX We acknowledge funding by the NSF (CISE 1110947, EHR 0965945) as well as American Heart Association (10GRNT4430029), the Georgia Economic Development Association, the Wallace H. Coulter Foundation, Centers for Disease Control and Prevention (CDC), NSF National Nanotechnology Infrastructure Network (NNIN), and from Georgia Tech: Institute for Bioengineering and Biosciences Junior Faculty Award, Technology Fee Fund, Invention Studio, and the George W. Woodruff School of Mechanical Engineering. We would like to personally thank Jing Zhang at the CDC for timely sample preparation. This research was performed under an appointment to the Department of Homeland Security (DHS) Scholarship and Fellowship Program, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U. S. Department of Energy (DOE) and DHS. ORISE is managed by Oak Ridge Associated Universities (ORAU) under DOE contract number DE-AC05-06OR23100. All opinions expressed in this paper are the authors' and do not necessarily reflect the policies and views of DHS, DOE, or ORAU/ORISE. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 63 TC 2 Z9 4 U1 3 U2 31 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1387-2176 J9 BIOMED MICRODEVICES JI Biomed. Microdevices PD APR PY 2013 VL 15 IS 2 BP 221 EP 231 DI 10.1007/s10544-012-9720-1 PG 11 WC Engineering, Biomedical; Nanoscience & Nanotechnology SC Engineering; Science & Technology - Other Topics GA 107FV UT WOS:000316201300003 PM 23080522 ER PT J AU Kato, K Wong, LY Basden, BJ Calafat, AM AF Kato, Kayoko Wong, Lee-Yang Basden, Brian J. Calafat, Antonia M. TI Effect of temperature and duration of storage on the stability of polyfluoroalkyl chemicals in human serum SO CHEMOSPHERE LA English DT Article DE Polyfluoroalkyl chemicals; Stability; Storage temperature; Biomonitoring ID PERFLUOROALKYL ACIDS AB We assessed the potential impact of temperature on the long-term stability of several polyfluoroalkyl chemicals in serum. We evaluated the concentrations of perfluorooctane sulfonate, perfluorohexane sulfonate, perfluorooctanoate and perfluorononanoate in 16 human serum samples stored at room temperature, 5 degrees C, -20 degrees C and -70 degrees C at several time points during an eight month period. Concentrations of the target analytes remained unchanged under all studied conditions, even when serum was kept at room temperature for 10 days. Published by Elsevier Ltd. C1 [Kato, Kayoko; Wong, Lee-Yang; Basden, Brian J.; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Kato, K (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM kkato1@cdc.gov FU National Center for Environmental Health, Division of Laboratory Sciences; Oak Ridge Institute for Science and Education FX This research was supported, in part, by an appointment (B.B.) to the Research Participation Program at the National Center for Environmental Health, Division of Laboratory Sciences, administered by the Oak Ridge Institute for Science and Education through, an interagency agreement between the US Department of Energy and the Centers for Disease Control and Prevention (CDC). NR 14 TC 6 Z9 6 U1 0 U2 31 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 J9 CHEMOSPHERE JI Chemosphere PD APR PY 2013 VL 91 IS 2 BP 115 EP 117 DI 10.1016/j.chemosphere.2012.11.013 PG 3 WC Environmental Sciences SC Environmental Sciences & Ecology GA 105SA UT WOS:000316091600001 PM 23232044 ER PT J AU Hopf, NB Ruder, AM Waters, MA Succop, P AF Hopf, Nancy B. Ruder, Avima M. Waters, Martha A. Succop, Paul TI Concentration-dependent half-lives of polychlorinated biphenyl in sera from an occupational cohort SO CHEMOSPHERE LA English DT Article DE Polychlorinated biphenyls; PCB; Half-life; Serum PCB ID CAPACITOR MANUFACTURING WORKERS; PCB CONGENERS; ELIMINATION KINETICS; YUSHO PATIENTS; EXPOSURE; LIFE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; MORTALITY; SEVESO; AGE AB Polychlorinated biphenyls (PCBs) are carcinogenic. Estimating PCB half-life in the body based on levels in sera from exposed workers is complicated by the fact that occupational exposure to PCBs was to commercial PCB products (such as Aroclors 1242 and 1254) comprised of varying mixtures of PCB congeners. Half-lives were estimated using sera donated by 191 capacitor manufacturing plant workers in 1976 during PCB use (1946-1977), and post-exposure (1979, 1983, and 1988). Our aims were to: (1) determine the role of covariates such as gender on the half-life estimates, and (2) compare our results with other published half-life estimates based on exposed workers. All serum PCB levels were adjusted for PCB background levels. A linear spline model with a single knot was used to estimate two separate linear equations for the first two serum draws (Equation A) and the latter two (Equation B). Equation A gave half-life estimates of 1.74 years and 6.01 years for Aroclor 1242 and Aroclor 1254, respectively. Estimates were 21.83 years for Aroclor 1242 and 133.33 years for Aroclor 1254 using Equation B. High initial body burden was associated with rapid PCB elimination in workers at or shortly after the time they were occupationally exposed and slowed down considerably when the dose reached background PCB levels. These concentration-dependent half-life estimates had a transition point of 138.57 and 34.78 ppb for Aroclor 1242 and 1254, respectively. This result will help in understanding the toxicological and epidemiological impact of exposure to PCBs in humans. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Hopf, Nancy B.] Inst Work & Hlth IST, CH-1011 Lausanne, Switzerland. [Ruder, Avima M.; Waters, Martha A.] NIOSH, Ctr Dis Control & Prevent CDC, Cincinnati, OH 45226 USA. [Succop, Paul] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA. RP Hopf, NB (reprint author), Inst Work & Hlth IST, Rue Bugnon 21, CH-1011 Lausanne, Switzerland. EM Nancy.Hopf@hospvd.ch; amr2@cdc.gov; maw0@cdc.gov; succopa@uc.edu NR 37 TC 6 Z9 6 U1 2 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 J9 CHEMOSPHERE JI Chemosphere PD APR PY 2013 VL 91 IS 2 BP 172 EP 178 DI 10.1016/j.chemosphere.2012.12.039 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA 105SA UT WOS:000316091600010 PM 23336921 ER PT J AU Barnett, ED Weld, LH McCarthy, AE So, H Walker, PF Stauffer, W Cetron, M AF Barnett, Elizabeth D. Weld, Leisa H. McCarthy, Anne E. So, Heidi Walker, Patricia F. Stauffer, William Cetron, Martin CA GeoSentinel Surveillance Network TI Spectrum of Illness in International Migrants Seen at GeoSentinel Clinics in 1997-2009, Part 1: US-Bound Migrants Evaluated by Comprehensive Protocol-Based Health Assessment SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Burmese and Somali refugees; tuberculosis; hepatitis; noncommunicable diseases (NCDs) ID SCREENING-PROGRAMS; AFRICAN REFUGEES; PREVALENCE; TRAVELERS; RATES AB Background. Many nations are struggling to develop structured systems and guidelines to optimize the health of new arrivals, but there is currently no international consensus about the best approach. Methods. Data on 7792 migrants who crossed international borders for the purpose of resettlement and underwent a protocol-based health assessment were collected from the GeoSentinel Surveillance network. Demographic and health characteristics of a subgroup of these migrants seen at 2 US-based GeoSentinel clinics for protocol-based health assessments are described. Results. There was significant variation over time in screened migrant populations and in their demographic characteristics. Significant diagnoses identified in all migrant groups included latent tuberculosis, found in 43% of migrants, eosinophilia in 15%, and hepatitis B infection in 6%. Variation by region occurred for select diagnoses such as parasitic infections. Notably absent were infectious tuberculosis, soil-transmitted helminths, and malaria. Although some conditions would be unfamiliar to clinicians in receiving countries, universal health problems such as dental caries, anemia, ophthalmologic conditions, and hypertension were found in 32%, 11%, 10%, and 5%, respectively, of screened migrants. Conclusions. Data from postarrival health assessments can inform clinicians about screening tests to perform in new immigrants and help communities prepare for health problems expected in specific migrant populations. These data support recommendations developed in some countries to screen all newly arriving migrants for some specific diseases (such as tuberculosis) and can be used to help in the process of developing additional screening recommendations that might be applied broadly or focused on specific at-risk populations. C1 [Barnett, Elizabeth D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA USA. [Barnett, Elizabeth D.] Boston Univ, Boston, MA 02215 USA. [Weld, Leisa H.] Int Soc Travel Med GeoSentinel Stat Consultant, Victoria, BC, Canada. [McCarthy, Anne E.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada. [So, Heidi] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada. [Walker, Patricia F.; Stauffer, William] Hlth Partners, Ctr Int Hlth, Minneapolis, MN USA. [Walker, Patricia F.; Stauffer, William] Univ Minnesota, Minneapolis, MN USA. [Stauffer, William; Cetron, Martin] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Cetron, M (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS E-03, Atlanta, GA 30333 USA. EM mcetron@cdc.gov OI McCarthy, Anne/0000-0001-7195-6366; Barnett, Elizabeth/0000-0003-4822-5949 FU GeoSentinel Surveillance Network; Centers for Disease Control and Prevention (CDC) [5U50CI000359]; International Society of Travel Medicine FX This work was supported by the GeoSentinel Surveillance Network through a cooperative agreement with the Centers for Disease Control and Prevention (CDC; grant number 5U50CI000359), and by funding from the International Society of Travel Medicine. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 45 TC 14 Z9 14 U1 3 U2 18 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2013 VL 56 IS 7 BP 913 EP 924 DI 10.1093/cid/cis1015 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 106TG UT WOS:000316167000005 PM 23223584 ER PT J AU McCarthy, AE Weld, LH Barnett, ED So, H Coyle, C Greenaway, C Stauffer, W Leder, K Lopez-Velez, R Gautret, P Castelli, F Jenks, N Walker, PF Loutan, L Cetron, M AF McCarthy, Anne E. Weld, Leisa H. Barnett, Elizabeth D. So, Heidi Coyle, Christina Greenaway, Christina Stauffer, William Leder, Karin Lopez-Velez, Rogelio Gautret, Phillipe Castelli, Francesco Jenks, Nancy Walker, Patricia F. Loutan, Louis Cetron, Martin CA GeoSentinel Surveillance Network TI Spectrum of Illness in International Migrants Seen at GeoSentinel Clinics in 1997-2009, Part 2: Migrants Resettled Internationally and Evaluated for Specific Health Concerns SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE migrant; tuberculosis; hepatitis; Strongyloides; schistosomiasis ID INFECTIOUS-DISEASES; REFUGEE POPULATION; SUDANESE REFUGEES; UNITED-STATES; TUBERCULOSIS; IMMIGRANTS; AUSTRALIA; PERSISTENT; GUIDELINES; TRAVELERS AB Background. Increasing international migration may challenge healthcare providers unfamiliar with acute and long latency infections and diseases common in this population. This study defines health conditions encountered in a large heterogenous group of migrants. Methods. Migrants seen at GeoSentinel clinics for any reason, other than those seen at clinics only providing comprehensive protocol-based health screening soon after arrival, were included. Proportionate morbidity for syndromes and diagnoses by country or region of origin were determined and compared. Results. A total of 7629 migrants from 153 countries were seen at 41 GeoSentinel clinics in 19 countries. Most (59%) were adults aged 19-39 years; 11% were children. Most (58%) were seen >1 year after arrival; 27% were seen after >5 years. The most common diagnoses were latent tuberculosis (22%), viral hepatitis (17%), active tuberculosis (10%), human immunodeficiency virus (HIV)/AIDS (7%), malaria (7%), schistosomiasis (6%), and strongyloidiasis (5%); 5% were reported healthy. Twenty percent were hospitalized (24% for active tuberculosis and 21% for febrile illness [83% due to malarial), and 13 died. Tuberculosis diagnoses and HIV/AIDS were reported from all regions, strongyloidiasis from most regions, and chronic hepatitis B virus (HBV) particularly in Asian immigrants. Regional diagnoses included schistosomiasis (Africa) and Chagas disease (Americas). Conclusions. Eliciting a migration history is important at every encounter; migrant patients may have acute illness or chronic conditions related to exposure in their country of origin. Early detection and treatment, particularly for diagnoses related to tuberculosis, HBV, Strongyloides, and schistosomiasis, may improve outcomes. Policy makers should consider expansion of refugee screening programs to include all migrants. C1 [McCarthy, Anne E.] Ottawa Hosp, Dept Med, Victoria, BC, Canada. [McCarthy, Anne E.] Univ Ottawa, Victoria, BC, Canada. [So, Heidi] Univ Ottawa, Dept Epidemiol & Community Med, Victoria, BC, Canada. [Weld, Leisa H.] Int Soc Travel Med GeoSentinel Statistician Consu, Victoria, BC, Canada. [Greenaway, Christina] McGill Univ, Jewish Gen Hosp, Div Infect Dis, Montreal, PQ H3T 1E2, Canada. [Barnett, Elizabeth D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA USA. [Barnett, Elizabeth D.] Boston Univ, Boston, MA 02215 USA. [Coyle, Christina] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA. [Jenks, Nancy] Peekskill Area Hlth Ctr, Peekskill, NY USA. [Stauffer, William; Walker, Patricia F.] HealthPartners, Ctr Int Hlth, Minneapolis, MN USA. [Stauffer, William; Walker, Patricia F.] Univ Minnesota, Minneapolis, MN USA. [Stauffer, William; Cetron, Martin] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Leder, Karin] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia. [Lopez-Velez, Rogelio] Hosp Ramon & Cajal, Trop Med & Clin Parasitol Infect Dis Dept, E-28034 Madrid, Spain. [Gautret, Phillipe] Hop Nord Marseille, AP HM, Serv Malad Infect & Trop, Marseille, France. [Castelli, Francesco] Univ Brescia, Inst Infect & Trop Dis, I-25121 Brescia, Italy. [Loutan, Louis] Univ Hosp Geneva, Dept Int & Humanitarian Med, Geneva, Switzerland. [Loutan, Louis] Univ Hosp Geneva, Dept Community Med & Primary Care, Geneva, Switzerland. RP Cetron, M (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E-03, Atlanta, GA 30333 USA. EM mcetron@mac.com OI McCarthy, Anne/0000-0001-7195-6366; Leder, Karin/0000-0003-1368-1039; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Barnett, Elizabeth/0000-0003-4822-5949 FU GeoSentinel Surveillance Network; CDC [5U50CI000359]; International Society of Travel Medicine; National Institute of Health Research Cambridge Biomedical Research Centre FX This work was supported by the GeoSentinel Surveillance Network through a cooperative agreement with the CDC (grant number 5U50CI000359), and funding from the International Society of Travel Medicine. The Cambridge UK site is also supported by the National Institute of Health Research Cambridge Biomedical Research Centre. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 31 TC 20 Z9 20 U1 0 U2 32 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2013 VL 56 IS 7 BP 925 EP 933 DI 10.1093/cid/cis1016 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 106TG UT WOS:000316167000006 PM 23223602 ER PT J AU Frank, E Schlair, S Elon, L Saraiya, M AF Frank, Erica Schlair, Sheira Elon, Lisa Saraiya, Mona TI Do US medical students report more training on evidence-based prevention topics? SO HEALTH EDUCATION RESEARCH LA English DT Article ID POPULATION HEALTH; PRIMARY-CARE; TEACHING PREVENTION; ATTITUDES; EDUCATION; CURRICULUM; PHYSICIANS; PROGRAM; SCHOOL; DEPARTMENTS AB Little is known about the extent to which evidence-based prevention topics are taught in medical school. All class of 2003 medical students (n = 2316) at 16 US schools were eligible to complete three questionnaires: at the beginning of first and third years and in their senior year, with 80.3% responding. We queried these students about 21 preventive medicine topics, concerning the extent of their training and their patient counseling frequency at some of these time points. At the beginning of the third year, self-reported extensive training was low for all preventive medicine topics (range 7-26%). USPSTF-recommended topics received more curricular time (median for topics: 36% if recommended versus 24.5% if not, P = 0.025), as did topics addressed through testing rather than through discussion (median for topics: 37% for testing and 25% for discussion, P = 0.005). Extensive training was always associated with higher counseling frequency, and intention to go into primary care, female gender, a positive attitude toward prevention and positive personal health habits were associated with higher counseling frequency. Although some bemoan the overall low levels of US medical students' prevention-related training and practice, we demonstrate that at least they are preferentially evidence-based, a novel and encouraging finding for preventionists. C1 [Frank, Erica] Univ British Columbia, Sch Populat & Publ Hlth, Fac Med, Vancouver, BC V6T 1Z3, Canada. [Schlair, Sheira] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Gen Internal Med, Bronx, NY 10467 USA. [Elon, Lisa] Emory Univ, Dept Biostat & Bioinformat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. RP Schlair, S (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Gen Internal Med, Bronx, NY 10467 USA. EM sschlair@montefiore.org NR 46 TC 0 Z9 0 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1153 J9 HEALTH EDUC RES JI Health Educ. Res. PD APR PY 2013 VL 28 IS 2 BP 265 EP 275 DI 10.1093/her/cys073 PG 11 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 108DY UT WOS:000316273100007 PM 22730492 ER PT J AU Chen, Z Roy, K Crawford, CAG AF Chen, Zhuo (Adam) Roy, Kakoli Crawford, Carol A. Gotway TI Obesity Prevention: The Impact of Local Health Departments SO HEALTH SERVICES RESEARCH LA English DT Article DE Behavioral risk factor surveillance system; multilevel logit; local health departments; obesity prevention ID BODY-MASS INDEX; PUBLIC-HEALTH; UNITED-STATES; ADDRESS OBESITY; ADOLESCENTS; PREVALENCE; MORTALITY; CHILDREN; PROGRAM; GENDER AB Objective To examine the association between bodyweight status and provision of population-based prevention services. Data Sources The National Association of City and County Health Officials 2005 Profile survey data, linked with two cross-sections of the Behavioral Risk Factor Surveillance System (BRFSS) survey in 2004 and 2005. Study Design Multilevel logistic regressions were used to examine the association between provision of obesity-prevention services and the change in risk of being obese or morbidly obese among BRFSS respondents. The estimation sample was stratified by sex. Low-income samples were also examined. Falsification tests were used to determine whether there is counterevidence. Principal Findings Provision of population-based obesity-prevention services within the jurisdiction of local health departments and specifically those provided by the local health departments are associated with reduced risks of obesity and morbid obesity from 2004 to 2005. The magnitude of the association appears to be stronger among low-income populations and among women. Results of the falsification tests provide additional support of the main findings. Conclusions Population-based obesity-prevention services may be useful in containing the obesity epidemic. C1 [Chen, Zhuo (Adam)] Ctr Dis Control & Prevent, Div Epidemiol & Analyt Methods Populat Hlth Propo, Epidemiol & Anal Program Off, Off Surveillance, Atlanta, GA 30333 USA. [Chen, Zhuo (Adam)] Ctr Dis Control & Prevent, Div Epidemiol & Analyt Methods Populat Hlth Propo, Epidemiol & Anal Program Off, Off Epidemiol, Atlanta, GA 30333 USA. [Chen, Zhuo (Adam)] Ctr Dis Control & Prevent, Div Epidemiol & Analyt Methods Populat Hlth Propo, Epidemiol & Anal Program Off, Off Lab Serv, Atlanta, GA 30333 USA. [Roy, Kakoli] Ctr Dis Control & Prevent, Policy Res Anal & Dev Off, Off Associate Director Policy, Off Director, Atlanta, GA 30333 USA. [Crawford, Carol A. Gotway] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance & Informat Program Off Pro, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Chen, Z (reprint author), Ctr Dis Control & Prevent, Div Epidemiol & Analyt Methods Populat Hlth Propo, Epidemiol & Anal Program Off, Off Surveillance, 1600 Clifton Rd,NE,MS-E33, Atlanta, GA 30333 USA. EM fov7@cdc.gov OI Chen, Zhuo/0000-0002-5351-3489 NR 40 TC 3 Z9 3 U1 1 U2 29 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2013 VL 48 IS 2 BP 603 EP 627 DI 10.1111/j.1475-6773.2012.01447.x PN 1 PG 25 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 106CW UT WOS:000316120200014 PM 22816510 ER PT J AU Kostis, WJ Cabrera, J Hooper, WC Whelton, PK Espeland, MA Cosgrove, NM Cheng, JQ Deng, YZ De Staerck, C Pyle, M Maruthur, N Reyes, I Anderson, CAM Liu, J Kostis, JB AF Kostis, William J. Cabrera, Javier Hooper, W. Craig Whelton, Paul K. Espeland, Mark A. Cosgrove, Nora M. Cheng, Jerry Q. Deng, Yingzi De Staerck, Christine Pyle, Meredith Maruthur, Nisa Reyes, Ingrid Anderson, Cheryl A. M. Liu, Jie Kostis, John B. TI Relationships Between Selected Gene Polymorphisms and Blood Pressure Sensitivity to Weight Loss in Elderly Persons With Hypertension SO HYPERTENSION LA English DT Article DE blood pressure; genetics; obesity; sodium ID SALT SENSITIVITY; NONPHARMACOLOGIC INTERVENTIONS; SODIUM REDUCTION; DIETARY-SODIUM; OLDER PERSONS; TRIAL; ASSOCIATION; PREVENTION; CONTRIBUTE; DISEASE AB Salt sensitivity, the heterogeneity in the response of blood pressure (BP) to alterations in sodium intake, has been studied extensively, whereas weight sensitivity, the heterogeneity in BP response to weight change, has received scant attention. We examined the relationship of 21 gene polymorphisms previously found to be associated with hypertension, diabetes mellitus, or obesity, with weight sensitivity in the Trial of Nonpharmacologic Interventions in the Elderly, where participants with hypertension were randomized to receive intensive dietary intervention of sodium reduction, weight loss, both, or attention control, whereas pharmacological therapy was kept constant. After correcting for multiplicity, we identified significant associations of 3 polymorphisms with weight sensitivity of systolic BP (rs4646994, rs2820037, and rs1800629) and 3 polymorphisms for diastolic BP (rs4646994, rs2820037, and rs5744292). A recursive partitioning algorithm selected the combination of rs4646994, rs1800629, rs1982073, and rs1800896 as the set associated with the highest weight sensitivity. Polymorphisms related to hypertension, obesity, and diabetes mellitus are associated with weight sensitivity of BP. (Hypertension. 2013;61:857-863.) circle Online Data Supplement C1 [Kostis, William J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Cabrera, Javier; Reyes, Ingrid; Liu, Jie] Rutgers State Univ, Dept Stat, Piscataway, NJ USA. [Cabrera, Javier; Cosgrove, Nora M.; Cheng, Jerry Q.; Deng, Yingzi; Kostis, John B.] UMDNJ Robert Wood Johnson Med Sch, Cardiovasc Inst, New Brunswick, NJ USA. [Hooper, W. Craig; De Staerck, Christine; Pyle, Meredith] Ctr Dis Control & Prevent, Atlanta, GA USA. [Whelton, Paul K.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Maruthur, Nisa] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Maruthur, Nisa; Anderson, Cheryl A. M.] Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA. RP Kostis, WJ (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRB 800, Boston, MA 02114 USA. EM wkostis@partners.org FU National Institute on Aging; National Heart, Lung, and Blood Institute; Robert Wood Johnson Foundation FX This study was supported, in part, by the National Institute on Aging, the National Heart, Lung, and Blood Institute, and the Robert Wood Johnson Foundation. NR 34 TC 6 Z9 6 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD APR PY 2013 VL 61 IS 4 BP 857 EP + DI 10.1161/HYPERTENSIONAHA.111.00712 PG 23 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 106AC UT WOS:000316112800030 PM 23438931 ER PT J AU Murphy, MW Lando, JF Kieszak, SM Sutter, ME Noonan, GP Brunkard, JM McGeehin, MA AF Murphy, M. W. Lando, J. F. Kieszak, S. M. Sutter, M. E. Noonan, G. P. Brunkard, J. M. McGeehin, M. A. TI Formaldehyde levels in FEMA-supplied travel trailers, park models, and mobile homes in Louisiana and Mississippi SO INDOOR AIR LA English DT Article DE Formaldehyde; Trailer; US Federal Emergency Management Agency; Gulf Coast; Indoor air; Temporary housing ID HUMIDITY AB In 2006, area physicians reported increases in upper respiratory symptoms in patients living in U.S. Federal Emergency Management Agency (FEMA)-supplied trailers following Hurricanes Katrina and Rita. One potential etiology to explain their symptoms included formaldehyde; however, formaldehyde levels in these occupied trailers were unknown. The objectives of our study were to identify formaldehyde levels in occupied trailers and to determine factors or characteristics of occupied trailers that could affect formaldehyde levels. A disproportionate random sample of 519 FEMA-supplied trailers was identified in Louisiana and Mississippi in November 2007. We collected and tested an air sample from each trailer for formaldehyde levels and administered a survey. Formaldehyde levels among all trailers in this study ranged from 3 parts per billion (ppb) to 590ppb, with a geometric mean (GM) of 77ppb [95% confidence interval (CI): 7085; range: 3590ppb]. There were statistically significant differences in formaldehyde levels between trailer types (P<0.01). The GM formaldehyde level was 81ppb (95% CI: 7292) among travel trailers (N=360), 57ppb (95% CI: 4965) among mobile homes (N=57), and 44ppb (95% CI: 3853) among park models (N=44). Among travel trailers, formaldehyde levels varied significantly by brand. While formaldehyde levels varied by trailer type, all types tested had some levels >= 100ppb. C1 [Murphy, M. W.; Lando, J. F.; Kieszak, S. M.; Sutter, M. E.; Noonan, G. P.; McGeehin, M. A.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Murphy, M. W.; Brunkard, J. M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Sutter, M. E.] Univ Calif Davis, Davis Dept Emergency Med, Sacramento, CA 95817 USA. [Brunkard, J. M.] Louisiana Off Publ Hlth, Baton Rouge, LA USA. [McGeehin, M. A.] Res Triangle Inst Int, Atlanta, GA USA. RP Murphy, MW (reprint author), CDC NCEH DEHHE HSB, 4770 Buford Hwy NE,MS F-57, Atlanta, GA 30341 USA. EM MMurphy@cdc.gov RI Osborne, Nicholas/N-4915-2015; OI Osborne, Nicholas/0000-0002-6700-2284; Brunkard, Joan/0000-0001-5270-2627 NR 28 TC 5 Z9 5 U1 3 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0905-6947 J9 INDOOR AIR JI Indoor Air PD APR PY 2013 VL 23 IS 2 BP 134 EP 141 DI 10.1111/j.1600-0668.2012.00800.x PG 8 WC Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health SC Construction & Building Technology; Engineering; Public, Environmental & Occupational Health GA 107HU UT WOS:000316207400006 PM 22804791 ER PT J AU Libby, TE Lindley, MC Lorick, SA MacCannell, T Lee, SJ Smith, C Geevarughese, A Makvandi, M Nace, DA Ahmed, F AF Libby, Tanya E. Lindley, Megan C. Lorick, Suchita A. MacCannell, Taranisia Lee, Soo-Jeong Smith, Carmela Geevarughese, Anita Makvandi, Monear Nace, David A. Ahmed, Faruque TI Reliability and Validity of a Standardized Measure of Influenza Vaccination Coverage among Healthcare Personnel SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID LONG-TERM-CARE; DECLINATION STATEMENTS; POSITION PAPER; UNITED-STATES; RATES; WORKERS; HOSPITALS; REQUIREMENTS; MORTALITY; TRIAL AB OBJECTIVE. To evaluate the reliability and validity of a standardized measure of healthcare personnel (HCP) influenza vaccination. SETTING. Acute care hospitals, long-term care facilities, ambulatory surgery centers, physician practices, and dialysis centers from 3 US jurisdictions. PARTICIPANTS. Staff from 96 healthcare facilities randomly sampled from 234 facilities that completed pilot testing to assess the feasibility of the measure. METHODS. Reliability was assessed by comparing agreement between facility staff and project staff on the classification of HCP numerator (vaccinated at facility, vaccinated elsewhere, contraindicated, declined) and denominator (employees, credentialed nonemployees, other nonemployees) categories. To assess validity, facility staff completed a series of case studies to evaluate how closely classification of HCP groups aligned with the measure's specifications. In a modified Delphi process, experts rated face validity of the proposed measure elements on a Likert-type scale. RESULTS. Percent agreement was high for HCP vaccinated at the facility (99%) and elsewhere (95%) and was lower for HCP who declined vaccination (64%) or were medically contraindicated (64%). While agreement was high (more than 90%) for all denominator categories, many facilities' staff excluded nonemployees for whom numerator and denominator status was difficult to determine. Validity was lowest for credentialed and other nonemployees. CONCLUSIONS. The standardized measure of HCP influenza vaccination yields reproducible results for employees vaccinated at the facility and elsewhere. Adhering to true medical contraindications and tracking declinations should improve reliability. Difficulties in establishing denominators and determining vaccination status for credentialed and other nonemployees challenged the measure's validity and prompted revision to include a more limited group of nonemployees. Infect Control Hosp Epidemiol 2013;34(4):335-345 C1 [Libby, Tanya E.; Lindley, Megan C.; Lorick, Suchita A.; Ahmed, Faruque] Ctr Dis Control & Prevent CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [MacCannell, Taranisia] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA USA. [Lee, Soo-Jeong] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Smith, Carmela] CDC Contractor New Mexico Dept Hlth, Santa Fe, NM USA. [Geevarughese, Anita] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Makvandi, Monear] New Mexico Dept Hlth, Epidemiol & Response Div, Santa Fe, NM USA. [Nace, David A.] Univ Pittsburgh, Pittsburgh, PA USA. RP Libby, TE (reprint author), Calif Emerging Infect Program, 360 22nd St,Suite 750, Oakland, CA 94612 USA. EM tlibby@ceip.us RI Nace, David/D-2638-2014 FU US Centers for Disease Control and Prevention FX This work was funded by the US Centers for Disease Control and Prevention. NR 34 TC 6 Z9 6 U1 0 U2 8 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2013 VL 34 IS 4 BP 335 EP 345 DI 10.1086/669859 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 106FH UT WOS:000316127700001 PM 23466904 ER PT J AU Snyder, GM Patel, PR Kallen, AJ Strom, JA Tucker, JK D'Agata, EMC AF Snyder, Graham M. Patel, Priti R. Kallen, Alexander J. Strom, James A. Tucker, J. Kevin D'Agata, Erika M. C. TI Antimicrobial Use in Outpatient Hemodialysis Units SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INFECTIOUS-DISEASES-SOCIETY; STAPHYLOCOCCUS-AUREUS BACTEREMIA; CLINICAL-PRACTICE GUIDELINES; AMERICA GUIDELINES; DIALYSIS PATIENTS; DIAGNOSIS; VANCOMYCIN; MANAGEMENT; OUTCOMES; ADULTS AB OBJECTIVE. To quantify and characterize overall antimicrobial use, including appropriateness of indication, among patients receiving chronic hemodialysis. DESIGN. Retrospective and prospective observational study. SETTING. Two outpatient hemodialysis units. PATIENTS. All patients receiving chronic hemodialysis. METHODS. The rate of parenteral antimicrobial use (number of doses per 100 patient-months) was calculated retrospectively from September 2008 through July 2011. Indication and appropriateness of antimicrobial doses were characterized prospectively from August 2010 through July 2011. Inappropriate administration was defined as occasions when criteria for infection based on national guidelines were not met, failure to choose a more narrow-spectrum antimicrobial on the basis of culture data, or occasions when indications for surgical prophylaxis were not met. RESULTS. Over the 35-month retrospective study period, the rate of parenteral antimicrobial use was 32.9 doses per 100 patient-months. Vancomycin was the most commonly prescribed antimicrobial, followed by cefazolin and third-or fourth-generation cephalosporins. Over the 12-month prospective study, 1,003 antimicrobial doses were prescribed. Among the 926 (92.3%) doses for which an indication for administration was available, 276 (29.8%) were classified as inappropriate. Of these, a total of 146 (52.9%) did not meet criteria for infection, 74 (26.8%) represented failure to choose a more narrow-spectrum antimicrobial, and 56 (20.3%) did not meet criteria for surgical prophylaxis. The most common inappropriately prescribed antimicrobials were vancomycin and third-or fourth-generation cephalosporins. CONCLUSIONS. Parenteral antimicrobial use was extensive, and as much as one-third was categorized as inappropriate. The findings of this study provide novel information toward minimizing inappropriate antimicrobial use. Infect Control Hosp Epidemiol 2013;34(4):349-357 C1 [Snyder, Graham M.; D'Agata, Erika M. C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis, Boston, MA 02215 USA. [Patel, Priti R.; Kallen, Alexander J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Strom, James A.] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Boston, MA 02111 USA. [Tucker, J. Kevin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Snyder, GM (reprint author), Beth Israel Deaconess Med Ctr, Div Infect Dis, 330 Brookline Ave,Mail Stop SL-435, Boston, MA 02215 USA. EM gsnyder@bidmc.harvard.edu FU CDC Division of Healthcare Quality Promotion [10IPA1004108] FX This work was funded by the CDC Division of Healthcare Quality Promotion (Intergovernmental Personnel Agreement 10IPA1004108). NR 35 TC 9 Z9 9 U1 0 U2 10 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2013 VL 34 IS 4 BP 349 EP 357 DI 10.1086/669869 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 106FH UT WOS:000316127700003 PM 23466906 ER PT J AU Lu, XY Trujillo-Lopez, E Lott, L Erdman, DD AF Lu, Xiaoyan Trujillo-Lopez, Elizabeth Lott, Lisa Erdman, Dean D. TI Quantitative Real-Time PCR Assay Panel for Detection and Type-Specific Identification of Epidemic Respiratory Human Adenoviruses SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID RAPID DETECTION; MILITARY CAMP; SEROTYPE 14; DISEASE; OUTBREAK; INFECTION; PNEUMONIA; ILLNESS; COINFECTIONS; SPECIMENS AB Outbreaks of human adenovirus (HAdV) acute respiratory illness (ARI) have been well documented among civilians and unvaccinated military recruits. Among the 7 recognized HAdV species (A to G), species B (particularly serotypes 3, 7, 11, 14, and 21) and E (serotype 4) have more often been associated with epidemic ARI. Rapid detection and type-specific identification of these viruses would enhance outbreak response and help guide prevention and control measures. To this end, we developed type-specific real-time quantitative PCR (qPCR) assays for HAdV types 3, 4, 7, 11, 14, 16, and 21 targeting the HAdV hexon gene. All type-specific qPCR assays reproducibly detected as few as 10 copies/reaction of quantified hexon recombinant plasmids with a linear dynamic range of 8 log units (10(1) to 10(8) copies); in contrast, a generic qPCR assay that detects all HAdV types run concurrently detected between 10 and 100 copies/reaction, depending on the virus type. No nonspecific amplifications were observed with concentrated nucleic acid from 51 HAdV prototype strains or other common respiratory pathogens. All members of a panel of 137 previously typed HAdV field isolates and positive clinical specimens were correctly characterized by the type-specific qPCR assays; two different HAdV types were detected in three of the clinical specimens and confirmed by amplicon sequencing. The qPCR assays permit sensitive, specific, and quantitative detection and identification of seven clinically important respiratory HAdVs and should provide a convenient adjunct to classical typing methods for a rapid response to HAdV outbreaks. C1 [Lu, Xiaoyan; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA 30333 USA. [Trujillo-Lopez, Elizabeth; Lott, Lisa] Eagle Appl Sci LLC, San Antonio, TX USA. RP Erdman, DD (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA 30333 USA. EM dde1@cdc.gov NR 43 TC 8 Z9 9 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2013 VL 51 IS 4 BP 1089 EP 1093 DI 10.1128/JCM.03297-12 PG 5 WC Microbiology SC Microbiology GA 107MA UT WOS:000316220400006 PM 23325827 ER PT J AU Ouma, KN Basavaraju, SV Okonji, JA Williamson, J Thomas, TK Mills, LA Nkengasong, JN Zeh, C AF Ouma, Kenneth N. Basavaraju, Sridhar V. Okonji, Jully A. Williamson, John Thomas, Timothy K. Mills, Lisa A. Nkengasong, John N. Zeh, Clement TI Evaluation of Quantification of HIV-1 RNA Viral Load in Plasma and Dried Blood Spots by Use of the Semiautomated Cobas Amplicor Assay and the Fully Automated Cobas Ampliprep/TaqMan Assay, Version 2.0, in Kisumu, Kenya SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID VIRUS TYPE-1 RNA; RESOURCE-LIMITED SETTINGS; HEALTH-CARE WORKERS; ANTIRETROVIRAL THERAPY; TAQMAN HIV-1; DRUG-RESISTANCE; WHOLE-BLOOD; DIAGNOSIS; QUANTITATION; PERFORMANCE AB In Kenya, HIV-1 viral load monitoring is commonly performed with the Cobas Amplicor using plasma specimens. Interest is growing in transitioning to real-time PCR (RT-PCR), such as the Cobas Ampliprep/Cobas TaqMan (CAP/CTM), using dried blood spots (DBS). Before implementation, direct evaluation of the two assays using DBS field specimens is required. This study compares the sensitivity, specificity, negative and positive predictive values (NPV and PPV, respectively), concordance, and agreement between HIV-1 viral load measurements using plasma and DBS specimens obtained from 512 HIV-1-infected pregnant females enrolled in the Kisumu Breastfeeding Study and tested with the Cobas Amplicor and CAP/CTM assays. The sensitivity and NPV of viral load detection in DBS specimens were higher with CAP/CTM (sensitivity, 100%; 95% confidence interval [CI], 99.1 to 100.0%; NPV, 100%; 95% CI, 59.0 to 100.0%) than the Cobas Amplicor (sensitivity, 96.6%; 95% CI, 94.3 to 98.1%; NPV, 58.8%; 95% CI, 40.7 to 75.4%). The PPVs were comparable between both assays when using DBS. The specificity of viral load detection in DBS specimens was lower with CAP/CTM (77.8%; 95% CI, 40.0 to 97.2%) than that of the Cobas Amplicor (95.2%; 95% CI, 76.2 to 99.9%). Good concordance and agreement were observed when paired plasma and DBS specimens were tested with both assays. Lower specificity with the CAP/CTM is likely due to proviral HIV-1 DNA amplification and lower detection limits with RT-PCR. However, the CAP/CTM has better sensitivity and higher throughput than the Cobas Amplicor. These findings suggest that DBS may be a suitable alternative to plasma when using RT-PCR, which could increase access to viral load monitoring in resource-limited settings. C1 [Ouma, Kenneth N.; Okonji, Jully A.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Basavaraju, Sridhar V.] Ctr Dis Control & Prevent, HIV Prevent Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Williamson, John; Thomas, Timothy K.; Mills, Lisa A.; Zeh, Clement] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Kisumu, Kenya. [Nkengasong, John N.] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Zeh, C (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Kisumu, Kenya. EM czeh@ke.cdc.gov FU CDC FX This study was funded by CDC. NR 41 TC 11 Z9 12 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2013 VL 51 IS 4 BP 1208 EP 1218 DI 10.1128/JCM.03048-12 PG 11 WC Microbiology SC Microbiology GA 107MA UT WOS:000316220400024 PM 23390278 ER PT J AU Bandea, CI Joseph, K Secor, EW Jones, LA Igietseme, JU Sautter, RL Hammerschlag, MR Fajman, NN Girardet, RG Black, CM AF Bandea, Claudiu I. Joseph, Kahaliah Secor, Evan W. Jones, Laurie A. Igietseme, Joseph U. Sautter, Robert L. Hammerschlag, Margaret R. Fajman, Nancy N. Girardet, Rebecca G. Black, Carolyn M. TI Development of PCR Assays for Detection of Trichomonas vaginalis in Urine Specimens SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CHLAMYDIA-TRACHOMATIS; INFECTION; DIAGNOSIS; DNA; AMPLIFICATION; CULTURE; TETRATRICHOMONAS; IDENTIFICATION; EPIDEMIOLOGY; ACQUISITION AB Trichomonas vaginalis infections are usually asymptomatic or can result in nonspecific clinical symptoms, which makes laboratory-based detection of this protozoan parasite essential for diagnosis and treatment. We report the development of a battery of highly sensitive and specific PCR assays for detection of T. vaginalis in urine, a noninvasive specimen, and development of a protocol for differentiating among Trichomonas species that commonly infect humans. C1 [Bandea, Claudiu I.; Joseph, Kahaliah; Secor, Evan W.; Jones, Laurie A.; Igietseme, Joseph U.; Black, Carolyn M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sautter, Robert L.] Carolinas Pathol Grp, Charlotte, NC USA. [Hammerschlag, Margaret R.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Fajman, Nancy N.] Emory Univ, Sch Med, Atlanta, GA USA. [Girardet, Rebecca G.] Univ Texas Houston Med Sch, Houston, TX USA. RP Bandea, CI (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM cbandea@cdc.gov NR 26 TC 6 Z9 7 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2013 VL 51 IS 4 BP 1298 EP 1300 DI 10.1128/JCM.03101-12 PG 3 WC Microbiology SC Microbiology GA 107MA UT WOS:000316220400045 PM 23390274 ER PT J AU Johnson, EM Lanier, WA Merrill, RM Crook, J Porucznik, CA Rolfs, RT Sauer, B AF Johnson, Erin M. Lanier, William A. Merrill, Ray M. Crook, Jacob Porucznik, Christina A. Rolfs, Robert T. Sauer, Brian TI Unintentional Prescription Opioid-Related Overdose Deaths: Description of Decedents by Next of Kin or Best Contact, Utah, 2008-2009 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE chronic pain; illicit drug use; mental illness; opioids; overdose; overprescribed; prescription pain medication ID CHRONIC NONCANCER PAIN; DRUG OVERDOSE; UNITED-STATES; ABUSE; PREVALENCE; DISORDERS; RISK; RECIPIENTS; THERAPY; COHORT AB Little is known about the characteristics that may predispose an individual to being at risk for fatal overdose from prescription opioids. To identify characteristics related to unintentional prescription opioid overdose deaths in Utah. Interviews were conducted (October 2008-October 2009) with a relative or friend most knowledgeable about the decedent's life. Analyses involved 254 decedents aged 18 or older, where cause of death included overdose on at least one prescription opioid. Decedents were more likely to be middle-aged, Caucasian, non-Hispanic/Latino, less educated, not married, or reside in rural areas than the general adult population in Utah. In the year prior to death, 87.4 % were prescribed prescription pain medication. Reported potential misuse prescription pain medication in the year prior to their death was high (e.g., taken more often than prescribed [52.9 %], obtained from more than one doctor during the previous year [31.6 %], and used for reasons other than treating pain [29.8 %, almost half of which "to get high"]). Compared with the general population, decedents were more likely to experience financial problems, unemployment, physical disability, mental illness (primarily depression), and to smoke cigarettes, drink alcohol, and use illicit drugs. The primary source of prescription pain medication was from a healthcare provider (91.8 %), but other sources (not mutually exclusive) included: for free from a friend or relative (24 %); from someone without their knowledge (18.2 %); purchase from a friend, relative, or acquaintance (16.4 %); and purchase from a dealer (not a pharmacy) (11.6 %). The large majority of decedents were prescribed opioids for management of chronic pain and many exhibited behaviors indicative of prescribed medication misuse. Financial problems, unemployment, physical disability, depression, and substance use (including illegal drugs) were also common. C1 [Johnson, Erin M.; Rolfs, Robert T.] Utah Dept Hlth, Prescript Pain Medicat Program, Salt Lake City, UT 84116 USA. [Lanier, William A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Merrill, Ray M.] Brigham Young Univ, Dept Hlth Sci, Provo, UT 84602 USA. [Crook, Jacob] Utah Dept Hlth, Communicable Dis Epidemiol Program, Salt Lake City, UT 84116 USA. [Porucznik, Christina A.] Univ Utah, Sch Med, Dept Family & Prevent Med, Div Publ Hlth, Salt Lake City, UT 84112 USA. [Sauer, Brian] George E Wahlen Dept Vet Affairs Med Ctr, IDEAS Ctr, Salt Lake City, UT USA. RP Merrill, RM (reprint author), Brigham Young Univ, Dept Hlth Sci, Provo, UT 84602 USA. EM Ray_Merrill@byu.edu FU Centers for Disease Control and Prevention; Utah Department of Health FX This study was funded by the Centers for Disease Control and Prevention and the Utah Department of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. We express our appreciation to the next of kin of best contacts that consented to be interviewed after the death of a relative or friend as a result of a drug overdose. NR 40 TC 24 Z9 24 U1 2 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2013 VL 28 IS 4 BP 522 EP 529 DI 10.1007/s11606-012-2225-z PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 109VV UT WOS:000316398400008 PM 23070654 ER PT J AU Couch, J Gibbins, J Connor, TH AF Couch, James Gibbins, John Connor, Thomas H. TI Evaluation of Chemotherapy Drug Exposure at a Veterinary Teaching Hospital in Michigan SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article C1 [Couch, James; Gibbins, John; Connor, Thomas H.] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Couch, J (reprint author), 4676 Columbia Pkwy,MS R-11, Cincinnati, OH 45226 USA. EM Couchjr@umich.edu FU Intramural CDC HHS [CC999999] NR 10 TC 1 Z9 1 U1 1 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD APR 1 PY 2013 VL 10 IS 4 BP D45 EP D51 DI 10.1080/15459624.2013.766561 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 097QG UT WOS:000315488000001 PM 23441586 ER PT J AU Miller, JR Short, VL Wu, HM Waller, K Mead, P Kahn, E Bahn, BA Dale, JW Nasrullah, M Walton, SE Urdaneta, V Ostroff, S Averhoff, F AF Miller, Jeffrey R. Short, Vanessa L. Wu, Henry M. Waller, Kirsten Mead, Paul Kahn, Emily Bahn, Beth A. Dale, Jon W. Nasrullah, Muazzam Walton, Sabrina E. Urdaneta, Veronica Ostroff, Stephen Averhoff, Francisco TI Use of Nonpharmaceutical Interventions to Reduce Transmission of 2009 Pandemic Influenza A (pH1N1) in Pennsylvania Public Schools SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE influenza; human; prevention and control; schools ID H1N1 VIRUS; EPIDEMIC; VACCINATION; ILLNESS; CLOSURE; STRAIN AB BACKGROUND School-based recommendations for nonpharmaceutical interventions (NPIs) were issued in response to the threat of 2009 pandemic influenza A (pH1N1). The implementation and effectiveness of these recommendations has not been assessed. METHODS In November 2009, a Web-based survey of all Pennsylvania public schools was conducted to assess the use of recommended NPIs. RESULTS Overall, 1040 (31%) of 3351 schools participated in the survey. By fall 2009, 820 (84%) of 979 respondents reported that their school had an influenza plan in place, a 44% higher proportion than in the spring 2009 (p<.01). Most schools communicated health messages (eg, staying home when sick), implemented return to school requirements, and made hand sanitizer available. Schools with a spring influenza plan (N=568) were less likely to report substantial influenza-like illness (ILI) during the fall wave of influenza than the 299 schools without a spring influenza plan (63% vs 71%, p=.02). This association persisted after controlling for schools with substantial ILI in the spring. CONCLUSION The reported use of NPIs in participating Pennsylvania public schools improved substantially from spring to fall and was generally consistent with issued recommendations. The proactive implementation of a number of NPIs and the early implementation of communication and education initiatives might have cumulatively reduced the impact of pH1N1 in some schools. C1 [Miller, Jeffrey R.; Nasrullah, Muazzam] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Short, Vanessa L.; Waller, Kirsten] Penn Dept Hlth, Bur Epidemiol, Div Infect Dis Epidemiol, Harrisburg, PA 17120 USA. [Wu, Henry M.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. [Mead, Paul] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Kahn, Emily; Walton, Sabrina E.; Averhoff, Francisco] Ctr Dis Control & Prevent, Div Global Migrat & Quarant, Atlanta, GA 30329 USA. [Bahn, Beth A.; Dale, Jon W.] Penn Dept Hlth, Div Sch Hlth, Harrisburg, PA 17120 USA. [Urdaneta, Veronica] Global Med Safety, Horsham, PA 19044 USA. [Ostroff, Stephen] Penn Dept Hlth, Bur Epidemiol, Harrisburg, PA 17120 USA. RP Miller, JR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-E92, Atlanta, GA 30333 USA. EM jrmiller@cdc.gov; vanessa.short@msdh.state.ms.us; hwu@cdc.gov; kwaller@pa.gov; pmead@cdc.gov; ebk9@cdc.gov; bbahn@pa.gov; snasrullah@cdc.gov; sewal@bellsouth.net; vurdanet@its.jnj.com; sostroff@pa.gov; faverhoff@cdc.gov OI Kahn, Emily/0000-0001-7812-7958 NR 36 TC 4 Z9 4 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD APR PY 2013 VL 83 IS 4 BP 281 EP 289 DI 10.1111/josh.12028 PG 9 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 108YK UT WOS:000316332100008 PM 23488889 ER PT J AU Vagi, KJ Rothman, EF Latzman, NE Tharp, AT Hall, DM Breiding, MJ AF Vagi, Kevin J. Rothman, Emily F. Latzman, Natasha E. Tharp, Andra Teten Hall, Diane M. Breiding, Matthew J. TI Beyond Correlates: A Review of Risk and Protective Factors for Adolescent Dating Violence Perpetration SO JOURNAL OF YOUTH AND ADOLESCENCE LA English DT Review DE Teen dating violence; Adolescent dating violence; Perpetration; Risk factor; Protective factor ID SEXUAL ASSAULT PERPETRATION; INTIMATE PARTNER VIOLENCE; ROMANTIC RELATIONSHIPS; PHYSICAL AGGRESSION; CHILD MALTREATMENT; COLLEGE-STUDENTS; YOUNG ADULTHOOD; SCHOOL; PREDICTORS; VICTIMIZATION AB Dating violence is a serious public health problem. In recent years, the U.S. Centers for Disease Control and Prevention and other entities have made funding available to community based agencies for dating violence prevention. Practitioners who are tasked with developing dating violence prevention strategies should pay particular attention to risk and protective factors for dating violence perpetration that have been established in longitudinal studies. This has been challenging to date because the scientific literature on the etiology of dating violence is somewhat limited, and because there have been no comprehensive reviews of the literature that clearly distinguish correlates of dating violence perpetration from risk or protective factors that have been established through longitudinal research. This is problematic because prevention programs may then target factors that are merely correlated with dating violence perpetration, and have no causal influence, which could potentially limit the effectiveness of the programs. In this article, we review the literature on risk and protective factors for adolescent dating violence perpetration and highlight those factors for which temporal precedence has been established by one or more studies. This review is intended as a guide for researchers and practitioners as they formulate prevention programs. We reviewed articles published between 2000 and 2010 that reported on adolescent dating violence perpetration using samples from the United States or Canada. In total, 53 risk factors and six protective factors were identified from 20 studies. Next steps for etiological research in adolescent dating violence are discussed, as well as future directions for prevention program developers. C1 [Vagi, Kevin J.; Latzman, Natasha E.; Tharp, Andra Teten; Hall, Diane M.; Breiding, Matthew J.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. [Rothman, Emily F.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Vagi, KJ (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Hwy NE,MS F-63, Atlanta, GA 30341 USA. EM kvagi@cdc.gov OI Rothman, Emily/0000-0003-0113-2577 FU NIAAA NIH HHS [K01 AA017630] NR 60 TC 58 Z9 59 U1 5 U2 76 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0047-2891 J9 J YOUTH ADOLESCENCE JI J. Youth Adolesc. PD APR PY 2013 VL 42 IS 4 SI SI BP 633 EP 649 DI 10.1007/s10964-013-9907-7 PG 17 WC Psychology, Developmental SC Psychology GA 107GF UT WOS:000316202400012 PM 23385616 ER PT J AU Parker, ME Tembo, M Adair, L Chasela, C Piwoz, EG Jamieson, DJ Ellington, S Kayira, D Soko, A Mkhomawanthu, C Martinson, F van der Horst, CM Bentley, ME AF Parker, Megan E. Tembo, Martin Adair, Linda Chasela, Charles Piwoz, Ellen G. Jamieson, Denise J. Ellington, Sascha Kayira, Dumbani Soko, Alice Mkhomawanthu, Chimwemwe Martinson, Francis van der Horst, Charles M. Bentley, Margaret E. CA BAN Study Team TI The health of HIV-exposed children after early weaning SO MATERNAL AND CHILD NUTRITION LA English DT Article DE LNS; early breastfeeding cessation; HIV; Malawi; child growth ID UNINFECTED CHILDREN; INFECTED WOMEN; COMPLEMENTARY FOODS; PRESCHOOL-CHILDREN; PROSPECTIVE COHORT; CLINICAL-TRIAL; GROWTH; MALAWI; LILONGWE; INFANTS AB There are potential health risks associated with the use of early weaning to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-poor settings. Our objective was to examine growth and nutrient inadequacies among a cohort of children weaned early. Children participating in the Breastfeeding Antiretrovirals and Nutrition (BAN) Study in Lilongwe, Malawi, had HIV-infected mothers, were weaned at 6 months and fed LNS until 12 months. 40 HIV-negative, BAN-exited children were compared with 40 HIV-negative, community children matched on age, gender and local health clinic. Nutrient intake was calculated from 24-h dietary recalls collected from BAN-exited children. Anthropometric measurements were collected from BAN-exited and matched community children at 1516 months, and 2 months later. Longitudinal random effects sex-stratified models were used to evaluate anthropometric differences between the two groups. BAN-exited children consumed adequate energy, protein and carbohydrates but inadequate amounts of fat. The prevalence of inadequate micronutrient intakes were: 46% for vitamin A; 20% for vitamin B6; 69% for folate; 13% for vitamin C; 19% for iron; 23% for zinc. Regarding growth, BAN-exited girls gained weight at a significantly lower rate {0.02gkg1 per day [95% confidence interval (CI): 0.01, 0.03]} than their matched comparison [0.05gkg1 per day (95% CI: 0.03, 0.07)]; BAN girls grew significantly slower [0.73cm month1 (95% CI: 0.40,1.06)] than their matched comparison (1.55cm month1[95% CI: 0.98, 2.12]). Among this sample of BAN-exited children, early weaning was associated with dietary deficiencies and girls experienced reduced growth velocity. In resource-poor settings, HIV prevention programmes must ensure that breastfeeding stop only once a nutritionally adequate and safe diet without breast milk can be provided. C1 [Parker, Megan E.] Int Food Policy Res Inst, Washington, DC 20036 USA. [Tembo, Martin] PATH Malawi, Lilongwe, Malawi. [Adair, Linda; van der Horst, Charles M.; Bentley, Margaret E.] Univ N Carolina, Chapel Hill, NC USA. [Chasela, Charles; Kayira, Dumbani; Soko, Alice; Mkhomawanthu, Chimwemwe; Martinson, Francis] UNC Project, Lilongwe, Malawi. [Piwoz, Ellen G.] Bill & Melinda Gates Fdn, Seattle, WA USA. [Jamieson, Denise J.; Ellington, Sascha] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Parker, ME (reprint author), CRS Burundi, Muyinga 5,BP 665, Bujumbura, Burundi. EM M.Parker@cgiar.org OI Sellers, Christopher/0000-0003-4672-8198 FU Prevention Research Centers Special Interest Project, Centers for Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01]; NIAID, UNC Center for AIDS Research [P30-AI50410]; DHHS/NIH/FIC, AIDS International Training and Research Program [2-D43 Tw01039-06]; National Institutes of Health, National Institute of Child Health and Human Development (NICHD) [1R03HD057775-01]; Nutrition Obesity Research Center [NIH DK56350]; Fogarty International Clinical Research Fellows Program at Vanderbilt [R24 TW007988] FX This research was funded by the Prevention Research Centers Special Interest Project SIP 13-01 U48-CCU409660-09 and SIP 26-04 U48-DP000059-01, Centers for Disease Control and Prevention; supported by the NIAID P30-AI50410 UNC Center for AIDS Research; DHHS/NIH/FIC 2-D43 Tw01039-06 AIDS International Training and Research Program and the National Institutes of Health, National Institute of Child Health and Human Development (NICHD, 1R03HD057775-01), Nutrition Obesity Research Center (NIH DK56350) and Fogarty International Clinical Research Fellows Program at Vanderbilt (R24 TW007988). NR 65 TC 7 Z9 7 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1740-8695 J9 MATERN CHILD NUTR JI Matern. Child Nutr. PD APR PY 2013 VL 9 IS 2 BP 217 EP 232 DI 10.1111/j.1740-8709.2011.00369.x PG 16 WC Nutrition & Dietetics; Pediatrics SC Nutrition & Dietetics; Pediatrics GA 107IQ UT WOS:000316209900006 PM 22099216 ER PT J AU Huss, A Vermeulen, R Bowman, JD Kheifets, L Kromhout, H AF Huss, Anke Vermeulen, Roel Bowman, Joseph D. Kheifets, Leeka Kromhout, Hans TI Electric shocks at work in Europe: development of a job exposure matrix SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; OCCUPATIONAL-EXPOSURE; MAGNETIC-FIELDS; UTILITY WORKERS; INJURIES; METAANALYSIS; RECOMMENDATIONS; ASSOCIATION; DISEASE AB Objectives Electric shocks have been suggested as a potential risk factor for neurological disease, in particular for amyotrophic lateral sclerosis. While actual exposure to shocks is difficult to measure, occurrence and variation of electric injuries could serve as an exposure proxy. We assessed risk of electric injury, using occupational accident registries across Europe to develop an electric shock job-exposure-matrix (JEM). Materials and methods Injury data were obtained from five European countries, and the number of workers per occupation and country from EUROSTAT was compiled at a 3-digit International Standard Classification of Occupations 1988 level. We pooled accident rates across countries with a random effects model and categorised jobs into low, medium and high risk based on the 75th and 90th percentile. We next compared our JEM to a JEM that classified extremely low frequency magnetic field exposure of jobs into low, medium and high. Results Of 116 job codes, occupations with high potential for electric injury exposure were electrical and electronic equipment mechanics and fitters, building frame workers and finishers, machinery mechanics and fitters, metal moulders and welders, assemblers, mining and construction labourers, metal-products machine operators, ships' decks crews and power production and related plant operators. Agreement between the electrical injury and magnetic field JEM was 67.2%. Conclusions Our JEM classifies occupational titles according to risk of electric injury as a proxy for occurrence of electric shocks. In addition to assessing risk potentially arising from electric shocks, this JEM might contribute to disentangling risks from electric injury from those of extremely low frequency magnetic field exposure. C1 [Huss, Anke; Vermeulen, Roel; Kromhout, Hans] IRAS, Div Environm Epidemiol, NL-3584 CK Utrecht, Netherlands. [Huss, Anke] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland. [Vermeulen, Roel] Univ Med Ctr Utrecht, Julius Ctr Publ Hlth Sci & Primary Care, Utrecht, Netherlands. [Bowman, Joseph D.] NIOSH, Cincinnati, OH 45226 USA. [Kheifets, Leeka] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. RP Huss, A (reprint author), IRAS, Div Environm Epidemiol, Jenalaan 18D, NL-3584 CK Utrecht, Netherlands. EM a.huss@uu.nl RI Vermeulen, Roel/F-8037-2011 OI Vermeulen, Roel/0000-0003-4082-8163 FU ZonMW of the Dutch programme Electromagnetic Fields and Health Research, The Netherlands [85800001] FX We would like to thank the Dutch Labour Inspectorate (storybuilder), the German Social Accident Insurance (DGUV), the Swiss National Accident Insurance Fund (SUVA), the Austrian Workers' Compensation Board (AUVA) and the UK Health and Safety Executive (HSA) for providing us the data on electrical injury at work. This study was supported by the ZonMW grant number 85800001 of the Dutch programme Electromagnetic Fields and Health Research, The Netherlands. NR 26 TC 10 Z9 10 U1 2 U2 10 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD APR PY 2013 VL 70 IS 4 BP 261 EP 267 DI 10.1136/oemed-2012-100732 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 106CR UT WOS:000316119600007 PM 23175734 ER PT J AU Johnston, LG Prybylski, D Raymond, HF Mirzazadeh, A Manopaiboon, C McFarland, W AF Johnston, Lisa G. Prybylski, Dimitri Raymond, H. Fisher Mirzazadeh, Ali Manopaiboon, Chomnad McFarland, Willi TI Incorporating the Service Multiplier Method in Respondent-Driven Sampling Surveys to Estimate the Size of Hidden and Hard-to-Reach Populations: Case Studies From Around the World SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID INJECTION-DRUG USERS; FEMALE SEX WORKERS; CAPTURE-RECAPTURE; HIV-INFECTION; PREVALENCE; NUMBER; RISK; EPIDEMIOLOGY; HIV/AIDS; RUSSIA AB Background: Estimating the sizes of populations at highest risk for HIV is essential for developing and monitoring effective HIV prevention and treatment programs. We provide several country examples of how service multiplier methods have been used in respondent-driven sampling surveys and provide guidance on how to maximize this method's use. Methods: Population size estimates were conducted in 4 countries (Mauritius- intravenous drug users [IDU] and female sex workers [FSW]; Papua New Guinea-FSW and men who have sex with men [MSM]; Thailand-IDU; United States-IDU) using adjusted proportions of population members reporting attending a service, project or study listed in a respondent-driven sampling survey, and the estimated total number of population members who visited one of the listed services, projects, or studies collected from the providers. Results: The median population size estimates were 8866 for IDU and 667 for FSW in Mauritius. Median point estimates for FSW were 4190 in Port Moresby and 8712 in Goroka, Papua New Guinea, and 2,126 for MSM in Port Moresby and 4200 for IDU in Bangkok, Thailand. Median estimates for IDU were 1050 in Chiang Mai, Thailand, and 15,789 in 2005 and 15,554 in 2009 in San Francisco. Conclusion: Our estimates for almost all groups in each country fall within the range of other regional and national estimates, indicating that the service multiplier method, assuming all assumptions are met, can produce informative estimates. We suggest using multiple multipliers whenever possible, garnering program data from the widest possible range of services, projects, and studies. A median of several estimates is likely more robust to potential biases than a single estimate. C1 [Johnston, Lisa G.; Raymond, H. Fisher; McFarland, Willi] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Prybylski, Dimitri; Manopaiboon, Chomnad] Ctr Dis Control & Prevent, Global AIDS Program, Asia Reg Off, Nonthaburi, Thailand. [Prybylski, Dimitri] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Raymond, H. Fisher; McFarland, Willi] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Mirzazadeh, Ali] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran. RP Johnston, LG (reprint author), Nieuwezijds Voorburgwal 64F, NL-1012 SC Amsterdam, Netherlands. EM Lsjohnston.global@gmail.com OI Mirzazadeh, Ali/0000-0002-0478-3220 NR 30 TC 27 Z9 27 U1 1 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2013 VL 40 IS 4 BP 304 EP 310 DI 10.1097/OLQ.0b013e31827fd650 PG 7 WC Infectious Diseases SC Infectious Diseases GA 107CQ UT WOS:000316192700010 PM 23486495 ER PT J AU Peterman, TA Newman, DR Davis, D Su, JR AF Peterman, Thomas A. Newman, Daniel R. Davis, Darlene Su, John R. TI Do Women With Persistently Negative Nontreponemal Test Results Transmit Syphilis During Pregnancy? SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID CONGENITAL-SYPHILIS; DIAGNOSIS AB Background: Syphilis screening algorithms have been reversed to take advantage of new automated treponemal tests. Screening that begins with a treponemal test identifies persons with positive treponemal and negative nontreponemal test results who were missed when screening began with a nontreponemal test. The significance of these results is uncertain. We wondered if mothers with persistently negative nontreponemal test results could transmit syphilis to their newborns. Methods: We reviewed congenital syphilis cases reported to the Centers for Disease Control and Prevention to identify all instances where (1) the mother had persistently negative nontreponemal test results (best evidence would be multiple negative nontreponemal test results with at least one >30 days after birth) and (2) the child had evidence of infection (best evidence a confirmed case, older child, stillbirth, or "probable'' by the criteria of Kaufman et al.). Results: A total of 23,863 patients with congenital syphilis had birthdates between 1991 and 2009. Of 106 mothers initially classified as having only negative nontreponemal test results reported, 20 were misclassified; the remaining 86 mothers had no infants with confirmed syphilis and no syphilitic stillbirths. The 23,757 other mothers had 284 ( 1.2%) infants with confirmed syphilis and 1271 (5.4%) syphilitic stillbirths. Twelve of the 86 mothers had negative nontreponemal test results more than 30 days after delivery; none of their children had convincing evidence of infection. One mother had a negative nontreponemal test result 27 days after delivery of a child with "positive x-rays'' and elevated cerebro-spinal fluid cell count or protein, but details were unavailable. Fifty-nine children were diagnosed at age 1 year or older; nontreponemal test results were available for 13 of the mothers, and all were positive. Conclusions: We found no convincing evidence of syphilis transmission from mothers with persistently negative nontreponemal test results. Only 1 case suggested that transmission may have occurred, and records were incomplete. C1 [Peterman, Thomas A.; Newman, Daniel R.; Davis, Darlene; Su, John R.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Peterman, TA (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Mailstop E02,1600 Clifton Rd, Atlanta, GA 30333 USA. EM tap1@cdc.gov NR 19 TC 11 Z9 12 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2013 VL 40 IS 4 BP 311 EP 315 DI 10.1097/OLQ.0b013e318285c5a7 PG 5 WC Infectious Diseases SC Infectious Diseases GA 107CQ UT WOS:000316192700011 PM 23486496 ER PT J AU Katz, KA Raymond, HF Bernstein, KT Klausner, JD AF Katz, Kenneth A. Raymond, Henry Fisher Bernstein, Kyle T. Klausner, Jeffrey D. TI Knowledge, Attitudes, and Practices Regarding Syphilis Screening Among Men Who Have Sex With Men in San Francisco SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SOCIAL MARKETING CAMPAIGN; SECONDARY SYPHILIS; HIV-INFECTION; UNITED-STATES; BISEXUAL MEN; SURVEILLANCE; RISK; PREVENTION; INCREASE; GAY AB Background: Syphilis screening for men who have sex with men (MSM) in San Francisco (SF) is recommended every 3 to 6 months. We surveyed MSM in SF to determine the prevalence and factors associated with complying with that recommendation, identify screening barriers, and investigate whether identifying low perceived syphilis risk as a reason for not testing correlated with syphilis risk factors. Methods: We conducted a cross-sectional survey as part of the National HIV Behavioral Surveillance System. We used logistic regression to analyze factors associated with complying with the SF-specific screening recommendation and with identifying low perceived risk as a reason for not testing. We analyzed data on screening barriers descriptively. Results: Among 441 MSM, 37.5% (95% confidence interval [CI], 31.5%-43.6%) complied with the recommendation. Compliance was associated with human immunodeficiency virus infection (odds ratio [OR], 3.6; 95% CI, 1.7-7.8), more than 10 male sex partners (OR, 4.3; 95% CI, 1.6-12.0), having unprotected anal sex with a casual partner (OR, 4.2; 95% CI, 2.0-8.9), and knowing the recommendation (OR, 4.1; 95% CI, 2.1-8.2). Low perceived risk, time constraints, and not knowing that one should get screened were identified as reasons for not testing by 61.7%, 18.9%, and 18.8%, respectively. Identifying low perceived risk as a reason for not testing was associated with having more than 10 sex partners (OR, 0.2; 95% CI, 0.1-0.5). Conclusions: Attempts to improve compliance with the syphilis screening recommendation should include education regarding recommended screening frequency and syphilis risk factors and interventions to increase screening convenience. C1 [Katz, Kenneth A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Katz, Kenneth A.; Bernstein, Kyle T.; Klausner, Jeffrey D.] San Francisco Dept Publ Hlth, STD Prevent & Control Serv, San Francisco, CA USA. [Raymond, Henry Fisher] San Francisco Dept Publ Hlth, HIV Epidemiol Sect, San Francisco, CA USA. [Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA. [Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Los Angeles, CA 90095 USA. RP Klausner, JD (reprint author), 9911 West Pico Blvd, Los Angeles, CA 90035 USA. EM JDKlausner@mednet.ucla.edu FU Centers for Disease Control and Prevention [1U62PS000961] FX Supported by the Centers for Disease Control and Prevention (1U62PS000961). NR 27 TC 5 Z9 5 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2013 VL 40 IS 4 BP 318 EP 322 DI 10.1097/OLQ.0b013e3182809760 PG 5 WC Infectious Diseases SC Infectious Diseases GA 107CQ UT WOS:000316192700013 PM 23486497 ER PT J AU Torrone, EA Geisler, WM Gift, TL Weinstock, HS AF Torrone, Elizabeth A. Geisler, William M. Gift, Thomas L. Weinstock, Hillard S. TI Chlamydia trachomatis Infection Among Women 26 to 39 Years of Age in the United States, 1999 to 2010 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID COST-EFFECTIVENESS; DISEASE; DISPARITIES; COVERAGE AB Using data from a nationally representative survey, we identified predictors of chlamydial infection in women aged 26 to 39 years. Chlamydia prevalence was low overall but varied by sociodemographics and sexual behaviors. Findings support current recommendations that women older than 25 years should not be routinely screened for chlamydial infection. C1 [Torrone, Elizabeth A.; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Surveillance & Data Management Branch, Div STD Prevent, Atlanta, GA 30333 USA. [Geisler, William M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Gift, Thomas L.] Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Div STD Prevent, Atlanta, GA 30333 USA. RP Torrone, EA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,M-S E-02, Atlanta, GA 30333 USA. EM ETorrone@cdc.gov NR 24 TC 2 Z9 2 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2013 VL 40 IS 4 BP 335 EP 337 DI 10.1097/OLQ.0b013e31827cd60d PG 3 WC Infectious Diseases SC Infectious Diseases GA 107CQ UT WOS:000316192700016 PM 23486500 ER PT J AU Gastanaduy, PA Hall, AJ Curns, AT Parashar, UD Lopman, BA AF Gastanaduy, Paul A. Hall, Aron J. Curns, Aaron T. Parashar, Umesh D. Lopman, Benjamin A. TI Burden of Norovirus Gastroenteritis in the Ambulatory Setting-United States, 2001-2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE norovirus; gastroenteritis; ambulatory care; United States ID INFECTIOUS INTESTINAL DISEASE; SENTINEL GENERAL PRACTICES; ENGLAND; NETHERLANDS; OUTBREAKS; ETIOLOGY; CHILDREN; ILLNESS; INFANTS; VARIANT AB Background. Gastroenteritis remains an important cause of morbidity in the United States. The burden of norovirus gastroenteritis in ambulatory US patients is not well understood. Methods. Cause-specified and cause-unspecified gastroenteritis emergency department (ED) and outpatient visits during July 2001-June 2009 were extracted from MarketScan insurance claim databases. By using cause-specified encounters, time-series regression models were fitted to predict the number of unspecified gastroenteritis visits due to specific pathogens other than norovirus. Model residuals were used to estimate norovirus visits. MarketScan rates were extrapolated to the US population to estimate national ambulatory visits. Results. During 2001-2009, the estimated annual mean rates of norovirus-associated ED and outpatient visits were 14 and 57 cases per 10 000 persons, respectively, across all ages. Rates for ages 0-4, 5-17, 18-64, and >= 65 years were 38, 10, 12, and 15 ED visits per 10 000 persons, respectively, and 233, 85, 35, and 54 outpatient visits per 10 000 persons, respectively. Norovirus was estimated to cause 13% of all gastroenteritis-associated ambulatory visits, with similar to 50% of such visits occurring during November-February. Nationally, norovirus contributed to approximately 400 000 ED visits and 1.7 million office visits annually, resulting in $284 million in healthcare charges. Conclusions. Norovirus is a substantial cause of gastroenteritis in the ambulatory setting. C1 [Gastanaduy, Paul A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Gastanaduy, Paul A.; Hall, Aron J.; Curns, Aaron T.; Parashar, Umesh D.; Lopman, Benjamin A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Gastanaduy, PA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA. EM pgastanaduy@cdc.gov NR 29 TC 38 Z9 40 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2013 VL 207 IS 7 BP 1058 EP 1065 DI 10.1093/infdis/jis942 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 099SX UT WOS:000315643100006 PM 23300161 ER PT J AU Igietseme, JU Omosun, Y Partin, J Goldstein, J He, Q Joseph, K Ellerson, D Ansari, U Eko, FO Bandea, C Zhong, GM Black, CM AF Igietseme, Joseph U. Omosun, Yusuf Partin, James Goldstein, Jason He, Qing Joseph, Kahaliah Ellerson, Debra Ansari, Uzma Eko, Francis O. Bandea, Claudiu Zhong, Guangming Black, Carolyn M. TI Prevention of Chlamydia-Induced Infertility by Inhibition of Local Caspase Activity SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Chlamydia; Dicer; caspase; miRNAs; inflammasome; infertility and pathogenesis ID GENITAL-TRACT INFECTION; FEMALE REPRODUCTIVE-TRACT; MOUSE MODEL; CELLS; TRACHOMATIS; MICRORNAS; DICER; DISEASE; DEATH; MICE AB Tubal factor infertility (TFI) represents 36% of female infertility and genital infection by Chlamydia trachomatis (C. trachomatis) is a major cause. Although TFI is associated with host inflammatory responses to bacterial components, the molecular pathogenesis of Chlamydia-induced infertility remains poorly understood. We investigated the hypothesis that activation of specific cysteine proteases, the caspases, during C. trachomatis genital infection causes the disruption of key fertility-promoting molecules required for embryo development and implantation. We analyzed the effect of caspase inhibition on infertility and the integrity of Dicer, a caspase-sensitive, fertility-promoting ribonuclease III enzyme, and key micro-RNAs in the reproductive system. Genital infection with the inflammation-and caspase-inducing, wild-type C. trachomatis serovar L2 led to infertility, but the noninflammation-inducing, plasmid-free strain did not. We confirmed that caspase-mediated apoptotic tissue destruction may contribute to chlamydial pathogenesis. Caspase-1 or -3 deficiency, or local administration of the pan caspase inhibitor, Z-VAD-FMK into normal mice protected against Chlamydia-induced infertility. Finally, the oviducts of infected infertile mice showed evidence of caspase-mediated cleavage inactivation of Dicer and alteration in critical miRNAs that regulate growth, differentiation, and development, including mir-21. These results provide new insight into the molecular pathogenesis of TFI with significant implications for new strategies for treatment and prevention of chlamydial complications. C1 [Igietseme, Joseph U.; Omosun, Yusuf; Partin, James; Goldstein, Jason; He, Qing; Joseph, Kahaliah; Ellerson, Debra; Ansari, Uzma; Bandea, Claudiu; Black, Carolyn M.] Ctr Dis Control & Prevent CDC, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA USA. [Igietseme, Joseph U.; Omosun, Yusuf; He, Qing; Eko, Francis O.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [Zhong, Guangming] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. RP Igietseme, JU (reprint author), CDC, NCEZID, DSR, Mailstop G-36,1600 Clifton Rd, Atlanta, GA 30333 USA. EM jigietseme@cdc.gov OI Omosun, Yusuf/0000-0003-4759-6254 FU Centers for Disease Control and Prevention (CDC); NIH [AI41231, GM 08248, RR03034, 1SC1GM098197] FX This work was supported by the Centers for Disease Control and Prevention (CDC) and PHS grants (AI41231, GM 08248, RR03034, and 1SC1GM098197) from the NIH. NR 48 TC 17 Z9 18 U1 0 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2013 VL 207 IS 7 BP 1095 EP 1104 DI 10.1093/infdis/jit009 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 099SX UT WOS:000315643100010 PM 23303804 ER PT J AU Fleming-Dutra, KE Taylor, T Link-Gelles, R Garg, S Jhung, MA Finelli, L Jain, S Shay, D Chaves, SS Baumbach, J Hancock, EB Beall, B Bennett, N Zansky, S Petit, S Yousey-Hindes, K Farley, MM Gershman, K Harrison, LH Ryan, P Lexau, C Lynfield, R Reingold, A Schaffner, W Thomas, A Moore, MR AF Fleming-Dutra, Katherine E. Taylor, Thomas Link-Gelles, Ruth Garg, Shikha Jhung, Michael A. Finelli, Lyn Jain, Seema Shay, David Chaves, Sandra S. Baumbach, Joan Hancock, Emily B. Beall, Bernard Bennett, Nancy Zansky, Shelly Petit, Susan Yousey-Hindes, Kimberly Farley, Monica M. Gershman, Ken Harrison, Lee H. Ryan, Patricia Lexau, Catherine Lynfield, Ruth Reingold, Art Schaffner, William Thomas, Ann Moore, Matthew R. TI Effect of the 2009 Influenza A(H1N1) Pandemic on Invasive Pneumococcal Pneumonia SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Streptococcus pneumoniae; pneumonia; pneumococcal; Influenza A Virus; H1N1 Subtype ID UNITED-STATES; A H1N1; BACTERIAL PNEUMONIA; CHILDREN; VIRUS; SURVEILLANCE; DISEASE; VACCINE; IMPACT; HOSPITALIZATIONS AB Background. Because pneumococcal pneumonia was prevalent during previous influenza pandemics, we evaluated invasive pneumococcal pneumonia (IPP) rates during the 2009 influenza A(H1N1) pandemic. Methods. We identified laboratory-confirmed, influenza-associated hospitalizations and IPP cases (pneumococcus isolated from normally sterile sites with discharge diagnoses of pneumonia) using active, population-based surveillance in the United States. We compared IPP rates during peak pandemic months (April 2009-March 2010) to mean IPP rates in nonpandemic years (April 2004-March 2009) and, using Poisson models, to 20062008 influenza seasons. Results. Higher IPP rates occurred during the peak pandemic month compared to nonpandemic periods in 5-24 (IPP rate per 10 million: 48 vs 9 (95% confidence interval [CI], 5-13), 25-49 (74 vs 53 [CI, 41-65]), 50-64 (188 vs 114 [CI, 85-143]), and >= 65-year-olds (229 vs 187 [CI, 159-216]). In the models with seasonal influenza rates included, observed IPP rates during the pandemic peak were within the predicted 95% CIs, suggesting this increase was not greater than observed with seasonal influenza. Conclusions. The recent influenza pandemic likely resulted in an out-of-season IPP peak among persons >= 5 years. The IPP peak's magnitude was similar to that seen during seasonal influenza epidemics. C1 [Fleming-Dutra, Katherine E.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA USA. [Taylor, Thomas] CDC, DBD, NCIRD, Atlanta, GA 30333 USA. [Link-Gelles, Ruth; Beall, Bernard; Moore, Matthew R.] CDC, Resp Dis Branch, DBD, NCIRD, Atlanta, GA 30333 USA. [Garg, Shikha] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Jhung, Michael A.; Finelli, Lyn; Jain, Seema; Shay, David; Chaves, Sandra S.] CDC, Influenza Div, NCIRD, Atlanta, GA 30333 USA. [Baumbach, Joan; Hancock, Emily B.] New Mexico Emerging Infect Program EIP, Santa Fe, NM USA. [Bennett, Nancy] Univ Rochester, Sch Med & Dent, New York, NY USA. [Zansky, Shelly] New York EIP, Albany, NY USA. [Petit, Susan; Yousey-Hindes, Kimberly] Connecticut EIP, Hartford, CT USA. [Farley, Monica M.] Emory Univ, Georgia EIP, Atlanta, GA 30322 USA. [Farley, Monica M.] Atlanta VAMC, Atlanta, GA USA. [Gershman, Ken] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Lexau, Catherine; Lynfield, Ruth] Minnesota EIP, St Paul, MN USA. [Reingold, Art] Calif EIP, Oakland, CA USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Thomas, Ann] Oregon EIP, Portland, OR USA. RP Fleming-Dutra, KE (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,Mailstop C25, Atlanta, GA 30333 USA. EM keflemi@emory.edu OI Yousey-Hindes, Kimberly/0000-0002-9418-575X; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention (CDC) FX The Emerging Infections Program (EIP) is a collaboration of state health departments, academic institutions, and local partners and is funded by the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. NR 39 TC 17 Z9 18 U1 0 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2013 VL 207 IS 7 BP 1135 EP 1143 DI 10.1093/infdis/jit008 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 099SX UT WOS:000315643100014 PM 23303809 ER PT J AU Tsuiki, A Luo, W Henning, T Vishwanathan, S Dinh, C Adams, D Sweeney, E Mitchell, J Bachman, S Sharma, P Powell, N Hendry, M McNicholl, J Kersh, E AF Tsuiki, Ai Luo, Wei Henning, Tara Vishwanathan, Sundaram Dinh, Chuong Adams, Debra Sweeney, Elizabeth Mitchell, James Bachman, Shannon Sharma, Prachi Powell, Nathaniel Hendry, Michael McNicholl, Janet Kersh, Ellen TI Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article DE genital; HIV; non-human primates; topical gel ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO; MULTIPLE-SCLEROSIS; HIV-1 INFECTION; SEX WORKERS; TRANSMISSION; ACTIVATION; PREVENTION; CELLS; WOMEN AB Background FTY720 is an immunomodulatory agent that reduces lymphocytes in peripheral tissues and circulation. Such agents may be effective as vaginal microbicides for HIV prevention. Systemic or vaginal application of FTY720 may reduce lymphocyte concentrations in genital tissues, reducing HIV target cell numbers. Methods Five female pigtail macaques received topical vaginal gel FTY720 (n=2), intravenous (IV) FTY720 (n=2), or placebo gel (n=1) in this pilot study. Circulating and mucosal lymphocytes and genital mucosa, cytokines, and tissue histology were analyzed to document topical and IV FTY720 effects. Results Topical and IV FTY720 appeared to decrease the levels of cervicovaginal IL-8, IL-1ra, and genital inflammatory cells. Small sample size precluded statistical analysis. Topical administration had no overt adverse effects. Conclusions This study introduces FTY720 as an immunomodulatory agent for the vaginal mucosa, compares topical effects to those of IV administration, and provides the basis for future studies involving FTY720 for HIV prevention. C1 [Tsuiki, Ai; Powell, Nathaniel] CDC, Div Sci Resources, NCEZID, Atlanta, GA 30333 USA. [Luo, Wei; Henning, Tara; Vishwanathan, Sundaram; Adams, Debra; Sweeney, Elizabeth; Mitchell, James; Bachman, Shannon; Hendry, Michael; McNicholl, Janet; Kersh, Ellen] CDC, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. [Dinh, Chuong] Total Solut, Atlanta, GA USA. [Sharma, Prachi] Emory Univ, Div Pathol, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. RP Kersh, E (reprint author), CDC, Div HIV AIDS Prevent, NCHHSTP, 1600 Clifton Rd NE,MS A25, Atlanta, GA 30333 USA. EM ekersh@cdc.gov FU Centers for Disease Control and Prevention; Division of Scientific Resources; CDC [Y1-AI-0681-02]; NIH FX The authors would like to thank the animal care staff at the Centers for Disease Control and Prevention (CDC) for monitoring, maintaining, and assisting with animal procedures, the Magee Women's Research Institute (Pittsburgh, PA, USA) for vaginal microflora analysis, Yvonne Reed (CDC) and the CDC Laboratory Animal Medicine Residency Program for their assistance in this protocol, and Charles Dobard for advice on gel formulation. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. This work was funded by Centers for Disease Control and Prevention. A. T. was funded by Division of Scientific Resources. This work was partially supported by Interagency Agreement Y1-AI-0681-02 between CDC and NIH. NR 43 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD APR PY 2013 VL 42 IS 2 BP 89 EP 100 DI 10.1111/jmp.12033 PG 12 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 103MA UT WOS:000315919700006 PM 23311598 ER PT J AU Benson, SM Novak, DA Ogg, MJ AF Benson, Stacey M. Novak, Debra A. Ogg, Mary J. TI Proper Use of Surgical N95 Respirators and Surgical Masks in the OR SO AORN JOURNAL LA English DT Article DE surgical mask; filtering facepiece respirator; surgical N95 respirator; surgical smoke; smoke inhalation; health care worker safety AB Proper adherence to infection control precautions, including appropriate selection and use of personal protective equipment (PPE), is of significant importance to the health and well-being of perioperative personnel. Surgical masks are intended for use as a barrier to protect the wearer's face from large droplets and splashes of blood and other body fluids; however, surgical and high-filtration surgical laser masks do not provide enough protection to be considered respiratory PPE. Potential exposure to airborne contaminants and infectious agents, including those present in surgical smoke, necessitates the use of respiratory PPE, such as a surgical N95 particulate filtering facepiece respirator. Filtering facepiece respirators greatly reduce a wide size range of particles from entering the wearer's breathing zone and are designed to protect the user from both droplet and airborne particles. Every health care worker who must use a respirator to control hazardous exposures in the workplace must be trained to properly use the respirator and pass a fit test before using it in the workplace. Published by Elsevier, Inc., C1 [Benson, Stacey M.] Univ Pittsburgh, Grad Sch Publ Hlth, Program Epidemiol, Pittsburgh, PA 15260 USA. [Novak, Debra A.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Natl Personal Protect Technol Lab, Atlanta, GA USA. [Ogg, Mary J.] AORN Inc, Ctr Nursing Practice, Denver, CO USA. RP Benson, SM (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Program Epidemiol, Pittsburgh, PA 15260 USA. NR 48 TC 4 Z9 4 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0001-2092 J9 ASSOC OPER ROOM NURS JI AORN J. PD APR PY 2013 VL 97 IS 4 BP 457 EP 470 DI 10.1016/j.aorn.2013.01.015 PG 14 WC Nursing SC Nursing GA V42XS UT WOS:000209647100013 PM 23531312 ER PT J AU Safran, MA AF Safran, Marc A. TI Presidential Promotion of Health-Related Behaviors Through Words and Example SO MILITARY MEDICINE LA English DT Article AB This article addresses a topic that is part of the public consciousness yet is seldom explored in the public health literature: presidential promotion of health-related behaviors through words and example. The article explores the history of what some American presidents, as individuals, have conveyed to the population about health through their own actions (presidential modeling of health behavior) and words. The nature of such messages and how they are received has changed with advances in technology and will likely continue to evolve. C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Safran, MA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE Mail Stop E-44, Atlanta, GA 30333 USA. NR 34 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD APR PY 2013 VL 178 IS 4 BP 432 EP 437 DI 10.7205/MILMED-D-12-00416 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA AN7TY UT WOS:000340805100016 PM 23707830 ER PT J AU Bottero, D Griffith, MM Lara, C Flores, D Pianciola, L Gaillard, ME Mazzeo, M Zamboni, MI Spoleti, MJ Anchart, E Ruggeri, D Sorhouet, C Fiori, S Galas, M Tondella, ML Hozbor, DF AF Bottero, D. Griffith, M. M. Lara, C. Flores, D. Pianciola, L. Gaillard, M. E. Mazzeo, M. Zamboni, M. I. Spoleti, M. J. Anchart, E. Ruggeri, D. Sorhouet, C. Fiori, S. Galas, M. Tondella, M. L. Hozbor, D. F. TI Bordetella holmesii in children suspected of pertussis in Argentina SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Bordetella pertussis; emerging infections; pertussis (whooping cough) ID POLYMERASE-CHAIN-REACTION; NASOPHARYNGEAL SAMPLES; BACTEREMIA; INFECTION; ASSAY; DNA AB We describe nine patients (eight aged < 1 year) clinically diagnosed with pertussis yet laboratory-confirmed with Bordetella holmesii infections, a human pathogen normally isolated from blood. Most patients reported cough and cold symptoms. No death was reported. We report B. holmesii isolation in infants with respiratory symptoms in Argentina. C1 [Bottero, D.; Flores, D.; Gaillard, M. E.; Fiori, S.; Hozbor, D. F.] UNLP, CONICET, Lab VacSal, IBBM,FCE, La Plata, Buenos Aires, Argentina. [Griffith, M. M.; Tondella, M. L.] US Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Off Infect Dis, Atlanta, GA USA. [Lara, C.; Ruggeri, D.; Sorhouet, C.; Galas, M.] ANLIS Dr Carlos G Malbra, Serv Bacteriol Clin, INEI, Buenos Aires, DF, Argentina. [Pianciola, L.; Mazzeo, M.] Lab Cent Subsecretaria Salud Neuque, Neuquen, Argentina. [Zamboni, M. I.] CEMAR, Direcc Serv, Labs & Anal Clin, Secretaria Salud Publ Municipalidad Rosario, Santa Fe, NM, Argentina. [Spoleti, M. J.] Municipalidad Rosario Hosp, Rosario, Santa Fe, Argentina. [Anchart, E.] Minist Salud Prov Santa Fe, Direcc Prov Farm Bioquim & Drogueria Cent, Santa Fe, Santa Fe, Argentina. RP Hozbor, DF (reprint author), Univ Nacl La Plata, Inst Biotecnol & Biol Mol, Fac Ciencias Exactas, Lab VacSal,Dept Ciencias Biol,CCT La Plata CONICE, Calles 47 & 115, RA-1900 La Plata, Argentina. EM hozbor.daniela@gmail.com FU Agencia Nacional de Promocion Cientifica y Tecnologica - ANCPyT; ANLIS; Consejo Nacional de Investigaciones Cientificas y Tecnologicas - CONICET FX This work was supported by Agencia Nacional de Promocion Cientifica y Tecnologica - ANCPyT and ANLIS - Dr. Carlos Malbran grants to D.F.H. and M.G. D.F.H. is a member of the Scientific Career of CICBA. D.B. and M.E.G. are in receipt of fellowships from Consejo Nacional de Investigaciones Cientificas y Tecnologicas - CONICET. NR 11 TC 19 Z9 19 U1 0 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD APR PY 2013 VL 141 IS 4 BP 714 EP 717 DI 10.1017/S095026881200132X PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 096CU UT WOS:000315382400005 PM 22874073 ER PT J AU Freitas, FTM Cabral, APS Barros, ENC Burigo, MJO Prochnow, RD Silva, LA Widdowson, MA Sobel, J AF Freitas, F. T. M. Cabral, A. P. S. Barros, E. N. C. Burigo, M. J. O. Prochnow, R. D. Silva, L. A. Widdowson, M. A. Sobel, J. TI Pre-symptomatic transmission of pandemic influenza H1N1 2009: investigation of a family cluster, Brazil SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Brazil; disease outbreaks; influenza ID INFECTION; DISEASE AB We investigated the first cluster of pandemic influenza H1N1 2009 reported in Brazil in May 2009. The index case-patient had travelled from the USA and had contact with 11 relatives before she presented with symptoms. We conducted face-to-face or telephone interviews with the index case-patient and all suspect cases. We found evidence of pre-symptomatic transmission of the virus to four of her contacts. This finding has public health implications because it indicates that viral transmission in communities may not be prevented solely by isolating symptomatic case-patients. C1 [Freitas, F. T. M.; Cabral, A. P. S.; Barros, E. N. C.] Brazilian Minist Hlth, Secretariat Hlth Surveillance, Brasilia, DF, Brazil. [Burigo, M. J. O.; Prochnow, R. D.; Silva, L. A.] Secretariat Hlth Santa Catarina State, Florianopolis, SC, Brazil. [Widdowson, M. A.; Sobel, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Freitas, FTM (reprint author), Setor Comercial Sul, Secretaria Vigilancia Saude, Minist Saude, Quadra 4,Bloco A,2 Andar, BR-70304000 Brasilia, DF, Brazil. EM felipetmf@gmail.com OI Widdowson, Marc-Alain/0000-0002-0682-6933 NR 7 TC 1 Z9 1 U1 0 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD APR PY 2013 VL 141 IS 4 BP 763 EP 766 DI 10.1017/S0950268812001501 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 096CU UT WOS:000315382400010 PM 22793788 ER PT J AU Benoit, SR Burkom, H McIntyre, AF Kniss, K Brammer, L Finelli, L Jain, S AF Benoit, S. R. Burkom, H. McIntyre, A. F. Kniss, K. Brammer, L. Finelli, L. Jain, S. TI Pneumonia in US hospitalized patients with influenza-like illness: BioSense, 2007-2010 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Epidemiology; influenza; pneumonia; public health; surveillance system ID UNITED-STATES; VIRUS-INFECTION; H1N1; SURVEILLANCE; ADULTS AB We used data from BioSense, a national electronic surveillance system, to describe pneumonia in hospitalized patients with influenza-like illness (ILI). Ninety-five hospitals from 20 states reported ICD-9-CM-coded inpatient final diagnosis data during the study period of September 2007 to February 2010. We compared the characteristics of persons with and without pneumonia among those with ILI-related hospitalizations. BioSense captured 26 987 ILI-related inpatient hospitalizations; 8979 (33%) had a diagnosis of pneumonia. Analysis of trends showed highest counts of pneumonia during the 2007-2008 season and the second 2009 pandemic wave. Pneumonia was more common with increasing age. Microbiology and pharmacy data were available for a subset of patients; 107 (5%) with pneumonia had a bloodstream infection and 17% of patients were prescribed antiviral treatment. Our findings demonstrate the potential utility of electronic healthcare data to track trends in ILI and pneumonia, identify risk factors for disease, identify bacteraemia in patients with pneumonia, and monitor antiviral use. C1 [Benoit, S. R.] Ctr Dis Control & Prevent, Div Notifiable Dis & Healthcare Informat Proposed, Off Surveillance Epidemiol & Lab Serv, CDC, Atlanta, GA USA. [Burkom, H.] Johns Hopkins Univ, Appl Phys Lab, Natl Secur Technol Dept, Laurel, MD USA. [McIntyre, A. F.; Kniss, K.; Brammer, L.; Finelli, L.; Jain, S.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Benoit, SR (reprint author), CDC, Unit 3190,Box 146, Dpo, AA 34024 USA. EM bvy8@cdc.gov OI burkom, howard/0000-0003-0667-9467 NR 29 TC 1 Z9 1 U1 1 U2 12 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD APR PY 2013 VL 141 IS 4 BP 805 EP 815 DI 10.1017/S0950268812001549 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 096CU UT WOS:000315382400015 PM 22800659 ER PT J AU Tharp, AT Degue, S Valle, LA Brookmeyer, KA Massetti, GM Matjasko, JL AF Tharp, Andra Teten Degue, Sarah Valle, Linda Anne Brookmeyer, Kathryn A. Massetti, Greta M. Matjasko, Jennifer L. TI A Systematic Qualitative Review of Risk and Protective Factors for Sexual Violence Perpetration SO TRAUMA VIOLENCE & ABUSE LA English DT Review DE adolescent victims; sexual assault; adult victims; prevention ID INTIMATE PARTNER VIOLENCE; SOUTH-AFRICAN MEN; COLLEGE MEN; ASSAULT PERPETRATION; DATING RELATIONSHIPS; COMMUNITY SAMPLE; ATHLETIC PARTICIPATION; CONFLUENCE MODEL; NONSEX OFFENDERS; PERSONALITY-CHARACTERISTICS AB The current review summarized results of 191 published empirical studies that examined the risk and protective factors for sexual violence perpetration. Studies in the review examined factors for perpetration by and against adolescents and adults, by male and female perpetrators, and by those who offended against individuals of the same sex or opposite sex. Factors associated with child sexual abuse (CSA) perpetration were not included. In all, 2 societal and community factors, 23 relationship factors, and 42 individual-level factors were identified. Of these 67 factors, consistent significant support for their association with SV was found for 35, nonsignificant effects were found for 10, 7 factors had limited or sample-specific evidence that they were associated with SV but were in need of further study, and 15 demonstrated mixed results. The factors identified in the review underscore the need for comprehensive prevention programs that target multiple risk and protective factors as well as factors that occur across the social ecology. Moreover, we identified two domains of factors-the presence and acceptance of violence and unhealthy sexual behaviors, experiences, or attitudes-that had consistent significant associations with SV but are not typically addressed in prevention programs. Therefore, SV prevention may also benefit from learning from effective strategies in other areas of public health, namely sexual health and youth violence prevention. C1 [Tharp, Andra Teten; Degue, Sarah; Brookmeyer, Kathryn A.; Massetti, Greta M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Valle, Linda Anne] Ctr Dis Control & Prevent, Div Violence Prevent, Prevent Dev & Evaluat Branch, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Matjasko, Jennifer L.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. RP Tharp, AT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy MS F-64, Atlanta, GA 30341 USA. EM atharp@cdc.gov NR 257 TC 30 Z9 30 U1 12 U2 96 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8380 J9 TRAUMA VIOLENCE ABUS JI Trauma Violence Abus. PD APR PY 2013 VL 14 IS 2 BP 133 EP 167 DI 10.1177/1524838012470031 PG 35 WC Criminology & Penology; Family Studies; Social Work SC Criminology & Penology; Family Studies; Social Work GA 098TJ UT WOS:000315571700004 PM 23275472 ER PT J AU Wang, S Dong, C Dai, X Cheng, XF Liang, JH Dong, M Purdy, MA Meng, JH AF Wang, Song Dong, Chen Dai, Xing Cheng, Xianfeng Liang, Jiuhong Dong, Min Purdy, Michael A. Meng, Jihong TI Hepatitis E virus isolated from rabbits is genetically heterogeneous but with very similar antigenicity to human HEV SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE hepatitis E virus; rabbit; genotype; antigenicity ID ANTI-HEV; EASTERN CHINA; PHYLOGENETIC ANALYSIS; ANIMAL RESERVOIRS; UNITED-STATES; ANTIBODIES; INFECTION; GENOTYPE; SWINE; IDENTIFICATION AB Rabbit hepatitis E virus (HEV) in China may represent a novel HEV genotype, although no consensus has been reached. It is unclear whether the ORF2 capsid protein containing the immunodominant epitopes from rabbit HEV differs from those of human HEV. In this study, 661 bile samples collected from domestic rabbits in Jiangsu province, eastern China were amplified by RT-nPCR using a set of HEV universal ORF2 primers. All 42 (6.4%) positive PCR products were sequenced. Phylogenetic analysis using the ORF2 sequences of 557bp in length showed the Jiangsu isolates were separate from HEV genotypes 1, 2, 3, 4, avian HEV and rat HEV, and clustered together with rabbit HEV sequences. These 42 isolates were divided into five branches including two newly identified in the present study. Comparison with rabbit HEV sequences from China available in GenBank, using a 298bp ORF2 segment, showed these sequences clustered together into a unique rabbit HEV clade, and were divided into eight sub-branches with high genetic heterogeneity. In addition, 267 serum samples collected from domestic rabbits, serial serum samples from two rhesus monkeys experimentally infected with HEV genotype 1 or 4, and serial serum samples from two New-Zealand rabbits infected experimentally with rabbit HEV were tested simultaneously by EIA using recombinant truncated ORF2 capsid proteins derived from rabbit and human HEV. The virtually identical results obtained suggest that rabbit and human HEV ORF2 antigens contain very similar immunodominant epitopes. All these data are helpful to identify the biological characteristics of the newly identified rabbit HEV. J. Med. Virol. 85:627635, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Wang, Song; Meng, Jihong] Southeast Univ, Sch Med, Affiliated Zhongda Hosp, Dept Internal Med, Nanjing 210009, Jiangsu, Peoples R China. [Dong, Chen; Cheng, Xianfeng; Liang, Jiuhong; Dong, Min; Meng, Jihong] Southeast Univ, Sch Med, Dept Microbiol & Immunol, Nanjing 210009, Jiangsu, Peoples R China. [Dai, Xing] Southeast Univ, Sch Med, Affiliated Zhongda Hosp, Dept Dermatol, Nanjing, Jiangsu, Peoples R China. [Purdy, Michael A.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Meng, JH (reprint author), Southeast Univ, Sch Med, Affiliated Zhongda Hosp, Dept Internal Med, Nanjing 210009, Jiangsu, Peoples R China. EM mup3@cdc.gov; jihongmeng@163.com FU National Natural Science Foundation of China [30671858]; National High Technology Research and Development Program of China, 863 Program [2006AA02A235]; Science and Technology Support Program of Jiangsu province, China [BE2009664] FX Grant sponsor: National Natural Science Foundation of China; Grant number: 30671858; Grant sponsor: National High Technology Research and Development Program of China, 863 Program; Grant number: 2006AA02A235; Grant sponsor: Science and Technology Support Program of Jiangsu province, China; Grant number: BE2009664. NR 38 TC 9 Z9 9 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD APR PY 2013 VL 85 IS 4 BP 627 EP 635 DI 10.1002/jmv.23504 PG 9 WC Virology SC Virology GA 092LP UT WOS:000315123600010 PM 23364756 ER PT J AU Soileau, SL Schneider, E Erdman, DD Lu, XY Ryan, WD McAdams, RM AF Soileau, Stacey L. Schneider, Eileen Erdman, Dean D. Lu, Xiaoyan Ryan, William D. McAdams, Ryan M. TI Case report: Severe disseminated adenovirus infection in a neonate following water birth delivery SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE cidofovir; extracorporeal membrane oxygenation; pneumonia AB Adenovirus infections are a common cause of respiratory and enteric illnesses of late infancy and childhood. In neonates, adenovirus infections are rare, carrying a high morbidity and mortality rate. We present a case of infant who developed severe pneumonia and disseminated adenoviral infection following water birth delivery to a mother with gastroenteritis. The infant's infection was due to an adenovirus strain that has not been previously reported in neonates. J. Med. Virol. 85:667669, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Soileau, Stacey L.; McAdams, Ryan M.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Schneider, Eileen; Erdman, Dean D.; Lu, Xiaoyan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Ryan, William D.] Univ Washington, Seattle Childrens Hosp, Dept Pathol, Seattle, WA 98195 USA. RP McAdams, RM (reprint author), Univ Washington, Dept Pediat, Div Neonatol, Box 356320, Seattle, WA 98195 USA. EM mcadams@uw.edu NR 12 TC 2 Z9 2 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 J9 J MED VIROL JI J. Med. Virol. PD APR PY 2013 VL 85 IS 4 BP 667 EP 669 DI 10.1002/jmv.23517 PG 3 WC Virology SC Virology GA 092LP UT WOS:000315123600014 PM 23417617 ER PT J AU Anderson, A Bijlmer, H Fournier, PE Graves, S Hartzell, J Kersh, GJ Limonard, G Marrie, TJ Massung, RF McQuiston, JH Nicholson, WL Paddock, CD Sexton, DJ AF Anderson, Alicia Bijlmer, Henk Fournier, Pierre-Edouard Graves, Stephen Hartzell, Joshua Kersh, Gilbert J. Limonard, Gijs Marrie, Thomas J. Massung, Robert F. McQuiston, Jennifer H. Nicholson, William L. Paddock, Christopher D. Sexton, Daniel J. TI Diagnosis and Management of Q Fever - United States, 2013 Recommendations from CDC and the Q Fever Working Group SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID COXIELLA-BURNETII INFECTION; LONG-TERM PERSISTENCE; OF-THE-LITERATURE; SEROLOGICAL CROSS-REACTIONS; IMMUNE-RESPONSE GENES; BORNE Q-FEVER; FATIGUE-SYNDROME; FOLLOW-UP; PREGNANT-WOMEN; SEXUAL TRANSMISSION AB Q fever, a zoonotic disease caused by the bacterium Coxiella burnetii, can cause acute or chronic illness in humans. Transmission occurs primarily through inhalation of aerosols from contaminated soil or animal waste. No licensed vaccine is available in the United States. Because many human infections result in nonspecific or benign constitutional symptoms, establishing a diagnosis of Q fever often is challenging for clinicians. This report provides the first national recommendations issued by CDC for Q fever recognition, clinical and laboratory diagnosis, treatment, management, and reporting for health-care personnel and public health professionals. The guidelines address treatment of acute and chronic phases of Q fever illness in children, adults, and pregnant women, as well as management of occupational exposures. These recommendations will be reviewed approximately every 5 years and updated to include new published evidence. C1 [Anderson, Alicia; Kersh, Gilbert J.; Massung, Robert F.; McQuiston, Jennifer H.; Nicholson, William L.; Paddock, Christopher D.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Fournier, Pierre-Edouard] Fac Med Marseille, French Natl Ctr Study & Diag Q Fever, F-13385 Marseille, France. [Hartzell, Joshua] Walter Reed Natl Mil Med Ctr, Washington, DC USA. [Limonard, Gijs] Canisius Wilhelmina Hosp, Nijmegen, Netherlands. [Marrie, Thomas J.] Dalhousie Univ, Halifax, NS B3H 3J5, Canada. [Sexton, Daniel J.] Duke Univ, Sch Med, Durham, NC USA. RP Anderson, A (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS A-30, Atlanta, GA 30333 USA. EM aha5@cdc.gov NR 168 TC 68 Z9 71 U1 2 U2 23 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD MAR 29 PY 2013 VL 62 IS 3 BP 1 EP 28 PG 28 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 192NR UT WOS:000322492300001 PM 23535757 ER PT J AU Tsang, CA Tabnak, F Vugia, DJ Benedict, K Chiller, T Park, BJ AF Tsang, Clarisse A. Tabnak, Farzaneh Vugia, Duc J. Benedict, Kaitlin Chiller, Tom Park, Benjamin J. TI Increase in Reported Coccidioidomycosis - United States, 1998-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PULMONARY C1 [Benedict, Kaitlin; Chiller, Tom; Park, Benjamin J.] CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Benedict, K (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM kbenedict@cdc.gov NR 10 TC 54 Z9 54 U1 0 U2 9 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 29 PY 2013 VL 62 IS 12 BP 217 EP 221 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FF UT WOS:000322177000001 ER PT J AU Hill, M Risk, I Burnett, C Garcia, W Carter, A Guerra, L Goodsell, L Clark, L Redd, E Nelson, S Vernon, V Leniek, K Saw, L Seward, JF Kutty, PK Wallace, G Bellini, WJ Rota, PA Rota, J Lanier, WA AF Hill, Mary Risk, Ilene Burnett, Cindy Garcia, Wendy Carter, Amy Guerra, Lisa Goodsell, Leona Clark, LaPriel Redd, Edward Nelson, Shauna Vernon, Valoree Leniek, Karyn Saw, Louise Seward, Jane F. Kutty, Preeta K. Wallace, Greg Bellini, William J. Rota, Paul A. Rota, Jennifer Lanier, William A. TI Two Measles Outbreaks After Importation - Utah, March-June 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Vernon, Valoree; Leniek, Karyn; Saw, Louise] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Lanier, William A.] CDC, Atlanta, GA 30333 USA. RP Vernon, V (reprint author), Utah Dept Hlth, Salt Lake City, UT 84116 USA. EM vvernon@utah.gov NR 10 TC 7 Z9 8 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 29 PY 2013 VL 62 IS 12 BP 222 EP 225 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FF UT WOS:000322177000002 ER PT J AU Seetoo, K Carlos, MP Blythe, D Trivedi, L Myers, R England, T Agee, C Arnold, B Dobbs, C McIntyre, M Ramirez, E Morita, J Ewaidah, S Ishow, W Chou, T Soyemi, K Barskey, AE Fiebelkorn, AP Lucas, P Abernathy, ES Icenogle, JP Wallace, GS Reef, SE Grant, Y AF Seetoo, Kurt Carlos, Maria Paz Blythe, David Trivedi, Leena Myers, Robert England, Tracey Agee, Criscelia Arnold, Bill Dobbs, Carolyn McIntyre, Mary Ramirez, Enrique Morita, Julie Ewaidah, Saadeh Ishow, Wilete Chou, Teresa Soyemi, Kenneth Barskey, Albert E. Fiebelkorn, Amy Parker Lucas, Paul Abernathy, Emily S. Icenogle, Joseph P. Wallace, Gregory S. Reef, Susan E. Grant, Yoran TI Three Cases of Congenital Rubella Syndrome in the Postelimination Era - Maryland, Alabama, and Illinois, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Seetoo, Kurt; Carlos, Maria Paz; Blythe, David; Trivedi, Leena; Myers, Robert] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Ramirez, Enrique; Morita, Julie; Ewaidah, Saadeh; Ishow, Wilete] Chicago Dept Publ Hlth, Chicago, IL USA. [Soyemi, Kenneth] Illinois Dept Publ Hlth, Springfield, IL 62761 USA. [Barskey, Albert E.; Fiebelkorn, Amy Parker; Lucas, Paul; Abernathy, Emily S.; Icenogle, Joseph P.; Wallace, Gregory S.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Grant, Yoran] CDC, Atlanta, GA 30333 USA. RP Seetoo, K (reprint author), Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. EM abarskey@cdc.gov NR 10 TC 16 Z9 16 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 29 PY 2013 VL 62 IS 12 BP 226 EP 229 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FF UT WOS:000322177000003 ER PT J AU Bamberg, W Moore, M Stone, N Perz, J Dantes, R Wendt, J AF Bamberg, Wendy Moore, Matthew Stone, Nimalie Perz, Joseph Dantes, Raymund Wendt, Joyanna TI Outbreak of Severe Respiratory Illness in an Assisted-Living Facility - Colorado, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Dantes, Raymund; Wendt, Joyanna] CDC, Atlanta, GA 30333 USA. RP Wendt, J (reprint author), CDC, Atlanta, GA 30333 USA. EM jwendt@cdc.gov NR 6 TC 1 Z9 1 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 29 PY 2013 VL 62 IS 12 BP 230 EP 231 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FF UT WOS:000322177000004 ER PT J AU Haji, KA Khatib, BO Smith, S Ali, AS Devine, GJ Coetzee, M Majambere, S AF Haji, Khamis A. Khatib, Bakari O. Smith, Stephen Ali, Abdullah S. Devine, Gregor J. Coetzee, Maureen Majambere, Silas TI Challenges for malaria elimination in Zanzibar: pyrethroid resistance in malaria vectors and poor performance of long-lasting insecticide nets SO PARASITES & VECTORS LA English DT Article DE Anopheles gambiae; Anopheles arabiensis; Tanzania; LLINs; Insecticide resistance ID TREATED BED NETS; ANOPHELES-GAMBIAE; CULEX-QUINQUEFASCIATUS; WEST-AFRICA; MOSQUITOS; FUNESTUS; VILLAGES AB Background: Long-lasting insecticide treated nets (LLINs) and indoor residual house spraying (IRS) are the main interventions for the control of malaria vectors in Zanzibar. The aim of the present study was to assess the susceptibility status of malaria vectors against the insecticides used for LLINs and IRS and to determine the durability and efficacy of LLINs on the island. Methods: Mosquitoes were sampled from Pemba and Unguja islands in 2010-2011 for use in WHO susceptibility tests. One hundred and fifty LLINs were collected from households on Unguja, their physical state was recorded and then tested for efficacy as well as total insecticide content. Results: Species identification revealed that over 90% of the Anopheles gambiae complex was An. arabiensis with a small number of An. gambiae s.s. and An. merus being present. Susceptibility tests showed that An. arabiensis on Pemba was resistant to the pyrethroids used for LLINs and IRS. Mosquitoes from Unguja Island, however, were fully susceptible to all pyrethroids tested. A physical examination of 150 LLINs showed that two thirds were damaged after only three years in use. All used nets had a significantly lower (p < 0.001) mean permethrin concentration of 791.6 mg/m(2) compared with 944.2 mg/m(2) for new ones. Their efficacy decreased significantly against both susceptible An. gambiae s. s. colony mosquitoes and wild-type mosquitoes from Pemba after just six washes (p < 0.001). Conclusion: The sustainability of the gains achieved in malaria control in Zanzibar is seriously threatened by the resistance of malaria vectors to pyrethroids and the short-lived efficacy of LLINs. This study has revealed that even in relatively well-resourced and logistically manageable places like Zanzibar, malaria elimination is going to be difficult to achieve with the current control measures. C1 [Haji, Khamis A.; Khatib, Bakari O.; Ali, Abdullah S.] Zanzibar Malaria Control Program, Zanzibar, Tanzania. [Haji, Khamis A.; Coetzee, Maureen] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Malaria Entomol Res Unit, ZA-2193 Johannesburg, South Africa. [Smith, Stephen] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Devine, Gregor J.; Majambere, Silas] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Devine, Gregor J.] Cairns Publ Hlth Unit, Cairns, Qld 4870, Australia. [Devine, Gregor J.; Majambere, Silas] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Coetzee, M (reprint author), Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Malaria Entomol Res Unit, 7 York Rd, ZA-2193 Johannesburg, South Africa. EM Maureenc@nicd.ac.za RI Devine, Gregor/H-1141-2014 FU Bill and Melinda Gates Foundation [OPP52644]; South African DST/NRF Research Chairs Initiative FX This work was funded within a Bill and Melinda Gates Foundation project grant, ID OPP52644. We thank Nassor S Nassor, Haji Mwita, Kombo Haji, Badru Badru and Juma H. Mcha, for their help with bio-assays and net durability testing, Mount Dwight for his technical help with insecticide retention analysis, Adeline Chan for her help with net durability tests. Dr Pierre Guillet and the Africa Technical Research Center, Arusha, Tanzania, are thanked for the double cone test method for LLINs and the photograph used in Figure 3. MC is supported by the South African DST/NRF Research Chairs Initiative. NR 31 TC 21 Z9 21 U1 0 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD MAR 28 PY 2013 VL 6 AR 82 DI 10.1186/1756-3305-6-82 PG 9 WC Parasitology SC Parasitology GA 140HC UT WOS:000318644100001 PM 23537463 ER PT J AU Lurie, N Manolio, T Patterson, AP Collins, F Frieden, T AF Lurie, Nicole Manolio, Teri Patterson, Amy P. Collins, Francis Frieden, Thomas TI Research as a Part of Public Health Emergency Response SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Lurie, Nicole] Dept Hlth & Human Serv, Off Assistant Secretary Preparedness & Response, Washington, DC USA. [Manolio, Teri; Patterson, Amy P.; Collins, Francis] NIH, Bethesda, MD 20892 USA. [Frieden, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lurie, N (reprint author), Dept Hlth & Human Serv, Off Assistant Secretary Preparedness & Response, Washington, DC USA. NR 4 TC 44 Z9 44 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 28 PY 2013 VL 368 IS 13 BP 1251 EP 1255 DI 10.1056/NEJMsb1209510 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 116FU UT WOS:000316869000017 PM 23534565 ER PT J AU Benjakul, S Termsirikulchai, L Hsia, J Kengganpanich, M Puckcharern, H Touchchai, C Lohtongmongkol, A Andes, L Asma, S AF Benjakul, Sarunya Termsirikulchai, Lakkhana Hsia, Jason Kengganpanich, Mondha Puckcharern, Hataichanok Touchchai, Chitrlada Lohtongmongkol, Areerat Andes, Linda Asma, Samira TI Current manufactured cigarette smoking and rolly-our-own cigarette smoking in Thailand: findings from the 2009 Global Adult Tobacco Survey SO BMC PUBLIC HEALTH LA English DT Article DE Thailand; Manufactured cigarettes; Roll-your-own cigarettes (RYO); Prevalence of current smoking AB Background: Current smoking prevalence in Thailand decreased from 1991 to 2004 and since that time the prevalence has remained flat. It has been suggested that one of the reasons that the prevalence of current smoking in Thailand has stopped decreasing is due to the use of RYO cigarettes. The aim of this study was to examine characteristics of users of manufactured and RYO cigarettes and dual users in Thailand, in order to determine whether there are differences in the characteristics of users of the different products. Methods: The 2009 Global Adult Tobacco Survey (GATS Thailand) provides detailed information on current smoking patterns. GATS Thailand used a nationally and regionally representative probability sample of 20,566 adults (ages 15 years and above) who were chosen through stratified three-stage cluster sampling and then interviewed face-to-face. Results: The prevalence of current smoking among Thai adults was 45.6% for men and 3.1% for women. In all, 18.4% of men and 1.0% of women were current users of manufactured cigarettes only, while 15.8% of men and 1.7% of women were current users of RYO cigarettes only. 11.2% of men and 0.1% of women used both RYO and manufactured cigarettes. Users of manufactured cigarettes were younger and users of RYO were older. RYO smokers were more likely to live in rural areas. Smokers of manufactured cigarettes appeared to be more knowledgeable about the health risks of tobacco use. However, the difference was confounded with age and education; when demographic variables were controlled, the knowledge differences no longer remained. Smokers of manufactured cigarettes were more likely than dual users and those who used only RYO to report that they were planning on quitting in the next month. Users of RYO only appeared to be more addicted than the other two groups as measured by time to first cigarette. Conclusions: There appears to be a need for product targeted cessation and prevention efforts that are directed toward specific population subgroups in Thailand and include information on manufactured and RYO cigarettes. C1 [Benjakul, Sarunya] Minist Publ Hlth, Dept Dis Control, Bur Tobacco Control, Nonthaburi, Thailand. [Termsirikulchai, Lakkhana; Kengganpanich, Mondha] Mahidol Univ, Fac Sch Publ Hlth, Bangkok 10700, Thailand. [Hsia, Jason; Andes, Linda; Asma, Samira] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30329 USA. [Puckcharern, Hataichanok; Touchchai, Chitrlada; Lohtongmongkol, Areerat] Natl Stat Off, Bangkok, Thailand. RP Hsia, J (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30329 USA. EM JHsia@cdc.gov FU Bloomberg Initiative, Reduce Tobacco Use, a program of Bloomberg Philanthropies FX Funding for the 2009 Global Adult Tobacco Survey Thailand was provided by the Bloomberg Initiative, Reduce Tobacco Use, a program of Bloomberg Philanthropies. NR 12 TC 5 Z9 5 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD MAR 27 PY 2013 VL 13 AR 277 DI 10.1186/1471-2458-13-277 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 128LX UT WOS:000317771600001 PM 23530750 ER PT J AU da Costa, GCV Lery, LMS da Silva, ML Moura, H Peralta, RHS von Kruger, WMA Bisch, PM Barr, JR Peralta, JM AF Verissimo da Costa, Giovani Carlo Santos Lery, Leticia Miranda da Silva, Manuela Leal Moura, Hercules Saramago Peralta, Regina Helena Almeida von Krueger, Wanda Maria Bisch, Paulo Mascarello Barr, John R. Peralta, Jose Mauro TI The identification and characterization of epitopes in the 30-34 kDa Trypanosoma cruzi proteins recognized by antibodies in the serum samples of chagasic patients SO JOURNAL OF PROTEOMICS LA English DT Article DE Chagas disease; Serodiagnostics; Proteome; Co-immunoprecipitation; Mass spectrometry; Epitope detection ID ANTIGEN LINE IMMUNOASSAY; PROTEOMIC ANALYSIS; ENDOPEP-MS; DISEASE; RECOMBINANT; INFECTION; ASSAY; SERODIAGNOSIS; EPIDEMIOLOGY; CONFIRMATION AB Trypanosoma cruzi proteins with molecular weight between 30 and 34 kDa have shown high reactivity in western blot assays with serum samples from chagasic individuals. However, in-depth analysis of the constituents of these protein fractions has not been performed. This is the first report of an immunoaffinity proteomic approach to identify the immunodominant 30-34 kDa proteins of T. cruzi that could eventually be used for the diagnosis of Chagas disease. We used two different sample preparation protocols for protein digestion coupled:to mass spectrometry to identify proteins in the protein fraction. The immunodominant proteins and their respective epitopes were then identified by co-immunoprecipitation and excision-epitope mapping/mass spectrometry, using human sera followed by the prediction and three-dimensional structural modeling of reactive epitopes. The use of different sample preparation methods allowed the identification of a relatively high number of proteins, some of which were only identified after one or multiple sample preparation and digestion protocols. Seven immunodominant proteins were identified by co-immunoprecipitation with purified IgGs from chagasic serum samples. Moreover, six reactive peptide epitopes were detected in four of these proteins by excision-epitope mapping/mass spectrometry. Three-dimensional structural models were obtained for the immunoreactive peptides, which correlated well with the linear B-cell epitope prediction tools. (C) 2012 Published by Elsevier B.V. C1 [Verissimo da Costa, Giovani Carlo; Peralta, Jose Mauro] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil. [Santos Lery, Leticia Miranda; da Silva, Manuela Leal; Almeida von Krueger, Wanda Maria; Bisch, Paulo Mascarello] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil. [Moura, Hercules; Barr, John R.] Ctr Dis Control & Prevent, Biol Mass Spectrometry Lab, ERAT Branch, Atlanta, GA USA. [Moura, Hercules; Barr, John R.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Saramago Peralta, Regina Helena] Univ Fed Fluminense, Fac Med, Dept Patol, Rio De Janeiro, Brazil. RP da Costa, GCV (reprint author), Univ Fed Rio de Janeiro, CCS, Inst Microbiol Paulo de Goes, Bl 1,Cidade Univ, BR-21949900 Rio de Janeiro, RJ, Brazil. EM giovaniverissimo@gmail.br RI Inbeb, Inct/K-2317-2013 FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) FX The authors thank the work group of Dr. Russolina B. Zingali from UEMP (Unidade de Espectrometria de Massas e Proteomica, Universidade Federal do Rio de Janeiro, Brazil) and Dr Jonas Perales from the Laboratorio de Toxonologia (FIOCRUZ, Rio de Janeiro, Brazil) for their support during mass spectrometry analyses. This work was supported by grants from the Brazilian agencies: Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). NR 38 TC 0 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1874-3919 EI 1876-7737 J9 J PROTEOMICS JI J. Proteomics PD MAR 27 PY 2013 VL 80 BP 34 EP 42 DI 10.1016/j.jprot.2012.11.001 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 125MU UT WOS:000317544700003 ER PT J AU Farley, T DeMaria, AN Wright, J Conway, PH Valderrama, AL Blair, NA Kelly, M Popovic, T AF Farley, Thomas DeMaria, Anthony N. Wright, Janet Conway, Patrick H. Valderrama, Amy L. Blair, Nicole A. Kelly, Miriam Popovic, Tanja TI CDC Grand Rounds: The Million Hearts Initiative SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Farley, Thomas] New York City Dept Hlth & Mental Hyg, New York, NY USA. [DeMaria, Anthony N.] Univ Calif San Diego, San Diego, CA 92103 USA. [Wright, Janet] CDC, Ctr Medicare & Medicaid Innovat, CMS Innovat Ctr, Atlanta, GA 30333 USA. [Valderrama, Amy L.; Blair, Nicole A.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Kelly, Miriam; Popovic, Tanja] CDC, Off Director, Atlanta, GA 30333 USA. RP Valderrama, AL (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM avalderrama@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 27 PY 2013 VL 309 IS 12 BP 1221 EP 1223 DI 10.1001/jama.2013.221 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 112WO UT WOS:000316625200007 ER PT J AU Weiss, D Antwi, M Del Rosso, P Dorsinville, M Lee, L Lin, Y Kornblum, J Varma, JK Ridpath, A AF Weiss, Don Antwi, Mike Del Rosso, Paula Dorsinville, Marie Lee, Lillian Lin, Ying Kornblum, John Varma, Jay K. Ridpath, Alison TI Notes from the Field: Serogroup C Invasive Meningococcal Disease Among Men Who Have Sex With Men-New York City, 2010-2012 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Weiss, Don; Antwi, Mike; Del Rosso, Paula; Dorsinville, Marie; Lee, Lillian; Lin, Ying; Kornblum, John; Varma, Jay K.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Ridpath, Alison] CDC, EIS, Atlanta, GA 30333 USA. RP Ridpath, A (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM aridpath@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 27 PY 2013 VL 309 IS 12 BP 1224 EP 1224 DI 10.1001/jama.2013.109 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 112WO UT WOS:000316625200008 ER PT J AU Cogswell, M Wang, CY Chen, TC Pfeiffer, C Elliott, P Gillespie, C Carriquiry, A Sempos, C Liu, K Perrine, C Swanson, C Caldwell, K Loria, C AF Cogswell, Mary Wang, Chia-Yih Chen, Te-Ching Pfeiffer, Christine Elliott, Paul Gillespie, Cathleen Carriquiry, Alicia Sempos, Christopher Liu, Kiang Perrine, Cria Swanson, Christine Caldwell, Kathleen Loria, Catherine TI Validity of Predictive Equations for 24-Hour Urine Sodium Excretion in Young Black and Other Adults SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association on Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism CY MAR 19-22, 2013 CL New Orleans, LA SP Amer Heart Assoc DE Sodium; Epidemiologic methods; Nutrition C1 [Cogswell, Mary; Pfeiffer, Christine; Gillespie, Cathleen; Perrine, Cria; Caldwell, Kathleen] CDC, Atlanta, GA 30333 USA. [Wang, Chia-Yih; Chen, Te-Ching] CDC, Hyattsville, MD USA. [Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, London, England. [Carriquiry, Alicia] Iowa State Univ, Ames, IA USA. [Sempos, Christopher; Swanson, Christine; Loria, Catherine] NIH, Rockville, MD USA. [Liu, Kiang] Northwestern Univ, Evanston, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 26 PY 2013 VL 127 IS 12 SU S MA MP78 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 302HW UT WOS:000330596100125 ER PT J AU de Quevedo, IG Lobelo, F AF de Quevedo, Isabel Garcia Lobelo, Felipe TI Healthcare Providers as Role Models for Physical Activity SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association on Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism CY MAR 19-22, 2013 CL New Orleans, LA SP Amer Heart Assoc DE Physical activity; Patient education/teaching psychosocial aspects; Public health C1 [de Quevedo, Isabel Garcia; Lobelo, Felipe] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 26 PY 2013 VL 127 IS 12 SU S MA P420 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 302HW UT WOS:000330596100537 ER PT J AU Fulton, JE Watson, KB Carlson, SA Masse, LC AF Fulton, Janet E. Watson, Kathleen B. Carlson, Susan A. Masse, Louise C. TI Validity of the Aerobic Physical Activity Questions in the Behavioral Risk Factor Surveillance System SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions of the American-Heart-Association on Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism CY MAR 19-22, 2013 CL New Orleans, LA SP Amer Heart Assoc DE Physical activity; Pubic health C1 [Fulton, Janet E.; Watson, Kathleen B.; Carlson, Susan A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Masse, Louise C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 26 PY 2013 VL 127 IS 12 SU S MA P427 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 302HW UT WOS:000330596100544 ER PT J AU McCarthy, CF Voss, J Verani, AR Vidot, P Salmon, ME Riley, PL AF McCarthy, Carey F. Voss, Joachim Verani, Andre R. Vidot, Peggy Salmon, Marla E. Riley, Patricia L. TI Nursing and midwifery regulation and HIV scale-up: establishing a baseline in east, central and southern Africa SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Article DE human resources for health; task shifting; task sharing; HIV; AIDS; scale-up; pre-service; nurse-initiated ART ID PRESIDENTS EMERGENCY PLAN; HEALTH SYSTEMS; ANTIRETROVIRAL TREATMENT; AIDS RELIEF; CHALLENGES; RESOURCES; EDUCATION; PEPFAR; IMPACT; CARE AB Introduction: Shifting HIV treatment tasks from physicians to nurses and midwives is essential to scaling-up HIV services in sub-Saharan Africa. Updating nursing and midwifery regulations to include task shifting and pre-service education reform can help facilitate reaching new HIV targets. Donor-supported initiatives to update nursing and midwifery regulations are increasing. However, there are gaps in our knowledge of current practice and education regulations and a lack of information to target and implement regulation strengthening efforts. We conducted a survey of national nursing and midwifery councils to describe current nursing and midwifery regulations in 13 African countries. Methods: A 30-item survey was administered to a convenience sample of 13 national nursing and midwifery regulatory body leaders in attendance at the PEPFAR-supported African Health Profession Regulatory Collaborative meeting in Nairobi, Kenya on 28 February, 2011. The survey contained questions on task shifting and regulations such as registration, licensure, scope of practice, pre-service education accreditation, continuing professional development and use of international guidelines. Survey data were analyzed to present country-level, comparative and regional findings. Results: Task shifting to nurses and midwives was reported in 11 of the 13 countries. Eight countries updated their scope of practice within the last five years; only one reported their regulations to reflect task shifting. Countries vary with regard to licensure, pre-service accreditation and continuing professional development regulations in place. There was no consistency in terms of what standards were used to design national practice and education regulations. Discussion: Many opportunities exist to assist countries to modernise regulations to incorporate important advancements from task shifting and pre-service reform. Appropriate, revised regulations can help sustain successful health workforce strategies and contribute to further scale-up HIV services and other global health priorities. Conclusions: This study provides fundamental information from which to articulate goals and to measure the impact of regulation strengthening efforts. C1 [McCarthy, Carey F.; Verani, Andre R.; Riley, Patricia L.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Voss, Joachim] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Voss, Joachim] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Vidot, Peggy] Commonwealth Secretariat, Social Transformat Programmes Div, London, England. [Salmon, Marla E.] Univ Washington, Evans Sch Publ Affairs, Seattle, WA 98195 USA. RP McCarthy, CF (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, 1600 Clifton Rd MS E-30, Atlanta, GA 30333 USA. EM vej6@cdc.gov FU United States President's Emergency Plan for AIDS Relief FX This work was supported by the United States President's Emergency Plan for AIDS Relief. NR 37 TC 4 Z9 4 U1 0 U2 9 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD MAR 25 PY 2013 VL 16 AR 18051 DI 10.7448/IAS.16.1.18051 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 112EN UT WOS:000316575100001 PM 23531276 ER PT J AU Pierannunzi, C Hu, SS Balluz, L AF Pierannunzi, Carol Hu, Shaohua Sean Balluz, Lina TI A systematic review of publications assessing reliability and validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004-2011 SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Review ID TEST-RETEST RELIABILITY; PHYSICAL-ACTIVITY; SELF-REPORT; HEALTH SURVEY; PREVALENCE; QUESTIONS; ASCERTAINMENT; VALIDATION; ARTHRITIS; OBESITY AB Background: In recent years response rates on telephone surveys have been declining. Rates for the behavioral risk factor surveillance system (BRFSS) have also declined, prompting the use of new methods of weighting and the inclusion of cell phone sampling frames. A number of scholars and researchers have conducted studies of the reliability and validity of the BRFSS estimates in the context of these changes. As the BRFSS makes changes in its methods of sampling and weighting, a review of reliability and validity studies of the BRFSS is needed. Methods: In order to assess the reliability and validity of prevalence estimates taken from the BRFSS, scholarship published from 2004-2011 dealing with tests of reliability and validity of BRFSS measures was compiled and presented by topics of health risk behavior. Assessments of the quality of each publication were undertaken using a categorical rubric. Higher rankings were achieved by authors who conducted reliability tests using repeated test/retest measures, or who conducted tests using multiple samples. A similar rubric was used to rank validity assessments. Validity tests which compared the BRFSS to physical measures were ranked higher than those comparing the BRFSS to other self-reported data. Literature which undertook more sophisticated statistical comparisons was also ranked higher. Results: Overall findings indicated that BRFSS prevalence rates were comparable to other national surveys which rely on self-reports, although specific differences are noted for some categories of response. BRFSS prevalence rates were less similar to surveys which utilize physical measures in addition to self-reported data. There is very little research on reliability and validity for some health topics, but a great deal of information supporting the validity of the BRFSS data for others. Conclusions: Limitations of the examination of the BRFSS were due to question differences among surveys used as comparisons, as well as mode of data collection differences. As the BRFSS moves to incorporating cell phone data and changing weighting methods, a review of reliability and validity research indicated that past BRFSS landline only data were reliable and valid as measured against other surveys. New analyses and comparisons of BRFSS data which include the new methodologies and cell phone data will be needed to ascertain the impact of these changes on estimates in the future. C1 [Pierannunzi, Carol] Ctr Dis Control & Prevent, Div Behav Surveillance, Atlanta, GA 30329 USA. [Hu, Shaohua Sean] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Balluz, Lina] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Pierannunzi, C (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM ivk7@cdc.gov NR 40 TC 54 Z9 54 U1 2 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD MAR 24 PY 2013 VL 13 AR 49 DI 10.1186/1471-2288-13-49 PG 14 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 124OR UT WOS:000317474600001 PM 23522349 ER PT J AU Pallansch, MA Oberste, MS AF Pallansch, Mark A. Oberste, M. Steven TI Enterovirus 71 encephalitis: a new vaccine on the horizon? SO LANCET LA English DT Editorial Material ID MALAYSIA; SARAWAK C1 [Pallansch, Mark A.; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Pallansch, MA (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM map1@cdc.gov NR 6 TC 5 Z9 7 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD MAR 23 PY 2013 VL 381 IS 9871 BP 976 EP 977 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 117EU UT WOS:000316936800008 PM 23668563 ER PT J AU Lee, IM Bauman, AE Blair, SN Heath, GW Kohl, HW Pratt, M Hallal, PC AF Lee, I-Min Bauman, Adrian E. Blair, Steven N. Heath, Gregory W. Kohl, Harold W., III Pratt, Michael Hallal, Pedro C. TI Annual deaths attributable to physical inactivity: whither the missing 2 million? SO LANCET LA English DT Letter ID DISEASE; BURDEN C1 [Lee, I-Min] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA. [Bauman, Adrian E.] Univ Sydney, Sch Publ Hlth, Prevent Res Collaborat, Sydney, NSW 2006, Australia. [Blair, Steven N.] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA. [Blair, Steven N.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Epidemiol Biostat, Columbia, SC 29208 USA. [Heath, Gregory W.] Univ Tennessee, Chattanooga, TN USA. [Heath, Gregory W.] Univ Tennessee, Coll Med, Chattanooga, TN USA. [Kohl, Harold W., III] Univ Texas Hlth Sci Ctr, Houston Sch Publ Hlth, Houston, TX USA. [Kohl, Harold W., III] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA. [Pratt, Michael] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Hallal, Pedro C.] Univ Fed Pelotas, BR-96020220 Pelotas, RS, Brazil. RP Hallal, PC (reprint author), Univ Fed Pelotas, BR-96020220 Pelotas, RS, Brazil. EM prchallal@gmail.com RI Hallal, Pedro/A-3249-2011 OI Hallal, Pedro/0000-0003-1470-6461 FU Wellcome Trust [095582] NR 5 TC 11 Z9 12 U1 2 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD MAR 23 PY 2013 VL 381 IS 9871 BP 992 EP 993 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 117EU UT WOS:000316936800022 PM 23668575 ER PT J AU Cohn, AC MacNeil, JR Clark, TA Ortega-Sanchez, IR Briere, EZ Meissner, HC Baker, CJ Messonnier, NE AF Cohn, Amanda C. MacNeil, Jessica R. Clark, Thomas A. Ortega-Sanchez, Ismael R. Briere, Elizabeth Z. Meissner, H. Cody Baker, Carol J. Messonnier, Nancy E. TI Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP) SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID TOXOID CONJUGATE VACCINE; GUILLAIN-BARRE-SYNDROME; CAPSULAR POLYSACCHARIDE VACCINE; RANDOMIZED CONTROLLED-TRIAL; SINGLE-DOSE CIPROFLOXACIN; MENINGITIDIS SEROGROUP-C; A NEISSERIA-MENINGITIDIS; INFLUENZAE TYPE-B; UNITED-STATES; IMMUNE-RESPONSE AB Meningococcal disease describes the spectrum of infections caused by Neisseria meningiditis, including meningitdis, bacteremia, and bacteremic pneumonia. Two quadrivalent meningococcal polysaccharide-protein conjugate vaccines that provide protection against meningococcal serogroups A, C, W, and Y (MenACWY-D [Menactra, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania] and MenACWY-CRM [Menveo, manufactured by Novartis Vaccines, Cambridge, Massachusetts]) are licensed in the United States for use among persons aged 2 through 55 years. MenACWY-D also is licensed for use among infants and toddlers aged 9 through 23 months. Quadrivalent meningococcal polysaccharide vaccine (MPSV4 [Menommune, manufactured by sanofi pasteur, Inc., Swiftwater, Pennsylvania]) is the only vaccine licensed for use among persons aged >= 56 years. A bivalent meningococcal polysaccharide protein conjugate vaccine that provides protection against meningococcal serogroups C and Y along with Haemophilus influenzae type b (Hib) (Hib-MenCY-TT [MenHibrix, manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium]) is licensed for use in children aged 6 weeks through 18 months. This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of meningococcal disease in the United States, specifically the changes in the recommendations published since 2005 (CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2005; 54[No. RR-7]). As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations; it is intended for use by clinicians as a resource. ACIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ACIP also recommends routine vaccination for persons at increased risk for meningococcal disease (i.e., persons who have persistent complement component deficiencies, persons who have anatomic or functional asplenia, microbiologists who routinely are exposed to isolates of N. meningitidis, military recruits, and persons who travel to or reside in areas in which meningococcal disease is hyperendemic or epidemic). Guidelines for antimicrobial chemoprophylaxis and for evaluation and management of suspected outbreaks of meningococcal disease also are provided. C1 [Cohn, Amanda C.; MacNeil, Jessica R.; Clark, Thomas A.; Briere, Elizabeth Z.; Messonnier, Nancy E.] CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. [Ortega-Sanchez, Ismael R.] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. [Meissner, H. Cody] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Baker, Carol J.] Baylor Coll Med, Houston, TX 77030 USA. RP Cohn, AC (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM acohn@cdc.gov NR 129 TC 139 Z9 141 U1 2 U2 15 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD MAR 22 PY 2013 VL 62 IS 2 BP 1 EP 28 PG 28 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 192NQ UT WOS:000322492200001 PM 23515099 ER PT J AU Miramontes, R Pratt, R Price, SF Navin, TR Lo, TQ AF Miramontes, Roque Pratt, Robert Price, Sandy F. Navin, Thomas R. Lo, Terrence Q. TI World TB Day - March 24, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID COUNTY C1 [Miramontes, Roque; Pratt, Robert; Price, Sandy F.; Navin, Thomas R.; Lo, Terrence Q.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30333 USA. RP Lo, TQ (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30333 USA. EM tgl8@cdc.gov NR 6 TC 37 Z9 37 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 22 PY 2013 VL 62 IS 11 BP 201 EP 205 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FE UT WOS:000322176900001 ER PT J AU Burzynski, J Varma, JK Rodriquez, E Oxtoby, MJ Privett, T Forbes, A Tuckey, D Ruggiero, D Chorba, T AF Burzynski, Joseph Varma, Jay K. Rodriquez, Edwin Oxtoby, Margaret J. Privett, Thomas Forbes, Alstead Tuckey, Dawn Ruggiero, Donato Chorba, Terence TI Tuberculosis Control Activities Before and After Hurricane Sandy - Northeast and Mid-Atlantic States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Burzynski, Joseph; Varma, Jay K.] CDC, Div Dis Control, New York City Dept Hlth & Mental Hyg, Atlanta, GA 30333 USA. [Rodriquez, Edwin; Oxtoby, Margaret J.] CDC, New York State Dept Hlth, Bur TB Control, Atlanta, GA 30333 USA. [Privett, Thomas] CDC, New Jersey Dept Health, TB Program, Atlanta, GA 30333 USA. [Ruggiero, Donato; Chorba, Terence] CDC, Div TB Eliminat, Natl Ctr HIV STD & Prevent, Atlanta, GA 30333 USA. RP Forbes, A (reprint author), CDC, Div Dis Control, New York City Dept Hlth & Mental Hyg, Atlanta, GA 30333 USA. EM arf0@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 22 PY 2013 VL 62 IS 11 BP 206 EP 208 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FE UT WOS:000322176900002 ER PT J AU Li, YF Geiss, LS Burrows, NR Rolka, DB Albright, A AF Li, YanFeng Geiss, Linda S. Burrows, Nilka R. Rolka, Deborah B. Albright, Ann TI Awareness of Prediabetes - United States, 2005-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID REDUCTION; RISK C1 [Li, YanFeng; Geiss, Linda S.; Burrows, Nilka R.; Rolka, Deborah B.; Albright, Ann] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent Hlth Promot, Atlanta, GA 30333 USA. RP Li, YF (reprint author), CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent Hlth Promot, Atlanta, GA 30333 USA. EM yanfengli@cdc.gov NR 9 TC 36 Z9 36 U1 1 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 22 PY 2013 VL 62 IS 11 BP 209 EP 212 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FE UT WOS:000322176900003 ER PT J AU Forshey, TM Nowicki, S Mohr, M Roney, CS Gomez, TM Mitchell, JR Nguyen, TA Behravesh, CB AF Forshey, Tony M. Nowicki, Scott Mohr, Marika Roney, C. Stephen Gomez, Thomas M. Mitchell, Jennifer R. Nguyen, Thai-An Behravesh, Casey Barton TI Multistate Outbreak of Salmonella Infantis, Newport, and Lille Infections Linked to Live Poultry from a Single Mail-Order Hatchery in Ohio - March-September, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Forshey, Tony M.; Nowicki, Scott; Mohr, Marika] CDC, Ohio Dept Health, Atlanta, GA 30333 USA. [Roney, C. Stephen; Gomez, Thomas M.] CDC, USDA, Atlanta, GA 30333 USA. [Mitchell, Jennifer R.; Nguyen, Thai-An; Behravesh, Casey Barton] CDC, Atlanta, GA 30333 USA. RP Mitchell, JR (reprint author), CDC, Ohio Dept Health, Atlanta, GA 30333 USA. EM itz4@cdc.gov NR 4 TC 10 Z9 10 U1 0 U2 7 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 22 PY 2013 VL 62 IS 11 BP 213 EP 213 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FE UT WOS:000322176900004 ER PT J AU Yuan, BZ Chapman, J Ding, M Wang, JZ Jiang, BH Rojanasakul, Y Reynolds, SH AF Yuan, Bao-Zhu Chapman, Joshua Ding, Min Wang, Junzhi Jiang, Binghua Rojanasakul, Yon Reynolds, Steven H. TI TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages SO BMC CANCER LA English DT Article DE Malignant pleural mesothelioma; Apoptosis; Trail; Proteasome inhibitor; Mcl-1; Akt ID PHOSPHOINOSITIDE 3-KINASE; CANCER; PATHWAY; ACTIVATION; KINASE; CHEMOTHERAPY; MECHANISM; THERAPY; TARGETS; DEATH AB Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy closely associated with asbestos exposure and extremely resistant to current treatments. It exhibits a steady increase in incidence, thus necessitating an urgent development of effective new treatments. Methods: Proteasome inhibitors (PIs) and TNF alpha-Related Apoptosis Inducing Ligand (TRAIL), have emerged as promising new anti-MPM agents. To develop effective new treatments, the proapoptotic effects of PIs, MG132 or Bortezomib, and TRAIL were investigated in MPM cell lines NCI-H2052, NCI-H2452 and NCI-H28, which represent three major histological types of human MPM. Results: Treatment with 0.5-1 mu M MG132 alone or 30 ng/mL Bortezomib alone induced a limited apoptosis in MPM cells associated with the elevated Mcl-1 protein level and hyperactive PI3K/Akt signaling. However, whereas 10-20 ng/ml TRAIL alone induced a limited apoptosis as well, TRAIL and PI combination triggered a robust apoptosis in all three MPM cell lines. The robust proapoptotic activity was found to be the consequence of a positive feedback mechanism-governed amplification of caspase activation and cleavage of both Mcl-1 and Akt proteins, and exhibited a relative selectivity in MPM cells than in non-tumorigenic Met-5A mesothelial cells. Conclusion: The combinatorial treatment using TRAIL and PI may represent an effective new treatment for MPMs. C1 [Yuan, Bao-Zhu; Wang, Junzhi] Natl Inst Food & Drug Control, Beijing 100050, Peoples R China. [Yuan, Bao-Zhu; Chapman, Joshua; Ding, Min; Reynolds, Steven H.] NIOSH, CDC, Morgantown, WV 26505 USA. [Jiang, Binghua; Rojanasakul, Yon] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA. [Yuan, Bao-Zhu] Natl Inst Food & Drug Control, Dept Cell Biol, Beijing 100038, Peoples R China. RP Yuan, BZ (reprint author), Natl Inst Food & Drug Control, Beijing 100050, Peoples R China. EM ybao4356@gmail.com OI Rojanasakul, Yon/0000-0002-8839-6462 FU NIOSH/CDC; Chinese National Science and Technology Fund [H1609-81172102] FX The study was supported by the intramural funds from NIOSH/CDC and Chinese National Science and Technology Fund (H1609-81172102). NR 41 TC 7 Z9 7 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD MAR 22 PY 2013 VL 13 AR 140 DI 10.1186/1471-2407-13-140 PG 10 WC Oncology SC Oncology GA 157GH UT WOS:000319883600001 PM 23517112 ER PT J AU Payne, DC Vinje, J Szilagyi, PG Edwards, KM Staat, MA Weinberg, GA Hall, CB Chappell, J Bernstein, DI Curns, AT Wikswo, M Shirley, SH Hall, AJ Lopman, B Parashar, UD AF Payne, Daniel C. Vinje, Jan Szilagyi, Peter G. Edwards, Kathryn M. Staat, Mary Allen Weinberg, Geoffrey A. Hall, Caroline B. Chappell, James Bernstein, David I. Curns, Aaron T. Wikswo, Mary Shirley, S. Hannah Hall, Aron J. Lopman, Benjamin Parashar, Umesh D. TI Norovirus and Medically Attended Gastroenteritis in U.S. Children SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID UNITED-STATES; ROTAVIRUS-VACCINATION; IMPACT; SURVEILLANCE; SEASONALITY; REDUCTION; OUTBREAKS; DECLINE; DISEASE; RATES AB Background Cases of rotavirus-associated acute gastroenteritis have declined since the introduction of rotavirus vaccines, but the burden of norovirus-associated acute gastroenteritis in children remains to be assessed. Methods We conducted active surveillance for laboratory-confirmed cases of norovirus among children younger than 5 years of age with acute gastroenteritis in hospitals, emergency departments, and outpatient clinical settings. The children resided in one of three U.S. counties during the years 2009 and 2010. Fecal specimens were tested for norovirus and rotavirus. We calculated population-based rates of norovirus-associated acute gastroenteritis and reviewed billing records to determine medical costs; these data were extrapolated to the U.S. population of children younger than 5 years of age. Results Norovirus was detected in 21% of young children (278 of 1295) seeking medical attention for acute gastroenteritis in 2009 and 2010, with norovirus detected in 22% (165 of 742) in 2009 and 20% (113 of 553) in 2010 (P = 0.43). The virus was also detected in 4% of healthy controls (19 of 493) in 2009. Rotavirus was identified in 12% of children with acute gastroenteritis (152 of 1295) in 2009 and 2010. The respective rates of hospitalization, emergency department visits, and outpatient visits for the norovirus were 8.6, 146.7, and 367.7 per 10,000 children younger than 5 years of age in 2009 and 5.8, 134.3, and 260.1 per 10,000 in 2010, with an estimated cost per episode of $3,918, $435, and $151, respectively, in 2009. Nationally, we estimate that the average numbers of annual hospitalizations, emergency department visits, and outpatient visits due to norovirus infection in 2009 and 2010 among U.S. children in this age group exceeded 14,000, 281,000, and 627,000, respectively, with more than $273 million in treatment costs each year. Conclusions Since the introduction of rotavirus vaccines, norovirus has become the leading cause of medically attended acute gastroenteritis in U.S. children and is associated with nearly 1 million health care visits annually. (Funded by the Centers for Disease Control and Prevention.) C1 [Payne, Daniel C.; Curns, Aaron T.; Wikswo, Mary; Hall, Aron J.; Lopman, Benjamin; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Epidemiol Branch, Atlanta, GA 30333 USA. [Vinje, Jan; Shirley, S. Hannah] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA 30333 USA. [Szilagyi, Peter G.; Weinberg, Geoffrey A.; Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Chappell, James] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA. [Chappell, James] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA. [Staat, Mary Allen; Bernstein, David I.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Shirley, S. Hannah] Atlanta Res & Educ Fdn, Decatur, GA USA. RP Payne, DC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30333 USA. EM dvp6@cdc.gov OI Vinje, Jan/0000-0002-1530-3675 FU GlaxoSmithKline; Merck; Luminex Molecular Diagnostics FX Dr. Staat reports receiving consulting and lecture fees from GlaxoSmithKline and Merck and grant support through her institution from GlaxoSmithKline; Dr. Chappell, receiving consulting fees and grant support from Luminex Molecular Diagnostics; and Dr. Bernstein, receiving royalties, both individually and through his institution, for the Rotarix vaccine from GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported. NR 29 TC 189 Z9 196 U1 2 U2 22 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 21 PY 2013 VL 368 IS 12 BP 1121 EP 1130 DI 10.1056/NEJMsa1206589 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 108TH UT WOS:000316318600005 PM 23514289 ER PT J AU Graber, N Stavinsky, F Hoffman, R Button, J Clark, N Martin, S Robertson, A Hustedt, J AF Graber, Nathan Stavinsky, Faina Hoffman, Robert Button, Jessica Clark, Nancy Martin, Scott Robertson, Alison Hustedt, John TI Ciguatera Fish Poisoning-New York City, 2010-2011 (Reprinted from vol 4, pg 61, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Graber, Nathan; Stavinsky, Faina; Hoffman, Robert; Button, Jessica; Clark, Nancy] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Martin, Scott] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA. [Robertson, Alison] US FDA, Rockville, MD 20857 USA. [Hustedt, John] CDC, Publ Hlth Prevent Svc, Atlanta, GA 30333 USA. RP Hustedt, J (reprint author), CDC, Publ Hlth Prevent Svc, Atlanta, GA 30333 USA. EM johnhustedt@gmail.com NR 1 TC 1 Z9 1 U1 0 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 20 PY 2013 VL 309 IS 11 BP 1102 EP 1104 DI 10.1001/jama.2013.1523 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 108FF UT WOS:000316276500008 ER PT J AU Medah, I Yelbeogo, D Kambou, JL Wannemuehler, K Goodson, JL Flannery, B Cohn, A Novak, RT Clark, T Messonnier, NE Meyer, SA AF Medah, Isaie Yelbeogo, Denis Kambou, Jean Ludovic Wannemuehler, Kathleen Goodson, James L. Flannery, Brendan Cohn, Amanda Novak, Ryan T. Clark, Thomas Messonnier, Nancy E. Meyer, Sarah A. TI Serogroup A Meningococcal Conjugate Vaccine Coverage After the First National Mass Immunization Campaign-Burkina Faso, 2011 (vol 50, pg 1022, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID AFRICA C1 [Meyer, Sarah A.] CDC, Atlanta, GA 30333 USA. RP Meyer, SA (reprint author), CDC, Atlanta, GA 30333 USA. EM smeyer@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 20 PY 2013 VL 309 IS 11 BP 1104 EP 1106 DI 10.1001/jama.2013.225 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 108FF UT WOS:000316276500009 ER PT J AU Leder, K Torresi, J Libman, MD Cramer, JP Castelli, F Schlagenhauf, P Wilder-Smith, A Wilson, ME Keystone, JS Schwartz, E Barnett, ED von Sonnenburg, F Brownstein, JS Cheng, AC Sotir, MJ Esposito, DH Freedman, DO AF Leder, Karin Torresi, Joseph Libman, Michael D. Cramer, Jakob P. Castelli, Francesco Schlagenhauf, Patricia Wilder-Smith, Annelies Wilson, Mary E. Keystone, Jay S. Schwartz, Eli Barnett, Elizabeth D. von Sonnenburg, Frank Brownstein, John S. Cheng, Allen C. Sotir, Mark J. Esposito, Douglas H. Freedman, David O. CA GeoSentinel Surveillance Network TI GeoSentinel Surveillance of Illness in Returned Travelers, 2007-2011 SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; HUMAN AFRICAN TRYPANOSOMIASIS; US CITIZENS ABROAD; INTERNATIONAL TRAVEL; DEVELOPING-COUNTRIES; VISITING FRIENDS; INFECTIOUS-DISEASES; HEALTH-PROBLEMS; LARGE COHORT; NETWORK AB Background: International travel continues to increase, particularly to Asia and Africa. Clinicians are increasingly likely to be consulted for advice before travel or by ill returned travelers. Objective: To describe typical diseases in returned travelers according to region, travel reason, and patient demographic characteristics; describe the pattern of low-frequency travel-associated diseases; and refine key messages for care before and after travel. Design: Descriptive, using GeoSentinel records. Setting: 53 tropical or travel disease units in 24 countries. Patients: 42 173 ill returned travelers seen between 2007 and 2011. Measurements: Frequencies of demographic characteristics, regions visited, and illnesses reported. Results: Asia (32.6%) and sub-Saharan Africa (26.7%) were the most common regions where illnesses were acquired. Three quarters of travel-related illness was due to gastrointestinal (34.0%), febrile (23.3%), and dermatologic (19.5%) diseases. Only 40.5% of all ill travelers reported pretravel medical visits. The relative frequency of many diseases varied with both travel destination and reason for travel, with travelers visiting friends and relatives in their country of origin having both a disproportionately high burden of serious febrile illness and very low rates of advice before travel (18.3%). Life-threatening diseases, such as Plasmodium falciparum malaria, melioidosis, and African trypanosomiasis, were reported. Limitations: Sentinel surveillance data collected by specialist clinics do not reflect healthy returning travelers or those with mild or self-limited illness. Data cannot be used to infer quantitative risk for illness. Conclusion: Many illnesses may have been preventable with appropriate advice, chemoprophylaxis, or vaccination. Clinicians can use these 5-year GeoSentinel data to help tailor more efficient pretravel preparation strategies and evaluate possible differential diagnoses of ill returned travelers according to destination and reason for travel. C1 Univ Melbourne, Monash Univ, Austin Hosp, Victorian Infect Dis Serv,Royal Melbourne Hosp, Melbourne, Vic, Australia. Alfred Hosp, Melbourne, Vic, Australia. McGill Univ, Ctr Trop Dis, Montreal, PQ, Canada. Toronto Gen Hosp, Trop Dis Unit, Toronto, ON, Canada. Univ Toronto, Toronto, ON, Canada. Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany. Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany. Univ Munich, Munich, Germany. Univ Brescia, Brescia, Italy. Univ Zurich, World Hlth Org Collaborating Ctr Travelers Hlth, Ctr Travel Med, Zurich, Switzerland. Harvard Univ, Sch Publ Hlth, Boston Childrens Hosp, Maxwell Finland Lab Infect Dis,Boston Med Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Tel Hashomer, Israel. Tel Aviv Univ, IL-69978 Tel Aviv, Israel. Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. Univ Alabama Birmingham, Gorgas Ctr Geog Med, Birmingham, AL USA. RP Leder, K (reprint author), Monash Univ, Dept Epidemiol & Prevent Med, Alfred Ctr, 99 Commercial Rd, Melbourne, Vic 3004, Australia. EM karin.leder@monash.edu RI Wilder-Smith, Annelies/F-8751-2015; OI Barnett, Elizabeth/0000-0003-4822-5949; Okhuysen, Pablo/0000-0002-1596-3411; Ursing, Johan/0000-0002-5508-9327; Torresi, Joseph/0000-0002-8212-0887; Wilder-Smith, Annelies/0000-0003-0362-5375; Leder, Karin/0000-0003-1368-1039; Cheng, Allen/0000-0003-3152-116X; Aoun, Olivier/0000-0001-9554-8439; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330 FU Centers for Disease Control and Prevention FX Centers for Disease Control and Prevention. NR 68 TC 111 Z9 113 U1 1 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 19 PY 2013 VL 158 IS 6 BP 456 EP + DI 10.7326/0003-4819-158-6-201303190-00005 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 292YJ UT WOS:000329938300001 PM 23552375 ER PT J AU Castranova, V Schulte, PA Zumwalde, RD AF Castranova, Vincent Schulte, Paul A. Zumwalde, Ralph D. TI Occupational Nanosafety Considerations for Carbon Nanotubes and Carbon Nanofibers SO ACCOUNTS OF CHEMICAL RESEARCH LA English DT Review ID C57BL/6 MICE; IN-VITRO; EXPOSURE; LUNG; INHALATION; TOXICITY; INFLAMMATION; MOUSE; INSTILLATION; ASPIRATION AB Carbon nanotubes (CNTs) are carbon atoms arranged in a crystalline graphene lattice with a tubular morphology. CNTs exhibit high tensile strength, possess unique electrical properties, are durable, and can be functionalized. These properties allow applications as structural materials, in electronics, as heating elements, in batteries, in the production of stain-resistant fabric, for bone grafting and dental implants, and for targeted drug delivery. Carbon nanofibers (CNFs) are strong, flexible fibers that are currently used to produce composite materials. Agitation can lead to aerosolized CNTs and CNFs, and peak airborne particulate concentrations are associated with workplace activities such as weighing, transferring, mixing, blending, or sonication. Most airborne CNTs or CNFs found in workplaces are loose agglomerates of micrometer diameter. However, due to their low density, they linger in workplace air for a considerable time, and a large fraction of these structures are respirable. In rat and mouse models, pulmonary exposure to single-walled carbon nanotubes (SWCNTs), multi-walled carbon nanotubes (MWCNTs), or CNFs causes the following pulmonary reactions: acute pulmonary inflammation and injury, rapid and persistent formation of granulomatous lesions at deposition sites of large CNT agglomerates, and rapid and progressive alveolar interstitial fibrosis at deposition sites of more dispersed CNT or CNF structures. Pulmonary exposure to SWCNTs can induce oxidant stress in aortic tissue and increases plaque formation in an atherosclerotic mouse model. Pulmonary exposure to MWCNTs depresses the ability of coronary arterioles to respond to dilators. These cardiovascular effects may result from neurogenic signals from sensory irritant receptors in the lung. Pulmonary exposure to MWCNTs also upregulates mRNA for inflammatory mediators in selected brain regions, and pulmonary exposure to SWCNTs upregulates the baroreceptor reflex. In addition, pulmonary exposure to MWCNTs may induce levels of inflammatory mediators in the blood, which may affect the cardiovascular system. Intraperitoneal instillation of MWCNTs in mice has been associated with abdominal mesothelioma. MWCNTs deposited in the distal alveoli can migrate to the intrapleural space, and MWCNTs injected in the intrapleural space can cause lesions at the parietal pleura. However, further studies are required to determine whether pulmonary exposure to MWCNTs can induce pleural lesions or mesothelioma. In light of the anticipated growth in the production and use of CNTs and CNFs, worker exposure is possible. Because pulmonary exposure to CNTs and CNFs causes inflammatory and fibrotic reactions in the rodent lung, adverse health effects in workers represent a concern. NIOSH has conducted a risk assessment using available animal exposure response data and is developing a recommended exposure limit for CNTs and CNFs. Evidence indicates that engineering controls and personal protective equipment can significantly decrease workplace exposure to CNTs and CNFs. Considering the available data on health risks, it appears prudent to develop prevention strategies to minimize workplace exposure. These strategies would include engineering controls (endosure, exhaust ventilation), worker training, administrative controls, implementation of good handling practices, and the use of personal protective equipment (such as respirators) when necessary. NIOSH has published a document containing recommendations for the safe handling of nanomaterials. C1 [Castranova, Vincent] NIOSH, Morgantown, WV 26505 USA. [Schulte, Paul A.] NIOSH, EID, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Schulte, Paul A.] NIOSH, Nanotechnol Res Ctr, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Schulte, Paul A.] NIOSH, Prevent Design Programs, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Zumwalde, Ralph D.] NIOSH, EID, Cincinnati, OH 45226 USA. [Zumwalde, Ralph D.] NIOSH, Nanotechnol Res Ctr NTRC, Cincinnati, OH 45226 USA. [Zumwalde, Ralph D.] NIOSH, Document Dev Branch, EID, Cincinnati, OH 45226 USA. RP Castranova, V (reprint author), NIOSH, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM vic1@cdc.gov; pas4@cdc.gov; rdzl@cdc.gov FU Intramural CDC HHS [CC999999] NR 58 TC 51 Z9 53 U1 8 U2 146 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0001-4842 J9 ACCOUNTS CHEM RES JI Accounts Chem. Res. PD MAR 19 PY 2013 VL 46 IS 3 BP 642 EP 649 DI 10.1021/ar300004a PG 8 WC Chemistry, Multidisciplinary SC Chemistry GA 122KO UT WOS:000317317200005 PM 23210709 ER PT J AU Ivanov, IA Beshkov, D Shankar, A Hanson, DL Paraskevis, D Georgieva, V Karamacheva, L Taskov, H Varleva, T Elenkov, I Stoicheva, M Nikolova, D Switzer, WM AF Ivanov, Ivailo Alexiev Beshkov, Danail Shankar, Anupama Hanson, Debra L. Paraskevis, Dimitrios Georgieva, Viara Karamacheva, Lyudmila Taskov, Hristo Varleva, Tonka Elenkov, Ivaylo Stoicheva, Mariana Nikolova, Daniela Switzer, William M. TI Detailed Molecular Epidemiologic Characterization of HIV-1 Infection in Bulgaria Reveals Broad Diversity and Evolving Phylodynamics SO PLOS ONE LA English DT Article ID FULL-LENGTH GENOME; TRANSMITTED DRUG-RESISTANCE; FORMER SOVIET-UNION; SUBTYPE-I; MAXIMUM-LIKELIHOOD; GENETIC DIVERSITY; TYPE-1 STRAINS; VIRUS; RECOMBINATION; IDENTIFICATION AB Limited information is available to describe the molecular epidemiology of HIV-1 in Bulgaria. To better understand the genetic diversity and the epidemiologic dynamics of HIV-1 we analyzed 125 new polymerase (pol) sequences from Bulgarians diagnosed through 2009 and 77 pol sequences available from our previous study from persons infected prior to 2007. Epidemiologic and demographic information was obtained from each participant and phylogenetic analysis was used to infer HIV-1 evolutionary histories. 120 (59.5%) persons were infected with one of five different HIV-1 subtypes (A1, B, C, F1 and H) and 63 (31.2%) persons were infected with one of six different circulating recombinant forms (CRFs; 01_AE, 02_AG, 04_cpx, 05_DF, 14_BG, and 36_cpx). We also for the first time identified infection with two different clusters of unique A-like and F-like sub-subtype variants in 12 persons (5.9%) and seven unique recombinant forms (3.5%), including a novel J/C recombinant. While subtype B was the major genotype identified and was more prevalent in MSM and increased between 2000-2005, most non-B subtypes were present in persons >= 45 years old. CRF01_AE was the most common non-B subtype and was higher in women and IDUs relative to other risk groups combined. Our results show that HIV-1 infection in Bulgaria reflects the shifting distribution of genotypes coincident with the changing epidemiology of the HIV-1 epidemic among different risk groups. Our data support increased public health interventions targeting IDUs and MSM. Furthermore, the substantial and increasing HIV-1 genetic heterogeneity, combined with fluctuating infection dynamics, highlights the importance of sustained and expanded surveillance to prevent and control HIV-1 infection in Bulgaria. C1 [Ivanov, Ivailo Alexiev; Beshkov, Danail; Georgieva, Viara; Karamacheva, Lyudmila; Taskov, Hristo] Natl Ctr Infect & Parasit Dis, Natl Reference Lab HIV, Sofia, Bulgaria. [Shankar, Anupama; Hanson, Debra L.; Switzer, William M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Paraskevis, Dimitrios] Univ Athens, Sch Med, Natl Retrovirus Reference Ctr, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece. [Varleva, Tonka] Minist Hlth, Program Prevent & Control HIV AIDS, Sofia, Bulgaria. [Elenkov, Ivaylo] Hosp Infect & Parasit Dis, Sofia, Bulgaria. [Stoicheva, Mariana] Med Univ, Plovdiv, Bulgaria. [Nikolova, Daniela] Med Univ, Clin Infect Dis, Varna, Bulgaria. RP Ivanov, IA (reprint author), Natl Ctr Infect & Parasit Dis, Natl Reference Lab HIV, Sofia, Bulgaria. EM Ivoalexiev@yahoo.com OI Paraskevis, Dimitrios/0000-0001-6167-7152 FU Bulgarian Ministry of Health Directorate; European Commission [LSHPCT-2006-518211] FX This study was funded in part by the Bulgarian Ministry of Health Directorate "Management of Specialized Donor-funded Programs" and by the European Commission sixth framework supported programs EuropeHIVResistance, grant LSHPCT-2006-518211. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 5 Z9 5 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 19 PY 2013 VL 8 IS 3 AR e59666 DI 10.1371/journal.pone.0059666 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 125SR UT WOS:000317562100156 PM 23527245 ER PT J AU Lisko, JG Stanfill, SB Duncan, BW Watson, CH AF Lisko, Joseph G. Stanfill, Stephen B. Duncan, Bryce W. Watson, Clifford H. TI Application of GC-MS/MS for the Analysis of Tobacco Alkaloids in Cigarette Filler and Various Tobacco Species SO ANALYTICAL CHEMISTRY LA English DT Article ID LIQUID-CHROMATOGRAPHY; MINOR ALKALOIDS; NICOTINE; SMOKE; SPECTROMETRY AB This publication reports the first known use of gas chromatography-tandem mass spectrometry for the quantitation of five minor tobacco alkaloids (nornicotine, myosmine, anabasine, anatabine, and isonicoteine) in various tobacco samples. A summary of the concentrations of these minor alkaloid levels in the filler from 50 popular cigarette brands were found to be 659-986 mu g/g nornicotine, 8.64-17.3 mu g/g myosmine, 127-185 mu g/g anabasine, 927-1390 mu g/g anatabine, and 23.4-45.5 mu g/g isonicoteine. Levels of minor alkaloids found in reference cigarettes (1R5F, 2R4F, 3R4F, CM4, and CM6) as well as burley, flue-cured, oriental, reconstituted, and Nicotiana rustica and Nicotiana glauca tobacco types are also reported. Quantitation of the minor tobacco alkaloids is important because the alkaloids have been shown to be precursors of carcinogenic tobacco specific N' - nitrosamines. C1 [Lisko, Joseph G.; Stanfill, Stephen B.; Duncan, Bryce W.; Watson, Clifford H.] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Lisko, JG (reprint author), US Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F55, Atlanta, GA 30341 USA. EM jlisko@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 22 Z9 28 U1 3 U2 89 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 J9 ANAL CHEM JI Anal. Chem. PD MAR 19 PY 2013 VL 85 IS 6 BP 3380 EP 3384 DI 10.1021/ac400077e PG 5 WC Chemistry, Analytical SC Chemistry GA 111KP UT WOS:000316520500047 PM 23394466 ER PT J AU Ailes, E Budge, P Shankar, M Collier, S Brinton, W Cronquist, A Chen, M Thornton, A Beach, MJ Brunkard, JM AF Ailes, Elizabeth Budge, Philip Shankar, Manjunath Collier, Sarah Brinton, William Cronquist, Alicia Chen, Melissa Thornton, Andrew Beach, Michael J. Brunkard, Joan M. TI Economic and Health Impacts Associated with a Salmonella Typhimurium Drinking Water Outbreak-Alamosa, CO, 2008 SO PLOS ONE LA English DT Article ID REACTIVE ARTHRITIS; INFECTION; MILWAUKEE; ILLNESS; LOSSES AB In 2008, a large Salmonella outbreak caused by contamination of the municipal drinking water supply occurred in Alamosa, Colorado. The objectives of this assessment were to determine the full economic costs associated with the outbreak and the long-term health impacts on the community of Alamosa. We conducted a postal survey of City of Alamosa (2008 population: 8,746) households and businesses, and conducted in-depth interviews with local, state, and nongovernmental agencies, and City of Alamosa healthcare facilities and schools to assess the economic and long-term health impacts of the outbreak. Twenty-one percent of household survey respondents (n = 369/1,732) reported diarrheal illness during the outbreak. Of those, 29% (n = 108) reported experiencing potential long-term health consequences. Most households (n = 699/771, 91%) reported municipal water as their main drinking water source at home before the outbreak; afterwards, only 30% (n = 233) drank unfiltered municipal tap water. The outbreak's estimated total cost to residents and businesses of Alamosa using a Monte Carlo simulation model (10,000 iterations) was approximately $1.5 million dollars (range: $196,677-$6,002,879), and rose to $2.6 million dollars (range: $1,123,471-$7,792,973) with the inclusion of outbreak response costs to local, state and nongovernmental agencies and City of Alamosa healthcare facilities and schools. This investigation documents the significant economic and health impacts associated with waterborne disease outbreaks and highlights the potential for loss of trust in public water systems following such outbreaks. C1 [Ailes, Elizabeth; Collier, Sarah] Int Hlth Resources Consulting, Atlanta, GA USA. [Ailes, Elizabeth; Budge, Philip; Shankar, Manjunath; Collier, Sarah; Chen, Melissa; Thornton, Andrew; Beach, Michael J.; Brunkard, Joan M.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Brinton, William] San Luis Valley Publ Hlth Emergency Preparedness, Alamosa, CO USA. [Cronquist, Alicia] Colorado Dept Publ Hlth & Environm, Dis Control & Environm Epidemiol Div, Denver, CO USA. RP Brunkard, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM jbrunkard@cdc.gov OI Chen, Melissa/0000-0002-4569-5614; Brunkard, Joan/0000-0001-5270-2627 FU Environmental Protection Agency Office of Science and Technology FX The Environmental Protection Agency Office of Science and Technology provided funding for this project but had no role in project design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 19 TC 4 Z9 5 U1 1 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 18 PY 2013 VL 8 IS 3 AR e57439 DI 10.1371/journal.pone.0057439 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 109ZS UT WOS:000316411600003 PM 23526942 ER PT J AU Zhang, J Xu, AQ Ma, JX Shi, XM Guo, XL Engelgau, M Yan, LX Li, Y Li, YC Wang, HC Lu, ZL Zhang, JY Liang, XF AF Zhang, Juan Xu, Ai-qiang Ma, Ji-xiang Shi, Xiao-ming Guo, Xiao-lei Engelgau, Michael Yan, Liu-xia Li, Yuan Li, Yi-chong Wang, Hui-cheng Lu, Zi-long Zhang, Ji-yu Liang, Xiao-feng TI Dietary Sodium Intake: Knowledge, Attitudes and Practices in Shandong Province, China, 2011 SO PLOS ONE LA English DT Article ID CARDIOVASCULAR-DISEASE; SALT; HYPERTENSION; REDUCTION; PREVALENCE; AWARENESS AB Objective: To investigate the knowledge, attitudes and practices (KAP) for dietary sodium intake among adult residents of Shandong Province, China Methods: In 2011, we conducted a cross sectional survey among a representative sample of 15,350 adults aged 18 to 69 years using a standardized questionnaire to assess their KAP for sodium. Variation in the KAPs by gender, and residence location were compared using the Chi-square tests. Predictors for the 'intention to' and 'currently taking action to' reduce sodium intake were determined by multivariate logistic regression with adjustment for confounding factors. Results: KAPs for dietary sodium intake among urban residents was generally more favorable than among rural residents. Women were likely to have more favorable KAPs than men. About four fifth of subjects reported that they favored a low sodium diets. However, 31% reported that consumption of less sodium results in less physical strength. Overall, 70% indicated their intention to reduce sodium intake, although only 39 % reported that they had taken action to reduce sodium. Multiple logistic regression analyses indicated that favorable actions to dietary sodium reduction were more likely to occur among those who were aware of the link between sodium and hypertension, and less likely among those who had unfavorable attitudes towards dietary sodium reduction. Conclusion: Increasing knowledge levels about the benefits of sodium reduction will be a key success factor for effective sodium reduction initiatives and is linked to favorable behavioral change. Emphasis should be placed on the rural area. C1 [Zhang, Juan; Shi, Xiao-ming; Li, Yuan] Chinese Ctr Dis Control & Prevent, Div Noncommunicable Dis Control & Community Hlth, Beijing, Peoples R China. [Xu, Ai-qiang] Shandong Ctr Dis Control & Prevent, Jinan, Peoples R China. [Ma, Ji-xiang; Yan, Liu-xia; Li, Yi-chong; Wang, Hui-cheng] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Guo, Xiao-lei; Lu, Zi-long; Zhang, Ji-yu] Shandong Ctr Dis Control & Prevent, Inst NCD Control & Prevent, Jinan, Peoples R China. [Engelgau, Michael] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Liang, Xiao-feng] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. RP Liang, XF (reprint author), Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. EM liangxf@hotmail.com FU Chinese Center for Disease Control and Prevention; Shandong Center for Disease Control and Prevention FX The Chinese Center for Disease Control and Prevention, and Shandong Center for Disease Control and Prevention provided funding for data collection. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 9 Z9 13 U1 3 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 18 PY 2013 VL 8 IS 3 AR e58973 DI 10.1371/journal.pone.0058973 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 109ZS UT WOS:000316411600021 PM 23527061 ER PT J AU Kammerer, JS Shang, N Althomsons, SP Haddad, MB Grant, J Navin, TR AF Kammerer, J. Steve Shang, Nong Althomsons, Sandy P. Haddad, Maryam B. Grant, Juliana Navin, Thomas R. TI Using statistical methods and genotyping to detect tuberculosis outbreaks SO INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS LA English DT Article DE Tuberculosis; SaTScan; Outbreak detection; Genotyping; Log-likelihood ratio; Cumulative sums ID ABERRATION DETECTION METHODS; PUBLIC-HEALTH SURVEILLANCE; UNITED-STATES; DISEASE SURVEILLANCE; NEW-YORK; CLUSTER; EPIDEMIOLOGY; MULTISTATE; SERIES; FEVER AB Background: Early identification of outbreaks remains a key component in continuing to reduce the burden of infectious disease in the United States. Previous studies have applied statistical methods to detect unexpected cases of disease in space or time. The objectives of our study were to assess the ability and timeliness of three spatio-temporal methods to detect known outbreaks of tuberculosis. Methods: We used routinely available molecular and surveillance data to retrospectively assess the effectiveness of three statistical methods in detecting tuberculosis outbreaks: county-based log-likelihood ratio, cumulative sums, and a spatial scan statistic. Results: Our methods identified 8 of the 9 outbreaks, and 6 outbreaks would have been identified 1-52 months (median = 10 months) before local public health authorities identified them. Assuming no delays in data availability, 46 (59.7%) of the 77 patients in the 9 outbreaks were identified after our statistical methods would have detected the outbreak but before local public health authorities became aware of the problem. Conclusions: Statistical methods, when applied retrospectively to routinely collected tuberculosis data, can successfully detect known outbreaks, potentially months before local public health authorities become aware of the problem. The three methods showed similar results; no single method was clearly superior to the other two. Further study to elucidate the performance of these methods in detecting tuberculosis outbreaks will be done in a prospective analysis. C1 [Kammerer, J. Steve; Shang, Nong; Althomsons, Sandy P.; Haddad, Maryam B.; Grant, Juliana; Navin, Thomas R.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Kammerer, J. Steve] Northrop Grumman Corp, Atlanta, GA 30345 USA. RP Kammerer, JS (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM fzk3@cdc.gov NR 38 TC 5 Z9 5 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-072X J9 INT J HEALTH GEOGR JI Int. J. Health Geogr. PD MAR 16 PY 2013 VL 12 AR 15 DI 10.1186/1476-072X-12-15 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 114KJ UT WOS:000316739500001 PM 23497235 ER PT J AU Naumann, RB Dellinger, AM AF Naumann, Rebecca B. Dellinger, Ann M. TI Mobile Device Use While Driving - United States and Seven European Countries, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CELL PHONE USE C1 [Naumann, Rebecca B.; Dellinger, Ann M.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Naumann, RB (reprint author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM rnaumann@cdc.gov NR 10 TC 11 Z9 12 U1 1 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 15 PY 2013 VL 62 IS 10 BP 177 EP 182 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FB UT WOS:000322176600001 ER PT J AU Miles, IJ Le, BC Wejnert, C Oster, A DiNenno, E Paz-Bailey, G AF Miles, Isa J. Le, Binh C. Wejnert, Cyprian Oster, Alexandra DiNenno, Elizabeth Paz-Bailey, Gabriela TI HIV Infection Among Heterosexuals at Increased Risk - United States, 2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PREVENTION C1 [Miles, Isa J.; Le, Binh C.; Wejnert, Cyprian; Oster, Alexandra; DiNenno, Elizabeth; Paz-Bailey, Gabriela] CDC, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. RP Miles, IJ (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. EM imiles@cdc.gov NR 9 TC 26 Z9 26 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 15 PY 2013 VL 62 IS 10 BP 183 EP 188 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FB UT WOS:000322176600002 ER PT J AU Marchi, KS Braveman, PA Martin, K Curtis, M Stancil, T Harrison, L AF Marchi, Kristen S. Braveman, Paula A. Martin, Katie Curtis, Michael Stancil, Tonya Harrison, Leslie TI Eligibility and Enrollment in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-27 States and New York City, 2007-2008 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID BIRTH OUTCOMES; WIC PROGRAM; WEIGHT; PARTICIPATION C1 [Marchi, Kristen S.; Braveman, Paula A.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Stancil, Tonya; Harrison, Leslie] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Marchi, KS (reprint author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. EM marchik@fcm.ucsf.edu NR 10 TC 2 Z9 2 U1 1 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 15 PY 2013 VL 62 IS 10 BP 189 EP 193 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FB UT WOS:000322176600003 ER PT J AU Rha, B AF Rha, Brian TI Update: Severe Respiratory Illness Associated with a Novel Coronavirus - Worldwide, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SAUDI-ARABIA C1 CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Rha, B (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM wif8@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 15 PY 2013 VL 62 IS 10 BP 194 EP 195 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FB UT WOS:000322176600004 ER PT J AU Santos, HLC Bandyopadhyay, K Bandea, R Peralta, RHS Peralta, JM Da Silva, AJ AF Carneiro Santos, Helena Lucia Bandyopadhyay, Kakali Bandea, Rebecca Saramago Peralta, Regina Helena Peralta, Jose Mauro Da Silva, Alexandre Januario TI LUMINEX (R): a new technology for the simultaneous identification of five Entamoeba spp. commonly found in human stools SO PARASITES & VECTORS LA English DT Article DE Entamoeba; 18SrRNA; PCR; Molecular diagnostics; Multiplex assay ID REAL-TIME PCR; MULTIANALYTE PROFILING SYSTEM; LINKED-IMMUNOSORBENT-ASSAY; POLYMERASE-CHAIN-REACTION; RIBOSOMAL-RNA GENES; RAPID IDENTIFICATION; CRYPTOSPORIDIUM-PARVUM; GIARDIA-LAMBLIA; MULTIPLEX-PCR; ANTIGEN-DETECTION AB Background: Six species of the genus Entamoeba, i.e., E. histolytica, E. dispar, E. moshkovskii, E. polecki, E. coli, and E. hartmanii can be found in human stools. Among these, only E. histolytica is considered to be pathogenic, causing intestinal and extra-intestinal disease, but it is morphologically identical to E. dispar and E. moshkovskii. In general, E. polecki, E. coli, and E. hartmanii can be differentiated morphologically from E. histolytica, but some of their diagnostic morphologic features may overlap creating issues for the differential diagnosis. Moreover, the previous inability to differentiate among Entamoeba species has limited epidemiologic information on E histolytica. The objective of this study was to develop a rapid, high-throughput screening method using Luminex technique for the simultaneous detection and differentiation of Entamoeba species. Methods: PCR amplification was performed with biotinylated Entamoeba sp 18S rRNA gene primers, designed to amplify a fragment ranging from 382 to 429 bp of the Entamoeba spp studied. Regions of this fragment that could differentiate among E. histolytica, E. moshkovskii, E. dispar, E. hartmanii and E. coli were selected to design hybridization probes to link to Luminex beads. The assay was standardized with cloned DNA samples of each species and evaluated with 24 DNA extracts from samples obtained from individuals diagnosed with these amebas in their stools. Results: Using this approach we were able to correctly identify E. histoltyica, E. dispar, E hartmanni, E. coli and E. moshkovskii in all specimens studied. From twenty four samples tested by microscopy, PCR/DNA Sequencing and real-time PCR, 100% agreed with PCR-Luminex assay for identification of E. dispar, E. moshkovskii, E. hartmanni, E. histolytica, and E. coli. Conclusion: These results show that this method could be used in the diagnostic detection of Entamoeba spp in fecal samples. This diagnostic test was useful to clearly distinguish E histolytica from other species and also to strengthen epidemiologic data on Entamoeba spp. C1 [Carneiro Santos, Helena Lucia; Peralta, Jose Mauro] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil. [Carneiro Santos, Helena Lucia] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, LAPSA, Rio De Janeiro, Brazil. [Bandyopadhyay, Kakali; Bandea, Rebecca; Da Silva, Alexandre Januario] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [Saramago Peralta, Regina Helena] Univ Fed Fluminense, Dept Patol, Niteroi, RJ, Brazil. RP Peralta, JM (reprint author), Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil. EM peralta@micro.ufrj.br FU US National Food Safety Initiative; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) PhD programa/Brazil; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) FX This study received funds from the US National Food Safety Initiative, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) PhD programa/Brazil and Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 45 TC 7 Z9 7 U1 0 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD MAR 15 PY 2013 VL 6 AR 69 DI 10.1186/1756-3305-6-69 PG 9 WC Parasitology SC Parasitology GA 127GO UT WOS:000317686000001 PM 23497666 ER PT J AU Griffing, SM Viana, GMR Mixson-Hayden, T Sridaran, S Alam, MT de Oliveira, AM Barnwell, JW Escalante, AA Povoa, MM Udhayakumar, V AF Griffing, Sean M. Rachid Viana, Giselle M. Mixson-Hayden, Tonya Sridaran, Sankar Alam, Mohammad Tauqeer de Oliveira, Alexandre Macedo Barnwell, John W. Escalante, Ananias A. Povoa, Marinete Marins Udhayakumar, Venkatachalam TI Historical Shifts in Brazilian P. falciparum Population Structure and Drug Resistance Alleles SO PLOS ONE LA English DT Article ID MEROZOITE SURFACE PROTEIN-1; PLASMODIUM-FALCIPARUM; AMAZON REGION; SULFADOXINE-PYRIMETHAMINE; CHLOROQUINE RESISTANCE; MICROSATELLITE MARKERS; SELECTIVE SWEEPS; SOUTH-AMERICA; MALARIA; MUTATIONS AB Previous work suggests that Brazilian Plasmodium falciparum has limited genetic diversity and a history of bottlenecks, multiple reintroductions due to human migration, and clonal expansions. We hypothesized that Brazilian P. falciparum would exhibit clonal structure. We examined isolates collected across two decades from Amapa, Rondonia, and Para state (n = 190). By examining more microsatellites markers on more chromosomes than previous studies, we hoped to define the extent of low diversity, linkage disequilibrium, bottlenecks, population structure, and parasite migration within Brazil. We used retrospective genotyping of samples from the 1980s and 1990s to explore the population genetics of SP resistant dhfr and dhps alleles. We tested an existing hypothesis that the triple mutant dhfr mutations 50R/51I/108N and 51I/108N/164L developed in southern Amazon from a single origin of common or similar parasites. We found that Brazilian P. falciparum had limited genetic diversity and isolation by distance was rejected, which suggests it underwent bottlenecks followed by migration between sites. Unlike Peru, there appeared to be gene flow across the Brazilian Amazon basin. We were unable to divide parasite populations by clonal lineages and pairwise FST were common. Most parasite diversity was found within sites in the Brazilian Amazon, according to AMOVA. Our results challenge the hypothesis that triple mutant alleles arose from a single lineage in the Southern Amazon. SP resistance, at both the double and triple mutant stages, developed twice and potentially in different regions of the Brazilian Amazon. We would have required samples from before the 1980s to describe how SP resistance spread across the basin or describe the complex internal migration of Brazilian parasites after the colonization efforts of past decades. The Brazilian Amazon basin may have sufficient internal migration for drug resistance reported in any particular region to rapidly spread to other parts of basin under similar drug pressure. C1 [Griffing, Sean M.; Mixson-Hayden, Tonya; Sridaran, Sankar; Alam, Mohammad Tauqeer; de Oliveira, Alexandre Macedo; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Griffing, Sean M.; Mixson-Hayden, Tonya; Alam, Mohammad Tauqeer] Atlanta Res & Educ Fdn, Decatur, GA USA. [Sridaran, Sankar] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Escalante, Ananias A.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA. RP Udhayakumar, V (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA. EM vxu0@cdc.gov FU Antimicrobial Drug Resistance Working Group, Centers for Disease Control and Prevention, Atlanta Research and Education Foundation, Atlanta VA Medical Center; U.S. Agency for International Development; National Science Foundation; Association of Public Health Laboratories; Atlanta Research and Education Foundation; National Institutes of Health [R01GM084320] FX This work was financially supported in part by the Antimicrobial Drug Resistance Working Group, Centers for Disease Control and Prevention, Atlanta Research and Education Foundation, Atlanta VA Medical Center, and the U.S. Agency for International Development-supported Amazon Malaria Initiative. S. Griffing was supported by a National Science Foundation Graduate Research Fellowship. Luke Syphard and Sankar Sridaran were supported by Emerging Infectious Diseases fellowships from the Association of Public Health Laboratories. Andrea M. McCollum, Tonya Mixson-Hayden, Sean Griffing, and Sumiti Vinayak were supported by the Atlanta Research and Education Foundation. A. A. Escalante is supported by grant R01GM084320 from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 9 Z9 9 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 15 PY 2013 VL 8 IS 3 AR e58984 DI 10.1371/journal.pone.0058984 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 109ZC UT WOS:000316409800050 PM 23554964 ER PT J AU Moraru, GM Goddard, J Paddock, CD Varela-Stokes, A AF Moraru, Gail Miriam Goddard, Jerome Paddock, Christopher D. Varela-Stokes, Andrea TI Experimental infection of cotton rats and bobwhite quail with Rickettsia parkeri SO PARASITES & VECTORS LA English DT Article DE Rickettsia parkeri; Experimental infection; Cotton rat; Quail ID FEVER-GROUP RICKETTSIAE; GULF-COAST TICKS; SPOTTED-FEVER; AMBLYOMMA-MACULATUM; PHYLOGENETIC ANALYSIS; UNITED-STATES; SMALL MAMMALS; SAO-PAULO; IDENTIFICATION; TRANSMISSION AB Background: Amblyomma maculatum is the primary vector for Rickettsia parkeri, a spotted fever group rickettsia (SFGR) and human pathogen. Cotton rats and quail are known hosts for larval and nymphal A. maculatum; however, the role of these hosts in the ecology of R. parkeri is unknown. Methods: Cotton rats and quail were inoculated with low or high doses of R. parkeri (strain Portsmouth) grown in Vero cells to evaluate infection by R. parkeri in these two hosts species. Animals were euthanized 2, 4, 7, 10, and 14 days post-injection (dpi) and blood, skin, and spleen samples were collected to analyze by Vero cell culture and polymerase chain reaction (PCR). In a second trial, cotton rats and quail were inoculated with R. parkeri and nymphal A. maculatum ticks were allowed to feed on animals. Animals were euthanized on 14, 20, 28, 31, and 38 dpi and blood and tissues were collected for serology and PCR assays. Fed ticks were tested for R. parkeri by PCR and Vero cell culture. Results: Rickettsia parkeri was isolated in cell culture and detected by PCR in skin, blood, and spleen tissues of cotton rats in the initial trial 2, 4, and 7 dpi, but not in quail tissues. In the second trial, no ticks tested positive for R. parkeri by PCR or cell culture. Conclusions: These studies demonstrate that viable R. parkeri rickettsiae can persist in the tissues of cotton rats for at least 7 days following subcutaneous inoculation of these bacteria; however, quail are apparently resistant to infection. Rickettsia parkeri was not detected in nymphal ticks that fed on R. parkeri-inoculated cotton rats or quail, suggesting an alternate route of transmission to naive ticks. C1 [Moraru, Gail Miriam; Varela-Stokes, Andrea] Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Wise Ctr, Mississippi State, MS 39762 USA. [Goddard, Jerome] Mississippi State Univ, Dept Biochem Mol Biol Entomol & Plant Pathol, Mississippi State, MS 39762 USA. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Varela-Stokes, A (reprint author), Mississippi State Univ, Coll Vet Med, Dept Basic Sci, Wise Ctr, Spring St, Mississippi State, MS 39762 USA. EM stokes@cvm.msstate.edu NR 34 TC 7 Z9 7 U1 1 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD MAR 15 PY 2013 VL 6 AR 70 DI 10.1186/1756-3305-6-70 PG 5 WC Parasitology SC Parasitology GA 112VO UT WOS:000316622500001 PM 23497681 ER PT J AU Miles, M Ryman, TK Dietz, V Zell, E Luman, ET AF Miles, Melody Ryman, Tove K. Dietz, Vance Zell, Elizabeth Luman, Elizabeth T. TI Validity of vaccination cards and parental recall to estimate vaccination coverage: A systematic review of the literature SO VACCINE LA English DT Review DE Vaccination; Survey bias; Validity; Recall ID PEDIATRIC EMERGENCY-DEPARTMENT; IMMUNIZATION COVERAGE; MEDICAL-RECORDS; MOTHERS REPORTS; CHILDHOOD IMMUNIZATION; ADMINISTRATIVE DATA; PRESCHOOL-CHILDREN; MATERNAL RECALL; BURKINA-FASO; ACCURACY AB Immunization programs frequently rely on household vaccination cards, parental recall, or both to calculate vaccination coverage. This information is used at both the global and national level for planning and allocating performance-based funds. However, the validity of household-derived coverage sources has not yet been widely assessed or discussed. To advance knowledge on the validity of different sources of immunization coverage, we undertook a global review of literature. We assessed concordance, sensitivity, specificity, positive and negative predictive value, and coverage percentage point difference when subtracting household vaccination source from a medical provider source. Median coverage difference per paper ranged from -61 to +1 percentage points between card versus provider sources and -58 to +45 percentage points between recall versus provider source. When card and recall sources were combined, median coverage difference ranged from -40 to +56 percentage points. Overall, concordance, sensitivity, specificity, positive and negative predictive value showed poor agreement, providing evidence that household vaccination information may not be reliable, and should be interpreted with care. While only 5 papers (11%) included in this review were from low-middle income countries, low-middle income countries often rely more heavily on household vaccination information for decision making. Recommended actions include strengthening quality of child-level data and increasing investments to improve vaccination card availability and card marking. There is also an urgent need for additional validation studies of vaccine coverage in low and middle income countries. (c) 2013 Published by Elsevier Ltd. C1 [Miles, Melody; Ryman, Tove K.; Dietz, Vance; Zell, Elizabeth; Luman, Elizabeth T.] Ctr Dis Control & Prevent, Atlanta, GA 30307 USA. RP Miles, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A04, Atlanta, GA 30307 USA. EM ECL7@cdc.gov NR 68 TC 26 Z9 26 U1 1 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAR 15 PY 2013 VL 31 IS 12 BP 1560 EP 1568 DI 10.1016/j.vaccine.2012.10.089 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 111QK UT WOS:000316535600004 PM 23196207 ER PT J AU Marsden-Haug, N Goldoft, M Ralston, C Limaye, AP Chua, J Hill, H Jecha, L Thompson, GR Chiller, T AF Marsden-Haug, Nicola Goldoft, Marcia Ralston, Cindy Limaye, Ajit P. Chua, Jimmy Hill, Heather Jecha, Larry Thompson, George R., III Chiller, Tom TI Coccidioidomycosis Acquired in Washington State SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Coccidioides; coccidioidomycosis; endemic fungi; Washington AB Clinical, laboratory, and epidemiologic evidence suggest that 3 individuals with acute coccidioidomycosis were exposed in Washington State, significantly beyond previously identified endemic areas. Given the patients' lack of recent travel, coccidioidomycosis was not suspected, leading to delays in diagnosis and appropriate therapy. Clinicians should be aware of this possibility and consider the diagnosis. C1 [Marsden-Haug, Nicola; Goldoft, Marcia] Washington State Dept Publ Hlth, Off Communicable Dis Epidemiol, Shoreline, WA 98155 USA. [Ralston, Cindy; Hill, Heather; Jecha, Larry] Benton Franklin Hlth Dist, Communicable Dis Program, Kennewick, WA USA. [Chua, Jimmy] Kennewick Gen Hosp, Dept Infect Dis, Kennewick, WA USA. [Limaye, Ajit P.] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA. [Thompson, George R., III] Univ Calif Davis, Coccidioidomycosis Serol Lab, Davis, CA 95616 USA. [Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Marsden-Haug, N (reprint author), Washington State Dept Publ Hlth, 1610 NE 150th St,MS K17-9, Shoreline, WA 98155 USA. EM nicola.marsden-haug@doh.wa.gov FU Pfizer; Vertex; Merck; Forrest Pharma FX J. C. has received payment for lectures from and is a member of the speakers' bureaus for Pfizer, Vertex, Merck, and Forrest Pharma. All other authors report no potential conflicts. NR 17 TC 25 Z9 25 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2013 VL 56 IS 6 BP 847 EP 850 DI 10.1093/cid/cis1028 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 099OJ UT WOS:000315630800018 PM 23223598 ER PT J AU McDonald, LC AF McDonald, L. Clifford TI Virulence and Clinical Outcomes in Clostridium difficile Infection: A Complex Business SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID EPIDEMIOLOGY C1 Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A31, Atlanta, GA 30333 USA. EM cmcdonald1@cdc.gov NR 10 TC 6 Z9 6 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2013 VL 56 IS 6 BP 906 EP U206 DI 10.1093/cid/cis1001 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 099OJ UT WOS:000315630800030 PM 23196956 ER PT J AU Li, JZ Paredes, R Ribaudo, HJ Kozal, MJ Svarovskaia, ES Johnson, JA Geretti, AM Metzner, KJ Jakobsen, MR Hullsiek, KH Ostergaard, L Miller, MD Kuritzkes, DR AF Li, Jonathan Z. Paredes, Roger Ribaudo, Heather J. Kozal, Michael J. Svarovskaia, Evguenia S. Johnson, Jeffrey A. Geretti, Anna Maria Metzner, Karin J. Jakobsen, Martin R. Hullsiek, Katherine Huppler Ostergaard, Lars Miller, Michael D. Kuritzkes, Daniel R. TI Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV-1 drug resistance; minority variants; virologic failure; resistance genotyping ID ACTIVE ANTIRETROVIRAL THERAPY; DRUG-RESISTANCE; TREATMENT-NAIVE; HIV-1; NEVIRAPINE; EFAVIRENZ; VARIANTS; ESCAPE AB Drug-resistant human immunodeficiency virus type 1 (HIV-1) minority variants increase the risk of virologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. We performed a pooled analysis to evaluate the relationship between NNRTI-resistant minority variants and the likelihood and types of resistance mutations detected at virologic failure. In multivariable logistic regression analysis, higher NNRTI minority variant copy numbers, non-white race, and nevirapine use were associated with a higher risk of NNRTI resistance at virologic failure. Among participants on efavirenz, K103N was the most frequently observed resistance mutation at virologic failure regardless of the baseline minority variant. However, the presence of baseline Y181C minority variant was associated with a higher probability of Y181C detection after virologic failure. NNRTI regimen choice and preexisting NNRTI-resistant minority variants were both associated with the probability and type of resistance mutations detected after virologic failure. C1 [Li, Jonathan Z.; Kuritzkes, Daniel R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA. [Paredes, Roger] Irsi Caixa AIDS Res Inst, Badalona, Spain. [Paredes, Roger] Lluita SIDA Fdn, Badalona, Spain. [Ribaudo, Heather J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Kozal, Michael J.] Yale Univ, Sch Med, New Haven, CT USA. [Kozal, Michael J.] VA CT Healthcare Syst, New Haven, CT USA. [Svarovskaia, Evguenia S.; Miller, Michael D.] Gilead Sci Inc, Foster City, CA USA. [Johnson, Jeffrey A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Geretti, Anna Maria] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Metzner, Karin J.] Univ Zurich, Univ Zurich Hosp, Div Infect Dis, CH-8006 Zurich, Switzerland. [Metzner, Karin J.] Univ Zurich, Univ Zurich Hosp, Hosp Epidemiol, CH-8006 Zurich, Switzerland. [Jakobsen, Martin R.] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark. [Hullsiek, Katherine Huppler] Univ Minnesota, Minneapolis, MN USA. [Ostergaard, Lars] Aarhus Univ, Dept Infect Dis, Skejby, Denmark. RP Li, JZ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Sect Retroviral Therapeut, 65 Landsdowne St,Rm 435, Cambridge, MA 02139 USA. EM jli22@partners.org RI Infektiologie, USZ/A-6921-2011; Metzner, Karin/G-5319-2011 OI Metzner, Karin/0000-0003-4862-1503 FU Bristol-Myers Squibb; Tobira; Pfizer; Merck; Roche Diagnostics; ViiV Healthcare; Siemens; Boehringer Ingelheim; Gilead; Abbott; ViiV; Vertex; GlaxoSmithKline; Jenssen/Tibotec; Tibotec; Roche; Merck Sharp Dohme; Avexa; ViroStatistics; Harvard/MIT Health Sciences and Technology-Beth Israel Deaconess Medical Center; Pfizer Inc.; Merck Co.; CHAIN (Collaborative HIV and Anti-HIV Drug Resistance Network) [223131]; European Commission; National Institutes of Health (NIH; Statistical and Data Management Center of the AIDS Clinical Trials Group) [U01 AI068634]; National Institutes of Health (NIH; Harvard University CFAR) [P30 AI060354]; VA Merit Award; NIH [U01 AI042170, U01 AI 068636, K24 RR016482]; Swiss National Science Foundation (SNF) [324700-120793, CR32I2_127017]; European Community [223131]; Virology Specialty Laboratory from the ACTG FX J. Z. L. has received research support from Bristol-Myers Squibb and Tobira. R. P. has received consulting fees from Pfizer, Merck, Roche Diagnostics; the IrsiCaixa AIDS Research Institute and the Lluita contra la SIDA Foundation have received grant support from Pfizer, ViiV Healthcare, Siemens, Merck, and Boehringer Ingelheim for studies that R. P. serves as principal investigator. E. S. S. and M. D. M. are employees and stock-holders of Gilead Sciences, Inc. Yale University receives grant support from Merck, Pfizer, Gilead, Abbott, ViiV, Vertex, and Bristol-Myers Squibb for studies that M. D. K. serves as the principal investigator. M. D. K. receives royalties from patents owned by Stanford University for some HIV diagnostic tests. A. M. G. has served as a consultant to and/or has received research and travel grants from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Jenssen/Tibotec, and ViiV Healthcare. K. J. M. has received travel grants and honoraria from Gilead, Roche Diagnostics, GlaxoSmithKline, Bristol-Myers Squibb, Tibotec, and Abbott; and the University of Zurich received research grants from Gilead, Roche, and Merck Sharp & Dohme for studies that K. J. M. serves as principal investigator. D. R. K. has served as a consultant to and/or has received research grant support from Abbott, Avexa, Bristol-Myers Squibb, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Roche, Tobira, Vertex, ViroStatistics, and ViiV Healthcare; he has also received speaking honoraria from Gilead and Roche. J. Z. L. is the recipient of a Clinical Investigator Training Program Fellowship: Harvard/MIT Health Sciences and Technology-Beth Israel Deaconess Medical Center, in collaboration with Pfizer Inc. and Merck & Co. R. P. was supported in part by the CHAIN (Collaborative HIV and Anti-HIV Drug Resistance Network), Integrated Project no. 223131, funded by the European Commission Framework 7 Program. H. J. R. is supported in part by grants from the National Institutes of Health (NIH; Statistical and Data Management Center of the AIDS Clinical Trials Group U01 AI068634 and Harvard University CFAR P30 AI060354). D. K. is supported by a VA Merit Award. K. H. H. was supported in part by a grant from the NIH (U01 AI042170). K. J. M. is supported by the Swiss National Science Foundation (SNF), grants 324700-120793 and CR32I2_127017, and the European Community's Seventh Framework Programme (FP7/2007-2013) under the project "Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)," grant agreement no. 223131. R. K. is supported in part by grants from the NIH (U01 AI 068636, K24 RR016482) and a Virology Specialty Laboratory subcontract from the ACTG. NR 21 TC 26 Z9 28 U1 0 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2013 VL 207 IS 6 BP 893 EP 897 DI 10.1093/infdis/jis925 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 092XO UT WOS:000315156500004 PM 23264671 ER PT J AU Garg, S Moore, Z Lee, N McKenna, J Bishop, A Fleischauer, A Springs, CB Nguyen, HT Sheu, TG Sleeman, K Finelli, L Gubareva, L Fry, AM AF Garg, Shikha Moore, Zack Lee, Nicole McKenna, John Bishop, Amber Fleischauer, Aaron Springs, Chasisity B. Nguyen, Ha T. Sheu, Tiffany G. Sleeman, Katrina Finelli, Lyn Gubareva, Larisa Fry, Alicia M. TI A Cluster of Patients Infected With I221V Influenza B Virus Variants With Reduced Oseltamivir Susceptibility-North Carolina and South Carolina, 2010-2011 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza B virus; neuraminidase substitution; oseltamivir; antiviral resistance ID NEURAMINIDASE INHIBITOR-RESISTANT; UNITED-STATES; CLINICAL EFFECTIVENESS; SENSITIVITY; CHILDREN; RECOMMENDATIONS; SURVEILLANCE; PREVENTION; ZANAMIVIR; SEASONS AB Background. During 2010-2011, influenza B viruses with a novel neuraminidase substitution, denoted I221V (B/I221V), associated with reduced in vitro oseltamivir susceptibility were detected in North Carolina. Methods. We determined the prevalence of I221V among B viruses submitted to the Centers for Disease Control and Prevention for antiviral resistance surveillance, including all B viruses submitted to North Carolina and South Carolina state laboratories, during October 2010-September 2011. We conducted chart reviews and telephone interviews to characterize North Carolina and South Carolina patients with B/I221V vs wild-type B virus infection (B/WT). Results. We detected I221V in 45 (22%) of 209 B viruses from North Carolina and 8 (10%) of 82 B viruses from South Carolina. We detected I221V in 3 (0.3%) of 881 B viruses tested from 45 other states. B/I221V infection was not associated with differences in underlying conditions or illness severity, compared with B/WT infection. No patients with B/I221V infection received oseltamivir prior to specimen collection. Among patients who completed oseltamivir, those with B/I221V infection reported a longer duration until illness resolution (5 vs 3 days; P = .02). Conclusions. B/I221V cocirculated with B/WT in North Carolina and South Carolina during 2010-2011. I221V did not alter illness severity but may have reduced oseltamivir effectiveness. Thus, global surveillance for I221V is important. C1 [Garg, Shikha] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Garg, Shikha; McKenna, John; Bishop, Amber; Nguyen, Ha T.; Sheu, Tiffany G.; Sleeman, Katrina; Finelli, Lyn; Gubareva, Larisa; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Moore, Zack; Lee, Nicole; Fleischauer, Aaron] N Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Springs, Chasisity B.] S Carolina Dept Hlth & Environm Control, Columbia, SC USA. RP Garg, S (reprint author), 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30333 USA. EM sGarg1@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. NR 24 TC 15 Z9 15 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2013 VL 207 IS 6 BP 966 EP 973 DI 10.1093/infdis/jis776 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 092XO UT WOS:000315156500013 PM 23242536 ER PT J AU Ganova-Raeva, LM Dimitrova, ZE Campo, DS Lin, YL Ramachandran, S Xia, GL Honisch, C Cantor, CR Khudyakov, YE AF Ganova-Raeva, Lilia M. Dimitrova, Zoya E. Campo, David S. Lin, Yulin Ramachandran, Sumathi Xia, Guo-liang Honisch, Christiane Cantor, Charles R. Khudyakov, Yury E. TI Detection of Hepatitis C Virus Transmission by Use of DNA Mass Spectrometry SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE viral transmission; genetic distance; RNA Mass-spectrometry; relatedness; network ID POINT LIMITING-DILUTION; UNITED-STATES; HEALTH-CARE; GENETIC-HETEROGENEITY; INFECTION; EPIDEMIOLOGY; PREVALENCE; HCV; VARIABILITY; DISCOVERY AB The molecular detection of transmission of rapidly mutating pathogens such as hepatitis C virus (HCV) is commonly achieved by assessing the genetic relatedness of strains among infected patients. We describe the development of a novel mass spectrometry (MS)-based approach to identify HCV transmission. MS was used to detect products of base-specific cleavage of RNA molecules obtained from HCV polymerase chain reaction fragments. The MS-peak profiles were found to reflect variation in the HCV genomic sequence and the intrahost composition of the HCV population. Serum specimens originating from 60 case patients from 14 epidemiologically confirmed outbreaks and 25 unrelated controls were tested. Neighbor-joining trees constructed using MS-peak profile-based Hamming distances showed 100% accuracy, and linkage networks constructed using a threshold established from the Hamming distances between epidemiologically unrelated cases showed 100% sensitivity and 99.93% specificity in transmission detection. This MS-based approach is rapid, robust, reproducible, cost-effective, and applicable to investigating transmissions of other pathogens. C1 [Ganova-Raeva, Lilia M.; Dimitrova, Zoya E.; Campo, David S.; Lin, Yulin; Ramachandran, Sumathi; Xia, Guo-liang; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Mol Epidemiol & Bioinformat Lab, Atlanta, GA USA. [Honisch, Christiane; Cantor, Charles R.] Sequenom, San Diego, CA USA. RP Ganova-Raeva, LM (reprint author), 1600 Clifton Rd NE,MS A-33, Atlanta, GA 30329 USA. EM lkg7@cdc.gov RI Campo, David S./C-5072-2011 OI Campo, David S./0000-0002-8970-3436 FU Centers for Disease Control and Prevention FX This work was supported by intramural funding from the Centers for Disease Control and Prevention. NR 47 TC 5 Z9 6 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2013 VL 207 IS 6 BP 999 EP 1006 DI 10.1093/infdis/jis938 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 092XO UT WOS:000315156500017 PM 23300164 ER PT J AU Zhang, JX Joesoef, RM Bialek, S Wang, CB Harpaz, R AF Zhang, John X. Joesoef, Riduan M. Bialek, Stephanie Wang, Chengbin Harpaz, Rafael TI Association of Physical Trauma With Risk of Herpes Zoster Among Medicare Beneficiaries in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Herpes zoster; Medicare; risk factor; trauma ID COMPLICATION RATES; VACCINE; AGENTS AB Risk factors for herpes zoster (HZ) are poorly defined. An age-matched, case-control study was conducted to assess the effect of physical trauma on HZ, using Medicare data. HZ cases were 3.4 times as likely as controls to have experienced trauma in the week before HZ onset, but the magnitude of the association between trauma and HZ declined over time. Cases who had cranial HZ were >25 times as likely as controls to have had cranial trauma in the week before HZ onset. Therefore, recent trauma can be a trigger for HZ. C1 [Zhang, John X.; Joesoef, Riduan M.; Bialek, Stephanie; Wang, Chengbin; Harpaz, Rafael] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Zhang, JX (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30333 USA. EM jbz2@cdc.gov NR 15 TC 6 Z9 6 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 15 PY 2013 VL 207 IS 6 BP 1007 EP 1011 DI 10.1093/infdis/jis937 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 092XO UT WOS:000315156500018 PM 23307932 ER PT J AU Vaidyanathan, A Dimmick, WF Kegler, SR Qualters, JR AF Vaidyanathan, Ambarish Dimmick, William Fred Kegler, Scott R. Qualters, Judith R. TI Statistical air quality predictions for public health surveillance: evaluation and generation of county level metrics of PM2.5 for the environmental public health tracking network SO INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS LA English DT Article DE Particulate matter; Tracking Network; Hierarchical Bayesian; Air quality system; Geo-imputation ID POLLUTION; MORTALITY; EXPOSURE; CITIES; CMAQ AB Background: The Centers for Disease Control and Prevention (CDC) developed county level metrics for the Environmental Public Health Tracking Network (Tracking Network) to characterize potential population exposure to airborne particles with an aerodynamic diameter of 2.5 mu m or less (PM2.5). These metrics are based on Federal Reference Method (FRM) air monitor data in the Environmental Protection Agency (EPA) Air Quality System (AQS); however, monitor data are limited in space and time. In order to understand air quality in all areas and on days without monitor data, the CDC collaborated with the EPA in the development of hierarchical Bayesian (HB) based predictions of PM2.5 concentrations. This paper describes the generation and evaluation of HB-based county level estimates of PM2.5. Methods: We used three geo-imputation approaches to convert grid-level predictions to county level estimates. We used Pearson (r) and Kendall Tau-B (tau) correlation coefficients to assess the consistency of the relationship, and examined the direct differences (by county) between HB-based estimates and AQS-based concentrations at the daily level. We further compared the annual averages using Tukey mean-difference plots. Results: During the year 2005, fewer than 20% of the counties in the conterminous United States (U. S.) had PM2.5 monitoring and 32% of the conterminous U. S. population resided in counties with no AQS monitors. County level estimates resulting from population-weighted centroid containment approach were correlated more strongly with monitor-based concentrations (r = 0.9; tau = 0.8) than were estimates from other geo-imputation approaches. The median daily difference was -0.2 mu g/m(3) with an interquartile range (IQR) of 1.9 mu g/m(3) and the median relative daily difference was -2.2% with an IQR of 17.2%. Under-prediction was more prevalent at higher concentrations and for counties in the western U. S. Conclusions: While the relationship between county level HB-based estimates and AQS-based concentrations is generally good, there are clear variations in the strength of this relationship for different regions of the U. S. and at various concentrations of PM2.5. This evaluation suggests that population-weighted county centroid containment method is an appropriate geo-imputation approach, and using the HB-based PM2.5 estimates to augment gaps in AQS data provides a more spatially and temporally consistent basis for calculating the metrics deployed on the Tracking Network. C1 [Vaidyanathan, Ambarish; Qualters, Judith R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Dimmick, William Fred] US EPA, Off Res & Dev, Durham, NC 27711 USA. [Kegler, Scott R.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Vaidyanathan, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Mail Stop F60 4770 Buford Hwy, Atlanta, GA 30341 USA. EM Avaidyanathan@cdc.gov NR 25 TC 4 Z9 5 U1 0 U2 28 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-072X J9 INT J HEALTH GEOGR JI Int. J. Health Geogr. PD MAR 14 PY 2013 VL 12 AR 12 DI 10.1186/1476-072X-12-12 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 109KL UT WOS:000316366100001 PM 23497176 ER PT J AU Zou, W Chen, HC Hise, KB Tang, HL Foley, SL Meehan, J Lin, WJ Nayak, R Xu, JS Fang, H Chen, JJ AF Zou, Wen Chen, Hung-Chia Hise, Kelley B. Tang, Hailin Foley, Steven L. Meehan, Joe Lin, Wei-Jiun Nayak, Rajesh Xu, Joshua Fang, Hong Chen, James J. TI Meta-Analysis of Pulsed-Field Gel Electrophoresis Fingerprints Based on a Constructed Salmonella Database SO PLOS ONE LA English DT Article ID ENTERICA SEROVAR ENTERITIDIS; DRAFT GENOME SEQUENCES; TANDEM REPEAT ANALYSIS; MICROARRAY ANALYSIS; UNITED-STATES; SEROTYPES; IDENTIFICATION; TYPHIMURIUM; STRAINS; DISCRIMINATION AB A database was constructed consisting of 45,923 Salmonella pulsed-field gel electrophoresis (PFGE) patterns. The patterns, randomly selected from all submissions to CDC PulseNet during 2005 to 2010, included the 20 most frequent serotypes and 12 less frequent serotypes. Meta-analysis was applied to all of the PFGE patterns in the database. In the range of 20 to 1100 kb, serotype Enteritidis averaged the fewest bands at 12 bands and Paratyphi A the most with 19, with most serotypes in the 13215 range among the 32 serptypes. The 10 most frequent bands for each of the 32 serotypes were sorted and distinguished, and the results were in concordance with those from distance matrix and two-way hierarchical cluster analyses of the patterns in the database. The hierarchical cluster analysis divided the 32 serotypes into three major groups according to dissimilarity measures, and revealed for the first time the similarities among the PFGE patterns of serotype Saintpaul to serotypes Typhimurium, Typhimurium var. 5-, and I 4,[5], 12:i:-; of serotype Hadar to serotype Infantis; and of serotype Muenchen to serotype Newport. The results of the meta-analysis indicated that the pattern similarities/dissimilarities determined the serotype discrimination of PFGE method, and that the possible PFGE markers may have utility for serotype identification. The presence of distinct, serotype specific patterns may provide useful information to aid in the distribution of serotypes in the population and potentially reduce the need for laborious analyses, such as traditional serotyping. C1 [Zou, Wen; Chen, Hung-Chia; Meehan, Joe; Xu, Joshua; Chen, James J.] US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AR 72079 USA. [Chen, Hung-Chia] China Med Univ, Granduate Inst Biostat, Taichung, Taiwan. [Chen, Hung-Chia] China Med Univ, Ctr Biostat, Taichung, Taiwan. [Hise, Kelley B.] Ctr Dis Control & Prevent CDC, PulseNet Database Unit, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis,Natl Ctr, Atlanta, GA USA. [Foley, Steven L.; Nayak, Rajesh] US FDA, Natl Ctr Toxicol Res, Div Microbiol, Jefferson, AR 72079 USA. [Lin, Wei-Jiun] Feng Chia Univ, Dept Appl Math, Taichung 40724, Taiwan. [Fang, Hong] US FDA, Natl Ctr Toxicol Res, Off Sci Coordinat, Jefferson, AR 72079 USA. RP Zou, W (reprint author), US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AR 72079 USA. EM wen.zou@fda.hhs.gov FU Food Protection Plan of FDA FX This work was funded by Food Protection Plan of FDA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 9 Z9 9 U1 0 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 14 PY 2013 VL 8 IS 3 AR e59224 DI 10.1371/journal.pone.0059224 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 109YM UT WOS:000316407400099 PM 23516614 ER PT J AU Bowzard, JB Ranjan, P Sambhara, S AF Bowzard, J. Bradford Ranjan, Priya Sambhara, Suryaprakash TI RIG-I Goes Beyond Naked Recognition SO CELL HOST & MICROBE LA English DT Editorial Material ID RNA AB It is currently unclear at which point during viral replication that RNA genomes are first recognized as nonself by the immune system. In this issue of Cell Host & Microbe, Weber et al. show that incoming nucleocapsid-bound genomes are sufficient to bind and activate innate immune sensors. C1 [Bowzard, J. Bradford; Ranjan, Priya; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. RP Sambhara, S (reprint author), Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM ssambhara@cdc.gov NR 10 TC 5 Z9 6 U1 0 U2 6 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1931-3128 EI 1934-6069 J9 CELL HOST MICROBE JI Cell Host Microbe PD MAR 13 PY 2013 VL 13 IS 3 BP 247 EP 249 DI 10.1016/j.chom.2013.02.012 PG 4 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA AA1IS UT WOS:000330850400005 PM 23498950 ER PT J AU Nasrullah, M Wesolowski, LG Meyer, WA Owen, SM Masciotra, S Vorwald, C Becker, WJ Branson, BM AF Nasrullah, Muazzam Wesolowski, Laura G. Meyer, William A., III Owen, S. Michele Masciotra, Silvina Vorwald, Craig Becker, William J. Branson, Bernard M. TI Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm SO AIDS LA English DT Article DE fourth-generation immunoassay; HIV testing algorithms; specificity ID ANTIBODY-ASSAYS; UNITED-STATES; WESTERN-BLOT; P24 ANTIGEN; INFECTION; TRANSMISSION; RNA; SEROCONVERSION; IMMUNOASSAY; PLASMA AB Objective: We evaluated the performance of the GS fourth-generation antigen/antibody assay and compared Centers for Disease Control and Prevention's (CDC's) proposed alternative algorithm [repeatedly reactive fourth-generation immunoassay followed by an HIV-1/HIV-2 differentiation immunoassay and, if needed, nucleic acid test (NAT)] with the current algorithm (repeatedly reactive third-generation immunoassay followed by HIV-1 western blot). Design: A convenience sample of the following four specimen sets was acquired: 10 014 from insurance applicants, 493 known western blot-positive, 20 known western blot-indeterminate specimens, and 230 specimens from 26 HIV-1 seroconverters. Methods: Specimens were tested with the GS third-generation and fourth-generation immunoassays, the Multispot HIV-1/HIV-2 differentiation immunoassay, NAT, and western blot. We applied the two algorithms using these results. Results: Among insurance specimens, 13 (0.13%) specimens were immunoassay repeatedly reactive: two were HIV-positive (repeatedly reactive by third-generation and fourth-generation immunoassays, and western blot and Multispot positive); two third-generation repeatedly reactive and nine fourth-generation repeatedly reactive specimens were false-positive. Third-generation and fourth-generation specificities were 99.98% [95% confidence interval (CI) 99.93-100%] and 99.91% (95% CI 99.84-99.96%), respectively. All HIV-1 western blot-positive specimens were repeatedly reactive by third-generation and fourth-generation immunoassays. By Multispot, 491 (99.6%) were HIV-1-positive and two (0.4%) were HIV-2-positive. Only eight (40%) western blot-indeterminate specimens were fourth-generation repeatedly reactive: six were Multispot and NAT-negative and two were Multispot HIV-1-positive but NAT-negative. The alternative algorithm correctly classified as positive 102 seroconverter specimens with the third-generation immunoassay and 130 with the fourth-generation immunoassay compared with 56 using the western blot with either immunoassay. Conclusion: The alternative testing algorithm improved early infection sensitivity and identified HIV-2 infections. Two potential false-positive algorithm results occurred with western blot-indeterminate specimens. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:731-737 C1 [Nasrullah, Muazzam; Wesolowski, Laura G.; Owen, S. Michele; Masciotra, Silvina; Branson, Bernard M.] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. [Meyer, William A., III] Quest Diagnost, Baltimore, MD USA. [Vorwald, Craig] Quest Diagnost, Collegeville, PA USA. [Becker, William J.] Quest Diagnost, Lenexa, KS USA. RP Nasrullah, M (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30333 USA. EM snasrullah@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 15 Z9 15 U1 2 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD MAR 13 PY 2013 VL 27 IS 5 BP 731 EP 737 DI 10.1097/QAD.0b013e32835bc535 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 098CY UT WOS:000315524700006 PM 23135170 ER PT J AU Kourtis, AP Wiener, J Kayira, D Chasela, C Ellington, SR Hyde, L Hosseinipour, M van der Horst, C Jamieson, DJ AF Kourtis, Athena P. Wiener, Jeffrey Kayira, Dumbani Chasela, Charles Ellington, Sascha R. Hyde, Lisa Hosseinipour, Mina van der Horst, Charles Jamieson, Denise J. TI Health outcomes of HIV-exposed uninfected African infants SO AIDS LA English DT Article DE Africa; HIV; HIV-exposed; infant; morbidity; mortality; pediatric ID COTRIMOXAZOLE PROPHYLAXIS; INFECTED MOTHERS; CHILDREN BORN; ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSIONS; CLINICAL-TRIAL; RURAL UGANDA; SOUTH-AFRICA; MORTALITY; MORBIDITY AB Objectives: To evaluate severe (grade 3/4) morbidity and mortality in HIV-exposed, uninfected infants. Design: Secondary data analysis of The Breastfeeding, Antiretrovirals, and Nutrition (BAN) clinical trial. Methods: BAN randomized 2369 mother-infant pairs to maternal, infant, or no extended antiretroviral prophylaxis during breastfeeding. Morbidity outcomes examined were pneumonia/serious febrile illness, diarrhea/growth faltering, and malaria. Infant death was defined as neonatal (<30 days of life), and postneonatal (31 days to 48 weeks of life). Cox proportional hazards models were used to evaluate the effect of covariates on infant morbidity and mortality. Results: The rate of pneumonia/serious febrile illness was highest in the first 12 weeks (0.83/100 person-weeks) before rapidly decreasing; rates of all morbidity outcomes increased after 24 weeks. Rates of pneumonia/serious febrile illness and diarrhea/growth faltering were higher during the rainy season. Prophylactic infant cotrimoxazole significantly decreased the rates of all morbidity outcomes. White blood cell (WBC) count less than 9000/ml at birth was associated with increased diarrhea/growth faltering [adjusted hazard ratio (aHR) 1.73, P = 0.04] and malaria (aHR 2.18, P = 0.02). Low birth weight (2000-2499 g) was associated with neonatal death (aHR 12.3, P< 0.001). Factors associated with postneonatal death included rainy season (aHR 4.24, P = 0.002), infant cotrimoxazole (aHR 0.48, P = 0.03), and low infant WBC count at birth (aHR 2.53, P = 0.02). Conclusion: Infant morbidity rates increased after 24 weeks, when BAN infants weaned. Introduction of prophylactic cotrimoxazole was associated with reduced rates of morbidity and mortality in HIV-exposed uninfected infants. Unexpectedly, a low WBCcount at birth was significantly associated with later infant morbidity and mortality in this cohort. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:749-759 C1 [Kourtis, Athena P.; Wiener, Jeffrey; Ellington, Sascha R.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Kayira, Dumbani; Chasela, Charles; Hyde, Lisa; Hosseinipour, Mina] Univ North Carolina Project, Lilongwe, Malawi. [Hosseinipour, Mina; van der Horst, Charles] Univ N Carolina, Chapel Hill, NC USA. RP Kourtis, AP (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. EM AKourtis@cdc.gov FU Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP 1301 U48-CCU409660-09, SIP 26-04 U48-DP00005901, SIP 22-09 U48-DP001944-01]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; NIH Fogarty AIDS International Training and Research Program [DHHS/NIH/FIC 2-D43 TW01039-06, R24 TW007988]; Recovery and Reinvestment Act; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson and Johnson; US Agency for International Development; Abbott Laboratories; GlaxoSmithKline; Abbott FX The antiretrovirals used were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action for the Preventing Mother-to-Child Transmission program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson and Johnson, and the US Agency for International Development.; The BAN study was supported by grants from the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (SIP 1301 U48-CCU409660-09, SIP 26-04 U48-DP00005901, and SIP 22-09 U48-DP001944-01); the National Institute of Allergy and Infectious Diseases; the University of North Carolina Center for AIDS Research (P30-AI50410); and the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 TW01039-06 and R24 TW007988; the American Recovery and Reinvestment Act).; The University of North Carolina received grant support from Abbott Laboratories and GlaxoSmithKline. M.H. has received lecture fees from Abbott. All other authors declare that they have no conflicts of interest. NR 41 TC 26 Z9 26 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD MAR 13 PY 2013 VL 27 IS 5 BP 749 EP 759 DI 10.1097/QAD.0b013e32835ca29f PG 11 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 098CY UT WOS:000315524700008 PM 23719347 ER PT J AU Phillips, SJ Curtis, KM Polis, CB AF Phillips, Sharon J. Curtis, Kathryn M. Polis, Chelsea B. TI Effect of hormonal contraceptive methods on HIV disease progression: a systematic review SO AIDS LA English DT Article DE contraception; disease progression; HIV; hormonal; women ID INFECTED WOMEN; INTRAUTERINE SYSTEM; TYPE-1 INFECTION; PLASMA; PREGNANCY; SURVIVAL; COHORT; RISK AB Objective: Systematically assess from the literature whether women living with HIV who use hormonal contraception are at increased risk of HIV-disease progression compared with those who do not use hormonal contraception. Methods: We searched PUBMED and EMBASE for articles published in peer-reviewed journals through December 15, 2011 for evidence relevant to all hormonal contraceptive methods and HIV-disease progression. Results: Twelve reports of 11 studies met inclusion criteria. One randomized controlled trial (RCT) found increased risk for the composite outcome of a reduced CD4 cell count or death among hormonal contraceptive users when compared with copper intrauterine device (IUD) users. Ten cohort studies reported no increased risk for HIV disease progression (as measured by mortality, time to a CD4 cell count below 200, time to initiation of antiretroviral therapy, an increase in HIV-RNA viral load, or a decrease in CD4 count) among women who used hormonal contraception compared with those who did not. Conclusion: The preponderance of evidence indicates that HIV-positive women can use hormonal contraceptive methods without concerns related to HIV-disease progression. Cohort studies consistently found no association between hormonal contraceptive use and HIV-disease progression compared with nonuse of hormonal contraceptives. One RCT found that hormonal contraceptive use was associated with increased risk of HIV-disease progression when compared with IUD use, but this study had important methodological shortcomings. Prevention of unintended pregnancy among women living with HIV remains a public health priority to safeguard women's and infants' health and to prevent vertical transmission of HIV. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:787-794 C1 [Phillips, Sharon J.] World Hlth Org, Dept Reprod Hlth & Res, CH-1211 Geneva 27, Switzerland. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Polis, Chelsea B.] US Agcy Int Dev, Off Populat & Reprod Hlth, Washington, DC 20523 USA. RP Phillips, SJ (reprint author), World Hlth Org, Dept Reprod Hlth & Res, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM phillipss@who.int OI Polis, Chelsea/0000-0002-1031-7074; Phillips, Sharon/0000-0001-7157-4122 FU United States Agency for International Development; Centers for Disease Control and Prevention; WHO FX This review was supported by resources from the United States Agency for International Development, the Centers for Disease Control and Prevention, and the WHO. NR 34 TC 32 Z9 33 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD MAR 13 PY 2013 VL 27 IS 5 BP 787 EP 794 DI 10.1097/QAD.0b013e32835bb672 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 098CY UT WOS:000315524700012 PM 23135169 ER PT J AU van Griensven, F Thienkrua, W McNicholl, J Wimonsate, W Chaikummao, S Chonwattana, W Varangrat, A Sirivongrangson, P Mock, PA Akarasewi, P Tappero, JW AF van Griensven, Frits Thienkrua, Warunee McNicholl, Janet Wimonsate, Wipas Chaikummao, Supaporn Chonwattana, Wannee Varangrat, Anchalee Sirivongrangson, Pachara Mock, Philip A. Akarasewi, Pasakorn Tappero, Jordan W. TI Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Thailand SO AIDS LA English DT Article DE AIDS; Bangkok; HIV; male homosexuality; South-East Asia; Thailand ID RISK BEHAVIOR; UNITED-STATES; HOMOSEXUAL-MEN; HEPATITIS-B; YOUNG MEN; PREVALENCE; PREVENTION; TRENDS; TRANSMISSION; METAANALYSIS AB Objective: To assess HIV-prevalence, incidence and risk factors in a cohort of men who have sex with men (MSM) in Bangkok. Design: Cohort study with 4-monthly follow-up visits conducted between April 2006 and July 2012 at a dedicated study clinic in a central Bangkok hospital. Participants were 1744 homosexually active Thai men, at least 18 years old and residents of Bangkok. Methods: Men were tested for HIV-infection at every study visit and for sexually transmitted infections at baseline. Demographic and behavioural data were collected by audio-computer-assisted self-interview. Logistic regression analysis was used to evaluate risk factors for HIV-prevalence and Cox proportional hazard analysis to evaluate risk factors for HIV-incidence. Results: Baseline HIV-prevalence was 21.3% (n = 372) and 60 months cumulative HIV- incidence was 23.9% (n = 222). Overall HIV-incidence density was 5.9 per 100 person-years. Multivariate risk factors for HIV- prevalence were older age, secondary/vocational education (vs. university or higher), employed or unemployed (vs. studying), nitrate inhalation, drug use for sexual pleasure, receptive anal intercourse, history of sexual coercion, no prior HIV- testing, and anti-HSV-1 and 2 and Treponema pallidum positivity at baseline. Multivariate risk factors for HIV- incidence were younger age, living alone or with roommate (vs. with a partner or family), drug use for sexual pleasure, inconsistent condom use, receptive anal intercourse, group sex, and anti-HSV-1 and 2 and T. pallidum positivity at baseline. Having no anal intercourse partners was inversely associated with HIV- incidence. Conclusion: The high HIV prevalence and incidence in this cohort of Bangkok MSM documents an explosive epidemic. Additional preventive interventions for MSM are urgently needed. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:825-832 C1 [van Griensven, Frits; McNicholl, Janet] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [van Griensven, Frits; Thienkrua, Warunee; McNicholl, Janet; Wimonsate, Wipas; Chaikummao, Supaporn; Chonwattana, Wannee; Varangrat, Anchalee; Mock, Philip A.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [van Griensven, Frits] Thai Red Cross Soc AIDS Res Ctr, Bangkok 10330, Thailand. [Sirivongrangson, Pachara; Akarasewi, Pasakorn] Minist Publ Hlth, Nonthaburi, Thailand. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. RP van Griensven, F (reprint author), Thai Red Cross Soc AIDS Res Ctr, 104 Ratchadamri Rd, Bangkok 10330, Thailand. EM fritsvg@trcarc.org RI van Griensven, Frits/G-4719-2013 OI van Griensven, Frits/0000-0002-0971-2843 FU Thailand MOPH-US CDC Collaboration; Silom Community Clinic; US Centers for Disease Control and Prevention FX The authors kindly acknowledge the support of the personnel of the Thailand MOPH-US CDC Collaboration and the Silom Community Clinic. The authors also would like to express their gratitude towards the participants in the study for their time and dedication. Role of the study sponsor: The US Centers for Disease Control and Prevention sponsored this study. The study sponsor reviewed and approved of the study protocol and of this article. The study sponsor had no role in the analysis or interpretation of the data or in the writing of the article. NR 41 TC 52 Z9 53 U1 4 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD MAR 13 PY 2013 VL 27 IS 5 BP 825 EP 832 DI 10.1097/QAD.0b013e32835c546e PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 098CY UT WOS:000315524700016 PM 23169330 ER PT J AU Williams, WW Lu, PJ Greby, S Bridges, CB Ahmed, F Liang, JL Pilishvili, T Hales, C AF Williams, Walter W. Lu, Peng-Jun Greby, Stacie Bridges, Carolyn B. Ahmed, Faruque Liang, Jennifer L. Pilishvili, Tamara Hales, Craig TI Noninfluenza Vaccination Coverage Among Adults-United States, 2011 (Reprinted from MMWR, vol 6, pg 66-72, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Williams, Walter W.; Lu, Peng-Jun; Greby, Stacie; Bridges, Carolyn B.; Ahmed, Faruque] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Liang, Jennifer L.; Pilishvili, Tamara] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Hales, Craig] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Williams, WW (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM www1@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 13 PY 2013 VL 309 IS 10 BP 974 EP + DI 10.1001/jama.2013.1521 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 103SH UT WOS:000315938700009 ER PT J AU Barclay, L Wikswo, M Gregoricus, N Vinje, J Lopman, B Parashar, U Hall, A Leshem, E AF Barclay, Leslie Wikswo, Mary Gregoricus, Nicole Vinje, Jan Lopman, Ben Parashar, Umesh Hall, Aron Leshem, Eyal TI Notes from the Field: Emergence of New Norovirus Strain GII.4 Sydney-United States, 2012 (Reprinted from MMWR, vol 3, pg 55, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID OUTBREAKS C1 [Leshem, Eyal] CDC, Atlanta, GA 30333 USA. RP Leshem, E (reprint author), CDC, Atlanta, GA 30333 USA. EM eleshem@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 13 PY 2013 VL 309 IS 10 BP 979 EP 979 DI 10.1001/jama.2013.973 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 103SH UT WOS:000315938700010 ER PT J AU Oster, M Kim, CH Kusano, AS Cragan, JD Dressler, PB Rougeux, AH Mahle, W Correa, A AF Oster, Matthew Kim, Christopher H. Kusano, Aaron S. Cragan, Janet D. Dressler, Paul B. Rougeux, Alice H. Mahle, William Correa, Adolfo TI PRENATAL DIAGNOSIS OF CONGENITAL HEART DEFECTS: DOES IT MAKE A DIFFERENCE IN SURVIVAL? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 62nd Annual Scientific Session of the American-College-of-Cardiology CY MAR 09-11, 2013 CL San Francisco, CA SP Amer Coll Cardiol C1 CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. Childrens Healthcare Atlanta, Sibley Heart Ctr, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 SU S BP E476 EP E476 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 111XO UT WOS:000316555200476 ER PT J AU Simeone, RM Oster, M Cassell, CH Armour, B Honein, MA AF Simeone, Regina Marie Oster, Matthew Cassell, Cynthia H. Armour, Brian Honein, Margaret A. TI HOSPITAL RESOURCE USE FOR CRITICAL CONGENITAL HEART DEFECT PEDIATRIC ADMISSIONS SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 62nd Annual Scientific Session of the American-College-of-Cardiology CY MAR 09-11, 2013 CL San Francisco, CA SP Amer Coll Cardiol C1 Ctr Dis Control & Prevent, Atlanta, GA USA. Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 12 PY 2013 VL 61 IS 10 SU S BP E450 EP E450 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 111XO UT WOS:000316555200450 ER PT J AU Bailey, RL Gahche, JJ Miller, PE Thomas, PR Dwyer, JT AF Bailey, Regan L. Gahche, Jaime J. Miller, Paige E. Thomas, Paul R. Dwyer, Johanna T. TI Why US Adults Use Dietary Supplements SO JAMA INTERNAL MEDICINE LA English DT Article ID CARDIOVASCULAR-DISEASE; ALTERNATIVE MEDICINE; NATIONAL-HEALTH; UNITED-STATES; CANCER; VITAMIN; WOMEN; METAANALYSIS; PREVENTION; PATTERNS AB Background: Dietary supplements are used by more than half of adults, although to our knowledge, the reasons motivating use have not been previously examined in US adults using nationally representative data. The purpose of this analysis was to examine motivations for dietary supplement use, characterize the types of products used for the most commonly reported motivations, and to examine the role of physicians and health care practitioners in guiding choices about dietary supplements. Methods: Data from adults (>= 20 years; n = 11 956) were examined in the 2007-2010 National Health and Nutrition Examination Survey, a nationally representative, cross-sectional, population-based survey. Results: The most commonly reported reasons for using supplements were to "improve" (45%) or "maintain" (33%) overall health. Women used calcium products for "bone health" (36%), whereas men were more likely to report supplement use for "heart health or to lower cholesterol" (18%). Older adults (>= 60 years) were more likely than younger individuals to report motivations related to site-specific reasons like heart, bone and joint, and eye health. Only 23% of products were used based on recommendations of a health care provider. Multivitaminmineral products were the most frequently reported type of supplement taken, followed by calcium and omega-3 or fish oil supplements. Supplement users are more likely to report very good or excellent health, have health insurance, use alcohol moderately, eschew cigarette smoking, and exercise more frequently than nonusers. Conclusions: Supplement users reported motivations related to overall health more commonly than for supplementing nutrients from food intakes. Use of supplements was related to more favorable health and lifestyle choices. Less than a quarter of supplements used by adults were recommended by a physician or health care provider. C1 [Bailey, Regan L.; Thomas, Paul R.; Dwyer, Johanna T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Miller, Paige E.] NCI, NIH, Bethesda, MD 20892 USA. [Gahche, Jaime J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Dwyer, Johanna T.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Dwyer, Johanna T.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Dwyer, Johanna T.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. RP Bailey, RL (reprint author), NIH, Off Dietary Supplements, 6100 Execut Blvd,3B01, Bethesda, MD 20892 USA. EM baileyr@mail.nih.gov OI Dwyer, Johanna/0000-0002-0783-1769 FU NIH, Office of Dietary Supplements FX This work was supported by the NIH, Office of Dietary Supplements. NR 36 TC 124 Z9 125 U1 4 U2 53 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 11 PY 2013 VL 173 IS 5 BP 355 EP 361 DI 10.1001/jamainternmed.2013.2299 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 153OY UT WOS:000319613100007 PM 23381623 ER PT J AU Lucas, D Woodward, C Lincoln, J AF Lucas, Devin Woodward, Chelsea Lincoln, Jennifer TI Fatal and Nonfatal Injuries Involving Fishing Vessel Winches - Southern Shrimp Fleet, United States, 2000-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Lucas, Devin; Woodward, Chelsea; Lincoln, Jennifer] NIOSH, Alaska Pacific Off, CDC, Washington, DC USA. RP Lucas, D (reprint author), NIOSH, Alaska Pacific Off, CDC, Washington, DC USA. EM dlucas@cdc.gov NR 8 TC 5 Z9 5 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 8 PY 2013 VL 62 IS 9 BP 157 EP 160 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FA UT WOS:000322176500001 ER PT J AU Jacob, JT Klein, E Laxminarayan, R Beldavs, Z Lynfield, R Kallen, AJ Ricks, P Edwards, J Srinivasan, A Fridkin, S Rasheed, JK Lonsway, D Bulens, S Herrera, R McDonald, LC Patel, J Limbago, B Bell, M Cardo, D AF Jacob, Jesse T. Klein, Eili Laxminarayan, Ramanan Beldavs, Zintars Lynfield, Ruth Kallen, Alexander J. Ricks, Philip Edwards, Jonathan Srinivasan, Arjun Fridkin, Scott Rasheed, J. Kamile Lonsway, David Bulens, Sandie Herrera, Rosa McDonald, L. Clifford Patel, Jean Limbago, Brandi Bell, Michael Cardo, Denise TI Vital Signs: Carbapenem-Resistant Enterobacteriaceae SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID KLEBSIELLA-PNEUMONIAE; INFECTION; HOSPITALS; EMERGENCE; OUTBREAK; SPREAD AB Background: Enterobacteriaceae are a family of bacteria that commonly cause infections in health-care settings as well as in the community. Among Enterobacteriaceae, resistance to broad-spectrum carbapenem antimicrobials has been uncommon. Over the past decade, however, carbapenem-resistant Enterobacteriaceae (CRE) have been recognized in health-care settings as a cause of difficult-to-treat infections associated with high mortality. Methods: The percentage of acute-care hospitals reporting at least one CRE from health-care-associated infections (HAIs) in 2012 was estimated using data submitted to the National Healthcare Safety Network (NHSN) in 2012. The proportion of Enterobacteriaceae infections that were CRE was calculated using two surveillance systems: 1) the National Nosocomial Infection Surveillance system (NNIS) and NHSN (for 2001 and 2011, respectively) and 2) the Surveillance Network-USA (TSN) (for 2001 and 2010). Characteristics of CRE culture-positive episodes were determined using data collected as part of a population-based CRE surveillance project conducted by the Emerging Infections Program (EIP) in three states. Results: In 2012, 4.6% of acute-care hospitals reported at least one CRE HAI (short-stay hospitals, 3.9%; long-term acute-care hospitals, 17.8%). The proportion of Enterobacteriaceae that were CRE increased from 1.2% in 2001 to 4.2% in 2011 in NNIS/NHSN and from 0% in 2001 to 1.4% in 2010 in TSN; most of the increase was observed in Klebsiella species (from 1.6% to 10.4% in NNIS/NHSN). In the EIP surveillance, 92% of CRE episodes occurred in patients with substantial health-care exposures. Conclusions: Carbapenem resistance among common Enterobacteriaceae has increased over the past decade; most CRE are associated with health-care exposures. Implications for Public Health: Interventions exist that could slow the dissemination of CRE. Health departments are well positioned to play a leading role in prevention efforts by assisting with surveillance, situational awareness, and coordinating prevention efforts. C1 [Jacob, Jesse T.] Emory Univ, Sch Med, Atlanta, GA USA. [Klein, Eili] Johns Hopkins Univ, Ctr Adv Modeling, Dept Emergency Med, Baltimore, MD USA. [Lynfield, Ruth] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Kallen, Alexander J.; Ricks, Philip; Edwards, Jonathan; Srinivasan, Arjun; Fridkin, Scott; Rasheed, J. Kamile; Lonsway, David; Bulens, Sandie; Herrera, Rosa; McDonald, L. Clifford; Patel, Jean; Limbago, Brandi; Bell, Michael; Cardo, Denise] CDC, Natl Ctr Emerging & Zoonot Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Kallen, AJ (reprint author), CDC, Natl Ctr Emerging & Zoonot Dis, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM akallen@cdc.gov RI Jacob, Jesse/A-8836-2009; OI Klein, Eili/0000-0002-1304-5289 NR 18 TC 154 Z9 157 U1 5 U2 21 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 8 PY 2013 VL 62 IS 9 BP 165 EP 170 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FA UT WOS:000322176500003 ER PT J AU Reporter, R Pulido, M Bowen, A Karlsson, MS AF Reporter, Roshan Pulido, Marifi Bowen, Anna Karlsson, Maria Sjolund TI Outbreak of Infections Caused by Shigella sonnei with Decreased Susceptibility to Azithromycin - Los Angeles, California, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES C1 [Reporter, Roshan; Pulido, Marifi] Los Angeles Cty Dept Publ Hlth, Acute Communicable Dis Control Unit, Los Angeles, CA USA. [Bowen, Anna; Karlsson, Maria Sjolund] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Bowen, A (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM abowen@cdc.gov NR 4 TC 5 Z9 6 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 8 PY 2013 VL 62 IS 9 BP 171 EP 171 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FA UT WOS:000322176500004 ER PT J AU Morris, T Lang, F Christopher, R Plaskett, D Biggerstaff, B Horiuchi, K Han, G Ellis, B Amador, M Felix, G Beltran, M Tomashek, K Munoz-Jordan, J Hunsperger, E Barrera, R Margolis, H Thomas, D Ellis, E AF Morris, Thomas Lang, Francine Christopher, Romeo Plaskett, Darice Biggerstaff, Brad Horiuchi, Kalanthe Han, George Ellis, Brett Amador, Manuel Felix, Gilberto Beltran, Manuela Tomashek, Kay Munoz-Jordan, Jorge Hunsperger, Elizabeth Barrera, Roberto Margolis, Harold Thomas, Dana Ellis, Esther TI School Reporting of a Dengue Outbreak - St. Croix, US Virgin Islands, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Thomas, Dana; Ellis, Esther] CDC, Atlanta, GA 30333 USA. RP Thomas, D (reprint author), CDC, Atlanta, GA 30333 USA. EM wii6@cdc.gov; whz9@cdc.gov NR 4 TC 2 Z9 2 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 8 PY 2013 VL 62 IS 9 BP 172 EP 172 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188FA UT WOS:000322176500005 ER PT J AU Lin, F Lasry, A Sansom, SL Wolitski, RJ AF Lin, Feng Lasry, Arielle Sansom, Stephanie L. Wolitski, Richard J. TI Estimating the Impact of State Budget Cuts and Redirection of Prevention Resources on the HIV Epidemic in 59 California Local Health Departments SO PLOS ONE LA English DT Article ID NATIONAL PROBABILITY SAMPLE; BEHAVIORAL SURVEILLANCE SYSTEM; UNITED-STATES; ANTIRETROVIRAL THERAPY; SEXUAL-BEHAVIOR; CONDOM USE; PROSPECTIVE COHORT; TESTING BEHAVIORS; PERCEIVED HEALTH; AGES 14 AB Background: In the wake of a national economic downturn, the state of California, in 2009-2010, implemented budget cuts that eliminated state funding of HIV prevention and testing. To mitigate the effect of these cuts remaining federal funds were redirected. This analysis estimates the impact of these budget cuts and reallocation of resources on HIV transmission and associated HIV treatment costs. Methods and Findings: We estimated the effect of the budget cuts and reallocation for California county health departments (excluding Los Angeles and San Francisco) on the number of individuals living with or at-risk for HIV who received HIV prevention services. We used a Bernoulli model to estimate the number of new infections that would occur each year as a result of the changes, and assigned lifetime treatment costs to those new infections. We explored the effect of redirecting federal funds to more cost-effective programs, as well as the potential effect of allocating funds proportionately by transmission category. We estimated that cutting HIV prevention resulted in 55 new infections that were associated with $20 million in lifetime treatment costs. The redirection of federal funds to more cost-effective programs averted 15 HIV infections. If HIV prevention funding were allocated proportionately to transmission categories, we estimated that HIV infections could be reduced below the number that occurred annually before the state budget cuts. Conclusions: Reducing funding for HIV prevention may result in short-term savings at the expense of additional HIV infections and increased HIV treatment costs. Existing HIV prevention funds would likely have a greater impact on the epidemic if they were allocated to the more cost-effective programs and the populations most likely to acquire and transmit the infection. C1 [Lin, Feng; Lasry, Arielle; Sansom, Stephanie L.; Wolitski, Richard J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Sansom, SL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. EM sos9@cdc.gov NR 55 TC 3 Z9 3 U1 2 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 8 PY 2013 VL 8 IS 3 AR e55713 DI 10.1371/journal.pone.0055713 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 140TZ UT WOS:000318679900006 PM 23520447 ER PT J AU Horton, MK Bousleiman, S Jones, R Sjodin, A Liu, XH Whyatt, R Wapner, R Factor-Litvak, P AF Horton, Megan K. Bousleiman, Sabine Jones, Richard Sjodin, Andreas Liu, Xinhua Whyatt, Robin Wapner, Ronald Factor-Litvak, Pam TI Predictors of serum concentrations of polybrominated flame retardants among healthy pregnant women in an urban environment: a cross-sectional study SO ENVIRONMENTAL HEALTH LA English DT Article DE PBDEs; Human exposure; Diet; Lifestyle; Pregnancy ID DIPHENYL ETHERS PBDES; UMBILICAL-CORD BLOOD; HOUSE-DUST; HUMAN EXPOSURE; UNITED-STATES; GREAT-LAKES; POLYCHLORINATED-BIPHENYLS; DIETARY-INTAKE; MARKET BASKET; BODY BURDENS AB Background: Polybrominated diphenyl ethers (PBDEs) are a class of brominated flame retardants commonly used in a wide range of products. Prenatal exposure to PBDEs has been associated with adverse neurodevelopment. Our objective was to characterize predictors of exposure to PBDEs among a multi-ethnic, low-income cohort of pregnant women enrolled from highly urban communities in New York City between years 2009-2010. Methods: During the first half of pregnancy we collected 316 maternal serum samples and administered an extensive questionnaire including items on demographics, diet and lifestyle. We measured 12 PBDE congeners in blood samples. Using bivariate and multivariate approaches, we regressed the most commonly detected PBDE congeners (PBDE-47, -99, -100 and -153) against potential demographic, dietary and lifestyle predictor variables. Results: At least one PBDE congener was detected in each serum sample. Our analyses demonstrate unique predictor patterns for PBDE-47, -99, -100 and -153 based on demographic, lifestyle and dietary characteristics of women. Higher education and increased use of household electronics were associated with higher levels of all 4 congeners. Six characteristics were associated with PBDE-153 serum concentrations, more than for any other congener. These include maternal education, household income, body mass index, solid dairy consumption, processed meat consumption and frequent use of household electronics. Conclusions: PBDE exposure in this widespread in this cohort, though levels are lower than previous assessments of US pregnant women. Lower levels may be in response to legislation restricting the production, sale and use of these compounds. In our cohort, we did not observe any individual predictor or a consistent pattern of several predictors representing a significant source of PBDE exposure. These data suggest that legislation and policy may be more effective at reducing exposure than personal lifestyle modifications. C1 [Horton, Megan K.; Factor-Litvak, Pam] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA. [Horton, Megan K.] Columbia Univ, Sergievsky Ctr, New York, NY USA. [Bousleiman, Sabine; Wapner, Ronald] Columbia Univ, Med Ctr, Dept Obstet & Gynecol, New York, NY USA. [Jones, Richard; Sjodin, Andreas] Ctr Dis Control & Prevent, Atlanta, GA USA. [Liu, Xinhua] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. [Whyatt, Robin] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, Columbia Ctr Childrens Environm Hlth, New York, NY USA. RP Horton, MK (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA. EM mh2180@columbia.edu FU National Institute of Environmental Health Sciences [1R21 ES016610-01, 1K99 ESO20364-01] FX We acknowledge Glenys Webster, director of the Chemical, Health and Pregnancy (CHirP) Study at the University of British Columbia for generously assisting with our questionnaire development. This study was carried out with financial funding from the National Institute of Environmental Health Sciences (1R21 ES016610-01 and 1K99 ESO20364-01). NR 64 TC 12 Z9 12 U1 3 U2 38 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD MAR 8 PY 2013 VL 12 AR 23 DI 10.1186/1476-069X-12-23 PG 13 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 114IO UT WOS:000316734500001 PM 23497089 ER PT J AU Njuguna, HN Cosmas, L Williamson, J Nyachieo, D Olack, B Ochieng, JB Wamola, N Oundo, JO Feikin, DR Mintz, ED Breiman, RF AF Njuguna, Henry N. Cosmas, Leonard Williamson, John Nyachieo, Dhillon Olack, Beatrice Ochieng, John B. Wamola, Newton Oundo, Joseph O. Feikin, Daniel R. Mintz, Eric D. Breiman, Robert F. TI Use of Population-based Surveillance to Define the High Incidence of Shigellosis in an Urban Slum in Nairobi, Kenya SO PLOS ONE LA English DT Article ID RURAL WESTERN KENYA; ANTIMICROBIAL RESISTANCE; BACTERIAL DIARRHEA; CHILDREN; EPIDEMIOLOGY; MANAGEMENT; COUNTRIES; DISEASE; SUSCEPTIBILITY; MULTICENTER AB Background: Worldwide, Shigella causes an estimated 160 million infections and >1 million deaths annually. However, limited incidence data are available from African urban slums. We investigated the epidemiology of shigellosis and drug susceptibility patterns within a densely populated urban settlement in Nairobi, Kenya through population-based surveillance. Methods: Surveillance participants were interviewed in their homes every 2 weeks by community interviewers. Participants also had free access to a designated study clinic in the surveillance area where stool specimens were collected from patients with diarrhea (>= 3 loose stools within 24 hours) or dysentery (>= 1 stool with visible blood during previous 24 hours). We adjusted crude incidence rates for participants meeting stool collection criteria at household visits who reported visiting another clinic. Results: Shigella species were isolated from 224 (23%) of 976 stool specimens. The overall adjusted incidence rate was 408/100,000 person years of observation (PYO) with highest rates among adults 34-49 years old (1,575/100,000 PYO). Isolates were: Shigella flexneri (64%), S. dysenteriae (11%), S. sonnei (9%), and S. boydii (5%). Over 90% of all Shigella isolates were resistant to trimethoprim-sulfamethoxazole and sulfisoxazole. Additional resistance included nalidixic acid (3%), ciprofloxacin (1%) and ceftriaxone (1%). Conclusion: More than 1 of every 200 persons experience shigellosis each year in this Kenyan urban slum, yielding rates similar to those in some Asian countries. Provision of safe drinking water, improved sanitation, and hygiene in urban slums are needed to reduce disease burden, in addition to development of effective Shigella vaccines. C1 [Njuguna, Henry N.; Cosmas, Leonard; Williamson, John; Nyachieo, Dhillon; Olack, Beatrice; Ochieng, John B.; Wamola, Newton; Oundo, Joseph O.; Feikin, Daniel R.; Breiman, Robert F.] Ctr Dis Control & Prevent Kenya CDC K Collaborat, Kenya Med Res Inst KEMRI, Global Dis Detect Program, Nairobi, Kenya. [Njuguna, Henry N.; Cosmas, Leonard; Williamson, John; Nyachieo, Dhillon; Olack, Beatrice; Ochieng, John B.; Wamola, Newton; Oundo, Joseph O.; Feikin, Daniel R.; Breiman, Robert F.] Ctr Dis Control & Prevent Kenya CDC K Collaborat, Kenya Med Res Inst KEMRI, Global Dis Detect Program, Kisumu, Kenya. [Mintz, Eric D.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Njuguna, HN (reprint author), Ctr Dis Control & Prevent Kenya CDC K Collaborat, Kenya Med Res Inst KEMRI, Global Dis Detect Program, Nairobi, Kenya. EM hnjuguna@ke.cdc.gov FU Centers for Disease Control and Prevention (CDC US) FX This work was supported by the Centers for Disease Control and Prevention (CDC US). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 9 Z9 10 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 7 PY 2013 VL 8 IS 3 AR e58437 DI 10.1371/journal.pone.0058437 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 136BN UT WOS:000318334500083 PM 23505506 ER PT J AU De Cock, KM El-Sadr, WM AF De Cock, Kevin M. El-Sadr, Wafaa M. TI When to Start ART in Africa - An Urgent Research Priority SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID ANTIRETROVIRAL THERAPY C1 [De Cock, Kevin M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [El-Sadr, Wafaa M.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA. RP De Cock, KM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. FU Intramural NIH HHS [Z99 CL999999]; NIAID NIH HHS [UM1 AI068619, UM1 AI069466] NR 4 TC 42 Z9 42 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 7 PY 2013 VL 368 IS 10 BP 886 EP 889 DI 10.1056/NEJMp1300458 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 100BG UT WOS:000315669100003 PM 23425131 ER PT J AU Seaworth, BJ Field, K Flood, J Saliba, J Mase, SR Cronin, A Shah, N Jereb, J Chorba, T AF Seaworth, Barbara J. Field, Kim Flood, Jennifer Saliba, Jouhayna Mase, Sundari R. Cronin, Ann Shah, Neha Jereb, John Chorba, Terence TI Interruptions in Supplies of Second-Line Antituberculosis Drugs-United States, 2005-2012 (Reprinted from MMWR, vol 2, pg 23-26, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Seaworth, Barbara J.] Univ Texas Hlth Sci Ctr, San Antonio, TX USA. [Field, Kim] San Diego Cty TB Control Program, San Diego, CA USA. [Saliba, Jouhayna] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA. [Mase, Sundari R.; Cronin, Ann; Shah, Neha; Jereb, John; Chorba, Terence] CDC, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Mase, SR (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM smase@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 6 PY 2013 VL 309 IS 9 BP 866 EP 868 DI 10.1001/jama.2013.691 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 099PC UT WOS:000315632700009 ER PT J AU Saraiya, M King, J Thompson, T Watson, M Ajani, U Li, J Houston, KA AF Saraiya, Mona King, Jessica Thompson, Trevor Watson, Meg Ajani, Umed Li, Jun Houston, Keisha A. TI Cervical Cancer Screening Among Women Aged 18-30 Years-United States, 2000-2010 (Reprinted from MMWR, vol 51, pg 1038-1042, 2013) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Saraiya, Mona; King, Jessica; Thompson, Trevor; Watson, Meg; Ajani, Umed; Li, Jun] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA USA. [Houston, Keisha A.] CDC, Atlanta, GA 30333 USA. RP Houston, KA (reprint author), CDC, Atlanta, GA 30333 USA. EM kahouston@cdc.gov NR 1 TC 1 Z9 1 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 6 PY 2013 VL 309 IS 9 BP 868 EP 870 DI 10.1001/jama.2013.107 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 099PC UT WOS:000315632700010 ER PT J AU Bell, BP Khabbaz, RF AF Bell, Beth P. Khabbaz, Rima F. TI Responding to the Outbreak of Invasive Fungal Infections The Value of Public Health to Americans SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Bell, Beth P.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Khabbaz, Rima F.] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA 30333 USA. RP Bell, BP (reprint author), Ctr Dis Control & Prevent, Mailstop C-12,1600 Clifton Rd, Atlanta, GA 30333 USA. EM bzb8@cdc.gov NR 5 TC 10 Z9 10 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 6 PY 2013 VL 309 IS 9 BP 883 EP 884 DI 10.1001/jama.2013.526 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 099PC UT WOS:000315632700022 PM 23364868 ER PT J AU Knaack, JS Zhou, YT Magnuson, M Silvestri, E Johnson, RC AF Knaack, Jennifer S. Zhou, Yingtao Magnuson, Matthew Silvestri, Erin Johnson, Rudolph C. TI Performance of a Novel High Throughput Method for the Determination of VX in Drinking Water Samples SO ANALYTICAL CHEMISTRY LA English DT Article ID CHEMICAL WARFARE AGENTS; SOLID-PHASE EXTRACTION; NERVE AGENT; ORGANOPHOSPHORUS PESTICIDES; RETROSPECTIVE DETECTION; MASS-SPECTROMETRY; EXPOSURE; SARIN; BUTYRYLCHOLINESTERASE AB VX (O-ethyl-S-(2-diisopropylaminoethyl) methylphosphonothioate) is a highly toxic organophosphorus nerve agent, and even low levels of contamination in water can be harmful. Measurement of low concentrations of VX in aqueous matrixes is possible using an immunomagnetic scavenging technique and detection using liquid chromatography/tandem-mass spectrometry. Performance of the method was characterized in high-performance liquid chromatography (HPLC)-grade water preserved with sodium omadine, an antimicrobial agent, and sodium thiosulfate, a dechlorinating agent, over eight analytical batches with quality control samples analyzed over 10 days. The minimum reportable level was 25 ng/L with a linear dynamic range up to 4.0 mu g/L. The mean accuracies for two quality control samples containing VX at concentrations of 0.250 and 2.00 mu g/L were 102 +/- 3% and 103 +/- 6%, respectively. The stability of VX was determined in five tap water samples representing a range of water quality parameters and disinfection practices over a 91 day period. In preserved tap water samples, VX recovery was between 81 and 92% of the fortified amount, 2.0 mu g/L, when analyzed immediately after preparation. Recovery of VX decreased to between 31 and 45% of the fortified amount after 91 days, indicating hydrolysis of VX. However, the preservatives minimized the hydrolysis rate to close to the theoretical limit. The ability to detect low concentrations of VX in preserved tap water 91 days after spiking suggests applicability of this method for determining water contamination with VX and utility during environmental remediation. C1 [Knaack, Jennifer S.; Zhou, Yingtao; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Emergency Response Branch, Div Sci Lab, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Magnuson, Matthew; Silvestri, Erin] US EPA, Natl Homeland Secur Res Ctr, Cincinnati, OH 45268 USA. RP Johnson, RC (reprint author), Ctr Dis Control & Prevent, Emergency Response Branch, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F44, Chamblee, GA 30341 USA. EM RJohnson6@cdc.gov NR 24 TC 5 Z9 5 U1 1 U2 47 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 J9 ANAL CHEM JI Anal. Chem. PD MAR 5 PY 2013 VL 85 IS 5 BP 2611 EP 2616 DI 10.1021/ac3036102 PG 6 WC Chemistry, Analytical SC Chemistry GA 118NG UT WOS:000317031600011 PM 23402290 ER PT J AU Kato-Maeda, M Ho, C Passarelli, B Banaei, N Grinsdale, J Flores, L Anderson, J Murray, M Rose, G Kawamura, LM Pourmand, N Tariq, MA Gagneux, S Hopewell, PC AF Kato-Maeda, Midori Ho, Christine Passarelli, Ben Banaei, Niaz Grinsdale, Jennifer Flores, Laura Anderson, Jillian Murray, Megan Rose, Graham Kawamura, L. Masae Pourmand, Nader Tariq, Muhammad A. Gagneux, Sebastien Hopewell, Philip C. TI Use of Whole Genome Sequencing to Determine the Microevolution of Mycobacterium tuberculosis during an Outbreak SO PLOS ONE LA English DT Article ID SAN-FRANCISCO; UNITED-STATES; SURVEILLANCE AB Rationale: Current tools available to study the molecular epidemiology of tuberculosis do not provide information about the directionality and sequence of transmission for tuberculosis cases occurring over a short period of time, such as during an outbreak. Recently, whole genome sequencing has been used to study molecular epidemiology of Mycobacterium tuberculosis over short time periods. Objective: To describe the microevolution of M. tuberculosis during an outbreak caused by one drug-susceptible strain. Method and Measurements: We included 9 patients with tuberculosis diagnosed during a period of 22 months, from a population-based study of the molecular epidemiology in San Francisco. Whole genome sequencing was performed using Illumina's sequencing by synthesis technology. A custom program written in Python was used to determine single nucleotide polymorphisms which were confirmed by PCR product Sanger sequencing. Main results: We obtained an average of 95.7% (94.1-96.9%) coverage for each isolate and an average fold read depth of 73 (1 to 250). We found 7 single nucleotide polymorphisms among the 9 isolates. The single nucleotide polymorphisms data confirmed all except one known epidemiological link. The outbreak strain resulted in 5 bacterial variants originating from the index case A1 with 0-2 mutations per transmission event that resulted in a secondary case. Conclusions: Whole genome sequencing analysis from a recent outbreak of tuberculosis enabled us to identify microevolutionary events observable during transmission, to determine 0-2 single nucleotide polymorphisms per transmission event that resulted in a secondary case, and to identify new epidemiologic links in the chain of transmission. C1 [Kato-Maeda, Midori; Flores, Laura; Anderson, Jillian; Hopewell, Philip C.] Univ Calif San Francisco, Curry Int TB Ctr, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Ho, Christine; Grinsdale, Jennifer; Kawamura, L. Masae] San Francisco Dept Publ Hlth, TB Control Sect, San Francisco, CA USA. [Ho, Christine] Ctr Dis Control & Prevent CDC, Div TB Eliminat, Field Serv & Evaluat Branch CDC DTBE FSEB, Atlanta, GA USA. [Passarelli, Ben] Stanford Univ, Dept Bioengn, Palo Alto, CA 94304 USA. [Banaei, Niaz] Stanford Univ, Dept Pathol, Palo Alto, CA 94304 USA. [Murray, Megan] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Rose, Graham] Natl Inst Med Res, MRC, London NW7 1AA, England. [Pourmand, Nader; Tariq, Muhammad A.] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA. [Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Gagneux, Sebastien] Univ Basel, Basel, Switzerland. RP Kato-Maeda, M (reprint author), Univ Calif San Francisco, Curry Int TB Ctr, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. EM midori.kato-maeda@ucsf.edu OI Rose, Graham/0000-0002-5097-5426 FU National Institutes of Health [AI034238, P01-35HG000205]; Medical Research Council UK [U117588500] FX This work was supported by the National Institutes of Health (grants numbers AI034238 and P01-35HG000205) and the Medical Research Council UK (U117588500). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CDC was not engaged in human subject research as CDC staff provided technical support that did not involve possession or analysis of identifiable data. NR 29 TC 33 Z9 34 U1 2 U2 23 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 5 PY 2013 VL 8 IS 3 AR e58235 DI 10.1371/journal.pone.0058235 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 099RC UT WOS:000315637900110 PM 23472164 ER PT J AU Lingappa, UF Wu, XF Macieik, A Yu, SF Atuegbu, A Corpuz, M Francis, J Nichols, C Calayag, A Shi, H Ellison, JA Harrell, EKT Asundi, V Lingappa, JR Prasad, MD Lipkin, WI Dey, D Hurt, CR Lingappa, VR Hansen, WJ Rupprecht, CE AF Lingappa, Usha F. Wu, Xianfu Macieik, Amanda Yu, Shao Feng Atuegbu, Andy Corpuz, Michael Francis, Jean Nichols, Christine Calayag, Alfredo Shi, Hong Ellison, James A. Harrell, Emma K. T. Asundi, Vinod Lingappa, Jaisri R. Prasad, M. Dharma Lipkin, W. Ian Dey, Debendranath Hurt, Clarence R. Lingappa, Vishwanath R. Hansen, William J. Rupprecht, Charles E. TI Host-rabies virus protein-protein interactions as druggable antiviral targets SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE assembly intermediate; viral-host interaction; whole pathway screen; drug discovery paradigm; protein heterogeneity ID CELL-FREE SYSTEM; RNASE-L INHIBITOR; HIV-1 GAG; PRIMATE LENTIVIRUSES; CAPSIDS; COMPLEX; DOMAIN; ABCE1; PATHWAY; IDENTIFICATION AB We present an unconventional approach to antiviral drug discovery, which is used to identify potent small molecules against rabies virus. First, we conceptualized viral capsid assembly as occurring via a host-catalyzed biochemical pathway, in contrast to the classical view of capsid formation by self-assembly. This suggested opportunities for antiviral intervention by targeting previously unappreciated catalytic host proteins, which were pursued. Second, we hypothesized these host proteins to be components of heterogeneous, labile, and dynamic multi-subunit assembly machines, not easily isolated by specific target protein-focused methods. This suggested the need to identify active compounds before knowing the precise protein target. A cell-free translation-based small molecule screen was established to recreate the hypothesized interactions involving newly synthesized capsid proteins as host assembly machine substrates. Hits from the screen were validated by efficacy against infectious rabies virus in mammalian cell culture. Used as affinity ligands, advanced analogs were shown to bind a set of proteins that effectively reconstituted drug sensitivity in the cell-free screen and included a small but discrete subfraction of cellular ATP-binding cassette family E1 (ABCE1), a host protein previously found essential for HIV capsid formation. Taken together, these studies advance an alternate view of capsid formation (as a host-catalyzed biochemical pathway), a different paradigm for drug discovery (whole pathway screening without knowledge of the target), and suggest the existence of labile assembly machines that can be rendered accessible as next-generation drug targets by the means described. C1 [Lingappa, Usha F.; Macieik, Amanda; Yu, Shao Feng; Atuegbu, Andy; Corpuz, Michael; Francis, Jean; Nichols, Christine; Calayag, Alfredo; Shi, Hong; Harrell, Emma K. T.; Asundi, Vinod; Dey, Debendranath; Hurt, Clarence R.; Lingappa, Vishwanath R.; Hansen, William J.] Prosetta Antiviral Inc, San Francisco, CA 94107 USA. [Wu, Xianfu; Ellison, James A.; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Lingappa, Jaisri R.] Univ Washington, Dept Global Hlth, Seattle, WA 98102 USA. [Prasad, M. Dharma] Prosetta Bioconformat Pvt Ltd, Mysore, Karnataka, India. [Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA. RP Lingappa, VR (reprint author), Prosetta Antiviral Inc, San Francisco, CA 94107 USA. EM vlingappa@prosetta.com OI Ellison, James/0000-0003-4492-4857 FU Northeast Biodefense Consortium; National Institutes of Health FX We thank Helena Wagret, James Chamberlin, Yoko Marwidi, Hal Himmel, Iting Jaing, Ian Brown, Sean Broce, Scott Long, Connie Ewald, Sally Hansen, and Michael Farmer for contributions to these studies. Portions of this work were supported by grants from the Northeast Biodefense Consortium and from the National Institutes of Health. NR 49 TC 16 Z9 16 U1 0 U2 19 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 5 PY 2013 VL 110 IS 10 BP E861 EP E868 DI 10.1073/pnas.1210198110 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 109OH UT WOS:000316377400003 PM 23404707 ER PT J AU Morgan, RL Baack, B Smith, BD Yartel, A Pitasi, M Falck-Ytter, Y AF Morgan, Rebecca L. Baack, Brittney Smith, Bryce D. Yartel, Anthony Pitasi, Marc Falck-Ytter, Yngve TI Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma A Meta-analysis of Observational Studies SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID SUSTAINED VIROLOGICAL RESPONSE; PLUS RIBAVIRIN THERAPY; TERM-FOLLOW-UP; ALPHA-FETOPROTEIN LEVELS; HCV-RELATED CIRRHOSIS; INTERFERON THERAPY; UNITED-STATES; ANTIVIRAL THERAPY; RISK-FACTOR; MORTALITY AB Background: Hepatitis C virus (HCV) is a leading cause of hepatocellular carcinoma (HCC). In the United States, this form of cancer occurs in approximately 15 000 persons annually. A systematic review of the evidence is needed to assess the benefits of treatment of HCV-infected persons on development of HCC. Purpose: To systematically review observational studies to determine the association between response to HCV therapy and development of HCC among persons at any stage of fibrosis and those with advanced liver disease. Data Sources: MEDLINE, EMBASE, CINAHL, the Cochrane Library, Web of Science, and the Database of Abstracts of Reviews and Effectiveness from inception through February 2012. Study Selection: English-language observational studies that compared therapy-derived sustained virologic response (SVR) with no response to therapy among HCV-infected persons, targeted an adult population, and had an average follow-up of at least 2 years. Data Extraction: Two investigators independently extracted data into uniform relative risk measures. The Grading of Recommendations Assessment, Development and Evaluation framework was used to determine the quality of the evidence. Data Synthesis: Thirty studies fulfilled the inclusion criteria, and 18 provided adjusted effect estimates that were used to calculate pooled relative risks. Among HCV-infected persons, SVR was associated with reduced risk for HCC (relative risk for all persons, 0.24 [95% CI, 0.18 to 0.31], moderate-quality evidence; advanced liver disease hazard ratio, 0.23 [CI, 0.16 to 0.35], moderate-quality evidence). Limitation: In the meta-analyses, some variables could not be controlled for because of the observational design of the included studies. Conclusion: Sustained virologic response after treatment among HCV-infected persons at any stage of fibrosis is associated with reduced HCC. The evidence was determined to be of moderate quality. C1 [Morgan, Rebecca L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. Case Western Reserve Univ, Louis Stokes Vet Affairs Med Ctr, Cleveland, OH 44106 USA. Case Western Reserve Univ, Univ Hosp, Case Med Ctr, Cleveland, OH 44106 USA. RP Morgan, RL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM evf5@cdc.gov OI Yartel, Anthony/0000-0001-6586-9362 FU Centers for Disease Control and Prevention; Division of Viral Hepatitis at the Centers for Disease Control and Prevention FX Primary Funding Source: Centers for Disease Control and Prevention.; Financial Support: By the Division of Viral Hepatitis at the Centers for Disease Control and Prevention. NR 68 TC 189 Z9 193 U1 2 U2 20 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 5 PY 2013 VL 158 IS 5 BP 329 EP + DI 10.7326/0003-4819-158-5-201303050-00005 PN 1 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 105HP UT WOS:000316057700004 PM 23460056 ER PT J AU Kirkcaldy, RD Zaidi, A Hook, EW Holmes, KH Soge, O del Rio, C Hall, G Papp, J Bolan, G Weinstock, HS AF Kirkcaldy, Robert D. Zaidi, Akbar Hook, Edward W., III Holmes, King H. Soge, Olusegun del Rio, Carlos Hall, Geraldine Papp, John Bolan, Gail Weinstock, Hillard S. TI Neisseria gonorrhoeae Antimicrobial Resistance Among Men Who Have Sex With Men and Men Who Have Sex Exclusively With Women: The Gonococcal Isolate Surveillance Project, 2005-2010 SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID DISEASES-TREATMENT-GUIDELINES; HIGH-LEVEL RESISTANCE; UNITED-STATES; REDUCED SUSCEPTIBILITY; DRUG-RESISTANCE; FECAL LIPIDS; NO LONGER; AZITHROMYCIN; INFECTIONS; PENICILLIN AB Background: Gonorrhea treatment has been complicated by antimicrobial resistance in Neisseria gonorrhoeae. Gonococcal fluoroquinolone resistance emerged more rapidly among men who have sex with men (MSM) than men who have sex exclusively with women (MSW). Objective: To determine whether N. gonorrhoeae urethral isolates from MSM were more likely than isolates from MSW to exhibit resistance to or elevated minimum inhibitory concentrations (MICs) of antimicrobials used to treat gonorrhea. Design: 6 years of surveillance data from the Gonococcal Isolate Surveillance Project. Setting: Publicly funded sexually transmitted disease clinics in 30 U.S. cities. Patients: Men with a total of 34 600 episodes of symptomatic urethral gonorrhea. Measurements: Percentage of isolates exhibiting resistance or elevated MICs and adjusted odds ratios for resistance or elevated MICs among isolates from MSM compared with isolates from MSW. Results: In all U. S. regions except the West, isolates from MSM were significantly more likely to exhibit elevated MICs of ceftriaxone and azithromycin than isolates from MSW (P < 0.050). Isolates from MSM had a high prevalence of resistance to ciprofloxacin, penicillin, and tetracycline and were significantly more likely to exhibit antimicrobial resistance than isolates from MSW (P < 0.001). Limitations: Sentinel surveillance may not be representative of all patients with gonorrhea. HIV status, travel history, and antimicrobial use data were missing for some patients. Conclusion: Men who have sex with men are vulnerable to the emerging threat of antimicrobial-resistant N. gonorrhoeae. Because antimicrobial susceptibility testing is not routinely done in clinical practice, clinicians should monitor for treatment failures among MSM diagnosed with gonorrhea. Strengthened prevention strategies for MSM and new antimicrobial treatment options are needed. C1 [Kirkcaldy, Robert D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. Emory Univ, Atlanta, GA 30322 USA. Univ Alabama Birmingham, Birmingham, AL USA. Jefferson Cty Dept Hlth, Birmingham, AL USA. Univ Washington, Seattle, WA 98195 USA. Cleveland Clin, Cleveland, OH 44106 USA. RP Kirkcaldy, RD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E-02, Atlanta, GA 30333 USA. EM rkirkcaldy@cdc.gov RI del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 FU Centers for Disease Control and Prevention FX Financial Support: By the Centers for Disease Control and Prevention. NR 40 TC 29 Z9 30 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 5 PY 2013 VL 158 IS 5 BP 321 EP 328 DI 10.7326/0003-4819-158-5-201303050-00004 PN 1 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 105HP UT WOS:000316057700003 PM 23460055 ER PT J AU Jiang, YW Okoro, CA Oh, J Fuller, DL AF Jiang, Yongwen Okoro, Catherine A. Oh, Junhie Fuller, Deborah L. TI Sociodemographic and Health-Related Risk Factors Associated with Tooth Loss Among Adults in Rhode Island SO PREVENTING CHRONIC DISEASE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; ORAL-HEALTH; PERIODONTAL-DISEASE; CIGARETTE-SMOKING; SERVICES; DISABILITIES; INDICATORS; NUTRITION; JAPANESE; QUALITY AB Introduction Oral health is an integral component of overall health and well-being. Very little Rhode Island state-level information exists on the determinants of tooth loss. The objective of this study was to systematically identify sociodemographic characteristics, health behaviors, health conditions and disabilities, and dental insurance coverage associated with tooth loss among noninstitutionalized adults in Rhode Island. Methods We analyzed Rhode Island's 2008 and 2010 Behavioral Risk Factor Surveillance System survey data in 2011. The survey had 4 response categories for tooth loss: none, 1 to 5, 6 or more but not all, and all. We used multinomial logistic regression models to assess the relationship between 4 risk factor domains and tooth loss. Results An estimated 57.6% of Rhode Island adults had all their teeth, 28.9% had 1 to 5 missing teeth, 8.9% had 6 to 31 missing teeth, and 4.6% were edentulous. Respondents who had low income, low education, unhealthy behaviors (ie, were former or current smokers and did not engage in physical activity), chronic conditions (ie, diabetes and obesity) or disabilities, and no dental insurance coverage were more likely to have fewer teeth compared with their referent groups. However, the association of these variables with tooth loss was not uniform by age group. Conclusion Adults who report risky health behaviors or impaired health may be considered target subpopulations for prevention of tooth loss and promotion of good oral health. C1 [Jiang, Yongwen] Rhode Isl Dept Hlth, Ctr Hlth Data & Anal, Providence, RI 02908 USA. [Jiang, Yongwen; Oh, Junhie] Brown Univ, Sch Med, Providence, RI 02912 USA. [Okoro, Catherine A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Oh, Junhie; Fuller, Deborah L.] Rhode Isl Dept Hlth, Providence, RI 02908 USA. RP Jiang, YW (reprint author), Rhode Isl Dept Hlth, Ctr Hlth Data & Anal, 3 Capitol Hill, Providence, RI 02908 USA. EM charles@darwin.co.uk FU Chronic Disease Prevention and Health Promotion Programs Cooperative Agreement [5U58DP122791-05]; Oral Health Program Centers for Disease Control and Prevention Cooperative Agreement [5U58DP001595-03] FX We thank Dr Jana E. Hesser for her comments and suggestions on the early stage of the study, Laurie Leonard for reviewing and commenting on drafts of this article, and the following staff of the Centers for Disease Control and Prevention for reviewing and commenting on the final draft: Gina Thornton-Evans, DDS, MPH, Lina Balluz, PhD, Chaoyang Li, MD, PhD, Carol A. Gotway Crawford, PhD, MS, Mei Lin, MD, MPH, MS, Barbara F. Gooch, DMD, MPH, Frederic E. Shaw, MD, JD, and David M. Homa, PhD, MPH. This work and the Rhode Island BRFSS, was supported in part by the Chronic Disease Prevention and Health Promotion Programs Cooperative Agreement 5U58DP122791-05. The oral health module added to Rhode Island's BRFSS was supported in part by the Oral Health Program Centers for Disease Control and Prevention Cooperative Agreement 5U58DP001595-03. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Rhode Island Department of Health. The authors declare that there are no conflicts of interest. NR 32 TC 2 Z9 2 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2013 VL 10 AR UNSP 110285 DI 10.5888/pcd10.110285 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JK UT WOS:000329389800016 ER PT J AU Lam, E Rolle, I Shin, M Lee, KA AF Lam, Eugene Rolle, Italia Shin, Mikyong Lee, Kyung Ah TI Impact of Data Editing Methods on Estimates of Smoking Prevalence, Global Youth Tobacco Survey, 2007-2009 SO PREVENTING CHRONIC DISEASE LA English DT Article AB Accuracy of self-reported data may be improved by data editing, a mechanism to produce accurate information by excluding inconsistent data based on a set number of predetermined decision rules. We compared data editing methods in the Global Youth Tobacco Survey (GYTS) with other editing approaches and evaluated the effects of these on smoking prevalence estimates. We evaluated 5 approaches for handling inconsistent responses to questions regarding cigarette use: GYTS, do-nothing, gatekeeper, global, and preponderance. Compared with GYTS data edits, the do-nothing and gatekeeper approaches produced similar estimates, whereas the global approach resulted in lower estimates and the preponderance approach, higher estimates. Implications for researchers using GYTS include recognition of the survey's data editing methods and documentation in their study methods to ensure cross-study comparability. C1 [Lam, Eugene] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Lam, Eugene; Rolle, Italia; Shin, Mikyong] Ctr Dis Control & Prevent, Global Tobacco Control Branch, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Lee, Kyung Ah] Northrup Grumman Informat Syst, Atlanta, GA USA. RP Lam, E (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. EM elam@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2013 VL 10 AR UNSP 120202 DI 10.5888/pcd10.120202 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285JK UT WOS:000329389800009 ER PT J AU Roy, M Harris, J Afreen, S Deak, E Gade, L Balajee, SA Park, B Chiller, T Luby, S AF Roy, Monika Harris, Julie Afreen, Sadia Deak, Eszter Gade, Lalitha Balajee, S. Arunmozhi Park, Benjamin Chiller, Tom Luby, Stephen TI Aflatoxin contamination in food commodities in Bangladesh SO FOOD ADDITIVES & CONTAMINANTS PART B-SURVEILLANCE LA English DT Article DE food; aflatoxin; Bangladesh ID HEPATOCELLULAR-CARCINOMA; DEVELOPING-COUNTRIES; DIETARY AFLATOXIN; YOUNG-CHILDREN; WEST-AFRICA; EXPOSURE; HEALTH; RISK; BENIN; STRATEGIES AB During September 2009, we performed a rapid cross-sectional study to investigate the extent of aflatoxin contamination among common Bangladeshi foods. We collected eight common human food commodities (rice, lentils, wheat flour, dates, betelnut, red chili powder, ginger and groundnuts) and poultry feed samples from two large markets in each of three cities in Bangladesh. We quantified aflatoxin levels from pooled subsamples using fluorescence high-performance liquid chromatography. Aflatoxin levels were highest in dates and groundnuts (maximum 623 and 423 ng/g), respectively. Samples of betelnut (mean 30.6 ng/g), lentils (mean 21.2 ng/g) and red chili powder (> 20 ng/g) also had elevated levels. The mean aflatoxin level among poultry feed samples was 73.0 ng/g. Aflatoxin levels were above the US maximum regulatory levels of 20 ng/g in five of eight commonly ingested human food commodities tested. C1 [Roy, Monika; Harris, Julie; Deak, Eszter; Gade, Lalitha; Balajee, S. Arunmozhi; Park, Benjamin; Chiller, Tom; Luby, Stephen] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30329 USA. RP Roy, M (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30329 USA. EM ige6@cdc.gov NR 36 TC 4 Z9 4 U1 4 U2 12 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1939-3210 EI 1939-3229 J9 FOOD ADDIT CONTAM B JI Food Addit. Contam. Part B-Surveill. PD MAR 1 PY 2013 VL 6 IS 1 BP 17 EP 23 DI 10.1080/19393210.2012.720617 PG 7 WC Chemistry, Applied; Food Science & Technology; Toxicology SC Chemistry; Food Science & Technology; Toxicology GA 264XN UT WOS:000327914400004 PM 24786620 ER PT J AU Painter, JA Hoekstra, RM Ayers, T Tauxe, RV Braden, CR Angulo, FJ Griffin, PM AF Painter, John A. Hoekstra, Robert M. Ayers, Tracy Tauxe, Robert V. Braden, Christopher R. Angulo, Frederick J. Griffin, Patricia M. TI Attribution of Foodborne Illnesses, Hospitalizations, and Deaths to Food Commodities by using Outbreak Data, United States, 1998-2008 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MULTISTATE OUTBREAK; SALMONELLA-TYPHIMURIUM; DISEASE OUTBREAKS; RISK-FACTORS; INFECTION; MEAT; LISTERIOSIS; CONSUMPTION; PATHOGENS; TOMATOES AB Each year, >9 million foodborne illnesses are estimated to be caused by major pathogens acquired in the United States. Preventing these illnesses is challenging because resources are limited and linking individual illnesses to a particular food is rarely possible except during an outbreak. We developed a method of attributing illnesses to food commodities that uses data from outbreaks associated with both simple and complex foods. Using data from outbreak-associated illnesses for 1998-2008, we estimated annual US foodborne illnesses, hospitalizations, and deaths attributable to each of 17 food commodities. We attributed 46% of illnesses to produce and found that more deaths were attributed to poultry than to any other commodity. To the extent that these estimates reflect the commodities causing all foodborne illness, they indicate that efforts are particularly needed to prevent contamination of produce and poultry. Methods to incorporate data from other sources are needed to improve attribution estimates for some commodities and agents. C1 [Painter, John A.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Painter, John A.; Hoekstra, Robert M.; Ayers, Tracy; Tauxe, Robert V.; Braden, Christopher R.; Angulo, Frederick J.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Painter, JA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E03, Atlanta, GA 30333 USA. EM bzp3@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 NR 39 TC 213 Z9 217 U1 7 U2 76 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2013 VL 19 IS 3 BP 407 EP 415 DI 10.3201/eid1903.111866 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LU UT WOS:000328173000008 PM 23622497 ER PT J AU Borse, RH Shrestha, SS Fiore, AE Atkins, CY Singleton, JA Low, CF Meltzer, MI AF Borse, Rebekah H. Shrestha, Sundar S. Fiore, Anthony E. Atkins, Charisma Y. Singleton, James A. Low, Carolyn Fur Meltzer, Martin I. TI Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H1N1 2009; HOSPITALIZED-PATIENTS; 2009-JANUARY 2010; MONOVALENT; INFECTION; COVERAGE; WAVE AB In April 2009, the United States began a response to the emergence of a pandemic influenza virus strain: A(H1N1) pdm09. Vaccination began in October 2009. By using US surveillance data (April 12, 2009-April 10, 2010) and vaccine coverage estimates (October 3, 2009-April 18, 2010), we estimated that the A(H1N1)pdm09 virus vaccination program prevented 700,000-1,500,000 clinical cases, 4,000-10,000 hospitalizations, and 200-500 deaths. We found that the national health effects were greatly influenced by the timing of vaccine administration and the effectiveness of the vaccine. We estimated that recommendations for priority vaccination of targeted priority groups were not inferior to other vaccination prioritization strategies. These results emphasize the need for relevant surveillance data to facilitate a rapid evaluation of vaccine recommendations and effects. C1 [Borse, Rebekah H.; Shrestha, Sundar S.; Fiore, Anthony E.; Atkins, Charisma Y.; Singleton, James A.; Low, Carolyn Fur; Meltzer, Martin I.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Meltzer, MI (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C18, Atlanta, GA 30333 USA. EM qzm4@cdc.gov NR 39 TC 24 Z9 27 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2013 VL 19 IS 3 BP 439 EP 448 DI 10.3201/eid1903.120394 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LU UT WOS:000328173000012 PM 23622679 ER PT J AU Lindquist, S Allen, S Field, K Ghosh, S Haddad, MB Narita, M Oren, E AF Lindquist, Scott Allen, Sheanne Field, Kim Ghosh, Smita Haddad, Maryam B. Narita, Masahiro Oren, Eyal TI Prioritizing Tuberculosis Clusters by Genotype for Public Health Action, Washington, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; MOLECULAR EPIDEMIOLOGY; TRANSMISSION AB Groups of tuberculosis cases with indistinguishable Mycobacterium tuberculosis genotypes (clusters) might represent recent transmission. We compared geospatial concentration of genotype clusters with independent priority rankings determined by local public health officials; findings were highly correlated. Routine use of geospatial statistics could help health departments identify recent disease transmission. C1 [Lindquist, Scott] Kitsap Cty Hlth Dist, Bremerton, WA 98337 USA. [Lindquist, Scott; Allen, Sheanne; Field, Kim] Washington State Dept Hlth, Washington, DC USA. [Ghosh, Smita; Haddad, Maryam B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Narita, Masahiro; Oren, Eyal] Publ Hlth Seattle & King Cty TB Control Program, Seattle, WA USA. RP Lindquist, S (reprint author), Kitsap Publ Hlth Dist, Kitsap Cty Hlth Dist, 345 6th St,Suite 300, Bremerton, WA 98337 USA. EM scott.lindquist@kitsappublichealth.org OI Oren, Eyal/0000-0001-7817-3516 NR 10 TC 11 Z9 11 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2013 VL 19 IS 3 BP 493 EP 495 DI 10.3201/eid1903.121453 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LU UT WOS:000328173000024 PM 23621956 ER PT J AU Kunadharaju, R Choe, U Harris, JR Lockhart, SR Greene, JN AF Kunadharaju, Rajesh Choe, Ulyee Harris, Julie R. Lockhart, Shawn R. Greene, John N. TI Cryptococcus gattii, Florida, USA, 2011 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID PACIFIC-NORTHWEST; BRITISH-COLUMBIA; UNITED-STATES; NEOFORMANS; INFECTION C1 [Kunadharaju, Rajesh; Choe, Ulyee; Greene, John N.] Univ S Florida, Morsani Coll Med, Tampa, FL 33612 USA. [Harris, Julie R.; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Greene, John N.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. RP Greene, JN (reprint author), Univ S Florida, Morsani Coll Med, Moffitt Canc Ctr, 12092 Magnolia Dr,FOB 3, Tampa, FL 33612 USA. EM john.greene@moffitt.org NR 10 TC 10 Z9 10 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2013 VL 19 IS 3 BP 519 EP 521 DI 10.3201/eid1903.121399 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LU UT WOS:000328173000037 PM 23750364 ER PT J AU Potter, P AF Potter, Polyxeni TI Captain Consumption and the Collector of Souls SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2013 VL 19 IS 3 BP 524 EP 525 DI 10.3201/eid1903.AC1903 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LU UT WOS:000328173000042 ER PT J AU Birbari, W Bunning, VK Dessai, U Dole, R Engeljohn, D Garrett, S Glass, K Golden, D Grooters, SV Hardin, M Hoover, D Johnson, L Knabel, S Natrajan, N Ruple, A Tauxe, R Whitaker, R Zink, D AF Birbari, Wafa Bunning, V. Kelly Dessai, Uday Dole, Robert Engeljohn, Daniel Garrett, Spencer Glass, Kathleen Golden, David Grooters, Susan Vaughn Hardin, Margaret Hoover, Dallas Johnson, Lee Knabel, Stephen Natrajan, Nandini Ruple, Angela Tauxe, Robert Whitaker, Robert Zink, Donald CA Natl Advisory Comm Microbiol TI Expedited Response to the Questions Posed by the United States Department of Agriculture Agricultural Marketing Service To Support Ground Beef Purchase for the Federal Food and Nutrition Assistance Programs SO JOURNAL OF FOOD PROTECTION LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; MEAT; POULTRY C1 [Glass, Kathleen] Univ Wisconsin, Madison, WI 53706 USA. [Golden, David] Univ Tennessee, Knoxville, TN 37996 USA. [Hoover, Dallas] Univ Delaware, Newark, DE 19716 USA. [Knabel, Stephen] Penn State Univ, University Pk, PA 16802 USA. [Ruple, Angela] US Dept Commerce, Natl Seafood Inspect Lab, Washington, DC 20230 USA. [Tauxe, Robert] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Zink, Donald] US FDA, US Dept HHS, CFSAN, Rockville, MD 20857 USA. NR 34 TC 1 Z9 1 U1 0 U2 3 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD MAR PY 2013 VL 76 IS 3 BP 523 EP 537 DI 10.4315/0362-028X.JFP-12-453 PG 15 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 240EV UT WOS:000326078600020 ER PT J AU Frazer, DG Lindsley, WG McKinney, W Reynolds, JS Franz, GN Jackson, M Goldsmith, WT AF Frazer, D. G. Lindsley, W. G. McKinney, W. Reynolds, J. S. Franz, G. N. Jackson, M. Goldsmith, W. T. TI A Model of the Recruitment-Derecruitment and Volume of Lung Units in an Excised Lung as it is Inflated-Deflated Between Minimum and Maximum Lung Volume SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE lung mechanics; models; pressure-volume loops ID RAT LUNGS; TRAPPED GAS; HYSTERESIS; BEHAVIOR; AIRWAYS; TISSUE AB The role of the recruitment-derecruitment of small structures in the lung (lung units) as the lung increases and decreases in volume has been debated. The objective of this study was to develop a model to estimate the change in the number and volume of open lung units as an excised lung is inflated-deflated between minimum and maximum lung volume. The model was formulated based on the observation that the compliance of the slowly changing quasi-static pressure-volume (P-V) curve of an excised rat lung can differ from the compliance of a faster changing small sinusoidal pressure volume perturbations superimposed on the curve. In those regions of the curve where differences in compliance occur, the lung tissue properties exhibit nonlinear characteristics, which cannot be linearized using "incremental" or "small signal" analysis. The model attributes the differences between the perturbation and quasi-static compliance to an additional nonlinear compliance term that results from the sequential opening and closing of lung units. Using this approach, it was possible to calculate the normalized average volume and the normalized number of open units as the lung is slowly inflated-deflated. Results indicate that the normalized average volume and the normalized number of open units are not linearly related to normalized lung volume, and at equal lung volumes the normalized number of open units is greater and the normalized average lung unit volume is smaller during lung deflation when compared to lung inflation. In summary, a model was developed to describe the recruitment-derecruitment process in excised lungs based on the differences between small signal perturbation compliance and quasi-static compliance. Values of normalized lung unit volume and the normalized number of open lung units were shown to be nonlinear functions of both transpulmonary pressure and normalized lung volume. C1 [Frazer, D. G.; Lindsley, W. G.; McKinney, W.; Reynolds, J. S.; Jackson, M.] NIOSH, CDC, Morgantown, WV 26505 USA. [Franz, G. N.] WVU Robert C Byrd Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26505 USA. [Goldsmith, W. T.] NIOSH, CDC, WVU Sch Publ Hlth, Morgantown, WV 26505 USA. RP Frazer, DG (reprint author), NIOSH, CDC, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM dgf1@cdc.gov; wdl7@cdc.gov; wdm9@cdc.gov; jsr0@cdc.gov; gnfranz@msn.com; moj8@cdc.gov; wbg4@cdc.gov OI Lindsley, William/0000-0003-0720-5829 FU Intramural CDC HHS [CC999999] NR 28 TC 0 Z9 0 U1 0 U2 1 PU ASME PI NEW YORK PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 EI 1528-8951 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD MAR PY 2013 VL 135 IS 3 AR 034503 DI 10.1115/1.4023372 PG 5 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 240EB UT WOS:000326076400008 PM 24231819 ER PT J AU Ye, XY Zhou, XL Hennings, R Kramer, J Calafat, AM AF Ye, Xiaoyun Zhou, Xiaoliu Hennings, Ryan Kramer, Joshua Calafat, Antonia M. TI Potential External Contamination with Bisphenol A and Other Ubiquitous Organic Environmental Chemicals during Biomonitoring Analysis: An Elusive Laboratory Challenge SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE benzophenone-3; biomonitoring; bisphenol A; exposure assessment; parabens; reagent blank; triclosan ID STANDARD REFERENCE MATERIALS; HPLC-MS/MS METHOD; HUMAN EXPOSURE; PRENATAL EXPOSURE; INDOOR DUST; HUMAN SERUM; URINE; EXTRACTION; SAMPLES; MILK AB BACKGROUND: Biomonitoring studies are conducted to assess internal dose (i.e., body burden) to environmental chemicals. However, because of the ubiquitous presence in the environment of some of these chemicals, such as bisphenol A (BPA), external contamination during handling and analysis of the biospecimens collected for biomonitoring evaluations could compromise the reported concentrations of such chemicals. OBJECTIVES: We examined the contamination with the target analytes during analysis of biological specimens in biomonitoring laboratories equipped with state-of-the-art analytical instrumentation. DISCUSSIONS: We present several case studies using the quantitative determination of BPA and other organic chemicals (i.e., benzophenone-3, triclosan, parabens) in human urine, milk, and serum to identify potential contamination sources when the biomarkers measured are ubiquitous environmental contaminants. CONCLUSIONS: Contamination with target analytes during biomonitoring analysis could result from solvents and reagents, the experimental apparatus used, the laboratory environment, and/or even the analyst. For biomonotoring data to be valid-even when obtained from high-quality analytical methods and good laboratory practices-the following practices must be followed to identify and track unintended contamination with the target analytes during analysis of the biological specimens: strict quality control measures including use of laboratory blanks; replicate analyses; engineering controls (e. g., clean rooms, biosafety cabinets) as needed; and homogeneous matrix-based quality control materials within the expected concentration ranges of the study samples. C1 [Ye, Xiaoyun; Zhou, Xiaoliu; Hennings, Ryan; Kramer, Joshua; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Calafat, AM (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F17, Atlanta, GA 30341 USA. EM aic7@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX This work was supported in part by appointments (R. H. and J.K.) to the Research Participation Program at the Centers for Disease Control and Prevention (CDC), administered by the Oak Ridge Institute for Science and Education through an inter-agency agreement between the U. S. Department of Energy and the CDC. NR 35 TC 58 Z9 59 U1 6 U2 55 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2013 VL 121 IS 3 BP 283 EP 286 DI 10.1289/ehp.1206093 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208TU UT WOS:000323703500017 PM 23458838 ER PT J AU Aylward, LL Kirman, CR Schoeny, R Portier, CJ Hays, SM AF Aylward, Lesa L. Kirman, Christopher R. Schoeny, Rita Portier, Christopher J. Hays, Sean M. TI Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Review DE biomonitoring; Biomonitoring Equivalents; blood; cancer risk; CDC National Exposure Report; hazard quotient; NHANES; risk assessment; urine ID EQUIVALENTS EXPERT WORKSHOP; SCREENING CRITERIA; US POPULATION; DOSSIER; HEALTH; GUIDELINES AB BACKGROUND: Biomonitoring data reported in the National Report on Human Exposure to Environmental Chemicals [NER; Centers for Disease Control and Prevention (2012)] provide information on the presence and concentrations of > 400 chemicals in human blood and urine. Biomonitoring Equivalents (BEs) and other risk assessment-based values now allow interpretation of these biomonitoring data in a public health risk context. OBJECTIVES: We compared the measured biomarker concentrations in the NER with BEs and similar risk assessment values to provide an across-chemical risk assessment perspective on the measured levels for approximately 130 analytes in the NER. METHODS: We identified available risk assessment-based biomarker screening values, including BEs and Human Biomonitoring-I (HBM-I) values from the German Human Biomonitoring Commission. Geometric mean and 95th percentile population biomarker concentrations from the NER were compared to the available screening values to generate chemical-specific hazard quotients (HQs) or cancer risk estimates. CONCLUSIONS: Most analytes in the NER show HQ values of < 1; however, some (including acrylamide, dioxin-like chemicals, benzene, xylene, several metals, di-2(ethylhexyl) phthalate, and some legacy organochlorine pesticides) approach or exceed HQ values of 1 or cancer risks of > 1 x 10(-4) at the geometric mean or 95th percentile, suggesting exposure levels may exceed published human health benchmarks. This analysis provides for the first time a means for examining population biomonitoring data for multiple environmental chemicals in the context of the risk assessments for those chemicals. The results of these comparisons can be used to focus more detailed chemical-specific examination of the data and inform priorities for chemical risk management and research. C1 [Aylward, Lesa L.] Summit Toxicol LLP, Falls Church, VA 22044 USA. [Kirman, Christopher R.] Summit Toxicol LLP, Orange Village, OH USA. [Schoeny, Rita] US EPA, Off Res & Dev, Washington, DC 20460 USA. [Portier, Christopher J.] Agcy Tox Subst & Dis Registry, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hays, Sean M.] Summit Toxicol LLP, Lyons, CO USA. RP Aylward, LL (reprint author), Summit Toxicol LLP, 6343 Carolyn Dr, Falls Church, VA 22044 USA. EM laylward@summittoxicology.com RI Portier, Christopher/A-3160-2010; Aylward, Lesa/F-7418-2012 OI Portier, Christopher/0000-0002-0954-0279; Aylward, Lesa/0000-0003-3191-8175 FU American Chemistry Council FX L.L.A., S. M. H., and C. R. K. received funding to support the preparation of this review from the American Chemistry Council. NR 43 TC 44 Z9 45 U1 5 U2 56 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2013 VL 121 IS 3 BP 287 EP 294 DI 10.1289/ehp.1205740 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208TU UT WOS:000323703500018 PM 23232556 ER PT J AU Dadvand, P Parker, J Bell, ML Bonzini, M Brauer, M Darrow, LA Gehring, U Glinianaia, SV Gouveia, N Ha, EH Leem, JH van den Hooven, EH Jalaludin, B Jesdale, BM Lepeule, J Morello-Frosch, R Morgan, GG Pesatori, AC Pierik, FH Pless-Mulloli, T Rich, DQ Sathyanarayana, S Seo, J Slama, R Strickland, M Tamburic, L Wartenberg, D Nieuwenhuijsen, MJ Woodruff, TJ AF Dadvand, Payam Parker, Jennifer Bell, Michelle L. Bonzini, Matteo Brauer, Michael Darrow, Lyndsey A. Gehring, Ulrike Glinianaia, Svetlana V. Gouveia, Nelson Ha, Eun-hee Leem, Jong Han van den Hooven, Edith H. Jalaludin, Bin Jesdale, Bill M. Lepeule, Johanna Morello-Frosch, Rachel Morgan, Geoffrey G. Pesatori, Angela Cecilia Pierik, Frank H. Pless-Mulloli, Tanja Rich, David Q. Sathyanarayana, Sheela Seo, Juhee Slama, Remy Strickland, Matthew Tamburic, Lillian Wartenberg, Daniel Nieuwenhuijsen, Mark J. Woodruff, Tracey J. TI Maternal Exposure to Particulate Air Pollution and Term Birth Weight: A Multi-Country Evaluation of Effect and Heterogeneity SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE air pollution; fetal growth; heterogeneity; ICAPPO; low birth weight; meta-analysis; meta-regression; multi-center study; particulate matter; pregnancy ID PREGNANCY OUTCOMES; METAANALYSIS; RISK; INFANTS; HEALTH AB BACKGROUND: A growing body of evidence has associated maternal exposure to air pollution with adverse effects on fetal growth; however, the existing literature is inconsistent. OBJECTIVES: We aimed to quantify the association between maternal exposure to particulate air pollution and term birth weight and low birth weight (LBW) across 14 centers from 9 countries, and to explore the influence of site characteristics and exposure assessment methods on between-center heterogeneity in this association. METHODS: Using a common analytical protocol, International Collaboration on Air Pollution and Pregnancy Outcomes (ICAPPO) centers generated effect estimates for term LBW and continuous birth weight associated with PM10 and PM2.5 (particulate matter <= 10 and 2.5 mu m). We used meta-analysis to combine the estimates of effect across centers (similar to 3 million births) and used meta-regression to evaluate the influence of center characteristics and exposure assessment methods on between-center heterogeneity in reported effect estimates. RESULTS: In random-effects meta-analyses, term LBW was positively associated with a 10-mu g/m(3) increase in PM10 [odds ratio (OR) = 1.03; 95% CI: 1.01, 1.05] and PM2.5 (OR = 1.10; 95% CI: 1.03, 1.18) exposure during the entire pregnancy, adjusted for maternal socioeconomic status. A 10-mu g/m(3) increase in PM10 exposure was also negatively associated with term birth weight as a continuous outcome in the fully adjusted random-effects meta-analyses (-8.9 g; 95% CI: -13.2, -4.6 g). Meta-regressions revealed that centers with higher median PM2.5 levels and PM2.5: PM10 ratios, and centers that used a temporal exposure assessment (compared with spatiotemporal), tended to report stronger associations. CONCLUSION: Maternal exposure to particulate pollution was associated with LBW at term across study populations. We detected three site characteristics and aspects of exposure assessment methodology that appeared to contribute to the variation in associations reported by centers. C1 [Dadvand, Payam; Nieuwenhuijsen, Mark J.] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Dadvand, Payam; Nieuwenhuijsen, Mark J.] Hosp del Mar, IMIM, Municipal Inst Med Res, Barcelona, Spain. [Parker, Jennifer] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Bell, Michelle L.] Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA. [Bonzini, Matteo] Univ Insubria, Dept Clin & Expt Med, Varese, Italy. [Brauer, Michael] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Darrow, Lyndsey A.; Strickland, Matthew] Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA. [Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands. [Glinianaia, Svetlana V.; Pless-Mulloli, Tanja] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Gouveia, Nelson] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil. [Ha, Eun-hee; Seo, Juhee] Ewha Womans Univ, Dept Prevent Med, Seoul, South Korea. [Leem, Jong Han] Inha Univ, Dept Occupat & Environm Med, Inchon, South Korea. [van den Hooven, Edith H.] Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands. [van den Hooven, Edith H.; Pierik, Frank H.] TNO, Utrecht, Netherlands. [Jalaludin, Bin] Ctr Res Evidence Management & Surveillance, Sydney, NSW, Australia. [Jalaludin, Bin] South Western Sydney Local Hlth Dist, Sydney, NSW, Australia. [Jalaludin, Bin] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia. [Jesdale, Bill M.; Morello-Frosch, Rachel] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA. [Lepeule, Johanna] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Lepeule, Johanna; Slama, Remy] INSERM, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France. [Lepeule, Johanna; Slama, Remy] Grenoble Univ, Inst Albert Bonniot, U823, Grenoble, France. [Morello-Frosch, Rachel] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Morgan, Geoffrey G.] North Coast Area Hlth Serv, Lismore, NSW, Australia. [Morgan, Geoffrey G.] Univ Sydney, Univ Ctr Rural Health North Coast, Sydney, NSW 2006, Australia. [Pesatori, Angela Cecilia] Univ Milan, Dept Occupat & Environm Hlth, Milan, Italy. [Rich, David Q.] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA. [Sathyanarayana, Sheela] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA. [Tamburic, Lillian] Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada. [Wartenberg, Daniel] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA. [Woodruff, Tracey J.] Univ Calif San Francisco, Ctr Reprod Hlth & Environm, San Francisco, CA 94143 USA. RP Dadvand, P (reprint author), CREAL, Barcelona Biomed Res Pk,Dr Aiguader 88, Barcelona 08003, Spain. EM pdadvand@creal.cat RI lepeule, johanna/N-2579-2013; Gouveia, Nelson/C-4580-2013; LEPEULE, Johanna/K-1085-2016; Slama, Remy/M-1755-2013; Bonzini, Matteo/K-7540-2016; Nieuwenhuijsen, Mark/C-3914-2017; OI Brauer, Michael/0000-0002-9103-9343; Gouveia, Nelson/0000-0003-0625-0265; Slama, Remy/0000-0002-8980-8529; Bonzini, Matteo/0000-0002-6405-7554; Nieuwenhuijsen, Mark/0000-0001-9461-7981; Morello-Frosch, Rachel/0000-0003-1153-7287; Gehring, Ulrike/0000-0003-3612-5780; pesatori, angela/0000-0002-0261-3252 FU U.S. Environmental Protection Agency [EP-W-05-022]; National Institute of Environmental Health Sciences [R01ES016317, R01ES019587]; Wellcome Trust [072465/Z/03/Z]; Juan de la Cierva fellowship [JCI-2011-09937]; Spanish Ministry of Science and Innovation FX This project was supported by the U.S. Environmental Protection Agency under contract number EP-W-05-022 and by the National Institute of Environmental Health Sciences (R01ES016317, R01ES019587). For the Vancouver analysis, the British Columbia (BC) Ministry of Health, the BC Vital Statistics Agency, and the BC Reproductive Care Program approved access to and use of the data facilitated by Population Data BC. The U.K. PAMPER study was supported by the Wellcome Trust (grant 072465/Z/03/Z). P. D. is funded by a Juan de la Cierva fellowship (JCI-2011-09937) awarded by the Spanish Ministry of Science and Innovation. NR 38 TC 113 Z9 115 U1 10 U2 75 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2013 VL 121 IS 3 BP 367 EP 373 DI 10.1289/ehp.1205575 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208TU UT WOS:000323703500029 PM 23384584 ER PT J AU Lowe, MJ Yantek, DS Yang, JY Schuster, KC Mechling, JJ AF Lowe, M. Jenae Yantek, David S. Yang, Junyi Schuster, Kevin C. Mechling, Jessie J. TI A noise control package for vibrating screens SO NOISE CONTROL ENGINEERING JOURNAL LA English DT Article AB Hearing loss was the second-most common illness reported to the Mine Safety and Health Administration (MSHA) in 2009. Furthermore, between 2000 and 2010, 30% of all noise-related injury complaints reported to MSHA were for coal preparation plant employees. Previous National Institute for Occupational Safety and Health (NIOSH) studies have shown that vibrating screens are key noise sources to address in order to reduce coal preparation plant noise. In response, NIOSH researchers have developed a suite of noise controls for vibrating screens consisting of constrained layer damping (CLD) treatments, a tuned mechanism suspension, an acoustic enclosure, and spring inserts. Laboratory testing demonstrates that this noise control suite reduces the A-weighted sound power level of the vibrating screen by 6 dB. To provide a comparison to laboratory results and prove durability, field testing of two noise controls was performed on a vibrating screen in a working coal preparation plant. The spring inserts and CLD treatments were selected due to their ease of installation and practicability. Field testing of these controls yielded reductions that were comparable to laboratory results. (C) 2013 Institute of Noise Control Engineering. C1 [Lowe, M. Jenae; Yantek, David S.; Yang, Junyi; Mechling, Jessie J.] NIOSH, Pittsburgh, PA 15236 USA. [Schuster, Kevin C.] US Steel Corp, Pittsburgh, PA 15207 USA. [Schuster, Kevin C.] CDC, Atlanta, GA 30333 USA. RP Lowe, MJ (reprint author), NIOSH, 626 Cochrans Mill Rd,POB 18070, Pittsburgh, PA 15236 USA. EM MLowe@cdc.gov; DYantek@cdc.gov; JYang4@cdc.gov; KevinSchuster100@gmail.com; JMechling@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 0 Z9 0 U1 2 U2 16 PU INST NOISE CONTROL ENGINEERING PI AMES PA IOWA STATE UNIV, COLLEGE ENGINEERING, 212 MARSTON HALL, AMES, IA 50011-2152 USA SN 0736-2501 J9 NOISE CONTROL ENG J JI Noise Control Eng. J. PD MAR PY 2013 VL 61 IS 2 BP 127 EP 144 PG 18 WC Acoustics; Engineering, Multidisciplinary SC Acoustics; Engineering GA 210KH UT WOS:000323831000002 PM 26257468 ER PT J AU Brener, ND Kann, L Shanklin, S Kinchen, S Eaton, DK Hawkins, J Flint, KH AF Brener, Nancy D. Kann, Laura Shanklin, Shari Kinchen, Steve Eaton, Danice K. Hawkins, Joseph Flint, Katherine H. TI Methodology of the Youth Risk Behavior Surveillance System-2013 SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID HIGH-SCHOOL-STUDENTS; PAPER-AND-PENCIL; DRUG-USE; SURVEY QUESTIONNAIRE; UNITED-STATES; HEALTH; RELIABILITY; PREVALENCE; ADOLESCENTS; VALIDITY AB Priority health-risk behaviors (i.e., interrelated and preventable behaviors that contribute to the leading causes of morbidity and mortality among youths and adults) often are established during childhood and adolescence and extend into adulthood. The Youth Risk Behavior Surveillance System (YRBSS), established in 1991, monitors six categories of priority health-risk behaviors among youths and young adults: 1) behaviors that contribute to unintentional injuries and violence; 2) sexual behaviors that contribute to human immunodeficiency virus (HIV) infection, other sexually transmitted diseases, and unintended pregnancy; 3) tobacco use; 4) alcohol and other drug use; 5) unhealthy dietary behaviors; and 6) physical inactivity. In addition, YRBSS monitors the prevalence of obesity and asthma among this population. YRBSS data are obtained from multiple sources including a national school-based survey conducted by CDC as well as school-based state, territorial, tribal, and large urban school district surveys conducted by education and health agencies. These surveys have been conducted biennially since 1991 and include representative samples of students in grades 9-12. In 2004, a description of the YRBSS methodology was published (CDC. Methodology of the Youth Risk Behavior Surveillance System. MMWR 2004; 53 [No RR-12]). Since 2004, improvements have been made to YRBSS, including increases in coverage and expanded technical assistance. This report describes these changes and updates earlier descriptions of the system, including questionnaire content; operational procedures; sampling, weighting, and response rates; data-collection protocols; data-processing procedures; reports and publications; and data quality. This report also includes results of methods studies that systematically examined how different survey procedures affect prevalence estimates. YRBSS continues to evolve to meet the needs of CDC and other data users through the ongoing revision of the questionnaire, the addition of new populations, and the development of innovative methods for data collection. C1 [Brener, Nancy D.; Kann, Laura; Shanklin, Shari; Kinchen, Steve] CDC, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Eaton, Danice K.] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Hawkins, Joseph] WESTAT Corp, Rockville, MD 20850 USA. [Flint, Katherine H.] ICF Int, Calverton, MD USA. RP Brener, ND (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 4770 Buford Highway NE,MS K-33, Atlanta, GA 30341 USA. EM nad1@cdc.gov NR 96 TC 64 Z9 65 U1 4 U2 12 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD MAR 1 PY 2013 VL 62 IS 1 BP 1 EP 20 PG 20 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 192NM UT WOS:000322491700001 ER PT J AU Haynes, AK Prill, MM Iwane, MK AF Haynes, Amber K. Prill, Mila M. Iwane, Marika K. CA Natl Resp Enteric Virus Surveillan TI Respiratory Syncytial Virus Activity - United States, July 2011-January 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHILDREN; SEASON C1 [Haynes, Amber K.; Prill, Mila M.; Iwane, Marika K.; Natl Resp Enteric Virus Surveillan] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Haynes, AK (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM ahaynes1@cdc.gov NR 8 TC 14 Z9 14 U1 1 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 1 PY 2013 VL 62 IS 8 BP 141 EP 144 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EW UT WOS:000322176100001 ER PT J AU Shao, H McDonald, EC Ginsberg, MM Yee, LM Montgomery, JR Allan-Martinez, F Reynolds, MG Tack, DM Davidson, W Patel, N Joseph, R AF Shao, Hai McDonald, Eric C. Ginsberg, Michele M. Yee, Lisa M. Montgomery, Jay R. Allan-Martinez, Frances Reynolds, Mary G. Tack, Danielle M. Davidson, Whitni Patel, Nishi Joseph, Rachael TI Secondary and Tertiary Transmission of Vaccinia Virus After Sexual Contact with a Smallpox Vaccinee - San Diego, California, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INFECTION C1 [Shao, Hai] Scripps Mercy Hosp, San Diego, CA USA. [McDonald, Eric C.; Ginsberg, Michele M.; Yee, Lisa M.] Cty San Diego Hlth & Human Svcs Agcy, Publ Hlth Svcs, San Diego, CA USA. [Joseph, Rachael] CDC, Atlanta, GA 30333 USA. RP Joseph, R (reprint author), CDC, Atlanta, GA 30333 USA. EM rjoseph@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 1 PY 2013 VL 62 IS 8 BP 145 EP 147 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EW UT WOS:000322176100002 ER PT J AU Chimbwandira, F Mhango, E Makombe, S Midiani, D Mwansambo, C Njala, J Chirwa, Z Jahn, A Schouten, E Phelps, BR Gieselman, A Holmes, CB Maida, A Gupta, S Barr, BAT Modi, S Dale, H Aberle-Grasse, J Davis, M Bell, D Houston, J AF Chimbwandira, Frank Mhango, Eustice Makombe, Simon Midiani, Dalitso Mwansambo, Charles Njala, Joseph Chirwa, Zengani Jahn, Andreas Schouten, Erik Phelps, B. Ryan Gieselman, Anna Holmes, Charles B. Maida, Alice Gupta, Sundeep Barr, Beth A. Tippett Modi, Surbhi Dale, Helen Aberle-Grasse, John Davis, Margarett Bell, David Houston, James TI Impact of an Innovative Approach to Prevent Mother-to-Child Transmission of HIV - Malawi, July 2011-September 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MORTALITY C1 [Njala, Joseph; Chirwa, Zengani; Jahn, Andreas] Univ Washington, Int Training & Educ Ctr Hlth, Dept Global Hlth, Seattle, WA 98195 USA. [Phelps, B. Ryan] US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA. [Gieselman, Anna; Holmes, Charles B.] US Dept State, Off US Global AIDS Coordinator, Washington, DC USA. [Houston, James] CDC, Atlanta, GA 30333 USA. RP Houston, J (reprint author), CDC, Atlanta, GA 30333 USA. EM jchouston@cdc.gov NR 10 TC 66 Z9 66 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 1 PY 2013 VL 62 IS 8 BP 148 EP 151 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 188EW UT WOS:000322176100003 ER PT J AU Cho, KJ Turkevich, L Miller, M Mckay, R Grinshpun, SA Ha, K Reponen, T AF Cho, Kyungmin Jacob Turkevich, Leonid Miller, Matthew McKay, Roy Grinshpun, Sergey A. Ha, KwonChul Reponen, Tiina TI Penetration of Fiber Versus Spherical Particles Through Filter Media and Faceseal Leakage of N95 Filtering Facepiece Respirators with Cyclic Flow SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE particle shape; protection factor; total inward leakage ID PERFORMANCE; MASK AB This study investigated differences in penetration between fibers and spherical particles through faceseal leakage of an N95 filtering facepiece respirator. Three cyclic breathing flows were generated corresponding to mean inspiratory flow rates (MIF) of 15, 30, and 85 L/min. Fibers had a mean diameter of 1m and a median length of 4.9m (calculated aerodynamic diameter, d(ae) = 1.73m). Monodisperse polystyrene spheres with a mean physical diameter of 1.01m (PSI) and 1.54m (PSII) were used for comparison (calculated d(ae) = 1.05 and 1.58m, respectively). Two optical particle counters simultaneously determined concentrations inside and outside the respirator. Geometric means (GMs) for filter penetration of the fibers were 0.06, 0.09, and 0.08% at MIF of 15, 30, and 85 L/min, respectively. Corresponding values for PSI were 0.07, 0.12, and 0.12%. GMs for faceseal penetration of fibers were 0.40, 0.14, and 0.09% at MIF of 15, 30, and 85 L/min, respectively. Corresponding values for PSI were 0.96, 0.41, and 0.17%. Faceseal penetration decreased with increased breathing rate for both types of particles (p 0.001). GMs of filter and faceseal penetration of PSII at an MIF of 30 L/min were 0.14% and 0.36%, respectively. Filter penetration and faceseal penetration of fibers were significantly lower than those of PSI (p < 0.001) and PSII (p < 0.003). This confirmed that higher penetration of PSI was not due to slightly smaller aerodynamic diameter, indicating that the shape of fibers rather than their calculated mean aerodynamic diameter is a prevailing factor on deposition mechanisms through the tested respirator. In conclusion, faceseal penetration of fibers and spherical particles decreased with increasing breathing rate, which can be explained by increased capture by impaction. Spherical particles had 2.0-2.8times higher penetration through faceseal leaks and 1.1-1.5 higher penetration through filter media than fibers, which can be attributed to differences in interception losses. C1 [Cho, Kyungmin Jacob; McKay, Roy; Grinshpun, Sergey A.; Reponen, Tiina] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Turkevich, Leonid; Miller, Matthew] NIOSH, Cincinnati, OH 45226 USA. [Miller, Matthew] Univ Cincinnati, Dept Chem Engn, Cincinnati, OH 45267 USA. [Ha, KwonChul] Changwon Natl Univ, Dept Biochem & Hlth Sci, Chang Won, South Korea. RP Reponen, T (reprint author), Univ Cincinnati, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA. EM tiina.reponen@uc.edu FU National Institute for Occupational Safety and Health [NIOSH R01 OH004085] FX This research was supported by the National Institute for Occupational Safety and Health (NIOSH R01 OH004085). Koken Ltd. (Tokyo, Japan) made the nebulizer and the breathing simulation system available to this study. NR 16 TC 2 Z9 2 U1 4 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAR 1 PY 2013 VL 10 IS 3 BP 109 EP 115 DI 10.1080/15459624.2012.752321 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 172DT UT WOS:000320980900005 PM 23339437 ER PT J AU Ashley, K Harper, M AF Ashley, Kevin Harper, Martin TI Analytical Performance Issues: Closed-Face Filter Cassette (CFC) SamplingGuidance on Procedures for Inclusion of Material Adhering to Internal Sampler Surfaces SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article ID WALL DEPOSITS; EXTRACTION; BERYLLIUM; METALS; DUSTS C1 [Ashley, Kevin] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Harper, Martin] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Morgantown, WV USA. RP Ashley, K (reprint author), NIOSH, US Dept HHS, Ctr Dis Control & Prevent, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM kashley@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 14 Z9 14 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAR 1 PY 2013 VL 10 IS 3 BP D29 EP D33 DI 10.1080/15459624.2012.750554 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 172DT UT WOS:000320980900001 PM 23339418 ER PT J AU Ceballos, D Sylvain, D Kiefer, M AF Ceballos, Diana Sylvain, David Kiefer, Max TI Case Study: Evaluation of Air Sampling Methods for Abrasive Blasting SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article C1 [Ceballos, Diana; Sylvain, David; Kiefer, Max] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Ceballos, D (reprint author), NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. FU Intramural CDC HHS [CC999999] NR 11 TC 1 Z9 1 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD MAR 1 PY 2013 VL 10 IS 3 BP D34 EP D39 DI 10.1080/15459624.2012.750555 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 172DT UT WOS:000320980900002 PM 23351070 ER PT J AU Lewis-Bell, K Luciani, S Unger, ER Hariri, S McFarlane, S Steinau, M Prieto-Lara, E Vicari, AS Irons, B Lewis, MJ Andrus, JK AF Lewis-Bell, Karen Luciani, Silvana Unger, Elizabeth R. Hariri, Susan McFarlane, Shelly Steinau, Martin Prieto-Lara, Elisa Vicari, Andrea S. Irons, Beryl Lewis, Merle J. Andrus, Jon Kim TI Genital human papillomaviruses among women of reproductive age in Jamaica SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Papillomavirus infections; incidence; uterine cervical neoplasms; papillomavirus vaccines; Jamaica; Caribbean region ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; UNITED-STATES; PREVALENCE; FEMALES AB Objective. To characterize the prevalence and distribution of genital human papillomavirus (HPV) types among women in Jamaica, and to explore risk factors associated with HPV infection. Methods. This was a cross-sectional study that took place in April-July 2010 with 852 sexually-active women, 16-49 years of age, who had attended a selected public or private primary health clinic in one of Jamaica's four health authority regions. Sociodemographic data was collected from each participant by trained study staff. Each participant had a gynecological examination that included a clinical Pap test and a cervical sample for HPV detection and typing-performed using the Research Use Only Linear Array (LA) genotyping assay (Roche Diagnostics Corp., Indianapolis, Indiana, United States). Overall and type-specific prevalence of HPV infection was calculated for 37 HPV types included in the LA genotyping assay. Results. HPV DNA was detected in 460 of the 852 women (54.0%). Oncogenic HPV was detected in 297 women (34.9%) and HPV types 16/ 18 were found in 86 women (10.1%). The most frequently occurring HPV types were: 16 (6.2%); 35 (6.0%); 62 and 83 (5.5%); 61 and 58 (5.4%); 84 (4.7%); 18 (4.3%); and, 66 and 81 (4.2%). HPV prevalence was highest among women who were single, young (16-19 years), and had had more than three sexual partners in their lifetime. Conclusions. These results, coupled with high rates of cervical cancer, support introducing HPV vaccines while maintaining and strengthening cervical cancer screening services. Policy decisionmaking that reflects these results is instrumental to establishing a comprehensive cervical cancer program in Jamaica. C1 [Lewis-Bell, Karen; McFarlane, Shelly] Minist Hlth, Immunizat Program, Kingston, Jamaica. [Luciani, Silvana; Prieto-Lara, Elisa] PAHO, Chron Dis Prevent & Control Project, Washington, DC USA. [Unger, Elizabeth R.; Steinau, Martin] CDC, Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Hariri, Susan] CDC, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. [Vicari, Andrea S.] PAHO, Immunizat Project, Washington, DC USA. [Irons, Beryl] Caribbean Epidemiol Ctr, Port Of Spain, Trinid & Tobago. [Lewis, Merle J.] PAHO, Off Eastern Caribbean Coordinat, Bridgetown, Barbados. [Andrus, Jon Kim] PAHO, Off Deputy Director, Washington, DC USA. RP Luciani, S (reprint author), PAHO, Chron Dis Prevent & Control Project, Washington, DC USA. EM lucianis@paho.org OI Unger, Elizabeth/0000-0002-2925-5635 NR 15 TC 2 Z9 2 U1 1 U2 5 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD MAR PY 2013 VL 33 IS 3 BP 159 EP 165 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 159DY UT WOS:000320025800001 PM 23698134 ER PT J AU Belser, JA Rota, PA Tumpey, TM AF Belser, Jessica A. Rota, Paul A. Tumpey, Terrence M. TI Ocular Tropism of Respiratory Viruses SO MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS LA English DT Review ID INFLUENZA-A VIRUS; CONGENITAL-RUBELLA SYNDROME; ADENOVIRUS TYPE-5 INFECTION; CORNEAL EPITHELIAL-CELLS; HUMAN CORONAVIRUS NL63; HERPES-SIMPLEX-VIRUS; H5N1 AVIAN INFLUENZA; NF-KAPPA-B; SYNCYTIAL VIRUS; SIALIC-ACID AB Respiratory viruses (including adenovirus, influenza virus, respiratory syncytial virus, coronavirus, and rhinovirus) cause a broad spectrum of disease in humans, ranging from mild influenza-like symptoms to acute respiratory failure. While species D adenoviruses and subtype H7 influenza viruses are known to possess an ocular tropism, documented human ocular disease has been reported following infection with all principal respiratory viruses. In this review, we describe the anatomical proximity and cellular receptor distribution between ocular and respiratory tissues. All major respiratory viruses and their association with human ocular disease are discussed. Research utilizing in vitro and in vivo models to study the ability of respiratory viruses to use the eye as a portal of entry as well as a primary site of virus replication is highlighted. Identification of shared receptor-binding preferences, host responses, and laboratory modeling protocols among these viruses provides a needed bridge between clinical and laboratory studies of virus tropism. C1 [Belser, Jessica A.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rota, Paul A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Belser, JA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jbelser@cdc.gov NR 203 TC 11 Z9 12 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1092-2172 EI 1098-5557 J9 MICROBIOL MOL BIOL R JI Microbiol. Mol. Biol. Rev. PD MAR PY 2013 VL 77 IS 1 BP 144 EP 156 DI 10.1128/MMBR.00058-12 PG 13 WC Microbiology SC Microbiology GA 157NF UT WOS:000319903400005 PM 23471620 ER PT J AU Nelson, K Marienau, K Schembri, C Redd, S AF Nelson, Kailey Marienau, Karen Schembri, Christopher Redd, Susan TI Measles transmission during air travel, United States, December 1, 2008-December 31, 2011 SO TRAVEL MEDICINE AND INFECTIOUS DISEASE LA English DT Article DE Measles; Contact tracing; Travel medicine ID DISEASES; SURVEILLANCE; EXPOSURE AB Background: Flight-related measles contact investigations in the United States are coordinated by the Centers for Disease Control and Prevention (CDC). To evaluate the efficiency of CDC's measles protocol, we analyzed data from contact investigations conducted December 2008-December 2011. Methods: Cases were defined as travelers diagnosed with measles that were infectious at the time of the flight. Passengers seated within 2 rows of the case-traveler and all babies-in-arms were defined as contacts. Contact information obtained from airlines was distributed to US health departments; reporting of outcomes was requested. We cross-referenced the National Notifiable Diseases Surveillance System and CDC's National Center for Immunization and Respiratory Diseases to identify unreported cases in passenger-contacts and in passengers not identified as contacts. Results: Our evaluation included 74 case-travelers on 108 flights. Information for 2673 (79%) of 3399 passenger-contacts was provided to health departments; 9 cases of secondary measles were reported. No additional cases were identified. Conclusion: Our evaluation provided evidence of measles transmission related to air travel. CDC's protocol efficiently identifies passengers most at risk of exposure and infection for flights into and within the United States. Published by Elsevier Ltd. C1 [Nelson, Kailey; Marienau, Karen; Schembri, Christopher] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Nelson, Kailey] Council State & Territorial Epidemiologists, Atlanta, GA 30341 USA. [Redd, Susan] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Marienau, K (reprint author), HHH Terminal,Suite 2168,7150 Humphrey Dr, Minneapolis, MN 55450 USA. EM kqm5@cdc.gov FU Applied Epidemiology Fellowship Program; Centers for Disease Control and Prevention (CDC) [5U38HM000414-04] FX This work was supported in part by the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement # - 5U38HM000414-04. NR 31 TC 6 Z9 6 U1 1 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1477-8939 J9 TRAVEL MED INFECT DI JI Travel Med. Infect. Dis. PD MAR-APR PY 2013 VL 11 IS 2 BP 81 EP 89 DI 10.1016/j.tmaid.2013.03.007 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 164MC UT WOS:000320413200002 PM 23562445 ER PT J AU Neatherlin, J Cramer, EH Dubray, C Marienau, KJ Russell, M Sun, H Whaley, M Hancock, K Duong, KK Kirking, HL Schembri, C Katz, JM Cohen, NJ Fishbein, DB AF Neatherlin, John Cramer, Elaine H. Dubray, Christine Marienau, Karen J. Russell, Michelle Sun, Hong Whaley, Melissa Hancock, Kathy Duong, Krista K. Kirking, Hannah L. Schembri, Christopher Katz, Jacqueline M. Cohen, Nicole J. Fishbein, Daniel B. TI Influenza A(H1N1)pdm09 during air travel SO TRAVEL MEDICINE AND INFECTIOUS DISEASE LA English DT Article DE H1N1; Influenza A; Air travel; Transmission risk; Aircraft; Pandemic ID A H1N1 VIRUS; NEW-YORK-CITY; HOUSEHOLD TRANSMISSION; UNITED-STATES; A/H1N1 2009; OUTBREAK; INFECTION; AIRPLANE; AIRLINER; SCHOOL AB The global spread of the influenza A(H1N1)pdm09 virus (pH1N1) associated with travelers from North America during the onset of the 2009 pandemic demonstrates the central role of international air travel in virus migration. To characterize risk factors for pH1N1 transmission during air travel, we investigated travelers and airline employees from four North American flights carrying ill travelers with confirmed pH1N1 infection. Of 392 passengers and crew identified, information was available for 290 (74%) passengers were interviewed. Overall attack rates for acute respiratory infection and influenza-like illness 1-7 days after travel were 5.2% and 2.4% respectively. Of 43 individuals that provided sera, 4 (9.3%) tested positive for pH1N1 antibodies, including 3 with serologic evidence of asymptomatic infection. Investigation of novel influenza aboard aircraft may be instructive. However, beyond the initial outbreak phase, it may compete with community-based mitigation activities, and interpretation of findings will be difficult in the context of established community transmission. Published by Elsevier Ltd. C1 [Neatherlin, John; Cramer, Elaine H.; Dubray, Christine; Marienau, Karen J.; Russell, Michelle; Sun, Hong; Whaley, Melissa; Hancock, Kathy; Duong, Krista K.; Kirking, Hannah L.; Schembri, Christopher; Katz, Jacqueline M.; Cohen, Nicole J.; Fishbein, Daniel B.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Cramer, Elaine H.; Schembri, Christopher] SRA Int, Global Hlth Sector, Atlanta, GA 30329 USA. [Kirking, Hannah L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53792 USA. RP Cohen, NJ (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,NE Mailstop C-01, Atlanta, GA 30333 USA. EM ncohen@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 6 Z9 6 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1477-8939 J9 TRAVEL MED INFECT DI JI Travel Med. Infect. Dis. PD MAR-APR PY 2013 VL 11 IS 2 BP 110 EP 118 DI 10.1016/j.tmaid.2013.02.004 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 164MC UT WOS:000320413200007 PM 23523241 ER PT J AU Erol, E Jackson, C Bai, Y Sells, S Locke, S Kosoy, M AF Erol, Erdal Jackson, Carney Bai, Ying Sells, Stephen Locke, Steve Kosoy, Michael TI Bartonella bovis isolated from a cow with endocarditis SO JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION LA English DT Article DE Bartonella bovis; cattle; endocarditis; multilocus sequencing ID RIBOSOMAL-RNA; SYNTHASE GENE; DIFFERENTIATION; CATTLE; IDENTIFICATION; PRIMERS; SPP. AB A 7-year-old pregnant Angus cow was found dead in the field. At necropsy, the aortic valve was expanded by moderate fibrous connective tissue and acidophilic coagulum containing multifocal marked bacteria, mineral, neutrophils, and red blood cells. Numerous tiny grayish, opaque bacterial colonies were detected on blood agar plates at 7 days after inoculation with a swab of the heart valve of the cow. The bacterium was a Gram-negative, very small coccobacillus that was catalase, oxidase, and urease negative, and did not change litmus milk, triple sugar iron agar, and sulfide-indole-motility medium. The bacterium was negative for esculin hydrolysis, phenylalanine deaminase, nitrate reduction, and gelatin hydrolysis. The isolate did not produce acid from glycerol, inulin, lactose, maltose, mannose, raffinose, salicin, sorbitol, sucrose, trehalose, glycogen, ribose, or starch. Polymerase chain reaction tests for the gltA, ssrA, ftsZ, ribC, rpoB, and 16S ribosomal RNA genes of Bartonella species were positive for the isolate. Amplicons were sequenced, and the gltA, ribC, ssrA, and 16S ribosomal RNA gene sequences were found to have 100% homology to the type strain of Bartonella bovis, whereas the fts and rpoB sequences showed 99.9% and 99.6% homology, respectively, to the type strain of Bartonella bovis. Diagnosticians should be aware of slow-growing microorganisms, and culture media should be incubated beyond the standard period to enhance the recovery of Bartonella species. C1 [Erol, Erdal; Jackson, Carney; Sells, Stephen; Locke, Steve] Univ Kentucky, Vet Diagnost Lab, Lexington, KY 40512 USA. [Bai, Ying; Kosoy, Michael] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. RP Erol, E (reprint author), Univ Kentucky, Vet Diagnost Lab, POB 14125, Lexington, KY 40512 USA. EM erdal.erol@uky.edu NR 15 TC 11 Z9 11 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1040-6387 J9 J VET DIAGN INVEST JI J. Vet. Diagn. Invest. PD MAR PY 2013 VL 25 IS 2 BP 288 EP 290 DI 10.1177/1040638713477408 PG 3 WC Veterinary Sciences SC Veterinary Sciences GA 148CM UT WOS:000319220300019 PM 23512923 ER PT J AU Chiu, CY Yagi, S Lu, XY Yu, GX Chen, EC Liu, M Dick, EJ Carey, KD Erdman, DD Leland, MM Patterson, JL AF Chiu, Charles Y. Yagi, Shigeo Lu, Xiaoyan Yu, Guixia Chen, Eunice C. Liu, Maria Dick, Edward J., Jr. Carey, Kenneth D. Erdman, Dean D. Leland, Michelle M. Patterson, Jean L. TI A Novel Adenovirus Species Associated with an Acute Respiratory Outbreak in a Baboon Colony and Evidence of Coincident Human Infection SO MBIO LA English DT Article ID WORLD MONKEY ADENOVIRUS; GENOME SEQUENCE; CLINICAL-FEATURES; GASTROENTERITIS; RECOMBINATION; ANTIBODIES; CONTAINS; PRIMATES; CHILDREN; DISTINCT AB Adenoviruses (AdVs) are DNA viruses that infect many vertebrate hosts, including humans and nonhuman primates. Here we identify a novel AdV species, provisionally named "simian adenovirus C (SAdV-C)," associated with a 1997 outbreak of acute respiratory illness in captive baboons (4 of 9) at a primate research facility in Texas. None of the six AdVs recovered from baboons (BaAdVs) during the outbreak, including the two baboons who died from pneumonia, were typeable. Since clinical samples from the two fatal cases were not available, whole-genome sequencing of nasal isolates from one sick baboon and three asymptomatic baboons during the outbreak was performed. Three AdVs were members of species SAdV-C (BaAdV-2 and BaAdV-4 were genetically identical, and BaAdV-3), while one (BaAdV-1) was a member of the recently described SAdV-B species. BaAdV-3 was the only AdV among the 4 isolated from a sick baboon, and thus was deemed to be the cause of the outbreak. Significant divergence (<58% amino acid identity) was found in one of the fiber proteins of BaAdV-3 relative to BaAdV-2 and -4, suggesting that BaAdV-3 may be a rare SAdV-C recombinant. Neutralizing antibodies to the other 3 AdVs, but not BaAdV-3, were detected in healthy baboons from 1996 to 2003 and staff personnel from 1997. These results implicate a novel adenovirus species (SAdV-C) in an acute respiratory outbreak in a baboon colony and underscore the potential for cross-species transmission of AdVs between humans and nonhuman primates. IMPORTANCE Adenoviruses (AdVs) are DNA viruses that infect many animals, including humans and monkeys. In 1997, an outbreak of acute respiratory illness from AdVs occurred in a baboon colony in Texas. Here we use whole-genome sequencing and antibody testing to investigate new AdVs in baboons (BaAdVs) during the outbreak, one of which, BaAdV-3, came from a sick animal. By sequence analysis, BaAdV-3 may be a recombinant strain that arose from a related BaAdV found in baboons nearby in the colony (who were not sick) and yet another unknown AdV. We also found antibodies to these new BaAdVs in baboons and staff personnel at the facility. Taken together, our findings of a new AdV species as the cause of an acute respiratory outbreak in a baboon colony underscore the ongoing threat from emerging viruses that may carry the potential for cross-species transmission between monkeys and humans. C1 [Chiu, Charles Y.; Yu, Guixia; Chen, Eunice C.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Chiu, Charles Y.; Yu, Guixia; Chen, Eunice C.] Univ Calif San Francisco, UCSF Abbott Viral Diagnost & Discovery Ctr, San Francisco, CA 94143 USA. [Chiu, Charles Y.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA USA. [Yagi, Shigeo; Liu, Maria] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA USA. [Lu, Xiaoyan; Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Dick, Edward J., Jr.; Carey, Kenneth D.; Patterson, Jean L.] Texas Biomed Res Inst, San Antonio, TX USA. [Leland, Michelle M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Chiu, CY (reprint author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. EM charles.chiu@ucsf.edu; jpatters@txbiomed.org OI Chiu, Charles/0000-0003-2915-2094 FU NIH HHS [P51 OD011133] NR 45 TC 5 Z9 5 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD MAR-APR PY 2013 VL 4 IS 2 AR e00084-13 DI 10.1128/mBio.00084-13 PG 12 WC Microbiology SC Microbiology GA 137JI UT WOS:000318431500015 PM 23592261 ER PT J AU Ezeoke, I Klenk, HP Potter, G Schumann, P Moser, BD Lasker, BA Nicholson, A Brown, JM AF Ezeoke, Ifeoma Klenk, Hans-Peter Poetter, Gabriele Schumann, Peter Moser, Ben D. Lasker, Brent A. Nicholson, Ainsley Brown, June M. TI Nocardia amikacinitolerans sp nov., an amikacin-resistant human pathogen SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID TRANSVALENSIS-COMPLEX; ACID; CLASSIFICATION; EXTRACTION; MEMBERS AB Five nocardioform isolates from human clinical sources were evaluated. Analysis of the nearly full-length 16S rRNA gene showed 99.9-100% similarity among the strains. The results of a comparative phylogenetic analysis of the 16S rRNA gene sequences indicated that the isolates belonged to the genus Nocardia. Phenotypic and molecular analyses were performed on the clinical isolates. Traditional phenotypic analyses included morphological, biochemical/physiological, chemotaxonomic and antimicrobial susceptibility profiling. Molecular studies included 1441-bp 16S rRNA and 1246-bp gyrB gene sequence analyses, as well as DNA-DNA hybridizations. Biochemical analysis failed to differentiate the putative novel species from its phylogenetic neighbours; however, molecular studies were able to distinguish the patient strains and confirm them as members of a single species. Based on 16S rRNA gene sequence analysis, similarity between the isolates and their closest relatives (type strains of Nocardia araoensis, N. arthritidis, N. beijingensis and N. niwae) was <= 99.3%. Analysis of partial gyrB gene sequences showed 98-99.7% relatedness among the isolates. Nocardia lijiangensis and N. xishanensis were the closest related species to the isolates based on gyrB gene sequence analysis, and their type strains showed 95.7 and 95.3% similarity, respectively, to strain W9988(T). Resistance to amikacin and molecular analyses, including DNA-DNA hybridization, distinguished the five patient strains from their phylogenetic neighbours, and the results of this polyphasic study indicated the existence of a novel species of Nocardia, for which we propose the name Nocardia amikacinitolerans sp. nov., with strain W9988(T) (=DSM 45539(T) =CCUG 59655(T)) as the type strain. C1 [Ezeoke, Ifeoma; Moser, Ben D.; Lasker, Brent A.; Nicholson, Ainsley; Brown, June M.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Klenk, Hans-Peter; Poetter, Gabriele; Schumann, Peter] DSMZ German Collect Microorganisms & Cell Culture, D-38124 Braunschweig, Germany. RP Lasker, BA (reprint author), Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM blasker@cdc.gov NR 31 TC 10 Z9 10 U1 2 U2 6 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1466-5026 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD MAR PY 2013 VL 63 BP 1056 EP 1061 DI 10.1099/ijs.0.039990-0 PN 3 PG 6 WC Microbiology SC Microbiology GA 138TU UT WOS:000318533700042 PM 22707533 ER PT J AU Dawood, FS Iuliano, AD Widdowson, MA AF Dawood, Fatimah S. Iuliano, A. Danielle Widdowson, Marc-Alain TI The 2009 influenza pandemic Reply SO LANCET INFECTIOUS DISEASES LA English DT Letter C1 [Dawood, Fatimah S.; Iuliano, A. Danielle; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Dawood, FS (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. EM fdawood@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAR PY 2013 VL 13 IS 3 BP 194 EP 195 DI 10.1016/S1473-3099(13)70040-9 PG 2 WC Infectious Diseases SC Infectious Diseases GA 136TK UT WOS:000318386100011 PM 23427885 ER PT J AU Matteelli, A Schlagenhauf, P Carvalho, ACC Weld, L Davis, XM Wilder-Smith, A Barnett, ED Parola, P Pandey, P Han, P Castelli, F AF Matteelli, Alberto Schlagenhauf, Patricia Carvalho, Anna C. C. Weld, Leisa Davis, Xiaohong M. Wilder-Smith, Annelies Barnett, Elizabeth D. Parola, Philippe Pandey, Prativa Han, Pauline Castelli, Francesco CA GeoSentinel Surveillance Network TI Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database SO LANCET INFECTIOUS DISEASES LA English DT Article ID HIV TRANSMISSION; RISK BEHAVIOR; DISEASES; HEALTH; COUNTRIES; NETWORK; ORIGIN; SEX AB Background Travel is thought to be a risk factor for the acquisition of sexually transmitted infections (STIs), but no multicentre analyses have been done. We aimed to describe the range of diseases and the demographic and geographical factors associated with the acquisition of travel-related STIs through analysis of the data gathered by GeoSentinel travel medicine clinics worldwide. Methods We gathered data from ill travellers visiting GeoSentinel clinics worldwide between June 1,1996, and Nov 30,2010, and analysed them to identify STIs in three clinical settings: after travel, during travel, or immigration travel. We calculated proportionate morbidity for each of the three traveller groups and did logistic regression to assess the association between STIs and demographic, geographical, and travel variables. Findings Our final analysis was of 112180 ill travellers-64335 patients seen after travel, 38 287 patients seen during travel, and 9558 immigrant patients. 974 patients (0.9%) had diagnoses of STIs, and 1001 STIs were diagnosed. The proportionate STI morbidities were 6.6, 10.2, and 16.8 per 1000 travellers in the three groups, respectively. STIs varied substantially according to the traveller category. The most common STI diagnoses were non-gonococcal or unspecified urethritis (30.2%) and acute HIV infection (27.6%) in patients seen after travel; non-gonococcal or unspecified urethritis (21.1%), epididymitis (15.2%), and cervicitis (12.3%) in patients seen during travel; and syphilis in immigrant travellers (67.8%). In ill travellers seen after travel, significant associations were noted between diagnosis of STIs and male sex, travelling to visit friends or relatives, travel duration of less than 1 month, and not having pretravel health consultations. Interpretation The range of STIs varies substantially according to traveller category. STI preventive strategies should be particularly targeted at men and travellers visiting friends or relatives. Our data suggest target groups for pretravel interventions and should assist in post-travel screening and decision making. C1 [Matteelli, Alberto; Carvalho, Anna C. C.; Castelli, Francesco] Univ Brescia, Inst Infect & Trop Dis, Brescia, Italy. [Schlagenhauf, Patricia] Univ Zurich, WHO Collaborating Ctr Travel Med, Zurich, Switzerland. [Davis, Xiaohong M.; Han, Pauline] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Wilder-Smith, Annelies] Natl Univ Singapore, Dept Med, Singapore 117548, Singapore. [Wilder-Smith, Annelies] Heidelberg Univ, Inst Publ Hlth, Baden Wurttemberg, Germany. [Barnett, Elizabeth D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA USA. [Parola, Philippe] Aix Marseille Univ, Univ Hosp Inst Infect & Trop Dis, Marseille, France. [Parola, Philippe] Assistance Publ Hop Marseille, Marseille, France. [Pandey, Prativa] CIWEC Clin Travel Med Ctr, Kathmandu, Nepal. RP Matteelli, A (reprint author), Inst Infect andTrop Dis, Piazzale Spedali Civili, I-25123 Brescia, Italy. EM matteelli@med.unibs.it RI Wilder-Smith, Annelies/F-8751-2015; Matteelli, Alberto/M-8784-2015; OI Matteelli, Alberto/0000-0001-5109-9248; Barnett, Elizabeth/0000-0003-4822-5949; Okhuysen, Pablo/0000-0002-1596-3411; Wilder-Smith, Annelies/0000-0003-0362-5375; Aoun, Olivier/0000-0001-9554-8439; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330 FU US Centers for Disease Control and Prevention; International Society of Travel Medicine; GeoSentinel Surveillance Network through US Centers for Disease Control and Prevention [5U50CI000359] FX US Centers for Disease Control and Prevention, and International Society of Travel Medicine.; This work was supported by the GeoSentinel Surveillance Network through a cooperative agreement with the US Centers for Disease Control and Prevention (grant 5U50CI000359) and funding from the International Society of Travel Medicine. The findings and conclusions in this Article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 25 TC 20 Z9 20 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAR PY 2013 VL 13 IS 3 BP 205 EP 213 DI 10.1016/S1473-3099(12)70291-8 PG 9 WC Infectious Diseases SC Infectious Diseases GA 136TK UT WOS:000318386100021 PM 23182931 ER PT J AU Stier, DD AF Stier, Daniel D. TI PREFACE: Thanking Those Who Made It Happen SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article C1 [Stier, Daniel D.] CDC, Publ Hlth Law Program, Atlanta, GA 30333 USA. FU Robert Wood Johnson Foundation FX Daniel D. Stier, J.D., is the National Coordinating Center Director of the Network for Public Health Law, a national initiative funded by the Robert Wood Johnson Foundation to build the field of public health law. He is a veteran attorney and administrator with decades of experience at state and federal levels. Mr. Stier previously served as a Senior Public Health Analyst with CDC's Public Health Law Program. He worked closely with state public health officials and attorneys, guided by the Program's mission "to advance the public's health through law." Before joining CDC, Mr. Stier had a long and varied career in Wisconsin state government, including service as Chief Legal Counsel with the Department of Health and Family Services, Assistant Attorney General in the Department of Justice, and Deputy Secretary of the Department of Veterans Affairs. He is a member of the State Bars of Wisconsin and Georgia, and is a graduate of the University of Wisconsin Law School. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1073-1105 J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SPR PY 2013 VL 41 SU 1 SI SI BP 7 EP 8 DI 10.1111/jlme.12029 PG 2 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA 130JF UT WOS:000317910100001 PM 23590731 ER PT J AU Rao, AK Luckman, E Wise, ME MacCannell, T Blythe, D Lin, YL Xia, GL Drobeniuc, J Noble-Wang, J Arduino, MJ Thompson, ND Patel, PK Wilson, LE AF Rao, Agam K. Luckman, Emily Wise, Matthew E. MacCannell, Taranisia Blythe, David Lin, Yulin Xia, Guoliang Drobeniuc, Jan Noble-Wang, Judith Arduino, Matthew J. Thompson, Nicola D. Patel, Priti R. Wilson, Lucy E. TI Outbreak of Hepatitis C Virus Infections At an Outpatient Hemodialysis Facility: The Importance of Infection Control Competencies SO NEPHROLOGY NURSING JOURNAL LA English DT Article DE Disease outbreaks; hepatitis C; hemodialysis; infection control; education; training ID UNITED-STATES; TRANSMISSION; PREVALENCE AB Rao, A.K., Luckman, E., Wise, M.E., MacCannell, T., Blythe, D., Lin, Y... Wilson, L.E. (2013). Outbreak of hepatitis C virus infections at an outpatient hemodialysis facility: The importance of infection control competencies. Nephrology Nursing Journal, 40(2), 101-110, 164. In the United States, the prevalence of hepatitis C virus infection among patients treated in hemodialysis facilities is five times higher than among the general population. This study investigated eight new hepatitis C virus infections among patients treated at an outpatient hemodialysis facility. Epidemiologic investigation and viral sequencing demonstrated that transmission likely occurred between patients typically treated during the same or consecutive shifts at the same or a nearby station. Several infection control breaches were observed; including lapses involving the preparation, handling, and administration of parenteral medications. Improved infection control education and training for all hemodialysis facility staff is an important component of assuring adherence to appropriate procedures and preventing future outbreaks. C1 [Rao, Agam K.; Wise, Matthew E.; MacCannell, Taranisia; Noble-Wang, Judith; Patel, Priti R.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Luckman, Emily] Maryland Dept Hlth & Mental Hyg, Off Infect Dis Epidemiol & Outbreak Response, Div Outbreak Invest, Baltimore, MD USA. [Blythe, David] Maryland Dept Hlth & Mental Hyg, Prevent & Hlth Promot Adm, Baltimore, MD USA. [Lin, Yulin; Xia, Guoliang; Drobeniuc, Jan; Thompson, Nicola D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Arduino, Matthew J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Clin & Environm Microbiol Branch, Atlanta, GA USA. [Wilson, Lucy E.] Maryland Dept Hlth & Mental Hyg, Prevent & Hlth Promot Adm, Ctr Surveillance Infect Prevent & Outbreak Respon, Baltimore, MD USA. RP Rao, AK (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM akrao@cdc.gov NR 28 TC 5 Z9 6 U1 0 U2 4 PU JANNETTI PUBLICATIONS, INC PI PITMAN PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA SN 1526-744X J9 NEPHROL NURS J JI Nephrol. Nurs. J. PD MAR-APR PY 2013 VL 40 IS 2 BP 101 EP + PG 11 WC Nursing; Urology & Nephrology SC Nursing; Urology & Nephrology GA 125RJ UT WOS:000317558700003 PM 23785746 ER PT J AU Rath, BA Gentsch, J Seckinger, J Ward, K Deputy, S AF Rath, Barbara A. Gentsch, Jon Seckinger, Joerg Ward, Kenneth Deputy, Stephen TI Rotavirus Encephalitis With Basal Ganglia Involvement in an 8-Month-Old Infant SO CLINICAL PEDIATRICS LA English DT Article ID CEREBROSPINAL-FLUID SAMPLES; OF-THE-LITERATURE; CORPUS-CALLOSUM; SIGNAL CHANGES; ENCEPHALOPATHY; GASTROENTERITIS; CEREBELLITIS; INFECTION; CHILD; MENINGOENCEPHALITIS C1 [Rath, Barbara A.; Ward, Kenneth; Deputy, Stephen] Childrens Hosp New Orleans, New Orleans, LA USA. [Rath, Barbara A.; Seckinger, Joerg] Tulane Univ, Med Ctr, New Orleans, LA USA. [Rath, Barbara A.] Charite Univ Med Ctr, D-13353 Berlin, Germany. [Seckinger, Joerg] Ctr Dis Control & Prevent, Atlanta, GA USA. [Seckinger, Joerg] Univ Heidelberg Hosp, Heidelberg, Germany. RP Rath, BA (reprint author), Charite Univ Med Ctr, Div Pneumonol Allergol, Dept Pediat, Augustenburger Pl 1, D-13353 Berlin, Germany. EM barbara.rath@gmail.com NR 26 TC 1 Z9 1 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD MAR PY 2013 VL 52 IS 3 BP 260 EP 264 DI 10.1177/0009922811417301 PG 5 WC Pediatrics SC Pediatrics GA 129OE UT WOS:000317849900008 PM 21868600 ER PT J AU Howard, DH Tangka, FK Guy, GP Ekwueme, DU Lipscomb, J AF Howard, David H. Tangka, Florence K. Guy, Gery P. Ekwueme, Donatus U. Lipscomb, Joseph TI Prostate Cancer Screening In Men Ages 75 And Older Fell By 8 Percentage Points After Task Force Recommendation SO HEALTH AFFAIRS LA English DT Article ID PRIMARY-CARE-PHYSICIANS; US; GUIDELINES; MORTALITY AB In 2008 the US Preventive Services Task Force recommended against screening men ages 75 and older for prostate cancer. Using Medicare Current Beneficiary Survey Access to Care files and linked claims, we compared trends in prostate-specific antigen (PSA) testing rates between men ages 75 and older and men ages 65-74. We estimate that the revised recommendation led to a 7.9-percentage-point decline in annual PSA testing rates over two years among men ages 75 and older. Although 42 percent of men in this age group continue to receive PSA tests, our results highlight the potential of guidelines with negative recommendations to reduce the use of low-value medical care. C1 [Howard, David H.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Howard, David H.] Emory Univ, Dept Econ, Atlanta, GA 30322 USA. [Tangka, Florence K.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Guy, Gery P.; Ekwueme, Donatus U.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Lipscomb, Joseph] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Howard, DH (reprint author), Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. EM david.howard@emory.edu FU Centers for Disease Control and Prevention FX This research was presented at the annual meeting of the American Society of Health Economists, Minneapolis, Minnesota, June 2012. David Howard's work was supported by an Interagency Personnel Agreement with the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 24 TC 16 Z9 17 U1 0 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAR PY 2013 VL 32 IS 3 BP 596 EP 602 DI 10.1377/hlthaff.2012.0555 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 111YK UT WOS:000316557900020 PM 23459740 ER PT J AU Robles, B Wood, M Kimmons, J Kuo, T AF Robles, Brenda Wood, Michelle Kimmons, Joel Kuo, Tony TI Comparison of Nutrition Standards and Other Recommended Procurement Practices for Improving Institutional Food Offerings in Los Angeles County, 2010-2012 SO ADVANCES IN NUTRITION LA English DT Article; Proceedings Paper CT Symposium on Adopting Healthy and Sustainable Food Service Guidelines - Emerging Evidence from Implementation at the United States Federal Government, New York City, Los Angeles County, and Kaiser Permanente CY APR 21, 2012 CL San Diego, CA SP Amer Soc Nutr ID PHYSICAL-ACTIVITY; SCIENTIFIC STATEMENT; INCREASING FRUIT; VEGETABLE INTAKE; HEALTH IMPACT; LOCAL-POLICY; ENVIRONMENTS; CONSUMPTION; PREVENTION; OBESITY AB National, state, and local institutions that procure, distribute, sell, and/or serve food to employees, students, and the public are increasingly capitalizing on existing operational infrastructures to create healthier food environments. Integration of healthy nutrition standards and other recommended practices [e.g., energy (kilocalories) postings at point-of-purchase, portion size restrictions, product placement guidelines, and signage] into new or renewing food service and vending contracts codifies an institution's commitment to increasing the availability of healthful food options in their food service venues and vending machines. These procurement requirements, in turn, have the potential to positively influence consumers' food-purchasing behaviors. Although these strategies are becoming increasingly popular, much remains unknown about their context, the processes required to implement them effectively, and the factors that facilitate their sustainability, especially in such broad and diverse settings as schools, county government facilities, and cities. To contribute to this gap in information, we reviewed and compared nutrition standards and other best practices implemented recently in a large school district, in a large county government, and across 10 municipalities in Los Angeles County. We report lessons learned from these efforts. Adv. Nutr. 4: 191-202 2013. C1 [Robles, Brenda; Wood, Michelle; Kuo, Tony] Los Angeles Cty Dept Publ Hlth, Div Chron Dis & Injury Prevent, Los Angeles, CA USA. [Kimmons, Joel] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Kuo, Tony] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90095 USA. RP Kuo, T (reprint author), Los Angeles Cty Dept Publ Hlth, Div Chron Dis & Injury Prevent, Los Angeles, CA USA. EM tkuo@ph.lacounty.gov FU NCCDPHP CDC HHS [3U58DP002485-01S1, 1U58DP003061-01] NR 37 TC 12 Z9 12 U1 4 U2 26 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 2161-8313 J9 ADV NUTR JI Adv. Nutr. PD MAR PY 2013 VL 4 IS 2 BP 191 EP 202 DI 10.3945/an.112.003285 PG 12 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 120HJ UT WOS:000317161100007 PM 23493535 ER PT J AU Herman, WH Edelstein, SL Ratner, RE Montez, MG Ackermann, RT Orchard, TJ Foulkes, MA Zhang, P Saudek, CD Brown, MB AF Herman, William H. Edelstein, Sharon L. Ratner, Robert E. Montez, Maria G. Ackermann, Ronald T. Orchard, Trevor J. Foulkes, Mary A. Zhang, Ping Saudek, Christopher D. Brown, Morton B. CA Diabet Prevention Program Res Grp TI Effectiveness and Cost-Effectiveness of Diabetes Prevention Among Adherent Participants SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; WEIGHT-LOSS; METFORMIN; PROGRAM; OUTCOMES; THERAPY; OBESITY; ADULTS AB Objectives: We report the 10-year effectiveness and within-trial cost-effectiveness of the Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) interventions among participants who were adherent to the interventions. Study Design: DPP was a 3-year randomized clinical trial followed by 7 years of open-label modified intervention follow-up. Methods: Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives. Lifestyle adherence was defined as achieving and maintaining a 5% reduction in initial body weight, and metformin adherence as taking metformin at 80% of study visits. Results: The relative risk reduction was 49.4% among adherent lifestyle participants and 20.8% among adherent metformin participants compared with placebo. Over 10 years, the cumulative, undiscounted, per capita direct medical costs of the interventions, as implemented during the DPP, were greater for adherent lifestyle participants ($4810) than adherent metformin participants ($2934) or placebo ($768). Over 10 years, the cumulative, per capita non-intervention-related direct medical costs were $4250 greater for placebo participants compared with adherent lifestyle participants and $3251 greater compared with adherent metformin participants. The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.80) than metformin (6.74) or placebo (6.67). Without discounting, from a modified societal perspective (excluding participant time) and a full societal perspective (including participant time), lifestyle cost 45000 per QALY-gained and metformin was cost saving compared with placebo. Conclusions: Over 10 years, lifestyle intervention and metformin were cost-effective or cost saving compared with placebo. These analyses confirm that lifestyle and metformin represent a good value for money. Am J Manag Care. 2013;19(3):794-202 C1 [Herman, William H.] Univ Michigan, Dept Endocrinol, Ann Arbor, MI 48109 USA. [Edelstein, Sharon L.; Foulkes, Mary A.] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Ratner, Robert E.] Medstar Res Inst, Washington, DC USA. [Montez, Maria G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ackermann, Ronald T.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA. [Orchard, Trevor J.] Univ Pittsburgh, Pittsburgh, PA USA. [Zhang, Ping] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brown, Morton B.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Diabet Prevention Program Res Grp] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Saudek, Christopher D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Herman, WH (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Ste 750, Rockville, MD 20852 USA. EM dppmail@biostat.bsc.gwu.edu OI orchard, trevor/0000-0001-9552-3215 FU Michigan Diabetes Research and Training Center [P60 DK020572]; Michigan Center for Diabetes Translational Resegrch [P30 DK092926] FX The Research Group gratefully acknowledges the commitment and dedication of the participants of the DPP and DPPOS. During the DPPOS, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study, and collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK, including its Intramural Research Program, and the Indian Health Service. The General Clinical Research Center Program, National Center for Research. Resources, supported data collection at many of the clinical centers. Funding was also provided by the National Institute of Child Health and Human Development, the National Institute on Aging, the National Eye Institute, the National Heart Lung and Blood Institute, the Office of Research on Women's Health, the National Center for Minority Health and Human Disease, the Centers for Disease Control and Prevention, and the American Diabetes Association. Bristol-Myers Squibb and Parke-Davis provided additional funding and material support during the DPP, Lipha (Merck-Sante) provided medication, and Life Scan Inc donated materials during the DPP and DPPOS. Economic analyses were supported in part by the Michigan Diabetes Research and Training Center (P60 DK020572) and the Michigan Center for Diabetes Translational Resegrch (P30 DK092926). The opinions expressed are those of the investigators and do not necessarily reflect the views of the funding agencies. A complete list of Centers, investigators, and staff can be found in the eAppendix. NR 22 TC 29 Z9 29 U1 0 U2 5 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAR PY 2013 VL 19 IS 3 BP 194 EP 202 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 123GI UT WOS:000317376000003 PM 23544761 ER PT J AU Wang, DY Sleeman, K Huang, WJ Nguyen, HT Levine, M Cheng, YH Li, XY Tan, MJ Xing, XH Xu, XY Klimov, AI Gubareva, LV Shu, YL AF Wang, Dayan Sleeman, Katrina Huang, Weijuan Nguyen, Ha T. Levine, Marnie Cheng, Yanhui Li, Xiyan Tan, Minju Xing, Xiaohui Xu, Xiyan Klimov, Alexander I. Gubareva, Larisa V. Shu, Yuelong TI Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir SO ANTIVIRAL RESEARCH LA English DT Article DE Neuraminidase inhibitor; Zanamivir; Oseltamivir; Influenza B ID IMMUNOCOMPROMISED CHILD; UNITED-STATES; A H1N1; RESISTANT; SURVEILLANCE; SENSITIVITY; INFECTIONS; RECOVERY; STRAIN AB Influenza type B viruses are responsible for substantial morbidity and mortality in humans. Antiviral drugs are an important supplement to vaccination for reducing the public health impact of influenza virus infections. Influenza B viruses are not sensitive to M2 inhibitors which limit the current therapeutic options to two neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, which are licensed in many countries. Drug resistance is a public health concern which has necessitated monitoring of influenza virus drug susceptibilities through active global surveillance. Here, we report the results of drug susceptibility surveillance of influenza type B viruses (n = 680) collected in mainland China during two calendar years, 2010 and 2011, assessed using functional neuraminidase (NA) inhibition (NI) assays. Four influenza B viruses exhibited reduced susceptibilities to oseltamivir, but not zanamivir, and shared the amino acid substitution I221T (ATC -> ACC), at this conserved residue in the NA active site (I222T in N2 numbering). Additionally, a single virus with reduced susceptibility to both oseltamivir and zanamivir was identified and contained an amino acid substitution D197N (GAC -> AAC) at another conserved residue in the NA active site (D198N in N2 numbering). This report underlies the importance of continued influenza antiviral susceptibility surveillance globally, even in countries where the use of NAIs has been low or non-existing. (C) 2012 Elsevier B.V. All rights reserved. C1 [Wang, Dayan; Huang, Weijuan; Cheng, Yanhui; Li, Xiyan; Tan, Minju; Xing, Xiaohui; Shu, Yuelong] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Chinese Natl Influenza Ctr, Beijing, Peoples R China. [Sleeman, Katrina; Nguyen, Ha T.; Levine, Marnie; Klimov, Alexander I.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Nguyen, Ha T.; Levine, Marnie] Battelle Mem Inst, Atlanta, GA USA. RP Shu, YL (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Chinese Natl Influenza Ctr, Beijing, Peoples R China. EM yshu@cnic.org.cn FU National Basic Research Program of China (973 program) [2011CB504704]; China Mega-Project for Infectious Disease [2012ZX10004215-002] FX This work was partly supported by National Basic Research Program of China (973 program, No. 2011CB504704) and China Mega-Project for Infectious Disease (2012ZX10004215-002). NR 24 TC 11 Z9 13 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 J9 ANTIVIR RES JI Antiviral Res. PD MAR PY 2013 VL 97 IS 3 BP 240 EP 244 DI 10.1016/j.antiviral.2012.12.013 PG 5 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 127OX UT WOS:000317709400004 PM 23267831 ER PT J AU Shenk, MK Starkweather, K Kress, HC Alam, N AF Shenk, Mary K. Starkweather, Kathrine Kress, Howard C. Alam, Nurul TI Does Absence Matter? A Comparison of Three Types of Father Absence in Rural Bangladesh SO HUMAN NATURE-AN INTERDISCIPLINARY BIOSOCIAL PERSPECTIVE LA English DT Article DE Father absence; Paternal investment; Psychosocial stress; Labor migration; Belsky-Draper hypothesis; Child development theory; Bangladesh ID REPRODUCTIVE STRATEGY; CHILDHOOD EXPERIENCE; PATERNAL INVESTMENT; SEXUAL-BEHAVIOR; PUBERTAL MATURATION; CONTRACEPTIVE USE; EARLY STRESS; MENARCHE; AGE; MORTALITY AB This paper examines the effects of three different types of father absence on the timing of life history events among women in rural Bangladesh. Age at marriage and age at first birth are compared across women who experienced different father presence/absence conditions as children. Survival analyses show that daughters of fathers who divorced their mothers or deserted their families have consistently younger ages at marriage and first birth than other women. In contrast, daughters whose fathers were labor migrants have consistently older ages at marriage and first birth. Daughters whose fathers died when they were children show older ages at marriage and first birth than women with divorced/deserted fathers and women with fathers present. These effects may be mediated by high socioeconomic status and high levels of parental investment among the children of labor migrants, and a combination of low investment, high psychosocial stress, and low alloparental investment among women with divorced/deserted fathers. Our findings are most consistent with the Child Development Theory model of female life history strategies, though the Paternal Investment and Psychosocial Acceleration models also help explain differences between women in low paternal investment situations (e.g., father divorced/abandoned vs. father dead). Father absence in and of itself seems to have little effect on the life history strategies of Bangladeshi women once key reasons for or correlates of absence are controlled, and none of the models is a good predictor of why women with deceased fathers have delayed life histories compared with women whose fathers are present. C1 [Shenk, Mary K.; Starkweather, Kathrine] Univ Missouri, Dept Anthropol, Columbia, MO 65211 USA. [Kress, Howard C.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Alam, Nurul] Int Ctr Diarrhoeal Dis Res, Hlth & Demog Surveillance Unit Dhaka, Dhaka 1000, Bangladesh. RP Shenk, MK (reprint author), Univ Missouri, Dept Anthropol, 107 Swallow Hall, Columbia, MO 65211 USA. EM shenkm@missouri.edu; kesc99@mail.missouri.edu; hkress3@gmail.com; nalam@icddrb.org OI Shenk, Mary/0000-0003-2002-1469 NR 77 TC 11 Z9 11 U1 0 U2 39 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1045-6767 J9 HUM NATURE-INT BIOS JI Hum. Nat.-Interdiscip. Biosoc. Perspect. PD MAR PY 2013 VL 24 IS 1 SI SI BP 76 EP 110 DI 10.1007/s12110-013-9160-5 PG 35 WC Anthropology; Social Sciences, Biomedical SC Anthropology; Biomedical Social Sciences GA 124NQ UT WOS:000317471800005 PM 23355056 ER PT J AU Errett, NA Barnett, DJ Thompson, CB Tosatto, R Austin, B Schaffzin, S Ansari, A Semon, NL Balicer, RD Links, JM AF Errett, Nicole A. Barnett, Daniel J. Thompson, Carol B. Tosatto, Rob Austin, Brad Schaffzin, Samuel Ansari, Armin Semon, Natalie L. Balicer, Ran D. Links, Jonathan M. TI Assessment of Medical Reserve Corps Volunteers' Emergency Response Willingness Using a Threat- and Efficacy-Based Model SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Article ID PARALLEL PROCESS MODEL; WORKERS WILLINGNESS; PANDEMIC INFLUENZA; COMMUNICATION; PREPAREDNESS AB The goal of this study was to investigate the willingness of Medical Reserve Corps (MRC) volunteers to participate in public health emergency-related activities by assessing their attitudes and beliefs. MRC volunteers responded to an online survey organized around the Extended Parallel Process Model (EPPM). Respondents reported agreement with attitude/belief statements representing perceived threat, perceived efficacy, and personal/ organizational preparedness in 4 scenarios: a weather-related disaster, a pandemic influenza emergency, a radiological ("dirty bomb'') emergency, and an inhalational anthrax bioterrorism emergency. Logistic regression analyses were used to evaluate predictors of volunteer response willingness. In 2 response contexts (if asked and regardless of severity), self-reported willingness to respond was higher among those with a high perceived self-efficacy than among those with low perceived self-efficacy. Analyses of the association between attitude/belief statements and the EPPM profiles indicated that, under all 4 scenarios and with few exceptions, those with a perceived high threat/ high efficacy EPPM profile had statistically higher odds of agreement with the attitude/belief statements than those with a perceived low threat/ low efficacy EPPM profile. The radiological emergency consistently received the lowest agreement rates for the attitude/belief statements and response willingness across scenarios. The findings suggest that enrollment with an MRC unit is not automatically predictive of willingness to respond in these types of scenarios. While MRC volunteers' self-reported willingness to respond was found to differ across scenarios and among different attitude and belief statements, the identification of self-efficacy as the primary predictor of willingness to respond regardless of severity and if asked highlights the critical role of efficacy in an organized volunteer response context. C1 [Tosatto, Rob] US Dept HHS, Div Civilian Volunteer Med Reserve Corps, Rockville, MD USA. [Austin, Brad] US Dept HHS, Off Assistant Secretary Preparedness & Response, Ogdensburg, NY USA. [Schaffzin, Samuel] US Dept HHS, Ctr Medicare, Baltimore, MD USA. [Schaffzin, Samuel] US Dept HHS, Ctr Medicaid Serv, Baltimore, MD USA. [Ansari, Armin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Balicer, Ran D.] Ben Gurion Univ Negev, Dept Epidemiol, Tel Aviv, Israel. RP Errett, NA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 513, Baltimore, MD 21205 USA. EM nerrett@jhsph.edu FU OPHPR CDC HHS [1P01TP00288- 01]; PHS HHS [104264] NR 20 TC 9 Z9 9 U1 2 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD MAR PY 2013 VL 11 IS 1 BP 29 EP 40 DI 10.1089/bsp.2012.0047 PG 12 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA 116CO UT WOS:000316860400009 PM 23477632 ER PT J AU Koonin, LM Hanfling, D AF Koonin, Lisa M. Hanfling, Dan TI Broadening Access to Medical Care During a Severe Influenza Pandemic: The CDC Nurse Triage Line Project SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Editorial Material ID EMERGENCY-DEPARTMENT; H1N1 INFLUENZA; SURGE-CAPACITY; CALL CENTER; CENTERS; IMPACT AB The impact of a severe influenza pandemic could be overwhelming to hospital emergency departments, clinics, and medical offices if large numbers of ill people were to simultaneously seek care. While current planning guidance to reduce surge on hospitals and other medical facilities during a pandemic largely focuses on improving the "supply'' of medical care services, attention on reducing "demand'' for such services is needed by better matching patient needs with alternative types and sites of care. Based on lessons learned during the 2009 H1N1 pandemic, the Centers for Disease Control and Prevention and its partners are currently exploring the acceptability and feasibility of using a coordinated network of nurse triage telephone lines during a pandemic to assess the health status of callers, help callers determine the most appropriate site for care (eg, hospital ED, outpatient center, home), disseminate information, provide clinical advice, and provide access to antiviral medications for ill people, if appropriate. As part of this effort, the integration and coordination of poison control centers, existing nurse advice lines, 2-1-1 information lines, and other hotlines are being investigated. C1 [Koonin, Lisa M.] Ctr Dis Control & Prevent, Influenza Coordinat Unit, Off Infect Dis, Atlanta, GA 30329 USA. [Hanfling, Dan] Inova Hlth Syst, Emergency Preparedness & Response, Falls Church, VA USA. [Hanfling, Dan] George Washington Univ, Dept Emergency Med, Washington, DC USA. [Hanfling, Dan] UPMC, Ctr Biosecur, Baltimore, MD USA. RP Koonin, LM (reprint author), Ctr Dis Control & Prevent, Influenza Coordinat Unit, 1600 Clifton Rd NE,MS A-28, Atlanta, GA 30329 USA. EM LKoonin@cdc.gov NR 38 TC 4 Z9 4 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD MAR PY 2013 VL 11 IS 1 BP 75 EP 80 DI 10.1089/bsp.2013.0012 PG 6 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA 116CO UT WOS:000316860400014 PM 23458098 ER PT J AU Lumpkin, JR Miller, YK Inglesby, T Links, JM Schwartz, AT Slemp, CC Burhans, RL Blumenstock, J Khan, AS AF Lumpkin, John R. Miller, Yoon K. Inglesby, Tom Links, Jonathan M. Schwartz, Angela T. Slemp, Catherine C. Burhans, Robert L. Blumenstock, James Khan, Ali S. TI The Importance of Establishing a National Health Security Preparedness Index SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Editorial Material AB Natural disasters, infectious disease epidemics, terrorism, and major events like the nuclear incident at Fukushima all pose major potential challenges to public health and security. Events such as the anthrax letters of 2001, Hurricanes Katrina, Irene, and Sandy, severe acute respiratory syndrome (SARS) and West Nile virus outbreaks, and the 2009 H1N1 influenza pandemic have demonstrated that public health, emergency management, and national security efforts are interconnected. These and other events have increased the national resolve and the resources committed to improving the national health security infrastructure. However, as fiscal pressures force federal, state, and local governments to examine spending, there is a growing need to demonstrate both what the investment in public health preparedness has bought and where gaps remain in our nation's health security. To address these needs, the Association of State and Territorial Health Officials (ASTHO), through a cooperative agreement with the Centers for Disease Control and Prevention (CDC) Office of Public Health Preparedness and Response (PHPR), is creating an annual measure of health security and preparedness at the national and state levels: the National Health Security Preparedness Index (NHSPI). C1 [Lumpkin, John R.] Robert Wood Johnson Fdn, Hlth Care Grp, Princeton, NJ 08540 USA. [Miller, Yoon K.; Schwartz, Angela T.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Inglesby, Tom] UPMC, Ctr Biosecur, Baltimore, MD USA. [Links, Jonathan M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Slemp, Catherine C.] West Virginia Bur Publ Hlth, Charleston, WV USA. [Blumenstock, James] Assoc State & Territorial Hlth Officials, Arlington, VA USA. RP Khan, AS (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, 1600 Clifton Rd NE,MS D44, Atlanta, GA 30333 USA. EM ask0@cdc.gov NR 11 TC 1 Z9 1 U1 0 U2 20 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD MAR PY 2013 VL 11 IS 1 BP 81 EP 87 DI 10.1089/bsp.2013.0026 PG 7 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA 116CO UT WOS:000316860400015 PM 23506403 ER PT J AU Miller, CW Whitcomb, RC AF Miller, Charles W. Whitcomb, Robert C., Jr. TI Medical planning and response for a nuclear detonation: a practical guide (vol 10, pg 346, 2012) SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Correction C1 [Miller, Charles W.] Ctr Dis Control & Prevent, Radiat Studies Branch, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. [Whitcomb, Robert C., Jr.] Ctr Dis Control & Prevent, Radiat Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Miller, CW (reprint author), Ctr Dis Control & Prevent, Radiat Studies Branch, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. NR 1 TC 2 Z9 2 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD MAR PY 2013 VL 11 IS 1 BP 88 EP 88 DI 10.1089/bsp.2013.2020 PG 1 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA 116CO UT WOS:000316860400016 ER PT J AU Williams, LB Sattin, RW Dias, J Garvin, JT Marion, L Joshua, T Kriska, A Kramer, MK Echouffo-Tcheugui, JB Freeman, A Narayan, KMV AF Williams, Lovoria B. Sattin, Richard W. Dias, James Garvin, Jane T. Marion, Lucy Joshua, Thomas Kriska, Andrea Kramer, M. Kaye Echouffo-Tcheugui, Justin B. Freeman, Arin Narayan, K. M. Venkat TI Design of a cluster-randomized controlled trial of a diabetes prevention program within African-American churches: The Fit Body and Soul study SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE African-American; Church; Cluster; Translation research; Diabetes prevention; Obesity ID LIFE-STYLE INTERVENTION; DIETARY INTERVENTION; PHYSICAL-ACTIVITY; HEALTH PROMOTION; WEIGHT-LOSS; COMMUNITY; FEASIBILITY; TRANSLATION; PREVALENCE; DELIVERY AB Evidence from varied community settings has shown that the Group Lifestyle Balance (GLB) Program and other adaptations of the Diabetes Prevention Program (DPP) intervention are effective in lowering diabetes risk. Most DPP data originated from studies of pre-diabetic whites, with only sparse evidence of the effect of DPP in African Americans (AAs) in community settings. This paper describes the design, methods, baseline characteristics and cost effective measures, of a single-blinded, cluster-randomized trial of a faith-based adaptation of the GLB program, Fit Body and Soul (FBAS). The major aims are to test efficacy and cost utility of FBAS in twenty AA churches. Randomization occurred at the church level and 604 AA overweight/obese (BMI >= 25 kg/m(2)) adults with fasting plasma glucose range from normal to pre-diabetic received either FBAS or a health-education comparison program. FBAS is a group-based, multi-level intervention delivered by trained church health advisors (health professionals from within the church), with the goal of 7;% weight loss, achieved through increasing physical activity, healthy eating and behavior modification. The primary outcome is weight change at 12 weeks post intervention. Secondary outcomes include hemoglobin A1C, fasting plasma glucose, waist circumference, blood pressure, physical activity level, quality of life measures, and cost-effectiveness. FBAS is the largest known cohort of AAs enrolled in a faith-based DPP translation. Reliance on health professionals from within the church for program implementation and the cost analysis are unique aspects of this trial. The design provides a model for faith-based DPPs and holds promise for program sustainability and widespread dissemination. (C) 2013 Elsevier Inc. All rights reserved. C1 [Williams, Lovoria B.; Garvin, Jane T.; Marion, Lucy; Joshua, Thomas; Freeman, Arin] Georgia Regents Univ, Coll Nursing, Augusta, GA 30912 USA. [Sattin, Richard W.] Med Coll Georgia, Dept Emergency Med, Augusta, GA 30912 USA. [Dias, James] Med Coll Georgia, Dept Biostat & Epidemiol, Augusta, GA 30912 USA. [Kriska, Andrea; Kramer, M. Kaye] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Freeman, Arin] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Echouffo-Tcheugui, Justin B.; Narayan, K. M. Venkat] Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. RP Williams, LB (reprint author), Georgia Regents Univ, Coll Nursing, 987 St Sebastian Way,EC-4511, Augusta, GA 30912 USA. EM LWilliams@gru.edu; RSattin@gru.edu; JDias@gru.edu; BGarvin@gru.edu; LuMarion@gru.edu; TJoshua@gru.edu; KriskaA@edc.pitt.edu; Kramerk@edc.pitt.edu; jechouf@emory.edu; arinfreeman@gmail.com; KNaraya@emory.edu RI Narayan, K.M. Venkat /J-9819-2012; OI Narayan, K.M. Venkat /0000-0001-8621-5405; Garvin, Jane/0000-0001-6023-3269; Kriska, Andrea/0000-0002-3522-0869 FU National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [R18DK082401]; Diabetes Prevention Support Center of the University of Pittsburgh FX Funded by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, grant R18DK082401. The sponsor did not have a role in the design; collection, analysis, or interpretation of data; writing of the paper; or the decision to submit the paper for publication.; We are indebted to Jeannette Andrews, PhD, RN and the Georgia Health Sciences University Community Advisory Board for identifying the need for community-based research related to obesity and diabetes among AAs. We acknowledge the Diabetes Prevention Support Center of the University of Pittsburgh for the training and support in the Group Lifestyle Balance program; the FBAS program is a derivative of this material. We appreciate the support of the pastors, congregations, church health advisors, and GHSU volunteer data collectors for their role in project implementation. We also appreciate the pastors and CHAs who reviewed the manuscript prior to submission. We also acknowledge Ken Resnicow, PhD for the motivational-interviewing consultations and Sunita Dodani, MD, for her initial contributions to the study. We are also indebted to our research assistants Kamilah Freeman and Lauren Morris for their commitment to all aspects of the study implementation. NR 41 TC 16 Z9 16 U1 3 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2013 VL 34 IS 2 BP 336 EP 347 DI 10.1016/j.cct.2013.01.002 PG 12 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 120KL UT WOS:000317169100019 PM 23354313 ER PT J AU Li, W Cama, V Akinbo, FO Ganguly, S Kiulia, NM Zhang, XC Xiao, LH AF Li, Wei Cama, Vitaliano Akinbo, Frederick O. Ganguly, Sandipan Kiulia, Nicholas M. Zhang, Xichen Xiao, Lihua TI Multilocus sequence typing of Enterocytozoon bieneusi: Lack of geographic segregation and existence of genetically isolated sub-populations SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Enterocytozoon bieneusi; Population genetics; Population structure; Linkage disequilibrium; Gene diversity; Multi locus sequence typing ID HIV-INFECTED PATIENTS; CRYPTOSPORIDIUM-PARVUM; POPULATION; MICROSPORIDIOSIS; SELECTION; IDENTIFICATION; EPIDEMIOLOGY; MUTATIONS; GENOTYPES; ANIMALS AB The population structure of Enterocyrozoon bieneusi was examined by multilocus sequence typing (MLST) of 64 specimens from AIDS patients in Peru, Nigeria, and India and five specimens from captive baboons in Kenya using a combination of the ribosomal internal transcribed spacer (ITS) and four microsatellite and minisatellite markers. Parasites in different geographic locations (Peru, India, and Nigeria) all had strong and significant linkage disequilibrium (LD) and only limited recombination, indicative of a clonal population structure in E. bieneusi from each location. When isolates of various geographical areas were treated as a single population, phylogenetic analysis and substructural analysis using STRUCTURE found no evidence for the existence of geographically segregated sub-populations. Nevertheless, both analyses revealed the presence of two major genetically isolated groups of E. bieneusi: one (sub-population 1) contained all isolates of the anthroponotic ITS genotype A. whereas the other (sub-population 2) harbored isolates of multiple ITS genotypes with zoonotic potential. This was also supported by F-ST analysis. The measurement of LD and recombination rates indicated that sub-population 2 had a clonal population structure, whereas sub-population 1 had an epidemic population structure. The data confirmed the existence of genetic sub-populations in E. bieneusi that may be transmitted differently in humans. Published by Elsevier B.V. C1 [Li, Wei; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Li, Wei] Northeast Agr Univ, Coll Vet Med, Harbin 150030, Peoples R China. [Cama, Vitaliano] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Akinbo, Frederick O.] Univ Benin, Dept Med Lab Sci, Benin, Nigeria. [Ganguly, Sandipan] Natl Inst Cholera & Enter Dis, Div Parasitol, Kolkata 700010, W Bengal, India. [Kiulia, Nicholas M.] Inst Primate Res, Enter Viruses Res Grp, Nairobi 00502, Kenya. [Zhang, Xichen] Jilin Univ, Coll Anim Sci & Vet Med, Changchun 130062, Peoples R China. RP Xiao, LH (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Kiulia, Nicholas /B-8655-2015; OI Xiao, Lihua/0000-0001-8532-2727; Kiulia, Nicholas /0000-0001-8754-4227; Li, Wei/0000-0002-4264-1864 NR 41 TC 18 Z9 22 U1 1 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD MAR PY 2013 VL 14 BP 111 EP 119 DI 10.1016/j.meegid.2012.11.021 PG 9 WC Infectious Diseases SC Infectious Diseases GA 115WE UT WOS:000316841800016 PM 23262155 ER PT J AU Pavan, MG Mesquita, RD Lawrence, GG Lazoski, C Dotson, EM Abubucker, S Mitreva, M Randall-Maher, J Monteiro, FA AF Pavan, Marcio G. Mesquita, Rafael D. Lawrence, Gena G. Lazoski, Cristiano Dotson, Ellen M. Abubucker, Sahar Mitreva, Makedonka Randall-Maher, Jennifer Monteiro, Fernando A. TI A nuclear single-nucleotide polymorphism (SNP) potentially useful for the separation of Rhodnius prolixus from members of the Rhodnius robustus cryptic species complex (Hemiptera: Reduviidae) SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Rhodnius; Cryptic species; SNP; Nuclear DNA ID CHAGAS-DISEASE VECTORS; GENOME SIZE; TRIATOMINAE; PROTEIN; PHYLOGEOGRAPHY; ELIMINATION; PHYLOGENIES; SEQUENCES; FAMILIES; INSECT AB The design and application of rational strategies that rely on accurate species identification are pivotal for effective vector control. When morphological identification of the target vector species is impractical, the use of molecular markers is required. Here we describe a non-coding, single-copy nuclear DNA fragment that contains a single-nucleotide polymorphism (SNP) with the potential to distinguish the important domestic Chagas disease vector, Rhodnius prolixus, from members of the four sylvatic Rhodnius robustus cryptic species complex. A total of 96 primer pairs obtained from whole genome shotgun sequencing of the 12: prolixus genome (12,626 random reads) were tested on 43 R. prolixus and R. robustus s.l. samples. One of the seven amplicons selected (AmpG) presented a SNP, potentially diagnostic for R. prolixus, on the 280th site. The diagnostic nature of this SNP was then confirmed based on the analysis of 154 R. prolixus and R. robustus s.l. samples representing the widest possible geographic coverage. The results of a 60% majority-rule Bayesian consensus tree and a median-joining network constructed based on the genetic variability observed reveal the paraphyletic nature of the R. robustus species complex, with respect to R. prolixus. The AmpG region is located in the fourth intron of the Transmembrane protein 165 gene, which seems to be in the R. prolixus X chromosome. Other possible chromosomal locations of the AmpG region in the R. prolixus genome are also presented and discussed. (C) 2013 Elsevier B.V. All rights reserved. C1 [Pavan, Marcio G.; Monteiro, Fernando A.] Fiocruz MS, Inst Oswaldo Cruz, Lab Sistematicae Bioquim, BR-21045900 Rio De Janeiro, RJ, Brazil. [Mesquita, Rafael D.] Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, Lab Bioinformat, Rio De Janeiro, Brazil. [Lawrence, Gena G.; Dotson, Ellen M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA 30329 USA. [Lazoski, Cristiano] Univ Fed Rio de Janeiro, Inst Biol, Lab Biodiversidade Mol, Rio De Janeiro, Brazil. [Abubucker, Sahar; Mitreva, Makedonka; Randall-Maher, Jennifer] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA. RP Monteiro, FA (reprint author), Fiocruz MS, Inst Oswaldo Cruz, Lab Sistematicae Bioquim, Ave Brazil,4365,Pavilhao Arthur Neiva,Sala 21A-22, BR-21045900 Rio De Janeiro, RJ, Brazil. EM fam@ioc.fiocruz.br RI Lazoski, Cristiano/H-6192-2013; Pavan, Marcio/F-3270-2015 OI Pavan, Marcio/0000-0002-5699-242X FU Brazilian Research Council (CNPq); Brazilian Ministry of Science, Technology and Innovation (MCTI); NIH [U54 HG003079] FX This work was supported by the Brazilian Research Council (CNPq), the Brazilian Ministry of Science, Technology and Innovation (MCTI), and NIH Grant No. U54 HG003079. The sponsors did not take part nor influenced the any aspect of this study. NR 35 TC 5 Z9 5 U1 0 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD MAR PY 2013 VL 14 BP 426 EP 433 DI 10.1016/j.meegid.2012.10.018 PG 8 WC Infectious Diseases SC Infectious Diseases GA 115WE UT WOS:000316841800053 PM 23219914 ER PT J AU Bishnu, B Bhaduri, S Kumar, AMV Click, ES Chadha, VK Satyanarayana, S Nair, SA Gupta, D Ahmed, QT Sarkar, S Paul, D Dewan, P AF Bishnu, Bipra Bhaduri, Sudipto Kumar, Ajay M. V. Click, Eleanor S. Chadha, Vineet Kumar Satyanarayana, Srinath Nair, Sreenivas Achutan Gupta, Devesh Ahmed, Quazi T. Sarkar, Silajit Paul, Durba Dewan, Puneet TI What Are the Reasons for Poor Uptake of HIV Testing among Patients with TB in an Eastern India District? SO PLOS ONE LA English DT Article ID TUBERCULOSIS PATIENTS; MISSED OPPORTUNITIES; IMPLEMENTATION; UGANDA AB Background: National policy in India recommends HIV testing of all patients with TB. In West Bengal state, only 28% of patients with TB were tested for HIV between April-June, 2010. We conducted a cross-sectional survey to understand patient, provider and health system related factors associated with low uptake of HIV testing among patients with TB. Methods: We reviewed TB and HIV program records to assess the HIV testing status of patients registered for anti-TB treatment from July-September 2010 in South-24-Parganas district, West Bengal, assessed availability of HIV testing kits and interviewed a random sample of patients with TB and providers. Results: Among 1633 patients with TB with unknown HIV status at the time of diagnosis, 435 (26%) were tested for HIV within the intensive phase of TB treatment. Patients diagnosed with and treated for TB at facilities with co-located HIV testing services were more likely to get tested for HIV than at facilities without [RR = 1.27, (95% CI 1.20-3.35)]. Among 169 patients interviewed, 67 reported they were referred for HIV testing, among whom 47 were tested. During interviews, providers attributed the low proportion of patients with TB being referred and tested for HIV to inadequate knowledge among providers about the national policy, belief that patients will not test for HIV even if they are referred, shortage of HIV testing kits, and inadequate supervision by both programs. Discussion: In West Bengal, poor uptake of HIV testing among patients with TB was associated with absence of HIV testing services at sites providing TB care services and to poor referral practices among providers. Comprehensive strategies to change providers' beliefs and practices, decentralization of HIV testing to all TB care centers, and improved HIV test kit supply chain management may increase the proportion of patients with TB who are tested for HIV. C1 [Bishnu, Bipra; Nair, Sreenivas Achutan; Ahmed, Quazi T.; Sarkar, Silajit; Paul, Durba; Dewan, Puneet] WHO, Country Off, Off World Hlth Org WHO Representat India, New Delhi, India. [Bhaduri, Sudipto] Govt West Bengal, Minist Hlth & Family Welf, Dist TB Ctr, Kolkata, India. [Kumar, Ajay M. V.; Satyanarayana, Srinath] South East Asia Reg Off, Int Union TB & Lung Dis Union, New Delhi, India. [Click, Eleanor S.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Chadha, Vineet Kumar] Natl TB Inst, Bangalore, Karnataka, India. [Gupta, Devesh] Govt India, Minist Hlth & Family Welf, Directorate Gen Hlth Serv, Cent TB Div, New Delhi, India. RP Bishnu, B (reprint author), WHO, Country Off, Off World Hlth Org WHO Representat India, New Delhi, India. EM bsinha008@gmail.com FU Union from Global Fund Round 9 India TB Project funds; WHO-India from USAID funds FX Funding support was provided in part by the Union from Global Fund Round 9 India TB Project funds and the remaining part by WHO-India from USAID funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 5 Z9 5 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 1 PY 2013 VL 8 IS 3 AR e55229 DI 10.1371/journal.pone.0055229 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 103EI UT WOS:000315897100004 PM 23469163 ER PT J AU Tharp, AT Schumacher, JA Samper, RE McLeish, AC Coffey, SF AF Tharp, Andra Teten Schumacher, Julie A. Samper, Rita E. McLeish, Alison C. Coffey, Scott F. TI Relative Importance of Emotional Dysregulation, Hostility, and Impulsiveness in Predicting Intimate Partner Violence Perpetrated by Men in Alcohol Treatment SO PSYCHOLOGY OF WOMEN QUARTERLY LA English DT Article DE intimate partner violence; hostility; impulsiveness; emotional dysregulation; alcohol abuse ID CONFLICT-TACTICS-SCALES; SUBSTANCE USE DISORDER; RISK-FACTORS; MULTIPLE-REGRESSION; MARITAL AGGRESSION; DOMINANCE ANALYSIS; EARLY AGE; SAMPLE; ABUSE; VALIDATION AB The current study employs dominance analysis to assess the relative importance of three constructs-hostility, impulsiveness, and emotional dysregulation (difficulties managing one's emotions when experiencing negative emotion or distress)-in explaining psychological, physical, and sexual intimate partner violence (IPV) perpetration by men seeking alcohol treatment. A sample of 121 predominantly White, heterosexual men (average age 33.28, range = 18-62) enrolled in residential substance abuse treatment completed measures of emotional dysregulation, hostility, and impulsiveness, which are three highly related constructs identified as risk factors for both substance use disorders and IPV. The constructs collectively accounted for 20-25% of the variance in each form of IPV. Because impulsiveness, hostility, and emotional dysregulation are highly correlated, dominance analysis was used to examine which factor most strongly predicted each form of IPV. Dominance analysis findings favored hostility as a predictor of physical IPV perpetration and impulsiveness as a predictor of sexual and psychological IPV perpetration. Differential associations between the constructs and each form of IPV may be used to inform assessment and treatment planning of men who abuse alcohol. Better understanding, preventing, and treating male-to-female IPV will protect women from the far-reaching consequences of this violence. C1 [Tharp, Andra Teten] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Schumacher, Julie A.; Samper, Rita E.; Coffey, Scott F.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA. [McLeish, Alison C.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA. RP Tharp, AT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy MS F-64, Atlanta, GA 30341 USA. EM atharp@cdc.gov NR 50 TC 5 Z9 5 U1 2 U2 17 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0361-6843 EI 1471-6402 J9 PSYCHOL WOMEN QUART JI Psychol. Women Q. PD MAR PY 2013 VL 37 IS 1 BP 51 EP 60 DI 10.1177/0361684312461138 PG 10 WC Psychology, Multidisciplinary; Women's Studies SC Psychology; Women's Studies GA 119BC UT WOS:000317070700004 ER PT J AU Loustalot, F Carlson, SA Kruger, J Buchner, DM Fulton, JE AF Loustalot, Fleetwood Carlson, Susan A. Kruger, Judy Buchner, David M. Fulton, Janet E. TI Muscle-Strengthening Activities and Participation Among Adults in the United States SO RESEARCH QUARTERLY FOR EXERCISE AND SPORT LA English DT Article DE guidelines; physical activity; public health; strength training ID PHYSICAL-ACTIVITY; MUSCULAR STRENGTH; US ADULTS; PREVALENCE; DETERMINANTS; MEN AB Purpose: To describe those who reported meeting the 2008 Physical Activity Guidelines for Americans (2008 Guidelines) muscle-strengthening standard of 2 or more days per week, including all seven muscle groups, and to assess the type and location of muscle-strengthening activities performed. Method: Data from HealthStyles 2009, a cross-sectional, consumer mail-panel survey, was used for analyses (n = 4,271). The prevalence estimates with 95% confidence intervals of those meeting the 2008 Guidelines standards were calculated. Pairwise t-tests were performed to examine differences between estimates, tests for linear trends were performed among age, education, and body mass index (BMI) groups, and differences and trends were considered statistically significant at p < .05. Results: Overall, 6.0% of participants reported meeting 2008 Guidelines, and there were no significant differences between sex and racial/ethnic groups. A significant linear increase was noted among education groups, with respondents who reported lower levels of educational attainment having lower levels of participation compared with respondents who reported higher levels of educational attainment. A significant linear decrease was noted among each BMI group, with those classified as underweight/normal reporting higher levels of participation, compared with those classified as obese. Free weights and calisthenics were the most common types of activities; the home was the most common location. Conclusions: Few adults reported meeting current muscle-strengthening standards. Future public health efforts to increase participation should use the most frequently reported type and location of muscle-strengthening activities outlined in this study to guide interventions and communication campaigns. C1 [Loustalot, Fleetwood; Carlson, Susan A.; Kruger, Judy; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Buchner, David M.] Univ Illinois, Urbana, IL 61801 USA. RP Loustalot, F (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS F-72, Atlanta, GA 30341 USA. EM floustalot@cdc.gov NR 26 TC 14 Z9 14 U1 1 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0270-1367 J9 RES Q EXERCISE SPORT JI Res. Q. Exerc. Sport PD MAR PY 2013 VL 84 IS 1 BP 30 EP 38 DI 10.1080/02701367.2013.762289 PG 9 WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences SC Social Sciences - Other Topics; Psychology; Sport Sciences GA 120GV UT WOS:000317159700005 PM 23611006 ER PT J AU Ndze, VN Achidi, EA Papp, H Kovacs, E Farkas, S Adiogo, D Kisfali, P Ngeng, MB Abena, MTO Martella, V Esona, MD Banyai, K AF Ndze, Valentine Ngum Achidi, Eric Akum Papp, Hajnalka Kovacs, Eszter Farkas, Szilvia Adiogo, Dieudonne Kisfali, Peter Ngeng, Marxcel Bong Abena, Marie Therese Obama Martella, Vito Esona, Mathew Dioh Banyai, Krisztian TI SHARED G12 VP7 GENE AMONG HUMAN AND BOVINE ROTA VIRUSES DETECTED IN CAMEROONIAN VILLAGES SO ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA LA English DT Article DE enteric zoonosis; interspecies transmission; Cameroon ID GROUP-A ROTAVIRUS; GLOBAL SPREAD; UNITED-STATES; STRAINS; DIVERSITY; DIARRHEA; HUNGARY; SPECIFICITY; GENOTYPE; VACCINE AB Group A rotaviruses (RVA) are an important enteric pathogen in humans and livestock animals. Transmission of animal RVA strains to humans has been documented on several occasions. A reverse route of transmission of RVA under natural circumstances is anticipated, although evidence is scarce. However, experimental studies indicated that animals can be infected with human RVAs. By screening the stool samples collected from 157 cattle during 2011 in two Cameroonian villages, four samples (2.5%) were found positive for RVA. Upon sequence analysis of a 410 bp fragment of the VP7 gene, the RVA strains shared up to 100% nt identity to each other and to G12 RVAs identified in human patients living in the same geographic regions. This finding provides evidence for a human-to-animal transmission of an epidemic human rotavirus strain. C1 [Ndze, Valentine Ngum; Abena, Marie Therese Obama] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon. [Achidi, Eric Akum] Univ Buea, Fac Hlth Sci, Buea, Cameroon. [Papp, Hajnalka; Kovacs, Eszter; Farkas, Szilvia; Banyai, Krisztian] Hungarian Acad Sci, Inst Vet Med Res, H-1143 Budapest, Hungary. [Adiogo, Dieudonne] Univ Douala, Fac Med & Pharmaceut Sci, Douala, Cameroon. [Kisfali, Peter] Univ Pecs, Dept Med Genet & Child Dev, Pecs, Hungary. [Ngeng, Marxcel Bong] Reg Hosp Maroua, Med Diagnost Lab, Maroua, Cameroon. [Martella, Vito] Univ Aldo Moro Bari, Dipartimento Sanita Pubbl & Zootecnia, Bari, Italy. [Esona, Mathew Dioh] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Banyai, K (reprint author), Hungarian Acad Sci, Inst Vet Med Res, Hungaria Krt 21, H-1143 Budapest, Hungary. EM bkrota@hotmail.com RI Martella, Vito/K-3146-2016; OI Martella, Vito/0000-0002-5740-6947; Banyai, Krisztian/0000-0002-6270-1772 FU Janos Bolyai Research Scholarship; Hungarian Academy of Sciences (Momentum program) [OTKA-PD76364, OTKA-K100727] FX We acknowledge the technical assistance of Anett Horvath at the Pathogen Discovery unit, Institute for Veterinary Medical Research, Budapest, Hungary. We also acknowledge our colleagues in Cameroon for helping in sample collection (Tang Wilfred and Zang Magdaleine at the Esu Intergreted Health Center, Ngu Felix at the Regional Hospital, Bamenda, and Dr Konyuy Emmanuel at the ELBA, range Esu). S.L.F. was supported by the Janos Bolyai Research Scholarship. K.B. was supported by the Hungarian Academy of Sciences (Momentum program, OTKA-PD76364, OTKA-K100727). NR 34 TC 3 Z9 4 U1 0 U2 5 PU AKADEMIAI KIADO RT PI BUDAPEST PA PRIELLE K U 19, PO BOX 245,, H-1117 BUDAPEST, HUNGARY SN 1217-8950 J9 ACTA MICROBIOL IMM H JI Acta Microbiol. Immunol. Hung. PD MAR PY 2013 VL 60 IS 1 BP 21 EP 28 DI 10.1556/AMicr.60.2013.1.3 PG 8 WC Immunology; Microbiology SC Immunology; Microbiology GA 112UZ UT WOS:000316620900003 PM 23529296 ER PT J AU Schiffer, JM Maniatis, P Garza, I Steward-Clark, E Korman, LT Pittman, PR Mei, JV Quinn, CP AF Schiffer, Jarad M. Maniatis, Panagiotis Garza, Ilana Steward-Clark, Evelene Korman, Lawrence T. Pittman, Phillip R. Mei, Joanne V. Quinn, Conrad P. TI Quantitative assessment of anthrax vaccine immunogenicity using the dried blood spot matrix SO BIOLOGICALS LA English DT Article DE Anthrax; Emergency response; Enzyme-linked immunosorbent assay; Dried blood spots; Protective antigen; Assay validation ID LINKED-IMMUNOSORBENT-ASSAY; IMMUNOGLOBULIN-G; ANTIBODIES AB The collection, processing and transportation to a testing laboratory of large numbers of clinical samples during an emergency response situation present significant cost and logistical issues. Blood and serum are common clinical samples for diagnosis of disease. Serum preparation requires significant on-site equipment and facilities for immediate processing and cold storage, and significant costs for cold-chain transport to testing facilities. The dried blood spot (DBS) matrix offers an alternative to serum for rapid and efficient sample collection with fewer on-site equipment requirements and considerably lower storage and transport costs. We have developed and validated assay methods for using DBS in the quantitative anti-protective antigen IgG enzyme-linked immunosorbent asay (ELISA), one of the primary assays for assessing immunogenicity of anthrax vaccine and for confirmatory diagnosis of Bacillus anthracis infection in humans. We have also developed and validated high-throughput data analysis software to facilitate data handling for large clinical trials and emergency response. Published by Elsevier Ltd on behalf of The International Alliance for Biological Standardization. C1 [Schiffer, Jarad M.; Steward-Clark, Evelene; Mei, Joanne V.; Quinn, Conrad P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Maniatis, Panagiotis; Garza, Ilana] Logist Hlth Inc, La Crosse, WI 54601 USA. [Korman, Lawrence T.; Pittman, Phillip R.] USA, Med Res Inst Infect Dis, Ft Detrick, MD USA. RP Schiffer, JM (reprint author), Ctr Dis Control & Prevent, Microbial Pathogenesis & Immune Response Lab, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis,Natl Ctr Immunizat & Resp Dis, Mail Stop D-01,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jschiffer@cdc.gov FU Centers for Disease Control and Prevention, Office for Public Health Preparedness and Response FX This publication was supported by funds made available from the Centers for Disease Control and Prevention, Office for Public Health Preparedness and Response. NR 19 TC 0 Z9 0 U1 0 U2 9 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1045-1056 J9 BIOLOGICALS JI Biologicals PD MAR PY 2013 VL 41 IS 2 BP 98 EP 103 DI 10.1016/j.biologicals.2012.11.003 PG 6 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 115WX UT WOS:000316843700007 PM 23266055 ER PT J AU Makelarski, JA Romitti, PA Sun, LX Burns, TL Druschel, CM Suarez, L Olshan, AF Siega-Riz, AM Olney, RS AF Makelarski, Jennifer A. Romitti, Paul A. Sun, Lixian Burns, Trudy L. Druschel, Charlotte M. Suarez, Lucina Olshan, Andrew F. Siega-Riz, Anna Maria Olney, Richard S. CA Natl Birth Defects Prevention TI Periconceptional maternal alcohol consumption and neural tube defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE alcohol; birth defects; neural tube defects; pregnancy ID FOOD FREQUENCY QUESTIONNAIRE; BIRTH-DEFECTS; CONGENITAL-ANOMALIES; BINGE DRINKING; PLASMA FOLATE; SPINA-BIFIDA; ETHANOL; RISK; PREVENTION; PREGNANCY AB BACKGROUND: Neural tube defects (NTD)s, which occur when the neural tube fails to close during early gestation, are some of the most common birth defects worldwide. Alcohol is a known teratogen and has been shown to induce NTDs in animal studies, although most human studies have failed to corroborate these results. Using data from the National Birth Defects Prevention Study, associations between maternal reports of periconceptional (1 month prior through 2 months postconception) alcohol consumption and NTDs were examined. METHODS: NTD cases and unaffected live born control infants, delivered from 1997 through 2005, were included. Interview reports of alcohol consumption (quantity, frequency, variability, and type) were obtained from 1223 case mothers and 6807 control mothers. Adjusted odds ratios (aOR)s and 95% confidence intervals were estimated using multivariable logistic regression analysis. RESULTS: For all NTDs combined, most aORs for any alcohol consumption, one or more binge episodes, and different type(s) of alcohol consumed were near unity or modestly reduced (0.7= 14 years of age, who reported lymphedema lasting more than three months in one or both legs, were recruited from villages in the Bolagarh sub-district, Khurda District, Orissa, India. The World Health Organization Disability Assessment Schedule II was administered to participants at baseline (July, 2009), and then at regular intervals through 24 months (July, 2011), to assess patients' perceived disability. Disability scores decreased significantly (p<0.0001) from baseline to 24 months. Multivariable analysis using mixed effects modeling found that employment and time in the program were significantly associated with lower disability scores after two years of program involvement. Older age, female gender, the presence of other chronic health conditions, moderate (Stage 3) or advanced (Stage 4-7) lymphedema, reporting an adenolymphangitis (ADL) episode during the previous 30 days, and the presence of inter-digital lesions were associated with higher disability scores. Patients with moderate or advanced lymphedema experienced greater improvements in perceived disability over time. Patients participating in the program for at least 12 months also reported losing 2.5 fewer work days per month (p<0.001) due to their lymphedema, compared to baseline. Significance: These results indicate that community-based lymphedema management programs can reduce disability and prevent days of work lost. These effects were sustained over a 24 month period. C1 [Budge, Philip J.; Kennedy, Erin D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Budge, Philip J.; Little, Kristen M.; Mues, Katherine E.; Fox, LeAnne M.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Mues, Katherine E.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Prakash, Aiysha; Rout, Jonathan] Churchs Auxiliary Social Act, East Zone, Kolkata, India. RP Budge, PJ (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM Philip.budge@vanderbilt.edu FU USAID [OGH99-005]; Agency for Healthcare Research and Quality [T32 HS013833]; Orissa Ministry of Health and Family Welfare FX Funding for this work came from USAID Grant No. OGH99-005 (http://www.usaid.gov). PJB was supported in part by the Agency for Healthcare Research and Quality T32 HS013833 (http://www.ahrq.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We are grateful to the lymphedema patients of Khurda District, Bolargarh Block, without whom this work could not be accomplished. We gratefully acknowledge the assistance of the CASA staff in Bhubaneswar including Soumendra Dhir, Grace Rao, Rajdeep Puri, Saroj Behera, Kuber Behera, and the CASA staff in New Delhi including Mr. Aloke Michyari and Mr. Sushant Agrawal, CASA Director. We also thank Dr. David Addiss of Children Without Worms, Dr. Michael Deming and Anna Blackstock of CDC, and Ann Varghese, Erika Pearl, Dr. Sarla Chand, Paul Derstine and Rick Santos of IMA World Health. We also acknowledge the cooperation and support of the Orissa Ministry of Health and Family Welfare. NR 24 TC 6 Z9 6 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2013 VL 7 IS 3 AR e2100 DI 10.1371/journal.pntd.0002100 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 117HI UT WOS:000316943800020 PM 23516648 ER PT J AU Schirmer, PL Lucero-Obusan, CA Benoit, SR Santiago, LM Stanek, D Dey, A Martinez, M Oda, G Holodniy, M AF Schirmer, Patricia L. Lucero-Obusan, Cynthia A. Benoit, Stephen R. Santiago, Luis M. Stanek, Danielle Dey, Achintya Martinez, Mirsonia Oda, Gina Holodniy, Mark TI Dengue Surveillance in Veterans Affairs Healthcare Facilities, 2007-2010 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID KEY-WEST; FEVER; FLORIDA AB Background: Although dengue is endemic in Puerto Rico (PR), 2007 and 2010 were recognized as epidemic years. In the continental United States (US), outside of the Texas-Mexico border, there had not been a dengue outbreak since 1946 until dengue re-emerged in Key West, Florida (FL), in 2009-2010. The objective of this study was to use electronic and manual surveillance systems to identify dengue cases in Veterans Affairs (VA) healthcare facilities and then to clinically compare dengue cases in Veterans presenting for care in PR and in FL. Methodology: Outpatient encounters from 1/2007-12/2010 and inpatient admissions (only available from 10/2009-12/2010) with dengue diagnostic codes at all VA facilities were identified using VA's Electronic Surveillance System for Early Notification of Community-based Epidemics (ESSENCE). Additional case sources included VA data from Centers for Disease Control and Prevention BioSense and VA infection preventionists. Case reviews were performed. Categorical data was compared using Mantel-Haenszel or Fisher Exact tests and continuous variables using t-tests. Dengue case residence was mapped. Findings: Two hundred eighty-eight and 21 PR and FL dengue cases respectively were identified. Of 21 FL cases, 12 were exposed in Key West and 9 were imported. During epidemic years, FL cases had significantly increased dengue testing and intensive care admissions, but lower hospitalization rates and headache or eye pain symptoms compared to PR cases. There were no significant differences in clinical symptoms, laboratory abnormalities or outcomes between epidemic and non-epidemic year cases in FL and PR. Confirmed/probable cases were significantly more likely to be hospitalized and have thrombocytopenia or leukopenia compared to suspected cases. Conclusions: Dengue re-introduction in the continental US warrants increased dengue surveillance and education in VA. Throughout VA, under-testing of suspected cases highlights the need to emphasize use of diagnostic testing to better understand the magnitude of dengue among Veterans. C1 [Schirmer, Patricia L.; Lucero-Obusan, Cynthia A.; Oda, Gina; Holodniy, Mark] Off Publ Hlth, Dept Vet Affairs, Palo Alto, CA 94303 USA. [Benoit, Stephen R.; Dey, Achintya] Ctr Dis Control & Prevent, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Santiago, Luis M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA. [Stanek, Danielle] Florida Dept Hlth, Bur Environm Publ Hlth Med, Tallahassee, FL USA. [Martinez, Mirsonia] Vet Affairs Caribbean Healthcare Syst San Juan, Dept Vet Affairs, San Juan, PR USA. [Holodniy, Mark] Stanford Univ, Div Infect Dis & Geog Med, Palo Alto, CA 94304 USA. RP Schirmer, PL (reprint author), Off Publ Hlth, Dept Vet Affairs, Palo Alto, CA 94303 USA. EM Patricia.Schirmer@va.gov FU VA FX This study was supported by VA intramural funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 18 TC 0 Z9 1 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2013 VL 7 IS 3 AR e2040 DI 10.1371/journal.pntd.0002040 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 117HI UT WOS:000316943800005 PM 23516642 ER PT J AU Wisnewski, AV Mhike, M Hettick, JM Liu, J Siegel, PD AF Wisnewski, Adam V. Mhike, Morgen Hettick, Justin M. Liu, Jian Siegel, Paul D. TI Hexamethylene diisocyanate (HDI) vapor reactivity with glutathione and subsequent transfer to human albumin SO TOXICOLOGY IN VITRO LA English DT Article DE Hexamethylene diisocyanate (HDI); Vapor; Aliphatic; Albumin; Carbamoylation; Glutathione (GSH) ID BRONCHIAL EPITHELIAL-CELLS; TOLUENE DIISOCYANATE; OXIDATIVE STRESS; CYSTIC-FIBROSIS; DIPHENYLMETHANE DIISOCYANATE; BRONCHOALVEOLAR LAVAGE; INHALATION TOXICITY; HUMAN LUNG; IN-VITRO; ASTHMA AB Introduction: Airway fluid glutathione (GSH) reactivity with inhaled vapors of diisocyanate, a common occupational allergen, is postulated to be a key step in exposure-induced asthma pathogenesis. Methods: A mixed (vapor/liquid) phase exposure system was used to model the in vivo reactivity of inhaled HDI vapor with GSH in the airway fluid. HDI-GSH reaction products, and their capacity to transfer HDI to human albumin, were characterized through mass spectrometry and serologic assays, using HDI-specific polyclonal rabbit serum. Results: HDI vapor exposure of 10 mM GSH solutions resulted in primarily S-linked, bis(GSH)-HDI reaction products. In contrast, lower GSH concentrations (100 mu M) resulted in mainly mono(GSH)-HDI conjugates, with varying degrees of HDI hydrolysis, dimerization and/or intra-molecular cyclization, depending upon the presence/absence of H2PO4-/HPO42- and Na+/Cl- ions. The ion composition and GSH concentration of the fluid phase, during HDI vapor exposure, strongly influenced the transfer of HDI from GSH to albumin, as did the pH and duration of the carbamoylating reaction. When carbamoylation was performed overnight at pH 7, 25 of albumin's lysines were identified as potential sites of conjugation with partially hydrolyzed HDI. When carbamoylation was performed at pH 9, more rapid (within 3 h) and extensive modification was observed, including additional lysine sites, intra-molecular cross-linkage with HDI, and novel HDI-GSH conjugation. Conclusions: The data define potential mechanisms by which the levels of GSH, H2PO4-/HPO42-, and/or other ions (e.g. H+/OH-, Na+, Cl-) affect the reactivity of HDI vapor with self-molecules in solution (e.g. airway fluid), and thus, might influence the clinical response to HDI respiratory tract exposure. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Wisnewski, Adam V.; Liu, Jian] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. [Mhike, Morgen; Hettick, Justin M.; Siegel, Paul D.] NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Morgantown, WV USA. RP Wisnewski, AV (reprint author), Yale Univ, Sch Med, 300 Cedar St,TAC-S4157,POB 208057, New Haven, CT 06520 USA. EM adam.wisnewski@yale.edu RI Hettick, Justin/E-9955-2010 FU National Institute of Environmental Health Sciences [ES016728, ES018021] FX The studies were supported by Grants ES016728 and ES018021 from the National Institute of Environmental Health Sciences. NR 47 TC 8 Z9 8 U1 0 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-2333 J9 TOXICOL IN VITRO JI Toxicol. Vitro PD MAR PY 2013 VL 27 IS 2 BP 662 EP 671 DI 10.1016/j.tiv.2012.11.013 PG 10 WC Toxicology SC Toxicology GA 113CC UT WOS:000316642800016 PM 23178851 ER PT J AU Te, HS Drobeniuc, J Kamili, S Dong, C Hart, J Sharapov, UM AF Te, H. S. Drobeniuc, J. Kamili, S. Dong, C. Hart, J. Sharapov, U. M. TI Hepatitis E Virus Infection in a Liver Transplant Recipient in the United States: A Case Report SO TRANSPLANTATION PROCEEDINGS LA English DT Article ID KIDNEY-TRANSPLANT; RIBAVIRIN; EPIDEMIOLOGY; CIRRHOSIS AB Background. Chronic infection with hepatitis E virus (REV) has recently been recognized in immunocompromised or immunosuppressed individuals. Case Report. We report a case of concurrent REV and human herpes virus-6 (HHV-6) infection, documented by serum HEV RNA and HHV-6 DNA, in an orthotopic liver transplant (OLT) recipient in the United States, where HEV genotype 3 infection, although prevalent, is considered to be self-limited and almost always asymptomatic. The coinfection was accompanied by elevated serum aminotransaminases, liver biopsies demonstrating chronic hepatitis, and the presence of REV RNA in the tissue. After lowering of immunosuppressive therapy and 2 courses of valganciclovir, sequential clearance of the viruses and normalization of the serum aminotransaminases were observed. Conclusions. REV infection can lead to chronic hepatitis in OLT recipients, and evaluation of this virus should be considered in immunosuppressed individuals with unexplained liver test abnormalities. C1 [Te, H. S.] Univ Chicago Med, Dept Med, Ctr Liver Dis, Chicago, IL USA. [Drobeniuc, J.; Kamili, S.; Dong, C.; Sharapov, U. M.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Hart, J.] Univ Chicago Med, Dept Pathol, Chicago, IL USA. RP Te, HS (reprint author), 5841 S MarylandAve,MC 7120, Chicago, IL 60637 USA. EM hte@medicine.bsd.uchicago.edu NR 20 TC 13 Z9 13 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0041-1345 J9 TRANSPL P JI Transplant. Proc. PD MAR PY 2013 VL 45 IS 2 BP 810 EP 813 DI 10.1016/j.transproceed.2012.08.020 PG 4 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 114WA UT WOS:000316772500061 PM 23498824 ER PT J AU Mutapi, F Billingsley, PF Secor, WE AF Mutapi, Francisca Billingsley, Peter F. Secor, W. Evan TI Infection and treatment immunizations for successful parasite vaccines SO TRENDS IN PARASITOLOGY LA English DT Review DE immunization; treatment; vaccine; malaria; schistosomiasis; parasite ID SCHISTOSOMA-HAEMATOBIUM INFECTION; REGULATORY T-CELLS; PLASMODIUM-FALCIPARUM MALARIA; IMMUNE-RESPONSE; ANTIBODY-RESPONSES; ECHINOCOCCUS-GRANULOSUS; SPOROZOITE INOCULATION; VETERINARY VACCINES; PROTECTIVE IMMUNITY; HELMINTH-PARASITES AB Since the advent of techniques for the expression of recombinant peptide antigens, the availability of human vaccines for parasitic diseases has been 'imminent'. Yet vaccines based on recombinant proteins are still largely aspirations, not realities. It is now apparent that vaccine development needs additional knowledge about host protective immune response(s), antigen characteristics, and the delivery required to induce those responses. The most successful immune protection against parasites has been generated by infection and treatment, the induction of protective immunity by truncating the course of an infection with drug treatment. Here, we consider the characteristics of an effective, protective anti-parasite vaccine and propose a conceptual framework to aid parasite vaccine development using malaria and schistosomiasis as examples. C1 [Mutapi, Francisca] Univ Edinburgh, Sch Biol Sci, Ctr Immun Infect & Evolut, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland. [Billingsley, Peter F.] Sanaria Inc, Rockville, MD 20850 USA. [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. RP Mutapi, F (reprint author), Univ Edinburgh, Sch Biol Sci, Ctr Immun Infect & Evolut, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland. EM fmutapi@staffmail.ed.ac.uk; wsecor@cdc.gov FU World Health Organisation; Wellcome Trust [WT082028MA]; Thrasher Foundation FX We thanks Drs. S. Chakravarty and S.L. Hoffman for critical reading of the manuscript during its preparation. FM acknowledges support from the World Health Organisation (www.who.org); the Wellcome Trust (http://www.wellcome.ac.uk/) [grant number WT082028MA] and the Thrasher Foundation (http://www.thrasherresearch.org/). NR 90 TC 14 Z9 16 U1 1 U2 34 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4922 J9 TRENDS PARASITOL JI Trends Parasitol. PD MAR PY 2013 VL 29 IS 3 BP 135 EP 141 DI 10.1016/j.pt.2013.01.003 PG 7 WC Parasitology SC Parasitology GA 114BP UT WOS:000316715300006 PM 23415733 ER PT J AU Flannery, B Samad, S de Moraes, JC Tate, JE Danovaro-Holliday, MC de Oliveira, LH Rainey, JJ AF Flannery, Brendan Samad, Samia de Moraes, Jose Cassio Tate, Jacqueline E. Danovaro-Holliday, M. Carolina de Oliveira, Lucia Helena Rainey, Jeanette J. TI Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program SO VACCINE LA English DT Article DE Rotavirus; Rotavirus vaccine; Immunization coverage; Immunization timing ID INTUSSUSCEPTION; MORTALITY; DIARRHEA; CHILDREN; MEXICO AB Introduction: In March, 2006, oral rotavirus vaccine was added to Brazil's infant immunization schedule with recommended upper age limits for initiating (by age 14 weeks) and completing (by age 24 weeks) the two-dose series to minimize age-specific risk of intussusception following rotavirus vaccination. Several years after introduction, estimated coverage with rotavirus vaccine (83%) was lower compared to coverage for other recommended childhood immunizations (>= 94%). Methods: We analyzed data from Brazil's national immunization program on uptake of oral rotavirus vaccine by geographic region and compared administrative coverage estimates for first and second doses of oral rotavirus vaccine (Rota1 and Rota2) with first and second doses of diphtheria-tetanus-pertussis-Haemophilus influenzae type b vaccine (DTP-Hib1 and DTP-Hib2). For 27 Brazilian cities, we compared differences between estimated rotavirus and DTP-Hib coverage in 2010 with delayed receipt of DTP-Hib vaccine among a cohort of children surveyed before rotavirus introduction. Results: In 2010, infant vaccination coverage was 99.0% for DTP-Hib1 versus 95.2% for Rota1 (3.8% difference), and 98.4% for DTP-Hib2 versus 83.0% for Rota2 (15.4% difference), with substantial regional variation. Differences between DTP-Hib and rotavirus vaccination coverage in Brazilian cities correlated with delay in DTP-Hib vaccination among children surveyed. Age restrictions for initiating and completing the rotavirus vaccination series likely contributed to lower coverage with rotavirus vaccine in Brazil. Conclusion: To maximize benefits of rotavirus vaccination, strategies are needed to improve timeliness of routine immunizations; monitoring rotavirus vaccine uptake and intussusception risk is needed to guide further recommendations for rotavirus vaccination. Published by Elsevier Ltd. C1 [Flannery, Brendan; Tate, Jacqueline E.; Rainey, Jeanette J.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Samad, Samia] Minist Hlth, Secretariat Hlth Surveillance, Natl Immunizat Program, Brasilia, DF, Brazil. [de Moraes, Jose Cassio] Sch Med Sci Santa Casa, Sao Paulo, Brazil. [Danovaro-Holliday, M. Carolina; de Oliveira, Lucia Helena] Pan Amer Hlth Org, Washington, DC USA. RP Flannery, B (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-04, Atlanta, GA 30333 USA. EM bflannery@cdc.gov FU Brazilian Ministry of Health FX The vaccination coverage survey was wholly financed by the Brazilian Ministry of Health. NR 24 TC 12 Z9 12 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAR 1 PY 2013 VL 31 IS 11 BP 1523 EP 1528 DI 10.1016/j.vaccine.2013.01.004 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 111MT UT WOS:000316526100011 PM 23313652 ER PT J AU Gaur, AH Cohen, RA Read, JS Hance, LF Dominguez, K Alarcon, JO Menezes, J Peixoto, MF Mussi-Pinhata, MM Coelho, DF Mitchell, C Siberry, GK AF Gaur, Aditya H. Cohen, Rachel A. Read, Jennifer S. Hance, Laura Freimanis Dominguez, Kenneth Alarcon, Jorge O. Menezes, Jacqueline Peixoto, Mario F. Mussi-Pinhata, Marisa M. Coelho, Debora F. Mitchell, Charles Siberry, George K. TI Prechewing and Prewarming Food for HIV-Exposed Children: A Prospective Cohort Experience from Latin America SO AIDS PATIENT CARE AND STDS LA English DT Editorial Material ID PREMASTICATION; TRANSMISSION; INFANTS; PROMOTE; HEALTH C1 [Gaur, Aditya H.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA. [Cohen, Rachel A.; Hance, Laura Freimanis] Westat Corp, Rockville, MD USA. [Read, Jennifer S.; Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, DHHS, Bethesda, MD USA. [Dominguez, Kenneth] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Alarcon, Jorge O.] Univ San Marcos, Inst Med Trop Daniel Alcides Carrion, Seccion Epidemiol, Lima, Peru. [Menezes, Jacqueline] Hosp Fed Servidores Estado, Rio De Janeiro, Brazil. [Peixoto, Mario F.] Hosp Femina, Unidade Prevencao Transmissao Vertical, Porto Alegre, RS, Brazil. [Mussi-Pinhata, Marisa M.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil. [Coelho, Debora F.] Santa Casa Misericordia Porto Alegre, Ctr Pesquisa Maternoinfantil Irmandade, Porto Alegre, RS, Brazil. [Mitchell, Charles] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA. RP Gaur, AH (reprint author), St Jude Childrens Res Hosp, Dept Infect Dis, MS 600,262 Danny Thomas Pl, Memphis, TN 38105 USA. EM aditya.gaur@stjude.org OI Alarcon, Jorge/0000-0002-0800-2380 FU NICHD NIH HHS [N01-HD-8-0001, N01-HD-3-3345]; PHS HHS [HHSN267200800001C] NR 11 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD MAR PY 2013 VL 27 IS 3 BP 142 EP 145 DI 10.1089/apc.2012.0459 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 105EK UT WOS:000316048200002 PM 23477456 ER PT J AU Turbyville, JC Dunford, JC Nelson, MR AF Turbyville, Joseph C. Dunford, James C. Nelson, Michael R. TI Hymenoptera of Afghanistan and the central command area of operations: Assessing the threat to deployed US service members with insect venom hypersensitivity SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article; Proceedings Paper CT Annual Scientific Meeting of the American-College-of-Allergy-Asthma-and-Immunology CY NOV 06, 2011 CL Boston, MA SP Amer Coll Allergy, Asthma & Immunol ID HIMALAYAN REGIONS; STING CHALLENGE; FORMICIDAE; VESPIDAE; VESPINAE; RECORDS; ANTS; IRAN AB Insect venom hypersensitivity can pose a threat to personnel deployed to a combat zone but the exposure risk in Afghanistan is currently unknown. This study was designed to assess the threat of Hymenoptera stings and associated allergic reactions in Afghanistan. Hymenoptera species were collected during a deployment to southern Afghanistan from June 2010 through January 2011. The literature was also reviewed to determine species of medically important Hymenoptera recorded in the region. The U.S. Army theater electronic medical data system was mined for ICD-9 codes associated with insect stings to determine the number of theater medical clinic encounters addressing insect sting reactions. Three species of flying hymenoptera were commonly encountered during the study period: Vespa orientalis L., Polistes wattii Cameron, and Vespula germanica (F.). A literature review also confirms the presence of honeybees (Apidae), numerous velvet ant (Mutillidae) species, and various ant (Formicidae) species all capable of stinging. No evidence was identified to suggest that fire ants (Solenopsis ssp.) are a threat in the region. Based on electronic medical records from the U.S. Central Command area of operations over a 2-year period, roughly 1 in 500 clinic visits involved a patient with a diagnosis of insect bite or sting. Cross-reactive members of all five flying Hymenoptera species commonly assessed for in Hymenoptera allergy evaluations are present in Afghanistan. The review of in-theater medical records confirms that insect stings pose an environmental threat to deployed service members. (Allergy Asthma Proc 34:179-184, 2013; doi: 10.2500/aap.2013.34.3638) C1 [Turbyville, Joseph C.] Ireland Army Community Hosp, Dept Allergy Immunol, Ft Knox, KY 40121 USA. [Dunford, James C.] Ctr Dis Control & Prevent, Navy & Marine Corps Publ Hlth Ctr Detachment, Atlanta, GA USA. [Nelson, Michael R.] Walter Reed Natl Mil Med Ctr, Washington, DC USA. RP Turbyville, JC (reprint author), Ireland Army Community Hosp, Dept Allergy Immunol, 851 Ireland Loop, Ft Knox, KY 40121 USA. EM jturbyville@familyallergy.com NR 27 TC 2 Z9 3 U1 0 U2 8 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD MAR-APR PY 2013 VL 34 IS 2 BP 179 EP 184 DI 10.2500/aap.2013.34.3638 PG 6 WC Allergy SC Allergy GA 107SE UT WOS:000316240300011 PM 23484895 ER PT J AU Upreti, SR Janusz, KB Schluter, WW Bichha, RP Shakya, G Biggerstaff, BJ Shrestha, MM Sedai, TR Fischer, M Gibbons, RV Shrestha, SK Hills, SL AF Upreti, Shyam Raj Janusz, Kristen B. Schluter, W. William Bichha, Ram Padarath Shakya, Geeta Biggerstaff, Brad J. Shrestha, Murari Man Sedai, Tika Ram Fischer, Marc Gibbons, Robert V. Shrestha, Sanjaya K. Hills, Susan L. TI Estimation of the Impact of a Japanese Encephalitis Immunization Program with Live, Attenuated SA 14-14-2 Vaccine in Nepal SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID KATHMANDU; VIRUS AB Wider availability of the live, attenuated SA 14-14-2 Japanese encephalitis (JE) vaccine has facilitated introduction or expansion of immunization programs in many countries. However, information on their impact is limited. In 2006, Nepal launched a JE immunization program, and by 2009, mass campaigns had been implemented in 23 districts. To describe the impact, we analyzed surveillance data from 2004 to 2009 on laboratory-confirmed JE and clinical acute encephalitis syndrome (AES) cases. The post-campaign JE incidence rate of 1.3 per 100,000 population was 72% lower than expected if no campaigns had occurred, and an estimated 891 JE cases were prevented. In addition, AES incidence was 58% lower, with an estimated 2,787 AES cases prevented, suggesting that three times as many disease cases may have been prevented than indicated by the laboratory-confirmed JE cases alone. These results provide useful information on preventable JE disease burden and the potential value of JE immunization programs. C1 [Upreti, Shyam Raj] Minist Hlth & Populat, Child Hlth Div, Kathmandu, Nepal. [Janusz, Kristen B.; Fischer, Marc; Hills, Susan L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO 80521 USA. [Schluter, W. William; Shrestha, Murari Man; Sedai, Tika Ram] WHO, Programme Immunizat Preventable Dis, Kathmandu, Nepal. [Bichha, Ram Padarath] Kanti Childrens Hosp, Kathmandu, Nepal. [Shakya, Geeta] Natl Publ Hlth Lab, Kathmandu, Nepal. [Biggerstaff, Brad J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Off Director, Ft Collins, CO 80521 USA. [Gibbons, Robert V.] Armed Forces Res Inst Med Sci, US Army Med Component, Bangkok 10400, Thailand. RP Hills, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Arboviral Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM drshyam@hotmail.com; kbjanusz@aol.com; schluterw@wpro.who.int; drrpbichha@gmail.com; geetanphl@yahoo.com; bbiggerstaff@cdc.gov; Shresthamu@searo.who.int; Sedait@searo.who.int; mfischer@cdc.gov; Robert.Gibbons@afrims.org; shresthask@afrims.org; shills@cdc.gov FU Bill & Melinda Gates Foundation through the US Centers for Disease Control and Prevention FX The Bill & Melinda Gates Foundation provided financial support for this evaluation through a grant to the US Centers for Disease Control and Prevention. NR 20 TC 11 Z9 11 U1 0 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAR PY 2013 VL 88 IS 3 BP 464 EP 468 DI 10.4269/ajtmh.12-0196 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 106QC UT WOS:000316158800012 PM 23358643 ER PT J AU Lorenzi, OD Gregory, CJ Santiago, LM Acosta, H Galarza, IE Hunsperger, E Munoz, J Bui, DM Oberste, MS Penaranda, S Garcia-Gubern, C Tomashek, KM AF Lorenzi, Olga D. Gregory, Christopher J. Santiago, Luis Manuel Acosta, Hector Galarza, Ivonne E. Hunsperger, Elizabeth Munoz, Jorge Bui, Duy M. Oberste, M. Steven Penaranda, Silvia Garcia-Gubern, Carlos Tomashek, Kay M. CA St Luke's Acute Febrile Illness In TI Acute Febrile Illness Surveillance in a Tertiary Hospital Emergency Department: Comparison of Influenza and Dengue Virus Infections SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID BLOOD-STREAM INFECTIONS; PUERTO-RICO; CLINICAL SPECIMENS; DIAGNOSIS; ADULTS; PCR; ENTEROVIRUSES; SEROTYPES; ETIOLOGY; UTILITY AB In 2009, an increased proportion of suspected dengue cases reported to the surveillance system in Puerto Rico were laboratory negative. As a result, enhanced acute febrile illness (AFI) surveillance was initiated in a tertiary care hospital. Patients with fever of unknown origin for 2-7 days duration were tested for Leptospira, enteroviruses, influenza, and dengue virus. Among the 284 enrolled patients, 31 dengue, 136 influenza, and 3 enterovirus cases were confirmed. Nearly half (48%) of the confirmed dengue cases met clinical criteria for influenza. Dengue patients were more likely than influenza patients to have hemorrhage (81% versus 26%), rash (39% versus 9%), and a positive tourniquet test (52% versus 18%). Mean platelet and white blood cell count were lower among dengue patients. Clinical diagnosis can be particularly difficult when outbreaks of other AFI occur during dengue season. A complete blood count and tourniquet test may be useful to differentiate dengue from other AFIs. C1 [Lorenzi, Olga D.; Gregory, Christopher J.; Santiago, Luis Manuel; Hunsperger, Elizabeth; Munoz, Jorge; Tomashek, Kay M.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Dengue Branch, San Juan, PR 00920 USA. [Acosta, Hector; Garcia-Gubern, Carlos] Ponce Sch Med, Emergency Med Residency Program, Ponce, PR USA. [Galarza, Ivonne E.] Ponce Sch Med, Pediat Residency Program, Ponce, PR USA. [Bui, Duy M.] Ctr Dis Control & Prevent, Zoonot & Select Agent Lab, Atlanta, GA USA. [Oberste, M. Steven] Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Atlanta, GA USA. [Penaranda, Silvia] Ctr Dis Control & Prevent, Polio & Picornavirus Branch, Atlanta, GA USA. RP Lorenzi, OD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Div Vector Borne Infect Dis, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. EM oal9@cdc.gov; hgk4@cdc.gov; zwt3@cdc.gov; hacosta73@gmail.com; ivonnegalarza@hotmail.com; enh4@cdc.gov; ckq2@cdc.gov; dbui85@gmail.com; mbo2@cdc.gov; sxp9@cdc.gov; cgarcia@psm.edu; kct9@cdc.gov NR 46 TC 6 Z9 6 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAR PY 2013 VL 88 IS 3 BP 472 EP 480 DI 10.4269/ajtmh.12-0373 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 106QC UT WOS:000316158800014 PM 23382160 ER PT J AU Knobel, DL Maina, AN Cutler, SJ Ogola, E Feikin, DR Junghae, M Halliday, JEB Richards, AL Breiman, RF Cleaveland, S Njenga, MK AF Knobel, Darryn L. Maina, Alice N. Cutler, Sally J. Ogola, Eric Feikin, Daniel R. Junghae, Muthoni Halliday, Jo E. B. Richards, Allen L. Breiman, Robert F. Cleaveland, Sarah Njenga, M. Kariuki TI Coxiella burnetii in Humans, Domestic Ruminants, and Ticks in Rural Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID Q-FEVER; MORBIDITY; OUTBREAK; SEROPREVALENCE; SURVEILLANCE; MORTALITY; HISTORY; DISEASE; CATTLE; HEALTH AB We conducted serological surveys for Coxiella burnetii in archived sera from patients that visited a rural clinic in western Kenya from 2007 to 2008 and in cattle, sheep, and goats from the same area in 2009. We also conducted serological and polymerase chain reaction-based surveillance for the pathogen in 2009-2010, in human patients with acute lower respiratory illness, in ruminants following parturition, and in ticks collected from ruminants and domestic dogs. Antibodies against C. burnetii were detected in 30.9% (N = 246) of archived patient sera and in 28.3% (N = 463) of cattle, 32.0% (N = 378) of goats, and 18.2% (N = 159) of sheep surveyed. Four of 135 (3%) patients with acute lower respiratory illness showed seroconversion to C. burnetii. The pathogen was detected by polymerase chain reaction in specimens collected from three of six small ruminants that gave birth within the preceding 24 hours, and in five of 10 pools (50%) of Haemaphysalis leachi ticks collected from domestic dogs. C1 [Knobel, Darryn L.] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa. [Maina, Alice N.; Richards, Allen L.] USN, Med Res Ctr, Viral & Rickettsial Dis Dept, Silver Spring, MD USA. [Cutler, Sally J.] Univ E London, Sch Hlth Sports & Biosci, London E15 4LZ, England. [Feikin, Daniel R.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Baltimore, MD USA. [Halliday, Jo E. B.; Cleaveland, Sarah] Univ Glasgow, Coll Med Vet & Life Sci, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland. RP Knobel, DL (reprint author), Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa. EM darryn.knobel@up.ac.za; alicemaina727@gmail.com; S.Cutler@uel.ac.uk; EOgola@kemricdc.org; dfeikin@jhsph.edu; mjunghae@ke.cdc.gov; jo.halliday@glasgow.ac.uk; allen.richards@med.navy.mil; rbreiman@ke.cdc.gov; sarah.cleaveland@glasgow.ac.uk; knjenga@ke.cdc.gov RI Valle, Ruben/A-7512-2013; OI Halliday, Jo/0000-0002-1329-9035 FU Wellcome Trust, UK [081828/B/06/Z]; U.S. Centers of Disease Control and Prevention and Global Emerging Infections Surveillance and Response System Program [188M.0931.001.A0074] FX This research was supported by the Wellcome Trust, UK (grant no. 081828/B/06/Z) and U.S. Centers of Disease Control and Prevention and Global Emerging Infections Surveillance and Response System Program (work unit no. 188M.0931.001.A0074). NR 32 TC 16 Z9 16 U1 0 U2 14 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAR PY 2013 VL 88 IS 3 BP 513 EP 518 DI 10.4269/ajtmh.12-0169 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 106QC UT WOS:000316158800020 PM 23382156 ER PT J AU Eberhard, ML Ostovar, GA Chundu, K Hobohm, D Feiz-Erfan, I Mathison, BA Bishop, HS Cantey, PT AF Eberhard, Mark L. Ostovar, Gholamabbas Amin Chundu, Kote Hobohm, Dan Feiz-Erfan, Iman Mathison, Blaine A. Bishop, Henry S. Cantey, Paul T. TI Case Report: Zoonotic Onchocerca lupi Infection in a 22-Month-Old Child in Arizona: First Report in the United States and a Review of the Literature SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Review ID WILD BOAR; DEWITTEI-JAPONICA; 2 DOGS; FILARIASIS; RESIDENT; JAPAN; OITA; PATHOLOGY; PARASITE; DISEASE AB A 22-month-old girl presented with neck pain and stiffness and magnetic resonance imaging showed an extradural mass extending from C2 through the C4 level with moderate to severe compression of the cord. A left unilateral C2-C4 laminectomy was performed revealing an extradural rubbery tumor; a small biopsy was obtained. Examination of stained tissue revealed the presence of a parasitic worm that was identified as a gravid female Onchocerca lupi. A magnetic resonance imaging at 7 weeks follow-up showed a significantly decreased size of the enhancing lesion and the patient's symptoms gradually resolved. This is the first report of zoonotic O. lupi in the United States. The parasite has been reported in dogs and cats in the western United States, and from people in four cases reported from Europe. A great deal more needs to be learned, including full host range and geographic distribution, before we fully understand O. lupi infections in animals and man. C1 [Eberhard, Mark L.; Mathison, Blaine A.; Bishop, Henry S.; Cantey, Paul T.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Ostovar, Gholamabbas Amin; Chundu, Kote] Maricopa Cty Gen Hosp, Dept Pediat, Phoenix, AZ USA. [Hobohm, Dan] Maricopa Cty Gen Hosp, Dept Pathol, Phoenix, AZ USA. [Feiz-Erfan, Iman] Maricopa Cty Gen Hosp, Div Neurosurg, Phoenix, AZ USA. RP Eberhard, ML (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM mle1@cdc.gov; Amin_Ostovar@dmgaz.org; Kote_Chundu@dmgaz.org; Dan_Hobohm@dmgaz.org; Iman_Feiz-Erfan@dmgaz.org; gqa4@cdc.gov; hsb2@cdc.gov; gdn9@cdc.gov NR 33 TC 25 Z9 28 U1 0 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAR PY 2013 VL 88 IS 3 BP 601 EP 605 DI 10.4269/ajtmh.12-0733 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 106QC UT WOS:000316158800036 PM 23382171 ER PT J AU Katapodi, MC Northouse, LL Schafenacker, AM Duquette, D Duffy, SA Ronis, DL Anderson, B Janz, NK McLosky, J Milliron, KJ Merajver, SD Duong, LM Copeland, G AF Katapodi, Maria C. Northouse, Laurel L. Schafenacker, Ann M. Duquette, Debra Duffy, Sonia A. Ronis, David L. Anderson, Beth Janz, Nancy K. McLosky, Jennifer Milliron, Kara J. Merajver, Sofia D. Duong, Linh M. Copeland, Glenn TI Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening SO BMC CANCER LA English DT Article DE Breast cancer screening; Familial breast cancer; Young breast cancer survivors; High-risk relatives; Randomized trial; Targeted and enhanced tailored intervention; Screening mammography; Genetic testing; Cancer registry; State-wide community-based sample ID MAMMOGRAPHY; WOMEN; METAANALYSIS; STRATEGIES; HEREDITARY; HISTORY AB Background: The Michigan Prevention Research Center, the University of Michigan Schools of Nursing, Public Health, and Medicine, and the Michigan Department of Community Health propose a multidisciplinary academic-clinical practice three-year project to increase breast cancer screening among young breast cancer survivors and their cancer-free female relatives at greatest risk for breast cancer. Methods/design: The study has three specific aims: 1) Identify and survey 3,000 young breast cancer survivors (diagnosed at 20-45 years old) regarding their breast cancer screening utilization. 2) Identify and survey survivors' high-risk relatives regarding their breast cancer screening utilization. 3) Test two versions (Targeted vs. Enhanced Tailored) of an intervention to increase breast cancer screening among survivors and relatives. Following approval by human subjects review boards, 3,000 young breast cancer survivors will be identified through the Michigan Cancer Registry and mailed an invitation letter and a baseline survey. The baseline survey will obtain information on the survivors': a) current breast cancer screening status and use of genetic counseling; b) perceived barriers and facilitators to screening; c) family health history. Based on the family history information provided by survivors, we will identify up to two high-risk relatives per survivor. Young breast cancer survivors will be mailed consent forms and baseline surveys to distribute to their selected high-risk relatives. Relatives' baseline survey will obtain information on their: a) current breast cancer screening status and use of genetic counseling; and b) perceived barriers and facilitators to screening. Young breast cancer survivors and high-risk relatives will be randomized as a family unit to receive two versions of an intervention aiming to increase breast cancer screening and use of cancer genetic services. A follow-up survey will be mailed 9 months after the intervention to survivors and high-risk relatives to evaluate the efficacy of each intervention version on: a) use of breast cancer screening and genetic counseling; b) perceived barriers and facilitators to screening; c) self-efficacy in utilizing cancer genetic and screening services; d) family support related to screening; e) knowledge of breast cancer genetics; and f) satisfaction with the intervention. Discussion: The study will enhance efforts of the state of Michigan surrounding cancer prevention, control, and public health genomics. C1 [Katapodi, Maria C.; Northouse, Laurel L.; Schafenacker, Ann M.; Duffy, Sonia A.; Ronis, David L.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Duquette, Debra; Anderson, Beth; McLosky, Jennifer] Michigan Dept Community Hlth, Canc Genom Program, Lansing, MI USA. [Duffy, Sonia A.] VA Hosp, Ann Arbor, MI USA. [Ronis, David L.] VA Ctr Clin Management Res, Ann Arbor, MI USA. [Janz, Nancy K.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Milliron, Kara J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Merajver, Sofia D.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. [Merajver, Sofia D.] Ctr Comprehens Canc, Ann Arbor, MI USA. [Duong, Linh M.] Ctr Dis Control & Prevent, Canc Surveillance Branch, Div Canc Prevent & Control, Atlanta, GA USA. [Copeland, Glenn] Michigan Canc Surveillance Program, Lansing, MI USA. RP Katapodi, MC (reprint author), Univ Michigan, Sch Nursing, 400 N Ingalls Bldg,Room 2158, Ann Arbor, MI 48109 USA. EM mkatapo@umich.edu FU Department of Health and Human Services, Centers for Disease Control and Prevention [5 U48 DP001901-03] FX Study Sponsor: Department of Health and Human Services, Centers for Disease Control and Prevention.; Grant No: 5 U48 DP001901-03, Project Period: 09/30/2011-09/29/2014. NR 27 TC 4 Z9 4 U1 1 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD MAR 1 PY 2013 VL 13 AR 97 DI 10.1186/1471-2407-13-97 PG 9 WC Oncology SC Oncology GA 107BI UT WOS:000316189300001 PM 23448100 ER PT J AU Lappi, V Archer, JR Cebelinski, E Leano, F Besser, JM Klos, RF Medus, C Smith, KE Fitzgerald, C Davis, JP AF Lappi, Victoria Archer, John R. Cebelinski, Elizabeth Leano, Fe Besser, John M. Klos, Rachel F. Medus, Carlota Smith, Kirk E. Fitzgerald, Collette Davis, Jeffrey P. TI An Outbreak of Foodborne Illness Among Attendees of a Wedding Reception in Wisconsin Likely Caused by Arcobacter butzleri SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID PCR ASSAY; CAMPYLOBACTER-JEJUNI; DIARRHEAL ILLNESS; BROILER-CHICKENS; PREVALENCE; SPP.; CRYAEROPHILUS; WATER; MEAT; ORGANISMS AB Background: Arcobacter species, primarily Arcobacter butzleri, are widely distributed among animals, infrequently isolated from humans, and previously not associated with outbreaks of foodborne illness. We report results of an investigation of a foodborne outbreak that occurred among attendees of a wedding reception in Wisconsin, United States, and was likely caused by A. butzleri. Methods: We conducted a case-control study among reception attendees and a laboratory investigation to determine the extent, source, and cause of the outbreak. A clinical case was defined as diarrhea in an attendee with illness onset <= 7 days following the wedding reception. Results: The case-control study included 47 of 51 case patients and 43 non-ill attendees. Results demonstrated that consuming broasted chicken was the only factor significantly associated with illness (odds ratio 10.51; 95% confidence interval 1.28, 476.4). Five patients provided stool specimens. Comprehensive culture and polymerase chain reaction (PCR) testing did not detect common bacterial or viral pathogens. Subsequent testing with PCRs targeting 16S/23S rDNA of the three most clinically relevant Arcobacter spp. and the rpoB/C gene of A. butzleri provided products confirmed as A. butzleri (four patients) and A. cryaerophilus (one patient) by sequence analysis. Conclusions: The results of this investigation suggest that A. butzleri should be considered an agent that can cause outbreaks of foodborne illness. Rigorous investigation of outbreaks of undetermined etiology is valuable for incrementally increasing our understanding of emerging agents causing foodborne illnesses. C1 [Lappi, Victoria; Cebelinski, Elizabeth; Leano, Fe; Besser, John M.] Minnesota Dept Hlth, Publ Hlth Lab, St Paul, MN USA. [Archer, John R.; Klos, Rachel F.; Davis, Jeffrey P.] Wisconsin Div Publ Hlth, Bur Communicable Dis & Emergency Response, Madison, WI 53702 USA. [Medus, Carlota; Smith, Kirk E.] Minnesota Dept Hlth, Acute Dis Invest & Control Sect, St Paul, MN USA. [Fitzgerald, Collette] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. RP Davis, JP (reprint author), Wisconsin Div Publ Hlth, Bur Communicable Dis & Emergency Response, 1 West Wilson St,Room 318, Madison, WI 53702 USA. EM jeffrey.davis@wisconsin.gov FU Wisconsin Division of Public Health; Centers for Disease Control and Prevention Public Health Emergency Response; Epidemiology and Laboratory Capacity cooperative agreements; Minnesota Department of Health; Centers for Disease Control and Prevention, Emerging Infections Program, Foodborne Disease Active Surveillance Network [U50/CCU511190] FX We thank Sue Hansen, Chua Xiong, John Paul, Marty Adams, and Judy Frederichs, Brown County Health Departments; Lois Gruetzmacher and Melody Bockenfeld, Outagamie County Health Department and Rick Heffernan, Wisconsin Division of Public Health, for their assistance during this field investigation and Erik Reisdorf and Tim Monson, Wisconsin State Laboratory of Hygiene for their assistance during the laboratory investigation. This work was supported by the Wisconsin Division of Public Health with funding from the Centers for Disease Control and Prevention Public Health Emergency Response and Epidemiology and Laboratory Capacity cooperative agreements, and by the Minnesota Department of Health with funding provided through a cooperative agreement (U50/CCU511190) with the Centers for Disease Control and Prevention as part of the Emerging Infections Program, Foodborne Disease Active Surveillance Network. NR 41 TC 19 Z9 19 U1 0 U2 14 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD MAR PY 2013 VL 10 IS 3 BP 250 EP 255 DI 10.1089/fpd.2012.1307 PG 6 WC Food Science & Technology SC Food Science & Technology GA 106YI UT WOS:000316181200008 PM 23379282 ER PT J AU Terrault, NA Dodge, JL Murphy, EL Tavis, JE Kiss, A Levin, TR Gish, RG Busch, MP Reingold, AL Alter, MJ AF Terrault, Norah A. Dodge, Jennifer L. Murphy, Edward L. Tavis, John E. Kiss, Alexi Levin, T. R. Gish, Robert G. Busch, Michael P. Reingold, Arthur L. Alter, Miriam J. TI Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study SO HEPATOLOGY LA English DT Article ID INFECTED MEN; SEMINAL FLUID; VIRAL-RNA; SEMEN; GLOBULIN; SEQUENCE; OUTCOMES; ABSENCE; SALIVA AB The efficiency of hepatitis C virus (HCV) transmission by sexual activity remains controversial. We conducted a cross-sectional study of HCV-positive subjects and their partners to estimate the risk for HCV infection among monogamous heterosexual couples. A total of 500 antiHCV-positive, human immunodeficiency virusnegative index subjects and their long-term heterosexual partners were studied. Couples were interviewed separately for lifetime risk factors for HCV infection, within-couple sexual practices, and sharing of personal grooming items. Blood samples were tested for anti-HCV, HCV RNA, and HCV genotype and serotype. Sequencing and phylogenetic analysis determined the relatedness of virus isolates among genotype-concordant couples. The majority of HCV-positive index subjects were non-Hispanic white, with a median age of 49 years (range, 26-79 years) and median of 15 years (range, 2-52 years) of sexual activity with their partners. Overall, HCV prevalence among partners was 4% (n = 20), and nine couples had concordant genotype/serotype. Viral isolates in three couples (0.6%) were highly related, consistent with transmission of virus within the couple. Based on 8,377 person-years of follow-up, the maximum incidence rate of HCV transmission by sex was 0.07% per year (95% confidence interval, 0.01-0.13) or approximately one per 190,000 sexual contacts. No specific sexual practices were related to HCV positivity among couples. Conclusion: The results of this study provide quantifiable risk information for counseling long-term monogamous heterosexual couples in which one partner has chronic HCV infection. In addition to the extremely low estimated risk for HCV infection in sexual partners, the lack of association with specific sexual practices provides unambiguous and reassuring counseling messages. (HEPATOLOGY 2013) C1 [Terrault, Norah A.; Dodge, Jennifer L.; Murphy, Edward L.; Busch, Michael P.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Murphy, Edward L.; Busch, Michael P.] Blood Syst Res Inst, San Francisco, CA USA. [Tavis, John E.; Kiss, Alexi] St Louis Univ, St Louis, MO 63103 USA. [Levin, T. R.] Kaiser Permanente, Div Res, Oakland, CA USA. [Gish, Robert G.] Calif Pacific Med Ctr, San Francisco, CA USA. [Reingold, Arthur L.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Alter, Miriam J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Terrault, NA (reprint author), Univ Calif San Francisco, Div Gastroenterol, 513 Parnassus Ave,S357,Box 0538, San Francisco, CA 94143 USA. EM norah.terrault@ucsf.edu FU NIDDK NIH HHS [U01 DK060346, P30 DK026743, R01 DK074515, U01 DK060345] NR 26 TC 75 Z9 77 U1 0 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAR PY 2013 VL 57 IS 3 BP 881 EP 889 DI 10.1002/hep.26164 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 099TG UT WOS:000315644200007 PM 23175457 ER PT J AU Perz, JF Grytdal, S Beck, S Fireteanu, AM Poissant, T Rizzo, E Bornschlegel, K Thomas, A Balter, S Miller, J Klevens, RM Finelli, L AF Perz, Joseph F. Grytdal, Scott Beck, Suzanne Fireteanu, Ana Maria Poissant, Tasha Rizzo, Elena Bornschlegel, Katherine Thomas, Ann Balter, Sharon Miller, Jeremy Klevens, R. Monina Finelli, Lyn TI Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections? SO HEPATOLOGY LA English DT Article ID UNITED-STATES; VIRUS-INFECTION; INJECTION PRACTICES; RISK-FACTORS; TRANSMISSION; PREVALENCE; SETTINGS AB Reports of hepatitis B virus (HBV) and hepatitis C virus (HCV) transmission associated with unsafe medical practices have been increasing in the United States. However, the contribution of healthcare exposures to the burden of new infections is poorly understood outside of recognized outbreaks. We conducted a case-control study at three health departments that perform enhanced viral hepatitis surveillance in New York and Oregon. Reported cases of symptomatic acute hepatitis B and hepatitis C occurring in persons 55 years of age from 2006 to 2008 were enrolled. Controls were identified using telephone directories and matched to individual cases by age group (55-59, 60-69, and 70 years) and residential postal code. Data collection covered exposures within 6 months before symptom onset (cases) or date of interview (controls). Forty-eight (37 hepatitis B and 11 hepatitis C) case and 159 control patients were enrolled. Case patients were more likely than controls to report one or more behavioral risk exposures, including sexual or household contact with an HBV or HCV patient, >1 sex partner, illicit drug use, or incarceration (21% of cases versus 4% of controls exposed; matched odds ratio [mOR] = 7.1; 95% confidence interval [CI]: 2.1, 24.1). Case patients were more likely than controls to report hemodialysis (8% of cases; mOR = 13.0; 95% CI: 1.5, 115), injections in a healthcare setting (58%; mOR = 2.7; 95% CI: 1.3, 5.3), and surgery (33%; mOR = 2.3; 95% CI: 1.1, 4.7). In a multivariate model, behavioral risks (adjusted OR [aOR] = 5.4; 95% CI: 1.5, 19.0; 17% attributable risk), injections (aOR = 2.7; 95% CI: 1.3, 5.8; 37% attributable risk), and hemodialysis (aOR = 11.5; 95% CI: 1.2, 107; 8% attributable risk) were associated with case status. Conclusion: Healthcare exposures may represent an important source of new HBV and HCV infections among older adults. (HEPATOLOGY 2013) C1 [Perz, Joseph F.; Grytdal, Scott; Miller, Jeremy; Klevens, R. Monina; Finelli, Lyn] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Beck, Suzanne; Rizzo, Elena] New York State Dept Hlth, New York, NY USA. [Fireteanu, Ana Maria; Bornschlegel, Katherine; Balter, Sharon] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Poissant, Tasha; Thomas, Ann] State Oregon Publ Hlth Div, Portland, OR USA. RP Perz, JF (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. EM JPERZ@CDC.GOV OI Poissant, Tasha/0000-0003-4407-272X FU Division of Viral Hepatitis, Centers for Disease Control and Prevention FX Primary support for this investigation was provided by the Division of Viral Hepatitis, Centers for Disease Control and Prevention; staff were funded by their primary institutions. NR 45 TC 16 Z9 16 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAR PY 2013 VL 57 IS 3 BP 917 EP 924 DI 10.1002/hep.25688 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 099TG UT WOS:000315644200012 PM 22383058 ER PT J AU Lin, YS Caffrey, JL Hsu, PC Chang, MH Faramawi, MF Lin, JW AF Lin, Yu-Sheng Caffrey, James L. Hsu, Ping-Chi Chang, Man-Huei Faramawi, Mohammed F. Lin, Jou-Wei TI Environmental exposure to dioxin-like compounds and the mortality risk in the U.S. population (vol 215, pg 541, 2012) SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Correction C1 [Lin, Yu-Sheng] Univ N Texas, Hlth Sci Ctr, Dept Environm & Occupat Hlth, Ft Worth, TX 76107 USA. [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Dept Integrat Physiol, Ft Worth, TX 76107 USA. [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Cardiovasc Res Inst, Ft Worth, TX 76107 USA. [Hsu, Ping-Chi] Natl Kaohsiung First Univ Sci & Technol, Dept Safety Hlth & Environm Engn, Kaohsiung, Taiwan. [Chang, Man-Huei] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Faramawi, Mohammed F.] Univ N Texas, Hlth Sci Ctr, Dept Epidemiol, Ft Worth, TX 76107 USA. [Lin, Jou-Wei] Natl Taiwan Univ Hosp, Yun Lin Branch, Ctr Cardiovasc, Dou Liou City, Yun Lin, Taiwan. [Lin, Jou-Wei] Natl Taiwan Univ Hosp, Yun Lin Branch, Hlth Management Ctr, Dou Liou City, Yun Lin, Taiwan. RP Lin, JW (reprint author), Natl Taiwan Univ Hosp, Yun Lin Branch, Ctr Cardiovasc, Dou Liou City, Yun Lin, Taiwan. EM jouweilin@yahoo.com NR 1 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD MAR PY 2013 VL 216 IS 2 BP 216 EP 216 DI 10.1016/j.ijheh.2012.09.003 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 110JR UT WOS:000316438900016 ER PT J AU Okoro, CA Zhao, GX Li, CY Balluz, LS AF Okoro, Catherine A. Zhao, Guixiang Li, Chaoyang Balluz, Lina S. TI Has the Use of Complementary and Alternative Medicine Therapies by U.S. Adults with Chronic Disease-Related Functional Limitations Changed from 2002 to 2007? SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID HEALTH INTERVIEW SURVEY; CLINICAL-PRACTICE GUIDELINE; LOW-BACK-PAIN; UNITED-STATES; PHYSICAL-DISABILITIES; INSURANCE-COVERAGE; NATIONAL-SURVEY; CARE; PROVIDERS; CANCER AB Objectives: This study examined changes in the use of complementary and alternative medicine (CAM) therapies by U.S. adults aged 18 years or older with chronic disease-related functional limitations between 2002 and 2007. Design: The study was a cross-sectional survey. Setting/location: The study was conducted in the United States. Subjects: The study comprised adults aged 18 years or older with chronic disease-related functional limitations. Methods: Data were obtained from the 2002 and 2007 U. S. National Health Interview Survey to compare the use of 22 CAM therapies (n = 9313 and n = 7014, respectively). Estimates were age adjusted to the year 2000 U.S. standard population. Results: The unadjusted and age-standardized prevalence of overall CAM use (22 therapies comparable between both survey years) was higher in 2007 than in 2002 (30.6% versus 26.9%, p < 0.001 and 34.4% versus 30.6%, p < 0.001, respectively). Adults with functional limitations that included changing and maintaining body position experienced a significant increase in CAM use between 2002 and 2007 (31.1%-35.0%, p < 0.01). The use of deep breathing exercises was the most prevalent CAM therapy in both 2002 and 2007 and increased significantly during this period (from 17.9% to 19.9%, p < 0.05). The use of meditation, massage, and yoga also increased significantly from 2002 and 2007 (11.0%-13.5%, p < 0.01; 7.0%-10.9%, p < 0.0001; and 5.1% to 6.6%, p < 0.05, respectively), while the use of the Atkins diet decreased (2.2%-1.4%, p < 0.01). Conclusions: Among U.S. adults with chronic disease-related functional limitations, the overall increase in CAM use from 2002 to 2007 was significant, particularly among those with changing and maintaining body position limitations. C1 [Okoro, Catherine A.; Zhao, Guixiang; Li, Chaoyang; Balluz, Lina S.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Publ Hlth Surveillance & Informat Program Off, Div Behav Surveillance, Atlanta, GA 30333 USA. RP Okoro, CA (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Publ Hlth Surveillance & Informat Program Off, 1600 Clifton Rd NE,M-S E-97, Atlanta, GA 30333 USA. EM COkoro@cdc.gov NR 40 TC 13 Z9 14 U1 3 U2 18 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD MAR PY 2013 VL 19 IS 3 BP 217 EP 223 DI 10.1089/acm.2012.0009 PG 7 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 110RW UT WOS:000316464200006 PM 23072266 ER PT J AU Oza-Frank, R Hade, EM Norton, A Scarpitti, H Conrey, EJ AF Oza-Frank, Reena Hade, Erinn M. Norton, Angela Scarpitti, Heidi Conrey, Elizabeth J. TI Trends in Body Mass Index among Ohio's Third-Grade Children: 2004-2005 to 2009-2010 SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Body mass index; Children's health; Obesity; Overweight; Ohio ID UNITED-STATES; CHILDHOOD OVERWEIGHT; LOW-INCOME; OBESITY; PREVALENCE; SURVEILLANCE; SCHOOL AB Substantial variation across states in the prevalence and trends in childhood overweight and obesity indicate a need for state-specific surveillance to make state comparisons to national estimates and identify high-risk populations. The purpose of this study was to examine body mass index (BMI) trends among third-grade children in Ohio between the 2004-2005 and 2009-2010 school years and examine changes in prevalence of obesity by specific demographic subgroups. Third-grade children (n=33,672) were directly weighed and measured throughout the school years by trained health care professionals. Trends in overweight/obesity (>= 85th percentile of BMI by age/sex), obesity (>= 95th percentile), and obesity level 2 (>= 97th percentile) over five time periods (2004-2005, 2006-2007, 2007-2008, 2008-2009, 2009-2010) were modeled using logistic regression, accounting for the survey design and adjusting for sex, race/ethnicity, National School Lunch Program (NSLP) participation, and age. Differences in these BMI categories were also examined by these subgroups. BMI estimates did not demonstrate a statistically significant trend over the five time periods for overweight/obesity (34% to 36%), obesity (18% to 20%), or obesity level 2 (12% to 14%). However, increases in overweight/obesity prevalence were found in Hispanic children (37.8% vs 53.1%; P<0.01). Decreases in obesity (16.6% vs 14.1%; P=0.02) and obesity level 2(11.3% vs 9.3%; P=0.02) were found among children not participating in NSLP and residing in suburban counties (obesity [17.3% vs 14.7%; P=0.03] and obesity level 2 [11.8% vs 9.8%; P=0.05]). Finally, decreases in overweight/obesity and obesity level 2 among boys were Observed (15% vs 12.9%; P=0.02). Despite no significant overall trends in overweight/obesity, obesity, or obesity level 2 between 2004 and 2010, prevalence changed among specific subgroups. Obesity prevention efforts should be widespread and include special emphasis on groups experiencing increases or no change in prevalence. J Acad Nutr Diet. 2013;113:440-446. C1 [Oza-Frank, Reena] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA. [Oza-Frank, Reena] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. [Oza-Frank, Reena; Conrey, Elizabeth J.] Ohio Dept Hlth, State Epidemiol Off, Columbus, OH 43266 USA. [Hade, Erinn M.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA. [Norton, Angela; Scarpitti, Heidi] Ohio Dept Hlth, Bur Community Hlth Serv, Sch & Adolescent Hlth Sect, Columbus, OH 43266 USA. [Conrey, Elizabeth J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Oza-Frank, R (reprint author), Nationwide Childrens Hosp, Res Inst, 700 Childrens Dr,Res Bldg 3, Columbus, OH 43205 USA. EM reena.oza-frank@nationwidechildrens.org FU Centers for Disease Control and Prevention (CDC) [5U38HM000414]; Applied Epidemiology Fellowship Program FX This study was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council for State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement no. 5U38HM000414. NR 31 TC 7 Z9 7 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD MAR PY 2013 VL 113 IS 3 BP 440 EP 446 DI 10.1016/j.jand.2012.11.005 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 102JU UT WOS:000315841700009 PM 23438495 ER PT J AU Mallin, K Palis, BE Watroba, N Stewart, AK Walczak, D Singer, J Barron, J Blumenthal, W Haydu, G Edge, SB AF Mallin, Katherine Palis, Bryan E. Watroba, Nancy Stewart, Andrew K. Walczak, Daniel Singer, Joseph Barron, John Blumenthal, Wendy Haydu, Georgette Edge, Stephen B. TI Completeness of American Cancer Registry Treatment Data: Implications for Quality of Care Research SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID BREAST-CANCER; UNITED-STATES; INFORMATION; AGREEMENT; THERAPY AB BACKGROUND: Evaluating and improving the quality of cancer care requires complete information on cancer stage and treatment. Hospital-based registries are a key tool in this effort, but reports in the 1990s showed that they fail to identify a major fraction of outpatient-administered treatment, including chemotherapy, endocrine therapy, and radiation. This can limit their value for evaluating patterns and quality of care. To determine the completeness of registry data in more recent years, we linked administrative claims from 2 private payers in Ohio to the National Cancer Data Base and Ohio Cancer Incidence and Surveillance System. METHODS: Incident breast and colorectal cancers among Ohio residents diagnosed in 2004-2006 were identified from linkage of the National Cancer Data Base, Ohio Cancer Incidence and Surveillance System, and payer insurance claims using ICD-9 and CPT procedure codes, and ICD-9 diagnosis codes. Linkage was accomplished using patient demographics, surgery dates, and hospital facility. Treatment found in claims and registry data were compared and assessed using the kappa statistic. RESULTS: The analytic cohort included 2,552 breast and 822 colorectal cases. Results showed high agreement for breast surgery type, and moderately high agreement for colorectal surgery type. For breast cases, the registries captured 87% of chemotherapy, 86% of radiation, and 64% of endocrine treatment in claims. For colorectal cases, the registry captured 83% of chemotherapy and 84% of radiation in claims. CONCLUSIONS: Hospital-based registries for breast and colon cancer diagnosed in 2004-2006 captured about 85% of radiation and chemotherapy data compared with claims data, a higher percentage than earlier reports. These findings provide direction and a cautionary note to those using registry data for study of patterns and quality of systemic and radiation therapy care. (J Am Coll Surg 2013;216:428-437. (C) 2013 by the American College of Surgeons) C1 [Mallin, Katherine; Palis, Bryan E.; Stewart, Andrew K.] Amer Coll Surg, Commiss Canc, Chicago, IL USA. [Watroba, Nancy; Edge, Stephen B.] SUNY Buffalo, Roswell Pk Canc Inst, Buffalo, NY 14260 USA. [Walczak, Daniel] UnitedHlth Care, Edina, MN USA. [Singer, Joseph; Barron, John] Healthcore, Wilmington, DE USA. [Blumenthal, Wendy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Haydu, Georgette] Ohio Dept Hlth, Columbus, OH 43266 USA. RP Edge, SB (reprint author), Roswell Pk Canc Inst, Elm & Carlton St, Buffalo, NY 14263 USA. EM Stephen.edge@roswellpark.org OI Mallin, Katherine/0000-0001-9663-5702 FU CDC contract through Northrop Grumman [RFP CIO-SP2-2305-BMH-ACS]; Margaret L Wendt Foundation FX Supported by CDC contract through Northrop Grumman RFP CIO-SP2-2305-BMH-ACS to the American College of Surgeons' National Cancer Data Base. Preliminary work supported by a grant from the Margaret L Wendt Foundation to Roswell Park Cancer Institute. NR 20 TC 25 Z9 25 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAR PY 2013 VL 216 IS 3 BP 428 EP 437 DI 10.1016/j.jamcollsurg.2012.12.016 PG 10 WC Surgery SC Surgery GA 109GH UT WOS:000316353900012 PM 23357724 ER PT J AU Dwyer, LL Harris-Kojetin, LD Valverde, RH Frazier, JM Simon, AE Stone, ND Thompson, ND AF Dwyer, Lisa L. Harris-Kojetin, Lauren D. Valverde, Roberto H. Frazier, Joyce M. Simon, Alan E. Stone, Nimalie D. Thompson, Nicola D. TI Infections in Long-Term Care Populations in the United States SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE infections; nursing homes; home health; hospice ID HOME-ASSOCIATED INFECTIONS; NURSING-HOMES; ACQUIRED INFECTIONS; RISK-FACTORS; PREVALENCE; FACILITIES; RESIDENTS AB Objectives To estimate infection prevalence and explore associated risk factors in nursing home (NH) residents, individuals receiving home health care (HHC), and individuals receiving hospice care. Design Cross-sectional. Setting Nationally representative samples of 1,174 U.S. NHs in the 2004 National Nursing Home Survey (NNHS) and 1,036 U.S. HHC and hospice agencies in the 2007 National Home and Hospice Care Survey (NHHCS). Participants A nationally representative sample of 12,270 NH residents, 4,394 individuals receiving HHC, and 4,410 individuals receiving hospice care. Measurements International Classification of Diseases, Ninth Revision, Clinical Modification, codes were used to identify the presence of infection, including community-acquired infection and those acquired during earlier healthcare exposures. Results Unweighted response rates were 78% for the 2004 NHHS and 67% for the 2007 NHHCS. Approximately 12% of NH residents and 12% of individuals receiving HHC had an infection at the time of the survey interview, and more than 10% of individuals receiving hospice care had an infection when discharged from hospice care. The most common infections were urinary tract infection (3.05.2%), pneumonia (2.24.4%), and cellulitis (1.62.0%). Short length of care and recent inpatient stay in a healthcare facility were associated with infections in all three populations. Taking 10 or more medications and urinary catheter exposure were significant in two of these three long-term care populations. Conclusion Infection prevalence in HHC, hospice, and NH populations is similar. Although these infections may be community acquired or acquired during earlier healthcare exposures, these findings fill an important gap in understanding the national infection burden and may help inform future research on infection epidemiology and prevention strategies in long-term care populations. C1 [Dwyer, Lisa L.; Harris-Kojetin, Lauren D.; Valverde, Roberto H.; Frazier, Joyce M.; Simon, Alan E.] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Stone, Nimalie D.; Thompson, Nicola D.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Dwyer, LL (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm 3438, Hyattsville, MD 20782 USA. EM cey9@cdc.gov FU Centers for Disease Control and Prevention FX The surveys used for this study were funded by the Centers for Disease Control and Prevention. NR 28 TC 15 Z9 15 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2013 VL 61 IS 3 BP 341 EP 349 DI 10.1111/jgs.12153 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 108ZM UT WOS:000316334900004 ER PT J AU Boneva, RS Lin, JMS Unger, ER AF Boneva, Roumiana S. Lin, Jin-Mann S. Unger, Elizabeth R. TI Early Menopause and other Gynecologic Risk Indicators for CFS in Women: A Population-based Case-control Study SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Boneva, Roumiana S.; Lin, Jin-Mann S.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2013 VL 22 IS 3 MA P8 BP 4 EP 5 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 105IU UT WOS:000316061700009 ER PT J AU Robbins, CL Dietz, PM Cox, S Kuklina, EV AF Robbins, Cheryl L. Dietz, Patricia M. Cox, Shanna Kuklina, Elena V. TI Risk-Based Cholesterol Screening for Women SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Robbins, Cheryl L.; Dietz, Patricia M.; Cox, Shanna] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2013 VL 22 IS 3 MA P100 BP 39 EP 40 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 105IU UT WOS:000316061700101 ER PT J AU Stanley, S King, J Thomas, C Richardson, L AF Stanley, Sandte King, Jessica Thomas, Cheryll Richardson, Lisa TI Health Belief Model Predictors of Never Being Screened for Cervical Cancer by Metropolitan and Non-Metropolitan Areas SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Stanley, Sandte; King, Jessica; Thomas, Cheryll; Richardson, Lisa] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2013 VL 22 IS 3 MA P104 BP 41 EP 41 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 105IU UT WOS:000316061700105 ER PT J AU Goodman, A Bushar, J Kendrick, JS Pirretti, A Grider, T AF Goodman, Andrea Bushar, Jessica Kendrick, Juliette S. Pirretti, Amy Grider, Tamara TI Text4baby as a Valuable Tool for Providers and Patients SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Goodman, Andrea; Bushar, Jessica; Pirretti, Amy; Grider, Tamara] Hlth Babies Coalit, Alexandria, VA USA. [Kendrick, Juliette S.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2013 VL 22 IS 3 MA P116 BP 45 EP 46 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 105IU UT WOS:000316061700117 ER PT J AU Ellington, SR Kourtis, AP Curtis, KM Tepper, N Gorman, S Jamieson, DJ Zotti, M Barfield, W AF Ellington, Sascha R. Kourtis, Athena P. Curtis, Kathryn M. Tepper, Naomi Gorman, Susan Jamieson, Denise J. Zotti, Marianne Barfield, Wanda TI Contraceptive Availability During an Emergency Response in the United States SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HURRICANE-KATRINA; YUZPE REGIMEN; LEVONORGESTREL; DISASTERS; ACCESS; WOMEN AB This article provides the evidence for contraceptive need to prevent unintended pregnancy during an emergency response, discusses the most appropriate types of contraceptives for disaster situations, and details the current provisions in place to provide contraceptives during an emergency response. C1 [Ellington, Sascha R.; Kourtis, Athena P.; Curtis, Kathryn M.; Tepper, Naomi; Jamieson, Denise J.; Zotti, Marianne; Barfield, Wanda] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Gorman, Susan] Ctr Dis Control & Prevent, Div Strateg Natl Stockpile, Atlanta, GA 30341 USA. RP Ellington, SR (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,Mailstop K34, Atlanta, GA 30341 USA. EM sellington@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 4 Z9 4 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2013 VL 22 IS 3 BP 189 EP 193 DI 10.1089/jwh.2012.4178 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 105IU UT WOS:000316061700124 PM 23421580 ER PT J AU Steinberg, L Sharp, C Stanford, MS Tharp, AT AF Steinberg, Lynne Sharp, Carla Stanford, Matthew S. Tharp, Andra Teten TI New Tricks for an Old Measure: The Development of the Barratt Impulsiveness Scale-Brief (BIS-Brief) SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE Barratt Impulsiveness Scale; item response theory; assessment ID ITEM RESPONSE THEORY; BORDERLINE-PERSONALITY-DISORDER; SELF-REPORT MEASURES; LIMITED-INFORMATION; AGGRESSIVE-BEHAVIOR; CONCURRENT VALIDITY; CONTINGENCY-TABLES; IMPULSE CONTROL; FACTOR MODEL; MSI-BPD AB The Barratt Impulsivity Scale (BIS), a 30-item self-report measure, is one of the most commonly used scales for the assessment of the personality construct of impulsiveness. It has recently marked 50 years of use in research and clinical settings. The current BIS-11 is held to measure 3 theoretical subtraits, namely, attentional, motor, and non-planning impulsiveness. We evaluated the factor structure of the BIS using full information item bifactor analysis for Likert-type items. We found no evidence supporting the 3-factor model. In fact, half of the items do not share any relation with other items and do not form any factor. In light of this, we introduce a unidimensional Barratt Impulsiveness Scale Brief (BIS-Brief) that includes 8 of the original BIS-11 items. Next, we present evidence of construct validity comparing scores obtained with the BIS-Brief against the original BIS total scores using data from (a) a community sample of borderline personality patients and normal controls, (b) a forensic sample, and (c) an inpatient sample of young adults and adolescents. We demonstrated similar indices of construct validity that is observed for the BIS-11 total score with the BIS-Brief score. Use of the BIS-Brief in clinical assessment settings and large epidemiological studies of psychiatric disorders will reduce the burden on respondents without loss of information. C1 [Steinberg, Lynne; Sharp, Carla] Univ Houston, Dept Psychol, Houston, TX 77204 USA. [Stanford, Matthew S.] Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA. [Tharp, Andra Teten] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Steinberg, L (reprint author), Univ Houston, Dept Psychol, 126 Heyne Bldg, Houston, TX 77204 USA. EM lsteinberg@uh.edu OI Sharp, Carla/0000-0001-8349-4701; Steinberg, Lynne/0000-0002-3265-1778 NR 59 TC 32 Z9 33 U1 4 U2 41 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD MAR PY 2013 VL 25 IS 1 BP 216 EP 226 DI 10.1037/a0030550 PG 11 WC Psychology, Clinical SC Psychology GA 104EH UT WOS:000315974000020 PM 23148649 ER PT J AU Douglas, JM Fenton, KA AF Douglas, John M., Jr. Fenton, Kevin A. TI UNDERSTANDING SEXUAL HEALTH AND ITS ROLE IN MORE EFFECTIVE PREVENTION PROGRAMS SO PUBLIC HEALTH REPORTS LA English DT Editorial Material C1 [Douglas, John M., Jr.; Fenton, Kevin A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Douglas, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM jyd3@cdc.gov NR 21 TC 8 Z9 8 U1 0 U2 4 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 SU 1 BP 1 EP 4 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 103PP UT WOS:000315931600001 PM 23450880 ER PT J AU Penman-Aguilar, A Carter, M Snead, MC Kourtis, AP AF Penman-Aguilar, Ana Carter, Marion Snead, M. Christine Kourtis, Athena P. TI Socioeconomic Disadvantage as a Social Determinant of Teen Childbearing in the U.S. SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; ADOLESCENT CHILDBEARING; RISK; FERTILITY; PREGNANCY; COMMUNITY; HEALTH; BIRTHS; OPPORTUNITY; EXPANSIONS AB Objective. We reviewed the literature focused on socioeconomic influences on teen childbearing and suggested directions for future research and practice related to this important indicator of teen sexual health. Methods. We conducted an electronic search of Medline, ERIC, PsychLit, and Sociological Abstracts databases for articles published from January 1995 to November 2011. Selected articles from peer-reviewed journals included original quantitative analyses addressing socioeconomic influences on first birth among teen women in the U.S. Articles were abstracted for key information, ranked for quality according to the U.S. Preventive Services Task Force guidelines, assessed for bias, and synthesized. Results. We selected articles with a range of observational study designs. Risk for bias varied across studies. All 12 studies that considered socioeconomic factors as influences on teen childbearing (vs. moderators or mediators of other effects) reported at least one statistically significant association relating low socioeconomic status, underemployment, low income, low education levels, neighborhood disadvantage, neighborhood physical disorder, or neighborhood-level income inequality to teen birth. Few reports included any associations contradicting this pattern. Conclusions. This review suggests that unfavorable socioeconomic conditions experienced at the community and family levels contribute to the high teen birth rate in the U.S. Future research into social determinants of sexual health should include multiple levels of measurement whenever possible. Root causes of teen childbearing should be evaluated in various populations and contexts. Interventions that address socioeconomic influences at multiple levels could positively affect large numbers of teens and help eliminate disparities in teen childbearing. C1 [Penman-Aguilar, Ana] Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Equ, Atlanta, GA 30333 USA. [Carter, Marion; Snead, M. Christine; Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Penman-Aguilar, A (reprint author), Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Equ, 4770 Buford Hwy NE,MS-K77, Atlanta, GA 30333 USA. EM bpv4@cdc.gov NR 47 TC 26 Z9 27 U1 9 U2 52 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 SU 1 BP 5 EP 22 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 103PP UT WOS:000315931600002 PM 23450881 ER PT J AU Murray, CC Hatfield-Timajchy, K Kraft, JM Bergdall, AR Habel, MA Kottke, M DiClemente, RJ AF Murray, Colleen Crittenden Hatfield-Timajchy, Kendra Kraft, Joan Marie Bergdall, Anna R. Habel, Melissa A. Kottke, Melissa DiClemente, Ralph J. TI In Their Own Words: Romantic Relationships and the Sexual Health of Young African American Women SO PUBLIC HEALTH REPORTS LA English DT Article ID HETEROSEXUAL COUPLES; DUAL PROTECTION; CONDOM USE; PREVENTION; INTERVENTION; ADOLESCENTS; TRIAL; PREGNANCY; EFFICACY; BEHAVIOR AB Objective. We assessed young African American women's understanding of "dual protection" (DP) (i.e., strategies that simultaneously protect against unintended pregnancies and sexually transmitted diseases [STDs]) and how relationship factors influence their use of DP methods. Methods. We conducted 10 focus groups with African American women (n=51) aged 15-24 years in Atlanta, Georgia, to identify barriers to and facilitators of their DP use. Focus group participants also completed a brief self-administered questionnaire that assessed demographics and sexual behaviors. We analyzed focus group data by theme: relationships, planning for sex, pregnancy intentions, STD worries, the trade-off between pregnancy and STDs, attitudes toward condoms and contraceptives, and understanding of DP. Results. From the questionnaire, 51% of participants reported that an STD would be the "worst thing that could happen," and 26% reported that being pregnant would be "terrible." Focus group data suggested that most participants understood what DP was but thought it was not always feasible. Relationship factors (e.g., trust, intimacy, length of relationship, and centrality) affected pregnancy intentions, STD concerns, and use of DR Social influences (e.g., parents) and pregnancy and STD history also affected attitudes about pregnancy, STDs, and relationships. Conclusions. Although participants identified risks associated with sex, a complex web of social and relationship factors influenced the extent to which they engaged in protective behavior. The extent to which relationship factors influence DP may reflect developmental tasks of adolescence and should be considered in any program promoting sexual health among young African American women. C1 [Murray, Colleen Crittenden; DiClemente, Ralph J.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hatfield-Timajchy, Kendra; Kraft, Joan Marie] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Bergdall, Anna R.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Habel, Melissa A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Kottke, Melissa] Emory Univ, Sch Med, Atlanta, GA 30322 USA. RP Murray, CC (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE,Room 436, Atlanta, GA 30322 USA. EM ccritte@emory.edu NR 27 TC 12 Z9 12 U1 1 U2 8 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 SU 1 BP 33 EP 42 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 103PP UT WOS:000315931600004 PM 23450883 ER PT J AU Robinson, SJ Stellato, A Stephens, J Kirby, S Forsythe, A Ivankovich, MB AF Robinson, Susan J. Stellato, Adam Stephens, Jennifer Kirby, Susan Forsythe, Ann Ivankovich, Megan B. TI On the Road to Well-Being: The Development of a Communication Framework for Sexual Health SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; PREVALENCE AB Objectives. Recognizing the need to work with all partners who have an interest in addressing sexual health issues, we explored values held by diverse stakeholders in the United States. Based on these findings, we developed a framework for use in communicating about sexual health issues and potential solutions. Methods. Our methods included an environmental scan, small-group metaphor elicitation and message framing assessments, interviews, and online surveys with diverse members of the public and health professionals. Results. Of four overarching value-based themes, two were best accepted across audiences: the first theme emphasized the importance of protecting health along the road of life through enabling good choices, and the second called for adding health promotion approaches to traditional disease prevention control. Nearly all supporting statements evaluated were effective and can be used to support either of the two best accepted overarching themes. Conclusions. Although there is a great diversity of opinion regarding how to address sexual health issues in the U.S., among diverse stakeholders we found some common values in our exploratory work. These common values were translated into message frameworks. In particular, the idea of broadening sexual health programs to include wellness-related approaches to help expand disease control and prevention efforts resonated with stakeholders across the political spectrum. These findings show promise for improved sexual health communication and a foundation on which to build support across various audiences, key opinion leaders, and stakeholders. C1 [Robinson, Susan J.; Ivankovich, Megan B.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Stellato, Adam; Stephens, Jennifer] Amer Inst Res, Washington, DC USA. [Kirby, Susan] Kirby Mkt Solut, San Diego, CA USA. [Forsythe, Ann] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Robinson, SJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM sjr2@cdc.gov NR 18 TC 3 Z9 3 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 SU 1 BP 43 EP 52 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 103PP UT WOS:000315931600005 PM 23450884 ER PT J AU Ivankovich, MB Leichliter, JS Douglas, JM AF Ivankovich, Megan B. Leichliter, Jami S. Douglas, John M., Jr. TI Measurement of Sexual Health in the U.S.: An Inventory of Nationally Representative Surveys and Surveillance Systems SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; BEHAVIOR AB Objectives. To identify opportunities within nationally representative surveys and surveillance systems to measure indicators of sexual health, we reviewed and inventoried existing data systems that include variables relevant to sexual health. Methods. We searched for U.S. nationally representative surveys and surveillance systems that provided individual-level sexual health data. We assessed the methods of each data system and catalogued them by their measurement of the following domains of sexual health: knowledge, communication, attitudes, service access and utilization, sexual behaviors, relationships, and adverse health outcomes. Results. We identified 18 U.S.-focused, nationally representative data systems: six assessing the general population, seven focused on special populations, and five addressing health outcomes. While these data systems provide a rich repository of information from which to assess national measures of sexual health, they present several limitations. Most importantly, apart from data on service utilization, routinely gathered, national data are currently focused primarily on negative aspects of sexual health (e.g., risk behaviors and adverse health outcomes) rather than more positive attributes (e.g., healthy communication and attitudes, and relationship quality). Conclusion. Nationally representative data systems provide opportunities to measure a broad array of domains of sexual health. However, current measurement gaps indicate the need to modify existing surveys, where feasible and appropriate, and develop new tools to include additional indicators that address positive domains of sexual health of the U.S. population across the life span. Such data can inform the development of effective policy actions, services, prevention programs, and resource allocation to advance sexual health. C1 [Ivankovich, Megan B.; Leichliter, Jami S.; Douglas, John M., Jr.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Douglas, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM jyd3@cdc.gov FU U.S. Department of Energy; CDC FX The authors acknowledge the contributions of Makia Powers, MD, MPH, FAAP, 2010-2011 Health Policy Leadership Fellow, Satcher Health Leadership Institute, Morehouse School of Medicine (Assistant Professor and Assistant Clerkship Director, Department of Pediatrics, Morehouse School of Medicine), who assisted with this research. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. NR 47 TC 9 Z9 9 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 SU 1 BP 62 EP 72 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 103PP UT WOS:000315931600007 PM 23450886 ER PT J AU Ford, JV Barnes, R Rompalo, A Hook, EW AF Ford, Jessie V. Barnes, Rheta Rompalo, Anne Hook, Edward W., III TI Sexual Health Training and Education in the U.S. SO PUBLIC HEALTH REPORTS LA English DT Article ID MEDICAL-SCHOOLS; STIGMA; RESOURCES; CAMPAIGNS; CURRICULA; GONORRHEA; INTERNET; HISTORY; WOMEN; CARE AB In 2011, both the National Prevention Strategy and Healthy People 2020 recognized "reproductive and sexual health" as a key area for improving the lives of Americans.(1,2) This increasing national emphasis on sexual health provides an important opportunity to refocus the efforts of U.S. health-care professionals. While reproductive health has historically been considered a U.S. public health priority,(3) the addition of sexual health to the short list of national priorities has important implications for clinicians and patients. Broadly embracing the concept of sexual health in health-care settings has the potential to reduce redundancy in care compared with current, more categorical approaches and to minimize the stigma associated with some aspects of sexuality and related adverse outcomes. These changes could increase both clinical efficiency and the proportion of the population receiving sexual health services. To foster sexual health, the National Prevention Strategy and Healthy People 2020 recommend increasing access to sexual health services, emphasizing sexual health education and encouraging screening for sexually transmitted infections (STIs) including human immunodeficiency virus (HIV).(1,2) To be most effective, these activities should involve both health-care providers (physicians, nurses, and related clinical providers) and patient audiences. Although this new national emphasis represents an opportunity to improve sexual health throughout the country, it also represents a challenge for the health-care community. The approach to patient care in matters of sexuality and sexual behavior will need to be reframed in subtle but critical ways. To meet this challenge, educational efforts for both health-care providers and patients will need to shift to support a more comprehensive approach to understanding and promoting sexual health throughout the life span. C1 [Ford, Jessie V.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, Atlanta, GA 30333 USA. [Barnes, Rheta] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Program Dev & Qual Improvement Branch, Atlanta, GA 30333 USA. [Rompalo, Anne] Johns Hopkins Univ, Johns Hopkins Sch Med, STD HIV Prevent Training Ctr, Baltimore, MD USA. [Hook, Edward W., III] Univ Alabama Birmingham, Dept Epidemiol & Microbiol, Birmingham, AL USA. [Hook, Edward W., III] Jefferson Cty Dept Hlth, Clin STD Control Program, Birmingham, AL USA. [Hook, Edward W., III] Alabama North Carolina STD HIV Prevent Training C, Birmingham, AL USA. RP Ford, JV (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, 1600 Clifton Rd NE,MS E-44, Atlanta, GA 30333 USA. EM cze8@cdc.gov NR 48 TC 11 Z9 11 U1 3 U2 18 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 SU 1 BP 96 EP 101 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 103PP UT WOS:000315931600011 PM 23450890 ER PT J AU Ivankovich, MB Fenton, KA Douglas, JM AF Ivankovich, Megan B. Fenton, Kevin A. Douglas, John M., Jr. TI Considerations for National Public Health Leadership in Advancing Sexual Health SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; SURVEILLANCE; PREVALENCE; BEHAVIORS; US AB Nations across the globe face significant public heath challenges in optimizing sexual health, including reducing human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), sexually transmitted infections (STIs), unintended pregnancies, and sexual violence, and mitigating the associated adverse social and economic impacts. In response, some countries have implemented national strategies and other efforts focused on promoting more holistic and integrated approaches for addressing these syndemics. This article describes opportunities for national leadership to use a more holistic approach to improve the sexual health of individuals and communities. C1 [Ivankovich, Megan B.; Fenton, Kevin A.; Douglas, John M., Jr.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Douglas, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM jyd3@cdc.gov FU U.S. Department of Energy; CDC FX The authors acknowledge the contributions of the Centers for Disease Control and Prevention (CDC)/Health Resources and Services Administration Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment, Workgroup on Sexual Health; and other CDC staff and external partners for their advice on concepts presented in this article. This research was supported in part by an appointment to the Research Participation Program at CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. NR 63 TC 11 Z9 11 U1 0 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 SU 1 BP 102 EP 110 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 103PP UT WOS:000315931600012 PM 23450891 ER PT J AU Greene, E Frye, V Mansergh, G Colfax, GN Hudson, SM Flores, SA Hoover, DR Bonner, S Koblin, BA AF Greene, Emily Frye, Victoria Mansergh, Gordon Colfax, Grant N. Hudson, Sharon M. Flores, Stephen A. Hoover, Donald R. Bonner, Sebastian Koblin, Beryl A. TI Correlates of Unprotected Vaginal or Anal Intercourse with Women Among Substance-Using Men Who Have Sex with Men SO AIDS AND BEHAVIOR LA English DT Article DE Bisexual; Heterosexual; HIV; MSMW; Condom usage ID BISEXUALLY ACTIVE MEN; BLACK-MEN; RISK BEHAVIORS; UNITED-STATES; TREATMENT OPTIMISM; HIV TRANSMISSION; SAN-FRANCISCO; GAY; PARTNERS; SAMPLE AB The role men who have sex with men and women (MSMW) play in heterosexual HIV transmission is not well understood. We analyzed baseline data from Project MIX, a behavioral intervention study of substance-using men who have sex with men (MSM), and identified correlates of unprotected vaginal intercourse, anal intercourse, or both with women (UVAI). Approximately 10 % (n = 194) of the men reported vaginal sex, anal sex, or both with a woman; of these substance-using MSMW, 66 % (129) reported UVAI. Among substance-using MSMW, multivariate analyses found unemployment relative to full/part-time employment (OR = 2.28; 95 % CI 1.01, 5.17), having a primary female partner relative to no primary female partner (OR = 3.44; CI 1.4, 8.46), and higher levels of treatment optimism (OR = 1.73; 95 % CI 1.18, 2.54) increased odds of UVAI. Strong feelings of connection to a same-race gay community (OR = 0.71; 95 % CI 0.56, 0.91) and Viagra use (OR = 0.31; 95 % CI 0.10, 0.95) decreased odds of UVAI. This work suggests that although the proportion of substance-using MSM who also have sex with women is low, these men engage in unprotected sex with women, particularly with primary female partners. This work highlights the need for further research with the substance using MSMW population to inform HIV prevention interventions specifically for MSMW. C1 [Greene, Emily; Frye, Victoria] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, New York, NY 10065 USA. [Greene, Emily] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Frye, Victoria] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA. [Mansergh, Gordon; Flores, Stephen A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Colfax, Grant N.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Hudson, Sharon M.] Hlth Res Assoc, Los Angeles, CA USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Hoover, Donald R.] Rutgers State Univ, Inst Hlth Care Policy & Aging Res, Piscataway, NJ USA. [Koblin, Beryl A.] New York Blood Ctr, Lab Infect Dis Prevent, Lindsley F Kimball Res Inst, New York, NY 10065 USA. RP Greene, E (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, 310 East 67th St, New York, NY 10065 USA. EM egreene@nybloodcenter.org FU NIDA NIH HHS [T32 DA031099, K01 DA020774, K01-DA-020774]; PHS HHS [U65/CCU922213, U65/CCU222309, U65/CCU922215, U65/CCU522209] NR 42 TC 3 Z9 3 U1 1 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2013 VL 17 IS 3 BP 889 EP 899 DI 10.1007/s10461-012-0357-0 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 099VC UT WOS:000315649700008 PM 23229336 ER PT J AU Hock-Long, L Henry-Moss, D Carter, M Hatfield-Timajchy, K Erickson, PI Cassidy, A Macauda, M Singer, M Chittams, J AF Hock-Long, Linda Henry-Moss, Dare Carter, Marion Hatfield-Timajchy, Kendra Erickson, Pamela I. Cassidy, Amy Macauda, Mark Singer, Merrill Chittams, Jesse TI Condom Use with Serious and Casual Heterosexual Partners: Findings from a Community Venue-Based Survey of Young Adults SO AIDS AND BEHAVIOR LA English DT Article DE Heterosexual partners; Condom use; Pregnancy; Sexually transmitted infections ID SEXUALLY-TRANSMITTED-DISEASES; CHLAMYDIA-TRACHOMATIS; LATINO MEN; LAST SEX; RISK; PREVENTION; PREGNANCY; ADOLESCENTS; HIV; BEHAVIOR AB Given the racial/ethnic disparities that characterize STI trends and recent increases in heterosexually transmitted HIV infection in the US, an understanding of factors underlying condom use among young adults in minority communities is vitally important. To this end, this paper presents findings from a community venue-based survey examining the influence of motivations, heuristics, and relationship factors on condom behaviors with serious and casual heterosexual partners in a sample of urban African American and Puerto Rican males and females ages 18-25 (n = 380). Condom use rates at time of last sex were considerably higher with casual partners (n = 87) than with serious (n = 313) partners, 77.9% vs. 38.7%. While dual pregnancy/STI prevention was the most frequently cited reason for use at last sex with casual partners, pregnancy prevention was the most frequently cited reason for use with serious partners. Bivariate conditional logistic regression analyses found two factors to be associated with condom use at last sex with casual partners: use at first sex with the partner and belief that neighborhood peers worried some/a lot about HIV. In contrast, such factors as condom heuristics (e.g., nonuse symbolizes trust), contraceptive status, and markers of emotional intimacy were associated with condom use with serious partners in both bivariate and multivariable analyses. C1 [Hock-Long, Linda; Henry-Moss, Dare; Cassidy, Amy] Family Planning Council, Res Dept, Philadelphia, PA 19103 USA. [Carter, Marion; Hatfield-Timajchy, Kendra] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Erickson, Pamela I.; Macauda, Mark; Singer, Merrill] Univ Connecticut, Dept Anthropol, Storrs, CT USA. [Chittams, Jesse] Drexel Univ, Sch Publ Hlth, Biostat Serv Ctr, Philadelphia, PA 19104 USA. RP Hock-Long, L (reprint author), Family Planning Council, Res Dept, 1700 Market St,18th Floor, Philadelphia, PA 19103 USA. EM linda@familyplanning.org OI HENRY-MOSS, DARE/0000-0002-4088-0028 FU PHS HHS [U58/CCU123064, U58/CCU323065] NR 47 TC 12 Z9 12 U1 0 U2 14 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2013 VL 17 IS 3 BP 900 EP 913 DI 10.1007/s10461-012-0177-2 PG 14 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 099VC UT WOS:000315649700009 PM 22460225 ER PT J AU Hampton, MC Halkitis, PN Storholm, ED Kupprat, SA Siconolfi, DE Jones, D Steen, JT Gillen, S McCree, DH AF Hampton, Melvin C. Halkitis, Perry N. Storholm, Erik D. Kupprat, Sandra A. Siconolfi, Daniel E. Jones, Donovan Steen, Jeff T. Gillen, Sara McCree, Donna Hubbard TI Sexual Risk Taking in Relation to Sexual Identification, Age, and Education in a Diverse Sample of African American Men Who Have Sex with Men (MSM) in New York City SO AIDS AND BEHAVIOR LA English DT Article DE African American MSM; HIV; Sexual risk-taking; Sexual identity; Age; Education ID HIV RISK; UNITED-STATES; BLACK-MEN; SURVEILLANCE SYSTEM; UNPROTECTED SEX; BISEXUAL MEN; DRUG-USERS; WHITE MEN; GAY MEN; BEHAVIOR AB HIV disproportionately affects African American men who have sex with men (MSM) in the United States. To inform this epidemiological pattern, we examined cross-sectional sexual behavior data in 509 African American MSM. Bivariate logistic regression analyses were conducted to examine the extent to which age, education, and sexual identity explain the likelihood of engaging in sex with a partner of a specific gender and the likelihood of engaging in unprotected sexual behaviors based on partner gender. Across all partner gender types, unprotected sexual behaviors were more likely to be reported by men with lower education. Younger, non-gay identified men were more likely to engage in unprotected sexual behaviors with transgender partners, while older, non-gay identified men were more likely to engage in unprotected sexual behaviors with women. African American MSM do not represent a monolithic group in their sexual behaviors, highlighting the need to target HIV prevention efforts to different subsets of African American MSM communities as appropriate. C1 [Hampton, Melvin C.; Halkitis, Perry N.; Storholm, Erik D.; Kupprat, Sandra A.; Siconolfi, Daniel E.; Jones, Donovan; Steen, Jeff T.] NYU, Ctr Hlth Ident Behav & Prevent Studies, Steinhardt Sch Culture Educ & Human Dev, New York, NY 10003 USA. [Gillen, Sara] Harlem United, New York, NY USA. [McCree, Donna Hubbard] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Halkitis, PN (reprint author), NYU, Ctr Hlth Ident Behav & Prevent Studies, Steinhardt Sch Culture Educ & Human Dev, 82 Washington Sq East,Pless 555, New York, NY 10003 USA. EM pnh1@nyu.edu FU NCHHSTP CDC HHS [1UR6 PS000369] NR 40 TC 11 Z9 11 U1 2 U2 12 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2013 VL 17 IS 3 BP 931 EP 938 DI 10.1007/s10461-012-0139-8 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 099VC UT WOS:000315649700012 PM 22298339 ER PT J AU Conner, LC Wiener, J Lewis, JV Phill, R Peralta, L Chandwani, S Koenig, LJ AF Conner, Latoya C. Wiener, Jeffrey Lewis, Jennifer V. Phill, Rhonda Peralta, Ligia Chandwani, Sulachni Koenig, Linda J. TI Prevalence and Predictors of Drug Use Among Adolescents with HIV Infection Acquired Perinatally or Later in Life SO AIDS AND BEHAVIOR LA English DT Article DE Adolescents; HIV/AIDS; Drug use; Public health ID HUMAN-IMMUNODEFICIENCY-VIRUS; BECK DEPRESSION INVENTORY; SUBSTANCE USE; UNITED-STATES; MEDICATION ADHERENCE; USE DISORDERS; YOUTH; SYMPTOMS; RISK; HIV/AIDS AB We examined the prevalence and predictors of drug use among a diverse group of adolescents living with HIV infection acquired perinatally or through sexual risk behaviors ("behaviorally acquired"). Adolescents ages 13-21 (n = 166) who were receiving care at one of five pediatric/adolescent HIV clinics in three US cities (Baltimore MD, Washington DC, and New York NY) and were enrolled in a behavioral intervention were interviewed at baseline regarding lifetime drug use experiences and depression symptoms. A majority of study participants reported using alcohol (57.2%) and marijuana (51.2%); 48.8% reported tobacco/cigarette use. The mean age of onset of use for each type of drug was 14 years or younger. A larger proportion of participants with behaviorally acquired HIV than adolescents with perinatally acquired HIV reported lifetime use of alcohol (76.1 vs. 44.4%), marijuana (73.1 vs. 36.4%), tobacco (70.2 vs. 34.3%), and club drugs (22.4 vs. 3%) (all p < 0.001). C1 [Conner, Latoya C.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Wiener, Jeffrey; Koenig, Linda J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Lewis, Jennifer V.; Chandwani, Sulachni] New York Univ Hosp, New York, NY USA. [Phill, Rhonda; Peralta, Ligia] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. RP Koenig, LJ (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS D-21, Atlanta, GA 30333 USA. EM lek5@cdc.gov OI Lewis, Jennifer V./0000-0002-3573-5125 FU PHS HHS [U64CCU319455, U64CCU319459, U64CCU219448] NR 54 TC 3 Z9 3 U1 2 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2013 VL 17 IS 3 BP 976 EP 986 DI 10.1007/s10461-011-9950-x PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 099VC UT WOS:000315649700016 PM 21842420 ER PT J AU Sapiano, TN Moore, A Kalayil, EJ Zhang, X Chen, B Uhl, G Patel-Larson, A Williams, W AF Sapiano, Tobey N. Moore, A. Kalayil, E. J. Zhang, X. Chen, B. Uhl, G. Patel-Larson, A. Williams, W. TI Evaluation of an HIV Prevention Intervention Designed for African American Women: Results from the SISTA Community-Based Organization Behavioral Outcomes Project SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Risk reduction behavior; Behavioral interventions; African American; Women; Program evaluation; SISTA; Sisters Informing Sisters about Topics on AIDS ID LONGITUDINAL DATA-ANALYSIS; UNITED-STATES; HIV/AIDS CRISIS; SEXUAL RISK; METAANALYSIS; DISPARITIES; ADAPTATION; INFECTION; DIFFUSION; DIAGNOSES AB One of the Centers for Disease Control and Prevention's strategies for addressing racial disparities within the HIV epidemic is to support the implementation of HIV prevention behavioral interventions designed for African Americans. One such intervention is Sisters Informing Sisters about Topics on AIDS (SISTA), a culturally relevant and gender-specific, five-session, group-level, HIV prevention intervention designed for African American women. In 2008, the Centers for Disease Control and Prevention funded five community-based organizations to conduct outcome monitoring of SISTA to assess the outcomes associated with implementation in the field. Using a 90-day recall, demographic and sexual risk data were collected from participants at baseline and at 90 and 180 days post-intervention. Findings reveal that women participating in SISTA (n = 432) demonstrated a significant reduction in sexual risk between baseline and both follow-up time points for each of the six outcomes being measured (e.g., any unprotected sex, all protected sex). C1 [Sapiano, Tobey N.; Moore, A.; Zhang, X.; Uhl, G.; Patel-Larson, A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Kalayil, E. J.; Chen, B.; Williams, W.] MANILA Consulting Grp Inc, Mclean, VA USA. RP Sapiano, TN (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E59, Atlanta, GA 30333 USA. EM gvf8@cdc.gov NR 31 TC 11 Z9 11 U1 2 U2 13 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2013 VL 17 IS 3 BP 1052 EP 1067 DI 10.1007/s10461-012-0292-0 PG 16 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 099VC UT WOS:000315649700022 PM 22990762 ER PT J AU Bradley, H Asbel, L Bernstein, K Mattson, M Pathela, P Mohamed, M Samuel, MC Schwebke, J Stenger, M Tabidze, I Zenilman, J Dowell, D Weinstock, H AF Bradley, Heather Asbel, Lenore Bernstein, Kyle Mattson, Melanie Pathela, Preeti Mohamed, Mukhtar Samuel, Michael C. Schwebke, Jane Stenger, Mark Tabidze, Irina Zenilman, Jonathan Dowell, Deborah Weinstock, Hillard TI HIV Testing Among Patients Infected with Neisseria gonorrhoeae: STD Surveillance Network, United States, 2009-2010 SO AIDS AND BEHAVIOR LA English DT Article DE HIV testing; Neisseria gonorrhoeae ID SEXUALLY-TRANSMITTED-DISEASES; PREVALENCE; CLINICS; MEN; SEX AB We used data from the STD Surveillance Network to estimate HIV testing among patients being tested or treated for gonorrhea. Of 1,845 gonorrhea-infected patients identified through nationally notifiable disease data, only 51% were tested for HIV when they were tested or treated for gonorrhea. Among the 10 geographic sites in this analysis, the percentage of patients tested for HIV ranged from 22-63% for men and 20-79% for women. Nearly 33% of the un-tested patients had never been previously HIV-tested. STD clinic patients were more likely to be HIV-tested than those in other practice settings. C1 [Bradley, Heather; Dowell, Deborah; Weinstock, Hillard] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Bradley, Heather] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Asbel, Lenore] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Bernstein, Kyle] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Mattson, Melanie] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Pathela, Preeti] New York City Dept Hlth & Mental Hyg, Queens, NY USA. [Mohamed, Mukhtar] Connecticut Dept Publ Hlth, Hartford, CT USA. [Schwebke, Jane] Univ Alabama Birmingham, Birmingham, AL USA. [Stenger, Mark] Washington State Dept Hlth, Olympia, WA USA. [Tabidze, Irina] Chicago Dept Publ Hlth, Chicago, IL USA. [Zenilman, Jonathan] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Bradley, H (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,NE,MS E-02, Atlanta, GA 30333 USA. EM iyk5@cdc.gov NR 16 TC 5 Z9 5 U1 2 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2013 VL 17 IS 3 BP 1205 EP 1210 DI 10.1007/s10461-012-0304-0 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 099VC UT WOS:000315649700036 PM 22983501 ER PT J AU Owusu-Edusei, K Gift, TL Chesson, HW Kent, CK AF Owusu-Edusei, Kwame, Jr. Gift, Thomas L. Chesson, Harrell W. Kent, Charlotte K. TI Investigating the Potential Public Health Benefit of Jail-based Screening and Treatment Programs for Chlamydia SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE chlamydia; jail-based screening; mathematical transmission modeling ID SEXUALLY-TRANSMITTED INFECTION; NEISSERIA-GONORRHOEAE; MATHEMATICAL-MODELS; UNITED-STATES; CORRECTIONAL FACILITIES; TRACHOMATIS INFECTIONS; SYPHILIS CONTROL; SAN-FRANCISCO; COUNTY JAIL; COMMUNITY AB Observational studies have found mixed results on the impact of jail-based chlamydia screen-and-treat programs on community prevalence. In the absence of controlled trials or prospectively designed studies, dynamic mathematical models that incorporate movements in and out of jail and sexual contacts (including disease transmission) can provide useful information. We explored the impact of jail-based chlamydia screening on a hypothetical community's prevalence with a deterministic compartmental model focusing on heterosexual transmission. Parameter values were obtained from the published literature. Two analyses were conducted. One used national values (large community); the other used values reported among African Americans-the population with the highest incarceration rates and chlamydia burden (small community). A comprehensive sensitivity analysis was carried out. For the large-community analysis, chlamydia prevalence decreased by 13% (from 2.3% to 2.0%), and based on the ranges of parameter values (including screening coverage of 10%-100% and a post-screening treatment rate of 50%-100%) used in the sensitivity analysis, this decrease ranged from 0.1% to 58%. For the small-community analysis, chlamydia prevalence decreased by 54% (from 4.6% to 2.1%). Jail-based chlamydia screen-and-treat programs have the potential to reduce chlamydia prevalence in communities with high incarceration rates. However, the magnitude of this potential decrease is subject to considerable uncertainty. C1 [Owusu-Edusei, Kwame, Jr.; Gift, Thomas L.; Chesson, Harrell W.; Kent, Charlotte K.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE,Mailstop E-80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov RI Barley, Kamal/F-9579-2011 OI Barley, Kamal/0000-0003-1874-9813 NR 65 TC 10 Z9 10 U1 3 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 1 PY 2013 VL 177 IS 5 BP 463 EP 473 DI 10.1093/aje/kws240 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 100LV UT WOS:000315703600011 PM 23403986 ER PT J AU Townsend, JS Steele, CB Richardson, LC Stewart, SL AF Townsend, Julie S. Steele, C. Brooke Richardson, Lisa C. Stewart, Sherri L. TI Health behaviors and cancer screening among Californians with a family history of cancer SO GENETICS IN MEDICINE LA English DT Article DE behavioral risk factors; breast neoplasms; cancer screening; colorectal neoplasms; family medical history ID LIFE-STYLE BEHAVIORS; BREAST-CANCER; COLORECTAL-CANCER; RISK-FACTORS; PHYSICAL-ACTIVITY; LYNCH SYNDROME; WOMEN; METAANALYSIS; US; INFORMATION AB Purpose: The purpose of this study was to compare health behaviors and cancer screening among Californians with and without a family history of cancer. Methods: We analyzed data from the 2005 California Health Interview Survey to ascertain cancer screening test use and to estimate the prevalence of health behaviors that may reduce the risk of cancer. We used logistic regression to control for demographic factors and health-care access. Results: Women with a family history of breast or ovarian cancer were more likely to be up to date with mammography as compared with women with no family history of cancer (odds ratio = 1.69, 95% confidence interval (1.39, 2.04)); their health behaviors were similar to other women. Men and women with a family history of colorectal cancer were more likely to be up to date with colorectal cancer screening as compared with individuals with no family history of cancer (odds ratio = 2.77, 95% confidence interval (2.20, 3.49)) but were less likely to have a body mass index <25 kg/m(2) (odds ratio = 0.80, 95% confidence interval (0.67, 0.94)). Conclusion: Innovative methods are needed to encourage those with a moderate-to-strong familial risk for breast cancer and colorectal cancer to increase their physical activity levels, strive to maintain a healthy weight, quit smoking, and reduce alcohol use. Genet Med 2013:15(3):212-221 C1 [Townsend, Julie S.; Steele, C. Brooke; Richardson, Lisa C.; Stewart, Sherri L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA. RP Townsend, JS (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA. EM jtownsend@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 9 Z9 9 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD MAR PY 2013 VL 15 IS 3 BP 212 EP 221 DI 10.1038/gim.2012.118 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 101AI UT WOS:000315747000008 PM 23018750 ER PT J AU Wang, Y Kennedy, J Caggana, M Zimmerman, R Thomas, S Berninger, J Harris, K Green, NS Oyeku, S Hulihan, M Grant, AM Grosse, SD AF Wang, Ying Kennedy, Joseph Caggana, Michele Zimmerman, Regina Thomas, Sanil Berninger, John Harris, Katharine Green, Nancy S. Oyeku, Suzette Hulihan, Mary Grant, Althea M. Grosse, Scott D. TI Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity SO GENETICS IN MEDICINE LA English DT Article DE ethnicity; foreign-born; incidence rate; maternal race; nativity; newborn screening; records linkage; sickle cell disease; US-born ID RECORD-LINKAGE; FOLLOW-UP; DATA SETS; POPULATION; EXPERIENCE; DATABASES; ETHNICITY; CHILDREN AB Purpose: Sickle cell disease is estimated to occur in 1:300-400 African-American births, with higher rates among immigrants from Africa and the Caribbean, and is less common among Hispanic births. This study determined sickle cell disease incidence among New York State newborns stratified by maternal race/ethnicity and nativity. Methods: Newborns with confirmed sickle cell disease born to New York State residents were identified by the New York State newborn screening program for the years 2000-2008 and matched to birth records to obtain birth and maternal information. Annual incidence rates were computed and bivariate analyses were conducted to examine associations with maternal race/ethnicity and nativity. Results: From 2000 to 2008, 1,911 New York State newborns were diagnosed with sickle cell disease and matched to the birth certificate files. One in every 1,146 live births was diagnosed with sickle cell disease. Newborns of non-Hispanic black mothers accounted for 86% of sickle cell disease cases whereas newborns of Hispanic mothers accounted for 12% of cases. The estimated incidence was 1:230 live births for non-Hispanic black mothers, 1:2,320 births for Hispanic mothers, and 1:41,647 births for non-Hispanic white mothers. Newborns of foreign-born non-Hispanic black mothers had a twofold higher incidence of sickle cell disease than those born to US-born non-Hispanic black mothers (P < 0.001). Conclusion: This study provides the first US estimates of sickle cell disease incidence by maternal nativity. Women born outside the United States account for the majority of children with sickle cell disease born in New York State. Such findings identify at-risk populations and inform outreach activities that promote ongoing, high-quality medical management to affected children. Genet Med 2013:15(3):222-228 C1 [Wang, Ying; Thomas, Sanil] Bur Environm & Occupat Epidemiol, Congenital Malformat Registry, Ctr Environm Hlth, New York State Dept Hlth, Albany, NY USA. [Wang, Ying] SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, Albany, NY USA. [Kennedy, Joseph; Zimmerman, Regina] Bur Vital Stat, New York City Dept Hlth & Mental Hyg, New York, NY USA. [Caggana, Michele] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA. [Caggana, Michele; Berninger, John; Harris, Katharine] New York State Dept Hlth, Newborn Screening Program, Wadsworth Ctr, Albany, NY USA. [Green, Nancy S.] Columbia Univ, Med Ctr, Div Hematol, Irving Inst Clin & Translat Res, New York, NY USA. [Oyeku, Suzette] Yeshiva Univ Albert Einstein Coll Med, Childrens Hosp Montefiore, Bronx, NY 10461 USA. [Hulihan, Mary; Grant, Althea M.; Grosse, Scott D.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Wang, Y (reprint author), Bur Environm & Occupat Epidemiol, Congenital Malformat Registry, Ctr Environm Hlth, New York State Dept Hlth, Albany, NY USA. EM wxy01@health.state.ny.us OI Green, Nancy/0000-0002-9877-1561 FU US Centers for Disease Control and Prevention; National Heart, Lung and Blood Institute [U50DD000722] FX This project was supported, in part, by the US Centers for Disease Control and Prevention and the National Heart, Lung and Blood Institute, cooperative agreement no. U50DD000722. The authors thank Christopher Johnson of the NBS Program of the NYS Department of Health for preparing the newborn screening data for this project. NR 23 TC 8 Z9 8 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD MAR PY 2013 VL 15 IS 3 BP 222 EP 228 DI 10.1038/gim.2012.128 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 101AI UT WOS:000315747000009 PM 23018751 ER PT J AU Henley, SJ Larson, TC Wu, MX Antao, VCS Lewis, M Pinheiro, GA Eheman, C AF Henley, S. Jane Larson, Theodore C. Wu, Manxia Antao, Vinicius C. S. Lewis, Mary Pinheiro, Germania A. Eheman, Christie TI Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008 SO INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Mesothelioma; Incidence; Cancer surveillance ID ASBESTOS EXPOSURE; MALIGNANT MESOTHELIOMA; PLEURAL MESOTHELIOMA; PERITONEAL MESOTHELIOMA; ENVIRONMENTAL EXPOSURE; CANCER RATES; LUNG-CANCER; EPIDEMIOLOGY; UPDATE; SURVEILLANCE AB Background: The decline in asbestos use in the United States may impact mesothelioma incidence. Objective: This report provides national and state-specific estimates of mesothelioma incidence in the United States using cancer surveillance data for the entire US population. Methods: Data from the National Program for Cancer Registries and the Surveillance, Epidemiology, and End Results program were used to calculate incidence rates and annual percent change. Results: During 2003-2008, an average of 1.05 mesothelioma cases per 100 000 persons were diagnosed annually in the United States; the number of cases diagnosed each year remained level, whereas rates decreased among men and were stable among women. Conclusion: US population-based cancer registry data can be used to determine the burden of mesothelioma and track its decline. Even 30 years after peak asbestos use in the United States, 3200 mesothelioma cases are diagnosed annually, showing that the US population is still at risk. C1 [Henley, S. Jane; Wu, Manxia; Lewis, Mary; Eheman, Christie] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Larson, Theodore C.; Antao, Vinicius C. S.] Ctr Dis Control & Prevent, Div Hlth Studies, Agcy Toxic Subst & Dis Registry, Atlanta, GA 30341 USA. [Pinheiro, Germania A.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. RP Henley, SJ (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-69, Atlanta, GA 30341 USA. EM skh3@cdc.gov OI Henley, S Jane/0000-0002-2420-306X FU Intramural CDC HHS [CC999999] NR 64 TC 25 Z9 26 U1 1 U2 10 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1077-3525 EI 2049-3967 J9 INT J OCCUP ENV HEAL JI Int. J. Occup. Environ. Health PD MAR PY 2013 VL 19 IS 1 BP 1 EP 10 DI 10.1179/2049396712Y.0000000016 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 104PS UT WOS:000316007300001 PM 23582609 ER PT J AU Donohue, KM Miller, RL Perzanowski, MS Just, AC Hoepner, LA Arunajadai, S Canfield, S Resnick, D Calafat, AM Perera, FP Whyatt, RM AF Donohue, Kathleen M. Miller, Rachel L. Perzanowski, Matthew S. Just, Allan C. Hoepner, Lori A. Arunajadai, Srikesh Canfield, Stephen Resnick, David Calafat, Antonia M. Perera, Frederica P. Whyatt, Robin M. TI Prenatal and postnatal bisphenol A exposure and asthma development among inner-city children SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Bisphenol A; asthma; wheeze; children; exhaled nitric oxide; IgE; cohort study ID ISAAC VIDEO QUESTIONNAIRE; EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; PRESCHOOL-CHILDREN; BIRTH COHORT; DAY-CARE; T-CELLS; WHEEZE; PREGNANCY; DESIGN AB Background: Bisphenol A (BPA) is used widely to manufacture food container linings. Mouse models suggest exposure to BPA might increase allergic inflammation. Objectives: We hypothesized that BPA exposure, as assessed based on urinary BPA concentrations, would be associated with increased odds of wheeze and asthma and increased fraction of exhaled nitric oxide (FENO) values in children. Methods: The Columbia Center for Children's Environmental Health recruited pregnant women for a prospective birth cohort study (n = 568). Mothers during the third trimester and children at ages 3, 5, and 7 years provided spot urine samples. Total urinary BPA concentrations were measured by using online solid-phase extraction, high-performance liquid chromatography, isotope-dilution tandem mass spectrometry. Wheeze in the last 12 months was measured by using questionnaires at ages 5, 6, and 7 years. Asthma was determined by a physician once between ages 5 and 12 years. FENO values were measured at ages 7 to 11 years. Results: Prenatal urinary BPA concentrations were associated inversely with wheeze at age 5 years (odds ratio [OR], 0.7; 95% CI, 0.5-0.9; P = .02). Urinary BPA concentrations at age 3 years were associated positively with wheeze at ages 5 years (OR, 1.4; 95% CI, 1.1-1.8; P = .02) and 6 years (OR, 1.4; 95% CI, 1.0-1.9; P = .03). BPA concentrations at age 7 years were associated with wheeze at age 7 years (OR, 1.4; 95% CI, 1.0-1.9; P = .04) and FENO values (beta = 0.1; 95% CI, 0.02-0.2; P = .02). BPA concentrations at ages 3, 5, and 7 years were associated with asthma (OR, 1.5 [95% CI, 1.1-2.0], P = .005; OR, 1.4 [95% CI, 1.0-1.9], P = .03; and OR, 1.5 [95% CI, 1.0-2.1], P = .04, respectively). Conclusions: This is the first report of an association between postnatal urinary BPA concentrations and asthma in children. (J Allergy Clin Immunol 2013;131:736-42.) C1 [Donohue, Kathleen M.; Miller, Rachel L.; Canfield, Stephen] Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care, New York, NY 10032 USA. [Miller, Rachel L.; Resnick, David] Columbia Univ Coll Phys & Surg, Div Pediat Allergy & Immunol, New York, NY 10032 USA. [Donohue, Kathleen M.; Miller, Rachel L.; Perzanowski, Matthew S.; Just, Allan C.; Hoepner, Lori A.; Perera, Frederica P.; Whyatt, Robin M.] Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY USA. [Miller, Rachel L.; Perzanowski, Matthew S.; Just, Allan C.; Hoepner, Lori A.; Perera, Frederica P.; Whyatt, Robin M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA. [Arunajadai, Srikesh] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA. RP Donohue, KM (reprint author), Columbia Univ, Div Gen Med, 622 West 168th St,PH9E Rm 105K, New York, NY 10032 USA. EM Kd2128@columbia.edu RI Osborne, Nicholas/N-4915-2015; OI Osborne, Nicholas/0000-0002-6700-2284; Hoepner, Lori/0000-0002-4404-8140; Just, Allan/0000-0003-4312-5957 FU National Institute of Environmental Health Sciences [RC2ES018784, R01ES014393, P30ES009089, R01ES08977, PO1ES09600, R01ES013163]; US Environmental Protection Agency [R827027, RD832141, RD834509]; John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; Educational Foundation of America; Millstream Fund; New York Community Trust; NIH; US Environmental Protection Agency (EPA); National Institute of Environmental Health Sciences FX Supported by the National Institute of Environmental Health Sciences (RC2ES018784, R01ES014393, P30ES009089, R01ES08977, R01ES013163, and PO1ES09600), the US Environmental Protection Agency (R827027, RD832141, and RD834509), the John and Wendy Neu Family Foundation, the Blanchette Hooker Rockefeller Fund, New York Community Trust, the Educational Foundation of America, and the Millstream Fund. The findings expressed in this article are the opinions of the authors and do not necessarily reflect the official opinion of the Centers for Disease Control and Prevention.; K. M. Donohue has received research and travel support from the National Institutes of Health (NIH), is employed by Columbia University, and has received travel support from the Alpha-1 Foundation. R. L. Miller has received research support from the NIH and the US Environmental Protection Agency (EPA). M.S. Perzanowski has received research support from the NIH and has received travel support from Indoor Biotechnology. L. A. Hoepner has received research support from the National Institute of Environmental Health Sciences. S. Canfield has received research support from the NIH and EPA and has received travel support from the NIH. D. Resnick has received research support from the NIH. R. M. Whyatt has received research and travel support from the NIH and is employed by Columbia University. The rest of the authors declare that they have no relevant conflicts of interest. NR 57 TC 65 Z9 66 U1 0 U2 39 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2013 VL 131 IS 3 BP 736 EP + DI 10.1016/j.jaci.2012.12.1573 PG 13 WC Allergy; Immunology SC Allergy; Immunology GA 098ZM UT WOS:000315587800015 PM 23452902 ER PT J AU Herman, EK Greninger, AL Visvesvara, GS Marciano-Cabral, F Dacks, JB Chiu, CY AF Herman, Emily K. Greninger, Alexander L. Visvesvara, Govinda S. Marciano-Cabral, Francine Dacks, Joel B. Chiu, Charles Y. TI The Mitochondrial Genome and a 60-kb Nuclear DNA Segment from Naegleria fowleri, the Causative Agent of Primary Amoebic Meningoencephalitis SO JOURNAL OF EUKARYOTIC MICROBIOLOGY LA English DT Article DE amoebic infections; amoebic mitochondrial genome; deep sequencing; encephalitis; genomics; infectious disease; meningitis; PAM; whole-genome sequencing ID FREE-LIVING AMEBAS; CYSTEINE PROTEASES; MAXIMUM-LIKELIHOOD; TRYPANOSOMA-BRUCEI; MIXED MODELS; EVOLUTION; GENE; INFECTION; SEQUENCE; GROWTH AB Naegleria fowleri is a unicellular eukaryote causing primary amoebic meningoencephalitis, a neuropathic disease killing 99% of those infected, usually within 714days. Naegleria fowleri is found globally in regions including the US and Australia. The genome of the related nonpathogenic species Naegleria gruberi has been sequenced, but the genetic basis for N. fowleri pathogenicity is unclear. To generate such insight, we sequenced and assembled the mitochondrial genome and a 60-kb segment of nuclear genome from N. fowleri. The mitochondrial genome is highly similar to its counterpart in N. gruberi in gene complement and organization, while distinct lack of synteny is observed for the nuclear segments. Even in this short (60-kb) segment, we identified examples of potential factors for pathogenesis, including ten novel N. fowleri-specific genes. We also identified a homolog of cathepsin B; proteases proposed to be involved in the pathogenesis of diverse eukaryotic pathogens, including N. fowleri. Finally, we demonstrate a likely case of horizontal gene transfer between N. fowleri and two unrelated amoebae, one of which causes granulomatous amoebic encephalitis. This initial look into the N. fowleri nuclear genome has revealed several examples of potential pathogenesis factors, improving our understanding of a neglected pathogen of increasing global importance. C1 [Herman, Emily K.; Dacks, Joel B.] Univ Alberta, Dept Cell Biol, Fac Med & Dent, Edmonton, AB T6G 2H7, Canada. [Greninger, Alexander L.; Chiu, Charles Y.] Univ Calif San Francisco, Abbott Viral Diagnost & Discovery Ctr, San Francisco, CA 94143 USA. [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Marciano-Cabral, Francine] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Sch Med, Richmond, VA 23298 USA. [Chiu, Charles Y.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA. [Chiu, Charles Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. RP Dacks, JB (reprint author), Univ Alberta, Dept Cell Biol, 5-31 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada. EM dacks@ualberta.ca; charles.chiu@ucsf.edu OI Chiu, Charles/0000-0003-2915-2094 FU Alberta Innovates - Health Solutions Graduate Studentship Award; Canada Research Chair in Evolutionary Cell Biology; Alberta Ingenuity New Faculty Award; NIH [R56-AI08953]; University of California; Abbott Pathogen Discovery Award FX E.K.H is supported by an Alberta Innovates - Health Solutions Graduate Studentship Award. J.B.D. is supported by a Canada Research Chair in Evolutionary Cell Biology, and an Alberta Ingenuity New Faculty Award. C.Y.C. is supported by NIH grant R56-AI08953, a University of California Discovery Grant on the development of novel diagnostics for encephalitis, and an Abbott Pathogen Discovery Award. We would like to thank Dr. Bart Hazes for constructive criticism and suggestions on early versions of this work, and Mike Gray for helpful discussion. We thank Rama Sriram for help in growing amoebae, and Macrogen, Inc. (Korea) for advice on the construction of paired-end libraries for 454 pyrosequencing. NR 64 TC 14 Z9 14 U1 0 U2 36 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5234 J9 J EUKARYOT MICROBIOL JI J. Eukaryot. Microbiol. PD MAR-APR PY 2013 VL 60 IS 2 BP 179 EP 191 DI 10.1111/jeu.12022 PG 13 WC Microbiology SC Microbiology GA 099SZ UT WOS:000315643300006 PM 23360210 ER PT J AU Eisen, L Wong, D Shelus, V Eisen, RJ AF Eisen, Lars Wong, David Shelus, Victoria Eisen, Rebecca J. TI What is the Risk for Exposure to Vector-Borne Pathogens in United States National Parks? SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE flea; mosquito; national park; tick; vector-borne disease ID COLORADO TICK FEVER; GREAT-SMOKY-MOUNTAINS; IXODES PACIFICUS ACARI; BORRELIA-BURGDORFERI; RELAPSING FEVER; IXODIDAE NYMPHS; LYME-DISEASE; AMBLYOMMA-AMERICANUM; MICROTUS-MONTANUS; YERSINIA-PESTIS AB United States national parks attract >275 million visitors annually and collectively present risk of exposure for staff and visitors to a wide range of arthropod vector species (most notably fleas, mosquitoes, and ticks) and their associated bacterial, protozoan, or viral pathogens. We assessed the current state of knowledge for risk of exposure to vector-borne pathogens in national parks through a review of relevant literature, including internal National Park Service documents and organismal databases. We conclude that, because of lack of systematic surveillance for vector-borne pathogens in national parks, the risk of pathogen exposure for staff and visitors is unclear. Existing data for vectors within national parks were not based on systematic collections and rarely include evaluation for pathogen infection. Extrapolation of human-based surveillance data from neighboring communities likely provides inaccurate estimates for national parks because landscape differences impact transmission of vector-borne pathogens and human-vector contact rates likely differ inside versus outside the parks because of differences in activities or behaviors. Vector-based pathogen surveillance holds promise to define when and where within national parks the risk of exposure to infected vectors is elevated. A pilot effort, including 5-10 strategic national parks, would greatly improve our understanding of the scope and magnitude of vector-borne pathogen transmission in these high-use public settings. Such efforts also will support messaging to promote personal protection measures and inform park visitors and staff of their responsibility for personal protection, which the National Park Service preservation mission dictates as the core strategy to reduce exposure to vector-borne pathogens in national parks. C1 [Eisen, Lars] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Wong, David] Natl Pk Serv, Albuquerque, NM 87106 USA. [Shelus, Victoria] Natl Pk Serv, Ft Collins, CO 80525 USA. [Shelus, Victoria] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA. [Eisen, Rebecca J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80522 USA. RP Eisen, L (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, 3195 Rampart Rd, Ft Collins, CO 80523 USA. EM lars.eisen@colostate.edu FU Intramural CDC HHS [CC999999] NR 88 TC 5 Z9 5 U1 4 U2 38 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAR PY 2013 VL 50 IS 2 BP 221 EP 230 DI 10.1603/ME12228 PG 10 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 104MK UT WOS:000315997300003 PM 23540107 ER PT J AU Johnson, NL Giarelli, E Lewis, C Rice, CE AF Johnson, Norah L. Giarelli, Ellen Lewis, Celine Rice, Catherine E. TI Genomics and Autism Spectrum Disorder SO JOURNAL OF NURSING SCHOLARSHIP LA English DT Article DE Autism; autism spectrum disorder; genetics; genomics ID DE-NOVO MUTATIONS; INTELLECTUAL DISABILITY; LINKAGE-DISEQUILIBRIUM; TUBEROUS SCLEROSIS; MENTAL-RETARDATION; TWIN PAIRS; RISK; GENETICS; PREVALENCE; CHILDREN AB Purpose: To present the current state of the evidence regarding translation of genetics (the study of single genes) and genomics (the study of all genes and gene-gene or gene-environment interactions) into health care of children with autism spectrum disorder (ASD). Methods: This article presents an overview of ASD as an international health challenge, the emerging science related to broad diagnostic criteria, and the role of the nurse in research, education, and practice. Findings: Much progress is being made in the understanding of genetics and genomics of ASD. Environmental factors are thought to contribute to the risk of developing ASD by interacting with a number of genes in different ways, thus suggesting causal heterogeneity. The rising identified prevalence of ASD, the changing diagnostic criteria for ASD, and the complexity of the core and associated features have made it difficult to define the ASD phenotype (observable behaviors that result from gene-environment interaction). Because early identification improves opportunities for intervention, researchers are looking for a useful biomarker to detect ASD. This search is complicated by the likelihood that there are multiple causes for multiple expressions that are defined as the autism spectrum. Conclusions: To date, genetic and genomic research on ASD have underscored the complexity of the causes of ASD indicating that there are very complex genetic processes involved that are still not well understood. Clinical Relevance: Nurses will benefit from new knowledge related to early identification, diagnosis, and implications for the family to promote early intervention. Families who have a child with ASD will require nursing support for advocacy for optimal health outcomes. C1 [Johnson, Norah L.] Marquette Univ, Coll Nursing, Milwaukee, WI 53201 USA. [Giarelli, Ellen] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA. [Lewis, Celine] Genet Alliance UK, London, England. [Rice, Catherine E.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Johnson, NL (reprint author), Marquette Univ, Coll Nursing, Clark Hall 325,POB 1881, Milwaukee, WI 53201 USA. EM norah.johnson@marquette.edu RI Rice, Catherine/D-6305-2016; OI Johnson, Norah L./0000-0001-6030-6739 FU Intramural CDC HHS [CC999999] NR 71 TC 5 Z9 5 U1 1 U2 60 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6546 J9 J NURS SCHOLARSHIP JI J. Nurs. Scholarsh. PD MAR PY 2013 VL 45 IS 1 BP 69 EP 78 DI 10.1111/j.1547-5069.2012.01483.x PG 10 WC Nursing SC Nursing GA 099RV UT WOS:000315639800010 PM 23368711 ER PT J AU Park, S AF Park, Sohyun TI Removing dietary liquid calories prevents accelerated body mass index increase SO JOURNAL OF PEDIATRICS LA English DT Editorial Material ID BEVERAGES; WEIGHT C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 5 TC 0 Z9 0 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD MAR PY 2013 VL 162 IS 3 BP 655 EP 655 PG 1 WC Pediatrics SC Pediatrics GA 101QS UT WOS:000315790100055 PM 23438926 ER PT J AU Selent, MU Molinari, NM Baxter, A Nguyen, AV Siegelson, H Brown, CM Plummer, A Higgins, A Podolsky, S Spandorfer, P Cohen, NJ Fishbein, DB AF Selent, Monica U. Molinari, NoelleAngelique M. Baxter, Amy Nguyen, An V. Siegelson, Henry Brown, Clive M. Plummer, Andrew Higgins, Andrew Podolsky, Susan Spandorfer, Philip Cohen, Nicole J. Fishbein, Daniel B. TI Mass Screening for Fever in Children A Comparison of 3 Infrared Thermal Detection Systems SO PEDIATRIC EMERGENCY CARE LA English DT Article DE fever; mass screening; skin temperature; thermometry ID ACUTE RESPIRATORY SYNDROME; HEALTH-CARE SETTINGS; INFLUENZA-A H1N1; EMERGENCY-DEPARTMENT; INFECTIOUS-DISEASES; BODY-TEMPERATURE; SARS; TRANSMISSION; VIRUS; WORKERS AB Objectives: Infrared thermal detection systems (ITDSs) have been used with limited success outside the United States to screen for fever during recent outbreaks of novel infectious diseases. Although ITDSs are fairly accurate in detecting fever in adults, there is little information about their utility in children. Methods: In a pediatric emergency department, we compared temperatures of children (<18 years old) measured using 3 ITDSs (OptoTherm Thermoscreen, FLIR ThermoVision 360, and Thermofocus 0800H3) to standard, age-appropriate temperature measurements (confirmed fever defined as >38.0 degrees C [oral or rectal], >= 37.0 degrees C [axillary]). Measured temperatures were compared with parental reports of fever using descriptive, multivariate, and receiver operating characteristic analyses. Results: Of 855 patients, 400 (46.8%) had parent-reported fever, and 306 (35.8%) had confirmed fever. At optimal fever thresholds, OptoTherm and FLIR had sensitivity (83.0% and 83.7%, respectively) approximately equal to parental report (83.9%) and greater than Thermofocus (76.8%), and specificity (86.3% and 85.7%) greater than parental report (70.8%) and Thermofocus (79.4%). Correlation coefficients between traditional thermometry and ITDSs were 0.78 (OptoTherm), 0.75 (FLIR), and 0.66 (Thermofocus). Conclusions: Compared with traditional thermometry, FLIR and OptoTherm were reasonably accurate in detecting fever in children and better predictors of fever than parental report. These findings suggest that ITDSs could be a useful noninvasive screening tool for fever in the pediatric age group. C1 [Selent, Monica U.; Molinari, NoelleAngelique M.; Nguyen, An V.; Brown, Clive M.; Plummer, Andrew; Higgins, Andrew; Cohen, Nicole J.; Fishbein, Daniel B.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Baxter, Amy; Spandorfer, Philip] Childrens Healthcare Atlanta, Atlanta, GA USA. [Nguyen, An V.] Council State & Terr Epidemiologists, Atlanta, GA USA. [Siegelson, Henry] Piedmont Hosp, Atlanta, GA USA. [Podolsky, Susan] Emory Univ, Atlanta, GA 30322 USA. RP Selent, MU (reprint author), USAFSAM PHR, 2510 5th St, Wright Patterson AFB, OH 45433 USA. EM monica.selent@us.af.mil NR 42 TC 6 Z9 6 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-5161 J9 PEDIATR EMERG CARE JI Pediatr. Emerg. Care PD MAR PY 2013 VL 29 IS 3 BP 305 EP 313 DI 10.1097/PEC.0b013e3182854465 PG 9 WC Emergency Medicine; Pediatrics SC Emergency Medicine; Pediatrics GA 103WA UT WOS:000315949000007 PM 23426254 ER PT J AU Kit, BK Simon, AE Brody, DJ Akinbami, LJ AF Kit, Brian K. Simon, Alan E. Brody, Debra J. Akinbami, Lara J. TI US Prevalence and Trends in Tobacco Smoke Exposure Among Children and Adolescents With Asthma SO PEDIATRICS LA English DT Article DE asthma; low income; environmental tobacco smoke; second-hand smoke; smoking ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; INNER-CITY CHILDREN; SECONDHAND SMOKE; UNITED-STATES; CHILDHOOD ASTHMA; URBAN CHILDREN; PARENTAL SMOKING; DISPARITIES; PHYSICIANS AB OBJECTIVE: To examine exposure to tobacco smoke products (TSPs), environmental tobacco smoke (ETS), and in-home smoke among youth with asthma in the United States. METHODS: Nationally representative, cross-sectional data from 2250 youth aged 4 to 19 years with current asthma in the 19881994, 1999-2004, and 2005-2010 National Health and Nutrition Examination Survey (NHANES) were analyzed. Outcomes were use of TSPs (serum cotinine level >10 ng/mL or self-reported recent use of cigarettes, cigars, or pipes) and, among non-TSP users, ETS exposure (serum cotinine >= 0.05 ng/mL) and in-home smoke exposure (reported). Multiple logistic regression analyses assessed the associations between the outcomes and age, gender, race/ethnicity, and family income. RESULTS: Among adolescents (aged 12-19 years) with asthma in 2005-2010, 17.3% reported TSP use. Among youth (aged 4-19 years) with asthma who did not use TSPs, 53.2% were exposed to ETS and 17.6% had in-home smoke exposure. Among low-income youth, 70.1% and 28.1% had exposure to ETS and in-home smoke, respectively. After controlling for sociodemographic factors, higher prevalence of exposure to ETS and in-home smoke persisted among low-income youth. Between 1988-1994 and 2005-2010, there was a decline in ETS and in-home smoke exposure (both P < .001). CONCLUSIONS: ETS exposure among youth with asthma declined between 1988-1994 and 2005-2010, but a majority remained exposed in 2005-2010, with higher exposure among low-income youth. More than 1 in 6 youth with asthma in 2005-2010 were exposed to in-home smoke and a similar portion of adolescents used TSPs. Pediatrics 2013;131:407-414 C1 [Kit, Brian K.; Brody, Debra J.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Simon, Alan E.; Akinbami, Lara J.] Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Kit, Brian K.; Akinbami, Lara J.] US PHS, Rockville, MD USA. RP Kit, BK (reprint author), 3311 Toledo Rd,Room 4419, Hyattsville, MD 20782 USA. EM igd0@cdc.gov NR 45 TC 24 Z9 24 U1 1 U2 28 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2013 VL 131 IS 3 BP 407 EP 414 DI 10.1542/peds.2012-2328 PG 8 WC Pediatrics SC Pediatrics GA 098ZI UT WOS:000315587400046 PM 23400612 ER PT J AU Duty, SM Mendonca, K Hauser, R Calafat, AM Ye, XY Meeker, JD Ackerman, R Cullinane, J Faller, J Ringer, S AF Duty, Susan M. Mendonca, Kaitlin Hauser, Russ Calafat, Antonia M. Ye, Xiaoyun Meeker, John D. Ackerman, Robin Cullinane, Judi Faller, Josephine Ringer, Steven TI Potential Sources of Bisphenol A in the Neonatal Intensive Care Unit SO PEDIATRICS LA English DT Article DE bisphenol A; exposure; medical devices; nutrition; premature ID EXTREMELY PREMATURE-INFANTS; HPLC-MS/MS METHOD; HUMAN-MILK; ENVIRONMENTAL PHENOLS; EXPOSURE; URINE AB OBJECTIVES: To determine whether nutritional intake and medical devices are bisphenol A (BPA) exposure sources among premature infants in the NICU. METHODS: Mothers and their premature infants cared for in the NICU for the past 3 days were recruited for this exposure assessment study. Forty-three mothers contributed 1 nutrition sample (breast milk or formula) to characterize the infant's intake. Two urine samples (before and after feeding) were collected from each of 55 infants. Medical device use was categorized as "low" or "high" based on the number and invasiveness of devices used. BPA urinary concentrations used as a biomarker to estimate BPA exposure were measured by online solid-phase extraction, high performance liquid chromatography, isotope dilution, tandem mass spectrometry. Nonparametric equivalence tests, intraclass correlations, and hierarchical linear mixed-effects models were conducted. RESULTS: Breast milk and formula samples did not differ in total BPA concentration nor did infants' median urinary concentration of total BPA before or after feedings. However, the median urinary total BPA concentration among infants who required the use of 4 or more medical devices in the past 3 days was significantly higher (36.6 mu g/L) than among infants who required the use of 0 to 3 devices (13.9 mu g/L). The calculated BPA exposures are lower than the US Environmental Protection Agency reference dose, but considerably higher (16- to 32-fold) than among infants or children from the general population. CONCLUSIONS: The number of medical devices used in the past 3 days, but not nutritional intake, was positively associated with exposure to BPA. Pediatrics 2013;131:483-489 C1 [Duty, Susan M.; Mendonca, Kaitlin; Cullinane, Judi; Faller, Josephine] Simmons Coll, Sch Nursing & Hlth Sci, Dept Nursing, Boston, MA 02115 USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Meeker, John D.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Ackerman, Robin] Occupat Safety & Hlth Adm, Washington, DC USA. [Ringer, Steven] Brigham & Womens Hosp, Dept Newborn Med, Boston, MA 02115 USA. RP Duty, SM (reprint author), Simmons Coll, Sch Nursing & Hlth Sci, Sci Bldg Room 314,300 Fenway, Boston, MA 02115 USA. EM susan.duty@simmons.edu OI Meeker, John/0000-0001-8357-5085 FU HSPH-NIEHS Center for Environmental Health [ES000002]; Passport Foundation, Science Innovation Fund; HSPH-NIEHS Pilot grant [P30ES000002]; National Institutes of Health (NIH) FX Supported in part by Pilot Project funding from the HSPH-NIEHS Center for Environmental Health (ES000002) and from the Passport Foundation, Science Innovation Fund. Ms Mendonca was supported by training grant HSPH-NIEHS Pilot grant P30ES000002. Funding sources had no role in study design, data collection, analysis, interpretation of data, or in the decision of whether to publish the results. Funded by the National Institutes of Health (NIH). NR 25 TC 26 Z9 27 U1 1 U2 29 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2013 VL 131 IS 3 BP 483 EP 489 DI 10.1542/peds.2012-1380 PG 7 WC Pediatrics SC Pediatrics GA 098ZI UT WOS:000315587400055 PM 23420909 ER PT J AU Hamilton, BE Hoyert, DL Martin, JA Strobino, DM Guyer, B AF Hamilton, Brady E. Hoyert, Donna L. Martin, Joyce A. Strobino, Donna M. Guyer, Bernard TI Annual Summary of Vital Statistics: 2010-2011 SO PEDIATRICS LA English DT Article DE birth; death; teenaged fertility; infant mortality; low birth weight; mortality; multiple births; cesarean rate; vital statistics; ICD-10; revised certificates ID INFANT-MORTALITY; UNITED-STATES; INTERNATIONAL RANKINGS AB The number of births in the United States declined by 1% between 2010 and 2011, to a total of 3 953 593. The general fertility rate also declined by 1% to 63.2 births per 1000 women, the lowest rate ever reported. The total fertility rate was down by 2% in 2011 (to 1894.5 births per 1000 women). The teenage birth rate fell to another historic low in 2011, 31.3 births per 1000 women. Birth rates also declined for women aged 20 to 29 years, but the rates increased for women aged 35 to 39 and 40 to 44 years. The percentage of all births to unmarried women declined slightly to 40.7% in 2011, from 40.8% in 2010. In 2011, the cesarean delivery rate was unchanged from 2010 at 32.8%. The preterm birth rate declined for the fifth straight year in 2011 to 11.72%; the low birth weight rate declined slightly to 8.10%. The infant mortality rate was 6.05 infant deaths per 1000 live births in 2011, which was not significantly lower than the rate of 6.15 deaths in 2010. Life expectancy at birth was 78.7 years in 2011, which was unchanged from 2010. Crude death rates for children aged 1 to 19 years did not change significantly between 2010 and 2011. Unintentional injuries and homicide were the first and second leading causes of death, respectively, in this age group. These 2 causes of death jointly accounted for 47.0% of all deaths of children and adolescents in 2011. Pediatrics 2013;131:548-558 C1 [Hamilton, Brady E.; Hoyert, Donna L.; Martin, Joyce A.] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Strobino, Donna M.; Guyer, Bernard] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat & Family Hlth Sci, Baltimore, MD USA. RP Hamilton, BE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 7416, Hyattsville, MD 20782 USA. EM boh5@cdc.gov NR 27 TC 157 Z9 161 U1 0 U2 11 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2013 VL 131 IS 3 BP 548 EP 558 DI 10.1542/peds.2012-3769 PG 11 WC Pediatrics SC Pediatrics GA 098ZI UT WOS:000315587400059 PM 23400611 ER PT J AU Lamont, JH Devore, CD Allison, M Ancona, R Barnett, SE Gunther, R Holmes, B Minier, M Okamoto, JK Wheeler, LSM Young, T Murray, RD Magalnick, H Monteverdi, GJ Gereige, RS Pattishall, EG Roland, MM Vernon-Smiley, M Duff, C Grant, L Johnson, V Davis-Alldritt, L Wallace, R Blum, AB Delack, S Guinn-Jones, M AF Lamont, Jeffrey H. Devore, Cynthia D. Allison, Mandy Ancona, Richard Barnett, Stephen E. Gunther, Robert Holmes, Breena Minier, Mark Okamoto, Jeffrey K. Wheeler, Lani S. M. Young, Thomas Murray, Robert D. Magalnick, Harold Monteverdi, George J. Gereige, Rani S. Pattishall, Evan G., III Roland, Michele M. Vernon-Smiley, Mary Duff, Carolyn Grant, Linda Johnson, Veda Davis-Alldritt, Linda Wallace, Robert Blum, Alex B. Delack, Sandi Guinn-Jones, Madra TI Out-of-School Suspension and Expulsion SO PEDIATRICS LA English DT Article DE suspension; expulsion; school; discipline ID PREDICTORS; SUPPORT; SAFETY AB The primary mission of any school system is to educate students. To achieve this goal, the school district must maintain a culture and environment where all students feel safe, nurtured, and valued and where order and civility are expected standards of behavior. Schools cannot allow unacceptable behavior to interfere with the school district's primary mission. To this end, school districts adopt codes of conduct for expected behaviors and policies to address unacceptable behavior. In developing these policies, school boards must weigh the severity of the offense and the consequences of the punishment and the balance between individual and institutional rights and responsibilities. Out-of-school suspension and expulsion are the most severe consequences that a school district can impose for unacceptable behavior. Traditionally, these consequences have been reserved for offenses deemed especially severe or dangerous and/or for recalcitrant offenders. However, the implications and consequences of out-of-school suspension and expulsion and "zero-tolerance" are of such severity that their application and appropriateness for a developing child require periodic review. The indications and effectiveness of exclusionary discipline policies that demand automatic or rigorous application are increasingly questionable. The impact of these policies on offenders, other children, school districts, and communities is broad. Periodic scrutiny of policies should be placed not only on the need for a better understanding of the educational, emotional, and social impact of out-of-school suspension and expulsion on the individual student but also on the greater societal costs of such rigid policies. Pediatricians should be prepared to assist students and families affected by out-of-school suspension and expulsion and should be willing to guide school districts in their communities to find more effective and appropriate alternatives to exclusionary discipline policies for the developing child. A discussion of preventive strategies and alternatives to out-of-school suspension and expulsion, as well as recommendations for the role of the physician in matters of out-of-school suspension and expulsion are included. School-wide positive behavior support/positive behavior intervention and support is discussed as an effective alternative. Pediatrics 2013;131:e1000-e1007 C1 [Vernon-Smiley, Mary] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 38 TC 7 Z9 7 U1 5 U2 34 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2013 VL 131 IS 3 BP E1000 EP E1007 DI 10.1542/peds.2012-3932 PG 8 WC Pediatrics SC Pediatrics GA 098ZI UT WOS:000315587400042 ER PT J AU Odom, EC Li, RW Scanlon, KS Perrine, CG Grummer-Strawn, L AF Odom, Erika C. Li, Ruowei Scanlon, Kelley S. Perrine, Cria G. Grummer-Strawn, Laurence TI Reasons for Earlier Than Desired Cessation of Breastfeeding SO PEDIATRICS LA English DT Article DE breastfeeding; duration; intention; lactation ID CLINICIAN; INTENTION; SUPPORT; ROUTINE AB OBJECTIVE: To describe the prevalence and factors associated with not meeting desired breastfeeding duration. METHODS: Data were analyzed from 1177 mothers aged >= 18 years who responded to monthly surveys from pregnancy until their child was 1 year old. When breastfeeding stopped, mothers were asked whether they breastfed as long as they wanted (yes or no) and to rate the importance of 32 reasons for stopping on a 4-point Likert scale. Multiple logistic regressions were used to examine the association between the importance of each reason and the likelihood of mothers not meeting their desired breastfeeding duration. RESULTS: Approximately 60% of mothers who stopped breastfeeding did so earlier than desired. Early termination was positively associated with mothers' concerns regarding: (1) difficulties with lactation; (2) infant nutrition and weight; (3) illness or need to take medicine; and (4) the effort associated with pumping milk. CONCLUSIONS: Our findings indicate that the major reasons why mothers stop breastfeeding before they desire include concerns about maternal or child health (infant nutrition, maternal illness or the need for medicine, and infant illness) and processes associated with breastfeeding (lactation and milk-pumping problems). Continued professional support may be necessary to address these challenges and help mothers meet their desired breastfeeding duration. Pediatrics 2013; 131:e726-e732 C1 [Odom, Erika C.; Li, Ruowei; Scanlon, Kelley S.; Perrine, Cria G.; Grummer-Strawn, Laurence] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Odom, EC (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd,MS E-64, Atlanta, GA 30333 USA. EM ecodom@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 61 Z9 64 U1 0 U2 31 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2013 VL 131 IS 3 BP E726 EP E732 DI 10.1542/peds.2012-1295 PG 7 WC Pediatrics SC Pediatrics GA 098ZI UT WOS:000315587400009 PM 23420922 ER PT J AU Saydah, S Bullard, KM Imperatore, G Geiss, L Gregg, EW AF Saydah, Sharon Bullard, Kai McKeever Imperatore, Giuseppina Geiss, Linda Gregg, Edward W. TI Cardiometabolic Risk Factors Among US Adolescents and Young Adults and Risk of Early Mortality SO PEDIATRICS LA English DT Article DE adolescents; mortality; cardiometabolic risk factors; NHANES ID BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; SUBSEQUENT MORTALITY; PREMATURE DEATH; SECULAR TRENDS; BLOOD-PRESSURE; LIFETIME RISK; CHILDHOOD; CHILDREN; OBESITY AB OBJECTIVE: To determine the risk of mortality associated with cardiometabolic risk factors in a national sample of adolescents and young adults. METHODS: Prospective study of participants in the third NHANES (1988-1994), aged 12 to 39 years at the time of the survey (n = 9245). Risk factors included 3 measures of adiposity, glycated hemoglobin (HbA1c) level, cholesterol levels, blood pressure, self-reported smoking status, and cotinine level. Death before age 55 (n = 298) was determined by linkage to the National Death Index through 2006. Proportional hazards models, with age as the time scale, were used to determine the risk of death before age 55 years after adjusting for gender, race/ethnicity, and presence of comorbid conditions. RESULTS: After adjusting for age, gender, and race/ethnicity, results of categorical analyses showed that current smokers were at 86% greater risk for early death than those classified as never smokers; that those with a waist-to-height ratio >0.65 were at 139% greater risk than those with a WHR <0.5; and that those with an HbA1c level >6.5% were at 281% greater risk than those with an HbA1c level <5.7%. Neither high-density lipoprotein nor non-high-density lipoprotein cholesterol measures were associated with risk for early death. CONCLUSIONS: Our finding that risk for death before age 55 among US adolescents and young adults was associated with central obesity, smoking, and hyperglycemia supports reducing the prevalence of these risk factors among younger US residents. Pediatrics 2013;131:e679-e686 C1 [Saydah, Sharon; Bullard, Kai McKeever; Imperatore, Giuseppina; Geiss, Linda; Gregg, Edward W.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA. RP Saydah, S (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Hwy,NE,Mailstop K-10, Atlanta, GA 30341 USA. EM ssaydah@cdc.gov FU Intramural CDC HHS [CC999999] NR 40 TC 25 Z9 25 U1 0 U2 13 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAR PY 2013 VL 131 IS 3 BP E679 EP E686 DI 10.1542/peds.2012-2583 PG 8 WC Pediatrics SC Pediatrics GA 098ZI UT WOS:000315587400003 PM 23420920 ER PT J AU Peters, SL Lind, JN Humphrey, JR Friedman, JM Honein, MA Tassinari, MS Moore, CA Mathis, LL Broussard, CS AF Peters, Stacey L. Lind, Jennifer N. Humphrey, Jasmine R. Friedman, Jan M. Honein, Margaret A. Tassinari, Melissa S. Moore, Cynthia A. Mathis, Lisa L. Broussard, Cheryl S. TI Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE medication; pregnancy; women; drug safety; Internet; TERIS; pharmacoepidemiology AB Purpose Medication use during pregnancy is common and increasing. Women are also increasingly getting healthcare information from sources other than their physicians. Methods This report summarizes an environmental scan that identified 25 active Internet sites that list medications reported to be safe for use in pregnancy and highlights the inadequate evidence base and inconsistent guidance provided by these sites. Results These lists included 245 different products, of which 103 unique components had been previously evaluated in terms of fetal risk by the Teratogen Information System (TERIS), a resource that assesses risk of birth defects after exposure under usual conditions by consensus of clinical teratology experts. For 43 (42%) of the 103 components that were listed as safe' on one or more of the Internet sites surveyed, the TERIS experts were unable to determine the fetal risk based on published scientific literature. For 40 (93%) of these 43, either no data were available to assess human fetal risk or the available data were limited. Conclusions Women who see a medication on one of these safe' lists would be led to believe that there is no increased risk of birth defects resulting from exposure. Thus, women are being reassured that fetal exposure to these medications is safe even though a sufficient evidence base to determine the relative safety or risk does not exist. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Peters, Stacey L.; Humphrey, Jasmine R.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Peters, Stacey L.; Lind, Jennifer N.; Humphrey, Jasmine R.; Honein, Margaret A.; Moore, Cynthia A.; Broussard, Cheryl S.] Ctr Dis Control & Prevent, NCBDDD, Atlanta, GA 30333 USA. [Lind, Jennifer N.] Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA. [Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Tassinari, Melissa S.; Mathis, Lisa L.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA. RP Broussard, CS (reprint author), Ctr Dis Control & Prevent, NCBDDD, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM cbroussard@cdc.gov OI Friedman, Jan/0000-0002-7482-9570 FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 12 TC 14 Z9 14 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAR PY 2013 VL 22 IS 3 BP 324 EP 328 DI 10.1002/pds.3410 PG 5 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 099VN UT WOS:000315651200014 PM 23359404 ER PT J AU O'Leary, ST Allison, MA Stokley, S Crane, LA Hurley, LP Beaty, B Kempe, A AF O'Leary, Sean T. Allison, Mandy A. Stokley, Shannon Crane, Lori A. Hurley, Laura P. Beaty, Brenda Kempe, Allison TI Physicians' confidence in vaccine safety studies SO PREVENTIVE MEDICINE LA English DT Article DE Vaccination; Preventive medicine; Pediatrics; Family practice; Attitude of health personnel ID IMMUNE THROMBOCYTOPENIC PURPURA; IMMUNIZATION; RISK; DATALINK; CHILDREN; INFANTS; TRUST AB Objectives. To ascertain, through two separate surveys among nationally representative networks of pediatricians (Peds) and family physicians (FM): 1) physicians' reported level of confidence in pre- and post-licensure vaccine safety studies; and 2) changes in reported level of confidence from 2007 to 2010/11. Methods. Two surveys were conducted in August to October 2007 and in November 2010 to January 2011. The survey response rates were 81% (FM, 79%, Peds, 84%, p = 0.07) for the 2007 survey (691/848) and 66% (FM, 61%, Peds, 70%, p = 0.003) for the 2010/11 survey (532/811). Results. One in three family physicians compared to one in ten pediatricians in both surveys reported little or no confidence in pre-licensure vaccine safety studies (p<0.001). Compared to pre-licensure studies, higher percentages of both specialties reported a great deal of confidence in post-licensure vaccine safety studies in both years, and more physicians from both specialties reported a great deal of confidence in 2010/11 than in 2007. Conclusion. While most family physicians and pediatricians report confidence in post-licensure vaccine safety studies, one third of family physicians report little or no confidence in pre-licensure studies. More research is needed to better understand the reasons behind some physicians' lack of confidence in vaccine safety studies. (c) 2013 Elsevier Inc. All rights reserved. C1 [O'Leary, Sean T.; Allison, Mandy A.; Kempe, Allison] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA. [Beaty, Brenda; Kempe, Allison] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO 80045 USA. [O'Leary, Sean T.; Allison, Mandy A.; Crane, Lori A.; Hurley, Laura P.; Beaty, Brenda; Kempe, Allison] Childrens Hosp Colorado, Childrens Outcomes Res Program, Aurora, CO USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Crane, Lori A.] Denver Hlth, Colorado Sch Publ Hlth, Denver, CO USA. [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO USA. RP O'Leary, ST (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM sean.o'leary@childrenscolorado.org FU Centers for Disease Control and Prevention PEP through the Association of American Medical Colleges, Washington, DC [MM-1040-08/08] FX Dr. O'Leary had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This investigation was funded by a grant from the Centers for Disease Control and Prevention PEP (MM-1040-08/08) through the Association of American Medical Colleges, Washington, DC. We thank Lynn Olson, PhD, and Karen O'Connor from the Department of Research, AAP, Herbert Young, MD, and Bellinda Schoof, MHA, at the AAFP, and the leaders of the AAP and AAFP for collaborating in the establishment of the sentinel networks in pediatrics and family medicine. We also thank all pediatricians and family medicine physicians in the networks for participating and responding to this survey. NR 19 TC 2 Z9 2 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR-APR PY 2013 VL 56 IS 3-4 BP 231 EP 233 DI 10.1016/j.ypmed.2013.01.001 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 101FM UT WOS:000315760600013 PM 23333206 ER PT J AU Orenstein, WA Gellin, BG Beigi, RH Buck, T Despres, S LaRussa, PS Lynfield, R Maldonado, Y Morita, J Mouton, C Pisani, A Rothholz, MC Stenvig, TE Tan, L Torres, C Hetherington, S Lewin, C Bailowitz, A Baker, C Daum, RS Douglas, C Hannan, C Jarris, P Rawlins, W Richardson, V Salisbury, D AF Orenstein, Walter A. Gellin, Bruce G. Beigi, Richard H. Buck, Tawny Despres, Sarah LaRussa, Philip S. Lynfield, Ruth Maldonado, Yvonne Morita, Julie Mouton, Charles Pisani, Amy Rothholz, Mitchel C. Stenvig, Thomas E. Tan, Litjen (LJ) Torres, Catherine Hetherington, Seth Lewin, Clement Bailowitz, Anne Baker, Carol Daum, Robert S. Douglas, Charlene Hannan, Claire Jarris, Paul Rawlins, Wayne Richardson, Vesta Salisbury, David CA Natl Vaccine Advisory Comm TI Protecting the Public's Health: Critical Functions of the Section 317 Immunization Program-A Report of the National Vaccine Advisory Committee SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; COVERAGE; MEASLES C1 [Orenstein, Walter A.] Emory Univ, Atlanta, GA 30322 USA. [Gellin, Bruce G.] US Dept HHS, Natl Vaccine Program Off, Washington, DC 20201 USA. [Beigi, Richard H.] Magee Womens Hosp, Pittsburgh, PA USA. [LaRussa, Philip S.] Columbia Univ, Dept Pediat, New York, NY 10027 USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Maldonado, Yvonne] Stanford Univ, Stanford, CA 94305 USA. [Morita, Julie] Chicago Dept Publ Hlth, Chicago, IL USA. [Mouton, Charles] Meharry Med Coll, Nashville, TN 37208 USA. [Pisani, Amy] Every Child Two, Mystic, CT USA. [Rothholz, Mitchel C.] Amer Pharmacists Assoc, Alexandria, VA USA. [Stenvig, Thomas E.] S Dakota State Univ, Coll Nursing, Brookings, SD 57007 USA. [Tan, Litjen (LJ)] Amer Med Assoc, Chicago, IL 60610 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Hetherington, Seth] Genocea Biosci, Cambridge, MA USA. [Lewin, Clement] Novartis Vaccines & Diagnost, Cambridge, MA USA. [Bailowitz, Anne] Natl Assoc Cty & City Hlth Officials, Baltimore, MD USA. [Baker, Carol] Ctr Dis Control & Prevent, Advisory Comm Immunizat Practices, Houston, TX USA. [Daum, Robert S.] US FDA, Vaccines & Related Biol Prod Advisory Comm, Chicago, IL USA. [Douglas, Charlene] Advisory Comm Childhood Vaccines, Fairfax, VA USA. [Hannan, Claire] Assoc Immunizat Management, Rockville, MD USA. [Jarris, Paul] Assoc State & Terr Hlth Officials, Arlington, VA USA. [Rawlins, Wayne] Amer Hlth Insurance Plans, Hartford, CT USA. [Richardson, Vesta] Hlth Minist Mexico, Mexico City, DF, Mexico. [Salisbury, David] Dept Hlth, London SE1 6TE, England. RP Orenstein, WA (reprint author), Emory Univ, Atlanta, GA 30322 USA. NR 35 TC 0 Z9 0 U1 1 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 IS 2 BP 78 EP 95 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 098GT UT WOS:000315537600003 ER PT J AU Bertolli, J Garland, PM Valverde, EE Beer, L Fagan, JL Hart, C AF Bertolli, Jeanne Garland, Pamela Morse Valverde, Eduardo E. Beer, Linda Fagan, Jennifer L. Hart, Clyde CA Never Care Pilot Project Team TI Missed Connections: HIV-Infected People Never in Care SO PUBLIC HEALTH REPORTS LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; MEDICAL-CARE; VIRAL LOAD; HETEROSEXUAL TRANSMISSION; UNITED-STATES; CELL COUNT; RISK-FACTORS; HEALTH; TYPE-1 AB Objective. Clinical interventions that lengthen life after HIV infection and significantly reduce transmission could have greater impact if more HIV-diagnosed people received HIV care. We tested a surveillance-based approach to investigating reasons for delayed entry to care. Methods. Health department staff in three states and two cities contacted eligible adults diagnosed with HIV four to 24 months previously who had no reported CD4+ lymphocyte (CD4) or viral load (VL) tests. The staff conducted interviews, performed CD4 and VL testing, and provided referrals to HIV medical care. Reported CD4 and VL tests were prospectively monitored to determine if respondents had entered care after the interview. Results. Surveillance-based follow-up uncovered problems with reporting CD4 and VL tests, resulting in surveillance improvements. However, reporting problems led to misspent effort locating people who were already in care. Follow-up proved difficult because contact information in surveillance case records was often outdated or incorrect. Of those reached, 37% were in care and 29% refused participation. Information from 132 people interviewed generated ideas for service improvements, such as emphasizing the benefits of early initiation of HIV care, providing coverage eligibility information soon after diagnosis, and leveraging other medical appointments to provide assistance with linkage to HIV care. Conclusions. Surveillance-based follow-up of HIV-diagnosed individuals not linked to care provided information to improve both surveillance and linkage services, but was inefficient because of difficulties identifying, locating, and recruiting eligible people. Inefficiencies attributable to missing, incomplete, or inaccurate surveillance records are likely to diminish as data quality is improved through ongoing use. C1 [Bertolli, Jeanne; Garland, Pamela Morse; Valverde, Eduardo E.; Beer, Linda; Fagan, Jennifer L.; Hart, Clyde; Never Care Pilot Project Team] Ctr Dis Control Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Bertolli, J (reprint author), Ctr Dis Control Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM JBertolli@cdc.gov NR 47 TC 2 Z9 2 U1 2 U2 12 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2013 VL 128 IS 2 BP 117 EP 126 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 098GT UT WOS:000315537600007 PM 23450876 ER PT J AU Kim, AA Morales, S de Rivera, IL Paredes, M Juarez, S Alvarez, B Liu, X Parekh, B Monterroso, E Paz-Bailey, G AF Kim, Andrea A. Morales, Sonia Lorenzana de Rivera, Ivette Paredes, Mayte Juarez, Sandra Alvarez, Berta Liu, Xin Parekh, Bharat Monterroso, Edgar Paz-Bailey, Gabriela TI Short Communication HIV Incidence Among Vulnerable Populations in Honduras: Results from an Integrated Behavioral and Biological Survey Among Female Sex Workers, Men Who Have Sex with Men, and Garifuna in Honduras, 2006 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HIDDEN POPULATIONS; RISK BEHAVIORS; INFECTION; SUBTYPES AB Honduras has one of the highest HIV prevalence rates in Central America. Data on HIV incidence are needed to identify groups at greatest need of prevention interventions to inform the national HIV response. We applied a test for recent infection to HIV-positive specimens from a biological and behavioral survey to estimate assay-derived incidence among men who have sex with men (MSM), female sex workers (FSW), and the Garifuna population in Honduras. Assay-derived estimates were compared to the mathematically modeled estimates in the same populations to assess plausibility of the assay-based estimates. Assay-derived incidence was 1.1% (95% CI 0.2-2.0) among MSM, 0.4% (95% CI 0.1-0.8) among the Garifuna, and 0% (95% CI 0-0.01) among FSWs. The modeled incidence estimates were similar at 1.03% among MSM, 0.30% among the Garifuna, and 0.23% among FSWs. HIV incidence based on the assay was highest among MSM in Honduras, lowest among FSWs, and similar to modeled incidence in these groups. Targeted programs on HIV prevention, care, and treatment are urgently needed for the MSM population. Continued support for existing prevention programs for FSWs and Garifuna are recommended. C1 [Kim, Andrea A.; Liu, Xin; Parekh, Bharat; Monterroso, Edgar] Ctr Dis Control & Prevent, HHS, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Morales, Sonia; Alvarez, Berta; Paz-Bailey, Gabriela] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Lorenzana de Rivera, Ivette; Paredes, Mayte] Minist Hlth Honduras, Tegucigalpa, Honduras. [Juarez, Sandra] Ctr Dis Control & Prevent, HHS, Div Global HIV AIDS, Reg Off Cent Amer & Panama, Guatemala City, Guatemala. [Paz-Bailey, Gabriela] Tephinet Inc, Atlanta, GA USA. RP Kim, AA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Global Hlth, Div Global HIV AIDS, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM aakim@cdc.gov FU U.S. President's Emergency Plan for AIDS Relief FX This work was funded by the U.S. President's Emergency Plan for AIDS Relief. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the U.S. Centers for Disease Control and Prevention (CDC). NR 25 TC 2 Z9 2 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD MAR PY 2013 VL 29 IS 3 BP 516 EP 519 DI 10.1089/aid.2012.0032 PG 4 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 096VY UT WOS:000315434000016 PM 23034068 ER PT J AU Johnson, DL Mead, KR Lynch, RA Hirst, DVL AF Johnson, David L. Mead, Kenneth R. Lynch, Robert A. Hirst, Deborah V. L. TI Lifting the lid on toilet plume aerosol: A literature review with suggestions for future research SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Review DE Aerosol; Droplet nuclei; Airborne infection; Bioaerosol ID RESISTANT STAPHYLOCOCCUS-AUREUS; ACUTE RESPIRATORY SYNDROME; H1N1 2009 INFLUENZA; AIRBORNE TRANSMISSION; ENVIRONMENTAL CONTAMINATION; NONTUBERCULOUS MYCOBACTERIA; HOUSEHOLD TRANSMISSION; SARS CORONAVIRUS; NORWALK VIRUS; UNITED-STATES AB Background: The potential risks associated with "toilet plume" aerosols produced by flush toilets is a subject of continuing study. This review examines the evidence regarding toilet plume bioaerosol generation and infectious disease transmission. Methods: The peer-reviewed scientific literature was searched to identify articles related to aerosol production during toilet flushing, as well as epidemiologic studies examining the potential role of toilets in infectious disease outbreaks. Results: The studies demonstrate that potentially infectious aerosols may be produced in substantial quantities during flushing. Aerosolization can continue through multiple flushes to expose subsequent toilet users. Some of the aerosols desiccate to become droplet nuclei and remain adrift in the air currents. However, no studies have yet clearly demonstrated or refuted toilet plume-related disease transmission, and the significance of the risk remains largely uncharacterized. Conclusion: Research suggests that toilet plume could play a contributory role in the transmission of infectious diseases. Additional research in multiple areas is warranted to assess the risks posed by toilet plume, especially within health care facilities. Copyright (C) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Johnson, David L.; Lynch, Robert A.] Univ Oklahoma, Dept Occupat & Environm Hlth, Coll Publ Hlth, Oklahoma City, OK 73126 USA. [Mead, Kenneth R.; Hirst, Deborah V. L.] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Johnson, DL (reprint author), Univ Oklahoma, Dept Occupat & Environm Hlth, Coll Publ Hlth, POB 26901,Room 431, Oklahoma City, OK 73126 USA. EM David-Johnson@ouhsc.edu FU Intramural CDC HHS [CC999999] NR 80 TC 14 Z9 14 U1 2 U2 34 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR PY 2013 VL 41 IS 3 BP 254 EP 258 DI 10.1016/j.ajic.2012.04.330 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 094WH UT WOS:000315295000016 PM 23040490 ER PT J AU Hollis, ND Allen, EG Oliver, TR Tinker, SW Druschel, C Hobbs, CA O'Leary, LA Romitti, PA Royle, MH Torfs, CP Freeman, SB Sherman, SL Bean, LJH AF Hollis, NaTasha D. Allen, Emily G. Oliver, Tiffany Renee Tinker, Stuart W. Druschel, Charlotte Hobbs, Charlotte A. O'Leary, Leslie A. Romitti, Paul A. Royle, Marjorie H. Torfs, Claudine P. Freeman, Sallie B. Sherman, Stephanie L. Bean, Lora J. H. TI Preconception folic acid supplementation and risk for chromosome 21 nondisjunction: A report from the National Down Syndrome Project SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE Down syndrome; trisomy 21; aneuploidy; nondisjunction; chromosome segregation; folic acid; meiosis ID NEURAL-TUBE DEFECTS; MATERNAL AGE; MEIOTIC RECOMBINATION; BIRTH-DEFECTS; UNITED-STATES; TRISOMY-21; FORTIFICATION; PREVALENCE; ASSOCIATION; PREVENTION AB Both a lack of maternal folic acid supplementation and the presence of genetic variants that reduce enzyme activity in folate pathway genes have been linked to meiotic nondisjunction of chromosome 21; however, the findings in this area of research have been inconsistent. To better understand these inconsistencies, we asked whether maternal use of a folic acid-containing supplement before conception reduces risk for chromosome 21 nondisjunction. Using questionnaire data from the National Down Syndrome Project, a population-based casecontrol study, we compared the use of folic acid-containing supplements among mothers of infants with full trisomy 21 due to maternal nondisjunction (n=702) and mothers of infants born with no major birth defects (n=983). Using logistic regression, adjusting for maternal age, race/ethnicity, and infant age at maternal interview, we found no evidence of an association between lack of folic acid supplementation and maternal nondisjunction among all case mothers (OR=1.16; 95% CI: 0.901.48). In analyses stratified by meiotic stage and maternal age (<35 or 35 years), we found an association among older mothers experiencing meiosis II nondisjunction errors (OR=2.00; 95% CI: 1.083.71). These data suggest that lack of folic acid supplementation may be associated specifically with MII errors in the aging oocyte. If confirmed, these results could account for inconsistencies among previous studies, as each study sample may vary by maternal age structure and proportion of meiotic errors. (c) 2013 Wiley Periodicals, Inc. C1 [Hollis, NaTasha D.; Allen, Emily G.; Oliver, Tiffany Renee; Tinker, Stuart W.; Freeman, Sallie B.; Sherman, Stephanie L.; Bean, Lora J. H.] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA. [Druschel, Charlotte] New York State Dept Hlth, Troy, NY USA. [Hobbs, Charlotte A.] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA. [O'Leary, Leslie A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Romitti, Paul A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Royle, Marjorie H.] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [Torfs, Claudine P.] Birth Defects Studies, Inst Publ Hlth, Emeryville, CA USA. RP Bean, LJH (reprint author), Emory Univ, Dept Human Genet, 615 Michael St Suite 301, Atlanta, GA 30322 USA. EM ljbean@emory.edu FU NIH [R01 HD38979] FX Grant sponsor: NIH; Grant number: R01 HD38979. NR 36 TC 11 Z9 13 U1 3 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD MAR PY 2013 VL 161A IS 3 BP 438 EP 444 DI 10.1002/ajmg.a.35796 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 095NQ UT WOS:000315341700005 PM 23401135 ER PT J AU Jackson, L Jackson, ML Phillips, CH Benoit, J Belongia, EA Cole, D Kopitzke, S Koepel, TAK McLean, HQ Meece, JK Strey, SK Sundaram, ME Vandermause, M Gaglani, M Song, J Clipper, L Kjar, D Robertson, A Murthy, K Dunnahoo, M Oliver, S Weir, M Gonzales, H Zayed, M Reis, M Rivera, C Morgan, D Piedra, P Avadhanula, V Monto, AS Ohmit, SE Petrie, JG Johnson, E Cross, RT Martens, C Zervos, M Lamerato, L Eng, H Nowalk, MP Wisniewski, SR Zimmerman, RK Rinaldo, CR Bullotta, A Suyama, J Reis, E Middleton, DB Hess, R Thompson, M Fry, AM Thaker, SN Spencer, S Cheng, PY Shay, DK Berman, L Bresee, J Burns, E Tokars, J Cox, N AF Jackson, Lisa Jackson, Michael L. Phillips, C. Hallie Benoit, Joyce Belongia, Edward A. Cole, Deanna Kopitzke, Sarah Koepel, Tamara A. Kronenwetter McLean, Huong Q. Meece, Jennifer K. Strey, Sandra K. Sundaram, Maria E. Vandermause, Mary Gaglani, Manjusha Song, Juhee Clipper, Lydia Kjar, Dean Robertson, Anne Murthy, Kempapura Dunnahoo, Melinda Oliver, Stephanie Weir, Monica Gonzales, Hope Zayed, Martha Reis, Michael Rivera, Cathleen Morgan, David Piedra, Pedro Avadhanula, Vasanthi Monto, Arnold S. Ohmit, Suzanne E. Petrie, Joshua G. Johnson, Emileigh Cross, Rachel T. Martens, Casey Zervos, Marcus Lamerato, Lois Eng, Heather Nowalk, Mary Patricia Wisniewski, Stephen R. Zimmerman, Richard K. Rinaldo, Charles R., Jr. Bullotta, Arlene Suyama, Joe Reis, Evelyn Middleton, Donald B. Hess, Rachel Thompson, Mark Fry, Alicia M. Thaker, Swathi N. Spencer, Sarah Cheng, Po-Yung Shay, David K. Berman, LaShondra Bresee, Joseph Burns, Erin Tokars, Jeremy Cox, Nancy TI Early Estimates of Seasonal Influenza Vaccine Effectiveness-United States, January 2013 (Reprinted from the MMWR, vol 62, pg 1, 2013) SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Reprint C1 [Jackson, Lisa; Jackson, Michael L.; Phillips, C. Hallie; Benoit, Joyce] Grp Hlth Res Inst, Seattle, WA USA. [Belongia, Edward A.; Cole, Deanna; Kopitzke, Sarah; Koepel, Tamara A. Kronenwetter; McLean, Huong Q.; Meece, Jennifer K.; Strey, Sandra K.; Sundaram, Maria E.; Vandermause, Mary] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha; Song, Juhee; Clipper, Lydia; Kjar, Dean; Robertson, Anne; Murthy, Kempapura; Dunnahoo, Melinda; Oliver, Stephanie; Weir, Monica; Gonzales, Hope; Zayed, Martha; Reis, Michael; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Avadhanula, Vasanthi] Scott & White Healthcare, Temple, TX USA. [Gaglani, Manjusha; Song, Juhee; Clipper, Lydia; Kjar, Dean; Robertson, Anne; Murthy, Kempapura; Dunnahoo, Melinda; Oliver, Stephanie; Weir, Monica; Gonzales, Hope; Zayed, Martha; Reis, Michael; Rivera, Cathleen; Morgan, David; Piedra, Pedro; Avadhanula, Vasanthi] Baylor Coll Med, Houston, TX 77030 USA. [Monto, Arnold S.; Ohmit, Suzanne E.; Petrie, Joshua G.; Johnson, Emileigh; Cross, Rachel T.; Martens, Casey; Zervos, Marcus; Lamerato, Lois] Univ Michigan, Ann Arbor, MI 48109 USA. [Monto, Arnold S.; Ohmit, Suzanne E.; Petrie, Joshua G.; Johnson, Emileigh; Cross, Rachel T.; Martens, Casey; Zervos, Marcus; Lamerato, Lois] Henry Ford Hlth Syst, Detroit, MI USA. [Eng, Heather; Nowalk, Mary Patricia; Wisniewski, Stephen R.; Zimmerman, Richard K.; Rinaldo, Charles R., Jr.; Bullotta, Arlene; Suyama, Joe; Reis, Evelyn; Middleton, Donald B.; Hess, Rachel] Univ Pittsburgh, Sch Hlth Sci, Pittsburgh, PA USA. [Eng, Heather; Nowalk, Mary Patricia; Wisniewski, Stephen R.; Zimmerman, Richard K.; Rinaldo, Charles R., Jr.; Bullotta, Arlene; Suyama, Joe; Reis, Evelyn; Middleton, Donald B.; Hess, Rachel] UPMC, Pittsburgh, PA USA. [Thompson, Mark; Fry, Alicia M.; Thaker, Swathi N.; Spencer, Sarah; Cheng, Po-Yung; Shay, David K.; Berman, LaShondra; Bresee, Joseph; Burns, Erin; Tokars, Jeremy; Cox, Nancy] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Thompson, M (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM isq8@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAR PY 2013 VL 13 IS 3 BP 811 EP 814 DI 10.1111/ajt.12203 PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA 097CW UT WOS:000315452600036 ER PT J AU Marrero-Santos, KM Beltran, M Carrion-Lebron, J Sanchez-Vegas, C Hamer, DH Barnett, ED Santiago, LM Hunsperger, EA AF Marrero-Santos, Karla M. Beltran, Manuela Carrion-Lebron, Jessica Sanchez-Vegas, Carolina Hamer, Davidson H. Barnett, Elizabeth D. Santiago, Luis M. Hunsperger, Elizabeth A. TI Optimization of the Cutoff Value for a Commercial Anti-Dengue Virus IgG Immunoassay SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID BLOOD-DONORS; PUERTO-RICO; ANTIBODIES; TRAVELERS; FEVER; WEST AB A commercial anti-dengue virus (anti-DENV) indirect IgG enzyme-linked immunosorbent assay (ELISA) for serological diagnosis was evaluated for its utility in determining previous DENV exposure in U.S. travelers. The Boston Area Travel Medicine Network clinics used Focus Diagnostics anti-DENV IgG ELISA to measure anti-DENV IgG antibodies in 591 pretravel specimens from U.S. residents who had traveled to countries where dengue is endemic. When using the manufacturer's index cutoff value for this ELISA, false-positive results were observed that overestimated the perceived past DENV exposure in U.S. travelers. Validation of 121 of these anti-DENV IgG results by plaque reduction neutralization test (PRNT) was used for receiver operating characteristic (ROC) curve optimization of the index cutoff value from 1 to 3.0, improving the specificity of the anti-DENV IgG ELISA from 24% to 95.7%. Additionally, previous vaccination with yellow fever virus contributed to 52.8% of the false-positive rate in the anti-DENV IgG ELISA results. Optimization of the cutoff value of the anti-DENV IgG ELISA provided better interpretation and confidence in the results and eliminated the need for confirmation by PRNT. The travel history of U.S. travelers was also useful for categorizing these travelers into groups for analysis of previous DENV exposure. C1 [Marrero-Santos, Karla M.; Beltran, Manuela; Carrion-Lebron, Jessica; Santiago, Luis M.; Hunsperger, Elizabeth A.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA. [Sanchez-Vegas, Carolina] Miami Childrens Hosp, Miami, FL USA. [Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Dept Int Hlth, Boston, MA USA. [Sanchez-Vegas, Carolina] Boston Univ, Sch Med, Dept Med, Infect Dis Sect, Boston, MA 02118 USA. [Barnett, Elizabeth D.] Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA USA. RP Hunsperger, EA (reprint author), Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA. EM enh4@cdc.gov OI Barnett, Elizabeth/0000-0003-4822-5949; Hamer, Davidson/0000-0002-4700-1495 NR 18 TC 1 Z9 1 U1 2 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAR PY 2013 VL 20 IS 3 BP 358 EP 362 DI 10.1128/CVI.00429-12 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 096NL UT WOS:000315411100005 PM 23302742 ER PT J AU Rota, JS Rosen, JB Doll, MK McNall, RJ McGrew, M Williams, N Lopareva, EN Barskey, AE Punsalang, A Rota, PA Oleszko, WR Hickman, CJ Zimmerman, CM Bellini, WJ AF Rota, Jennifer S. Rosen, Jennifer B. Doll, Margaret K. McNall, Rebecca J. McGrew, Marcia Williams, Nobia Lopareva, Elena N. Barskey, Albert E. Punsalang, Amado, Jr. Rota, Paul A. Oleszko, William R. Hickman, Carole J. Zimmerman, Christopher M. Bellini, William J. TI Comparison of the Sensitivity of Laboratory Diagnostic Methods from a Well-Characterized Outbreak of Mumps in New York City in 2009 SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID HIGHLY VACCINATED POPULATION; SCHOOL POPULATION; UNITED-STATES; MEASLES; FAILURE; VIRUS; RUBELLA; COVERAGE; STUDENTS; RNA AB A mumps outbreak in upstate New York in 2009 at a summer camp for Orthodox Jewish boys spread into Orthodox Jewish communities in the Northeast, including New York City. The availability of epidemiologic information, including vaccination records and parotitis onset dates, allowed an enhanced analysis of laboratory methods for mumps testing. Serum and buccal swab samples were collected from 296 confirmed cases with onsets from September through December 2009. All samples were tested using the Centers for Disease Control and Prevention (CDC) capture IgM enzyme immunoassay (EIA) and a real-time reverse transcription-PCR (rRT-PCR) that targets the short hydrophobic gene. A subset of the samples (n = 205) was used to evaluate 3 commercial mumps IgM assays and to assess the sensitivity of using an alternative target gene (nucleoprotein) in the rRT-PCR protocol. Among 115 cases of mumps with 2 documented doses of measles, mumps, and rubella (MMR) vaccine, the CDC capture IgM EIA detected IgM in 51% of serum samples compared to 9% to 24% using three commercial IgM assays. The rRT-PCR that targeted the nucleoprotein gene increased RNA detection by 14% compared to that obtained with the original protocol. The ability to detect IgM improved when serum was collected 3 days or more after symptom onset, whereas sensitivity of RNA detection by rRT-PCR declined when buccal swabs were collected later than 2 days after onset. Selection of testing methods and timing of sample collection are important factors in the ability to confirm infection among vaccinated persons. These results reinforce the need to use virus detection assays in addition to serologic tests. C1 [Rota, Jennifer S.; McNall, Rebecca J.; McGrew, Marcia; Williams, Nobia; Lopareva, Elena N.; Barskey, Albert E.; Rota, Paul A.; Hickman, Carole J.; Bellini, William J.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rosen, Jennifer B.; Doll, Margaret K.; Punsalang, Amado, Jr.; Oleszko, William R.; Zimmerman, Christopher M.] New York City Dept Hlth & Mental Hyg, New York, NY USA. RP Rota, JS (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jrota@cdc.gov OI Doll, Margaret/0000-0002-2125-7820 NR 22 TC 22 Z9 23 U1 1 U2 13 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAR PY 2013 VL 20 IS 3 BP 391 EP 396 DI 10.1128/CVI.00660-12 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 096NL UT WOS:000315411100009 PM 23324519 ER PT J AU Adetona, O Li, Z Sjodin, A Romanoff, LC Aguilar-Villalobos, M Needham, LL Hall, DB Cassidy, BE Naeher, LP AF Adetona, Olorunfemi Li, Zheng Sjoedin, Andreas Romanoff, Lovisa C. Aguilar-Villalobos, Manuel Needham, Larry L. Hall, Daniel B. Cassidy, Brandon E. Naeher, Luke P. TI Biomonitoring of polycyclic aromatic hydrocarbon exposure in pregnant women in Trujillo, Peru - Comparison of different fuel types used for cooking SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Indoor air pollution; Biomass; Gas; hydroxyl-substituted polycyclic aromatic hydrocarbon; Pregnant women; Peru ID INDOOR AIR-POLLUTION; LOW-BIRTH-WEIGHT; OCCUPATIONAL-EXPOSURE; BIOMASS COMBUSTION; CARBON-MONOXIDE; WOOD SMOKE; RISK; 1-HYDROXYPYRENE; METABOLITES; BIOMARKERS AB Women and children in developing countries are often exposed to high levels of air pollution including polycyclic aromatic hydrocarbons (PAHs), which may negatively impact their health, due to household combustion of biomass fuel for cooking and heating. We compared creatinine adjusted hydroxy-PAH (OH-PAH) concentrations in pregnant women in Trujillo, Peru who cook with wood to levels measured in those who cook with kerosene, liquefied petroleum gas or a combination of fuels. Seventy-nine women were recruited for the study between May and July 2004 in the first trimester of their pregnancy. Urine samples were collected from the subjects in the first, second and third trimesters for OH-PAH analyses. The concentrations of the OH-PAHs were compared across the type of fuel used for cooking and pregnancy trimesters. The relationships between OH-PAHs levels in the first trimester and concurrently measured personal exposures to PM2.5, carbon monoxide and nitrogen dioxide together with their indoor and outdoor air concentrations were also investigated. Women cooking with wood or kerosene had the highest creatinine adjusted OH-PAH concentrations compared with those using gas, coal briquette or a combination of fuels. Concentrations of creatinine adjusted 2-hydroxy-fluorene, 3-hydroxy-fluorene, 1-hydroxy-fluorene, 2-hydroxy-phenanthrene and 4-hydroxy-phenanthrene were significantly higher (p<0.05) in women who used wood or kerosene alone compared with women who used liquefied petroleum gas (LPG), coal briquette or a combination of fuels. An increase in the concentrations of creatinine adjusted 9-hydroxy-fluorene, 1-hydroxy-phenanthrene, 2-hydroxy-phenanthrene, 4-hydroxy-phenanthrene and 1-hydroxy-pyrene in the third trimesters was also observed. Weak positive correlation (Spearman correlation coefficient, p<0.4; p<0.05) was absented between all first trimester creatinine adjusted OH-PAHs and indoor (kitchen and living room), and personal 48-h TWA PM2.5. Women who cooked exclusively with wood or kerosene had higher creatinine adjusted OH-PAH levels in their urine samples compared to women who cooked with LPG or coal briquette. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Adetona, Olorunfemi; Cassidy, Brandon E.; Naeher, Luke P.] Univ Georgia, Dept Environm Hlth Sci, Coll Publ Hlth, Athens, GA 30602 USA. [Li, Zheng; Sjoedin, Andreas; Romanoff, Lovisa C.; Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Aguilar-Villalobos, Manuel] Asociac Aire Ambiental, Lima, Peru. [Hall, Daniel B.] Univ Georgia, Dept Stat, Franklin Coll Arts & Sci, Athens, GA 30602 USA. RP Naeher, LP (reprint author), Univ Georgia, Dept Environm Hlth Sci, Coll Publ Hlth, Athens, GA 30602 USA. EM lnaeher@uga.edu FU International Society of Exposure Science (ISES); American Chemistry Council (ACC) through the ISEA Young Investigator Award FX The authors thank the International Society of Exposure Science (ISES) [formerly International Society of Exposure Assessment (ISEA)] and the American Chemistry Council (ACC) for funding support for this study through the ISEA Young Investigator Award to Dr. Luke P. Naeher. The organizations were not involved in the study design; collection, analyses and interpretation of data; the writing of this manuscript; nor the decision to submit it to Environment International. NR 52 TC 11 Z9 11 U1 3 U2 76 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 J9 ENVIRON INT JI Environ. Int. PD MAR PY 2013 VL 53 BP 1 EP 8 DI 10.1016/j.envint.2012.11.010 PG 8 WC Environmental Sciences SC Environmental Sciences & Ecology GA 098LV UT WOS:000315551700001 PM 23314038 ER PT J AU Melius, EJ Davis, SI Redd, JT Lewin, M Herlihy, R Henderson, A Sobel, J Gold, B Cheek, JE AF Melius, E. J. Davis, S. I. Redd, J. T. Lewin, M. Herlihy, R. Henderson, A. Sobel, J. Gold, B. Cheek, J. E. TI Estimating the prevalence of active Helicobacter pylori infection in a rural community with global positioning system technology-assisted sampling SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Epidemiology; gastrointestinal infections; Helicobacter; Helicobacter pylori ID AMERICAN-INDIANS; UNITED-STATES; BREATH TEST; ADULTS; EPIDEMIOLOGY; POPULATION; SMOKING; CANCER AB We investigated a possible outbreak of H. pylori in a rural Northern Plains community. In a cross-sectional survey, we randomly sampled 244 households from a geocoded emergency medical system database. We used a complex survey design and global positioning system units to locate houses and randomly selected one eligible household member to administer a questionnaire and a C-13-urea breath test for active H. pylori infection (n=166). In weighted analyses, active H. pylori infection was detected in 55.0% of the sample. Factors associated with infection on multivariate analysis included using a public drinking-water supply [odds ratio (OR) 12.2, 95% confidence interval (CI) 2.9-50.7] and current cigarette smoking (OR 4.1, 95% CI 1.7-9.6). People who lived in houses with more rooms, a possible indicator of decreased crowding in the home, were less likely to have active H. pylori infections (OR 0.7, 95% CI 0.5-0.9 for each additional room). C1 [Melius, E. J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Melius, E. J.; Redd, J. T.; Cheek, J. E.] Indian Hlth Serv, Off Publ Hlth Support, Div Epidemiol & Dis Prevent, Albuquerque, NM USA. [Davis, S. I.; Lewin, M.; Henderson, A.] Agcy Tox Subst & Dis Registry, Div Hlth Studies, Atlanta, GA USA. [Herlihy, R.] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA. [Sobel, J.; Gold, B.] Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Atlanta, GA USA. [Gold, B.] Emory Univ, Sch Med, Atlanta, GA USA. RP Melius, EJ (reprint author), 3311 NE 163rd St, Lake Forest Pk, WA 98155 USA. EM bmelius@u.washington.edu NR 25 TC 0 Z9 0 U1 1 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAR PY 2013 VL 141 IS 3 BP 472 EP 480 DI 10.1017/S0950268812000714 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 095ZX UT WOS:000315374600004 PM 22595455 ER PT J AU Petersen, LR Carson, PJ Biggerstaff, BJ Custer, B Borchardt, SM Busch, MP AF Petersen, L. R. Carson, P. J. Biggerstaff, B. J. Custer, B. Borchardt, S. M. Busch, M. P. TI Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Epidemiology; incidence; West Nile virus; zoonoses ID UNITED-STATES; DISEASE; EPIDEMIC; COLORADO; RISK; MOSQUITOS AB West Nile virus (WNV) was first recognized in the USA in 1999. We estimated the cumulative incidence of WNV infection in the USA from 1999 to 2010 using recently derived age- and sex-stratified ratios of infections to WNV neuroinvasive disease (WNND) and the number of WNND cases reported to national surveillance. We estimate that over 3 million persons have been infected with WNV in the USA, with the highest incidence rates in the central plains states. These 3 million infections would have resulted in about 780 000 illnesses. A substantial number of WNV infections and illnesses have occurred during the virus' first decade in the USA. C1 [Petersen, L. R.; Biggerstaff, B. J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Carson, P. J.; Borchardt, S. M.] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA. [Carson, P. J.] Sanford Hlth, Fargo, ND USA. [Custer, B.; Busch, M. P.] Blood Syst Res Inst, San Francisco, CA USA. [Borchardt, S. M.] Fargo Vet Affairs Med Ctr, Fargo, ND USA. [Borchardt, S. M.] Wisconsin Dept Hlth, Madison, WI USA. [Busch, M. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Petersen, LR (reprint author), Ctr Dis Control & Prevent, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM lxp2@cdc.gov FU Centers for Disease Control and Prevention [R01-CI-000214]; National Heart Lung and Blood Institute [RC2-HL-101632] FX This work was funded in part by grants from the Centers for Disease Control and Prevention (R01-CI-000214) and the National Heart Lung and Blood Institute (RC2-HL-101632). NR 24 TC 44 Z9 45 U1 3 U2 26 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAR PY 2013 VL 141 IS 3 BP 591 EP 595 DI 10.1017/S0950268812001070 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 095ZX UT WOS:000315374600019 PM 22640592 ER PT J AU Kim, L Moonan, PK Woodruff, RSY Kammerer, JS Haddad, MB AF Kim, L. Moonan, P. K. Woodruff, R. S. Yelk Kammerer, J. S. Haddad, M. B. TI Epidemiology of recurrent tuberculosis in the United States, 1993-2010 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE Mycobacterium tuberculosis; recurrence; surveillance AB Recurrent tuberculosis (TB) can result from reactivation of a previous TB episode or reinfection with a new Mycobacterium tuberculosis strain. A retrospective analysis of all recurrent TB cases reported in the United States during 1993-2010 was conducted. The proportion of recurrent cases remained stable during the study period (annual range 4.2-5.7%). Compared with persons without a previous diagnosis of TB, persons with recurrent TB experienced lower treatment completion within 12 months and higher mortality during the recurrent episode. Persons with recurrent TB have poorer outcomes, suggesting the need for targeted interventions to ensure treatment completion. C1 [Kim, L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Kim, L.; Moonan, P. K.; Woodruff, R. S. Yelk; Kammerer, J. S.; Haddad, M. B.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Kammerer, J. S.] Northrop Grumman Corp, Publ Hlth Operating Unit, Atlanta, GA USA. RP Kim, L (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop C-25, Atlanta, GA 30333 USA. EM iyn2@cdc.gov RI Moonan, Patrick/F-4307-2014; OI Moonan, Patrick/0000-0002-3550-2065 NR 10 TC 3 Z9 3 U1 0 U2 6 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAR PY 2013 VL 17 IS 3 BP 357 EP 360 DI 10.5588/ijtld.12.0640 PG 4 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 095BI UT WOS:000315309100017 PM 23321472 ER PT J AU Auld, SC Pevzner, E AF Auld, Sara C. Pevzner, Eric TI Reaching beyond our Xpert potential: reflections on the 43rd Union World Conference SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Letter ID TUBERCULOSIS C1 [Auld, Sara C.; Pevzner, Eric] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Auld, SC (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM via1@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAR PY 2013 VL 17 IS 3 BP 423 EP 424 DI 10.5588/ijtld.13.0023 PG 2 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 095BI UT WOS:000315309100028 PM 23407234 ER PT J AU Abadin, HG AF Abadin, Henry G. TI The Toxicological Profile Program at ATSDR SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article C1 Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Environm Toxicol Branch, Atlanta, GA 30341 USA. RP Abadin, HG (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Environm Toxicol Branch, 4770 Buford Highway,Mailstop F57, Atlanta, GA 30341 USA. EM HGA0@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2013 VL 75 IS 7 BP 42 EP 43 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 095ZF UT WOS:000315372800007 PM 23505774 ER PT J AU Brown, LG AF Brown, Laura Green TI EHS-Net Restaurant Food Safety Studies: What Have We Learned? SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article C1 Ctr Dis Control & Prevent, Emergency Hlth Serv, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. RP Brown, LG (reprint author), Ctr Dis Control & Prevent, Emergency Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-60, Chamblee, GA 30341 USA. EM lrgreen@cdc.gov NR 8 TC 1 Z9 1 U1 0 U2 3 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2013 VL 75 IS 7 BP 44 EP 45 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 095ZF UT WOS:000315372800008 PM 23505775 ER PT J AU Schneider, AK Brinsley-Rainisch, KJ Schaefer, MK Camilli, T Perz, JF Cochran, RL AF Schneider, Amy K. Brinsley-Rainisch, Kristin J. Schaefer, Melissa K. Camilli, Traci Perz, Joseph F. Cochran, Ronda L. TI Public Perceptions and Preferences for Patient Notification After an Unsafe Injection SO JOURNAL OF PATIENT SAFETY LA English DT Article DE patient notification; unsafe injections; safe injection practices; focus groups ID HEALTH-CARE SETTINGS; HEPATITIS-C VIRUS; PAIN MANAGEMENT PROCEDURES; MEDICAL ERRORS; UNITED-STATES; BLOOD-STREAM; INFECTIONS; TRANSMISSION; DISCLOSURE; OUTBREAK AB Background: Unsafe injection practices in health-care settings often result in notification of potentially affected patients, to disclose the error and recommend blood-borne pathogens testing. Few studies have assessed public perceptions and preferences for patient notification. Methods: Six focus groups were conducted during Fall 2009, with residents of Atlanta, GA, and New York City, NY. Questions focused on preferences for receiving health information, knowledge of safe injection practices, and responses to and preferences for a patient notification letter. A mixed-method analysis was performed for qualitative themes and descriptive statistics. Results: A total of 53 individuals participated; only 2 had ever heard of the term safe injection practices. After identification of unsafe injection practices, participants preferred to be notified via telephone, letter/mailing, email, or face-to-face from the facility where the incident occurred. More than 25 different types of information were mentioned as elements to be placed in a patient notification letter including: corrective actions by the facility, course of action for the patient, assurance of medical coverage, and how it happened/reason for the incident. Participants preferred that the tone of the letter be empathetic; nearly all indicated it was "very likely'' that they would seek testing if notified. Conclusions: Facilities and health departments should strive to assure the notification process is conducted swiftly, clearly guiding affected patients to the necessary course of action. Notification letters are not "one size fits all,'' and some preferences expressed by patients may not be feasible in all situations. Prevention efforts should be complemented by research on improving effective patient communications when unsafe injection practices necessitate patient notification. C1 [Schneider, Amy K.; Brinsley-Rainisch, Kristin J.; Schaefer, Melissa K.; Camilli, Traci; Perz, Joseph F.; Cochran, Ronda L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Cochran, RL (reprint author), Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. EM RLS7@CDC.GOV NR 36 TC 0 Z9 0 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1549-8417 J9 J PATIENT SAF JI J. Patient Saf. PD MAR PY 2013 VL 9 IS 1 BP 8 EP 12 DI 10.1097/PTS.0b013e318269992d PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 096MO UT WOS:000315408600002 PM 23007243 ER PT J AU Tahara, M Ohno, S Sakai, K Ito, Y Fukuhara, H Komase, K Brindley, MA Rota, PA Plemper, RK Maenaka, K Takeda, M AF Tahara, Maino Ohno, Shinji Sakai, Kouji Ito, Yuri Fukuhara, Hideo Komase, Katsuhiro Brindley, Melinda A. Rota, Paul A. Plemper, Richard K. Maenaka, Katsumi Takeda, Makoto TI The Receptor-Binding Site of the Measles Virus Hemagglutinin Protein Itself Constitutes a Conserved Neutralizing Epitope SO JOURNAL OF VIROLOGY LA English DT Article ID B-CELL RESPONSE; EPITHELIAL RECEPTOR; SLAM; LOCALIZATION; ERADICATION; ANTIBODIES; NECTIN-4; DOMAINS; FUSION; BLIND AB Here, we provide direct evidence that the receptor-binding site of measles virus (MV) hemagglutinin protein itself forms an effective conserved neutralizing epitope (CNE). Several receptor-interacting residues constitute the CNE. Thus, viral escape from neutralization has to be associated with loss of receptor-binding activity. Since interactions with both the signaling lymphocyte activation molecule (SLAM) and nectin4 are critical for MV pathogenesis, its escape, which results from loss of receptor-binding activity, should not occur in nature. C1 [Tahara, Maino; Sakai, Kouji; Komase, Katsuhiro; Takeda, Makoto] Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan. [Ohno, Shinji] Kyushu Univ, Fac Med, Dept Virol, Fukuoka 812, Japan. [Ito, Yuri; Fukuhara, Hideo; Maenaka, Katsumi] Hokkaido Univ, Lab Biomol Sci, Fac Pharmaceut Sci, Sapporo, Hokkaido 060, Japan. [Brindley, Melinda A.; Plemper, Richard K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Rota, Paul A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesviruses Lab Branch, Div Viral Dis, Atlanta, GA USA. RP Tahara, M (reprint author), Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan. EM maino@nih.go.jp FU NIAID NIH HHS [R01 AI083402] NR 26 TC 14 Z9 14 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2013 VL 87 IS 6 BP 3583 EP 3586 DI 10.1128/JVI.03029-12 PG 4 WC Virology SC Virology GA 095QD UT WOS:000315348500055 PM 23283964 ER PT J AU Nemejc, K Sak, B Kvetonova, D Kernerova, N Rost, M Cama, VA Kvac, M AF Nemejc, Karel Sak, Bohumil Kvetonova, Dana Kernerova, Nadezda Rost, Michael Cama, Vitaliano A. Kvac, Martin TI Occurrence of Cryptosporidium suis and Cryptosporidium scrofarum on commercial swine farms in the Czech Republic and its associations with age and husbandry practices SO PARASITOLOGY RESEARCH LA English DT Article ID PIG GENOTYPE II; POST-WEANED PIGS; MOLECULAR CHARACTERIZATION; SUS-SCROFA; FECAL TRANSMISSION; SP APICOMPLEXA; RISK-FACTORS; PREVALENCE; GIARDIA; PIGLETS AB From 2009 to 2011, the occurrence of Cryptosporidium spp. was investigated on 22 farms in the Czech Republic. A total of 1,620 individual faecal samples of pigs of all age categories (pre-weaned, starters, pre-growers, growers, and sows) were evaluated for presence of Cryptosporidium spp. by standard microscopy and molecular tools. Genotyping was done through PCR amplification and characterization of the SSU rRNA (species-specific protocols) and GP60 loci. Cryptosporidium spp. was found on 16 of 22 farms with a range 0.9-71.4 %. Overall, 194 (12 %) specimens were positive by microscopy and 353 (21.8 %) by PCR. While RFLP and direct sequencing of the PCR-amplified products showed presence of Cryptosporidium suis (142), Cryptosporidium scrofarum (195), Cryptosporidium muris (3) and 13 samples had mixed infections with C. suis and C. scrofarum, species-specific molecular tools identified C. suis (224), C. scrofarum (208), Cryptosporidium parvum subtype IIa A16G1R1b (1), and C. muris (3). In addition, a total of 82 pigs had concurrent infections with C. suis and C. scrofarum. The analysis by age showed that C. suis was primarily detected among pre-weaned, whereas C. scrofarum was mostly detected among starters, especially those weaned at a younger age. Moreover, C. scrofarum never has been detected in animals younger than 6 weeks of age. Also, piglets weaned at 3 weeks of age were twice more likely to be infected with C. scrofarum than piglets weaned at an older age. Pigs raised on straw bedding were more likely to have Cryptosporidium than pigs raised on slats/slurry systems. The infections with different species were not associated with loose faeces or intensity of oocyst shedding, even when comparing different age groups. C1 [Nemejc, Karel; Kernerova, Nadezda; Kvac, Martin] Univ South Bohemia, Fac Agr, Ceske Budejovice 37005, Czech Republic. [Sak, Bohumil; Kvetonova, Dana; Kvac, Martin] Acad Sci Czech Republic, Inst Parasitol, Ctr Biol, Vvi, CR-37005 Ceske Budejovice, Czech Republic. [Rost, Michael] Univ South Bohemia, Fac Econ, Ceske Budejovice 37005, Czech Republic. [Cama, Vitaliano A.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Kvac, M (reprint author), Acad Sci Czech Republic, Inst Parasitol, Ctr Biol, Vvi, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic. EM kvac@centrum.cz RI Kvac, Martin/G-7299-2014; Sak, Bohumil/G-9262-2014; Kernerova, Nadezda/D-9466-2016; OI Kvac, Martin/0000-0003-0013-6090; Kernerova, Nadezda/0000-0001-7087-6014 FU Ministry of Education, Youth and Sports of the Czech Republic [LH11061, MSM 6007665806]; Grant Agency of University of South Bohemia [022/2010/Z] FX This study was funded by projects of the Ministry of Education, Youth and Sports of the Czech Republic (LH11061 and MSM 6007665806) and project of the Grant Agency of University of South Bohemia (022/2010/Z). The authors thank to all farmers involved in the project for providing data and biology material for our research. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 75 TC 13 Z9 13 U1 1 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 J9 PARASITOL RES JI Parasitol. Res. PD MAR PY 2013 VL 112 IS 3 BP 1143 EP 1154 DI 10.1007/s00436-012-3244-8 PG 12 WC Parasitology SC Parasitology GA 096ZH UT WOS:000315443100027 PM 23271566 ER PT J AU Black, MH Lawrence, JM Pihoker, C Dolan, LM Anderson, A Rodriguez, B Marcovina, SM Mayer-Davis, EJ Imperatore, G Dabelea, D AF Black, Mary Helen Lawrence, Jean M. Pihoker, Catherine Dolan, Lawrence M. Anderson, Andrea Rodriguez, Beatriz Marcovina, Santica M. Mayer-Davis, Elizabeth J. Imperatore, Giuseppina Dabelea, Dana CA SEARCH Diabet Youth Study Grp TI HLA-Associated Phenotypes in Youth with Autoimmune Diabetes SO PEDIATRIC DIABETES LA English DT Article DE autoantibodies; DKA; FCP; HLA; type 1 diabetes ID GLUTAMIC-ACID DECARBOXYLASE; ISLET ANTIGEN-2; DQ HAPLOTYPES; TYPE-1; RISK; MELLITUS; ONSET; AUTOANTIBODIES; FAMILIES; SEARCH AB Black MH, Lawrence JM, Pihoker C, Dolan LM, Anderson A, Rodriguez B, Marcovina SM, Mayer-Davis EJ, Imperatore G, Dabelea D, for the SEARCH for Diabetes in Youth Study Group. HLA-associated phenotypes in youth with autoimmune diabetes. Pediatric Diabetes 2013: 14: 121-128. Objectives To examine human leukocyte antigen HLA DRB1DQB1 haplotypes within a multi-ethnic cohort and assess their association with characteristics of diabetes onset. Methods The sample included 1662 participants from the SEARCH for Diabetes in Youth Study who tested positive for GADA and/or IA-2A autoantibodies. Blood drawn at the study visit was used to measure fasting C-peptide (FCP) and genotype HLA DRB1 and DQB1 loci. Diabetic ketoacidosis (DKA) at diagnosis was determined from medical records. Multivariable linear and logistic regression models stratified by race/ethnicity were used to assess associations with DRB1DQB1 haplotypes. Results The frequency of DRB1*03 susceptibility haplotypes ranged 27.528.9% in all racial/ethnic groups. The frequency of susceptibility DRB1*04DQB1*0302 was higher in non-Hispanic White (NHW; 34.1%) and Hispanic (38.9%) compared to non-Hispanic Black (NHB; 20.8%) youth. Neutral and protective haplotypes were low frequency in all groups. DBR1*03 haplotypes were associated with younger age at diagnosis in NHW and positivity for multiple autoantibodies in Hispanics. DRB1*04DQB1*0302 haplotypes were associated with multiple autoantibody positivity in NHW and Hispanics, and lower FCP and higher odds of DKA in Hispanics only. Although protective DRB1*04DQB1*0301 haplotypes were associated with older age at diagnosis in NHW, they were also associated with multiple autoantibody positivity in these youth. Protective DRB1*13 haplotypes were associated with decreased odds of multiple autoantibody positivity in NHB youth. Conclusions The distribution of DRB1DQB1 haplotypes and their association with onset-related characteristics of autoimmune diabetes varies across major racial/ethnic groups in the USA. This may contribute to variation in clinical presentation of autoimmune diabetes by race/ethnicity. C1 [Black, Mary Helen; Lawrence, Jean M.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Pihoker, Catherine] Childrens Hosp & Reg Med Ctr, Dept Pediat Endocrinol, Seattle, WA USA. [Dolan, Lawrence M.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA. [Anderson, Andrea] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Rodriguez, Beatriz] Univ Hawaii Manoa, Honolulu, HI 96822 USA. [Marcovina, Santica M.] Northwest Lipid Res Labs, Dept Med, Seattle, WA USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Dabelea, Dana] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA. RP Black, MH (reprint author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Robles,2nd Floor, Pasadena, CA 91101 USA. EM MaryHelen.X.Black@kp.org FU Medical University of South Carolina (NIH/NCRR) [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; Institutional Clinical and Translational Science Award (CTSA), NIH/NCRR at the University of Cincinnati [1UL1RR026314-01]; SEARCH for Diabetes in Youth; Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-201035171] FX The authors wish to acknowledge the contributions of Dr. Gaur (University of Washington, Seattle), who performed the HLA genotyping, and Dr. Henry Erlich (Roche Molecular Systems, California), who provided the HLA haplotype data for this study. The authors also acknowledge the involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR Grant number UL1RR029882); Children's Hospital and Regional Medical Center (Grant Number M01RR00037); Colorado Pediatric General Clinical Research Center (Grant Number M01 RR00069) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the Institutional Clinical and Translational Science Award (CTSA), NIH/NCRR at the University of Cincinnati (Grant Number 1UL1RR026314-01). The SEARCH for Diabetes in Youth Study is indebted to the many youth and their families, and their health care providers, whose participation made this study possible. Grant Support: SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site Contract Numbers: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708-01), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-201035171). NR 21 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1399-543X J9 PEDIATR DIABETES JI Pediatr. Diabetes PD MAR PY 2013 VL 14 IS 2 BP 121 EP 128 DI 10.1111/j.1399-5448.2012.00905.x PG 8 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 097BI UT WOS:000315448600006 PM 22913598 ER PT J AU Coughlin, MM Bellini, WJ Rota, PA AF Coughlin, Melissa M. Bellini, William J. Rota, Paul A. TI Contribution of dendritic cells to measles virus induced immunosuppression SO REVIEWS IN MEDICAL VIROLOGY LA English DT Review ID DEFECTIVE INTERFERING PARTICLES; LYMPHOCYTIC ACTIVATION MOLECULE; CD4(+) T-CELLS; IMMUNE-RESPONSES; LANGERHANS CELLS; RHESUS-MONKEYS; INFLAMMATORY CYTOKINES; VIRAL GLYCOPROTEINS; INNATE IMMUNITY; INFECTION AB Measles virus (MV) remains an important pathogen in children worldwide. The morbidity and mortality of MV is associated with severe immune suppression. Dendritic cells (DCs) were identified as initial target cells in vivo, and DCs were efficiently infected by MV in vitro. MV infection of DCs likely contributes to functional deficiency in these cells; therefore playing a role in MV-induced immunosuppression. DCs appeared to mature phenotypically; however, the ability of infected cells to stimulate T cells was compromised. Phenotypic maturation of infected immature DCs was partially controlled by IFN production; however, infected DCs also maintained markers of an immature phenotype such as the continued uptake of antigen and lack of expression of chemokine receptor CCR7. Furthermore, mature DCs did not appear to maintain phenotypic maturation following infection demonstrated by decreased MHC and co-stimulatory molecule expression. Several mechanisms of MV-induced DC dysfunction have been suggested, each likely contributing to the immunosuppressive effect of MV-infected DCs. Infected DCs responded aberrantly to secondary maturation stimuli such as CD40L or TLR4 stimulation. MV infection resulted in apoptosis in DC/T-cell cocultures, which may contribute to a reduced T-cell response. Additionally, the immunological synapse between infected DCs and T cells was compromised resulting in reduced T-cell interaction times and activation signaling. The mechanisms of MV contribution to DC dysfunction appear multifaceted and central to MV-induced immunosuppression. Published 2012. This article is a U.S. Government work and is in the public domain in the USA. C1 [Coughlin, Melissa M.; Bellini, William J.; Rota, Paul A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesvirus Lab Branch, Atlanta, GA 30333 USA. RP Rota, PA (reprint author), Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesvirus Lab Branch, 1600 Clifton Rd,C22, Atlanta, GA 30333 USA. EM prota@cdc.gov NR 74 TC 7 Z9 7 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1052-9276 J9 REV MED VIROL JI Rev. Med. Virol. PD MAR PY 2013 VL 23 IS 2 BP 126 EP 138 DI 10.1002/rmv.1735 PG 13 WC Virology SC Virology GA 100ZL UT WOS:000315744300005 PM 23280948 ER PT J AU Gilbert, ME Hedge, JM Valentin-Blasini, L Blount, BC Kannan, K Tietge, J Zoeller, RT Crofton, KM Jarrett, JM Fisher, JW AF Gilbert, Mary E. Hedge, Joan M. Valentin-Blasini, Liza Blount, Benjamin C. Kannan, Kurunthachalam Tietge, Joseph Zoeller, R. Thomas Crofton, Kevin M. Jarrett, Jeffrey M. Fisher, Jeffrey W. TI An Animal Model of Marginal Iodine Deficiency During Development: The Thyroid Axis and Neurodevelopmental Outcome SO TOXICOLOGICAL SCIENCES LA English DT Article DE thyroid; iodine; hypothyroidism; hippocampus; neurodevelopment; learning; synaptic function; biologically based dose-response models; BBDR ID TANDEM MASS-SPECTROMETRY; IMPAIR NEURAL DEVELOPMENT; NEONATAL-RAT HIPPOCAMPUS; HORMONE DISRUPTION; POLYCHLORINATED-BIPHENYLS; SODIUM/IODIDE SYMPORTER; BRAIN-DEVELOPMENT; SYNAPTIC-TRANSMISSION; ION CHROMATOGRAPHY; REPRODUCTIVE AGE AB Thyroid hormones (THs) are essential for brain development, and iodine is required for TH synthesis. Environmental chemicals that perturb the thyroid axis result in modest reductions in TH, yet there is a paucity of data on the extent of neurological impairments associated with low-level TH disruption. This study examined the dose-response characteristics of marginal iodine deficiency (ID) on parameters of thyroid function and neurodevelopment. Diets deficient in iodine were prepared by adding 975, 200, 125, 25, or 0 g/kg potassium iodate to the base casein diet to produce five nominal iodine levels ranging from ample (Diet 1: 1000 g iodine/kg chow, D1) to deficient (Diet 5: 25 g iodine/kg chow, D5). Female Long Evans rats were maintained on these diets beginning 7 weeks prior to breeding until the end of lactation. Dams were sacrificed on gestational days 16 and 20, or when pups were weaned on postnatal day (PN) 21. Fetal tissue was harvested from the dams, and pups were sacrificed on PN14 and PN21. Blood, thyroid gland, and brain were collected for analysis of iodine, TH, and TH precursors and metabolites. Serum and thyroid gland iodine and TH were reduced in animals receiving two diets that were most deficient in iodine. T4 was reduced in the fetal brain but was not altered in the neonatal brain. Neurobehavior, assessed by acoustic startle, water maze learning, and fear conditioning, was unchanged in adult offspring, but excitatory synaptic transmission was impaired in the dentate gyrus in animals receiving two diets that were most deficient in iodine. A 15% reduction in cortical T4 in the fetal brain was sufficient to induce permanent reductions in synaptic function in adults. These findings have implications for regulation of TH-disrupting chemicals and suggest that standard behavioral assays do not readily detect neurotoxicity induced by modest developmental TH disruption. C1 [Gilbert, Mary E.] US EPA, Tox Assessment Div, Res Triangle Pk, NC 27711 USA. [Hedge, Joan M.; Crofton, Kevin M.] US EPA, Integrated Syst Biol Div, Res Triangle Pk, NC 27711 USA. [Valentin-Blasini, Liza; Blount, Benjamin C.; Jarrett, Jeffrey M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kannan, Kurunthachalam] SUNY Albany, New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12222 USA. [Kannan, Kurunthachalam] SUNY Albany, Dept Environm Hlth Sci, Sch Publ Hlth, Albany, NY USA. [Tietge, Joseph] US EPA, MidAtlantic Ecol Div, Duluth, MN USA. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA. [Fisher, Jeffrey W.] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA. RP Gilbert, ME (reprint author), US EPA, Tox Assessment Div MD B105 05, Natl Hlth & Environm Effects Res Lab, 109 TW Alexander Dr, Res Triangle Pk, NC 27711 USA. EM gilbert.mary@epa.gov RI Crofton, Kevin/J-4798-2015; OI Crofton, Kevin/0000-0003-1749-9971; Jarrett, Jeffery/0000-0001-5755-3552 FU U.S. Environmental Protection Agency [R832138, R832134] FX This work was partially supported by U.S. Environmental Protection Agency (R832138 to J.F.) and (R832134 to R.T.Z.). NR 71 TC 9 Z9 9 U1 1 U2 26 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD MAR PY 2013 VL 132 IS 1 BP 177 EP 195 DI 10.1093/toxsci/kfs335 PG 19 WC Toxicology SC Toxicology GA 096WB UT WOS:000315434300017 PM 23288053 ER PT J AU Park, RM Chen, WH AF Park, Robert M. Chen, Weihong TI Silicosis exposure-response in a cohort of tin miners comparing alternate exposure metrics SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE burden; cumulative exposure; exposure response; occupational disease; vanishing baseline ID RISK-ASSESSMENT; LUNG-CANCER; WORKERS; MODELS; DUST AB Background. The detailed lung radiographic response to silica exposure has not been described. In estimating the exposureresponse relationship in silicosis with statistical models, the absence of baseline (unattributable) risk can disable relative-rate estimation or produce widely varying estimates. This obstructs identification of optimum exposure metrics and invalidates comparisons and meta-analyses, which assume a common background rate. Methods. A cohort of 3,000 Chinese tin miners with more than 1,000 cases of silicosis was analyzed for the period 19611994. Regular surveillance documented three stages of silicosis. To examine the exposureresponse relationship, the intercept in relative-rate models was fixed to correspond to 1% of the observed silicosis rate. Exposure metrics for contributions in different time-windows were simultaneously evaluated, as were burden and cumulative burden metrics. Results. Silica exposures that most contributed to silicosis onset occurred in the period 510 years prior (excess annual rate per 10mg-year/m3, ER=0.158, 95% CI=0.1250.192, or 16% per year). During 1020 year prior, the excess rate contribution was much smaller (ER=0.048, 95% CI=0.0370.060) but larger again during 2030 year prior to onset (ER=0.112, 95% CI=0.0980.126). For advanced silicosis, all time periods contributed about equally to the rate of onset. Conclusions. Reliable estimates of parameters were observed, demonstrating exposure contributions over time. Burden metrics with different half-lives suggested some reversibility for silicosis onset with a half-life of 20 years. Advanced silicosis was best predicted with a cumulative burden metric which was consistent with prior observations that previously deposited silica continues to cause pulmonary damage. Am. J. Ind. Med. 56:267275, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Park, Robert M.] NIOSH, Risk Evaluat Branch, Cincinnati, OH 45226 USA. [Chen, Weihong] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Occupat & Environm Hlth, Wuhan 430074, Hubei, Peoples R China. RP Park, RM (reprint author), NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, MSC 15,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM rhp9@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 2 Z9 2 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD MAR PY 2013 VL 56 IS 3 BP 267 EP 275 DI 10.1002/ajim.22115 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 093MR UT WOS:000315196500001 PM 22996756 ER PT J AU Cummings, KJ Suarthana, E Edwards, N Liang, XM Stanton, ML Day, GA Saito, R Kreiss, K AF Cummings, Kristin J. Suarthana, Eva Edwards, Nicole Liang, Xiaoming Stanton, Marcia L. Day, Gregory A. Saito, Rena Kreiss, Kathleen TI Serial evaluations at an indium-tin oxide production facility SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE indium; indium-tin oxide; interstitial lung disease; occupational illness; surveillance ID POPULATION; INHALATION; WORKERS; VALUES; SAMPLE AB Background We evaluated the effectiveness of workplace changes to prevent indium lung disease, using 20022010 surveillance data collected by an indium-tin oxide production facility. Methods We assessed pulmonary function using lower limits of normal. Blood indium concentration and personal air sampling data were used to estimate exposure. Results Abnormalities were uncommon at hire. After hire, prevalence of spirometric restriction was 31% (n=14/45), about fourfold higher than expected. Excessive decline in FEV1 was elevated at 29% (n=12/41). Half (n=21/42) had blood indium 5 mu g/l. More recent hires had fewer abnormalities. There was a suggestion that abnormalities were more common among workers with blood indium 5 mu g/l, but otherwise an exposure-response relationship was not evident. Peak dust concentrations were obscured by time averaging. Conclusions Evolving lung function abnormalities consistent with subclinical indium lung disease appeared common and merit systematic investigation. Traditional measures of exposure and response were not illustrative, suggesting fresh approaches will be needed. Workplace changes seemed to have had a positive though incomplete impact; novel preventive interventions are warranted. Am. J. Ind. Med. 56:300307, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Cummings, Kristin J.; Suarthana, Eva; Edwards, Nicole; Liang, Xiaoming; Stanton, Marcia L.; Day, Gregory A.; Saito, Rena; Kreiss, Kathleen] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Suarthana, Eva] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA. RP Cummings, KJ (reprint author), NIOSH, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 2800, Morgantown, WV 26505 USA. EM kcummings@cdc.gov FU National Institute for Occupational Safety and Health, Centers for Diseases Control and Prevention FX Sponsor: National Institute for Occupational Safety and Health, Centers for Diseases Control and Prevention. NR 21 TC 14 Z9 14 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD MAR PY 2013 VL 56 IS 3 BP 300 EP 307 DI 10.1002/ajim.22125 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 093MR UT WOS:000315196500005 PM 23109040 ER EF